FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Gong, MN Zhou, W Williams, PL Thompson, BT Pothier, L Christiani, DC AF Gong, Michelle N. Zhou, Wei Williams, Paige L. Thompson, B. Taylor Pothier, Lucille Christiani, David C. TI Polymorphisms in the mannose binding lectin-2 gene and acute respiratory distress syndrome SO CRITICAL CARE MEDICINE LA English DT Article DE acute respiratory failure; genetic susceptibility; acute lung injury; molecular epidemiology ID MANNOSE-BINDING LECTIN; INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENE POLYMORPHISM; CYSTIC-FIBROSIS; NEISSERIA-MENINGITIDIS; ASSOCIATION; INFECTION; PROTEIN; DISEASE AB Objective: The variant alleles in the mannose binding lectin-2 (MBL-2) gene have been associated with MBL deficiency and increased susceptibility to sepsis. We postulate that the variant MBL-2 genotypes are associated with increased susceptibility to and mortality in acute respiratory distress syndrome (ARDS). Design. Nested case-control study. Setting: Tertiary academic medical center. Patients: Two hundred and twelve Caucasians with ARDS and 442 controls genotyped for the variant X, D, B, and C alleles of codon -221, 52, 54, and 57, respectively. Interventions. None. Measurements and Main Results. Patients homozygous for the variant codon 54B allele (54BB) had worse severity of illness on admission (p =.007), greater likelihood of septic shock (p =.04), and increased odds of ARDS (adjusted odds ratio, 6.7; 95% confidence interval, 1.5-31) when compared with heterozygotes and homozygotes for the wild-type allele. This association with ARDS was especially strong among the 311 patients with septic shock (adjusted odds ratio, 12.0; 95% confidence interval, 1.9-74). Among the patients with ARDS, the 54BB genotype was associated with more daily organ dysfunction (p =.01) and higher mortality (adjusted hazard rate, 4.0; 95% confidence interval, 1.6-10). Development of ARDS and outcomes in ARDS did not vary significantly with variant alleles of codon -221, 52, and 57, but the power to detect an effect was limited secondary to the low allele frequencies. Conclusions: The MBL-2 codon 54BB genotype may be important in ARDS susceptibility and outcome. Additional studies are needed to confirm these findings in other populations. C1 Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Pulm & Crit Care Unit, Boston, MA USA. Mt Sinai Sch Med, Dept Med, Div Pulm & Crit Care Med, New York, NY USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Christiani, DC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA. EM dchristi@hsph.harvard.edu FU NHLBI NIH HHS [K23 HL067197, K23 HL 67197, R01 HL 084060, R01 HL 60710, R01 HL060710, R01 HL084060]; NIMHD NIH HHS [L32 MD000662, L32 MD000662-02] NR 42 TC 46 Z9 48 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JAN PY 2007 VL 35 IS 1 BP 48 EP 56 DI 10.1097/01.CCM.0000251132.10689.F3 PG 9 WC Critical Care Medicine SC General & Internal Medicine GA 119XC UT WOS:000243046700008 PM 17133182 ER PT J AU Brown, L Boswell, S Raj, L Lee, SW AF Brown, Lauren Boswell, Sarah Raj, Lakshmi Lee, Sam W. TI Transcriptional targets of p53 that regulate cellular proliferation SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION LA English DT Review DE p53; transcription; cell cycle; proliferation; arrest ID SUPPRESSOR PROTEIN P53; WILD-TYPE P53; MICROTUBULE-ASSOCIATED PROTEIN; TOPOISOMERASE-II ALPHA; NERVE GROWTH-FACTOR; KH-DOMAIN PROTEINS; DNA-DAMAGE; TUMOR-SUPPRESSOR; CYCLE ARREST; C-MYC AB In response to various forms of cellular stress, including DNA damage, ribonucleotide depletion, and abnormal proliferative signals, p53 becomes activated as a transcription factor, targeting genes that induce cell-cycle arrest and apoptosis. Eliminating damaged, stressed, or abnormally proliferating cells from the replicating cell population prevents the propagation of potentially cancer-prone cells. Here we focus on the transcriptional targets of p53 that regulate the cell cycle. p53 induction of G1/S cell-cycle arrest is largely attributed to the transcriptional upregulation of p21(WAF1), and more recently, to the transcriptional repression of c-MYC. The role of p53 in G2/M cell-cycle arrest in response to DNA damage is more complex, involving multiple targets that can generally be considered to impinge upon either the cell cycle (e.g., Cyclin-B, cdc2, cdc25C) or the mitotic machinery (i.e., Topoisomerase II, B99/Gtse-1, and MAP4). The ability of p53 to regulate these two types of gene targets may reflect p53-mediated early versus late events in the G2/M cell-cycle arrest response. Together the information presented illustrates the need for further studies to precisely delineate the nature of G2/M cell-cycle arrest in response to cell stress, and defines the role of p53 in what is likely an important mechanism of tumor suppression. C1 Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Lee, SW (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA. EM sam.lee@cbrc2.mgh.harvard.edu NR 121 TC 29 Z9 30 U1 0 U2 6 PU BEGELL HOUSE INC PI REDDING PA 50 CROSS HIGHWAY, REDDING, CT 06896 USA SN 1045-4403 J9 CRIT REV EUKAR GENE JI Crit. Rev. Eukaryot. Gene Expr. PY 2007 VL 17 IS 1 BP 73 EP 85 PG 13 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 142UB UT WOS:000244674600005 PM 17361486 ER PT J AU Moore, DJ Kim, JI Sonawane, S Yeh, H Deng, SP Lee, MK Markmann, JF AF Moore, Daniel J. Kim, James I. Sonawane, Samsher Yeh, Heidi Deng, Shaoping Lee, Major Kenneth Markmann, James F. TI Progress toward antibody-induced transplantation tolerance SO CRITICAL REVIEWS IN IMMUNOLOGY LA English DT Review DE receptor; costimulation; regulation; thymus; T cell; rejection ID REGULATORY T-CELLS; RENAL-ALLOGRAFT REJECTION; ANTI-CD4 MONOCLONAL-ANTIBODY; LONG-TERM SURVIVAL; FUNCTION-ASSOCIATED ANTIGEN-1; PROTEIN-TYROSINE-PHOSPHATASE; DONOR-SPECIFIC TRANSFUSION; NONOBESE DIABETIC MICE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; LOW-DOSE CYCLOSPORINE AB Transplantation tolerance remains an elusive goal. Despite multiple animal models of tolerance induction using a variety of agents and protocols, it has yet to be achieved in humans with any predictability. In this review, we examine some of the antibodies directed toward T cells that show promise in prolonging graft survival in animal models and in preliminary clinical assessment. Because these antibodies work through multiple pathways, including depletion, downregulation, receptor-ligand blockade, and direct signaling, they have also helped us tease out the various components of long-lived donor-specific tolerance. In particular, we review the role of the thymus in therapies targeted at the peripheral immune system; the importance of the thymus in tolerance induced by anti-CD45RB suggests that central tolerance mechanisms may be more important than previously appreciated. C1 Univ Penn, Harrison Dept Surg Res, Dept Surg, Philadelphia, PA 19104 USA. RP Markmann, JF (reprint author), Massachusetts Gen Hosp, Dept Surg, 5th Floor,White Bldg,55 Fruit St, Boston, MA 02114 USA. RI Moore, Daniel/A-4924-2008 OI Moore, Daniel/0000-0002-6889-9345 NR 448 TC 1 Z9 1 U1 0 U2 1 PU BEGELL HOUSE INC PI REDDING PA 50 CROSS HIGHWAY, REDDING, CT 06896 USA SN 1040-8401 J9 CRIT REV IMMUNOL JI Crit. Rev. Immunol. PY 2007 VL 27 IS 2 BP 167 EP 218 PG 52 WC Immunology SC Immunology GA 197YY UT WOS:000248594500004 PM 17725502 ER PT J AU DiMasi, E Kwak, SY Pichon, BP Sommerdijk, NAJM AF DiMasi, Elaine Kwak, Seo-Young Pichon, Benoit P. Sommerdijk, Nico A. J. M. TI Structural adaptability in an organic template for CaCO3 mineralization SO CRYSTENGCOMM LA English DT Article ID X-RAY-DIFFRACTION; CALCIUM-OXALATE MONOHYDRATE; COMPRESSED LANGMUIR MONOLAYERS; STEARIC-ACID MONOLAYERS; DIRECTED INORGANIC CRYSTALLIZATION; BREWSTER-ANGLE MICROSCOPY; CARBONATE THIN-FILMS; AIR-WATER-INTERFACE; ORIENTED CRYSTALLIZATION; SELECTIVE CRYSTALLIZATION AB Biomimetic strategies to control mineral nucleation include the development of self-assembled monolayers with appropriate structural properties. We present a bis-urea based surfactant with variable structural adaptability, which induces habit modification in calcite crystals under optimal conditions. In situ surface-sensitive synchrotron X-ray scattering measurements are reported, which yield surprising conclusions for the film structure. In particular, it is found that nucleation of modified calcite is correlated with the release of two-dimensional ordering in the surfactant layer. The model system is discussed in the context of the history of Langmuir films as models for biomineralization. C1 Inst Phys & Chim Mat, F-67034 Strasbourg, France. Brookhaven Natl Lab, Upton, NY 11973 USA. Eindhoven Univ Technol, Lab Mol & Organ Chem, NL-5600 MB Eindhoven, Netherlands. Eindhoven Univ Technol, Soft Matter Cryo TEM Res Unit, NL-5600 MB Eindhoven, Netherlands. RP DiMasi, E (reprint author), The Forsyth Inst, Dept Biomineralizat, Boston, MA 02115 USA. EM dimasi@bnl.gov; N.Sommerdijk@tue.nl RI Sommerdijk, Nico/B-7239-2013 OI Sommerdijk, Nico/0000-0002-8956-195X NR 87 TC 26 Z9 26 U1 3 U2 28 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1466-8033 J9 CRYSTENGCOMM JI Crystengcomm PY 2007 VL 9 IS 12 BP 1192 EP 1204 DI 10.1039/b711153c PG 13 WC Chemistry, Multidisciplinary; Crystallography SC Chemistry; Crystallography GA 235XX UT WOS:000251268700017 ER PT J AU Longo, FM Yang, T Knowles, JK Xie, YM Moore, LA Massa, SM AF Longo, Frank M. Yang, Tao Knowles, Juliet K. Xie, Youmei Moore, Laura A. Massa, Stephen M. TI Small molecule neurotrophin receptor ligands: Novel strategies for targeting Alzheimer's disease mechanisms SO CURRENT ALZHEIMER RESEARCH LA English DT Article; Proceedings Paper CT 7th International Conference on Alzheimers Disease Drug Discovery CY OCT 12-13, 2006 CL New York, NY SP Alzheimers Drug Discovery Fdn, Accera Inc, Acumen Pharmaceut Inc, Eisai Inc, Elan Pharmaceut Inc, Forest Lab Inc, Marteck Biosci Corp, Neurochem Inc, Ortho-McNeil Neurol Inc, Pfizer Inc, Sanofi-Aventis US Inc, Wyeth Res, Targacept Inc ID NERVE GROWTH-FACTOR; BETA-AMYLOID PEPTIDE; N-TERMINAL KINASE; HUMAN BRAIN; P75; RAT; ACTIVATION; EXPRESSION; APOPTOSIS; P75(NTR) AB A number of factors limit the therapeutic application of neurotrophin proteins, such as nerve growth factor (NGF) and brain-derived growth factor (BDNF), for Alzheimer's and other neurodegenerative diseases. These factors include unfavorable pharmacological properties typical of proteins and the pleiotropic effects mediated by protein-ligand interactions with p75(NTR), Trk, and sortilin neurotrophin receptors. Targeted modulation of p75(NTR) provides a strategy for preventing degeneration without promoting TrkA-mediated deleterious effects, and targeted activation of TrkB might achieve more favorable neurotrophic effects than those achieved by concomitant activation of p75(NTR) and TrkB. The discovery of small molecules functioning as ligands at specific neurotrophin receptors has made possible for the first time approaches for modulating selected components of neurotrophin signaling processes for the purpose of modulating underlying Alzheimer's disease mechanisms. C1 [Longo, Frank M.; Yang, Tao; Knowles, Juliet K.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Longo, Frank M.; Xie, Youmei; Moore, Laura A.] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA. [Massa, Stephen M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Massa, Stephen M.] San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Longo, FM (reprint author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. EM longo@stanford.edu FU NIA NIH HHS [R01 AG09873] NR 48 TC 52 Z9 53 U1 0 U2 3 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1567-2050 J9 CURR ALZHEIMER RES JI Curr. Alzheimer Res. PY 2007 VL 4 IS 5 BP 503 EP 506 DI 10.2174/156720507783018316 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 268PP UT WOS:000253592000002 PM 18220511 ER PT J AU Webb, NR Moore, KJ AF Webb, Nancy R. Moore, Kathryn J. TI Macrophage-derived foam cells in atherosclerosis: Lessons from murine models and implications for therapy SO CURRENT DRUG TARGETS LA English DT Review DE macrophage foam cell; modified lipoprotein; scavenger receptor; oxidation; secretory phospholipase A2 ID LOW-DENSITY-LIPOPROTEIN; RECEPTOR CLASS-B; SECRETORY PHOSPHOLIPASE A(2); E-DEFICIENT MICE; CASSETTE TRANSPORTER A1; CORONARY-ARTERY-DISEASE; SMOOTH-MUSCLE-CELLS; SERUM-AMYLOID-A; SPHINGOMYELINASE INDUCES AGGREGATION; HERITABLE HYPERLIPIDEMIC RABBITS AB Macrophage-derived foam cells play integral roles in all stages of atherosclerosis. These lipid-laden immune cells are present from the earliest discernable fatty-streak lesions to advanced plaques, and are key regulators of the patho-logic behavior of plaques. This review summarizes the current understanding of the molecular mechanisms that regulate macrophage cholesterol uptake, foam cell formation, and lipid-driven pro-inflammatory responses that promote atherosclerosis. Specific emphasis will be placed on recent findings from mouse models of atherosclerosis regarding the pathways of macrophage differentiation into foam cells and their implications for developing macrophage-directed therapeutic targets. C1 [Moore, Kathryn J.] Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA. [Webb, Nancy R.] Univ Kentucky, Dept Internal Med, Lexington, KY USA. [Webb, Nancy R.] Univ Kentucky, Cardiovasc Res Ctr, Lexington, KY USA. RP Moore, KJ (reprint author), Massachusetts Gen Hosp, Lipid Metab Unit, 55 Fruit St,GRJ1328, Boston, MA 02114 USA. EM kmoore@molbio.mgh.harvard.edu FU NHLBI NIH HHS [R01 HL071098] NR 179 TC 52 Z9 55 U1 1 U2 3 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1389-4501 J9 CURR DRUG TARGETS JI Curr. Drug Targets PY 2007 VL 8 IS 12 BP 1249 EP 1263 DI 10.2174/138945007783220597 PG 15 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 268NW UT WOS:000253587500005 PM 18220702 ER PT J AU Stevceva, L Yoon, V Anastasiades, D Poznansky, MC AF Stevceva, Liljana Yoon, Victor Anastasiades, Daphne Poznansky, Mark C. TI Immune responses to HIV Gp120 that facilitate viral escape SO CURRENT HIV RESEARCH LA English DT Review DE HIV; gp120; T cells; B cells; structure; escape ID IMMUNODEFICIENCY-VIRUS TYPE-1; CYTOTOXIC T-LYMPHOCYTE; MACROPHAGE-TROPIC HIV-1; FOLLICULAR DENDRITIC CELLS; ENVELOPE GLYCOPROTEIN; PRODUCTIVE INFECTION; CHEMOKINE RECEPTORS; CD4 RECEPTOR; SOLUBLE CD4; V3 DOMAIN AB The gp160 complex of the envelope of the HIV virus and its component gp120 are essential for viral entry into the host cell. Gp120 binding to its receptor CD4 and co-receptor, CXCR4 or CCR5 is required for fusion of viral and cellular membranes. The presence of gp120 facilitates immune escape of the virus through its profound effect on the immune cells. It is a polyclonal activator of B cells, causing them to differentiate into immunoglobulin producing cells while activating the complement cascade. This results in the formation of immune complexes that are unable to kill the virus but instead shield it from the attack of other immune cells. Such HIV-1 virus that is trapped within immune complexes and is bound to the B cells via CD21 is more infectious than the free virion. In addition, HIV virions are trapped on the membrane of follicular dendritic cells (FDC) processes in immune complexes or through complement receptors. Thus, FDC can serve as a 'Trojan horse' and transmit the trapped virus to CD4+ T lymphocytes as they migrate through the germinal centre to the follicular mantle and paracortical areas. It was demonstrated that CXCR4-binding HIV-1 X4 gp120 causes the movement of T cells, including HIV-specific CTL, away from high concentrations of the viral protein and its expression by target cells reduces CTL efficacy in vitro. Therefore, apart from the essential role in viral attachment and infection of cells, gp 120 possesses several properties that affect the behavior of immune cells and skew the immune response to the virus facilitating viral escape. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr,Dept Infect Dis,CNY, Charlestown, MA 02129 USA. RP Stevceva, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr,Dept Infect Dis,CNY, Bldg 149,13th St,Room 5423E, Charlestown, MA 02129 USA. EM lstevceva@partners.org FU NIAID NIH HHS [T32 AI007387] NR 108 TC 9 Z9 9 U1 0 U2 1 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1570-162X J9 CURR HIV RES JI Curr. HIV Res. PD JAN PY 2007 VL 5 IS 1 BP 47 EP 54 DI 10.2174/157016207779316396 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 126GW UT WOS:000243501800004 PM 17266556 ER PT J AU Wang, SY Sun, YT Zhai, S Zhuang, Y Zhao, SG Kang, WZ Li, XH Huang, DD Yu, XG Walker, BD Altfeld, MA AF Wang, Shaoyang Sun, Yongtao Zhai, Song Zhuang, Yan Zhao, Shuguang Kang, Whenzhen Li, Xinhong Huang, Dedong Yu, Xu G. Walker, Bruce D. Altfeld, Marcus A. TI Identification of HLA-A11-restricted HIV-1-specific cytotoxic T-lymphocyte epitopes in China SO CURRENT HIV RESEARCH LA English DT Article DE HIV; cytotoxic T-lymphocyte; epitopes; enzyme-linked immunospot (ELISPOT) assay; intracellular gamma interferon staining (ICS) ID HUMAN-IMMUNODEFICIENCY-VIRUS; FEMALE SEX WORKERS; TYPE-1 INFECTION; IMMUNE-RESPONSES; CHIANG-RAI; HIV-1; VIREMIA; ESCAPE; PROTEIN; AIDS AB To fully define HLA-All-restricted HIV-1- specific cytotoxic T-lymphocyte epitopes in China, a method combining the enzyme-linked immunospot (ELISPOT) assay with intracellular gamma interferon staining (ICS) of peripheral blood mononuclear cells (PBMC) was used to map the optimal epitopes targeted by ELISPOT and then to define the FILA restriction of epitopes by ICS. A novel HLA-All-restricted CTL epitope and five other published HLA-All -restricted epitopes previously identified by reverse immunogenetics or other methods were defined. The approach of integrating ELISPOT with ICS is both convenient and useful for the characterization of CTL responses to HIV-1 infection; this method is practical for defining novel epitopes and facilitates in developing new strategies for future vaccine design in China and other Asian countries. C1 Fourth Mil Med Univ, Tangdu Hosp, Dept Infect Dis, Xian 710038, Peoples R China. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr, Boston, MA 02129 USA. RP Sun, YT (reprint author), Fourth Mil Med Univ, Tangdu Hosp, Dept Infect Dis, Xian 710038, Peoples R China. EM yongtaos@hotmail.com FU PHS HHS [N01-AL-30024] NR 39 TC 4 Z9 4 U1 1 U2 4 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1570-162X J9 CURR HIV RES JI Curr. HIV Res. PD JAN PY 2007 VL 5 IS 1 BP 119 EP 128 DI 10.2174/157016207779316404 PG 10 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 126GW UT WOS:000243501800011 PM 17266563 ER PT J AU Tang, XL AF Tang, Xiaolei TI Survival factors from activated accessory cells and their role in triggering autoimmune diseases SO CURRENT MEDICINAL CHEMISTRY LA English DT Review ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NECROSIS-FACTOR-ALPHA; CD8(+) T-CELLS; COLLAGEN-INDUCED ARTHRITIS; CENTRAL-NERVOUS-SYSTEM; NATURAL-KILLER-CELLS; ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; INTERFERON-GAMMA PRODUCTION; MESSENGER-RNA EXPRESSION; TOLL-LIKE RECEPTORS AB To maintain immune homeostasis, the immune system has evolved two "opposite" mechanisms to regulate the activation or expansion of effectors including potential auto-reactive lymphocytes following an immune response. One is to support the survival of activated effectors and thereby benefit the generation of memory response. However, an inappropriate survival of auto-reactive lymphocytes may lead to autoimmune diseases, e.g. multiple sclerosis (MS) and rheumatoid arthritis (R-A). The other is to induce apoptosis of most activated effectors, thereby bringing the immune system to a baseline level after an immune response. It is known that autoimmune diseases are due to uncontrolled growth of auto-reactive lymphocytes, eventually leading to damage of self-tissues or organs. Control of auto-reactive T lymphocytes therefore constitutes an attractive therapeutic strategy. Many studies on accessory cells and their secreted factors have focused on their role in the effector phase of a specific autoimmunc disease. Recent data, however, support their causative role in triggering autoimmune diseases. In the past several years, several cytokines from activated accessory cells were demonstrated to promote the survival of pathogenic auto-reactive lymphocytes in animal models of MS, RA, and other autoimmune diseases. This review therefore focuses on the current knowledge regarding the role of those soluble survival factors in the initiation of different autoimmune diseases. C1 Harvard Univ, Sch Med, Dept Pathol, Dept Canc Immunol & AIDS,Dana Farber Canc Inst, Boston, MA 02115 USA. RP Tang, XL (reprint author), Harvard Univ, Sch Med, Dept Pathol, Dept Canc Immunol & AIDS,Dana Farber Canc Inst, Room SM722,44 Binney St, Boston, MA 02115 USA. EM xiaolei_tang@dfci.harvard.edu NR 225 TC 0 Z9 0 U1 0 U2 1 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 0929-8673 J9 CURR MED CHEM JI Curr. Med. Chem. PY 2007 VL 14 IS 7 BP 797 EP 809 DI 10.2174/092986707780090918 PG 13 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 143EQ UT WOS:000244703200006 PM 17346164 ER PT J AU Bandyopadhyay, S Goldstein, LE Lahiri, DK Rogers, JT AF Bandyopadhyay, S. Goldstein, L. E. Lahiri, D. K. Rogers, J. T. TI Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease SO CURRENT MEDICINAL CHEMISTRY LA English DT Review DE APP proteolysis; soluble sAPP alpha; ADAM activators; signaling; drug screens; interleukin-1 ID PROTEIN-KINASE-C; BETA PRECURSOR PROTEIN; FIBRILS IN-VITRO; NF-KAPPA-B; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MUSCARINIC ACETYLCHOLINE-RECEPTOR; CRITICALLY ATTAINED THRESHOLD; RNA 5'-UNTRANSLATED REGION; CEREBRAL CORTICAL-NEURONS; IRON-RESPONSIVE ELEMENT AB Alzheimer's disease (AD) is the most prevalent form of dementia, and its effective disease modifying therapies are desperately needed. Promotion of non-amyloidogenic alpha (secretase cleavage of amyloid precursor protein (APP) to release soluble sAPP based on the most widely accepted "amyloid model" as a plausible mechanism for AD treatment, is the focus of this review. Modulation of secretase or "a disintegrin and metalloprotease (ADAM)"s activity via protein kinase C (PKC), calcium ion (Ca2+), tyrosine kinase (TK), MAP kinase (MAPK), and hormonal signaling, which regulate catabolic processing of APP, are discussed. The inhibition of amyloidogenic processing of APP by the beta (and gamma (secretase has been considered till now a promising strategy to treat AD. But and secretase inhibitors, along with the available therapeutic tools for AD, have side effects. These challenges can be circumvented to certain extent; but activation of sAPP release appears to be a potential alternative strategy to reduce cerebral amyloidosis. Drug screens have been performed to identify therapeutics for AD, but an effective screening strategy to isolate activators of secretase has been rarely reported. Novel reporter-based screens targeted toward APP mRNA 5' untranslated region (UTR), followed by counter-screens to detect secretase stimulators, could be important in detecting compounds to promote sAPP release and reduce amyloid beta (A buildup. The primary inflammatory cytokine interleukin-1, which stimulates APP 5'UTR-directed translation of cell-associated APP, enhances processing to sAPP in astrocytes and co-activates ADAM-10/ADAM-17 through MAPK signaling; thus illustrating a novel pathway that could serve as therapeutic model for AD. C1 [Bandyopadhyay, S.; Rogers, J. T.] Massachusetts Gen Hosp, Dept Psychiat Neurosci & Genet, Neurochem Lab, Boston, MA 02114 USA. [Bandyopadhyay, S.; Rogers, J. T.] Massachusetts Gen Hosp, Aging Res Unit, Boston, MA USA. [Goldstein, L. E.] Harvard Univ, Sch Med, Psychiat Brigham & Womens Hosp, Cambridge, MA 02138 USA. [Lahiri, D. K.] Indiana Univ, Sch Med, Dept Psychiat, Inst Psychiat Res,Lab Mol Neurogenet, Indianapolis, IN 46204 USA. RP Rogers, JT (reprint author), Massachusetts Gen Hosp, Dept Psychiat Neurosci & Genet, Neurochem Lab, Boston, MA 02114 USA. EM jtrogers@rics.bwh.harvard.edu NR 336 TC 47 Z9 47 U1 2 U2 9 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 0929-8673 J9 CURR MED CHEM JI Curr. Med. Chem. PY 2007 VL 14 IS 27 BP 2848 EP 2864 DI 10.2174/092986707782360060 PG 17 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 268KH UT WOS:000253578200002 PM 18045131 ER PT J AU Blutt, SE Conner, ME AF Blutt, Sarah E. Conner, Margaret E. TI Rotavirus: to the gut and beyond! SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Article DE antigenemia; extraintestinal; rotavirus; systemic; viremia ID EXTRAINTESTINAL SPREAD; HISTOLOGIC DISTRIBUTION; NEONATAL MOUSE; VIREMIA; GASTROENTERITIS; ANTIGENEMIA; INFECTION; CHILDREN; EFFICACY; DIARRHEA AB Purpose of review Rotavirus causes severe gastroenteritis in children. A principle of rotavirus pathogenesis has been that the infection remains localized to epithelial cells in the small intestine. This dogma was challenged by recent findings of rotavirus in the serum of experimentally infected animals and children with diarrhea. Repeated associations of rotavirus infections with a wide range of nongastroenteric clinical manifestations in humans were considered spurious because of lack of proof that rotavirus escaped the intestine. New data outlined in this review, however, show that rotavirus routinely infects systemically and highlight controversies and future research questions. Recent findings Rotavirus antigens (antigenemia), RNA, or infectious virus (viremia) has been demonstrated in the serum and many extraintestinal tissues in all experimental animal models. Rotavirus antigens and RNA have been detected in the sera of children with rotavirus diarrhea. The tissues and cell types that support rotavirus replication outside the intestine and the consequences of extraintestinal reservoirs of infection are beginning to be examined. Summary Rotavirus infection is systemic, with an acute active viremia and extraintestinal replication. The impact of systemic rotavirus on disease burden remains to be determined. C1 Baylor Coll Med, Dept Mol Virol & Microbiol, Michael E Debakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Conner, ME (reprint author), Baylor Coll Med, Dept Mol Virol & Microbiol, Michael E Debakey Vet Affairs Med Ctr, 1 Baylor Plaza, Houston, TX 77030 USA. EM mconner@bcm.edu FU NIAID NIH HHS [AI10604, AI24998]; NIDDK NIH HHS [DK56338] NR 24 TC 62 Z9 66 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD JAN PY 2007 VL 23 IS 1 BP 39 EP 43 DI 10.1097/MOG.0b013e328011829d PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 127KH UT WOS:000243584200008 PM 17133083 ER PT J AU Levine, RL Gilliland, DG AF Levine, Ross L. Gilliland, D. Gary TI JAK-2 mutations and their relevance to myeloproliferative disease SO CURRENT OPINION IN HEMATOLOGY LA English DT Article DE essential thrombocytosis; JAK2 tyrosine kinase; myelofibrosis; myeloproliferative disorders; polycythemia vera; thrombopoietin receptor ID CHRONIC MYELOMONOCYTIC LEUKEMIA; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; ACTIVATING MUTATION; V617F MUTATION; PHILADELPHIA-CHROMOSOME; MYELOID METAPLASIA; STEM-CELLS; BCR-ABL AB Purpose of review The identification of the JAK2V617F allele greatly improved our understanding of the molecular pathogenesis of myeloproliferative disorders. This review focuses on recent studies offering new genetic, biochemical, and functional insight into the role of JAK2V617F in the pathogenesis of these disorders. Recent findings JAK2V617F mutations are present in almost all patients with polycythemia vera, and in approximately half of those with essential thrombocytosis and myelofibrosis. JAK2V617F has constitutive tyrosine kinase activity, and is able to transform hematopoietic cells and activate JAK-STAT signaling when co-expressed with homodimeric type I cytokine receptors. Murine bone marrow transplant experiments demonstrate that JAK2V617F is sufficient for the development of polycythemia vera in recipient mice. These results suggested that JAK-STAT pathway activation might contribute to the pathogenesis of JAK2-negative myeloproliferative disorders, and led to the discovery of an activating mutation in the thrombopoietin receptor in JAK2-negative myelofibrosis and essential thrombocytosis. Summary The discovery of the JAK2V617F allele represents an important advance in our understanding of the molecular pathogenesis of myeloproliferative disorders, though many questions remain regarding the role of a single allele in three clinically distinct disorders, the mechanism of activation of JAK2V617F, and the pathogenesis of JAK2-negative myeloproliferative disorders. C1 Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. RP Levine, RL (reprint author), Karp Family Res Labs, 1 Blackfan Circle,Room 5210, Boston, MA 02116 USA. EM ross_levine@dfci.harvard.edu NR 37 TC 29 Z9 32 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1065-6251 J9 CURR OPIN HEMATOL JI Curr. Opin. Hematol. PD JAN PY 2007 VL 14 IS 1 BP 43 EP 47 DI 10.1097/00062752-200701000-00009 PG 5 WC Hematology SC Hematology GA 118SH UT WOS:000242961500008 PM 17133099 ER PT J AU Kaufmann, DE Walker, BD AF Kaufmann, Daniel E. Walker, Bruce D. TI Treatment interruption to boost specific HIV immunity in acute infection SO CURRENT OPINION IN HIV AND AIDS LA English DT Article DE acute HIV infection; antiviral therapy; CD4 T cell; CD8 T cell; lymphoid tissue; supervised treatment interruption AB Purpose of review To understand the potential benefits and limitations of the treatment of acute, or primary, HIV infection followed by supervised treatment interruptions as a strategy to augment immune responses. Recent findings Although this strategy led to the short-term control of virus replication after treatment interruption, follow-up data showed limited durability of control, and additional studies of short-term treatment in primary HIV infection show either a modest or no long-term benefit on CD4 cell counts and viral loads when compared with no therapy. Studies of gut-associated lymphatic tissue provide insights into the limitations of this approach because there has already been a massive destruction of the CD4 memory T-cell compartment by the time of symptomatic primary HIV infection by AIDS-associated retroviruses, which occurs before the emergence of cellular immune responses. Summary There is currently no confirmed benefit of treatment of primary HIV infection by antiviral therapy alone in terms of disease progression and HIV-specific T-cell responses once therapy is interrupted. Supervised treatment interruption in acute HIV infection treated by antiviral therapy alone should probably not be used as a therapeutic strategy. This approach should be differentiated from early treatment itself, with or without immune augmentation, which deserves further investigation. C1 [Kaufmann, Daniel E.; Walker, Bruce D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr, Boston, MA USA. [Kaufmann, Daniel E.; Walker, Bruce D.] Harvard Univ, Sch Med, Div Aids, Boston, MA USA. [Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA. RP Kaufmann, DE (reprint author), Massachusetts Gen Hosp E, Partners AIDS Res Ctr, Room 6618B,149 13th St, Charlestown, MA 02129 USA. EM dkaufmann@partners.org NR 46 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1746-630X J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD JAN PY 2007 VL 2 IS 1 BP 21 EP 25 DI 10.1097/COH.0b013e3280119275 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA V24NR UT WOS:000208417600004 PM 19372861 ER PT J AU Dutt, A Beroukhim, R AF Dutt, Amit Beroukhim, Rameen TI Single nucleotide polymorphism array analysis of cancer SO CURRENT OPINION IN ONCOLOGY LA English DT Review DE cancer; copy number variation; loss of heterozygosity; SNP array ID PROSTATE-CANCER; COPY NUMBER; OLIGONUCLEOTIDE ARRAYS; HETEROZYGOSITY ANALYSIS; MICROARRAY TECHNOLOGY; UNIPARENTAL DISOMY; GENOTYPING ARRAYS; MENDELIAN DISEASE; HUMAN GENOME; AMPLIFICATION AB Purpose of review Classifying tumors and identifying therapeutic targets requires a description of the genetic changes underlying cancer, Single nucleotide polymorphism (SNP) arrays provide a high-resolution platform for describing several types of genetic changes simultaneously. With the resolution of these arrays increasing exponentially, they are becoming increasingly powerful tools for describing the genetic events underlying cancer. Recent findings The ability to map loss of heterozygosity (LOH) and overall copy number variations using SNP arrays is known. Techniques have recently been developed to map LOH at high resolution in the absence of paired normal data. Copy number variations described by SNP array studies are now reaching resolutions enabling the identification of novel oncogenes and tumor suppressor genes. The ability to determine allele-specific copy number changes has only recently been described. Moreover, SNP arrays offer a high-throughput platform for large-scale association studies that are likely to lead to the identification of multiple germline variants that predispose to cancer. Summary SNP arrays are an ideal platform for identifying both somatic and germline genetic variants that lead to cancer. They provide a basis for DNA-based cancer classification and help to define the genes being modulated, improving understanding of cancer genesis and potential therapeutic targets. C1 Harvard Univ, Broad Inst, Cambridge, MA 02142 USA. MIT, Cambridge, MA 02142 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. RP Beroukhim, R (reprint author), Harvard Univ, Broad Inst, 7CC, Cambridge, MA 02142 USA. EM rameen@broad.mit.edu RI Dutt, Amit/I-1911-2013 OI Dutt, Amit/0000-0002-1119-4774 NR 45 TC 70 Z9 73 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8746 J9 CURR OPIN ONCOL JI Curr. Opin. Oncol. PD JAN PY 2007 VL 19 IS 1 BP 43 EP 49 DI 10.1097/CCO.0b013e328011a8c1 PG 7 WC Oncology SC Oncology GA 119ZW UT WOS:000243054000008 PM 17133111 ER PT J AU Maree, AO Jneid, H Palacios, IF Rosenfield, K MacRae, CA Fitzgerald, DJ AF Maree, Andrew O. Jneid, Hani Palacios, Igor F. Rosenfield, Kenneth MacRae, Calum A. Fitzgerald, Desmond J. TI Growth arrest specific gene (GAS) 6 modulates platelet thrombus formation and vascular wall homeostasis and represents an attractive drug target SO CURRENT PHARMACEUTICAL DESIGN LA English DT Review ID RECEPTOR TYROSINE KINASE; SMOOTH-MUSCLE-CELLS; ACUTE CORONARY SYNDROMES; CENTRAL-NERVOUS-SYSTEM; CARDIOVASCULAR-DISEASE; PROTEIN-S; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; SURVIVAL PATHWAY; TYRO-3 FAMILY AB GAS6, the product of growth arrest specific (GAS) gene 6 is a ligand for the tyrosine protein kinase receptors Ax1, Tyro3 and Mer whose signaling has been implicated in cell growth, survival, adhesion and migration. Although a secreted human vitamin K-dependent protein with close structural similarity with protein S, GAS6 does not exhibit anticoagulant properties but rather may be an important regulator of vascular homeostasis and platelet signaling. GAS6 signals via its receptor tyrosine kinases and appears to modulate platelet outside-in signaling via GP alpha(III),beta(III), playing a key role in the perpetuation of platelet aggregates and clot retraction. GAS6 is also implicated in foam cell formation and neointimal proliferation in response to vascular injury. Thus GAS6 acts at key points in the pathophysiology of atherosclerosis and thrombosis; two processes implicated in most acute cardiovascular pathology. Inhibition of GAS6 or its receptors may provide antithrombotic activity in the absence of increased bleeding and thus presents an attractive drug target. GAS6 signaling may be modulated through direct antibody inhibition, blockade of its receptors or GAS6 trapping. However, ubiquitous expression of GAS6 and its receptors and the diverse biological effects of the pathway may make selective drug targeting difficult. C1 Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Charlestown, MA USA. Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA. Univ Coll Dublin, Conway Inst, Dublin 2, Ireland. RP Maree, AO (reprint author), Massachusetts Gen Hosp, Div Cardiol, GRB 843,55 Fruit St, Boston, MA 02114 USA. EM amaree@mgh.harvard.edu NR 79 TC 12 Z9 14 U1 0 U2 4 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PY 2007 VL 13 IS 26 BP 2656 EP 2661 DI 10.2174/138161207781662948 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 208TE UT WOS:000249341300004 PM 17897008 ER PT J AU Komatsuzawa, H Ouhara, K Kawai, T Yamada, S Fujiwara, T Shiba, H Kurihara, H Taubman, MA Sugai, M AF Komatsuzawa, Hitoshi Ouhara, Kazuhisa Kawai, Toshihisa Yamada, Sakuo Fujiwara, Tamaki Shiba, Hideki Kurihara, Hidemi Taubman, Martin A. Sugai, Motoyuki TI Susceptibility of periodontopathogenic and cariogenic bacteria to Defensins and potential therapeutic use of Defensins in oral diseases SO CURRENT PHARMACEUTICAL DESIGN LA English DT Review DE antimicrobial peptides; caries; periodontitis; oral bacteria ID HUMAN BETA-DEFENSINS; ANTIMICROBIAL PEPTIDE EXPRESSION; GINGIVAL EPITHELIAL-CELLS; OUTER-MEMBRANE PROTEIN-100; HUMAN NEUTROPHIL DEFENSINS; CORONARY HEART-DISEASE; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; PERIODONTAL-DISEASE; PORPHYROMONAS-GINGIVALIS; HUMAN BETA-DEFENSIN-2 AB Antimicrobial peptides play an important role in the human innate immune defense system. In the oral cavity, a number of antimicrobial peptides, including defensins and LL37, are produced from various tissues such as salivary glands, gingival epithelium, tongue and buccal mucosa. These peptides are believed to function as a host defense system by controlling the activities of commensal bacteria and thus preventing the colonization and growth of pathogenic bacteria in oral cavity. Two major oral diseases, dental caries and periodontitis are known as infectious diseases. Therefore, it is of great interest to elucidate the mechanisms underlying the onset and progression of these diseases by investigating the interaction between cariogenic, or periodontopathogenic bacteria and antimicrobial peptides. Since these peptides have a broad antimicrobial spectrum, they are implicated as possible therapeutic agents. Therefore, in this review, we first focus on the susceptibility of oral bacteria, especially cariogenic and periodontopathogenic bacteria, to antimicrobial peptides, and then we discuss their potential diagnostic and clinical therapeutic uses. C1 Hiroshima Univ, Grad Sch Biomed Sci, Dept Bacteriol, Minami Ku, Hiroshima, Hiroshima 7348553, Japan. Hiroshima Univ, Grad Sch Biomed Sci, Dept Periodontal Med, Minami Ku, Hiroshima, Hiroshima 7348553, Japan. Forsyth Inst, Dept Immunol, Boston, MA 02115 USA. Kawasaki Med Univ, Dept Microbiol, Okayama 7010192, Japan. RP Komatsuzawa, H (reprint author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Bacteriol, Minami Ku, Kasumi 1-2-3, Hiroshima, Hiroshima 7348553, Japan. EM hkomatsu@hiroshima-u.acjp NR 186 TC 18 Z9 20 U1 1 U2 2 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PY 2007 VL 13 IS 30 BP 3084 EP 3095 DI 10.2174/138161207782110426 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 226EP UT WOS:000250570600005 PM 17979751 ER PT S AU Kow, LM Florea, C Schwanzel-Fukuda, M Devidze, N Kia, HK Lee, A Zhou, J MacLaughlin, D Donahoe, P Pfaff, D AF Kow, Lee-Ming Florea, Cristina Schwanzel-Fukuda, Marlene Devidze, Nino Kia, Hosein Kami Lee, Anna Zhou, Jin MacLaughlin, David Donahoe, Patricia Pfaff, Donald BE Schatten, GP TI Development of a Sexually Differentiated Behavior and Its Underlying CNS Arousal Functions SO CURRENT TOPICS IN DEVELOPMENTAL BIOLOGY, VOL 79 SE Current Topics in Developmental Biology LA English DT Review; Book Chapter ID MULLERIAN-INHIBITING SUBSTANCE; HORMONE-RELEASING HORMONE; CENTRAL-NERVOUS-SYSTEM; RIBONUCLEIC-ACID EXPRESSION; HUMAN OVARIAN-CANCER; BLOOD-BRAIN-BARRIER; FETAL-RAT LUNG; II RECEPTOR; IN-VIVO; LEYDIG-CELLS AB This chapter addresses questions regarding lordosis behavior, the most extremely sexually differentiated behavior that has been analyzed for its neural and molecular mechanisms. Analysis of this behavior has proved for the first time that specific biochemical reactions in specific nerve cell groups in the brain determine a mammalian behavior. Lordosis is done by the female but not by the male. How did the process of sexual differentiation occur? A large literature implicates high levels of testosterone during a critical period during development as being responsible for the defeminization of the brain. A new idea, however, offers the possibility of direct genetic influences independent of testosterone levels themselves. We propose here that Mullerian Inhibiting Substance (MIS) and its receptors could constitute an example of a nonandrogenic genetic influence. Further, specific sexual behaviors depend on underlying arousal states in the central nervous system (CNS). We have proposed the concept of generalized CNS arousal and provide information as to how generalized arousal forces interact with specifically sexual influences, thus to facilitate sexually differentiated mating behaviors. (C) 2007, Elsevier Inc. C1 [Kow, Lee-Ming; Florea, Cristina; Schwanzel-Fukuda, Marlene; Devidze, Nino; Kia, Hosein Kami; Lee, Anna; Zhou, Jin; Pfaff, Donald] Rockefeller Univ, Neurobiol & Behav Lab, New York, NY 10021 USA. [MacLaughlin, David; Donahoe, Patricia] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Surg, Boston, MA 02114 USA. RP Kow, LM (reprint author), Rockefeller Univ, Neurobiol & Behav Lab, 1230 York Ave, New York, NY 10021 USA. NR 71 TC 4 Z9 4 U1 2 U2 7 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0070-2153 BN 978-0-12-373913-1 J9 CURR TOP DEV BIOL JI Curr. Top. Dev. Biol. PY 2007 VL 79 BP 37 EP 59 DI 10.1016/S0070-2153(06)79002-0 PG 23 WC Developmental Biology SC Developmental Biology GA BQB84 UT WOS:000280599800002 PM 17498546 ER PT J AU Bargagna-Mohan, P Mohan, R Russo, L Kochevar, IE Fini, ME AF Bargagna-Mohan, Paola Mohan, Royce Russo, Laoti Kochevar, Irene E. Fini, M. Elizabeth TI Cell lines and transgenic mice expressing a matrix metalloproteinase-9 promoter-driven reporter gene: Potential for assay of ultraviolet light effects and light-inhibiting compounds SO CUTANEOUS AND OCULAR TOXICOLOGY LA English DT Article DE cell lines; cornea; MMP; skin; transcriptional promoter; transgenic mice; ultraviolet light ID METALLOPROTEINASE-GELATINASE-B; MATRIX METALLOPROTEINASES; IV COLLAGENASE; CORNEAL CELLS; MMP-9; MOUSE; SKIN; TRANSCRIPTION; INVOLVEMENT; ACTIVATION AB Acute and chronic exposure to ultraviolet (UV) wavelengths in sunlight can cause adverse reactions in exposed areas of the skin and corneas. UV exposure up-regulates the synthesis of Matrix Metalloproteinses (MMPs) and evidence suggests these enzymes mediate tissue damage. Therefore MMP gene activity can serve as a surrogate marker for bioassays. In this study, we tested the possible utility for this purpose of two stably transfected cell lines (from mouse keratinocytes and rabbit epithelial-like corneal cells) and a transgenic mouse line (line 3445), each harboring a DNA construct containing a bacterial beta-galactosidase (LacZ) reporter gene driven by the rabbit MMP-9 transcriptional promoter. We observed only a weak 2-fold maximal induction of LacZ reporter gene expression in the mouse epidermal cell line after exposure to UV-B irradiation (5, 10, 40 mJ/cm(2)) and no significant expression of the reporter gene in the rabbit epithelial-like cell line. Similarly negative results were obtained when primary corneal epithelial cells from human and rabbit were exposed to different doses of UV-B irradiation and endogenous MMP-9 gene expression was assayed by zymography and immunoprecipitation analysis. In contrast, when skin from 3-day-old transgenic mouse line 3445 was exposed to UV-B and UV-A, a clear dose-dependent induction of the LacZ reporter gene occurred and the location of gene expression was dependent on the wave-length of irradiation. These results suggest that line 3445 transgenic mice may serve as a useful tool to quantitatively and qualitatively assess the biological effects of UV light and the efficacy of therapeutic agents. C1 [Bargagna-Mohan, Paola; Mohan, Royce; Russo, Laoti; Fini, M. Elizabeth] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL USA. [Kochevar, Irene E.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Harvard Med Sch, Boston, MA 02114 USA. RP Fini, ME (reprint author), 1638 NW 10th Ave, Miami, FL 33136 USA. EM efini@med.miami.edu FU NEI NIH HHS [EY12651, P30 EY14801]; NIAMS NIH HHS [AR42981] NR 55 TC 1 Z9 1 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1556-9527 J9 CUTAN OCUL TOXICOL JI Cutan. Ocul. Toxicol. PY 2007 VL 26 IS 4 BP 383 EP 397 DI 10.1080/15569520701662924 PG 15 WC Ophthalmology; Toxicology SC Ophthalmology; Toxicology GA 242UF UT WOS:000251751000010 PM 18058311 ER PT J AU Hodge, JC Lawson-Yuen, A Stoler, JM Ligon, AH AF Hodge, J. C. Lawson-Yuen, A. Stoler, J. M. Ligon, A. H. TI Molecular studies of segmental aneusomy: FISHing for the atypical cry in del(5)(p15.3) SO CYTOGENETIC AND GENOME RESEARCH LA English DT Article ID DU-CHAT SYNDROME; PARTIAL TRISOMY 11Q; DUPLICATION; 5P; PHENOTYPE; DELETION; PATIENT; TRANSLOCATION; CHILD AB We report a newborn male with multiple congenital anomalies including growth retardation, hypotonia, dysmorphic facies, widely-spaced nipples, micropenis, cryptorchidism, optic nerve hypoplasia, heart disease, and a striking, high-pitched cry. Chromosome analysis revealed de novo partial trisomy 11q due to a der(5)t(5;11)(p15.3;q22). Fluorescence in situ hybridization ( FISH) showed loss of the 5p telomere signal on the der(5) chromosome, indicating the infant has partial monosomy 5p in addition to partial trisomy 11q. Among cases involving trisomy 11q, an unusual cry has only been documented in the presence of a der(5)t(5p;11q). This apparent dependence of the abnormal cry on monosomy 5p suggested the same genetic mechanism that occurs in Cri du chat syndrome (CDCS) may be responsible for the atypical cry in der(5)t(5p;11q) individuals. Neither a commercial CDCS probe (LSI D5S23, D5S721) nor a series of BAC clones encompassing distal regions implicated in the CDCS-associated cat-cry were deleted in our patient. These results suggest a second cry-modifying locus maps telomeric to BAC RP11-94J21 in band 5p15.33. This locus may not only cause the abnormal cry in individuals with a der(5)t(5p;11q) but could also contribute to the phenotypic variability and discordant mapping studies observed for CDCS. Copyright (C) 2007 S. Karger AG, Basel. C1 [Hodge, J. C.; Lawson-Yuen, A.; Stoler, J. M.; Ligon, A. H.] Harvard Med Sch, Boston, MA 02115 USA. [Hodge, J. C.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Ligon, A. H.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Lawson-Yuen, A.; Stoler, J. M.] Massachusetts Gen Hosp, Dept Pediat, Genet Serv, Cambridge, MA 02139 USA. [Lawson-Yuen, A.] Childrens Hosp Boston, Div Genet, Boston, MA USA. RP Hodge, JC (reprint author), Harvard Med Sch, 77 Ave Louis Pasteur, New Res Bldg,Rm 160, Boston, MA 02115 USA. EM jhodge1@partners.org FU NIGMS NIH HHS [T32-GM07748] NR 20 TC 2 Z9 2 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-8581 J9 CYTOGENET GENOME RES JI Cytogenet. Genome Res. PY 2007 VL 119 IS 1-2 BP 15 EP 20 DI 10.1159/000109613 PG 6 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA 245BO UT WOS:000251909600004 PM 18160776 ER PT J AU Edwards, K Royall, D Hershey, L Lichter, D Hake, A Farlow, M Pasquier, F Johnson, S AF Edwards, Keith Royall, Donald Hershey, Linda Lichter, David Hake, Ann Farlow, Martin Pasquier, Florence Johnson, Stewart TI Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 24-week open-label study SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE dementia with Lewy bodies; galantamine; cholinesterase inhibitors; visual hallucinations ID NICOTINIC ACETYLCHOLINE-RECEPTORS; ALZHEIMERS-DISEASE; SCALE; BODY; CONSORTIUM; INVENTORY; CLINICIAN; DIAGNOSIS; STRIATUM; THALAMUS AB Background: Dementia with Lewy bodies (DLB) is a common dementia of the elderly. A significant cholinergic deficit has been demonstrated that may be responsive to treatment by cholinesterase inhibitors (ChEIs). Methods: A 24-week, open-label study was designed to assess the efficacy and safety of a ChEI, galantamine, in 50 patients with DLB. Results: This study showed beneficial effects with galantamine in 2 of the 3 primary efficacy parameters. The scores on the Neuropsychiatric Inventory (NPI-12) improved by 8.24 points from baseline ( p = 0.01) especially in visual hallucinations and nighttime behaviors ( p = 0.004). The scores on the Clinician's Global Impression of Change improved by 0.5 points from baseline ( p = 0.01). The third primary efficacy parameter, the Cognitive Drug Research Computerized Cognitive Assessment System, was unchanged from baseline. Adverse events were generally mild and transient. Conclusion: Galantamine appears to be an effective and safe therapy for patients with DLB. Copyright (c) 2007 S. Karger AG, Basel. C1 Neurol Res Ctr Inc, Alzheimers Diagnost & Treatment Ctr, Bennington, VT 05201 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Affairs Hosp, San Antonio, TX USA. Buffalo Vet Affairs Hosp, Dept Neurol, Buffalo, NY USA. Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA. Williams Coll, Dept Math, Williamstown, MA 01267 USA. CHU Lille, Neurol Clin, EA 2691, F-59037 Lille, France. RP Edwards, K (reprint author), Neurol Res Ctr Inc, Alzheimers Diagnost & Treatment Ctr, 140 Hosp Dr,Suite 210, Bennington, VT 05201 USA. EM kedwards@vtneuro.com NR 28 TC 31 Z9 31 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2007 VL 23 IS 6 BP 401 EP 405 DI 10.1159/000101512 PG 5 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 166QN UT WOS:000246394200007 PM 17409748 ER PT J AU Houser, CR AF Houser, Carolyn R. TI Interneurons of the dentate gyrus: an overview of cell types, terminal fields and neurochemical identity SO DENTATE GYRUS: A COMPHREHENSIVE GUIDE TO STRUCTURE, FUNCTION, AND CLINICAL IMPLICATIONS SE PROGRESS IN BRAIN RESEARCH LA English DT Review DE GABA; glutamate decarboxylase (GAD); interneurons; hilus; parvalbumin; somatostatin; calretinin ID GLUTAMIC-ACID DECARBOXYLASE; RAT HIPPOCAMPAL-FORMATION; NERVE GROWTH-FACTOR; SOMATOSTATIN-LIKE IMMUNOREACTIVITY; GABAERGIC NONPRINCIPAL NEURONS; GAMMA-AMINOBUTYRIC-ACID; GABA(A) RECEPTOR; MESSENGER-RNAS; MEDIAL SEPTUM; POSTSYNAPTIC TARGETS AB Interneurons of the dentate gyrus are a diverse group of neurons that use GABA as their primary neurotransmitter. Morphological studies of these neurons have been challenging since no single neuro-anatomical method provides a complete view of these interneurons. However, through the integration of findings obtained from multiple methods, an interesting picture of this complex group of neurons is emerging, and this review focuses on studies in rats and mice. In situ hybridization of mRNAs for the two isoforms of the GABA synthesizing enzyme, glutamate decarboxylase (GAD65 and GAD67), demonstrates the abundance of GABA neurons in the dentate gyrus and their high concentration in the hilus and along the base of the granule cell layer. Likewise, immunohistochemical studies, particularly of GAD65, demonstrate the rich fields of GABA terminals not only around the somata of granule cells but also in the dendritic regions of the molecular layer. This broad group of GABA neurons and their terminals can be subdivided according to their morphological characteristics, including the distribution of their axonal plexus, and their neurochemical identity. Intracellular labeling of single interneurons has been instrumental in demonstrating the extensiveness of their axonal plexus and the relatively specific spatial distribution of their axonal fields. These findings have led to the broad classification of interneurons into those that terminate primarily at perisomatic regions and those that innervate the dendrites of granule cells. The interneurons also can be classified according to their neuropeptide and calcium-binding protein content. These and other molecules contribute to the rich diversity of dentate interneurons and may provide opportunities for selectively regulating specific groups of GABA neurons in the dentate gyrus in order to enhance their function or protect vulnerable neurons from damage. C1 [Houser, Carolyn R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Houser, Carolyn R.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Houser, Carolyn R.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. RP Houser, CR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. EM houser@mednet.ucla.edu FU NINDS NIH HHS [NS046524, NS051311] NR 81 TC 80 Z9 80 U1 2 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0079-6123 J9 PROG BRAIN RES PY 2007 VL 163 BP 217 EP + DI 10.1016/S0079-6123(07)63013-1 PG 17 WC Neurosciences SC Neurosciences & Neurology GA BHB02 UT WOS:000251961200014 PM 17765721 ER PT J AU Pollack, MH Lepola, U Koponen, H Simon, NM Worthington, JJ Emilien, G Tzanis, E Salinas, E Whitaker, T Gao, B AF Pollack, Mark H. Lepola, Ulla Koponen, Hamm Simon, Naomi M. Worthington, John J. Emilien, Gerard Tzanis, Evan Salinas, Eliseo Whitaker, Timothy Gao, Bo TI A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder SO DEPRESSION AND ANXIETY LA English DT Article DE panic disorder; venlafaxine ER; anxiety; paroxetine ID GENERALIZED ANXIETY DISORDER; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM TREATMENT; QUALITY-OF-LIFE; SEROTONIN REUPTAKE INHIBITORS; MAJOR DEPRESSION; DOSE-RESPONSE; PRIMARY-CARE; NONDEPRESSED OUTPATIENTS; MULTICENTER TRIAL AB To date, no large-scale, controlled trial comparing a serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor with placebo for the treatment of panic disorder has been reported. This double-blind study compares the efficacy of venlafaxine extended-release (ER) and paroxetine with placebo. A total of 664 nondepressed adult outpatients who met DSM-IV criteria for panic disorder (with or without agoraphobia) were randomly assigned to 12 weeks of treatment with placebo or fixed-dose venlafaxine ER (75 mg/day or 150 mg/day), or paroxetine 40 mg/day. The primary measure was the percentage of patients free from full-symptom panic attacks, assessed with the Panic and Anticipatory Anxiety Scale (PAAS). Secondary measures included the Panic Disorder Severity Scale, Clinical Global Impressions-Severity (CGI-S) and Improvement (CGI-I) scales; response (CGI-I rating of very much improved or much improved), remission (CGI-S rating of not at all ill or borderline ill and no PAAS full-symptom panic attacks); and measures of depression, anxiety, phobic fear and avoidance, anticipatory anxiety, functioning, and quality of life. Intent-to-treat, last observation carried forward analysis showed that mean improvement on most measures was greater with venlafaxine ER or paroxetine than with placebo. No significant differences were observed between active treatment groups. Panic-free rates at end point with active treatment ranged from 54% to 61%, compared with 35% for placebo. Approximately 75% of patients given active treatment were responders, and nearly 45% achieved remission. The placebo response rate was slightly above 55%, with remission near 25%. Adverse events were mild or moderate and similar between active treatment groups. Venlafaxine ER and paroxetine were effective and well tolerated in the treatment of panic disorder. C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Helsinki, Dept Psychiat, SF-00180 Helsinki, Finland. Univ Oulu, Dept Psychiat, Oulu, Finland. Wyeth Res, Paris, France. Wyeth Pharmaceut, Collegeville, PA USA. RP Pollack, MH (reprint author), Massachusetts Gen Hosp, WAC-B12,15 Parkham St, Boston, MA 02114 USA. EM mpollack@partners.org NR 66 TC 46 Z9 49 U1 6 U2 13 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2007 VL 24 IS 1 BP 1 EP 14 DI 10.1002/da.20218 PG 14 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 137BY UT WOS:000244269000002 PM 16894619 ER PT J AU Grubaugh, AL Elhai, JD Cusack, KJ Wells, C Frueh, BC AF Grubaugh, Anouk L. Elhai, Jon D. Cusack, Karen J. Wells, Chris Frueh, B. Christopher TI Screening for PTSD in public-sector mental health settings: The diagnostic utility of the PTSD checklist SO DEPRESSION AND ANXIETY LA English DT Article DE severe mental illness; trauma; PTSD; PCL; ROC; public psychiatric settings ID POSTTRAUMATIC-STRESS-DISORDER; PSYCHOMETRIC PROPERTIES; TRAUMA; ILLNESS; WOMEN; VICTIMIZATION; HISTORY; RELIABILITY; PREVALENCE; VALIDITY AB There are few available data on bow to accurately screen for and assess posttraumatic stress disorder (PTSD) among severely mentally ill adults, a group with high rates of unrecognized trauma and PTSD symptoms. We examined the diagnostic utility of a widely used screening instrument, the PTSD Checklist (PCL), for diagnosing PTSD among 44 traumatized, adult, public-sector mental health patients recruited through a community mental health program. Participants completed the PCL and the Clinician-Administered PTSD Scale (CAPS), which is considered the "gold standard" for determining PTSD diagnoses. Data provide preliminary support for the use of the PCL as a screening instrument in public psychiatric settings, indicating that the optimal cut-point for adults with severe mental illness is about 54 (with slightly higher or lower recommended cut-points depending on the clinical context and purpose of the PCL). Such data are critical to ensuring that public-sector mental health patients with trauma-related difficulties are identified and referred for appropriate services. C1 Med Univ S Carolina, Div Publ Psychiat, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. Univ S Dakota, Disaster Mental Hlth Inst, Vermillion, SD 57069 USA. Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA. S Carolina Dept Mental Hlth, Charleston, SC USA. RP Grubaugh, AL (reprint author), Med Univ S Carolina, Div Publ Psychiat, Dept Psychiat & Behav Sci, 67 President St,POB 250861, Charleston, SC 29425 USA. EM grubaugh@musc.edu FU NIMH NIH HHS [MH65248] NR 27 TC 36 Z9 39 U1 7 U2 12 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2007 VL 24 IS 2 BP 124 EP 129 DI 10.1002/da.20226 PG 6 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 149LE UT WOS:000245147600006 PM 16892418 ER PT J AU Hoge, EA Austin, ED Pollack, MH AF Hoge, Elizabeth A. Austin, Eloise D. Pollack, Mark H. TI Resilience: Research evidence and conceptual considerations for posttraumatic stress disorder SO DEPRESSION AND ANXIETY LA English DT Review DE resilience; hardiness; posttraumatic stress disorder; trauma; anxiety ID URINARY CORTISOL EXCRETION; VIETNAM COMBAT VETERANS; QUALITY-OF-LIFE; PERITRAUMATIC DISSOCIATION; RISK-FACTORS; DEHYDROEPIANDROSTERONE-SULFATE; PLASMA NOREPINEPHRINE; CATECHOLAMINE EXCRETION; PROTECTIVE FACTORS; SYMPTOM SEVERITY AB The growing recognition and occurrence of traumatic exposure in the general population has given increased salience to the need to understand the concept of resilience. More than just the 'flip side" of a risk factor, the notion of resilience encompasses psychological and biological characteristics, intrinsic to an individual, that might be modifiable and that confer protection against the development of psychopathology in the face of stress. In this review, we provide some perspective on the concept of "resilience" by examining early use of the term in research on "children at risk" and discuss the relationship between risk and resilience factors. We then review psychological and biological factors that may confer resilience to the development of posttraumatic stress disorder (PTSD) following trauma, examine bow resilience has been assessed and measured, and discuss issues to be addressed in furthering our understanding of this critical concept going forward. C1 Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, Dept Psychiat, Boston, MA 02114 USA. RP Hoge, EA (reprint author), Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, Dept Psychiat, Simches Res Bldg,185 Cambridge St,Suite 2200, Boston, MA 02114 USA. EM ehoge@partners.org RI Hoge, Elizabeth/H-5879-2012 OI Hoge, Elizabeth/0000-0002-5513-2292 NR 131 TC 88 Z9 90 U1 9 U2 39 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2007 VL 24 IS 2 BP 139 EP 152 DI 10.1002/da.20175 PG 14 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 149LE UT WOS:000245147600008 PM 16892420 ER PT J AU Charney, ME Orazem, RJ Keane, TM AF Charney, Meredith E. Orazem, Robert J. Keane, Terence M. TI Mississippi scale for combat-related PTSD: Analysis of factor structure SO DEPRESSION AND ANXIETY LA English DT Meeting Abstract ID POSTTRAUMATIC-STRESS-DISORDER C1 Boston Univ, Sch Med, VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA 02118 USA. NR 5 TC 0 Z9 0 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2007 VL 24 IS 4 BP 285 EP 286 PG 2 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 187GS UT WOS:000247836200016 ER PT J AU Orazem, RJ Charney, ME Keane, TM AF Orazem, Robert J. Charney, Meredith E. Keane, Terence M. TI Mississippi scale for combat-related PTSD: Analysis of reliability and validity SO DEPRESSION AND ANXIETY LA English DT Meeting Abstract ID POSTTRAUMATIC-STRESS-DISORDER; VETERANS C1 Boston Univ, Sch Med, Natl Ctr Posttraumat Stress Disorders, VA Boston Healthcare Syst, Boston, MA 02215 USA. NR 12 TC 0 Z9 0 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2007 VL 24 IS 5 BP 360 EP 362 PG 3 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 209CW UT WOS:000249367100011 ER PT J AU Farabaugh, A Mischoulon, D Schwartz, F Pender, M Fava, M Alpert, J AF Farabaugh, Amy Mischoulon, David Schwartz, Faye Pender, Maribeth Fava, Maurizio Alpert, Jonathan TI Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD SO DEPRESSION AND ANXIETY LA English DT Article DE dysfunctional attitudes; depressions; personality disorders ID COGNITIVE-BEHAVIOR-THERAPY; MAJOR DEPRESSION; OUTPATIENTS; PATHOLOGY; RELAPSE; SCALE; STATE AB A key component of how depression may impact personality pathology involves an understanding of how cognition and dysfunctional attitudes may change as a result of experiencing a depressive state, and how these changes may affect reporting of personality disorder symptoms. This study examines whether dysfunctional attitudes are related to the stability of personality disorder diagnoses. The sample comprised 64 outpatients who were treatment responders following an 8-week acute treatment phase for major depressive disorder (MDD), met criteria for remission throughout a 26-week continuation phase, and completed a personality disorder assessment Structured Clinical Interview for DSM-III-R Axis II Disorders (SCID-II) at the beginning and end of each treatment phase. The Dysfunctional Attitude Scale (DAS) was given to patients at the beginning of the continuation phase. We found that following successful treatment of the MDD, individuals with stable personality disorder diagnoses (e.g., meeting criteria for a personality disorder at both the beginning and endpoint of continuation treatment) had greater severity of dysfunctional attitudes (P =.001) at the beginning of the continuation treatment compared to those who never met criteria for a personality disorder during continuation treatment. Though there was no significant relationship between DAS scores and the stability of a Cluster A or Cluster B personality disorder diagnosis, there was a significant relationship between DAS scores and the stability of a Cluster C personality disorder diagnosis (P <. 001). Outpatients who had a stable Cluster C personality disorder diagnosis had higher scores on the DAS at the beginning of continuation treatment compared to outpatients who never met criteria for a Cluster C diagnosis. This finding suggests that dysfunctional attitudes that persist beyond remission of MDD may be a marker for certain personality disorders that are stable across long-term treatment. Depression and Anxiety 24:433-439, 2007. Published 2006 Wiley-Liss, Inc. C1 Massachusetts Gen Hosp, Dept Psychiat, Depress & Clin Res Program, Boston, MA 02114 USA. RP Farabaugh, A (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Depress & Clin Res Program, 15 Parkman St,WAC 812, Boston, MA 02114 USA. EM afarabaugh@partners.org OI Alpert, Jonathan/0000-0002-4332-908X FU NIMH NIH HHS [R01MH48483-05] NR 34 TC 7 Z9 9 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2007 VL 24 IS 6 BP 433 EP 439 DI 10.1002/da.20174 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 219JI UT WOS:000250080400007 PM 17086540 ER PT J AU Cannistraro, PA Makris, N Howard, JD Wedig, MM Hodge, SM Wilhelm, S Kennedy, DN Rauch, SL AF Cannistraro, Paul A. Makris, Nikos Howard, James D. Wedig, Michelle M. Hodge, Steven M. Wilhelm, Sabine Kennedy, David N. Rauch, Scott L. TI A diffusion tensor imaging study of white matter in obsessive-compulsive disorder SO DEPRESSION AND ANXIETY LA English DT Article DE magnetic resonance imaging; anxiety disorders; neurosurgery; cingulotomy; capsulotomy; cingulum bundle; anterior limb of the internal capsule ID GLUCOSE METABOLIC RATES; DEEP BRAIN-STIMULATION; CEREBRAL BLOOD-FLOW; ELECTRICAL-STIMULATION; SYMPTOM PROVOCATION; INTERNAL CAPSULES; ANTERIOR LIMBS; NUCLEUS; ABNORMALITIES; ACCURATE AB Our objective was to test for differences between subjects with obsessive-compulsive disorder (OCD) and healthy controls with respect to white matter architecture within the cingulum bundle (CB) and anterior limb of the internal capsule (ALIC). We studied eight subjects with active OCD and 10 matched healthy controls using diffusion tensor magnetic resonance, imaging (DT-MRI) at 1.5 T (Tesla). Fractional anisotropy (FA) was evaluated in both CB and ALIC. Both voxelwise and region-of-interest methods of analysis were employed. Within both the left CB and the left ALIC, subjects with OCD exhibited significantly greater FA than healthy controls. In the rig-fit CB, subjects with OCD exhibited significantly decreased FA versus healthy control subjects. Additionally, the OCD group exhibited abnormal asymmetry (left > right) of FA in the CB. These results provide preliminary evidence for abnormal architecture within the CB and ALIC in OCD. FA differences in these areas are consistent with the presence of abnormal connections between the nodes linked by these tracts. This could explain why surgically severing these tracts is therapeutic. Additional studies are needed to replicate these findings and to clarify their pathological and clinical significance. Depression and Anxiety 24:440-446, 2007. Publisbed 2006 Wiley-Liss, Inc. C1 Massachusetts Gen Hosp, Psychiat Neuroimaging Res Program, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Ctr Morphometr Anal, Charlestown, MA USA. Athinoula Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Rauch, SL (reprint author), Massachusetts Gen Hosp, Psychiat Neuroimaging Res Program, Bldg 149,13th St,Room 2618, Charlestown, MA 02129 USA. EM rauch@psych.mgh.harvard.edu RI Kennedy, David/H-3627-2012 FU NIBIB NIH HHS [EB001632-01]; NIMH NIH HHS [MH-60219] NR 49 TC 81 Z9 83 U1 0 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2007 VL 24 IS 6 BP 440 EP 446 DI 10.1002/da.20246 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 219JI UT WOS:000250080400008 PM 17096398 ER PT J AU Wall, TL Grassi, AM Avram, MM AF Wall, Tomi L. Grassi, Anita M. Avram, Mathew M. TI Clearance of multiple venous lakes with an 800-nm diode laser: A novel approach SO DERMATOLOGIC SURGERY LA English DT Editorial Material ID CRYOSURGERY; THERAPY C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Labs Photomed,Dept Dermatol, Boston, MA USA. RP Wall, TL (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Labs Photomed,Dept Dermatol, Boston, MA USA. EM tpandolfino@yahoo.com NR 13 TC 9 Z9 11 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1076-0512 J9 DERMATOL SURG JI Dermatol. Surg. PD JAN PY 2007 VL 33 IS 1 BP 100 EP 103 DI 10.1111/j.1524-4725.2007.33016.x PG 4 WC Dermatology; Surgery SC Dermatology; Surgery GA 122NN UT WOS:000243233800016 PM 17214688 ER PT J AU Collier, AP Heilig, LF Schilling, LM Dellavalle, RP AF Collier, A. P. Heilig, L. F. Schilling, L. M. Dellavalle, R. P. TI Clinical questions asked by medical students: A learning tool for dermatology rotations SO DERMATOLOGY LA English DT Article DE evidence-based medicine; clinical questions; dermatology; medical training ID CARE; EDUCATION AB Background/Aims: To determine whether having medical students answer self-generated patient-specific questions in a clinical setting promotes learning. Methods: Medical students rotating through dermatology clinics at the Denver Veterans' Affairs (VA) Medical Center were asked to formulate and answer one clinical question arising during patient encounters, and to complete a survey regarding their findings and experience. Results: 49% (44/89) of rotating medical students completed the exercise. Self-generated questions frequently addressed therapy (61%, 27/44), prognosis (13%, 6/44), etiology/ risk factors (7%, 3/44), and harm (5%, 2/44). The most frequently used sources of clinical information were journal abstracts/articles (55%, 24/44), UpToDate (50%, 22/44), websites (27%, 12/44) and printed textbooks (25%, 11/44). Medical students rated the impact of answers they obtained on a Likert scale of 1 (strongly disagree) to 5 (strongly agree) for the following: can be used to assist in patient's care (mean 4.1), improved care (mean 3.7), improved communication (mean 4.4), improved confidence in care (mean 4.2), improved knowledge (mean 4.6), and will improve future care (mean 4.5). Conclusions: Medical students report increased knowledge, confidence and patient care skills after completing a self-directed formal exercise consisting of formulating and answering a patient-specific clinical question. Copyright (c) 2007 S. Karger AG, Basel. C1 Univ Colorado, Denver VA Med Ctr, Hlth Sci Ctr, Denver, CO 80220 USA. Univ Colorado, Dept Dermatol, Hlth Sci Ctr, Denver, CO 80220 USA. Univ Colorado, Dept Prevent Med & Biometr, Hlth Sci Ctr, Denver, CO 80220 USA. Univ Colorado, Dept Med, Hlth Sci Ctr, Denver, CO 80220 USA. RP Dellavalle, RP (reprint author), Univ Colorado, Denver VA Med Ctr, Hlth Sci Ctr, 1055 Clermont St,Mail Stop 165, Denver, CO 80220 USA. EM robert.dellavalle@uchsc.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X FU NCI NIH HHS [CA92550]; NIAMS NIH HHS [T32 AR07411]; PHS HHS [5 D14HP00153-03] NR 14 TC 1 Z9 1 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-8665 J9 DERMATOLOGY JI Dermatology PY 2007 VL 214 IS 2 BP 108 EP 111 DI 10.1159/000098567 PG 4 WC Dermatology SC Dermatology GA 143TI UT WOS:000244747600002 PM 17341857 ER PT J AU Tseng, AS Adams, DS Qiu, DY Koustublian, P Levin, M AF Tseng, Ai-Sim Adams, Dany S. Qiu, Dayong Koustublian, Punita Levin, Michael TI Apoptosis is required during early stages of tail regeneration in Xenopus laevis SO DEVELOPMENTAL BIOLOGY LA English DT Article DE Xenopus; tail; regeneration; apoptosis; otolith; neuron ID AMPHIBIAN LIMB REGENERATION; TRANSCRIPTION FACTOR; BLASTEMA FORMATION; MOLECULAR-CLONING; NERVOUS-SYSTEM; SPINAL-CORD; TUNEL ASSAY; CELLS; EXPRESSION; EMBRYOGENESIS AB The Xenopus tadpole is able to regenerate its tail, including skin, muscle, notochord, spinal cord and neurons and blood vessels. This process requires rapid tissue growth and morphogenesis. Here we show that a focus of apoptotic cells appears in the regeneration bud within 12 h of amputation. Surprisingly, when caspase-3 activity is specifically inhibited, regeneration is abolished. This is true of tails both before and after the refractory period. Programmed cell death is only required during the first 24 h after amputation, as later inhibition has no effect on regeneration. Inhibition of caspase-dependent apoptosis results in a failure to induce proliferation in the growth zone, a mispatterning of axons in the regenerate, and the appearance of ectopic otoliths in the neural tube, in the context of otherwise normal continued development of the larva. Larvae amputated during the refractory stage exhibit a much broader domain of caspase-3-positive cells, suggesting a window for the amount of apoptosis that is compatible with normal regeneration. These data reveal novel roles for apoptosis in development and indicate that a degree of apoptosis is an early and obligate component of normal tail regeneration, suggesting the possibility of the existence of endogenous inhibitory cells that must be destroyed by programmed cell death for regeneration to occur. (c) 2006 Elsevier Inc. All rights reserved. C1 Harvard Univ, Sch Dent Med, Forsyth Inst, Ctr Regenerat & Dev Biol, Boston, MA 02115 USA. Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA. RP Levin, M (reprint author), Harvard Univ, Sch Dent Med, Forsyth Inst, Ctr Regenerat & Dev Biol, 140 Fenway, Boston, MA 02115 USA. EM mlevin@forsyth.org FU NCI NIH HHS [CO6RR11244]; NIDCR NIH HHS [K22 DE016633, K22 DE016633-02, 1 K22 DE016633-01] NR 55 TC 104 Z9 109 U1 3 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0012-1606 J9 DEV BIOL JI Dev. Biol. PD JAN 1 PY 2007 VL 301 IS 1 BP 62 EP 69 DI 10.1016/j.ydbio.2006.10.048 PG 8 WC Developmental Biology SC Developmental Biology GA 125UG UT WOS:000243467800006 PM 17150209 ER PT J AU Li, J Tewari, M Vidal, M Lee, SS AF Li, Ji Tewari, Muneesh Vidal, Marc Lee, Siu Sylvia TI The 14-3-3 protein FTT-2 regulates DAF-16 in Caenorhabditis elegans SO DEVELOPMENTAL BIOLOGY LA English DT Article DE 14-3-3; ftt-2; par-5; daf-16; FOXO; dqf-2; insulin signaling ID LIFE-SPAN; 14-3-3 PROTEINS; GENETIC INTERFERENCE; TRANSCRIPTION FACTOR; INTERACTING GENES; OXIDATIVE STRESS; CELL-SURVIVAL; LONGEVITY; PHOSPHORYLATION; BINDING AB The Caenorhabditis elegans daf-2/insulin-like signaling pathway is critical for regulating development, longevity, metabolism and stress resistance. We identified the 14-3-3 protein FTT-2 to be a new regulatory component of this pathway. We found that RNAi knock down of ftt-2 specifically enhanced the daf-2-mediated clatter formation phenotype. Furthermore, fitt-2 knock down caused the nuclear accumulation of DAF-16/FOXO, the forkhead transcription factor that is the major downstream effecter of daf-2/insulin-like signaling, and enhanced the transcriptional activities of DAF-16. In contrast to ftt-2, RNAi knock down of par-5/ftt-1, the only other gene predicted to encode a 14-3-3 protein in C. elegans, did not show any notable effect on clatter formation, DAF-16 localization, or DAF-16 downstream gene transcription, underscoring the functional specification of FTT-2 and PAR-5 despite their high sequence homology. Using co-immunoprecipitation, we revealed that FTT-2 formed a complex with GFP-fused DAF-16 in C. elegans. Our results indicate that FTT-2 binds to DAF-16 in C. elegans and regulates DAF-16 by sequestering it in the cytoplasm. A similar mechanism of regulation of FOXO by 14-3-3 has been reported in mammalian cells, highlighting the high degree of conservation of the daf-2/insulin-like signaling pathway. (c) 2006 Elsevier Inc. All rights reserved. C1 Cornell Univ, Dept Biol Mol, Ithaca, NY 14850 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Genet, Dept Canc Biol, Boston, MA 02115 USA. Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA. RP Lee, SS (reprint author), Cornell Univ, Dept Biol Mol, Ithaca, NY 14850 USA. EM SSL29@cornell.edu FU NIA NIH HHS [R01 AG024425, K08-AG21613, R01 AG024425-01, R01 AG024425-02, R56 AG024425] NR 54 TC 48 Z9 57 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0012-1606 J9 DEV BIOL JI Dev. Biol. PD JAN 1 PY 2007 VL 301 IS 1 BP 82 EP 91 DI 10.1016/j.ydbio.2006.10.013 PG 10 WC Developmental Biology SC Developmental Biology GA 125UG UT WOS:000243467800008 PM 17098225 ER PT J AU Cohen, DE Davidow, LS Erwin, JA Xu, N Warshawsky, D Lee, JT AF Cohen, Dena E. Davidow, Lance S. Erwin, Jennifer A. Xu, Na Warshawsky, David Lee, Jeannie T. TI The DXPas34 repeat regulates random and imprinted X inactivation SO DEVELOPMENTAL CELL LA English DT Article ID MURINE XCE LOCUS; CHROMOSOME INACTIVATION; TSIX TRANSCRIPTION; XIST RNA; ENDOGENOUS RETROVIRUS; MOUSE; GENE; ELEMENTS; CHOICE; MICE AB X chromosome inactivation (XCI) is initiated by expression of the noncoding Xist RNA in the female embryo. Tsix, the antisense noncoding partner of Xist, serves as its regulator during both imprinted and random XCI. Here, we show that Tsix in part acts through a 34mer repeat, DXPas34. DXPas34 contains bidirectional promoter activity, producing overlapping forward and reverse transcripts. We generate three new Tsix alleles in mouse embryonic stem cells and show that, while the Tsix promoter is unexpectedly dispensable, DXPas34 plays dual positive-negative functions. At the onset of XCI, DXPas34 stimulates Tsix expression through its enhancer activity. Once XCI is established, DXPas34 becomes repressive and stably silences Tsix. Germline transmission of the DXPas34 mutation demonstrates its necessity for both random and imprinted XCI in mice. Intriguingly, sequence analysis suggests that DXPas34 could potentially have descended from an ancient retrotransposon. We hypothesize that DXPas34 was acquired by Tsix to regulate antisense function. C1 Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. RP Lee, JT (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA. EM lee@molbio.mgh.harvard.edu FU NIGMS NIH HHS [R01-GM58839] NR 49 TC 55 Z9 57 U1 0 U2 1 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1534-5807 J9 DEV CELL JI Dev. Cell PD JAN PY 2007 VL 12 IS 1 BP 57 EP 71 DI 10.1016/j.devcel.2006.11.014 PG 15 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA 148PK UT WOS:000245086900008 PM 17199041 ER PT J AU Yu, A Rual, JF Tamai, K Harada, Y Vidal, M He, X Kirchhausen, T AF Yu, Anan Rual, Jean-Francois Tamai, Keiko Harada, Yuko Vidal, Marc He, Xi Kirchhausen, Tomas TI Association of dishevelled with the clathrin AP-2 adaptor is required for frizzled endocytosis and planar cell polarity signaling SO DEVELOPMENTAL CELL LA English DT Article ID SORTING SIGNALS; BETA-CATENIN; CONVERGENT-EXTENSION; XENOPUS EMBRYOS; VERTEBRATE GASTRULATION; DROSOPHILA EMBRYOS; APPENDAGE DOMAIN; BINDING-SITE; MU-2 SUBUNIT; WINGLESS AB Upon activation by Wnt, the Frizzled receptor is internalized in a process that requires the recruitment of Dishevelled. We describe a novel interaction between Dishevelled2 (Dvl2) and mu 2-adaptin, a subunit of the clathrin adaptor AP-2; this interaction is required to engage activated Frizzled4 with the endocytic machinery and for its internalization. The interaction of Dvl2 with AP-2 requires simultaneous association of the DEP domain and a peptide YHEL motif within Dvl2 with the C terminus of mu 2. Dvl2 mutants in the YHEL motif fail to associate with mu 2 and AP-2, and prevent Frizzled4 internalization. Corresponding Xenopus Dishevelled mutants show compromised ability to interfere with gastrulation mediated by the planar cell polarity (PCP) pathway. Conversely, a Dvl2 mutant in its DEP domain impaired in PCP signaling exhibits defective AP-2 interaction and prevents the internalization of Frizzled4. We suggest that the direct interaction of Dvl2 with AP-2 is important for Frizzled internalization and Frizzled/PCP signaling. C1 Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Canc Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Ctr Canc Syst Biol, Boston, MA 02115 USA. Harvard Univ, Childrens Hosp, Sch Med, Program Neurobiol, Boston, MA 02115 USA. RP Kirchhausen, T (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. EM kirchhausen@crystal.harvard.edu OI Rual, Jean-Francois/0000-0003-4465-8819 FU NIGMS NIH HHS [GM074241, R01 GM036548, GM036548, R01 GM036548-24, R01 GM074241, R01 GM075252] NR 71 TC 100 Z9 102 U1 1 U2 1 PU CELL PRESS PI CAMBRIDGE PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA SN 1534-5807 J9 DEV CELL JI Dev. Cell PD JAN PY 2007 VL 12 IS 1 BP 129 EP 141 DI 10.1016/j.devcel.2006.10.015 PG 13 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA 148PK UT WOS:000245086900013 PM 17199046 ER PT J AU Nagy, N Brewer, KC Mwizerwa, O Goldstein, AM AF Nagy, Nandor Brewer, Katherine C. Mwizerwa, Olive Goldstein, Allan M. TI Pelvic plexus contributes ganglion cells to the hindgut enteric nervous system SO DEVELOPMENTAL DYNAMICS LA English DT Article DE enteric nervous system; pelvic plexus; nerve of Remak; sacral neural crest; Hirschsprung's disease ID SACRAL NEURAL CREST; AVIAN HINDGUT; FOWL EMBRYO; CHICK; COLONIZATION; MIGRATION; DIFFERENTIATION; NEURONS; VAGAL; PRECURSORS AB The hindgut enteric nervous system (ENS) contains cells originating from vagal and sacral neural crest. In avians, the sacral crest gives rise to the nerve of Remak (NoR) and pelvic plexus. Whereas the NoR has been suggested to serve as the source of sacral crest-derived cells to the gut, the contribution of the pelvic ganglia is unknown. The purpose of this study was to test the hypothesis that the pelvic ganglia contribute ganglion cells to the hindgut ENS. We observed that the quail pelvic plexus develops from neural crest-derived cells that aggregate around the cloaca at embryonic day 5. Using chick-quail tissue recombinations, we found that hindgut grafts did not contain enteric ganglia unless the pelvic plexus was included. Neurofibers extended from the NoR into the intestine, but no ganglion cell contribution from the NoR was identified. These results demonstrate that the pelvic plexus, and not the NoR, serves as the staging area for sacral crest-derived cells to enter the avian hindgut, confirming the evolutionary conservation of this important embryologic process. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA. Semmelweis Univ, Fac Med, Dept Human Morphol & Dev Biol, H-1085 Budapest, Hungary. RP Goldstein, AM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Surg, Warren 1153, Boston, MA 02114 USA. EM agoldstein@partners.org FU NICHD NIH HHS [K08HD46655] NR 36 TC 11 Z9 11 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1058-8388 J9 DEV DYNAM JI Dev. Dyn. PD JAN PY 2007 VL 236 IS 1 BP 73 EP 83 DI 10.1002/dvdy.20933 PG 11 WC Anatomy & Morphology; Developmental Biology SC Anatomy & Morphology; Developmental Biology GA 125TT UT WOS:000243466400006 PM 16937371 ER PT J AU Rodacki, M Svoren, B Butty, V Besse, W Laffel, L Benoist, C Mathis, D AF Rodacki, Melanie Svoren, Britta Butty, Vincent Besse, Whitney Laffel, Lori Benoist, Christophe Mathis, Diane TI Altered natural killer cells in type 1 diabetic patients SO DIABETES LA English DT Article ID HEPARAN-SULFATE PROTEOGLYCANS; NOD MICE; NK CELLS; AUTOIMMUNE-DISEASE; CYTOTOXIC ACTIVITY; CANCER INCIDENCE; GENES INFLUENCE; MELLITUS; INSULIN; ANTIBODY AB Evidence from animal models suggests that natural killer (NK) cells can be important players in the development of type 1 diabetes, although data in humans are still sparse. We studied the frequency and activation state of blood NK cells at different stages of human type I diabetes, and whether genetic or phenotypic NK cell peculiarities could be associated with an early onset of diabetes. The onset period is marked by a slight reduction in blood NK cells, but these are unusually activated in some patients (gamma-interferon expression). This activation status does not correlate, however, with a particularly young age at onset. In contrast, NK cells in patients with long-standing type 1 diabetes had a markedly lower expression of p30/p46 NK-activating receptor molecules compared with those of control subjects. A slightly decreased expression of NKG2D in all type 1 diabetic patients relative to control subjects was observed, independent of the duration of disease, parallel to prior observations in the NOD mouse. Finally, type 1 diabetic patients had an increased frequency of KIR gene haplotypes that include the activating KIR2DS3 gene, with a genetic interaction between the KIR and HLA complexes. The reduced activation of NK cells in individuals with long-standing type 1 diabetes would seem to be a consequence rather than a cause, but other peculiarities may relate to type 1 diabetes pathogenesis. C1 Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. Joslin Diabet Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. RP Benoist, C (reprint author), Harvard Univ, Sch Med, 1 Joslin Pl, Boston, MA 02215 USA. EM cbdm@joslin.harvard.edu FU NIDDK NIH HHS [5T32DK063702] NR 47 TC 71 Z9 75 U1 0 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD JAN PY 2007 VL 56 IS 1 BP 177 EP 185 DI 10.2337/db06-0493 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 125TY UT WOS:000243466900024 PM 17192480 ER PT J AU Veluthakal, R Kaur, H Goalstone, M Kowluru, A AF Veluthakal, Rajakrishnan Kaur, Hitchintan Goalstone, Marc Kowluru, Anjaneyulu TI Dominant-negative alpha-subunit of farnesyl- and geranyltransferase inhibits glucose-stimulated, but not KCI-stimulated, insulin secretion in INS 832/13 cells SO DIABETES LA English DT Article ID GTP-BINDING PROTEINS; HUMAN PANCREATIC-ISLETS; BETA-CELLS; RHO-SUBFAMILY; NORMAL RAT; POSTTRANSLATIONAL MODIFICATIONS; DISSOCIATION INHIBITOR; CARBOXYL METHYLATION; CDC42; MODULATION AB The majority of small G-proteins undergo posttranslational modifications (e.g., isoprenylation) at their C-terminal cysteine residues. Such modifications increase their hydrophobicity, culminating in translocation of the modified proteins to their relevant membranous sites for interaction with their respective effectors. Previously, we reported glucose-dependent activation and membrane association of Rac1 in INS 832/13 cells. We also demonstrated modulatory roles for Rac1/GDP dissociation inhibitor in glucose-stimulated insulin secretion (GSIS) in INS 832/13 cells, further affirming roles for Racl in GSIS. Herein, we demonstrate that geranylgeranyltransferase inhibitor-2147 (GGTI-2147), an inhibitor of protein prenylation, markedly increased cytosolic accumulation of Racl and elicited significant inhibition of GSIS from INS 832/13 cells. In the current study, we also examined the localization of protein prenyltransferases (PPTases) and regulation of GSIS by PPTases in INS 832/13 cells. Western blot analyses indicated that the regulatory alpha-subunit and the structural R-subunit of PPTase holoenzyme are predominantly cytosolic in their distribution. Overexpression of an inactive mutant of the regulatory alpha-subunit of PPTase markedly attenuated glucose- but not KCI-induced insulin secretion from INS 832/13 cells. Together, our findings provide the first evidence for the regulation of GSIS by PPTase in INS 832/13 cells. Furthermore, they support our original hypothesis that prenylation of specific G-proteins may be necessary for GSIS. Diabetes C1 Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Detroit, MI 48201 USA. John D Dingell Vet Affairs Med Ctr, Beta Cell Biochem Res Lab, Detroit, MI USA. Denver VA Med Ctr, Res Serv, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80202 USA. RP Kowluru, A (reprint author), Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, 3601,259 Mack Ave, Detroit, MI 48201 USA. EM akowluru@med.wayne.edu FU NIDDK NIH HHS [R01 DK068326] NR 43 TC 34 Z9 34 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD JAN PY 2007 VL 56 IS 1 BP 204 EP 210 DI 10.2337/db06-0668 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 125TY UT WOS:000243466900027 PM 17192483 ER PT J AU Sanders, NM Taborsky, GJ Wilkinson, CW Daumen, W Figlewicz, DP AF Sanders, Nicole M. Taborsky, Gerald J., Jr. Wilkinson, Charles W. Daumen, Wendi Figlewicz, Dianne P. TI Antecedent hindbrain glucoprivation does not impair the counterregulatory response to hypoglycemia SO DIABETES LA English DT Article ID DEPENDENT DIABETES-MELLITUS; VENTROMEDIAL HYPOTHALAMUS; AUTONOMIC FAILURE; SUBSEQUENT HYPOGLYCEMIA; RECURRENT HYPOGLYCEMIA; EXTRACELLULAR GLUCOSE; ARCUATE NUCLEUS; BLOOD-GLUCOSE; RATS; 5-THIO-D-GLUCOSE AB Recurrent hypoglycemia impairs hormonal counter-regulatory responses (CRRs) to further bouts of hypoglycemia. The hypothalamus and hindbrain are both critical for sensing hypoglycemia and triggering CRRs. Hypothalamic glucose sensing sites are implicated in the pathogenesis of defective CRRs; however, the contribution of hindbrain glucose sensing has not been elucidated. Using a rat model, we compared the effect of antecedent glucoprivation targeting hindbrain or hypothalamic glucose sensing sites with the effect of antecedent recurrent hypoglycemia, on CRR to hypoglycemia induced 24 h later. Recurrent hypoglycemia decreased sympathoadrenal (1,470 +/- 325 vs. 3,811 +/- 540 pg/ml in controls [t = 60 min], P = 0.001) and glucagon secretion (222 +/- 43 vs. 494 +/- 56 pg/ml in controls [t = 60]), P = 0.003) in response to hypoglycemia. Antecedent 5-thio-glucose (5TG) injected into the hindbrain did not impair sympathoadrenal (3,806 344 pg/ml [t = 60]) or glucagon (513 56 pg/ml [t = 60]) responses to subsequent hypoglycemia. However, antecedent 5TG delivered into the third ventricle was sufficient to blunt CRRs to hypoglycemia. These results show that hindbrain glucose sensing is not involved in the development of defective CRRs. However, neural substrates surrounding the third ventricle are particularly sensitive to glueoprivic stimulation and may contribute importantly to the development of defective CRRs. C1 VA Puget Sound Hlth Care Syst, Div Endocrinol & Metab, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, Div Geriatr Res, Seattle, WA 98108 USA. Seattle Inst Biomed & Clin Res, Seattle, WA USA. RP Sanders, NM (reprint author), VA Puget Sound Hlth Care Syst, Div Endocrinol & Metab, S-151,1660 So Columbian Way, Seattle, WA 98108 USA. EM sandersn@u.washington.edu FU NIDDK NIH HHS [DK 40963, DK 50154, R01 DK040963, R01 DK050154, R01 DK050154-10, R56 DK050154] NR 42 TC 8 Z9 8 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD JAN PY 2007 VL 56 IS 1 BP 217 EP 223 DI 10.2337/db06-1025 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 125TY UT WOS:000243466900029 PM 17192485 ER PT J AU Rhodes, ET Laffel, LMB Gonzalez, TV Ludwig, DS AF Rhodes, Erinn T. Laffel, Lori M. B. Gonzalez, Tessa V. Ludwig, David S. TI Accuracy of administrative coding for type 2 diabetes in children, adolescents, and young adults SO DIABETES CARE LA English DT Article; Proceedings Paper CT 66th Annual Meeting of the American-Diabetes-Association CY JUN 09-13, 2006 CL Washington, DC SP Amer Diabet Assoc ID HEALTH MAINTENANCE ORGANIZATION; PREDICTIVE-VALUE; ICD-9-CM CODES; DISEASE; SENSITIVITY; PREVALENCE; VALIDATION; DIAGNOSIS C1 Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Boston, MA 02215 USA. RP Rhodes, ET (reprint author), Childrens Hosp, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA. EM erinn.rhodes@childrens.harvard.edu FU NCCDPHP CDC HHS [K01DP000089]; NIDDK NIH HHS [P30 DK040561, P30 DK040561-11] NR 18 TC 39 Z9 39 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2007 VL 30 IS 1 BP 141 EP 143 DI 10.2337/dc06-1142 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 125UZ UT WOS:000243469800025 PM 17192348 ER PT J AU Delahanty, LM Grant, RW Wittenberg, E Bosch, JL Wexler, DJ Cagliero, E Meigs, JB AF Delahanty, L. M. Grant, R. W. Wittenberg, E. Bosch, J. L. Wexler, D. J. Cagliero, E. Meigs, J. B. TI Association of diabetes-related emotional distress with diabetes treatment in primary care patients with Type 2 diabetes SO DIABETIC MEDICINE LA English DT Article DE diabetes-related emotional distress; primary care; quality of life; Type 2 diabetes ID QUALITY-OF-LIFE; PROBLEM AREAS; CONTROLLED-TRIAL; OUTCOMES; SCALE; THERAPY; HEALTH; IMPACT; DUTCH AB Aims To characterize the determinants of diabetes-related emotional distress by treatment modality (diet only, oral medication only, or insulin). Methods A total of 815 primary care patients with Type 2 diabetes completed the Problem Areas in Diabetes (PAID) Scale and other questions. We linked survey data to a diabetes clinical research database and used linear regression models to assess the associations of treatment with PAID score. Results PAID scores were significantly higher among insulin-treated (24.6) compared with oral-treated (17.8, P < 0.001) or diet-treated patients (14.7, P < 0.001), but not different between oral- vs. diet-treated patients (P = 0.2). Group scores remained similar, but the statistical significance of their differences was reduced and ultimately eliminated after sequential adjustment for diabetes severity, HbA(1c), body mass index, regimen adherence, and self-blood-glucose monitoring. Insulin-treated patients reported significantly higher distress than oral- or diet-treated patients on 16 of 20 PAID items. 'Worrying about the future' and 'guilt/anxiety when ... off track with diabetes' were the top two serious problems (PAID >= 5) in all treatment groups. Not accepting diabetes diagnosis was a top concern for oral- and diet-treated patients, and unclear management goals distressed diet-treated patients. Conclusions Primary care patients treated with insulin reported higher diabetes-related emotional distress compared with oral- or diet-treated patients. Greater distress was largely explained by greater disease severity and self-care burdens. To improve diabetes-specific quality of life, clinicians should address patients' sense of worry and guilt, uncertain acceptance of diabetes diagnosis, and unclear treatment goals. C1 Massachusetts Gen Hosp, MGH Diabet Ctr, Dept Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Gen Med, Dept Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. Erasmus MC Univ, Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands. Erasmus MC Univ, Med Ctr, Dept Radiol, Rotterdam, Netherlands. RP Delahanty, LM (reprint author), Massachusetts Gen Hosp, MGH Diabet Ctr, Dept Med, 50 Staniford St,Suite 340, Boston, MA 02114 USA. EM ldelahanty@partners.org OI Grant, Richard/0000-0002-6164-8025 FU NIDDK NIH HHS [K23 DK080228, DK067452] NR 23 TC 71 Z9 75 U1 4 U2 12 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0742-3071 J9 DIABETIC MED JI Diabetic Med. PD JAN PY 2007 VL 24 IS 1 BP 48 EP 54 DI 10.1111/j.1464-5491.2007.02028.x PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 124WS UT WOS:000243403200008 PM 17227324 ER PT B AU Wheeler, S Singh, N Boyko, EJ AF Wheeler, Stephanie Singh, Nalini Boyko, Edward J. BE Veves, A Malik, RA TI The Epidemiology of Diabetic Neuropathy SO DIABETIC NEUROPATHY: CLINICAL MANAGEMENT, SECOND EDITION SE Contemporary Diabetes LA English DT Article; Book Chapter DE Diabetic neuropathy; diabetes; epidemiology; incidence; prevalence; risk factors ID CARPAL-TUNNEL-SYNDROME; INFLAMMATORY DEMYELINATING POLYNEUROPATHY; RISK-FACTORS; SENSORY NEUROPATHY; PITTSBURGH EPIDEMIOLOGY; FOOT ULCERATION; GLYCEMIC CONTROL; MICROVASCULAR COMPLICATIONS; PERIPHERAL NEUROPATHY; AUTONOMIC NEUROPATHY AB Peripheral neuropathy is a devastating complication of diabetes mellitus because of the debilitating symptoms it causes or associated higher risk of other complications, in particular those involving the lower extremity. This chapter will review the prevalence, incidence, and risk factors for different types of diabetic neuropathy. There are seven major types of diabetic neuropathy: (1) distal symmetric polyneuropathy, (2) autonomic neuropathy, (3) nerve entrapment syndromes, (4) proximal asymmetric mononeuropathy (also known as diabetic amyotrophy), (5) truncal radiculopathy, (6) cranial mononeuropathy, and (7) chronic inflammatory demyelinating polyradiculopathy (CIDP). This chapter will focus mainly on the first two types of neuropathy, but will review the available data on the epidemiology of the other types of neuropathy. Cross-sectional or case-control Studies conducted in a population-based sample (such as a defined community or health plan enrollment) were considered for this chapter based on review of Medline citations using the keywords "epidemiology," "diabetes," and "neuropathy" from 1966 to February 2005 review of bibliographies of the articles obtained from the Medline search for relevant citations, and review of the authors' files. Clinic-based cross-sectional or case-control studies have not been considered except in the case of rare conditions, for which no other data exists. All prospective studies, and some randomized controlled trials, were considered. Of the five community-based cross-sectional studies reviewed of subjects with type 2 diabetes that presented data on risk factors for neuropathy, three reported a higher prevalence of this outcome with longer diabetes duration and higher glycosylated hemoglobin, and two found neuropathy prevalence correlated with age and height. Only three community-based cross-sectional studies addressed neuropathy prevalence in subjects with type 1 diabetes in association with risk factors. Two of these investigations reported a correlation between diabetes duration and neuropathy prevalence. No other significant risk factor was reported by more than one community-based study done with subjects with type 1 diabetes. Prospective research on the risk of distal symmetric polyneuropathy confirms its relationship to poorer glycemic control as reflected by fasting plasma glucose or hemoglobin A1c (HbA1c) at baseline. Four prospective studies reported duration of diabetes as a risk factor for neuropathy, three reported smoking Lis a risk factor, two reported age and two reported baseline coronary artery disease as risk factors for neuropathy. The literature on risk factors for diabetic autonomic neuropathy can be characterized as smaller in size and less consistent in comparison with that available for distal symmetric polyneuropathy. The only risk factor reported in more than one study was female gender, found to be associated with higher risk by two authors. There have been no prospective population-based studies of diabetic amyotrophy and mononeuropathies in subjects with diabetes. However, some prevalence figures for these types of neuropathy can be derived from a few cross-sectional studies, which are described in the chapter. CIDP is a relatively new diagnosis. In 1991, the American Academy of Neurology defined diagnostic clinical and electrophysiological criteria for CIDP. All studies on CIDP are cross-sectional and clinic-based. C1 [Wheeler, Stephanie; Singh, Nalini; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Wheeler, S (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 59 TC 2 Z9 3 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-626-9 J9 CONTEMP DIABETES PY 2007 BP 7 EP 30 DI 10.1007/978-1-59745-311-0_2 D2 10.1007/978-1-59745-311-0 PG 24 WC Endocrinology & Metabolism; Medicine, General & Internal; Clinical Neurology; Neurosciences; Pathology SC Endocrinology & Metabolism; General & Internal Medicine; Neurosciences & Neurology; Pathology GA BJT76 UT WOS:000267142500002 ER PT J AU Maiss, J Millermann, L Heinemann, K Naegel, A Peters, A Matthes, K Hahn, EG Hochberger, J AF Maiss, J. Millermann, L. Heinemann, K. Naegel, A. Peters, A. Matthes, K. Hahn, E. G. Hochberger, J. TI The compactEASIE (R) is a feasible training model for endoscopic novices: A prospective randomised trial SO DIGESTIVE AND LIVER DISEASE LA English DT Article; Proceedings Paper CT 11th UEGW Conference 2003 CY NOV, 2003 CL Madrid, SPAIN DE education; endoscopic haemostasis; endoscopy; training in endoscopy ID GASTROINTESTINAL ENDOSCOPY; SIMULATOR; GASTROENTEROLOGY; HEMOSTASIS; SKILLS AB Background. The objective benefit of a training using the compact Erlangen Active Simulator for Interventional Endoscopy-simulator was demonstrated in two prospective educational trials (New York, France). The present study analysed whether endoscopic novices are able to reach a comparable level of endoscopic skills as in the above-described projects. Methods. Twenty-seven endoscopic novices (medical students, first year residents) were enrolled in this prospective, randomised trial. The compact Erlangen Active Simulator for Interventional Endoscopy-simulator with an upper GI-organ package and blood perfusion system was used as a training tool. Basic evaluation of endoscopic skills was performed after a practical and theoretical course in diagnostic upper GI endoscopy followed by a stratified randomisation according to the rating in endoscopic skills into intensive (n = 14) and control group (n = 13). The intensive group was trained 12 times every second week over 7 months in 4 endoscopic disciplines (manual skills, injection therapy, haemoclip, band ligation) by skilled endoscopist (three trainees/simulator). Assessment was performed (single steps/overall) using an analogue scale from 1 to 10 (1 = worst, 10 = optimal performance) by expert tutors. The control group was not trained. Blinded final evaluation of all participants was performed in January 2003. Results. We observed in all techniques applied a significant improvement of endoscopic skills and of the performance time in the intensive group compared to the control group (p < 0.001). The comparison with the previous projects showed that the intensively trained novices achieved comparable levels of performance to the GI fellows in the New York and France Project (at least 80% of the median score in three out of four techniques). Conclusion. Endoscopic novices acquired notable skills in interventional endoscopy in the simulator by an intensive, periodical training using the compactEASIE (R). (C) 2006 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. C1 Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany. Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, D-91054 Erlangen, Germany. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA. St Bernward Hosp, Dept Med 3, D-31134 Hildesheim, Germany. RP Maiss, J (reprint author), Univ Erlangen Nurnberg, Dept Med 1, Ulmenweg 18, D-91054 Erlangen, Germany. EM juergen.maiss@med1.imed.uni-erlangen.de NR 23 TC 15 Z9 15 U1 0 U2 4 PU PACINI EDITORE PI PISA PA VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY SN 1590-8658 J9 DIGEST LIVER DIS JI Dig. Liver Dis. PD JAN PY 2007 VL 39 IS 1 BP 70 EP 78 DI 10.1016/j.dld.2006.07.007 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 160HI UT WOS:000245931100011 PM 16942923 ER PT J AU Zipfel, E Cooper, RA Pearlman, J Cooper, R McCartney, M AF Zipfel, Emily Cooper, Rory A. Pearlman, Jon Cooper, Rosemarie McCartney, Mark TI New design and development of a manual wheelchair for India SO DISABILITY AND REHABILITATION LA English DT Article DE assistive technology; wheelchair design; India ID FATIGUE-LIFE; PERFORMANCE AB Purpose. The most common methods of delivering assistive technology in developing countries are charitable donation and workshops. This describes a new approach to solving the problem, a collaboration undertaken by a US-based lab and a manufacturer in India to produce quality wheelchairs. One goal is to publicize the design free of charge to manufacturers and interested parties world-wide. The process, a demonstration of a new technology transfer method, and the product, an adult manual wheelchair, are described. Method. An iterative process occurred over four years to design and produce the wheelchair. This consisted of prototypes, small production runs, ANSI/RESNA testing, hardness and tensile testing and informal user testing. Results. The design is a manual folding cross-brace design with several points of adjustability. Final pre-production prototypes experienced fastener failures during durability testing. Higher grade bolts were specified. Trial-run production has begun. An ANSI/RESNA wheelchair test lab was constructed in India. Subsequent projects include power and pediatric tilt-in-space wheelchairs. Conclusions. The approach seems promising as a method to improve the quality of assistive technology available in India and begin to meet the vast need in India. Pitfalls encountered throughout the collaboration are described in this paper along with solutions to remedy these problems for future projects. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, 151-R1,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Pearlman, Jon/0000-0003-0830-9136 NR 24 TC 6 Z9 6 U1 1 U2 5 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0963-8288 J9 DISABIL REHABIL JI Disabil. Rehabil. PY 2007 VL 29 IS 11-12 BP 949 EP 962 DI 10.1080/09638280701240672 PG 14 WC Rehabilitation SC Rehabilitation GA 188PZ UT WOS:000247933100013 PM 17577729 ER PT J AU Authier, EL Pearlman, J Allegretti, AL Rice, I Cooper, RA AF Authier, Erica L. Pearlman, Jon Allegretti, Ana L. Rice, Ian Cooper, Rory A. TI A sports wheelchair for low-income countries SO DISABILITY AND REHABILITATION LA English DT Article DE wheelchair design; basketball; low-income country; sports wheelchair AB Purpose. Appropriate wheelchairs for basic mobility needs are still not commonly available in low-income countries, although several organizations are working toward this goal. After basic mobility is secured it is important to provide more diverse assistive technology to allow people with disabilities to more completely participate in society and live healthy lives. Our goal was to design an affordable sports wheelchair that would allow individuals in low-income countries to participate in basketball. Methods. Design requirements established for the sports wheelchair included: removable anti-tippers, adjustable tension backrest, 24" wheels, adjustable seat dump, variable camber, 4" casters, fore-aft axle position, removable bumpers, height adjustable footrest, four wheels, single anti-tipper (pivot), cost less than $125 without wheels, 16" seat width and backrest height, and nylon upholstery. The wheelchair was designed using 3D modeling, standard materials, and standard tools. Discussion. An affordable wheelchair, versatile enough to be used for a variety of sports and even everyday use, was designed and prototyped successfully. Documentation for the design including step-by-step directions, engineering drawings, and photographs are available at the Human Engineering Research Laboratories website (http://www.herlpitt.org/intw.htm). Future work on the prototype should include design refinement including adaptations for other sports, and standards testing. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Occupat Therapy, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, 151-R1,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper+@pitt.edu OI Pearlman, Jon/0000-0003-0830-9136 NR 9 TC 5 Z9 5 U1 0 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0963-8288 J9 DISABIL REHABIL JI Disabil. Rehabil. PY 2007 VL 29 IS 11-12 BP 963 EP 967 DI 10.1080/09638280701240714 PG 5 WC Rehabilitation SC Rehabilitation GA 188PZ UT WOS:000247933100014 PM 17577730 ER PT J AU Anderson, BJ Svoren, B Laffel, L AF Anderson, Barbara J. Svoren, Britta Laffel, Lori TI Initiatives to promote effective self-care skills in children and adolescents with diabetes mellitus SO DISEASE MANAGEMENT & HEALTH OUTCOMES LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; FAMILY SYSTEMS THERAPY; METABOLIC-CONTROL; GLYCEMIC CONTROL; FOLLOW-UP; INTENSIVE TREATMENT; IMPROVE ADHERENCE; BEHAVIOR-THERAPY; TYPE-1; MANAGEMENT AB Intensive management of type 1 diabetes mellitus (TIDM) is increasingly becoming the 'ideal' standard of care for pediatric patients at diabetes centers across the world. This 'ideal' standard is based on two landmark studies that documented that keeping blood glucose levels as close to normal as possible and achieving this as early as possible in the disease course helps to prevent or delay the devastating long-term complications of TIDM. Simultaneously, initiatives supplemental to the medical care of young patients with diabetes that are attempting to improve the self-care behavior and glycemic control of young patients with diabetes have been implemented. There is consensus among recent meta-analyses and critical reviews of these interventions that their overall impact on glycemic control is modest to moderate at best. Because of the need for healthcare cost containment and allocation of resources, we have attempted to identify the components of these different initiatives that have the potential to be practical, cost saving, and integrated into the routine clinical care of diabetes. Interventions based on coping-skills training, motivational interviewing, behavioral family systems therapy, and multisysternic therapy models require the expertise of a highly trained mental healthcare professional. Moreover, none of these interventions has yet been implemented or evaluated within the ongoing context of routine ambulatory diabetes care. Finally, each of these interventions requires additional time commitments from young patients with diabetes and their families. The Care Ambassador intervention and programs based on the Family Teamwork intervention do not require highly trained, expensive staff for delivery and have been successfully integrated into routine pediatric diabetes-care settings. Moreover, the Care Ambassador model has also been shown to reduce expensive adverse outcomes across a broad spectrum of youth with diabetes. Finally, telehealth interventions for youth with diabetes may hold great potential as a lower-cost intervention to supplement routine diabetes care and to optimize glycemic control for pediatric patients; however, we await the rigorous evaluation of the application of telehealth interventions across a range of outpatient pediatric diabetes-care settings. Pediatric diabetes care requires an environment of supportive, collaborative communication grounded in realistic expectations for youths. Thus, ongoing evaluations of outcomes of these various interventions are needed within multiple healthcare settings. C1 Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA. Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Anderson, BJ (reprint author), Baylor Coll Med, Childrens Nutr Res Ctr, 1100 Bates St, Houston, TX 77030 USA. EM bja@bcm.tmc.edu NR 69 TC 22 Z9 22 U1 6 U2 20 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1173-8790 J9 DIS MANAG HEALTH OUT JI Dis. Manag. Health Outcomes PY 2007 VL 15 IS 2 BP 101 EP 108 DI 10.2165/00115677-200715020-00005 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 178WD UT WOS:000247250000005 ER PT J AU Mok, SC Kwong, J Welch, WR Samimi, G Ozbun, L Bonome, T Birrer, MJ Berkowitz, RS Wong, KK AF Mok, Samuel C. Kwong, Joseph Welch, William R. Samimi, Goli Ozbun, Laurent Bonome, Tomas Birrer, Michael J. Berkowitz, Ross S. Wong, Kwong-Kwok TI Etiology and pathogenesis of epithelial ovarian cancer SO DISEASE MARKERS LA English DT Article DE ovarian cancer; microenvironment; inflammation; pathogenesis ID DELETION UNIT; INCESSANT OVULATION; SURFACE EPITHELIUM; SPONTANEOUS TRANSFORMATION; INFLAMMATORY REACTION; K-RAS; RISK; TUMORS; CELLS; WOMEN AB Ovarian cancer is complex disease composed of different histological grades and types. However, the underlying molecular mechanisms involved in the development of different phenotypes remain largely unknown. Epidemiological studies identified multiple exogenous and endogenous risk factors for ovarian cancer development. Among them, an inflammatory stromal microenvironment seems to play a critical role in the initiation of the disease. The interaction between such a microenvironment, genetic polymorphisms, and different epithelial components such as endosalpingiosis, endometriosis, and ovarian inclusion cyst in the ovarian cortex may induce different genetic changes identified in the epithelial component of different histological types of ovarian tumors. Genetic studies on different histological grades and types provide insight into the pathogenetic pathways for the development of different disease phenotypes. However, the link between all these genetic changes and the etiological factors remains to be established. C1 [Mok, Samuel C.; Kwong, Joseph; Berkowitz, Ross S.] Harvard Univ, Brigham & Womens Hosp, Sch Med,Lab Gynecol Oncol, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Mok, Samuel C.; Berkowitz, Ross S.] Harvard Univ, Dana Farber Canc Ctr, Gillette Ctr Womens Canc, Boston, MA 02115 USA. [Welch, William R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Samimi, Goli; Ozbun, Laurent; Bonome, Tomas; Birrer, Michael J.] NCI, Cell & Canc Biol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. [Samimi, Goli] Div Canc Prevent, Off Prevent Oncol, Canc Prevent Fellowship Program, Bethesda, MD 20892 USA. [Wong, Kwong-Kwok] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA. RP Mok, SC (reprint author), Brigham & Womens Hosp, Lab Gynecol Oncol, BLI 447,221 Longwood Ave, Boston, MA 02115 USA. EM scmok@rics.bwh.harvard.edu RI Kwong, Joseph/H-2368-2013; OI Wong, Kwong-Kwok/0000-0002-0375-6669 FU NCI NIH HHS [CA105009, R33CA103595] NR 68 TC 23 Z9 25 U1 0 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0278-0240 J9 DIS MARKERS JI Dis. Markers PY 2007 VL 23 IS 5-6 BP 367 EP 376 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology GA 249RH UT WOS:000252246900003 PM 18057520 ER PT J AU O'Rourke, RW Deveney, CW McConnell, DB Wolfe, BM Jobe, BA AF O'Rourke, R. W. Deveney, C. W. McConnell, D. B. Wolfe, B. M. Jobe, B. A. TI Esophageal motility disorders after gastric banding SO DISEASES OF THE ESOPHAGUS LA English DT Article DE esophageal motility disorder; gastric band; obesity ID MORBIDLY OBESE-PATIENTS; GASTROESOPHAGEAL-REFLUX DISEASE; FOLLOW-UP; SYMPTOMS; SYSTEM; RISK AB The long-term effects of gastric banding on esophageal function are not well described. This report describes a 28-year-old woman who developed signs and symptoms of abnormal esophageal motility and lower esophageal sphincter hypotension after gastric banding for morbid obesity. The current literature addressing the effects of gastric banding on esophageal function in light of this case report is discussed. C1 Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP O'Rourke, RW (reprint author), Oregon Hlth & Sci Univ, Dept Surg L223A, 3181 SW Sam JAckson Pk Rd, Portland, OR 97239 USA. EM orourkro@ohsu.edu NR 25 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1120-8694 J9 DIS ESOPHAGUS JI Dis. Esophagus PY 2007 VL 20 IS 3 BP 269 EP 273 DI 10.1111/j.1442-2050.2007.00685.x PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 169FL UT WOS:000246578000013 PM 17509126 ER PT B AU Novelline, RA AF Novelline, R. A. BE Hodler, J VonSchulthese, GK Zollikofer, CHL TI Imaging chest trauma SO Diseases of the Heart, Chest & Breast LA English DT Proceedings Paper CT 39th International Diagnostic Course Meeting CY MAR 25-27, 2007 CL Davos, SWITZERLAND SP Fdn Adv Educ Med Radiol ID AORTIC INJURY; RUPTURE; CT; DIAGNOSIS C1 Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiol, Boston, MA 02114 USA. RP Novelline, RA (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiol, Boston, MA 02114 USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG ITALIA PI MILAN PA MILAN, ITALY BN 978-88-470-0632-4 PY 2007 BP 83 EP 86 DI 10.1007/978-88-470-0633-1_13 PG 4 WC Oncology; Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging; Respiratory System SC Oncology; Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging; Respiratory System GA BGF45 UT WOS:000246436000013 ER PT J AU Perrimon, N Friedman, A Mathey-Prevot, B Eggert, US AF Perrimon, Norbert Friedman, Adam Mathey-Prevot, Bernard Eggert, Ulrike S. TI Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens SO DRUG DISCOVERY TODAY LA English DT Review ID JAK/STAT SIGNALING COMPONENTS; FUNCTIONAL GENOMIC ANALYSIS; CULTURED-CELLS; INTERFERENCE; MELANOGASTER; PATHWAYS; NEURODEGENERATION; INHIBITORS; INFECTION; GENETICS AB RNA interference (RNAi) and small-molecule approaches are synergistic on multiple levels, from technology and high-throughput screen development to target identification and functional studies. Here, we describe the RNAi screening platform that we have established and made available to the community through the Drosophila RNAi Screening Center at Harvard Medical School. We then illustrate how the combination of RNAi and small-molecule HTS can lead to effective identification of targets in drug discovery. C1 Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. RP Perrimon, N (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA. EM perrimon@receptor.med.harvard.edu FU NIGMS NIH HHS [R01GM067761] NR 39 TC 27 Z9 28 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1359-6446 J9 DRUG DISCOV TODAY JI Drug Discov. Today PD JAN PY 2007 VL 12 IS 1-2 BP 28 EP 33 DI 10.1016/j.drudis.2006.10.006 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 131IO UT WOS:000243862700004 PM 17198970 ER PT J AU Miller, JC Pien, HH Sorensen, AG AF Miller, Janet C. Pien, Homer H. Sorensen, A. Gregory TI Imaging biomarker applications in oncology drug development SO DRUG INFORMATION JOURNAL LA English DT Article DE imaging; biomarker; cancer; drug development; clinical trial ID POSITRON-EMISSION-TOMOGRAPHY; COMBRETASTATIN A4 PHOSPHATE; ADVANCED COLORECTAL-CANCER; SURROGATE END-POINTS; PHASE-I TRIAL; SOLID TUMORS; NEOADJUVANT CHEMOTHERAPY; ANGIOGENESIS INHIBITOR; LIVER METASTASES; CLINICAL-TRIALS AB At present, drug development is a long and costly process with an unacceptably high failure rate. As a result, both the Food and Drug Administration and the pharmaceutical industry have shown interest in using biomarkers of clinical response. Biomarker imaging is noninvasive, allows serial data collection, and lessens interpatient variability because each individual can serve as his or her own control. The only imaging biomarker currently accepted as a surrogate for clinical response is tumor shrinkage for accelerated approval. The imaging biomorker, F-18-fluoro-2-deoxy-D-glucose (FDG) and positron emission tomography (PET), is widely used clinically to assess response to therapy and, in some cases, correlates better with prolonged survival than tumor shrinkage. Other biomarkers, such as hemodynamic biomarkers, have been used in early clinical trials as a means to assess bioactivity within hours or days of the start of treatment and to determine drug dose in subsequent trials. Many others have found applications in assessing bioactivity in preclinical stages of drug development. With further validation, many of these imaging biomarkers could become valuable in measuring response to therapy much faster than present methods. In addition, pharmacokinetic imaging will provide both clinical and preclinical data on uptake, distribution, and excretion of drug candidates. C1 Massachusetts Gen Hosp, Ctr Biomarkers Imaging, Dept Radiol, Boston, MA 02114 USA. RP Sorensen, AG (reprint author), Massachusetts Gen Hosp, Ctr Biomarkers Imaging, Dept Radiol, 149 13th St, Cambridge, MA 02139 USA. EM sorensen@nmr.mgh.harvard.edu NR 48 TC 1 Z9 1 U1 0 U2 0 PU DRUG INFORMATION ASSOC PI HORSHAM PA 800 ENTERPRISE ROAD, SUITE 200, HORSHAM, PA 19044-3595 USA SN 0092-8615 J9 DRUG INF J JI Drug Inf. J. PY 2007 VL 41 IS 5 BP 561 EP 572 PG 12 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA 207YP UT WOS:000249287300003 ER PT J AU Seger, AC Jha, AK Bates, DW AF Seger, Andrew C. Jha, Ashish K. Bates, David W. TI Adverse drug event detection in a community hospital utilising computerised medication and laboratory data SO DRUG SAFETY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; COSTS; INSULIN; INJURY; SURVEILLANCE; MORTALITY; SYSTEM AB Objective: Computerised monitors can detect and, with clinical intervention, often prevent or ameliorate adverse drug events (ADEs). We evaluated whether a computer-based alerting system was useful in a community hospital setting. Methods: We evaluated 6 months of retrospectively collected medication and laboratory data from a 140-bed community hospital, and applied the rules from a computerised knowledge base to determine if the resulting alerts might have allowed a clinician to prevent or lessen harm related to medication toxicity. We randomly selected 11% (n = 58, of which 56 were available) of charts deemed to be high- or critical-priority alerts, based on the likelihood of the alerts being associated with injury, to determine the frequencies of ADEs and preventable ADEs. Results: In 6 months, there were 8829 activations of the rule set, generating a total of 3547 alerts. Of these, 528 were of high or critical priority, 664 were of medium priority and 2355 were of low priority. Chart review among the sample (56 charts) of high- or critical-priority alerts found five non-preventable and two preventable ADEs, suggesting that among the total high- or critical-priority alerts alone, there would be approximately 94 non-preventable ADEs and 37 preventable ADEs annually in this hospital that could be detected using this method. Conclusions: Computer-based rules engines have the potential to identify and, with clinical intervention, mitigate preventable ADEs, and implementation is feasible in community hospitals without an advanced information technology application. C1 Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA. Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. Boston VA Healthcare Syst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Seger, AC (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St,3rd Floor, Boston, MA 02120 USA. EM ASEGER@PARTNERS.ORG NR 26 TC 21 Z9 22 U1 7 U2 9 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0114-5916 J9 DRUG SAFETY JI Drug Saf. PY 2007 VL 30 IS 9 BP 817 EP 824 DI 10.2165/00002018-200730090-00007 PG 8 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology GA 216EV UT WOS:000249862200007 PM 17722972 ER PT J AU Rao, N Lipsky, BA AF Rao, Nalini Lipsky, Benjamin A. TI Optimising antimicrobial therapy in diabetic foot infections SO DRUGS LA English DT Review ID COLONY-STIMULATING FACTOR; RESISTANT STAPHYLOCOCCUS-AUREUS; LOWER-EXTREMITY INFECTIONS; SKIN-STRUCTURE INFECTIONS; OPEN-LABEL TRIAL; HYPERBARIC-OXYGEN; ANTIBIOTIC-THERAPY; COMPLICATED SKIN; MAGGOT THERAPY; CLINICAL-TRIAL AB Foot infections are common and the most serious lower extremity complication contributing to amputations, particularly in patients with diabetes mellitus. Infection is most often a consequence of foot ulcerations, which typically follows trauma to a neuropathic foot. Foot infections may be classified as mild, moderate and severe; this largely determines the approach to therapy. Gram-positive bacteria are the sole causative pathogens for most mild and moderate infections. These infections can usually be treated with culture-based narrow-spectrum antibacterials along with appropriate surgical debridement in an outpatient setting. In contrast, severe infections are often polymicrobial, requiring hospitalisation and treatment with broad-spectrum antibacterials along with appropriate medical and surgical interventions. The initial empirical antibacterial regimen may be tailored based on the results of culture and sensitivity tests from properly obtained specimens. Several antibacterial regimens have demonstrated effectiveness in randomised controlled trials, but no single regimen has shown superiority. Managing diabetic foot osteomyelitis is particularly controversial and requires reliable cultures to select an appropriate antibacterial regimen. Surgical resection of the infected and necrotic bone favours a good outcome in chronic osteomyelitis. The recommended duration of antibacterial therapy ranges from 1 to 4 weeks for soft tissue infection, to > 6 weeks for unresected osteomyelitis. The incidence of meticillin-resistant Staphylococcus aureus infection is increasing in both the healthcare setting and the community. This should be considered when selecting an antibacterial, especially if the patient does not improve with initial antibacterial therapy. Certain other organisms, such as Pseudomonas aeruginosa and Enterococcus spp., while potentially pathogenic, are often colonisers that do not require targeted therapy. C1 Univ Pittsburgh, Med Ctr, Div Infect Dis, Dept Med, Pittsburgh, PA 15232 USA. VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Rao, N (reprint author), Univ Pittsburgh, Med Ctr, Div Infect Dis, Dept Med, 5230 Ctr Ave, Pittsburgh, PA 15232 USA. EM raon@upmc.edu OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 147 TC 37 Z9 38 U1 2 U2 9 PU ADIS INTERNATIONAL LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0012-6667 J9 DRUGS JI Drugs PY 2007 VL 67 IS 2 BP 195 EP 214 DI 10.2165/00003495-200767020-00003 PG 20 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 146TL UT WOS:000244957500003 PM 17284084 ER PT J AU Steinman, MA Maaravi, Y Walter, LC Hammerman-Rozenberg, R Stessman, J AF Steinman, Michael A. Maaravi, Yoram Walter, Louise C. Hammerman-Rozenberg, Robert Stessman, Jochanan TI Evolution of medication use in Jerusalem elders - Results from the Jerusalem longitudinal study SO DRUGS & AGING LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc ID 70 YEAR OLDS; NONPRESCRIPTION DRUG-USE; SOCIAL NETWORKS; POPULATION; HEALTH; PRESCRIPTION; ISRAEL; POLYPHARMACY; DETERMINANTS; MEDICINES AB Background: While overall rates of medication use have been increasing over time, less is known about how medication use changes within individuals as they age. Objective: The aim of this study was to evaluate changes in medication use and predictors of medication accrual among community-dwelling elders followed for a 7-year period, from age 70 +/- 1 years to age 77 +/- 1 years. Methods: The study was a community-based, longitudinal, cohort study. The study group consisted of 280 patients from the Jerusalem Longitudinal Study, a population-based sample of Jerusalem residents born in 1920-1 who underwent extensive evaluation in 1990-1 and again in 1997-8. The main outcome measure of the study was the change in the total number of medications taken between baseline and follow-up. Medication use was assessed by home interviews. Results: Half of the sample were men. Medication use more than doubled over the 7-year study period, from a mean of 2.0 to 5.3 medications per patient (p < 0.001), and 57 patients (20%) increased their total drug use by six or more medications. Vitamins, minerals and cardiovascular medications were the most commonly prescribed medications at follow-up, and accounted for approximately half of the total increase in medication use. On multivariable logistic regression analyses, decline in self-rated health was the strongest predictor of above-median increases in medication use (odds ratio [OR] 3.2; 95% CI 1.8, 6.2). The only nonclinical predictor of above-median increases in medication use was good social engagement at baseline (OR 1.8; 95% CI 1.1, 3.1). Conclusion: Medication use in Jerusalem elders grew rapidly over the 1990s, more than doubling in volume over a 7-year period. While health status was the factor most strongly predictive of the degree of change, the magnitude of increase for elders as a whole suggests major changes in prescribing practices over this interval. C1 San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Hadassah Univ Hosp, Dept Rehabil & Geriatr, IL-91120 Jerusalem, Israel. RP Stessman, J (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu NR 32 TC 3 Z9 3 U1 0 U2 0 PU ADIS INTERNATIONAL LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-229X J9 DRUG AGING JI Drugs Aging PY 2007 VL 24 IS 2 BP 133 EP 145 DI 10.2165/00002512-200724020-00005 PG 13 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 152XB UT WOS:000245394500005 PM 17313201 ER PT J AU Seltzer, B AF Seltzer, Ben TI Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified? SO DRUGS & AGING LA English DT Review ID PLACEBO-CONTROLLED TRIAL; MILD COGNITIVE IMPAIRMENT; RANDOMIZED CONTROLLED-TRIAL; DONEPEZIL THERAPY; DOUBLE-BLIND; COST-EFFECTIVENESS; HEALTH ECONOMICS; OPEN-LABEL; GALANTAMINE TREATMENT; CHOLINERGIC SYSTEM AB The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine are the current mainstays in the drug treatment of Alzheimer's disease (AD). There is convincing evidence that these agents provide at least modest cognitive, behavioural and functional benefit for 6-12 months at all stages of the disease. Longer term benefits cannot be directly examined by placebo-controlled trials. Nevertheless, the results of virtually all open-label extensions of the pivotal trials, studies of patients with AD at different levels of severity and clinical trials using other designs favour treatment over no treatment for periods of up to 5 years. There are plausible biological reasons why ChEIs might be expected to work over a prolonged period of time although, to date, studies using various markers to chart the effects of medication on long-term disease progression have yielded mixed results. The most contentious issue regarding long-term treatment is economic, but the majority of available economic analyses suggest net savings over the long term if patients with AD receive persistent treatment with ChEIs. C1 Harvard Med Sch, VA Boston Healthcare Syst, Dept Neurol, Boston, MA USA. RP Seltzer, B (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA. EM bseltzer@partners.org NR 116 TC 12 Z9 12 U1 1 U2 5 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-229X J9 DRUG AGING JI Drugs Aging PY 2007 VL 24 IS 11 BP 881 EP 890 PG 10 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 230YF UT WOS:000250911600001 PM 17953456 ER PT J AU Ludlow, CL Humbert, I Saxon, K Poletto, C Sonies, B Crujido, L AF Ludlow, Christy L. Humbert, Ianessa Saxon, Keith Poletto, Christopher Sonies, Barbara Crujido, Lisa TI Effects of surface electrical stimulation both at rest and during swallowing in chronic pharyngeal dysphagia SO DYSPHAGIA LA English DT Article DE deglutition; deglutition disorders; hyolaryngeal movement; aspiration; penetration; sensory stimulation; resistance; transcutaneous neuromuscular stimulation ID BEHAVIOR AB We tested two hypotheses using surface electrical stimulation in chronic pharyngeal dysphagia: that stimulation (1) lowered the hyoid bone and/or larynx when applied at rest, and (2) increased aspiration, penetration, or pharyngeal pooling during swallowing. Bipolar surface electrodes were placed on the skin overlying the submandibular and laryngeal regions. Maximum tolerated levels of stimulation were applied while patients held their mouth closed at rest. Videofluoroscopic recordings were used to measure hyoid movements in the superior-inferior and anterior-posterior dimensions and the subglottic air column position while stimulation was on or off. Patients swallowed 5 ml liquid when stimulation was off, at low sensory stimulation levels, and at maximum tolerated levels (motor). Speech pathologists, blinded to condition, tallied the frequency of aspiration, penetration, pooling, and esophageal entry from videofluorographic recordings of swallows. Only significant (p = 0.0175) hyoid depression occurred during stimulation at rest. Aspiration and pooling were significantly reduced only with low sensory threshold levels of stimulation (p = 0.025) and not during maximum levels of surface electrical stimulation. Those patients who had reduced aspiration and penetration during swallowing with stimulation had greater hyoid depression during stimulation at rest (p = 0.006). Stimulation may have acted to resist patients' hyoid elevation during swallowing. C1 NINDS, Laryngeal & Speech Sect, Bethesda, MD 20892 USA. Univ Wisconsin, Dept Med, GRECC, Madison, WI USA. Univ Wisconsin, Dept Radiol, GRECC, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NIH, Dept Rehabil, Ctr Clin, Bethesda, MD 20892 USA. Arizona State Univ, Dept Speech & Hearing Sci, Tempe, AZ USA. RP Ludlow, CL (reprint author), 10 Ctr Dr MSC 1416 Bldg,10 Rm,5D38, Bethesda, MD 20892 USA. EM ludlowc@ninds.nih.gov OI Ludlow, Christy/0000-0002-2015-6171 FU Intramural NIH HHS; NINDS NIH HHS [Z01 NS 02980, Z01 NS002980, Z01 NS002980-08] NR 15 TC 91 Z9 114 U1 1 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0179-051X J9 DYSPHAGIA JI Dysphagia PD JAN PY 2007 VL 22 IS 1 BP 1 EP 10 DI 10.1007/s00455-006-9029-4 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA 132SN UT WOS:000243962600001 PM 16718620 ER PT J AU Scherrer-Crosbie, M Rodrigues, ACT Hataishi, R Picard, MH AF Scherrer-Crosbie, Marielle Rodrigues, Ana Clara T. Hataishi, Ryuji Picard, Michael H. TI Infarct size assessment in mice SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES LA English DT Article DE myocardial perfusion; myocardial contrast echocardiography; wall motion abnormality; ischemia reperfusion ID MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY; WALL-MOTION ABNORMALITIES; NITRIC-OXIDE SYNTHASE; MOUSE MODEL; RISK AREA; REPERFUSION INJURY; MURINE MODEL; ISCHEMIA; DEFICIENT; PERFUSION AB Genetically modified mice are used extensively in models of ischemia reperfusion (I/R) and nonreperfused myocardial infarction (MI) to gain insights into pathways involved in these pathologies. Echocardiography is an ideal noninvasive tool to serially monitor the cardiac murine phenotype. The present review details the surgical aspects of I/R and MI models and the measurement of MI size by pathology techniques and the input of echocardiographic techniques including the extent of wall motion abnormality and of perfusion defects using myocardial contrast echocardiography in the assessment of murine area at risk and MI size. C1 Massachusetts Gen Hosp, Dept Med, Div Cardiol, Cardiac Ultrasound Lab, Boston, MA 02114 USA. RP Scherrer-Crosbie, M (reprint author), Massachusetts Gen Hosp, Dept Med, Div Cardiol, Cardiac Ultrasound Lab, Boston, MA 02114 USA. EM marielle@crosbie.com OI Picard, Michael/0000-0002-9264-3243 NR 31 TC 11 Z9 12 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0742-2822 J9 ECHOCARDIOGR-J CARD JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech. PD JAN PY 2007 VL 24 IS 1 BP 90 EP 96 DI 10.1111/j.1540-8175.2007.00357.x PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 122NP UT WOS:000243234000017 PM 17214631 ER PT J AU Weisskopf, MG Proctor, SP Wright, RO Schwartz, J Spiro, A Sparrow, D Nie, HL Hu, H AF Weisskopf, Marc G. Proctor, Susan P. Wright, Robert O. Schwartz, Joel Spiro, Avron, III Sparrow, David Nie, Huiling Hu, Howard TI Cumulative lead exposure and cognitive performance among elderly men SO EPIDEMIOLOGY LA English DT Article ID NEUROBEHAVIORAL TEST-SCORES; BLOOD LEAD; LONGITUDINAL DECLINE; ALZHEIMERS-DISEASE; CHELATABLE LEAD; INORGANIC LEAD; BONE LEAD; WORKERS; AGE; TOXICITY AB Background: Recent evidence suggests that cumulative lead exposure among adults in nonoccupational settings can adversely affect cognitive function. Which cognitive domains are affected has not been explored in detail. Methods: We used nonlinear spline regressions and linear repeated-measures analysis to assess the association between scores on a battery of cognitive tests over time and both blood and bone lead concentrations in the Normative Aging Study, a cohort of community-dwelling elderly men. Bone lead was measured from 1991 through 1999 with K-shell x-ray fluorescence. A total of 1089 men with a mean ( standard deviation) age of 68.7 (+/-7.4) years with blood lead measurements, 761 of whom also had valid bone lead measurements, completed at least one of a battery of cognitive tests. Approximately 3.5 years later, 69% of the men had at least one repeat test. Cognitive testing was performed from 1993 through 2001. Results: On a cross-sectional basis, there was little association between blood or bone lead and cognitive test scores. Change in performance over time on virtually all tests worsened as bone lead increased, with the most robust effects on performance and reaction time scores on visuospatial/visuomotor tests. Conclusions: Low-level cumulative exposure to lead in nonoccupational settings may adversely affect cognitive function, particularly in the visuospatial/visuomotor domain. C1 Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Occupat Hlth Program,Landmark Ctr, Boston, MA 02215 USA. VA Boston Healthcare Syst, Boston, MA USA. Boston Univ, Sch Publ Hlth, Boston, MA USA. Childrens Hosp, Dept Pediat, Boston, MA 02115 USA. Harvard Univ, Sch Med, Channing Lab, Dept Med,Brigham & Womens Hosp, Boston, MA 02115 USA. Boston Univ, Sch Dent Med, Boston, MA 02215 USA. Boston Univ, Sch Med, Boston, MA 02118 USA. RP Weisskopf, MG (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Occupat Hlth Program,Landmark Ctr, 401 Park Dr,POB 15697, Boston, MA 02215 USA. EM mweissko@hsph.harvard.edu OI Spiro III, Avron/0000-0003-4080-8621 FU NCRR NIH HHS [M01RR02635]; NIA NIH HHS [R01-AG18436, R01-AG13006, R01-AG14345]; NIAAA NIH HHS [R01-AA08941]; NIEHS NIH HHS [2R44 ES03918-02, K01-ES012653, P30-ES00002, P42-ES05947, R01 ES005257, R01 ES005257-15, R01-ES05257] NR 39 TC 64 Z9 69 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1044-3983 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2007 VL 18 IS 1 BP 59 EP 66 DI 10.1097/01.ede.0000248237.35363.29 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 116XI UT WOS:000242836700012 PM 17130688 ER PT J AU Kerrigan, JF Ng, YT Prenger, E Krishnamoorthy, KS Wang, NC Rekate, HL AF Kerrigan, John F. Ng, Yu-tze Prenger, Erin Krishnamoorthy, Kalpathy S. Wang, Norman C. Rekate, Harold L. TI Hypothalamic hamartoma and infantile spasms SO EPILEPSIA LA English DT Article DE infantile spasms; hypothalamic hamartoma; subcortical epilepsy; gelastic seizures ID GELASTIC EPILEPSY; TRANSCALLOSAL RESECTION; INTRACTABLE EPILEPSY; SURGICAL-TREATMENT; SURGERY; CHILDREN; ADOLESCENTS; SEIZURES; PUBERTY; ADULTS AB Purpose: A small number of patients with hypothalamic hamartoma (HH) present with infantile spasms (IS) as an initial or early seizure type. We describe the clinical features of IS associated with HH. Methods: Our series of patients with HH and epilepsy was reviewed to identify cases with a history of IS. The clinical features and neuroradiological findings in this study group were compared to a control group of patients with HH and refractory epilepsy, but without a history of IS. Results: We identified six patients with HH and a history of IS in this series (n = 122, 4.9%). Five of the six are male. Four of the six patients (67%) developed IS as their first seizure type. The mean age for onset of IS was 6.2 months (range 4-9 months). Results of electroencephalographic (EEG) study at the time of IS diagnosis showed hypsarrhythmia in two (33%). Five patients were treated with adrenocorticotropic hormone (ACTH), and four of the five (80%) responded with control of IS. However, these patients developed other seizure types, and were ultimately refractory to medical management. Aside from the IS, no significant differences in clinical and imaging features were determined between the study group and the control group. Conclusions: HH should be included in the differential diagnosis for infants presenting with IS. These patients may have hypsarrhythmia on initial EEG, and may respond to ACTH treatment with improvement of IS. However, all became refractory with other seizure types, more commonly seen in HH patients. Focal pathologies associated with IS may be subcortical, as well as cortical, in nature. We have not identified any predictive features for the occurrence of IS in the HH population. C1 St Josephs Hosp, Barrow Neurol Inst, Epilepsy Ctr, Phoenix, AZ USA. St Josephs Hosp, Barrow Neurol Inst, Div Pediat Neurol, Phoenix, AZ USA. St Josephs Hosp, Barrow Neurol Inst, Div Neuroradiol, Phoenix, AZ USA. St Josephs Hosp, Barrow Neurol Inst, Div Neurosurg, Phoenix, AZ USA. St Josephs Hosp, Childrens Hlth Ctr, Phoenix, AZ USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pediat Neurol, Boston, MA USA. RP Kerrigan, JF (reprint author), Barrow Neurol Inst, 500 W Thomas Rd,S-930, Phoenix, AZ 85013 USA. EM jkerrigan@chw.edu NR 43 TC 13 Z9 13 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD JAN PY 2007 VL 48 IS 1 BP 89 EP 95 DI 10.1111/j.1528-1167.2006.00835.x PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 125WB UT WOS:000243473100011 PM 17241213 ER PT S AU Virmani, R Kolodgie, FD Finn, AV Gold, HK AF Virmani, Renu Kolodgie, Frank D. Finn, Aloke V. Gold, Herman K. BE Duckers, HJ Nabel, EG Serruys, PW TI Pathological Anatomy of Restenosis SO ESSENTIALS OF RESTENOSIS: FOR THE INTERVENTIONAL CARDIOLOGIST SE Contemporary Cardiology LA English DT Article; Book Chapter ID SIROLIMUS-ELUTING STENTS; HUMAN CORONARY-ARTERIES; HUMAN SAPHENOUS-VEIN; SMOOTH-MUSCLE CELLS; FIBRIN FRAGMENT-E; TISSUE-RESPONSE; PORCINE MODEL; ANGIOGENESIS; IMPLANTATION; PLAQUE C1 [Virmani, Renu; Kolodgie, Frank D.] Armed Forces Inst Pathol, Dept Cardiovasc Pathol, Washington, DC 20306 USA. [Finn, Aloke V.; Gold, Herman K.] Massachusetts Gen Hosp, Dept Internal Med, Cardiac Unit, Boston, MA 02114 USA. RP Virmani, R (reprint author), Armed Forces Inst Pathol, Dept Cardiovasc Pathol, Washington, DC 20306 USA. NR 49 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1191-7601 BN 978-1-59745-001-0 J9 CONTEMP CARDIOL JI Contemp. Cardiol. PY 2007 BP 47 EP + DI 10.1007/978-1-59745-001-0_4 D2 10.1007/978-1-59745-001-0 PG 14 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA BLY72 UT WOS:000271458800005 ER PT J AU Goodyer, E Hemmerich, S Muller, F Kobler, JB Hess, M AF Goodyer, Eric Hemmerich, Sandra Mueller, Frank Kobler, James B. Hess, Markus TI The shear modulus of the human vocal fold, preliminary results from 20 larynxes SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY LA English DT Article DE elasticity; shear modulus; vocal fold biomechanics; shear modulus of the vocal fold ID IN-VIVO; ELASTICITY AB Quantification of the elastic properties of the human vocal fold provides invaluable data for researchers deriving mathematical models of phonation, developing tissue engineering therapies, and as normative data for comparison between healthy and scarred tissue. This study measured the shear modulus of excised cadaver vocal folds from 20 subjects. Twenty freshly excised human larynxes were evaluated less than four days post-mortem. They were split along the saggital plane and mounted without tension. Shear modulus was obtained by two different methods. For method I cyclical shear stress was applied transversely to the mid-membranous portion of the vocal fold, and shear modulus derived by applying a simple shear model. For method 2 the apparatus was configured as an indentometer, and shear modulus obtained from the stress/strain data by applying an established analytical technique. Method 1 shear model for male larynxes yielded a range from 246 to 3,356 Pa, with a mean value of 1,008 and SID of 380. The range for female larynxes was 286-3,332 Pa, with a mean value of 1,237 and SD of 768. Method 2 indentometer model for male larynxes yielded a range from 552 to 2,741 Pa, with a mean value of 1,000 and SID of 460. The range for female larynxes was 509-1,989 Pa, with a mean value of 1,332 and SD of 428. We have successfully demonstrated two methodologies that are capable of directly measuring the shear modulus of the human vocal fold, without dissecting out the vocal fold cover tissue. The sample size of nine female and 11 male larynxes is too small to validate a general conclusion. The high degree of variability in this small cohort of subjects indicates that factors such as age, health status, and post-mortem delay may be significant; and that there is range of 'normality' for vocal fold tissue. C1 De Montfort Univ, Ctr Computat Intelligence, Bioinformat Grp, Leicester LE1 9BH, Leics, England. Univ Hamburg, Med Ctr, Dept Phoniatr & Pediat Audiol, D-20246 Hamburg, Germany. Massachusetts Gen Hosp, Ctr Laryngol Surg &Voice Rehabil, Boston, MA 02114 USA. RP Goodyer, E (reprint author), De Montfort Univ, Ctr Computat Intelligence, Bioinformat Grp, The Gateway, Leicester LE1 9BH, Leics, England. EM eg@dmu.ac.uk RI goodyer, eric/G-9191-2012; OI goodyer, eric/0000-0002-4414-0860; Muller, Frank/0000-0003-0566-3076 NR 15 TC 22 Z9 22 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0937-4477 J9 EUR ARCH OTO-RHINO-L JI Eur. Arch. Oto-Rhino-Laryn. PD JAN PY 2007 VL 264 IS 1 BP 45 EP 50 DI 10.1007/s00405-006-0133-8 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 124DK UT WOS:000243347400008 PM 16924433 ER PT J AU Raivio, T Wikstrom, AM Dunkel, L AF Raivio, Taneli Wikstrom, Anne M. Dunkel, Leo TI Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome SO EUROPEAN JOURNAL OF ENDOCRINOLOGY LA English DT Article ID FOLLICLE-STIMULATING-HORMONE; HUMAN CHORIONIC-GONADOTROPIN; ISOLATED HYPOGONADOTROPIC HYPOGONADISM; SERTOLI-CELL PROLIFERATION; INHIBIN B LEVELS; LUTEINIZING-HORMONE; HUMAN TESTIS; THERAPY; SPERMATOGENESIS; MUTATION AB Background: Boys with prepubertal onset of hypogonadotropic hypogonadism (HH) are at a risk of poor testis growth and impaired spermatogenesis. One potential cause for this is deficient proliferation of immature Sertoli cells before and during puberty due to the absence of FSH. Objective: To evaluate the effects of recombinant human FSH (r-hFSH) and human chorionicgonadotropin (hCG) on testicular function and pubertal development in boys with prepubertal onset of HH. Design: Retrospective clinical study. Setting: Two university central hospitals, pediatric referral endocrinology outpatient clinics. Patients: Fourteen boys (aged, 9.9-17.7 years) with prepubertal (testicular volume (TV) < 3 ml) onset of HH (idiopathic HH, n = 2; Kallman syndrome, it = 2; idiopathic panhypopituitarism, n = 4; organic panhypopituitarism, n = 6). Intervention: Treatment with r-hFSH alone (2 mo-2.8 years) prior to induction of puberty with the combination of FSH and hCG. Main outcome measures: Progression of puberty, change in serum inhibin B, spermatogenesis. Results: r-hFSH alone increased testicular volume twofold, from 0.9 +/- 0.6 ml (mean +/- S.D.) to 1.8 +/- 1.1 ml (P < 0.005), and serum inhibin B threefold, from 27 +/- 14 to 80 +/- 57 pg/ml (P < 0.01). Three boys with an apparent absence of postnatal hypothalamic-pituitary-testicular axis activation displayed attenuated inhibin B responses to long-term (>= 1 year) r-hFSH (P < 0.01). Further significant increase in both TV and inhibin B occurred with induction of puberty with FSH and hCG (P < 0.001). Seven boys provided semen samples: one had azoospermia, and others displayed a maximal sperm count range from 2.9 to 92 million/ml (median 8.5 million/ml). Conclusions: (i) r-hFSH induces prepubertal testis growth and increases circulating inhibin B levels, findings suggesting proliferation of immature Sertoli cells. (ii) Puberty was successfully induced with hCG and r-hFSH following r-hFSH priming. (iii) Inhibin B appears useful for monitoring spermatogenetic activity in boys treated with hCG. (iv) Despite the extremely small initial testis volume, six out of seven patients (86%) primed with r-hFSH displayed sperm in the ejaculate suggesting beneficial effect of r-hFSH priming on testicular function later in life. C1 Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, Helsinki, Finland. Univ Kuopio, Kuopio Univ Hosp, Dept Pediat, FIN-70211 Kuopio, Finland. RP Raivio, T (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, BHX 511,55 Fruit St, Boston, MA 02114 USA. EM traivio@gmail.com NR 34 TC 41 Z9 45 U1 1 U2 3 PU BIO SCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0804-4643 J9 EUR J ENDOCRINOL JI Eur. J. Endocrinol. PD JAN PY 2007 VL 156 IS 1 BP 105 EP 111 DI 10.1530/eje.1.02315 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 152JK UT WOS:000245358100013 PM 17218732 ER PT J AU Fan, Y Liu, ZY Weinstein, PR Fike, JR Liu, JL AF Fan, Yang Liu, Zhengyan Weinstein, Philip R. Fike, John R. Liu, Jialing TI Environmental enrichment enhances neurogenesis and improves functional outcome after cranial irradiation SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE cognitive impairment; dentate gyrus; gerbil; memory; neural precursor cells; radiation injury ID INDUCED COGNITIVE DYSFUNCTION; EARLY-ONSET STIMULATION; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; HIPPOCAMPAL NEUROGENESIS; DENTATE GYRUS; ADULT NEUROGENESIS; NEURONAL DIFFERENTIATION; NEUROTROPHIN LEVELS; CELL-PROLIFERATION AB Radiation therapy is a widely used treatment for brain tumors but it can cause delayed progressive cognitive decline and memory deficits. Previous studies suggested that this neurocognitive dysfunction might be linked to the impairment of hippocampal neurogenesis. However, little is known regarding how to reduce the cognitive impairment caused by radiation therapy. To investigate whether environmental enrichment (EE) promotes neurogenesis and cognitive function after irradiation, irradiated gerbils were housed in EE for 2 months and evaluated by neurobehavioral testing for learning and memory function, and immunohistochemical analysis for neurogenesis. Our results demonstrated that even relatively low doses (5-10 Gy) of irradiation could acutely abolish precursor cell proliferation in the dentate gyrus by more than 90%. This reduction in precursor proliferation was persistent and led to a significant decline in the granule cell population 9 months later. EE housing enhanced the number of newborn neurons and increased residual neurogenesis. EE also significantly increased the total number of immature neurons in the dentate gyrus. Furthermore, irradiated animals after EE housing showed a significant improvement in spatial learning and memory during the water-maze test and in rotorod motor learning over a 5-day training paradigm. In conclusion, EE has a positive impact on hippocampal neurogenesis and functional recovery in irradiated adult gerbils. Our data suggest that there is still a considerable amount of plasticity remaining in the hippocampal progenitor cells in adult animals after radiation injury, which can become a target of therapeutic intervention for radiation-induced cognitive dysfunction. C1 Univ Calif San Francisco, Dept Neurol Surg 112C, San Francisco, CA 94121 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Fudan Univ, HuaShan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China. RP Liu, JL (reprint author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA. EM jialing.liu@ucsf.edu RI Liu, Jialing/A-8627-2012 OI Liu, Jialing/0000-0003-4420-4382 FU NINDS NIH HHS [R01 NS40469, R21 NS051576, R01 NS46051] NR 64 TC 75 Z9 81 U1 1 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD JAN PY 2007 VL 25 IS 1 BP 38 EP 46 DI 10.1111/j.1460-9568.2006.05269.x PG 9 WC Neurosciences SC Neurosciences & Neurology GA 128TQ UT WOS:000243682100004 PM 17241265 ER PT J AU Kumar, S Szymusiak, R Bashir, T Rai, S McGinty, D Alam, MN AF Kumar, Sunil Szymusiak, Ronald Bashir, Tariq Rai, Seema McGinty, Dennis Alam, Md. Noor TI Effects of serotonin on perifornical-lateral hypothalamic area neurons in rat SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE hypocretin; melanin-concentrating hormone; orexin; serotonin; sleep ID DORSAL RAPHE NEURONS; EYE-MOVEMENT SLEEP; OREXIN/HYPOCRETIN NEURONS; HYPOCRETIN NEURONS; 5-HT1A RECEPTOR; OREXIN NEURONS; WAKING; NARCOLEPSY; WAKEFULNESS; MICRODIALYSIS AB The hypocretin (HCRT) system of the perifornical-lateral hypothalamic area (PF-LHA) has been implicated in the facilitation of behavioral arousal. HCRT neurons receive serotonergic afferents from the dorsal raphe nucleus. Although in-vitro pharmacological studies suggest that serotonin (5-HT) inhibits HCRT neurons, the in-vivo effects of 5-HT on HCRT neurons in the PF-LHA and associated behavioral changes have not been described. We examined the effects of 5-HT delivered locally into the PF-LHA using reverse microdialysis on its neuronal activity and the consequent sleep-wake changes in rats. First, we quantified Fos expression (Fos-IR) in HCRT and other PF-LHA neurons following unilateral 5-HT perfusion in awake rats. Second, we determined the transient effects of 5-HT perfusion on the extracellular activity of the PF-LHA neurons recorded via microwires placed adjacent to the microdialysis probe. Third, we examined the effects of 5-HT perfusion into the PF-LHA on the sleep-wake profiles of the rats during the lights-off period. Unilateral perfusion of 5-HT into the PF-LHA in awake rats dose-dependently decreased the number of HCRT neurons exhibiting Fos-IR. 5-HT also inhibited the discharge activity of four of five responsive wake-related, putative HCRT neurons. However, unilateral perfusion of 5-HT into the PF-LHA did not produce significant behavioral changes during the 2-h recording period. These results confirm the in-vitro findings that 5-HT exerts inhibitory influences on HCRT neurons but further suggest that the inactivation of a limited number of HCRT neurons by unilateral 5-HT microdialysis may not be sufficient to induce behavioral changes. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Univ Patna, Patna 800005, Bihar, India. RP Alam, MN (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, 16111 Plummer St,151A3, Sepulveda, CA 91343 USA. EM noor@ucla.edu FU NHLBI NIH HHS [HL60296]; NIMH NIH HHS [R01 MH075076, MH63323, MH47480]; NINDS NIH HHS [NS-050939] NR 45 TC 16 Z9 19 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD JAN PY 2007 VL 25 IS 1 BP 201 EP 212 DI 10.1111/j.1460-9568.2006.05268.x PG 12 WC Neurosciences SC Neurosciences & Neurology GA 128TQ UT WOS:000243682100020 PM 17241281 ER PT J AU Magruder, KM Yeager, DE AF Magruder, Kathryn M. Yeager, Derik E. TI Mental health problems in primary care: Progress in North America SO EUROPEAN JOURNAL OF PSYCHIATRY LA English DT Article DE mental health; primary health care; United States ID RANDOMIZED CONTROLLED-TRIAL; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CLINICAL-PRACTICE GUIDELINE; POSTTRAUMATIC-STRESS; NATIONAL TRENDS; DEPRESSION; MANAGEMENT; PREVALENCE; COMPUTER; INTERNET AB Background and Objectives: Research in the last decade has acknowledged that primary care plays a pivotal role in the delivery of mental health services. The aim of this paper is to review major accomplishments, emerging trends, and continuing gaps concerning mental health problems in primary care in North America. Methods: Literature from North America was reviewed and synthesized. Results: Major accomplishments include: the development and adoption of a number of clinical guidelines specifically for mental health conditions in primary care, the acceptance of the chronic care model as a framework for treating depression in primary care, and the clear adoption of pharmacologic approaches as the predominant mode for treating depression and anxiety. Emerging trends include: the use of non-physician facilitators as care managers in the treatment of depression in primary care, increasing use of technology in the assessment and treatment of mental health conditions in primary care, and dissemination and implementation of integrated mental health treatment approaches. Lingering issues include: the difficulty in moving beyond problem identification and initiation of treatment to sustaining evidence-based treatments, agreement on a common metric to evaluate outcomes, and the stigma still associated with mental illness. Conclusion: Though there now exists a solid and growing evidence base for the delivery of mental health services in primary care, there are still significant challenges which must be overcome in order to make further advances. C1 Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. RP Magruder, KM (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29425 USA. EM magrudkm@musc.edu NR 43 TC 3 Z9 4 U1 2 U2 5 PU EUROPEAN JOURNAL OF PSYCHIATRY PI SARAGOOSE PA PO BOX 6029, 50080 SARAGOOSE, SPAIN SN 0213-6163 J9 EUR J PSYCHIAT JI Eur. J. Psychiat. PD JAN-MAR PY 2007 VL 21 IS 1 BP 55 EP 61 PG 7 WC Psychiatry SC Psychiatry GA 181IX UT WOS:000247431500007 ER PT J AU Papakostas, GI Fava, M AF Papakostas, George I. Fava, Maurizio TI A meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder SO EUROPEAN NEUROPSYCHOPHARMACOLOGY LA English DT Article DE milnacipran; SSRI; major; depressive; disorder; response ID DOUBLE-BLIND; GENERAL-PRACTICE; PRIMARY-CARE; FLUOXETINE; SERTRALINE; EFFICACY; MULTICENTER; PAROXETINE; CITALOPRAM; OUTPATIENTS AB Context: Over the past few years, a number of studies have emerged suggesting that the treatment of major depressive disorder (MDD) with antidepressants which enhance both noradrenergic as well as serotonergic neurotransmission may result in higher response or remission rates than treatment with antidepressants which selectively enhance serotonergic neurotransmission. Objective: The objective of this paper was to compare response rates among patients with MDD treated with either mitnacipran, an antidepressant thought to simultaneously enhance both noradrenergic and serotonergic neurotransmission, or a selective serotonin reuptake inhibitor (SSRI). Data sources: Medline/Pubmed were searched. No year of publication or language limits were used. Study selection: Double-blind, randomized clinical trials comparing mitnacipran with an SSRI for the treatment of MDD. Data extraction: Data were extracted with the use of a pre-coded form. Data synthesis: Analyses were performed comparing response rates between the two antidepressant agents. Data from 6 reports involving a total of 1082 outpatients with MDD were identified and combined using a random-effects model. Patients randomized to treatment with mitnacipran were as likely to experience clinical response as patients randomized to treatment with an SSRI according to the MADRS (RR= 1.04, 95% CI: 0.88-1.23, p =0.533) or the HDRS (RR=1.06, 95% CI: 0.90-1.24, p=0.456) for the random effects model. Simply pooling MADRS-based response rates between the two agents revealed a 58.9% response rate for mitnacipran and a 58.3% response rate for the SSRIs. Similarly, HDRS-based response rates were 59.7% and 57.5%. There was also no difference in overall discontinuation rates (RR=0.93; 95% CI :0.76-1.14; p=0.506), the rate of discontinuation due to adverse events (RR=0.77; 95% CI: 0.55-1.1; p=0.157), or the rate of discontinuation due to inefficacy (RR=0.98; 95% CI: 0.71.38; p=0.95) between the two groups. Conclusions: These results suggest that miLnacipran and the SSRIs do not differ with respect to their overall efficacy in the treatment of MDD. (c) 2006 Elsevier B.V. and ECNP. All rights reserved. C1 Harvard Univ, Sch Med, Depress Clin & Res Program,Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Papakostas, GI (reprint author), Harvard Univ, Sch Med, Depress Clin & Res Program,Dept Psychiat, Massachusetts Gen Hosp, 15 Parkman St,WAC 812, Boston, MA 02114 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 NR 36 TC 24 Z9 24 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-977X EI 1873-7862 J9 EUR NEUROPSYCHOPHARM JI Eur. Neuropsychopharmacol. PD JAN PY 2007 VL 17 IS 1 BP 32 EP 36 DI 10.1016/j.euroneuro.2006.05.001 PG 5 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 119SI UT WOS:000243033200005 PM 16762534 ER PT J AU Barnes, DE Whitmer, RA Yaffe, K AF Barnes, Deborah E. Whitmer, Rachel A. Yaffe, Kristine TI Physical activity and dementia: The need for prevention trials SO EXERCISE AND SPORT SCIENCES REVIEWS LA English DT Review DE exercise; fitness; cognitive decline; aged; epidemiology; mechanisms ID COGNITIVE IMPAIRMENT; OLDER-ADULTS; CARDIOVASCULAR FITNESS; ALZHEIMERS-DISEASE; ELDERLY PERSONS; RISK; EXERCISE; HEALTH; INFLAMMATION; POPULATION AB Dementia is a common and debilitating disease that will increase dramatically for the next 50 years unless a prevention or treatment is identified. This review summarizes the evidence that physical activity is associated with a reduced risk of dementia in older adults and recommends that prevention trials be performed to determine whether this association is causal. C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Kaiser Permanente, Div Res, Oakland, CA USA. RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St 181G, San Francisco, CA 94121 USA. EM Deborah.Barnes@ucsf.edu FU NIA NIH HHS [K01 AG024069, K01 AG024069-01A1] NR 25 TC 26 Z9 28 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0091-6331 J9 EXERC SPORT SCI REV JI Exerc. Sport Sci. Rev. PD JAN PY 2007 VL 35 IS 1 BP 24 EP 29 DI 10.1097/JES.0b013e31802d6bc2 PG 6 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 127EE UT WOS:000243567300006 PM 17211190 ER PT J AU Cole, GM Frautschy, SA AF Cole, Greg M. Frautschy, Sally A. TI The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease SO EXPERIMENTAL GERONTOLOGY LA English DT Article; Proceedings Paper CT 8th International Symposium on the Neurobiology and Neuroendocrinology of Aging CY JUL 23-28, 2006 CL Bregenz, AUSTRIA DE insulin resistance; TZDs (thiazolidinediones); brain aging ID GROWTH-FACTOR-I; AMYLOID PRECURSOR PROTEIN; POLYUNSATURATED FATTY-ACIDS; MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E GENOTYPE; TRANSGENIC MOUSE MODEL; DOCOSAHEXAENOIC ACID; DEGRADING ENZYME; BETA-PROTEIN; CELL-SURVIVAL AB Although increased lifespan is associated with reduced insulin signaling, insulin signaling is essential for neuronal development and survival. Insulin resistance is central to Type II diabetes and is also implicated in the pathogenesis of Alzheimer's Disease (AD). This has prompted ongoing clinical trials in AD patients to test the efficacy of improving insulin - like signaling with dietary omega-3 fatty acids or insulin - sensitizing drugs as well as exercise regimens. Here we review the role of insulin signaling in brain aging and AD, concluding that the signaling pathways downstream to neurotrophic and insulin signaling are defective and coincident with aberrant phosphorylation and translocation of key components, notably AKT and GSK3 beta, but also rac > PAK signaling. These responses are likely to contribute to defects in synaptic plasticity, learning and memory. Both oligomers of beta-amyloid (which are elevated in the AD brain) and pro-inflammatory cytokines (which are elevated in the aged or AD brain) can be used to mimic the trophic factor/insulin resistance observed in AD, but details on other factors and mechanisms contributing to this resistance remain elusive. A better understanding of the precise mechanisms underlying alterations in the insulin/neurotrophic factor signal transduction pathways should aid the search for better AD therapeutic and prevention strategies. (c) 2006 Elsevier Inc. All rights reserved. C1 Greater Los Angeles Vet Affairs Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. RP Cole, GM (reprint author), Greater Los Angeles Vet Affairs Healthcare Syst, Ctr Geriatr Res Educ & Clin, 16111 Plummer St, Sepulveda, CA 91343 USA. EM gmcole@ucla.edu FU NCCIH NIH HHS [AT003008-01, R01 AT003008, R01 AT13741]; NIA NIH HHS [P50 AG016570, R01 AG013741]; RRD VA [I01 RX000669] NR 108 TC 111 Z9 117 U1 2 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD JAN-FEB PY 2007 VL 42 IS 1-2 SI SI BP 10 EP 21 DI 10.1016/j.exger.2006.08.009 PG 12 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 128HJ UT WOS:000243648500004 PM 17049785 ER PT S AU Parodi, K Ferrari, A Sommerer, F Paganetti, H AF Parodi, K. Ferrari, A. Sommerer, F. Paganetti, H. BE Reynaert, N TI A MC tool for CT-based calculations of dose delivery and beta(+)-activation in proton therapy SO FIRST EUROPEAN WORKSHOP ON MONTE CARLO TREATMENT PLANNING SE Journal of Physics Conference Series LA English DT Proceedings Paper CT 1st European Workshop on Monte Carlo Treatment Planning CY OCT 22-25, 2006 CL Gent, BELGIUM ID MONTE-CARLO SIMULATIONS; IN-BEAM PET; RADIATION-THERAPY; DISTRIBUTIONS; FLUKA AB The feasibility and value of offline PET/CT imaging for in-vivo, non-invasive verification of proton beam delivery is currently under investigation at Massachusetts General Hospital, Boston. Within this project we have developed a Monte Carlo framework for CT-based calculation of dose and irradiation induced positron emitter distributions using the FLUKA Monte Carlo code. Particle transport in the patient is performed on the CT grid, taking into account realistic tissue composition as well as the correlation between CT numbers and stopping power ratio to water as used by the commercial treatment planning system (XiO, Computerized Medical System Inc.). Positron emitter production is computed by combining during runtime proton fluence with experimental and evaluated cross-sections for all the major reaction channels yielding measurable tissue activation. In this paper we describe our dedicated implementation which might be easily generalised for use in other proton therapy centres or extended to include further activation reaction channels, provided that initial beam information or experimental cross sections are known. Further, we present clinical examples for calculation of delivered dose and irradiation induced PET activation. C1 [Parodi, K.; Paganetti, H.] Heidelberg Ion Therapy Ctr, Heidelberg, Germany. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Parodi, K (reprint author), Heidelberg Ion Therapy Ctr, Heidelberg, Germany. EM Katia.Parodi@med.uni-heidelberg.de FU NCI [5 P01 CA21239-25]; Proton Radiation Therapy Research FX This work was supported by NCI Grant 5 P01 CA21239-25 for Proton Radiation Therapy Research NR 20 TC 0 Z9 0 U1 0 U2 0 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1742-6588 J9 J PHYS CONF SER PY 2007 VL 74 DI 10.1088/1742-6596/74/1/012013 PG 6 WC Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging SC Physics; Radiology, Nuclear Medicine & Medical Imaging GA BGW86 UT WOS:000251015500013 ER PT S AU Seco, J Jiang, H Herrup, D Kooy, H Paganetti, H AF Seco, J. Jiang, H. Herrup, D. Kooy, H. Paganetti, H. BE Reynaert, N TI Monte Carlo tool for combined photon and proton treatment planning verification SO FIRST EUROPEAN WORKSHOP ON MONTE CARLO TREATMENT PLANNING SE Journal of Physics Conference Series LA English DT Proceedings Paper CT 1st European Workshop on Monte Carlo Treatment Planning CY OCT 22-25, 2006 CL Gent, BELGIUM ID MONTE-CARLO SIMULATIONS; NUCLEAR-INTERACTIONS; DOSE CALCULATIONS; BEAM; DISTRIBUTIONS; RADIATION; THERAPY; CODE AB Photons and protons are usually used independently to treat cancer. However, at MGH patients can be treated with both photons and protons since both modalities are available on site. A combined therapy can be advantageous in cancer therapy due to the skin sparing ability of photons and the sharp Bragg peak fall-off for protons beyond the tumor. In the present work, we demonstrate how to implement a combined 3D MC tootkit for photon and proton (ph-pr) therapy, which can be used for verification of the treatment plan. The commissioning of a MC system for combined ph-pr involves initially the development of a MC model of both the photon and proton treatment heads. The MC dose tool was evaluated on a head and neck patient treated with both combined photon and proton beams. The combined ph-pr dose agreed with measurements in solid water phantom to within 3%/3mm. Comparison with commercial planning system pencil beam prediction agrees within 3% (except for air cavities and bone regions). C1 [Seco, J.; Herrup, D.; Kooy, H.; Paganetti, H.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. [Jiang, H.] Univ Arkansas Med Sci, Little Rock, AR 72202 USA. RP Seco, J (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. EM jseco@partners.org FU NCI [P01 CA21239-25] FX From Massachusetts General Hospital, Boston, the authors wish to thank J Sisterson for providing literature data and useful discussion on experimental cross-sections and A Trofimov for help with the handling and display of patient planning data. This work was supported by NCI grant 5 P01 CA21239-25 for Proton Radiation Therapy Research. NR 19 TC 0 Z9 0 U1 0 U2 0 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1742-6588 J9 J PHYS CONF SER PY 2007 VL 74 DI 10.1088/1742-6596/74/1/012014 PG 6 WC Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging SC Physics; Radiology, Nuclear Medicine & Medical Imaging GA BGW86 UT WOS:000251015500014 ER PT J AU Angelini, M Brahmbhatt, Y AF Angelini, Michael Brahmbhatt, Yogini TI A review of the pharmacologic options for the treatment of alcohol dependence SO FORMULARY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; COGNITIVE-BEHAVIORAL THERAPY; DOUBLE-BLIND; RELAPSE PREVENTION; MAINTAINING ABSTINENCE; ORAL TOPIRAMATE; CLINICAL-TRIAL; UNITED-STATES; NALTREXONE AB The chronic and excessive use of alcohol adversely affects the healthcare system, work productivity, and familial and social relationships. Alcohol misuse accounts for 85,000 deaths per year in the United States, and the overall financial costs related to alcohol dependence are more than $100 billion annually. The reduction of alcohol misuse can be measured as an increase in the frequency of abstinence or a reduction in the frequency of relapses. The recommendation for alcohol dependence treatment is a combination of psychosocial support therapy and pharmacologic treatment. Currently, there are only 3 FDA-approved agents for the treatment of alcohol dependence: naltrexone, acamprosate, and disulfiram, The literature suggests that there may be varying expectations for the potential beneficial outcomes associated with each of these medications. Treatment with naltrexone has consistently demonstrated a decrease in overall alcohol consumption and fewer relapses when compared with placebo. Acamprosate has been associated with an improvement in maintaining abstinence and more total days of continuous abstinence compared with placebo. Disulfiram treatment has yielded inconsistent results in reducing alcohol consumption when compared with placebo, and observed administration may be the only way to ensure compliance. In general, since disulfiram treatment has not demonstrated long-term efficacy and because of its risk for causing hepatotoxicity, it is not considered a first-line medication option. Other pharmacologic options with differing effects on neurotransmitters also are being studied. Each agent, with its unique mechanism of action, seems to play a role in treating alcohol dependence, either as monotherapy or as part of polypharmacy. Future research is necessary to help specify which patient characteristics will predict the most effective pharmacologic treatment plan for the management of alcohol dependence. C1 Massachusetts Coll Pharm & Hlth Sci, Boston, MA 02115 USA. VA Boston Healthcare Syst, Boston, MA USA. Commonwealth Med Managed Care Residency Program, Clin Pharm Serv, Worcester, MA USA. RP Angelini, M (reprint author), Massachusetts Coll Pharm & Hlth Sci, Boston, MA 02115 USA. NR 74 TC 3 Z9 3 U1 5 U2 7 PU ADVANSTAR COMMUNICATIONS PI DULUTH PA 131 W FIRST ST, DULUTH, MN 55802 USA SN 1082-801X J9 FORMULARY JI Formulary PD JAN PY 2007 VL 42 IS 1 BP 14 EP + PG 15 GA 132AA UT WOS:000243912900004 ER PT J AU Perez, VI Pierce, A Masamsetti, P de Waal, EM Valerino, O Ward, WF Richardson, A Chaudhuri, A AF Perez, Viviana I. Pierce, Anson Masamsetti, Pragathi de Waal, Eric M. Valerino, Orlando Ward, Walter F. Richardson, Arlan Chaudhuri, Asish TI Detection of protein disulfides and aggregates in aging liver tissue: A fluorescence-based proteomic approach SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 14th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine CY NOV 14-18, 2007 CL Washington, DC SP Soc Free Rad Biol & Med C1 [Perez, Viviana I.; Pierce, Anson; Valerino, Orlando] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Masamsetti, Pragathi; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [de Waal, Eric M.] Univ Texas San Antonio, Dept Biol, San Antonio, TX USA. [Ward, Walter F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Chaudhuri, Asish] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2007 VL 43 SU 1 BP S114 EP S114 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 229WC UT WOS:000250835900306 ER PT J AU Perez, VI Masamsetti, P Pierce, A Mele, J Ward, WF Richardson, A Buffenstein, R Chaudhuria, A AF Perez, Viviana I. Masamsetti, Pragathi Pierce, Anson Mele, James Ward, Walter F. Richardson, Arlan Buffenstein, Rochelle Chaudhuria, Asish TI Resistance to protein unfolding and cysteine oxidation in long-lived naked mole rat during aging: Are these determinants for longevity? SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 14th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine CY NOV 14-18, 2007 CL Washington, DC SP Soc Free Rad Biol & Med C1 [Perez, Viviana I.; Pierce, Anson; Mele, James; Ward, Walter F.; Richardson, Arlan; Buffenstein, Rochelle] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Chaudhuria, Asish] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 NR 0 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2007 VL 43 SU 1 BP S113 EP S113 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 229WC UT WOS:000250835900305 ER PT J AU Rubio, A Redmond, RW AF Rubio, Aoemi Redmond, Robert W. TI Deleterious UVA-Generated bystander responses in vitro SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 14th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine CY NOV 14-18, 2007 CL Washington, DC SP Soc Free Rad Biol & Med C1 [Rubio, Aoemi; Redmond, Robert W.] Massachusetts Gen Hosp, Harvard Med Sch, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2007 VL 43 SU 1 BP S39 EP S39 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 229WC UT WOS:000250835900101 ER PT J AU Rubio, N Redmond, AW AF Rubio, Noemi Redmond, Androhert W. TI Cellular oxidative stress: What do the neighbours say? SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 14th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine CY NOV 14-18, 2007 CL Washington, DC SP Soc Free Rad Biol & Med C1 [Rubio, Noemi; Redmond, Androhert W.] Massachusetts Gen Hosp, Harvard Med Sch, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2007 VL 43 SU 1 BP S39 EP S39 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 229WC UT WOS:000250835900102 ER PT J AU Yao, M Bujold, KE Redmond, RW Kochevar, IE AF Yao, Min Bujold, Kenneth E. Redmond, Robert W. Kochevar, Irene E. TI A novel photoactivated dye technology for bonding tissue surfaces SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 14th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine CY NOV 14-18, 2007 CL Washington, DC SP Soc Free Rad Biol & Med C1 [Yao, Min; Bujold, Kenneth E.; Redmond, Robert W.; Kochevar, Irene E.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2007 VL 43 SU 1 BP S48 EP S48 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 229WC UT WOS:000250835900124 ER PT J AU Ji, XM Luo, YM Ling, F Stetler, RA Lan, J Cao, GD Chen, J AF Ji, Xunming Luo, Yumin Ling, Feng Stetler, R. Anne Lan, Jing Cao, Guodong Chen, Jun TI Mild hypothermia diminishes oxidative DNA damage and pro-death signaling events after cerebral ischemia: a mechanism for neuroprotection SO FRONTIERS IN BIOSCIENCE LA English DT Article DE hypothermia; neuroprotection; cerebral ischemia; reperfusion; oxidative stress; DNA damage; apoptosis; NAD depletion ID TRANSIENT FOCAL ISCHEMIA; EXPERIMENTAL STROKE; RAT-BRAIN; ENDONUCLEASE EXPRESSION; RADICAL PRODUCTION; STRAND BREAKS; CELL-DEATH; REPAIR; APOPTOSIS; REPERFUSION AB Mild hypothermia, applied either during or soon after cerebral ischemia, has been shown to confer robust neuroprotection against brain injury in experimental stroke and in patients recovering from cardiac arrest. However, the mechanism underlying hypothermic neuroprotection is not completely understood. In this study, the effect of mild hypothermia on the induction of oxidative DNA damage, an early harmful event during post-ischemic reperfusion that triggers both necrotic and apoptotic cell death in the brain, was studied using the rat model of middle cerebral artery occlusion (MCAO) and reperfusion. Rats were subjected to 2-hr MCAO and reperfusion of various durations up to 3 days. Selective brain hypothermia (33 degrees C) was induced at the onset of ischemia and terminated at the beginning of reperfusion, and this significantly decreased infarct volume 72 hr later. Correlated with this protective effect, intraischemic mild hypothermia markedly attenuated the nuclear accumulations of several oxidative DNA lesions, including 8-oxodG, AP sites, and DNA single-strand breaks, after 2-hr MCAO. Consequently, harmful DNA damage-dependent signaling events, including NAD depletion, p53 activation, and mitochondrial translocation of PUMA and NOXA, were reduced during post-ischemic reperfusion in hypothermia-treated brains. These results suggest that the attenuation of oxidative DNA damage and DNA damage-triggered pro-death signaling events may be an important mechanism underlying the neuroprotective effect of mild hypothermia against ischemic brain injury. reperfusion, and this significantly decreased infarct volume 72 hr later. Correlated with this protective effect, intraischemic mild hypothermia markedly attenuated the nuclear accumulations of several oxidative DNA lesions, including 8-oxodG, AP sites, and DNA single-strand breaks, after 2-hr MCAO. Consequently, harmful DNA damage-dependent signaling events, including NAD depletion, p53 activation, and mitochondrial translocation of PUMA and NOXA, were reduced during post-ischemic reperfusion in hypothermia-treated brains. These results suggest that the attenuation of oxidative DNA damage and DNA damage-triggered pro-death signaling events may be an important mechanism underlying the neuroprotective effect of mild hypothermia against ischemic brain injury. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. Capital Med Univ, Xuan Wu Hosp, Dept Neurosurg, Beijing, Peoples R China. Capital Med Univ, Xuan Wu Hosp, Cerebrovasc Res Inst, Beijing, Peoples R China. Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S507,Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu FU NINDS NIH HHS [NS38560, NS45048, NS36736] NR 33 TC 43 Z9 47 U1 0 U2 7 PU FRONTIERS IN BIOSCIENCE INC PI MANHASSET PA C/O NORTH SHORE UNIV HOSPITAL, BIOMEDICAL RESEARCH CENTER, 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1093-9946 J9 FRONT BIOSCI JI Front. Biosci. PD JAN 1 PY 2007 VL 12 BP 1737 EP 1747 DI 10.2741/2185 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 129QS UT WOS:000243745000142 PM 17127418 ER PT J AU Luo, YM Ji, XM Ling, F Li, WJ Zhang, F Cao, GD Chen, J AF Luo, Yumin Ji, Xunming Ling, Feng Li, Wenjin Zhang, Feng Cao, Guodong Chen, Jun TI Impaired DNA repair via the base-excision repair pathway after focal ischemic brain injury: a protein phosphorylation-dependent mechanism reversed by hypothermic neuroprotection SO FRONTIERS IN BIOSCIENCE LA English DT Article DE hypothermia; neuroprotection; cerebral ischemia; reperfusion; oxidative stress; DNA damage; DNA repair; base-excision repair; AP endonuclease; DNA polymerase-beta ID CEREBRAL-ISCHEMIA; POLYMERASE-BETA; RAT-BRAIN; RADICAL PRODUCTION; MILD HYPOTHERMIA; MAMMALIAN-CELLS; STRAND BREAKS; DAMAGE; REPERFUSION; LESIONS AB Cerebral ischemia and reperfusion induces rapid accumulation of oxidative DNA lesions in the brain, which, if not repaired promptly, may trigger cell death. The base-excision repair (BER) pathway is the main mechanism employed by neurons to repair various types of oxidative DNA damage. Recent studies have suggested that the cellular activity of BER is highly regulated (up- or down-regulated) after ischemic brain injury, and this regulation may contribute to the outcome of cell injury. The mechanism through which cellular BER is regulated in response to neuronal injury is currently poorly understood. In the present study, we have examined BER regulation in the rat model of focal ischemic brain injury induced by 2 hr of middle cerebral artery occlusion and 0-72 hr of reperfusion. As determined using cerebral nuclear extracts, focal ischemia resulted in a marked reduction in BER activities, including the overall BER activity, AP endonuclease activity and DNA polymerase-beta activity, indicating functional impairment of the BER pathway. BER reduction occurred as early as 0.5 hr after the onset of reperfusion. Thereafter, BER activity failed to recover, and there were persistent accumulations of apurinic/apyrimidinic abasic sites and DNA single-strand breaks in ischemic tissues. The reduction in BER during the early reperfusion phase (< 6 hr) was not accompanied by any alterations in the levels of essential BER enzymes in brain extracts. However, increased serine- and threonine- specific phosphorylation was detected for both AP endonuclease and DNA polymerase-beta after ischemia, with the time course of serine phosphorylation closely correlated to that of changes in BER activity. Furthermore, dephosphorylation of nuclear extracts with alkaline phosphatase largely restored AP endonuclease and DNA polymerase-beta activities. Taking advantage of the neuroprotective effect of mild hypothermia (33 degrees C), which was induced in the brain during the first 2 hr of reperfusion, we found that the post-ischemic suppression of BER activity is a reversible event. Hypothermic treatment diminished the serine- specific phosphorylation of AP endonuclease and DNA polymerase-beta, promoted BER activities, and attenuated the levels of oxidative DNA lesions after ischemia. These results suggest that the functional impairment of the BER pathway after severe focal cerebral ischemia is due to the loss-of-function post-translational modifications of repair enzymes. Further investigations elucidating the precise mechanism underlying the post-translational regulation of BER enzymes may lead to novel therapeutic strategies for cerebral ischemia. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. Capital Med Univ, Xuan Wu Hosp, Dept Neurosurg & Cerebrovasc Res Inst, Beijing, Peoples R China. Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S507,Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu FU NINDS NIH HHS [NS45048, NS36736, NS38560] NR 28 TC 22 Z9 24 U1 1 U2 3 PU FRONTIERS IN BIOSCIENCE INC PI MANHASSET PA C/O NORTH SHORE UNIV HOSPITAL, BIOMEDICAL RESEARCH CENTER, 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1093-9946 J9 FRONT BIOSCI JI Front. Biosci. PD JAN 1 PY 2007 VL 12 BP 1852 EP 1862 DI 10.2741/2193 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 129QS UT WOS:000243745000150 PM 17127426 ER PT J AU Zhao, QX Shao, JZ Chen, W Li, YP AF Zhao, Qingxiao Shao, Jianzhong Chen, Wei Li, Yi-Ping TI Osteoclast differentiation and gene regulation SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Review DE osteoporosis; osteoclast; PU.1; Mcsf; RANKL signaling; mitf; NF-kappa B; NFATc1; AP-1; c-Fos; c-Jun; review ID NF-KAPPA-B; COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR PU.1; CYTOKINE-MEDIATED OSTEOCLASTOGENESIS; ALPHA-INDUCED OSTEOCLASTOGENESIS; ACTIVATED PROTEIN-KINASE; EMBRYONIC STEM-CELLS; LACKING C-FOS; RECEPTOR ACTIVATOR; NUCLEAR-FACTOR AB Osteoclasts, the bone resorbing cells, play a key role both in normal bone remodeling and in the skeletal osteopenia of arthritis, osteoporosis, periodontal disease and certain malignancies. Osteoclast cellular commitment, differentiation and function depend upon the establishment of specific patterns of gene expression achieved through networks of transcription factors activated by osteoclastogenic cytokines. This review is an updated look at the various transcription factors and cytokines that have been demonstrated to play critical roles in osteoclast differentiation and function, along with their known animal models, such as: PU. 1, Mcsf, RANKL, NF- kappaB, AP-1, NFATc1, Mitf, Myc, and Src. Further studies on these transcription factors and cytokines will not only expand our basic understanding of the molecular mechanisms of osteoclast differentiation, but will also aid our ability to develop therapeutic means of intervention in osteoclast-related diseases. C1 Harvard Univ, Sch Dent Med, Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA. Zhejiang Univ, Life Sci Coll, Hangzhou 310027, Peoples R China. Harvard Univ, Sch Dent Med, Dept Oral Biol, Boston, MA 02115 USA. RP Li, YP (reprint author), Harvard Univ, Sch Dent Med, Forsyth Inst, Dept Cytokine Biol, 140 The Fenway, Boston, MA 02115 USA. EM ypli@forsyth.org FU NIAMS NIH HHS [AR-48133, AR44741] NR 104 TC 36 Z9 51 U1 1 U2 11 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2007 VL 12 BP 2519 EP 2529 DI 10.2741/2252 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 129QS UT WOS:000243745000209 PM 17127260 ER PT J AU Mahmood, U Wallace, MB AF Mahmood, Umar Wallace, Michael B. TI Molecular imaging in gastrointestinal disease SO GASTROENTEROLOGY LA English DT Article ID CANCER; COLONOSCOPY; EXPRESSION; PROBES; TUMORS; MICE C1 Mayo Clin, Dept Gastroenterol, Jacksonville, FL 32224 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Cambridge, MA 02138 USA. RP Wallace, MB (reprint author), Mayo Clin, Dept Gastroenterol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA. EM Wallace.michael@mayo.edu NR 12 TC 8 Z9 8 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 2007 VL 132 IS 1 BP 11 EP 14 DI 10.1053/j.gastro.2006.12.013 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 131BR UT WOS:000243843500007 PM 17241854 ER PT J AU Shiffman, ML Ghany, MG Morgan, TR Wright, EC Everson, GT Lindsay, KL Lok, ASF Bonkovsky, HL Di Bisceglie, AM Lee, WM Dienstag, JL Gretch, DR AF Shiffman, Mitchell L. Ghany, Marc G. Morgan, Timothy R. Wright, Elizabeth C. Everson, Gregory T. Lindsay, Karen L. Lok, Anna S. F. Bonkovsky, Herbert L. Di Bisceglie, Adrian M. Lee, William M. Dienstag, Jules L. Gretch, David R. CA HALT-C Trial Grp TI Impact of reducing peginterferon alfa-2a and ribavirin dose during Retreatment in patients with chronic hepatitis C SO GASTROENTEROLOGY LA English DT Article ID HCV-INFECTED PATIENTS; PLUS RIBAVIRIN; COMBINATION THERAPY; INITIAL TREATMENT; PEGYLATED INTERFERON; GENOTYPE-1 PATIENTS; DOUBLE-BLIND; TRIAL; MAINTENANCE; ANEMIA AB Background & Aims: Reducing the dose of peginterferon and/or ribavirin to < 80% when treating chronic hepatitis C virus has been associated with a reduction in sustained virologic response (SVR). However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment. Methods: Nine hundred thirty-six patients with chronic hepatitis C genotype 1, advanced fibrosis, or cirrhosis (Ishak 3-6) and prior nonresponse to standard interferon +/- ribavirin were retreated with peginterferon alfa-2a (180 mu g/wk) and ribavirin (1000-1200 mg/day) during the lead-in phase of the HALT-C trial. The percentage of each medication actually taken during treatment was calculated. Results: Reducing the total cumulative dose of peginterferon received during the first 20 weeks of treatment from full dose ( >= 98%) to <= 60% reduced week 20 virologic response (W20 VR) from 35% to 12% and SVR from 17% to 5%. Reducing the dose of ribavirin from full dose ( >= 98%) to <= 60% did not affect either W20 VR or SVR as long as ribavirin dosing was not interrupted for more than 7 consecutive days. Prematurely discontinuing ribavirin, even at full-dose peginterfero n, reduced W20 VR to <= 19% and SVR to <= 4%. Conclusions: Reducing the peginterferon dose during the first 20 weeks of treatment reduced viral clearance and SVR. In contrast, reducing ribavirin did not affect either W20 VR or SVR as long as patients remained on full-dose peginterferon. Discontinuing ribavirin prematurely was associated with a marked decline in both VR and SVR. C1 Virginia Commonwealth Univ, Med Ctr, Hepatol Sect, Richmond, VA 23298 USA. NIDDK, Liver Dis Branch, Div Digest Dis & Nutr, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA. Univ Calif Irvine, Div Gastroenterol, Irvine, CA 92717 USA. VA Long Beach Healthcare Syst, Serv Gastroenterol, Long Beach, CA USA. New England Res Inst, Watertown, MA 02172 USA. Univ Colorado, Sch Med, Sect Hepatol, Div Gastroenterol & Hepatol, Denver, CO 80202 USA. Univ So Calif, Keck Sch Med, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90089 USA. Univ Michigan, Med Ctr, Div Gastroenterol, Ann Arbor, MI 48109 USA. Univ Connecticut, Ctr Hlth, Dept Med, Storrs, CT 06269 USA. Univ Connecticut, Ctr Hlth, Dept Mol & Struct Biol, Storrs, CT 06269 USA. Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Storrs, CT 06269 USA. St Louis Univ, Sch Med, Div Gastroenterol & Hepatol, St Louis, MO 63103 USA. Univ Texas, SW Med Ctr, Div Digest & Liver Dis, Dallas, TX 75230 USA. Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. RP Shiffman, ML (reprint author), Virginia Commonwealth Univ, Med Ctr, Hepatol Sect, Box 980341, Richmond, VA 23298 USA. EM mshiffma@vcu.edu RI Lok, Anna /B-8292-2009; OI Yang, Shuman/0000-0002-9638-0890 NR 23 TC 138 Z9 146 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 2007 VL 132 IS 1 BP 103 EP 112 DI 10.1053/j.gastro.2006.11.011 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 131BR UT WOS:000243843500017 PM 17241864 ER PT J AU Goel, A Nagasaka, T Arnold, CN Inoue, T Hamilton, C Niedzwiecki, D Compton, C Mayer, RJ Goldberg, R Bertagnolli, MM Boland, CR AF Goel, Ajay Nagasaka, Takeshi Arnold, Christian N. Inoue, Toru Hamilton, Cody Niedzwiecki, Donna Compton, Carolyn Mayer, Robert J. Goldberg, Richard Bertagnolli, Monica M. Boland, C. Richard TI The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer SO GASTROENTEROLOGY LA English DT Article ID TUMOR-CELL-LINES; MICROSATELLITE INSTABILITY; DNA METHYLATION; COLON-CANCER; PROMOTER HYPERMETHYLATION; CARCINOGENESIS; INACTIVATION; EPIGENETICS; EXPRESSION; NEOPLASIA AB Background & Aims: The CpG island methylator phenotype (CIMP) is one of the mechanisms involved in colorectal carcinogenesis (CRC). Although CIMP is probably the cause of high-frequency microsatellite instability (MSI-H) sporadic CRCs, its role in microsatellite stable (MSS) tumors is debated. The majority of MSS CRCs demonstrate chromosomal instability (CIN) with frequent loss of heterozygosity (LOH) at key tumor suppressor genes. We hypothesized that the majority of sporadic CRCs without CIN would be associated with CIMP. Methods: We tested 126 sporadic CRCs for MSI and LOH and categorized tumors into MSI, LOH, or MSI-/LOH- subgroups. Methylation status was evaluated using 6 CIMP-related markers (MINT1, MINT2, MINT31, p10(INK4 alpha), p14(ARF) and hMLH1) and 6 tumor suppressor genes (PTEN, TLMP3, RUNX3, HIC1, APC, and RAR beta 2). BRAF V600E mutation analysis was performed using allele-specific polymerase chain reaction and DNA sequencing. Results: We observed frequent methylation at all 12 loci in all CRCs. BRAF V600E mutations correlated with the MSI (P < .0001) and MSI-/LOH- (P = .03) subgroups. MSI and MSI-/ LOH- tumors exhibited more promoter methylation than CRCs with LOH (P < .0001). We also found an inverse correlation between the frequencies of methylation and LOH (rho = -0.36; P < .0001). Conclusions: The associations between methylation frequencies at CIMP-related markers and MSI or MSI-/LOH- sporadic CRCs suggest that the majority of these tumors evolve through CIMP. These findings suggest that CIN and CIMP represent 2 independent and inversely related mechanisms of genetic and epigenetic instability in sporadic CRCs and confirm that MSI cancers arise as a consequence of CIMP. C1 Baylor Univ, Med Ctr, Gastrointestinal Canc Res Lab, Dallas, TX 75246 USA. Baylor Univ, Med Ctr, Dept Internal Med, Div Gastroenterol, Dallas, TX 75246 USA. Baylor Univ, Med Ctr, Baylor Charles A Sammons Canc Ctr, Dallas, TX 75246 USA. Univ Freiburg, Dept Internal Med, Div Gastroenterol, D-7800 Freiburg, Germany. Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 558, Japan. Baylor Univ, Med Ctr, Inst Hlth Care Res & Improvement, Waco, TX 76798 USA. Duke Univ, Med Ctr, CALGB Stat Ctr, Durham, NC 27706 USA. McGill Univ, Dept Pathol, Montreal, PQ H3A 2T5, Canada. Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA. Univ N Carolina, Chapel Hill, NC 27515 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. RP Goel, A (reprint author), Baylor Univ, Med Ctr, Gastrointestinal Canc Res Lab, 3500 Gaston Ave,Suite H-250, Dallas, TX 75246 USA. EM ajayg@baylorhealth.edu OI Nagasaka, Takeshi/0000-0002-4236-350X FU NCI NIH HHS [CA 31946, R01 CA 72851] NR 36 TC 177 Z9 182 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 2007 VL 132 IS 1 BP 127 EP 138 DI 10.1053/j.gastro.2006.09.018 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 131BR UT WOS:000243843500020 PM 17087942 ER PT J AU Kim, SS Peng, LF Lin, WY Choe, WH Sakamoto, N Schreiber, SL Chung, RT AF Kim, Sun Suk Peng, Lee F. Lin, Wenyu Choe, Won-Hyeok Sakamoto, Naoya Schreiber, Stuart L. Chung, Raymond T. TI A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication SO GASTROENTEROLOGY LA English DT Article ID BETA-LACTAMASE REPORTER; RNA REPLICATION; INTERFERON-ALPHA; IN-VITRO; CULTURE; INHIBITION; REPLICONS; THERAPY; PROTEIN; GERANYLGERANYLATION AB Background & Aims: Only half of patients with chronic hepatitis C virus (HCV) infection experience sustained virologic response to pegylated-interferon and ribavirin, which cause numerous side effects. Thus, the identification of more effective and better tolerated agents is a high priority. We applied chemical biology to screen small molecules that regulate HCV. Methods: We first optimized the Huh7/RepFeo replicon cell fine for the 384-well microplate format and used this line to screen a large library of well-characterized, known biologically active compounds using automated technology. After identifying several molecules capable of either stimulating or inhibiting HCV replication in this primary screen, we then validated our hit compounds using a full-length HCV replicon cell line in secondary screens. Results: We identified and validated a number of antiviral and proviral agents, including HMG-CoA reductase inhibitors (antiviral) and corticosteroids (proviral). The finding of increased replication associated with corticosteroids suggests that these agents directly promote viral replication independent of their suppressive effects on the immune response. The finding of antiviral activity associated with the HMG-CoA reductase inhibitors implies an important role for lipid metabolism in the viral life cycle. Conclusions: We have developed a simple, reproducible, and reliable cell-based high-throughput screening assay system using an HCV replicon model to identify small molecules that regulate HCV replication. This method can be used to identify not only putative antiviral agents, but also cellular regulators of viral replication. C1 Massachusetts Gen Hosp, GI Unit, Boston, MA 02114 USA. Gachon Univ, Gil Med Ctr, Dept Gastroenterol & Hepatol, Inchon, South Korea. Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. Harvard Univ, Broad Inst, Cambridge, MA USA. Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Tokyo 113, Japan. Howard Hughes Med Inst, Chevy Chase, MD USA. RP Chung, RT (reprint author), Massachusetts Gen Hosp, GI Unit, GRJ825A, Boston, MA 02114 USA. EM rtchung@partners.org RI Sakamoto, Naoya/G-2734-2012 FU NIDDK NIH HHS [5T32 DK 07191-31, K08 DK088951]; NINDS NIH HHS [NS 050854-01] NR 32 TC 59 Z9 62 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 2007 VL 132 IS 1 BP 311 EP 320 DI 10.1053/j.gastro.2006.10.032 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 131BR UT WOS:000243843500035 PM 17241881 ER PT J AU Evans, JA Bouma, BE Bressner, J Shishkov, M Lauwers, GY Mino-Kenudson, M Nishioka, NS Tearney, GJ AF Evans, John A. Bouma, Brett E. Bressner, Jason Shishkov, Milen Lauwers, Gregory Y. Mino-Kenudson, Mari Nishioka, Norman S. Tearney, Guillermo J. TI Identifying intestinal metaplasia at the squamocolumnar junction by using optical coherence tomography SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; HIGH-GRADE DYSPLASIA; BARRETTS-ESOPHAGUS; RISING INCIDENCE; ADENOCARCINOMA; ENDOSCOPY; HISTOLOGY; TRACT AB Background: Optical coherence tomography (OCT) is an optical imaging method that produces high-resolution cross-sectional images of the esophagus. The accuracy of OCT for differentiating tissue types at the squamocolumnar junction (SCJ) has not been established. Objective: The purpose of this study was to identify and validate OCT image criteria for distinguishing metaplastic from nonmetaplastic tissue at the SCJ. Design: A total of 196 biopsy-correlated OCT images of the SCJ were acquired from 113 patients undergoing upper endoscopy A pathologist blinded to the OCT results reviewed each pathology specimen and determined the presence of the following histopathology: gastric cardia, squamous mucosa, pancreatic metaplasia, and intestinal metaplasia. An algorithm for diagnosing specialized intestinal metaplasia (SIM) was created by reviewing a training set of 40 biopsy-correlated OCT images. Two blinded investigators prospectively tested the algorithm on a validation set of 123 images. Results: OCT images of squamous mucosa were characterized by a layered appearance without epithelial glands; gastric cardia, by vertical pit and gland structure, a well-defined epithelial Surface reflectivity, and relatively poor image penetration; and SIM by an irregular architecture and good image penetration. The OCT criteria were 85% sensitive and 95% specific for SIM when applied retrospectively to the training set. When applied to the validation set, the algorithm was 81% sensitive for both OCT readers and 66% and 57% specific for diagnosing SIM. The interobserver agreement was good (kappa = 0.53). Conclusions: OCT imaging can identify SIM at the SCJ with an accuracy similar to that of endoscopy. C1 Massachusetts Gen Hosp, Gastrointestinal Unit, Wellman Ctr Photomed, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Tearney, GJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol,Wellman Ctr Photomed, 40 Blossom St,BAR703, Boston, MA 02114 USA. FU NCI NIH HHS [R01 CA103769-03, R01 CA 103769, R01 CA103769] NR 21 TC 49 Z9 52 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2007 VL 65 IS 1 BP 50 EP 56 DI 10.1016/j.gie.2006.04.027 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 124IH UT WOS:000243361000010 PM 17137858 ER PT J AU Espinola-Nadurille, M Ramirez-Bermudez, J Fricchione, GL AF Espinola-Nadurille, Mariana Ramirez-Bermudez, Jesus Fricchione, Gregory L. TI Pregnancy and malignant catatonia SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE malignant catatonia; electroconvulsive therapy; lorazepam; pregnancy ID RATING-SCALE; ENTITY AB The occurrence of malignant catatonia in pregnancy is a psychiatric emergency. In this article, we present the case of a pregnant woman with a first psychotic episode with catatonic features, autonomic abnormalities and elevated creatinine phosphokinase levels in the context of a severe adverse reaction to antipsychotic pharmacotherapy who had good responses to electroconvulsive therapy and lorazepam. (c) 2007 Elsevier Inc. All rights reserved. C1 Natl Inst Neurol & Neurosurg, Neuropsychiat Unit, Mexico City 14269, DF, Mexico. Natl Inst Neurol & Neurosurg, Dept Clin Res, Mexico City 14269, DF, Mexico. Massachusetts Gen Hosp, Div Psychiat & Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Int Psychiat, Boston, MA 02114 USA. RP Espinola-Nadurille, M (reprint author), Natl Inst Neurol & Neurosurg, Neuropsychiat Unit, Mexico City 14269, DF, Mexico. EM menadu2002@yahoo.com.mx NR 10 TC 10 Z9 10 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD JAN-FEB PY 2007 VL 29 IS 1 BP 69 EP 71 DI 10.1016/j.genhosppsych.2006.10.003 PG 3 WC Psychiatry SC Psychiatry GA 125LS UT WOS:000243444000014 PM 17189750 ER PT J AU Stegh, AH Kim, H Bachoo, RM Forloney, KL Zhang, J Schulze, H Park, K Hannon, GJ Yuan, JY Louis, DN DePinho, RA Chin, L AF Stegh, Alexander H. Kim, Hyunggee Bachoo, Robert M. Forloney, Kristin L. Zhang, Jean Schulze, Harald Park, Kevin Hannon, Gregory J. Yuan, Junying Louis, David N. DePinho, Ronald A. Chin, Lynda TI Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma SO GENES & DEVELOPMENT LA English DT Article DE apoptosis; caspase-7; malignant glioma; necrosis ID ALPHA-B-CRYSTALLIN; LIGAND-INDUCED APOPTOSIS; NECROSIS-FACTOR FAMILY; HUMAN BRAIN-TUMORS; GROWTH-FACTOR; GLIOMA-CELLS; EXPRESSION ANALYSIS; MALIGNANT GLIOMA; DOWN-REGULATION; BCL-2 FAMILY AB Glioblastoma ( GBM) is an astrocytic brain tumor characterized by an aggressive clinical course and intense resistance to all therapeutic modalities. Here, we report the identification and functional characterization of Bcl2L12 ( Bcl2-like-12) that is robustly expressed in nearly all human primary GBMs examined. Enforced Bcl2L12 expression confers marked apoptosis resistance in primary cortical astrocytes, and, conversely, its RNA interference ( RNAi)-mediated knockdown sensitizes human glioma cell lines toward apoptosis in vitro and impairs tumor growth with increased intratumoral apoptosis in vivo. Mechanistically, Bcl2L12 expression does not affect cytochrome c release or apoptosome-driven caspase-9 activation, but instead inhibits post-mitochondrial apoptosis signaling at the level of effector caspase activation. One of Bcl2L12's mechanisms of action stems from its ability to interact with and neutralize caspase-7. Notably, while enforced Bcl2L12 expression inhibits apoptosis, it also engenders a pronecrotic state, which mirrors the cellular phenotype elicited by genetic or pharmacologic inhibition of post-mitochondrial apoptosis molecules. Thus, Bcl2L12 contributes to the classical tumor biological features of GBM such as intense apoptosis resistance and florid necrosis, and may provide a target for enhanced therapeutic responsiveness of this lethal cancer. C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Ctr Neurooncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. Dana Farber Canc Inst, Ctr Appl Canc Sci, Belfer Fdn Inst Innovat Canc Sci, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Pathol, Ctr Canc, Boston, MA 02115 USA. Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. RP Chin, L (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM ron_depinho@dfci.harvard.edu; lynda_chin@dfci.harvard.edu RI Kim, Hyunggee/F-2673-2013 OI Kim, Hyunggee/0000-0002-4738-0990 FU NCI NIH HHS [P01 CA095616, P01 CA95616, R01 CA057683, R01 CA099041, R01 CA57683]; NINDS NIH HHS [K08NS42737, K08 NS042737] NR 49 TC 79 Z9 80 U1 1 U2 4 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI WOODBURY PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA SN 0890-9369 J9 GENE DEV JI Genes Dev. PD JAN 1 PY 2007 VL 21 IS 1 BP 98 EP 111 DI 10.1101/gad.1480007 PG 14 WC Cell Biology; Developmental Biology; Genetics & Heredity SC Cell Biology; Developmental Biology; Genetics & Heredity GA 124PT UT WOS:000243382700010 PM 17210792 ER PT J AU Rakovski, CS Xu, X Lazarus, R Blacker, D Laird, NM AF Rakovski, Cyril S. Xu, Xin Lazarus, Ross Blacker, Deborah Laird, Nan M. TI A new multimarker test for family-based association studies SO GENETIC EPIDEMIOLOGY LA English DT Article DE FBAT; haplotype; tag SNP method; multiple SNPs; best strategy ID LINKAGE DISEQUILIBRIUM; GENOTYPE DATA; HUMAN GENOME; HAPLOTYPE; POWER; POPULATION AB We propose a new multimarker test for family-based studies in candidate genes. We use simulations under different genetic models to assess the performance of competing testing strategies, characterized in this study as combinations of the following important factors: genes, statistical tests, tag single nucleotide polymorphisms (SNP) methods, number of tag SNPs and family designs. An ANOVA model is employed to provide descriptive summaries of the effects on power of the above-mentioned factors. We find that tag SNP methods, gene characteristics and family designs have minimal impact on the best testing strategy. The familywise error rate (EWER) controlling multiple comparison procedure and the new multimarker test offer the highest power followed by the asymptotic global haplotype test. Both the FWER and the multimarker test are invariant to family designs and gain power as we increase the number of tag SNPs. However, the performance of the global haplotype test is slightly degraded when analyzing larger numbers of tag SNPs. Within the framework of our study, the best strategy for family-based studies in candidate genes that emerged from our analysis is to use the EWER or the multimarker test and select 6-10 tag SNPs using any of the tag SNP methods considered. We confirm the conclusions of our study with an application to Alzheimer's disease data. C1 Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Program Populat Genet, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Rakovski, CS (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA. EM crakovsk@hsph.harvard.edu OI lazarus, ross/0000-0003-3939-1961 FU NIEHS NIH HHS [ES007142]; NIMH NIH HHS [MH059532, MH60009-06] NR 22 TC 36 Z9 36 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PD JAN PY 2007 VL 31 IS 1 BP 9 EP 17 DI 10.1002/gepi.20186 PG 9 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA 116XX UT WOS:000242838200002 PM 17086514 ER PT S AU Chang, SK Solban, N Rizvi, L Errabelli, D Hasan, T AF Chang, Sung K. Solban, Nicolas Rizvi, Lmran Errabelli, Divya Hasan, Tayyaba BE Achilefu, S Bornhop, DJ Raghavachari, R Savitsky, AP Wachter, RM TI Molecular imaging of photodynamic therapy efficacy - art. no. 644902 SO Genetically Engineered and Optical Probes for Biomedical Applications IV SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Genetically Engineered and Optical Probes for Biomedical Applications IV CY JAN 23-24, 2007 CL San Jose, CA SP SPIE DE photodynamic therapy; optical imaging; molecular imaging ID ENDOTHELIAL GROWTH-FACTOR; PROSTATE-CANCER; RADIATION-THERAPY; VASCULAR DAMAGE; ANGIOGENESIS; METASTASIS; TUMORS; MODEL; MICE AB Recent advances in light sources, detectors and other optical imaging technologies coupled with the development of novel optical contrast agents have enabled real-time, high resolution, in vivo monitoring of molecular targets. Noninvasive monitoring of molecular targets can help optimize photodynamic therapy (PDT) by providing the capabilities to monitor the efficacy of treatment. Our lab has developed optical imaging technologies to investigate a wide range of molecular, physiological and morphological responses to photodynamic therapy (PDT). With the idea that drug delivery to the different compartments in the tumor is an important determinant of the treatment effect, we studied drug delivery in vitro and in vivo using optical imaging tools. A molecular specific contrast agent that targets the vascular endothelial growth factor (VEGF) was developed to monitor the changes in the protein expression following PDT. We also studied the PDT-induced physiological changes in vascular permeability and metastasis with in vivo imaging. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Chang, SK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 22 TC 0 Z9 0 U1 0 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-6562-7 J9 P SOC PHOTO-OPT INS PY 2007 VL 6449 BP 44902 EP 44902 AR 644902 DI 10.1117/12.714889 PG 6 WC Engineering, Biomedical; Optics; Imaging Science & Photographic Technology SC Engineering; Optics; Imaging Science & Photographic Technology GA BGC15 UT WOS:000245977300001 ER PT J AU Grabher, C Wittbrodt, J AF Grabher, Clemens Wittbrodt, Joachim TI Meganuclease and transposon mediated transgenesis in medaka SO GENOME BIOLOGY LA English DT Review AB From among a plethora of various gene delivery methods, the researcher must choose the right one according to availability for a given species and the precise application the transgenic animal is intended for. Here we review the progress in meganuclease and Sleeping Beauty transposon mediated transgenesis over recent years with a focus on medaka and zebrafish. We present a side-by-side comparison of these two approaches based on their biologic properties and provide interesting perspectives for future experiments and applications, which are different for the two techniques because of their distinct modes of action. C1 [Grabher, Clemens] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wittbrodt, Joachim] European Mol Biol Lab, Dev Biol Unit, D-69117 Heidelberg, Germany. RP Grabher, C (reprint author), Dana Farber Canc Inst, Binney St, Boston, MA 02115 USA. EM Clemens_grabher@dfci.harvard.edu RI Grabher, Clemens/H-2064-2013; Wittbrodt, Joachim/D-4735-2014 OI Wittbrodt, Joachim/0000-0001-8550-7377 FU German Research Foundation (DFG) FX We are grateful to our colleagues in the laboratory for critical and insightful input and helpful comments; to Thorsten Henrich for his pioneering experiments with SB; and to Erika Grzebisz for excellent animal husbandry. This work was supported by grants from the German Research Foundation (DFG) and the EU to JW. NR 79 TC 26 Z9 30 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2007 VL 8 SU 1 AR S10 DI 10.1186/gb-2007-8-S1-S10 PG 7 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA V12AK UT WOS:000207571900010 PM 18047687 ER PT J AU Heinrichs, S Look, AT AF Heinrichs, Stefan Look, A. Thomas TI Identification of structural aberrations in cancer by SNP array analysis SO GENOME BIOLOGY LA English DT Review ID ACUTE LYMPHOBLASTIC-LEUKEMIA; LOSS-OF-HETEROZYGOSITY; TUMOR SUPPRESSION; LUNG-CANCER; COPY NUMBER; GEFITINIB; SURVIVAL; GENOME AB Recent studies using single-nucleotide polymorphism arrays have pinpointed novel oncogenes and tumor suppressors involved in specific types of human cancers. C1 Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. RP Look, AT (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Binney St, Boston, MA 02215 USA. EM thomas_look@dfci.harvard.edu NR 26 TC 15 Z9 15 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2007 VL 8 IS 7 AR 219 DI 10.1186/gb-2007-8-7-219 PG 5 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 209VP UT WOS:000249416400002 PM 17666119 ER PT J AU Kaiser, S Park, YK Franklin, JL Halberg, RB Yu, M Jessen, WJ Freudenberg, J Chen, XD Haigis, K Jegga, AG Kong, S Sakthivel, B Xu, H Reichling, T Azhar, M Boivin, GP Roberts, RB Bissahoyo, AC Gonzales, F Bloom, GC Eschrich, S Carter, SL Aronow, JE Kleimeyer, J Kleimeyer, M Ramaswamy, V Settle, SH Boone, B Levy, S Graff, JM Doetschman, T Groden, J Dove, WF Threadgill, DW Yeatman, TJ Coffey, RJ Aronow, BJ AF Kaiser, Sergio Park, Young-Kyu Franklin, Jeffrey L. Halberg, Richard B. Yu, Ming Jessen, Walter J. Freudenberg, Johannes Chen, Xiaodi Haigis, Kevin Jegga, Anil G. Kong, Sue Sakthivel, Bhuvaneswari Xu, Huan Reichling, Timothy Azhar, Mohammad Boivin, Gregory P. Roberts, Reade B. Bissahoyo, Anika C. Gonzales, Fausto Bloom, Greg C. Eschrich, Steven Carter, Scott L. Aronow, Jeremy E. Kleimeyer, John Kleimeyer, Michael Ramaswamy, Vivek Settle, Stephen H. Boone, Braden Levy, Shawn Graff, Jonathan M. Doetschman, Thomas Groden, Joanna Dove, William F. Threadgill, David W. Yeatman, Timothy J. Coffey, Robert J., Jr. Aronow, Bruce J. TI Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer SO GENOME BIOLOGY LA English DT Article ID RECEPTOR-TYPE-II; COLORECTAL-CANCER; GENE-EXPRESSION; SMALL-INTESTINE; C-MYC; BETA-CATENIN; MUTANT MICE; STEM-CELLS; TUMORIGENESIS; APC AB Background: The expression of carcino-embryonic antigen by colorectal cancer is an example of oncogenic activation of embryonic gene expression. Hypothesizing that oncogenesis-recapitulating-ontogenesis may represent a broad programmatic commitment, we compared gene expression patterns of human colorectal cancers ( CRCs) and mouse colon tumor models to those of mouse colon development embryonic days 13.5- 18.5. Results: We report here that 39 colon tumors from four independent mouse models and 100 human CRCs encompassing all clinical stages shared a striking recapitulation of embryonic colon gene expression. Compared to normal adult colon, all mouse and human tumors over-expressed a large cluster of genes highly enriched for functional association to the control of cell cycle progression, proliferation, and migration, including those encoding MYC, AKT2, PLK1 and SPARC. Mouse tumors positive for nuclear beta-catenin shifted the shared embryonic pattern to that of early development. Human and mouse tumors differed from normal embryonic colon by their loss of expression modules enriched for tumor suppressors ( EDNRB, HSPE, KIT and LSPI). Human CRC adenocarcinomas lost an additional suppressor module ( IGFBP4, MAP4KI, PDGFRA, STABI and WNT4). Many human tumor samples also gained expression of a coordinately regulated module associated with advanced malignancy ( ABCCI, FOXO3A, LIF, PIK3RI, PRNP, TNC, TIMP3 and VEGF). Conclusion: Cross-species, developmental, and multi-model gene expression patterning comparisons provide an integrated and versatile framework for definition of transcriptional programs associated with oncogenesis. This approach also provides a general method for identifying pattern-specific biomarkers and therapeutic targets. This delineation and categorization of developmental and non-developmental activator and suppressor gene modules can thus facilitate the formulation of sophisticated hypotheses to evaluate potential synergistic effects of targeting within- and between-modules for next-generation combinatorial therapeutics and improved mouse models. C1 Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA. Vanderbilt Univ, Nashville, TN 37232 USA. Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA. Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA. Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA. Univ N Carolina, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA. Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA. Ohio State Univ, Coll Med, Div Human Canc Genet, Columbus, OH 43210 USA. Univ Arizona, Inst Collaborat Biores, Tucson, AZ 85721 USA. Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Harvard Univ, Sch Med,CHIP HST, Harvard Mit Div Hlth Sci & Technol, Childrens Hosp Informat Program, Boston, MA 02215 USA. Univ Texas, SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Aronow, BJ (reprint author), Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA. EM bruce.aronow@cchmc.org RI Aronow, Bruce/F-8438-2012; Eschrich, Steven/K-6848-2013; Jegga, Anil/H-6140-2011; Threadgill, David/N-4425-2013; OI Jegga, Anil/0000-0002-4881-7752; Threadgill, David/0000-0003-3538-1635; Jessen, Walter/0000-0003-3840-4337 FU NCI NIH HHS [U01 CA84239, P50 CA095103, P50 CA106991, P50 CA95103, R01 CA046413, R01 CA063507, R01 CA079869, R37 CA063677, R37 CA63677, U01 CA084239, U01 CA105417, U01 CA84227, U01 CA98013]; NHLBI NIH HHS [T32 HL007382, T32 HL07382-28]; NIDDK NIH HHS [R24 DK 064403, R24 DK064403] NR 72 TC 158 Z9 161 U1 0 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2007 VL 8 IS 7 AR R131 DI 10.1186/gb-2007-8-7-r131 PG 26 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 209VP UT WOS:000249416400011 PM 17615082 ER PT J AU Mckee, AE Neretti, N Carvalho, LE Meyer, CA Fox, EA Brodsky, AS Silver, PA AF Mckee, Adrienne E. Neretti, Nicola Carvalho, Luis E. Meyer, Clifford A. Fox, Edward A. Brodsky, Alexander S. Silver, Pamela A. TI Exon expression profiling reveals stimulus-mediated exon use in neural cells SO GENOME BIOLOGY LA English DT Article ID CEREBELLAR GRANULE CELLS; STRESS-INDUCED APOPTOSIS; GENE-EXPRESSION; NITRIC-OXIDE; DIFFERENTIAL EXPRESSION; ALTERNATIVE PROMOTERS; TRANSCRIPTION FACTORS; POTASSIUM CHANNELS; NERVOUS-SYSTEM; H+-ATPASE AB Background: Neuronal cells respond to changes in intracellular calcium ([Ca(2+)](i)) by affecting both the abundance and architecture of specific mRNAs. Although calcium-induced transcription and transcript variation have both been recognized as important sources of gene regulation, the interplay between these two phenomena has not been evaluated on a genome-wide scale. Results: Here, we show that exon-centric microarrays can be used to resolve the [Ca(2+)](i)(-) modulated gene expression response into transcript-level and exon-level regulation. Global assessments of affected transcripts reveal modulation within distinct functional gene categories. We find that transcripts containing calcium-modulated exons exhibit enrichment for calcium ion binding, calmodulin binding, plasma membrane associated, and metabolic proteins. Additionally, we uncover instances of regulated exon use in potassium channels, neuroendocrine secretory proteins and metabolic enzymes, and demonstrate that regulated changes in exon expression give rise to distinct transcript variants. Conclusion: Our findings connect extracellular stimuli to specific exon behavior, and suggest that changes in transcript and exon abundance are reflective of a coordinated gene expression response to elevated [Ca(2+)](i). The technology we describe here lends itself readily to the resolution of stimulus-induced gene expression at both the transcript and exon levels. C1 [Brodsky, Alexander S.] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02903 USA. [Mckee, Adrienne E.; Silver, Pamela A.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. [Neretti, Nicola] Brown Univ, Dept Phys, Inst Brain & Neural Syst, Providence, RI 02912 USA. [Neretti, Nicola] Brown Univ, Ctr Computat Mol Biol, Providence, RI 02912 USA. [Carvalho, Luis E.] Brown Univ, Dept Appl Math, Providence, RI 02912 USA. [Meyer, Clifford A.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Meyer, Clifford A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Fox, Edward A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Fox, Edward A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Brodsky, Alexander S.] Brown Univ, Ctr Genom & Proteom, Ctr Computat Mol Biol, Providence, RI 02903 USA. RP Brodsky, AS (reprint author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, 185 Meeting St, Providence, RI 02903 USA. EM alex_brodsky@brown.edu; pamela_silver@hms.harvard.edu FU NCI NIH HHS [T32CA09361, T32 CA009361]; NIDDK NIH HHS [T90 DK070078-01, T90 DK070078]; NIGMS NIH HHS [R01 GM041690, R01 GM-41690] NR 65 TC 29 Z9 30 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2007 VL 8 IS 8 AR R159 DI 10.1186/gb-2007-8-8-r159 PG 16 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 273NT UT WOS:000253938500011 PM 17683528 ER PT J AU Moffett, HF Novina, CD AF Moffett, Howell F. Novina, Carl D. TI A small RNA makes a Bic difference SO GENOME BIOLOGY LA English DT Review ID MICRORNA; DISCOVERY; SELECTION; LYMPHOMA; HODGKIN AB The first highly specific knockouts of a microRNA, miR/55, in mice result in multiple defects in adaptive immunity, and also show the feasibility of investigating at least some microRNAs by gene knockout. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Broad Inst, Cambridge, MA 02141 USA. MIT, Cambridge, MA 02141 USA. RP Novina, CD (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM carl_novina@dfci.harvard.edu NR 24 TC 9 Z9 12 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2007 VL 8 IS 7 AR 221 DI 10.1186/gb-2007-8-7-221 PG 4 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 209VP UT WOS:000249416400004 PM 17666120 ER PT J AU Song, JS Johnson, WE Zhu, XP Zhang, XM Li, W Manrai, AK Liu, JS Chen, RS Liu, XS AF Song, Jun S. Johnson, W. Evan Zhu, Xiaopeng Zhang, Xinmin Li, Wei Manrai, Arjun K. Liu, Jun S. Chen, Runsheng Liu, X. Shirley TI Model-based analysis of two-color arrays (MA2C) SO GENOME BIOLOGY LA English DT Article ID ELEGANS DOSAGE COMPENSATION; X-CHROMOSOME; HUMAN GENOME; CHIP-CHIP; NORMALIZATION; PROMOTERS; MICROARRAYS; RESOLUTION AB A novel normalization method based on the GC content of probes is developed for two-color tiling arrays. The proposed method, together with robust estimates of the model parameters, is shown to perform superbly on published data sets. A robust algorithm for detecting peak regions is also formulated and shown to perform well compared to other approaches. The tools have been implemented as a stand-alone Java program called MA2C, which can display various plots of statistical analysis for quality control. C1 [Song, Jun S.; Johnson, W. Evan; Li, Wei; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Song, Jun S.; Johnson, W. Evan; Li, Wei; Liu, Jun S.; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Zhu, Xiaopeng; Chen, Runsheng] Chinese Acad Sci, Inst Biophys, Bioinformat Lab, Beijing 100101, Peoples R China. [Zhang, Xinmin] NimbleGen Syst Inc, Madison, WI 53711 USA. [Manrai, Arjun K.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA. [Liu, Jun S.] Harvard Univ, Dept Stat, Cambridge, MA 02138 USA. RP Liu, XS (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, 44 Binney St, Boston, MA 02115 USA. EM xsliu@jimmy.harvard.edu RI Li, Wei/A-8544-2009; Zhu, Xiaopeng/A-6755-2011 OI Zhu, Xiaopeng/0000-0003-2007-9820 FU NCI NIH HHS [T32 CA009337]; NHGRI NIH HHS [1R01 HG004069-01, 1U01 HG004270-01, R01 HG004069, R01 HG004069-02, U01 HG004270] NR 24 TC 82 Z9 83 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2007 VL 8 IS 8 AR R178 DI 10.1186/gb-2007-8-8-r178 PG 13 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 273NT UT WOS:000253938500030 PM 17727723 ER PT J AU Wang, HD Segal, E Ben-Hur, A Li, QR Vidal, M Koller, D AF Wang, Haidong Segal, Eran Ben-Hur, Asa Li, Qian-Ru Vidal, Marc Koller, Daphne TI InSite: a computational method for identifying protein-protein interaction binding sites on a proteome-wide scale SO GENOME BIOLOGY LA English DT Article ID DOMAIN-DOMAIN INTERACTIONS; SACCHAROMYCES-CEREVISIAE; STRUCTURE PREDICTION; INTERACTION NETWORK; TRANSCRIPTIONAL RESPONSE; ENVIRONMENTAL-CHANGES; MASS-SPECTROMETRY; INTERACTION MAPS; GENE-EXPRESSION; GENOMIC SCALE AB We propose InSite, a computational method that integrates high-throughput protein and sequence data to infer the specific binding regions of interacting protein pairs. We compared our predictions with binding sites in Protein Data Bank and found significantly more binding events occur at sites we predicted. Several regions containing disease-causing mutations or cancer polymorphisms in human are predicted to be binding for protein pairs related to the disease, which suggests novel mechanistic hypotheses for several diseases. C1 [Wang, Haidong; Koller, Daphne] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA. [Segal, Eran] Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel. [Ben-Hur, Asa] Colorado State Univ, Dept Comp Sci, Ft Collins, CO 80523 USA. [Li, Qian-Ru; Vidal, Marc] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. [Li, Qian-Ru; Vidal, Marc] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Li, Qian-Ru; Vidal, Marc] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA. RP Koller, D (reprint author), Stanford Univ, Dept Comp Sci, Serra Mall, Stanford, CA 94305 USA. EM koller@cs.stanford.edu OI Ben-Hur, Asa/0000-0001-8269-6942; Segal, Eran/0000-0002-6859-1164 NR 78 TC 32 Z9 36 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2007 VL 8 IS 9 AR R192 DI 10.1186/gb-2007-8-9-r192 PG 18 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 247SO UT WOS:000252100800018 PM 17868464 ER PT J AU Davila, JA El-Serag, HB AF Davila, Jessica A. El-Serag, Hashem B. BE Talley, NJ Locke, GR Saito, YA TI Large Databases for Epidemiologic Studies SO GI EPIDEMIOLOGY LA English DT Article; Book Chapter ID CHRONIC DISEASE SCORE; OF-VETERANS-AFFAIRS; AUTOMATED PHARMACY DATA; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; INTRAHEPATIC CHOLANGIOCARCINOMA; ADMINISTRATIVE DATA; REFLUX DISEASE; RISK-FACTORS; CARE-SYSTEM C1 [Davila, Jessica A.] Vet Affairs Med Ctr, Gastroenterol Sect, Houston Dept, Houston, TX 77030 USA. [Davila, Jessica A.] Vet Affairs Med Ctr, Sect Hlth Serv, Houston Dept, Houston, TX 77030 USA. [El-Serag, Hashem B.] Baylor Coll Med, Houston VA Med Ctr, Houston, TX 77030 USA. RP Davila, JA (reprint author), Vet Affairs Med Ctr, Gastroenterol Sect, Houston Dept, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 32 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-69218-9 PY 2007 BP 78 EP 84 DI 10.1002/9780470692189.ch11 D2 10.1002/9780470692189 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BCJ73 UT WOS:000310305700013 ER PT J AU Prasad, R Giri, S Nath, N Singh, I Singh, AK AF Prasad, Ratna Giri, Shailendra Nath, Narender Singh, Inderjit Singh, Avtar K. TI GSNO attenuates EAE disease by S-nitrosylation-mediated modulation of endothelial-monocyte interactions SO GLIA LA English DT Article DE blood-brain barrier; intercellular cell adhesion molecule-1; cell adhesion molecule; phosphoinositide 3 kinase ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NITRIC-OXIDE; MULTIPLE-SCLEROSIS; DNA-BINDING; OLIGODENDROCYTE PROGENITORS; TRANSCRIPTIONAL REGULATION; CELLULAR-RESPONSES AB S-Nitrosoglutathione (GSNO) is an endogenous nitric oxide carrier and recently, has been documented for its anti-inflammatory effects in rat model of cerebral ischemia (Khan et al. (2005) J Cereb Blood Flow Metab 25:177-192). Here, we explored the neuroprotective effects mediated by GSNO in Lewis rat model of EAE and its mechanism of action using in vitro model of monocyte-endothelial cell interaction. Oral administration of GSNO attenuated the clinical disease course in EAE animals by inhibiting the infiltration of vascular immune cells in the CNS that subsequently led to the reduction in the expression of proinflammatory cytokines and consequently limited demyelination. Based on the inhibition in infiltration of immune cells, we hypothesized that GSNO modulated endothelial cell activation that led to reduce cellular infiltration in the CNS. Using an in vitro model, we established that GSNO inhibited monocyte adhesion to the activated endothelial cell, which was mediated by down regulation of endothelial cell adhesion molecules (CAMs). The mechanism by which GSNO modulated CAMs expression appeared to be via Snitrosylation of p65, which consequently inhibited nuclear factor kappa B (NF-kappa B) activation in endothelial cells. These observations suggest that GSNO exerts its protective effects in EAE by inhibition of cellular infiltration into the CNS by S-nitrosylation of p65, thereby modulating NF-kappa B-CAMs pathway in endothelial cells. (c) 2006 Wiley-Liss, Inc. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pediat, 513 Darby Childrens Res Inst, Charleston, SC 29425 USA. EM singha@musc.edu FU NCRR NIH HHS [C06 RR015455, C06 RR018823]; NINDS NIH HHS [NS-22576, NS-37766, NS-34741, NS-40144, NS-40810] NR 58 TC 59 Z9 61 U1 1 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-1491 J9 GLIA JI Glia PD JAN 1 PY 2007 VL 55 IS 1 BP 65 EP 77 DI 10.1002/glia.20436 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 104LT UT WOS:000241960600007 PM 17019693 ER PT J AU Korzenik, JR AF Korzenik, J. R. TI Is Crohn's disease due to defective immunity? SO GUT LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; INTESTINAL EPITHELIAL-CELLS; COLONY-STIMULATING FACTOR; NEUTROPHIL DYSFUNCTION; ULCERATIVE-COLITIS; RESPIRATORY BURST; PANETH CELLS; NOD2; SUSCEPTIBILITY; PATHOGENESIS C1 Massachusetts Gen Hosp, Dept Internal Med, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA. RP Korzenik, JR (reprint author), Massachusetts Gen Hosp, Dept Internal Med, MGH Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM jkorzenik@partners.org NR 45 TC 46 Z9 47 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD JAN PY 2007 VL 56 IS 1 BP 2 EP 5 DI 10.1136/gut.2006.095588 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 117UO UT WOS:000242899000002 PM 17172582 ER PT J AU del Carmen, MG Findley, M Muzikansky, A Roche, M Verrill, CL Horowitz, N Seiden, MV AF del Carmen, Marcela G. Findley, Molly Muzikansky, Alona Roche, Maria Verrill, Cori L. Horowitz, Neil Seiden, Michael V. TI Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy SO GYNECOLOGIC ONCOLOGY LA English DT Article DE colposcopy; Latinas; disparities; cervical cancer; screening ID INVASIVE CERVICAL-CANCER; ABNORMAL PAP-SMEARS; SELF-REPORTED USE; UNITED-STATES; SCREENING HISTORIES; PAPANICOLAOU SMEARS; ETHNIC-DIFFERENCES; URBAN-POPULATION; SEXUAL-BEHAVIORS; FOLLOW-UP AB Objective. Disparities occur in the incidence and mortality of cervical cancer among minority women in the US. Screening lowers cervical cancer incidence. Screening rates are lower for minority women than for White women in the US. This study sought to identify demographic, risk factor, and perception of the role of Pap smears between Latinas and non-Latinas. Methods. A written survey was administered to 150 Latinas and 150 non-Latinas attending a colposcopy unit. Data on demographics, risk factors, screening rates, knowledge about cervical cancer screening, and perceived barriers to participation in screening programs were collected. Results. A total of 140 Latinas and 146 non-Latinas completed the survey. Marital status and health insurance status were similar in the two groups. 30% of Latinas and 73.3% of non-Latinas reported completing college (p < 0.0001). Only 55.7% of Latinas were employed, compared to 82.2% of non-Latinas (p < 0.0001). 21% of Latinas and 53.4% of non-Latinas reported an annual income greater than $35,000 (P < 0.0001). Among Latinas, women with 1-5 lifetime Pap smears were less likely to have completed college than those with more than 5 lifetime Pap smears (OR=2.11; 95% CI 1.05-4.22) and to have an annual income of less than $ 35,000 (OR=3.81; 95% CI 1.64-8.87). Latinas were less likely to have >= 6 lifetime sexual partners, use tobacco, and have a history of sexually transmitted infections. Latinas more commonly reported fear of test results (OR, 0.04; 95% CI 0.02-0.09) and inability to communicate with their provider in Spanish (p < 0.0001) as bat-Hers to screening than the non-Latina respondents. Conclusions. Several of the barriers limiting access to cervical cancer screening programs are also present among screened Latinas undergoing further evaluation for abnormal Pap smears. (c) 2006 Elsevier Inc. All rights reserved. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Gynecol Oncol,Vincent Obstet & Gynecol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Div Hematol & Oncol, Boston, MA 02115 USA. RP del Carmen, MG (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Gynecol Oncol,Vincent Obstet & Gynecol, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM mdelcarmen@partners.org NR 39 TC 12 Z9 12 U1 2 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD JAN PY 2007 VL 104 IS 1 BP 70 EP 76 DI 10.1016/j.ygyno.2006.07.008 PG 7 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 129WI UT WOS:000243760400015 PM 16949138 ER PT J AU Holloway, CL Russell, AH Muto, M Albert, M Viswanathan, AN AF Holloway, Caroline L. Russell, Anthony H. Muto, Michael Albert, Michele Viswanathan, Akila N. TI Synovial cell sarcoma of the vulva: Multimodality treatment incorporating preoperative external-beam radiation, hemivulvectomy, flap reconstruction, interstitial brachytherapy, and chemotherapy SO GYNECOLOGIC ONCOLOGY LA English DT Article DE vulvar sarcoma; radiation therapy; brachytherapy ID SOFT-TISSUE SARCOMA; EXTREMITY AB Background. Vulvar synovial cell sarcomas are rare, with only four previously published cases in the literature. Traditionally, the primary management for these tumors has been surgery alone. Case. We report a case of a large vulvar synovial cell sarcoma in a 50-year-old woman treated with comprehensive combined multimodality management, including preoperative intensity-modulated radiation therapy, radical hemivulvectomy, flap reconstruction, interstitial low-dose-rate brachytherapy boost, and adjuvant chemotherapy. Conclusion. Based on this case and the limited data in the literature, multimodality treatment of advanced soft tissue sarcoma of the vulva may optimize local control and minimize toxicity while preserving sexual function. (c) 2006 Elsevier Inc. All rights reserved. C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA. RP Viswanathan, AN (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St L2, Boston, MA 02115 USA. EM aviswanathan@lroc.harvard.edu FU NCI NIH HHS [R25 CA089017] NR 11 TC 4 Z9 4 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD JAN PY 2007 VL 104 IS 1 BP 253 EP 256 DI 10.1016/j.ygyno.2006.09.018 PG 4 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 129WI UT WOS:000243760400043 PM 17070900 ER PT J AU Ruutu, T Barosi, G Benjamin, RJ Clark, RE George, JN Gratwohl, A Holler, E Lacobelli, M Kentouche, K Lammle, B Moake, JL Richardson, P Socie, G Zeigler, Z Niederwieser, D Barbui, T AF Ruutu, Tapani Barosi, Giovanni Benjamin, Richard J. Clark, Richard E. George, James N. Gratwohl, Alois Holler, Ernst Lacobelli, Massimo Kentouche, Karim Laemmle, Bernhard Moake, Joel L. Richardson, Paul Socie, Gerard Zeigler, Zella Niederwieser, Dietger Barbui, Tiziano CA European Grp Blood Marrow Transpl TI Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL LA English DT Article DE bone marrow transplantation; hematopoietic stem cell transplantation; thrombotic microangiopathy; thrombotic thrombocytopenic purpura; transplant-associated microangiopathy ID BONE-MARROW-TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VERSUS-HOST-DISEASE; HEMOLYTIC-UREMIC SYNDROME; PROPHYLAXIS; BLOOD AB Background and Objectives There are no widely accepted criteria for the definition of hematopoietic stem cell transplant -associated microangiopathy (TAM). An International Working Group was formed to develop a consensus formulation of criteria for diagnosing clinically significant TAM. Design and Methods The participants proposed a list of candidate criteria, selected those considered necessary, and ranked those considered optional to identify a core set of criteria. Three obligatory criteria and four optional criteria that ranked highest formed a core set. In an appropriateness panel process, the participants scored the diagnosis of 16 patient profiles as appropriate or not appropriate for TAM. Using the experts' ratings on the patient profiles as a gold standard, the sensitivity and specificity of 24 candidate definitions of the disorder developed from the core set of criteria were evaluated. A nominal group technique was used to facilitate consensus formation. The definition of TAM with the highest score formed the final proposal. Results The Working Group proposes that the diagnosis of TAM requires fulfilment of all of the following criteria: (i) > 4% schistocytes in blood; (ii) de novo, prolonged or progressive thrombocytopenia (platelet count < 50x10(9)/L or 50% or greater reduction from previous counts); (iii) sudden and persistent increase in lactate dehydrogenase concentration; (iv) decrease in hemoglobin concentration or increased transfusion requirement; and (v) decrease in serum haptoglobin. The sensitivity and specificity of this definition exceed 80%. Interpretation and Conclusions The Working Group recommends that the presented criteria of TAM be adopted in clinical use, especially in scientific trials. C1 Univ Helsinki, Cent Hosp, Dept Med, Div Hematol, Helsinki 00029, Finland. IRRCS Policlin S AMtteo, Lab Clin Epiemiol, Pavia, Italy. Amer Red Cross, Dedham, MA USA. Royal Liverpool Univ Hosp, Dept Hematol, Liverpool, Merseyside, England. Univ Oklahoma, Hlth Sci Ctr, Hrmatol Oncol Sect, Oklahoma City, OK USA. Univ Basel, Univ Hosp, Div Hematol, CH-4003 Basel, Switzerland. Univ Regensburg, Klinikum, Abt Hamatol Internol Oncol, D-8400 Regensburg, Germany. Gentium, Como, Italy. Univ Jena, Klin Kinder & Jugendmed, D-6900 Jena, Germany. Univ Hosp Bern, Dept Hematol, CH-3010 Bern, Switzerland. Univ Hosp Bern, Cent Hematol Lab, CH-3010 Bern, Switzerland. Baylor Coll Med, Houston, TX 77030 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Hop St Louis, Dept Hematol, Paris, France. Inst Transfus Med, Pittsburgh, PA USA. Univ Leipzig, Div Hematol & Oncol, D-7010 Leipzig, Germany. Osped Riuniti Bergamo, Div Hematol, Bergamo, Italy. RP Ruutu, T (reprint author), Univ Helsinki, Cent Hosp, Dept Med, Div Hematol, POB 340, Helsinki 00029, Finland. EM tapani.ruutu@hus.fi NR 22 TC 107 Z9 123 U1 2 U2 3 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 EI 1592-8721 J9 HAEMATOL-HEMATOL J JI Haematol-Hematol. J. PD JAN PY 2007 VL 92 IS 1 BP 95 EP 100 DI 10.3324/haematol.10699 PG 6 WC Hematology SC Hematology GA 129NN UT WOS:000243736300014 PM 17229640 ER PT S AU Casserly, IP Yadav, JS AF Casserly, Ivan P. Yadav, Jay S. BE Saw, J Exaire, JE Lee, DS Yadav, JS TI The Approach to Intracranial Carotid Artery Intervention SO HANDBOOK OF COMPLEX PERCUTANEOUS CAROTID INTERVENTION SE Contemporary Cardiology LA English DT Article; Book Chapter DE Intracranial atherosclerosis; intracranial stenting; stroke ID PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; MIDDLE CEREBRAL-ARTERY; ATHEROSCLEROTIC STENOSIS; BALLOON ANGIOPLASTY; ISCHEMIC-STROKE; CORONARY INTERVENTION; STENT IMPLANTATION; INITIAL-EXPERIENCE; RANDOMIZED-TRIAL; RISK-FACTORS AB Intracranial large vessel atherosclerosis is believed to account for approx 5-10% of all ischemic strokes in the United States. Compared with extracranial artery atherosclerosis, the natural history of intracranial atherosclerosis, and the effectiveness of medical therapy and revascularization in modifying the natural history of the disease, are poorly defined. This chapter summarizes our current understanding of intracranial atherosclerosis and describes the emerging practice of endovascular revascularization for the treatment of this disease. C1 [Casserly, Ivan P.] Denver Vet Affairs Med Ctr, Cardiol Sect, Denver, CO USA. [Yadav, Jay S.] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA. RP Casserly, IP (reprint author), Denver Vet Affairs Med Ctr, Cardiol Sect, Denver, CO USA. NR 35 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1191-7601 BN 978-1-59745-002-7 J9 CONTEMP CARDIOL JI Contemp. Cardiol. PY 2007 BP 189 EP 209 DI 10.1007/978-1-59745-002-7_13 D2 10.1007/978-1-59745-002-7 PG 21 WC Cardiac & Cardiovascular Systems; Surgery; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Surgery GA BLZ52 UT WOS:000271567000014 ER PT J AU Tellides, C Harrison, AM Neuhaus, EC Shapiro, ER AF Tellides, Catherine Harrison, Alexandra M. Neuhaus, Edmund C. Shapiro, Edward R. TI Strategic choices in the psychotherapy of a "fragile" patient SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article ID MODEL C1 Harvard Univ, Sch Med, Belmont, MA 02178 USA. McLean Hosp, Belmont, MA 02178 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Boston Psychoanalyt Soc & Inst Inc, Boston, MA USA. RP Tellides, C (reprint author), McLean Ctr Fernside, POB 1070, Princeton, MA 01541 USA. EM ctellides@mclean.harvard.edu NR 21 TC 1 Z9 1 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD JAN-FEB PY 2007 VL 15 IS 1 BP 18 EP 29 DI 10.1080/10673220601183949 PG 12 WC Psychiatry SC Psychiatry GA 140FW UT WOS:000244490900003 PM 17364970 ER PT J AU Limmroth, V Biondi, D Pfeil, J Schwalen, S AF Limmroth, Volker Biondi, David Pfeil, Joop Schwalen, Susanne TI Topiramate in patients with episodic migraine: Reducing the risk for chronic forms of headache SO HEADACHE LA English DT Article DE chronic headache; chronic migraine; medication overuse headache; topiramate; prevention ID CONTROLLED-TRIAL; DOUBLE-BLIND; POPULATION; PREVENTION; PREVALENCE; EPIDEMIOLOGY; PROPHYLAXIS; CRITERIA; BURDEN; DAMAGE AB Objective.-The aim was to evaluate whether preventive treatment with topiramate in patients with episodic migraine reduces the risk of developing chronic forms of headache. Background.-Chronic forms of headache, including chronic migraine or medication overuse headache (MOH), are characterized by 15 or more headache days per month. Acute medication overuse has been shown to be a risk factor for developing chronic headache, but it is not known whether preventive treatment can reduce the risk of developing chronic forms of headache or the development of MOH. Methods.-Pooled data from 3 trials in patients with episodic migraine randomized either to treatment with 100 mg topiramate per day (n = 384) or with placebo (n = 372) were analyzed with regard to the number of headache days during a prospective 4-week baseline period and the individual final 4 weeks of each patient's treatment during the planned 26-week double-blind treatment period. Results.-The number of headache days per month in the topiramate versus the placebo-treated groups was 7.3 +/- 3.0 versus 7.3 +/- 3.1 during baseline and 4.1 +/- 4.2 versus 5.6 +/- 4.9 during the final 4 weeks, respectively (P < .001). At the end of the study, 8 versus 16 patients fulfilled International Headache Society criteria of chronic headache (odds ratio: 2.11, P = .082). Moreover, a significantly lower number of patients receiving topiramate treatment reported an increase in headache days per month by the end of the study when compared to placebo (66 vs 88 patients, respectively; odds ratio: 1.49, P < .05). Finally, the number of days with usage of acute medication was significantly lower in the topiramate arm compared with placebo (3.3 +/- 3.7 vs 4.3 +/- 3.6, respectively; P < .001). Conclusion.-Preventive treatment with topiramate in patients with episodic migraine may reduce the risk of developing chronic forms of headache. C1 Cologne City Hosp, Dept Neurol, D-51109 Cologne, Germany. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Limmroth, V (reprint author), Cologne City Hosp, Dept Neurol, Ostmerheimerstr 200, D-51109 Cologne, Germany. NR 36 TC 32 Z9 34 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0017-8748 J9 HEADACHE JI Headache PD JAN PY 2007 VL 47 IS 1 BP 13 EP 21 DI 10.1111/j.1526-4610.2007.00648.x PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 125WL UT WOS:000243474100005 PM 17355489 ER PT J AU Wilson, CT Fisher, ES Welch, HG Siewers, AE Lucas, FL AF Wilson, Chad T. Fisher, Elliott S. Welch, H. Gilbert Siewers, Andrea E. Lucas, F. Lee TI US trends in CABG hospital volume: The effect of adding cardiac surgery programs SO HEALTH AFFAIRS LA English DT Article ID BYPASS GRAFT-SURGERY; SPECIALTY HOSPITALS; MORTALITY; COMMUNITY; STATES AB Hospital coronary artery bypass graft (CABG) volume is inversely related to mortality-with low-volume hospitals having the highest mortality. Medicare data (19922003) show that the number of CABG procedures increased from 158,000 in 1992 to a peak of 190,000 in 1996 and then fell to 152,000 in 2003, while the number of hospitals performing CABG increased steadily. Predictably, the proportion of CABG procedures performed at low-volume hospitals increased, and the proportion in high-volume hospitals declined. An unintended consequence of starting new cardiac surgery programs is declining CABG hospital volume-a side effect that might increase mortality. C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Dartmouth Coll Sch Med, Hanover, NH USA. Maine Med Ctr, Ctr Outcomes Res & Evaluat, Portland, ME 04102 USA. RP Wilson, CT (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM ctwilson@partners.org FU NIA NIH HHS [P01 AG019783, P01 AG019783-07, P01-AG19783] NR 25 TC 37 Z9 37 U1 0 U2 0 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2007 VL 26 IS 1 BP 162 EP 168 DI 10.1377/hlthaff.26.1.162 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 136LF UT WOS:000244223200018 PM 17211025 ER PT J AU O'Connell, KA Hosein, VL Schwartz, JE Leibowitz, RQ AF O'Connell, Kathleen A. Hosein, Vanessa L. Schwartz, Joseph E. Leibowitz, Ruth Q. TI How does coping help people resist lapses during smoking cessation? SO HEALTH PSYCHOLOGY LA English DT Article DE coping; smoking cessation; cognitive strategies; behavioral strategies; urge levels ID QUITTING SMOKING; NEGATIVE AFFECT; RELAPSE; TEMPTATIONS; STRATEGIES; ABSTINENCE; BEHAVIOR AB Objectives: To determine whether types of coping strategies have differential effects on preventing lapses and lowering urge levels and to investigate mechanisms by which coping strategies prevent lapses during smoking cessation. Design: Sixty-one respondents performed ecological momentary assessment using palm-top computers and tape recorders to report their coping strategies and urge levels before and after temptations to smoke. Multilevel linear regression models were used to compare the effects of individual strategy types with the average strategy. Main Outcome Measures: Lapses versus resisted temptations and changes in urge levels. Results: Number of strategies significantly predicted resisting smoking and change in urge levels. Compared with the effect of the average strategy, movement/exercise was marginally worse at preventing lapses, and food/drink was marginally related to higher postcoping urge levels. Conclusion: Although using multiple coping strategies helps people resist the urge to smoke, no particular coping strategy works better than any other. Coping strategies prevent lapses by reducing high urge levels during temptations. C1 Columbia Univ, Teachers Coll, Dept Hlth & Behav Studies, New York, NY 10027 USA. SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP O'Connell, KA (reprint author), Columbia Univ, Teachers Coll, Dept Hlth & Behav Studies, Box 35,525 W 120th St, New York, NY 10027 USA. EM oconnell@tc.columbia.edu NR 28 TC 35 Z9 35 U1 1 U2 9 PU AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 J9 HEALTH PSYCHOL JI Health Psychol. PD JAN PY 2007 VL 26 IS 1 BP 77 EP 84 DI 10.1037/0278-6133.26.1.77 PG 8 WC Psychology, Clinical; Psychology SC Psychology GA 125AF UT WOS:000243413200010 PM 17209700 ER PT B AU Cedolin, L Delgutte, B AF Cedolin, Leonardo Delgutte, Bertrand BE Kollmeier, B Hohmann, V Mauermann, M Verhey, J Klump, G Langemann, U Uppenkamp, S TI Spatio-temporal representation of the pitch of complex tones in the auditory nerve SO HEARING - FROM SENSORY PROCESSING TO PERCEPTION LA English DT Proceedings Paper CT International Symposium on Hearing CY AUG, 2006 CL Cloppenburg, GERMANY ID FIBER RESPONSES; PERCEPTION; SOUNDS; MODEL C1 [Cedolin, Leonardo; Delgutte, Bertrand] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. RP Cedolin, L (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. NR 18 TC 14 Z9 14 U1 1 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-73008-8 PY 2007 BP 61 EP 70 DI 10.1007/978-3-540-73009-5_8 PG 10 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA BHA48 UT WOS:000251909800008 ER PT B AU Hancock, KE AF Hancock, Kenneth E. BE Kollmeier, B Hohmann, V Mauermann, M Verhey, J Klump, G Langemann, U Uppenkamp, S TI A physiologically-based population rate code for interaural time differences (ITDs) predicts bandwidth-dependent lateralization SO HEARING - FROM SENSORY PROCESSING TO PERCEPTION LA English DT Proceedings Paper CT International Symposium on Hearing CY AUG, 2006 CL Cloppenburg, GERMANY ID COMPLEX BINAURAL STIMULI; SUPERIOR OLIVARY COMPLEX; SOUND LOCALIZATION; NEURONS; MODEL; DELAY C1 [Hancock, Kenneth E.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. RP Hancock, KE (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. NR 20 TC 6 Z9 6 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-73008-8 PY 2007 BP 389 EP 397 DI 10.1007/978-3-540-73009-5_42 PG 9 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA BHA48 UT WOS:000251909800042 ER PT B AU Devore, S Ihlefeld, A Shinn-Cunningham, BG Delgutte, B AF Devore, Sasha Ihlefeld, Antje Shinn-Cunningham, Barbara G. Delgutte, Bertrand BE Kollmeier, B Hohmann, V Mauermann, M Verhey, J Klump, G Langemann, U Uppenkamp, S TI Neural and behavioral sensitivities to azimuth degrade with distance in reverberant environments SO HEARING - FROM SENSORY PROCESSING TO PERCEPTION LA English DT Proceedings Paper CT International Symposium on Hearing CY AUG, 2006 CL Cloppenburg, GERMANY ID INFERIOR COLLICULUS; SOUND LOCALIZATION; RESPONSES C1 [Devore, Sasha; Delgutte, Bertrand] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Ihlefeld, Antje; Shinn-Cunningham, Barbara G.] Boston Univ, Hearing Res Ctr, Boston, MA 02215 USA. RP Devore, S (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. EM sashad@mit.edu; Bertrand_Delgutte@meei.harvard.edu NR 19 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-73008-8 PY 2007 BP 505 EP + DI 10.1007/978-3-540-73009-5_54 PG 5 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA BHA48 UT WOS:000251909800054 ER PT S AU Akashi, K AF Akashi, Koichi BE Kanz, L Weisel, KC Dick, JE Fibbe, WE TI Cartography of hematopoietic stem cell commitment dependent upon a reporter for transcription factor activation SO HEMATOPOIETIC STEM CELLS VI SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 6th Biennial International Symposium and Workshop on Hematopoietic Stem Cells CY SEP 14-16, 2006 CL Univ Tubingen, Tubingen, GERMANY HO Univ Tubingen DE hematopoietic stem cell; commitment; transcription factor ID BONE-MARROW; LINEAGE COMMITMENT; LYMPHOID PROGENITORS; PU.1; DIFFERENTIATION; IDENTIFICATION; EXPRESSION; RECEPTOR; C/EBP AB A hierarchical hematopoietic developmental tree has been proposed based on the result of prospective purification of lineage-restricted progenitors. For more detailed mapping for hematopoietic stem cell (HSC) commitment, we tracked the expression of PU.1, a major granulocyte/monocyte (GM)- and lymphoid-related transcription factor, from the HSC to the myelolymphoid progenitor stages by using a mouse line harboring a knockin reporter for PU.1. This approach enabled us to find a new progenitor population committed to GM and lymphoid lineages within the HSC fraction. This result suggests that there should be another developmental pathway independent of the conventional one with myeloid versus lymphoid bifurcation, represented by common myeloid progenitors and common lymphoid progenitors, respectively. The utilization of the transcription factor expression as a functional marker might be useful to obtain cartography of the hematopoietic development at a higher resolution. C1 Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Kyushu Univ Hosp, Ctr Cellular & Mol Med, Fukuoka 812, Japan. RP Akashi, K (reprint author), Smith 770,44 Binney St, Boston, MA 02115 USA. EM koichi_akashi@dfci.harvard.edu NR 22 TC 3 Z9 3 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-676-7 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2007 VL 1106 BP 76 EP 81 DI 10.1196/annals.1392.009 PG 6 WC Cell Biology; Hematology; Multidisciplinary Sciences SC Cell Biology; Hematology; Science & Technology - Other Topics GA BGL47 UT WOS:000248195300007 PM 17360807 ER PT S AU Lengerke, C Kim, K Lerou, P Daley, GQ AF Lengerke, Claudia Kim, Kitai Lerou, Paul Daley, George Q. BE Kanz, L Weisel, KC Dick, JE Fibbe, WE TI Differentiation potential of histocompatible parthenogenetic embryonic stem cells SO HEMATOPOIETIC STEM CELLS VI SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 6th Biennial International Symposium and Workshop on Hematopoietic Stem Cells CY SEP 14-16, 2006 CL Univ Tubingen, Tubingen, GERMANY HO Univ Tubingen DE parthenogenesis; embryonic stem cells; developmental potential; MHC-matched; Igf2 ID GROWTH-FACTOR-II; MOUSE EMBRYOS; OVARIAN TERATOMAS; CHIMERAS; OVEREXPRESSION; SURVIVAL; FATE; GENE; MICE AB Embryonic stem cells (ESCs) hold unique promise for the development of cell replacement therapies, but derivation of therapeutic products from ESCs is hampered by immunological barriers. Creation of HLA-typed ESC banks, or derivation of customized ESC lines by somatic cell nuclear transfer, have been envisioned for engineering histocompatible ESC-derived products. Proof of principle experiments in the mouse have demonstrated that autologous ESCs can be obtained via nuclear transfer and differentiated into transplantable tissues, yet nuclear transfer remains a technology with low efficiency. Parthenogenesis provides an additional means for deriving ESC lines. In parthenogenesis, artificial oocyte activation initiates development without sperm contribution and no viable offspring are produced in the absence of paternal gene expression. Development proceeds readily to the blastocyst stage, from which parthenogenetic ESC (pESC) lines can be derived with high efficiency. We have recently shown that when pESC lines are derived from hybrid mice, early recombination events produce heterozygosity at the major histocompatibility complex (MHC) loci in some of these lines, enabling the generation of histocompatible differentiated cells that can engraft immunocompetent MHC-matched mouse recipients. Here, we explore the differentiation potential of murine pESCs derived in our laboratory. C1 Childrens Hosp, Dana Farber Canc Inst, Div Pediat Hematol Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Biol & Chem & Mol Pharmacol, Boston, MA 02115 USA. Harvard Stem Cell Inst, Cambridge, MA 02138 USA. Brigham & Womens Hosp, Div Newborn Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA. Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. RP Daley, GQ (reprint author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA. EM george.daley@childrens.harvard.edu OI Lengerke, Claudia/0000-0001-5442-2805 FU NICHD NIH HHS [T32: HD07466] NR 28 TC 12 Z9 14 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-676-7 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2007 VL 1106 BP 209 EP 218 DI 10.1196/annals.1392.011 PG 10 WC Cell Biology; Hematology; Multidisciplinary Sciences SC Cell Biology; Hematology; Science & Technology - Other Topics GA BGL47 UT WOS:000248195300018 PM 17360798 ER PT J AU Bar, M Aminoff, E Mason, M Fenske, M AF Bar, Moshe Aminoff, Elissa Mason, Malia Fenske, Mark TI The units of thought SO HIPPOCAMPUS LA English DT Editorial Material DE default network; associations; medial parietal; medial prefrontal; parahippocampal cortex ID ASSOCIATIVE RECOGNITION MEMORY; POSITRON-EMISSION-TOMOGRAPHY; STIMULUS-INDEPENDENT THOUGHT; INFERIOR TEMPORAL CORTEX; CONSCIOUS RESTING STATE; PREFRONTAL CORTEX; EPISODIC MEMORY; ALZHEIMERS-DISEASE; BRAIN-REGIONS; HIPPOCAMPAL REGION AB That associative processing provides the vehicle of thought is a long-standing idea. We describe here observations from cognitive neuroimaging that elucidate the neural processing that mediates this element. This account further allows a more specific ascription of a cognitive function to the brain's '' default '' activity in mindwandering. We extend this account to argue that one primary outcome of associative processing is the generation of predictions, which approximate the immediately relevant future and thus facilitate perception, action, and the progression of thought. (C) 2007 Wiley-Liss, Inc. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr, Charlestown, MA 02129 USA. RP Bar, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr, 149 13th St, Charlestown, MA 02129 USA. EM bar@nmr.mgh.harvard.edu OI Aminoff, Elissa/0000-0002-6455-8930; Fenske, Mark/0000-0003-4338-7754 FU NINDS NIH HHS [R01-NS044319, R01-NS050615] NR 82 TC 75 Z9 76 U1 6 U2 18 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2007 VL 17 IS 6 BP 420 EP 428 DI 10.1002/hipo.20287 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 174VO UT WOS:000246971100002 PM 17455334 ER PT J AU Dickerson, BC Miller, SL Greve, DN Dale, AM Albert, MS Schacter, DL Sperling, RA AF Dickerson, B. C. Miller, S. L. Greve, D. N. Dale, A. M. Albert, M. S. Schacter, D. L. Sperling, R. A. TI Prefrontal-hippocampal-fusiform activity during encoding predicts intraindividual differences in free recall ability: An event-related functional-anatomic MRI study SO HIPPOCAMPUS LA English DT Article DE functional MRI; memory; entorhinal cortex; perirhinal cortex ID SURFACE-BASED ANALYSIS; EPISODIC MEMORY; BRAIN ACTIVITY; CORTEX; LANGUAGE; ACTIVATION; RETRIEVAL; FMRI; SEGMENTATION; RECOGNITION AB The ability to spontaneously recall recently learned information is a fundamental mnemonic activity of daily life, but has received little study using functional neuroimaging. We developed a functional MRI (fMRI) paradigm to study regional brain activity during encoding that predicts free recall. In this event-related fMRI study, ten lists of fourteen pictures of common objects were shown to healthy young individuals and regional brain activity during encoding was analyzed based on subsequent free recall performance. Free recall of items was predicted by activity during encoding in hippocampal, fusiform, and inferior prefrontal cortical regions. Within-subject variance in free recall performance for the ten lists was predicted by a linear combination of condition-specific inferior prefrontal, hippocampal, and fusiform activity. Recall performance was better for lists in which prefrontal activity was greater for all items of the list and hippocampal and fusiform activity were greater specifically for items that were recalled from the list. Thus, the activity of medial temporal, fusiform, and prefrontal brain regions during the learning of new information is important for the subsequent free recall of this information. These fronto-temporal brain regions act together as a large-scale memory-related network, the components of which make distinct yet interacting contributions during encoding that predict subsequent successful free recall performance. (C) 2007 Wiley-Liss, Inc. C1 Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Div Hlth Sci & Technol, Harvard Massachusetts Inst Technol, Athinoula A Martinous Ctr Biomed Imaging, Charlestown, MA USA. Brigham & Womens Hosp, Dept Neurol, Div Cognit & Behav Neurol, Boston, MA USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD USA. Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. RP Dickerson, BC (reprint author), MGH Gerontol Res Unit, 149 13th St,Suite 2691, Boston, MA 02129 USA. EM bradd@nmr.mgh.harvard.edu RI Dale, Anders/A-5180-2010; OI Schacter, Daniel/0000-0002-2460-6061 FU NCRR NIH HHS [P41-RR14075, P41 RR014075]; NIA NIH HHS [K23 AG022509, K23 AG022509-05, K23-AG22509, R01 AG008441, R01-AG08441]; NINDS NIH HHS [K23 NS002189, K23-NS02189] NR 45 TC 43 Z9 44 U1 1 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2007 VL 17 IS 11 BP 1060 EP 1070 DI 10.1002/hipo.20338 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 230EG UT WOS:000250858200006 PM 17604356 ER PT J AU Chua, EF Schacter, DL Rand-Giovannetti, E Sperling, RA AF Chua, Elizabeth F. Schacter, Daniel L. Rand-Giovannetti, Erin Sperling, Reisa A. TI Evidence for a specific role of the anterior hippocampal region in successful associative encoding SO HIPPOCAMPUS LA English DT Article DE medial temporal lobe; hippocampus; fMRI; memory; relational memory ID MEDIAL TEMPORAL-LOBE; EVENT-RELATED FMRI; FACE-NAME PAIRS; RECOGNITION MEMORY; FUNCTIONAL MRI; RELATIONAL MEMORY; BRAIN ACTIVITY; RETRIEVAL; ITEM; RECOLLECTION AB It has been well established that the hippocampal formation plays a critical role in the formation of memories. However, functional specialization within the hippocampus remains controversial. Using functional magnetic resonance imaging (fMRI) during a face-name associative encoding task, followed by a postscan recognition test for face memory and face-name pair memory, we investigated the roles of anterior and posterior hippocampal regions in successful encoding of associations and items. Whole-brain and region of interest (ROI) analyses revealed that the anterior hippocampal formation showed increased activation for subsequently remembered face-name associations compared with pairs that were forgotten. In contrast, the posterior hippocampal formation showed activation above baseline during attempted encoding of face-name pairs, but no evidence of differential activation based on subsequent memory. Furthermore, exploratory whole-brain analyses revealed that a parahippocampal region, most likely corresponding to perirhinal cortex, showed subsequent memory effects for faces. These data provide evidence for functional specialization within the hippocampal formation based on the associative nature of the stimuli and subsequent memory. (C) 2007 Wiley-Liss, Inc. C1 Brigham & Womens Hosp, Dept Neurol, Boston, MA USA. Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. RP Sperling, RA (reprint author), Memory Disorders Unit, 221 Longwood Ave, Boston, MA 02115 USA. EM reisa@rics.bwh.harvard.edu RI Chua, Elizabeth/B-3770-2010; OI Schacter, Daniel/0000-0002-2460-6061 FU NIA NIH HHS [P01-AG-04953, R01-AG027435]; NIMH NIH HHS [MH60941]; NINDS NIH HHS [K23-NS02189] NR 44 TC 99 Z9 102 U1 0 U2 13 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2007 VL 17 IS 11 BP 1071 EP 1080 DI 10.1002/hipo.20340 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 230EG UT WOS:000250858200007 PM 17604351 ER PT J AU Srivastava, A Lauwers, GY AF Srivastava, A. Lauwers, G. Y. TI Pathology of non-infective gastritis SO HISTOPATHOLOGY LA English DT Review DE classification; diagnostic features; gastritis; non-infective; stomach ID ANTRAL VASCULAR ECTASIA; PORTAL HYPERTENSIVE GASTROPATHY; ISOLATED GRANULOMATOUS GASTRITIS; UPPER GASTROINTESTINAL-TRACT; VERSUS-HOST DISEASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FOCALLY ENHANCED GASTRITIS; ARTERIAL INFUSION CHEMOTHERAPY; HELICOBACTER-PYLORI GASTRITIS; X-LINKED AGAMMAGLOBULINEMIA AB The discovery of Helicobacter pylori and its intimate role in the development of the most common form of chronic gastritis has elicited a much-needed interest in non-neoplastic gastric pathology. This has been paralleled by an increase in upper endoscopic examinations, which allow recognition of novel patterns and distribution of mucosal injury. Numerous attempts at classification have been made, most based on the acuteness or chronicity of gastric mucosal injury. In this review, we will not offer a new classification but present a detailed description of the major clinicopathological entities, based either on the salient morphological features or the underlying aetiologies, i.e. iatrogenic, autoimmune, vascular or idiopathic. C1 Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA. Dartmouth Coll Sch Med, Lebanon, NH USA. RP Lauwers, GY (reprint author), Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, 55 Fruit St,WRN 2, Boston, MA 02114 USA. EM glauwers@partners.org RI Srivastava, Amitabh/A-9386-2009 NR 164 TC 14 Z9 15 U1 0 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0309-0167 J9 HISTOPATHOLOGY JI Histopathology PD JAN PY 2007 VL 50 IS 1 BP 15 EP 29 DI 10.1111/j.1365-2559.2006.02553.x PG 15 WC Cell Biology; Pathology SC Cell Biology; Pathology GA 117HE UT WOS:000242863000003 PM 17204018 ER PT J AU Sherman, S Schlumberger, M Droz, JP Hofmann, M Wirth, L Bastholt, L Martins, R Licitra, L Shi, Y Stepan, D AF Sherman, S. Schlumberger, M. Droz, J. P. Hofmann, M. Wirth, L. Bastholt, L. Martins, R. Licitra, L. Shi, Y. Stepan, D. TI Initial results from a phase 2 trial of AMG 706 in patients (Pts) with differentiated thyroid cancer (DTC) SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Sherman, S.] Univ Texas, MD Anderson Canc Ctr, Houston, TX USA. [Schlumberger, M.] Inst Gustave Roussy, Nucl Med Serv, Villejuif, France. [Droz, J. P.] Ctr Leon Berard, F-69373 Lyon, France. [Hofmann, M.] Inselspital Bern, Sch Med, Bern, Switzerland. [Wirth, L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bastholt, L.] Odense Univ Hosp, DK-5000 Odense, Denmark. [Martins, R.] Seattle Canc Care Alliance, Seattle, WA USA. [Licitra, L.] Ist Nazl Tumori, Med Oncol Unit, I-20133 Milan, Italy. [Shi, Y.; Stepan, D.] Amgen Inc, Thousand Oaks, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2007 VL 68 SU 3 BP 4 EP 5 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 240WB UT WOS:000251617800010 ER PT J AU Schlumberger, M Elisei, R Sherman, S Bastholt, L Wirth, L Martins, R Licitra, L Jarzab, B Pacini, F Daumerie, C Droz, JP Shi, Y Sun, YN Stepan, D AF Schlumberger, M. Elisei, R. Sherman, S. Bastholt, L. Wirth, L. Martins, R. Licitra, L. Jarzab, B. Pacini, F. Daumerie, C. Droz, J. P. Shi, Y. Sun, Y. -N. Stepan, D. TI Initial results from a phase 2 trial of AMG 706 in patients (Pts) with medullary thyroid cancer (MTC) SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Schlumberger, M.] Inst Gustave Roussy, Nucl Med Serv, Villejuif, France. [Elisei, R.] Univ Pisa, I-56100 Pisa, Italy. [Sherman, S.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Bastholt, L.] Odense Univ Hosp, DK-5000 Odense, Denmark. [Wirth, L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Martins, R.] Seattle Canc Care Alliance Med Oncol, Seattle, WA USA. [Licitra, L.] Ist Nazl Tumori, Med Oncol Unit, I-20133 Milan, Italy. [Wirth, L.] Marie Curie Mem Canc Ctr, Inst Oncol, Gliwice, Poland. [Martins, R.] Univ Siena, I-53100 Siena, Italy. [Daumerie, C.] Catholic Univ Louvain, Brussels, Belgium. [Droz, J. P.; Sun, Y. -N.] Ctr Leon Berard, F-69373 Lyon, France. [Shi, Y.; Sun, Y. -N.; Stepan, D.] Amgen Inc, Thousand Oaks, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2007 VL 68 SU 3 BP 5 EP 5 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 240WB UT WOS:000251617800012 ER PT J AU Pacini, F Sherman, S Schlumberger, M Elisei, R Wirth, L Bastholt, L Droz, JP Martins, R Hofmann, M Locati, L Eschenberg, M Stepan, D AF Pacini, F. Sherman, S. Schlumberger, M. Elisei, R. Wirth, L. Bastholt, L. Droz, J. P. Martins, R. Hofmann, M. Locati, L. Eschenberg, M. Stepan, D. TI Exacerbation of postsurgical hypothyroidism during treatment of advanced differentiated (DTC) or medullary (MTC) thyroid carcinoma with AMG 706 SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Pacini, F.] Univ Siena, I-53100 Siena, Italy. [Sherman, S.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Schlumberger, M.] Inst Gustave Roussy, Serv Med Nucl, Villejuif, France. [Elisei, R.] Univ Pisa, Pisa, Italy. [Wirth, L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bastholt, L.] Odense Univ Hosp, DK-5000 Odense, Denmark. [Droz, J. P.] Ctr Leon Berard, Lyon, France. [Martins, R.] Seattle Canc Care Alliance, Seattle, WA USA. [Hofmann, M.] Inselspital Bern, Sch Med, Bern, Switzerland. [Locati, L.] Inst Nazl Tumori, Milan, Italy. [Eschenberg, M.; Stepan, D.] Amgen Inc, Thousand Oaks, CA 91320 USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2007 VL 68 SU 3 BP 29 EP 29 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 240WB UT WOS:000251617800075 ER PT J AU Biller, BMK AF Biller, Beverly M. K. TI Concepts in the diagnosis of adult growth hormone deficiency SO HORMONE RESEARCH LA English DT Article; Proceedings Paper CT 39th International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism CY MAY 11-12, 2007 CL Berlin, GERMANY SP Pfizer DE growth hormone deficiency; provocative testing; arginine-GH-releasing hormone ID GH DEFICIENCY; SEVERITY AB Background.-To make a diagnosis of growth hormone deficiency (GHD), individuals with normal GH levels must be distinguished from those who are deficient. This requires an understanding of how GH secretion and other related factors differs between these two groups. The presence of a normal insulin-like growth factor I (IGF-I) level does not necessarily preclude a diagnosis of GHD, whereas a low IGF-I level in a subject with three or four other hormone deficiencies and no conditions that would otherwise lower IGF-I might be sufficient to make the diagnosis. Provocative testing is a clinically relevant method of testing, but not all tests in use have comparable specificity and sensitivity. Conclusions: Insulin-induced hypoglycemia is the recommended test to diagnose GHD, but the arginine-GH-releasing hormone test achieves comparable separation between normal and hypopituitary subjects in most groups. Future studies using large surveillance databases may further expand our understanding of concepts underlying GHD and its diagnosis. Copyright (c) 2007 S. Karger AG, Basel. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroendocrine Unit,Neuroendocrine Clin Ctr, Boston, MA 02114 USA. RP Biller, BMK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroendocrine Unit,Neuroendocrine Clin Ctr, 55 Fruit St,Bulfinch 475B, Boston, MA 02114 USA. EM bbiller@partners.org NR 11 TC 5 Z9 5 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2007 VL 68 SU 5 BP 59 EP 65 DI 10.1159/000110478 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 247OE UT WOS:000252088400019 PM 18174710 ER PT J AU Xing, C Sestak, AL Kelly, JA Nguyen, KL Bruner, GR Harley, JB Gray-McGuire, C AF Xing, Chao Sestak, Andrea L. Kelly, Jennifer A. Nguyen, Kim L. Bruner, Gail R. Harley, John B. Gray-McGuire, Courtney TI Localization and replication of the systemic lupus erythematosus linkage signal at 4p16: interaction with 2p11, 12q24 and 19q13 in European Americans SO HUMAN GENETICS LA English DT Article ID SIB-PAIR FAMILIES; LOD SCORES; GENOME SCAN; SUSCEPTIBILITY GENES; MULTIPLEX FAMILIES; REVISED CRITERIA; COMPLEX TRAIT; UNITED-STATES; MODEL; LOCI AB Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by both population and phenotypic heterogeneity. Our group previously identified linkage to SLE at 4p16 in European Americans (EA). In the present study we replicate this linkage effect in a new cohort of 76 EA families multiplex for SLE by model-free linkage analysis. Using densely spaced microsatellite markers in the linkage region, we have localized the potential SLE susceptibility gene(s) to be telomeric to the marker D4S2928 by haplotype construction. In addition, marker D4S394 showed marginal evidence of linkage disequilibrium with the putative disease locus by the transmission disequilibrium test and significant evidence of association using a family-based association approach as implemented in the program ASSOC. We also performed both two-point and multipoint model-based analyses to characterize the genetic model of the potential SLE susceptibility gene(s), and the lod scores both maximized under a recessive model with penetrances of 0.8. Finally, we performed a genome-wide scan of the total 153 EA pedigrees and evaluated the possibility of interaction between linkage signals at 4p16 and other regions in the genome. Fourteen regions on 11 chromosomes (1q24, 1q42, 2p11, 2q32, 3p14.2, 4p16, 5p15, 7p21, 8p22, 10q22, 12p11, 12q24, 14q12, 19q13) showed evidence of linkage, among which, signals at 2p11, 12q24 and 19q13 also showed evidence of interaction with that at 4p16. These results provide important additional information about the SLE linkage effect at 4p16 and offer a unique approach to uncovering susceptibility loci involved in complex human diseases. C1 Case Western Reserve Univ, Dept Biostat & Epidemiol, Div Genet & Mol Epidemiol, Cleveland, OH 44106 USA. Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. Univ Oklahoma, Dept Med, Norman, OK 73019 USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Gray-McGuire, C (reprint author), Case Western Reserve Univ, Dept Biostat & Epidemiol, Div Genet & Mol Epidemiol, Wolstein Res Bldg,Rm 1312,10900 Euclid Ave, Cleveland, OH 44106 USA. EM chao.xing@case.edu; courtney.gray-mcguire@case.edu FU NCRR NIH HHS [M01 RR-14467, RR020143, RR03655]; NIAID NIH HHS [AI53747, AI062629, AI24717, AI31584]; NIAMS NIH HHS [AR049084, AR12253, AR42460, P30 AR053483]; NIDCR NIH HHS [DE015223] NR 44 TC 18 Z9 18 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0340-6717 J9 HUM GENET JI Hum. Genet. PD JAN PY 2007 VL 120 IS 5 BP 623 EP 631 DI 10.1007/s00439-006-0248-4 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 119GM UT WOS:000243000800003 PM 16983533 ER PT J AU Sieh, W Yu, CE Bird, TD Schellenberg, GD Wijsman, EM AF Sieh, Weiva Yu, Chang-En Bird, Thomas D. Schellenberg, Gerard D. Wijsman, Ellen M. TI Accounting for linkage disequilibrium among markers in linkage analysis: Impact of haplotype frequency estimation and molecular haplotypes for a gene in a candidate region for Alzheimer's disease SO HUMAN HEREDITY LA English DT Article DE Alzheimer's disease; familial Alzheimer's disease; chromosome 19 ID SINGLE-NUCLEOTIDE POLYMORPHISMS; MAXIMUM-LIKELIHOOD-ESTIMATION; SNPS; INFORMATION; STRATEGIES; EFFICIENCY; GENOME; MICROSATELLITES; GENOTYPES; FAMILIES AB Objectives: Linkage disequilibrium (LD) between closely spaced SNPs can be accommodated in linkage analysis by specifying the multi-SNP haplotype frequencies, if known. Phased haplotypes in candidate regions can provide gold standard haplotype frequency estimates, and may be of inherent interest as markers. We evaluated the effects of different methods of haplotype frequency estimation, and the use of marker phase information, on linkage analysis of a multi-SNP cluster in a candidate region for Alzheimer's disease (AD). Methods: We performed parametric linkage analysis of a five-SNP cluster in extended pedigrees to compare the use of: (1) haplotype frequencies estimated by molecular phase determination, maximum likelihood estimation, or by assuming linkage equilibrium (LE); (2) AD families or controls as the frequency source; and (3) unphased or molecularly phased SNP data. Results: There was moderate to strong pairwise LD among the five SNPs. Falsely assuming LE substantially inflated the LOD score, but the method of haplotype frequency estimation and particular sample used made little difference provided that LD was accommodated. Use of phased haplotypes produced a modest increase in the LOD score over unphased SNPs. Conclusions: Ignoring LD between markers can lead to substantially inflated evidence for linkage in LOD score analysis of extended pedigrees with missing data. Use of marker phase information in linkage analysis may be important in disease studies where the costs of family recruitment and phenotyping greatly exceed the costs of phase determination. Copyright (c) 2007 S. Karger AG, Basel. C1 Univ Washington, Div Med Genet, Dept Med, Seattle, WA 98195 USA. Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. Dept Genome Sci, Seattle, WA USA. RP Wijsman, EM (reprint author), Univ Washington, Div Med Genet, Dept Med, Box 357720, Seattle, WA 98195 USA. EM wijsman@u.washington.edu OI Wijsman, Ellen/0000-0002-2725-6669 FU NIA NIH HHS [AG 21544, U24 AG021886, AG 11762, AG 05136] NR 45 TC 5 Z9 5 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5652 J9 HUM HERED JI Hum. Hered. PY 2007 VL 63 IS 1 BP 26 EP 34 DI 10.1159/000098459 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 127DF UT WOS:000243564800003 PM 17215579 ER PT J AU Gewurz, BE Vyas, JM Ploegh, HL AF Gewurz, Benjamin E. Vyas, Jatin M. Ploegh, Hidde L. BE Arvin, A CampadelliFiume, G Mocarski, E Moore, PS Roizman, B Whitley, R Yamanishi, K TI Herpesvirus evasion of T-cell immunity SO HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS LA English DT Article; Book Chapter ID MAJOR HISTOCOMPATIBILITY COMPLEX; MHC CLASS-I; EPSTEIN-BARR-VIRUS; HUMAN CYTOMEGALOVIRUS US3; VARICELLA-ZOSTER-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; E3 UBIQUITIN LIGASE; RESTRICTED ANTIGEN PRESENTATION; ENDOPLASMIC-RETICULUM MEMBRANE; PEPTIDE-LOADING COMPLEX C1 [Gewurz, Benjamin E.; Ploegh, Hidde L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Vyas, Jatin M.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA. [Ploegh, Hidde L.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. RP Gewurz, BE (reprint author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA. NR 159 TC 2 Z9 2 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-82714-0 PY 2007 BP 1117 EP 1136 D2 10.2277/ 0521827140 PG 20 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BXR52 UT WOS:000296850300063 ER PT J AU Rockabrand, E Slepko, N Pantalone, A Nukala, VN Kazantsev, A Marsh, JL Sullivan, PG Steffan, JS Sensi, SL Thompson, LM AF Rockabrand, Erica Slepko, Natalia Pantalone, Antonello Nukala, Vidya N. Kazantsev, Aleksey Marsh, J. Lawrence Sullivan, Patrick G. Steffan, Joan S. Sensi, Stefano L. Thompson, Leslie Michels TI The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis SO HUMAN MOLECULAR GENETICS LA English DT Article ID HISTONE DEACETYLASE INHIBITORS; TRANSGENIC MOUSE MODEL; NF-KAPPA-B; RECEPTOR-MEDIATED EXCITOTOXICITY; NEURONAL INTRANUCLEAR INCLUSIONS; LENGTH MUTANT HUNTINGTIN; TRAUMATIC BRAIN-INJURY; STRIATAL CELLS; PERMEABILITY TRANSITION; GENE-EXPRESSION AB A truncated form of the Huntington's disease (HD) protein that contains the polyglutamine repeat, Httex1p, causes HD-like phenotypes in multiple model organisms. Molecular signatures of pathogenesis appear to involve distinct domains within this polypeptide. We studied the contribution of each domain, singly or in combination, to sub-cellular localization, aggregation and intracellular Ca2+ ([Ca2+](i)) dynamics in cells. We demonstrate that sub-cellular localization is most strongly influenced by the first 17 amino acids, with this sequence critically controlling Httex1p mitochondrial localization and also promoting association with the endoplasmic reticulum (ER) and Golgi. This domain also enhances the formation of visible aggregates and together with the expanded polyQ repeat acutely disrupts [Ca2+](i) levels in glutamate-challenged PC12 cells. Isolated cortical mitochondria incubated with Httex1p resulted in uncoupling and depolarization of these organelles, further supporting the idea that Httex1p-dependent mitochondrial dysfunction could be instrumental in promoting acute Ca2+ dyshomeostasis. Interestingly, neither mitochondrial nor ER associations seem to be required to promote long-term [Ca2+](i) dyshomeostasis. C1 Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92697 USA. Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA. Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA. Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA. Univ G DAnnunzio, Mol Neurol Unit, Ctr Excellence Aging, I-66013 Chieti, Italy. Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA. Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Cambridge, MA 02139 USA. Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA. Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA. RP Sensi, SL (reprint author), Univ Calif Irvine, Dept Psychiat & Human Behav, Gillespie 2121, Irvine, CA 92697 USA. EM ssensi@uci.edu RI Sensi, Stefano/J-3164-2016 OI Sensi, Stefano/0000-0002-0710-2574 FU NCI NIH HHS [CA-62203]; NICHD NIH HHS [HD36081]; NINDS NIH HHS [NS045283, NS42157-04] NR 95 TC 146 Z9 146 U1 1 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD JAN 1 PY 2007 VL 16 IS 1 BP 61 EP 77 DI 10.1093/hmg/ddl440 PG 17 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 127MY UT WOS:000243591600006 PM 17135277 ER PT J AU Weiss, LA Purcell, S Waggoner, S Lawrence, K Spektor, D Daly, MJ Sklar, P Skuse, D AF Weiss, Lauren A. Purcell, Shaun Waggoner, Skye Lawrence, Kate Spektor, David Daly, Mark J. Sklar, Pamela Skuse, David TI Identification of EFHC2 as a quantitative trait locus for fear recognition in Turner syndrome SO HUMAN MOLECULAR GENETICS LA English DT Article ID X-LINKED GENES; SOCIAL COGNITION; EMOTION RECOGNITION; ALZHEIMERS-DISEASE; HUMAN GENOME; AUTISM; AMYGDALA; SCHIZOPHRENIA; CHROMOSOME; EXPRESSION AB One-One-third of women with Turner syndrome (45, X) have autism- like social and communication difficulties, despite normal verbal IQ. Deletion mapping of the X-chromosome implicated 5 Mb of Xp11.3-4 as critical for recognition of facial fear, a quantitative measure of social cognition. Variability in fear recognition accuracy in Turner syndrome suggested the existence of a quantitative trait locus (QTL) revealed by X-monosomy. We aimed to identify the gene(s) influencing fear recognition by dense mapping of the 5 Mb region. Initial regression-based association mapping of fear recognition in 93 women with Turner syndrome across the critical region was performed, using genotype data at 242 single nucleotide polymorphisms (SNPs). We identified three regions of interest, in which 52 additional SNPs were genotyped. The third region then contained four SNPs associated with fear recognition (0.0030 > P > 0.00046). We obtained an independent sample of 77 Turner syndrome females that we genotyped for 77 SNPs in the initial regions of interest. Region three showed association in the same direction, maximal at SNPs rs7055196 and rs7887763 (P = 0.022 each). Four SNPs in strong linkage disequilibrium (LD), including this pair, span 40 kb within a novel transcript, EF-hand domain containing 2 (EFHC2). In the combined Turner syndrome samples, the most strongly associated SNP (P = 0.00007) has frequency of 8.8% and an estimated effect size accounting for over 13% of the variance in fear recognition. EFHC2 shows genealogy and extended LD consistent with directional selection. This novel QTL may influence social cognition in the general population and in autism. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Ctr Human Genet Res, Boston, MA 02114 USA. MIT, Broad Inst, Med & Populat Genet Grp, Cambridge, MA 02139 USA. Harvard Univ, Cambridge, MA 02138 USA. UCL, Inst Child Hlth, Brain & Behav Sci Unit, London, England. RP Sklar, P (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. EM sklar@chgr.mgh.harvard.edu FU Wellcome Trust NR 43 TC 17 Z9 17 U1 2 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD JAN 1 PY 2007 VL 16 IS 1 BP 107 EP 113 DI 10.1093/hmg/ddl445 PG 7 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 127MY UT WOS:000243591600010 PM 17164267 ER PT J AU Ahronowitz, I Xin, W Kiely, R Sims, K MacCollin, M Nunes, FP AF Ahronowitz, Iris Xin, Winnie Kiely, Rosemary Sims, Katherine MacCollin, Mia Nunes, Fabio P. TI Mutational spectrum of the NF2 gene: A meta-analyslis of 12 years of research and diagnostic laboratory findings SO HUMAN MUTATION LA English DT Article; Proceedings Paper CT 55th Annual Meeting of the American-Society-of-Human-Genetics CY OCT 25-29, 2005 CL Salt Lake City, UT SP Amer Soc Human Genet DE NF2; neurofibromatosis; schwannoma; meningioma; tumor suppressor gene ID NEUROFIBROMATOSIS TYPE-2 GENE; TUMOR-SUPPRESSOR GENE; GERM-LINE MUTATIONS; VESTIBULAR SCHWANNOMA; MULTIPLE MENINGIOMAS; SPORADIC MENINGIOMAS; FAMILIAL MENINGIOMA; CHROMOSOME 22Q; HETEROZYGOSITY ANALYSIS; RETINAL ABNORMALITIES AB The NF2 tumor suppressor gene on chromosome 22 is a member of the protein 4.1 family of cytoskeletal elements. A number of single, and multiple,tumor phenotypes have been linked to alterations of NF2 since its characterization in 1993. We present a meta-analysis of 967 constitutional and somatic NF2 alterations from 93 published reports, along with 59 additional unpublished events identified in our laboratory and 115 alterations identified in clinical samples submitted to the Massachusetts General Hospital (MGH) Neurogenetics DNA Diagnostic Laboratory. In total, these sources defined 1,070 small genetic changes detected primarily by exon scanning, 42 intragenic changes of one whole exon or larger, and 29 whole gene deletions and gross chromosomal rearrangements. Constitutional single-exon events (N = 422) were significantly more likely to be nonsense or splice site changes than somatic events (N = 533), which favored frameshift changes (chi(2) test; P < 0.001). Somatic events also differed markedly between tumors of different pathology, most significantly in the tendency of somatic events in meningiomas to lie within the 5' FERM domain of the transcript (Fisher's exact test; P < 0.01 in comparison to schwannomas) with a complete absence of mutations in exons 14 and 15. There was no statistically significant difference in mutation type or exon distribution between published constitutional events and those found by the clinical laboratory. Less than 10% of all published and unpublished small alterations are nontruncating (N = 63) and these changes are clustered in exons 2 and 3, suggesting that this region may be especially crucial to tumor suppressor activity in the protein. C1 Massachusetts Gen Hosp East, Mol Neurofibromatosis Lab, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Dept Neurol, Neurogenet DNA Diagnost Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Human Genom Res, Boston, MA 02114 USA. RP MacCollin, M (reprint author), Massachusetts Gen Hosp East, Mol Neurofibromatosis Lab, Bldg 149,13th St, Charlestown, MA 02129 USA. EM maccollin@helix.mgh.harvard.edu FU NINDS NIH HHS [1 R01 NS40527] NR 107 TC 44 Z9 48 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1059-7794 EI 1098-1004 J9 HUM MUTAT JI Hum. Mutat. PD JAN PY 2007 VL 28 IS 1 BP 1 EP 12 DI 10.1002/humu.20393 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA 117XY UT WOS:000242907800001 PM 16983642 ER PT J AU Ibrahim, EC Hims, MM Shomron, N Burge, CB Slaugenhaupt, SA Reed, R AF Ibrahim, El Cherif Hims, Matthew M. Shomron, Noam Burge, Christopher B. Slaugenhaupt, Susan A. Reed, Robin TI Weak definition of IKBKAP exon 20 leads to aberrant splicing in familial dysautonomia SO HUMAN MUTATION LA English DT Article DE RNA splicing; 5 ' splice site; exon skipping; familial dysautonomia; IKBKAP ID PRE-MESSENGER-RNA; TISSUE-SPECIFIC EXPRESSION; PROTEIN-PROTEIN INTERACTIONS; GENE-EXPRESSION; SITE SELECTION; SR-PROTEINS; ANTISENSE OLIGONUCLEOTIDES; TRANSCRIPTIONAL ELONGATION; SILENCER ELEMENT; II TRANSCRIPTION AB Splicing mutations that lead to devastating genetic diseases are often located in nonconserved or weakly conserved sequences that normally do not affect splicing. Thus, the underlying reason for the splicing defect is not immediately obvious. An example of this phenomenon is observed in the neurodevelopmental disease familial dysautonomia (F]D), which is caused by a single-base change in the 5' splice site (5'ss) of intron 20 in the IKBKAP gene (c.2204+6T > C). This mutation, which is in the sixth position of the intron and results in exon 20 skipping, has no phenotype in many other introns. To determine why the position 6 mutation causes aberrant splicing only in certain cases, we first used an in silico approach to identify potential sequences involved in exon 20 skipping. Computational analyses of the exon 20 5'ss itself predicted that this nine, nucleotide splicing signal, even when it contains the T > C mutation, is not sufficiently weak to explain the FD phenotype. However, the computational analysis predicted that both the upstream 3' splice site (3'ss) and exon 20 contain weak splicing signals, indicating that the FD 5'ss, together with the surrounding splicing signals, are not adequate for defining exon 20. These in silico predictions were corroborated using IKBKAP minigenes in a new rapid and simple in vitro coupled RNA polymerase (RNAP) 11 transcription/splicing assay. Finally, the weak splicing signals that flank the T > C mutation were validated as the underlying cause of familial dysautonomia in vivo using transient transfection assays. Together, our study demonstrates the general utility of combining in silico data with an in vitro RNAP 11 transcription/splicing system for rapidly identifying critical sequences that underlie the numerous splicing diseases caused by otherwise silent mutations. (c) 2006 Wiley-Liss, Inc. C1 Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. MIT, Dept Biol, Cambridge, MA USA. RP Slaugenhaupt, SA (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, LHRRB 501,240 Longwood Ave, Boston, MA 02115 USA. EM slaugenhaupt@chgr.mgh.harvard.edu; rreed@hms.harvard.edu RI Ibrahim, El Cherif/K-3899-2016 OI Ibrahim, El Cherif/0000-0003-3973-7862 NR 76 TC 13 Z9 13 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1059-7794 EI 1098-1004 J9 HUM MUTAT JI Hum. Mutat. PD JAN PY 2007 VL 28 IS 1 BP 41 EP 53 DI 10.1002/humu.20401 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA 117XY UT WOS:000242907800006 PM 16964593 ER PT J AU Ketelhut, DJ Niemi, SM AF Ketelhut, Diane Jass Niemi, Steven M. TI Emerging technologies in education and training: Applications for the laboratory animal science community SO ILAR JOURNAL LA English DT Article DE augmented reality; avatar; emerging technology; multi-user virtual environment (MUVE); pedagogy; radiofrequency identification (RFID); simulation; ubiquitous computing AB This article examines several new and exciting communication technologies. Many of the technologies were developed by the entertainment industry; however, other industries are adopting and modifying them for their own needs. These new technologies allow people to collaborate across distance and time and to learn in simulated work contexts. The article explores the potential utility of these technologies for advancing laboratory animal care and use through better education and training. Descriptions include emerging technologies such as augmented reality and multi-user virtual environments, which offer new approaches with different capabilities. Augmented reality interfaces, characterized by the use of handheld computers to infuse the virtual world into the real one, result in deeply immersive simulations. In these simulations, users can access virtual resources and communicate with real and virtual participants. Multi-user virtual environments enable multiple participants to simultaneously access computer-based three-dimensional virtual spaces, called "worlds," and to interact with digital tools. They allow for authentic experiences that promote collaboration, mentoring, and communication. Because individuals may learn or train differently, it is advantageous to combine the capabilities of these technologies and applications with more traditional methods to increase the number of students who are served by using current methods alone. The use of these technologies in animal care and use programs can create detailed training and education environments that allow students to learn the procedures more effectively, teachers to assess their progress more objectively, and researchers to gain insights into animal care. C1 Temple Univ, Coll Educ, CITE Dept, Ritter Hall, Philadelphia, PA 19122 USA. Temple Univ, Coll Educ, Philadelphia, PA USA. Massachusetts Gen Hosp, Ctr Comparat Med, Charlestown, MA USA. RP Ketelhut, DJ (reprint author), Temple Univ, Coll Educ, CITE Dept, Ritter Hall, 3rd Floor,1301 Cecil B Moore Ave, Philadelphia, PA 19122 USA. EM diane.jass.ketelhut@temple.edu NR 17 TC 4 Z9 4 U1 1 U2 6 PU INST LABORATORY ANIMAL RESEARCH, NATL RES COUNCIL PI WASHINGTON PA 500 FIFTH ST, N W, WASHINGTON, DC 20001 USA SN 1084-2020 J9 ILAR J JI ILAR J. PY 2007 VL 48 IS 2 BP 163 EP 169 PG 7 WC Veterinary Sciences SC Veterinary Sciences GA 176VD UT WOS:000247112100011 PM 17420537 ER PT S AU Sperling, R AF Sperling, Reisa BE DeLeon, MJ Snider, DA Federoff, H TI Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer's disease SO IMAGING AND THE AGING BRAIN SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Meeting on Imaging and the Aging Brain CY MAY 16-17, 2006 CL New York, NY SP NY Acad Sci DE fMRI; aging; Alzheimer's disease; hippocampus; memory ID POSITRON-EMISSION-TOMOGRAPHY; FACE-NAME PAIRS; HIPPOCAMPAL-FORMATION; MEMORY COMPLAINTS; DEFAULT-MODE; GENETIC RISK; ACTIVATION; DEMENTIA; FMRI; RETRIEVAL AB Functional magnetic resonance imaging (fMRI) is a non-invasive neuroimaging technique that can be used to study the neural correlates of complex cognitive processes, and the alterations in these processes that occur in the course of normal aging or superimposed neurodegenerative disease. Our studies have focused on the neural substrates of successful associative encoding, particularly of face-name associations. We have found that the specific regions of the hippocampus and prefrontal cortices are critical for successful memory in both young and healthy older subjects. Our fMRI studies, as well as those of several other groups, have consistently demonstrated that, compared to cognitively intact older subjects, patients with clinical Alzheimer's disease (AD) have decreased fMRI activation in the hippocampus and related structures within the medial temporal lobe during the encoding of new memories. More recently, fMRI studies of subjects at risk for AD, by virtue of their genetics or evidence of mild cognitive impairment (MCI), have yielded variable results. Some of these studies, including our own, suggest that there may be a phase of paradoxically increased activation early in the course of prodromal AD. Further studies to validate fMRI in these populations are needed, particularly longitudinal studies to investigate the pattern of alterations in functional activity over the course of prodromal AD and the relationship to AD pathology. C1 Brigham & Womens Hosp, Alzheimers Dis Res Ctr, Memory Disorders Unit, Dept Neurol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Gerontol Res Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02138 USA. RP Sperling, R (reprint author), Memory Disorders Unit, 221 Longwood Ave, Boston, MA 02215 USA. EM reisa@rics.bwh.harvard.edu FU NIA NIH HHS [P50-AG005134, DO1-AG04953, R01-AG027435] NR 49 TC 120 Z9 124 U1 4 U2 25 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-659-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2007 VL 1097 BP 146 EP 155 DI 10.1196/annals.1379.009 PG 10 WC Multidisciplinary Sciences; Clinical Neurology; Neuroimaging SC Science & Technology - Other Topics; Neurosciences & Neurology GA BGA72 UT WOS:000245814800013 PM 17413017 ER PT J AU Pipkin, ME Ljutic, B Cruz-Guilloty, F Nouzova, M Rao, A Zuniga-Pflucker, JC Lichtenheld, MG AF Pipkin, Matthew E. Ljutic, Belma Cruz-Guilloty, Fernando Nouzova, Marcela Rao, Anjana Zuniga-Pflucker, Juan Carlos Lichtenheld, Mathias G. TI Chromosome transfer activates and delineates a locus control region for perforin SO IMMUNITY LA English DT Article ID BETA-GLOBIN LOCUS; EMBRYONIC STEM-CELLS; POSITION EFFECT VARIEGATION; NATURAL-KILLER-CELLS; T-CELLS; CHROMATIN-STRUCTURE; IN-VITRO; TRANSCRIPTION FACTORS; MICROCELL HYBRIDS; GENE-EXPRESSION AB Perforin gene (PRF1) transcription regulates perforin expression in NK cells and CTL. Here we identified the locus-wide ensemble of cis-acting sequences that drives PRF1 transcription physiologically. By using chromosome transfer, we revealed that de novo, activation of a silent PRF1 locus was controlled by a 150 kb domain comprised of 16 DNase I hypersensitive sites (DHSs). These cis-acting sequences included a locus control region (LCR) and conferred developmentally appropriate and lineage-specific expression of human perforin from BAC transgenes. The LCR included four distal DHSs that were required for perforin expression from its natural locus, and their engineered deletion from the PRF1 BAC transgene abolished LCR function and led to rapid gene silencing. Thus, LCR function is central for regulating the developmental and activation-specific PRF1 promoter activity characteristic of NK cells and CTL. C1 Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA. Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA. Univ Toronto, Dept Immunol, Toronto, ON M4N 3M5, Canada. Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada. Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. RP Lichtenheld, MG (reprint author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA. EM mlichten@med.miami.edu RI Zuniga-Pflucker, Juan/H-1295-2012; OI Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178 FU NIAID NIH HHS [AI 44432] NR 50 TC 24 Z9 25 U1 0 U2 0 PU CELL PRESS PI CAMBRIDGE PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA SN 1074-7613 J9 IMMUNITY JI Immunity PD JAN PY 2007 VL 26 IS 1 BP 29 EP 41 DI 10.1016/j.immuni.2006.11.009 PG 13 WC Immunology SC Immunology GA 132RD UT WOS:000243959000007 PM 17222571 ER PT J AU Krueger, A von Boehmer, H AF Krueger, Andreas von Boehmer, Harald TI Identification of a T lineage-committed progenitor in adult blood SO IMMUNITY LA English DT Article ID HEMATOPOIETIC STEM-CELLS; MURINE FETAL LIVER; COMMON LYMPHOID PROGENITORS; MOUSE BONE-MARROW; THYMIC PROGENITORS; PRECURSOR CELLS; B-LINEAGE; PT-ALPHA; NOTCH; COMMITMENT AB With help of a hCD25 reporter controlled by pre-T cell receptor alpha (Ptcra) regulatory elements, T cell precursors were identified in peripheral blood. Sca-1(+)IL-7R alpha(+)Flt3(-) precursors that were c-kit(lo)Thy-1(hi) generated T lineage cells when cultured on OP9-DL1 stromal cells and upon transfer into Rag2(-/-)II2rg(-/-) mice. No B cells were generated in vivo and only few in vitro. These cells, which we call circulating T cell progenitors (CTP), were found at the same frequency in Foxn1(nu/n) thymus-deficient mice and wild-type mice, indicating that they were pre- rather than postthymic. Inhibition of Notch-dependent transcription in vivo reduced the frequency of intrathymic early T cell progenitors (ETP), but not CTP, indicating that the latter are less Notch dependent. Thus, CTP represent T lineage-committed T cell precursors linking extrathymic with intrathymic lymphopoiesis in adult mice. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP von Boehmer, H (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM harald_von_boehmer@dfci.harvard.edu RI Krueger, Andreas/B-9427-2009 OI Krueger, Andreas/0000-0001-7873-7334 FU NIAID NIH HHS [R01 AI051378, R01 AI045846, AI45846] NR 44 TC 66 Z9 67 U1 0 U2 1 PU CELL PRESS PI CAMBRIDGE PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA SN 1074-7613 J9 IMMUNITY JI Immunity PD JAN PY 2007 VL 26 IS 1 BP 105 EP 116 DI 10.1016/j.immuni.2006.12.004 PG 12 WC Immunology SC Immunology GA 132RD UT WOS:000243959000013 PM 17222572 ER PT J AU Davis, AE Cai, SH Liu, DX AF Davis, Alvin E., III Cai, Shenghe Liu, Dongxu TI C1 inhibitor: Biologic activities that are independent of protease inhibition SO IMMUNOBIOLOGY LA English DT Article; Proceedings Paper CT 6th International Workshop on the First Component of Complement C1 and Collectins CY JUN, 2006 CL Seeheim, GERMANY DE C1 inhibitor; cecal ligation and puncture model; endotoxin shock; gram negative bacterial sepsis; selectins; serine protemase inhibitors ID INFLAMMATION-INDUCED EXPRESSION; N-LINKED GLYCOSYLATION; CL-ESTERASE INHIBITOR; C1-ESTERASE INHIBITOR; LIPOPOLYSACCHARIDE-BINDING; LEUKOCYTE ADHESION; COMPLEMENT PATHWAY; REPERFUSION INJURY; ENDOTHELIAL-CELLS; ENDOTOXIN-SHOCK AB C1 inhibitor therapy improves outcome in several animal models of inflammatory disease. These include sepsis and Gram negative endotoxin shock, vascular leak syndromes, hyperacute transplant rejection, and ischemia-reperfusion injury. Furthermore, some data suggest a beneficial effect in human inflammatory disease. In many inflammatory conditions, complement system activation plays a role in pathogenesis. The contact system also very likely is involved in mediation of damage in inflammatory disease. Therefore, the beneficial effect of Cl inhibitor has been assumed to result from inhibition of one or both of these systems. Over the past several years, several other potential anti-inflammatory effects of Cl inhibitor have been described. These effects do not appear to require protease inhibition and depend on non-covalent interactions with other proteins, cell surfaces or lipids. In the first, C I inhibitor binds to a variety of extracellular matrix components including type IV collagen, laminin, entactin and fibrinogen. The biologic role of these reactions is unclear, but they may serve to concentrate C1 inhibitor at extravascular inflammatory sites. The second is a non-covalent interaction with C3b that results in inhibition of formation of the alternative pathway C3 convertase, a function analogous to that of factor H. The third is an interaction with E and P selectins on endothelial cells that is mediated by the Lewis(x) tetrasaccharides that are expressed on C1 inhibitor. These interactions result in suppression of leukocyte rolling and transmigration. The fourth interaction is the binding of C1 inhibitor to Gram negative bacterial endotoxin that results in suppression of endotoxin shock by interference with the interaction of endotoxin with its receptor complex on macrophages. Lastly, C1 inhibitor binds directly to Gram negative bacteria, which leads to suppression of the development of sepsis, as demonstrated in the cecal ligation and puncture model. These observations suggest that C1 inhibitor is a multi-faceted anti -inflammatory protein that exerts its effects through a variety of mechanisms including both protease inhibition and several different non-covalent interactions that are unrelated to protease inhibition. (c) 2006 Elsevier GmbH. All rights reserved. C1 Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02114 USA. RP Davis, AE (reprint author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 800 Huntington Ave, Boston, MA 02114 USA. EM aldavis@cbrinstitute.org FU NIAID NIH HHS [R01 AI057366-03]; NICHD NIH HHS [R37 HD022082-22] NR 93 TC 37 Z9 43 U1 0 U2 7 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 0171-2985 J9 IMMUNOBIOLOGY JI Immunobiology PY 2007 VL 212 IS 4-5 BP 313 EP 323 DI 10.1016/j.imbio.2006.10.003 PG 11 WC Immunology SC Immunology GA 185VL UT WOS:000247738400009 PM 17544816 ER PT J AU Yunis, EJ Zuniga, J Romero, V Yunis, EJ AF Yunis, Edmond J. Zuniga, Joaquin Romero, Viviana Yunis, Emilio J. TI Chimerism and tetragametic chimerism in humans: implications in autoimmunity, allorecognition and tolerance SO IMMUNOLOGIC RESEARCH LA English DT Article; Proceedings Paper CT 1st Robert-A-Good-Society Symposium CY 2006 CL St Petersburg, FL SP Robert A Good Soc ID T-CELL-RECEPTOR; BONE-MARROW-TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; MAJOR HISTOCOMPATIBILITY COMPLEX; IN-SITU HYBRIDIZATION; UMBILICAL-CORD BLOOD; FETAL MICROCHIMERISM; THYMECTOMIZED MICE; NEGATIVE SELECTION; SYSTEMIC-SCLEROSIS AB The presence of cells or tissues from two individuals, chimeras, or the presence of cells and tissues that include the gonads, tetragametic chimerism can be detected by the analysis of cytogenetics and analysis of polymorphic genetic markers, using patterns of pedigree inheritance. These methodologies include determination of sex chromosomes, major histocompatibility complex (MHC) polymorphisms and panels of short tandem repeats (STRs) that include mitochondrial DNA markers. Studies routinely involve cases of temporal chimerism in blood transfusion, or following allotransplantation to measure the outcome of the organ, lymphopoietic tissues or bone marrow grafts. Demonstration of persistent chimerism is usually discovered in cases of inter-sexuality due to fusion of fraternal twins or in cases of fusion of embryos with demonstrable allogeneic monoclonality of blood which, excluded maternity or paternity when blood alone is used as the source of DNA. In single pregnancies it is possible to produce two kinds of microchimerism: feto-maternal and materno-fetal, but in cases of fraternal twin pregnancies it is possible to identify three different kinds which are related to cases of vanishing twins that can be identified during pregnancy by imaging procedures; (1) hematopoietic, (2) gonadal, and (3) freemartins when the twins have different sex and the individual born is a female with either gonadal or both gonadal and hematopoietic tissues. Fraternal twin pregnancies can also produce fusion of embryos. Such cases could be of different sex presenting with inter-sexuality or in same sex twins. One of such cases, the best studied, showed evidence of chimerism and tetragametism. In this regard, the case was studied because of disputed maternity of two of her three children. All tissues studied, except for the blood, demonstrated four genetic components but only two in her blood of four possible showed alloaeneic monoclonality consistent with the interpretation that her blood originated from one hematopoietic stem cell. Also, microchimerism, due to traffic of cells via materno-fetal or feto-maternal has been prompted by reports of their potential association with the development of autoimmune disorders including systemic lupus erythematosus (SLE) and systemic sclerosis, and in allotransplantation. In addition, their relevance of chimerism in the positive and negative selection of T cells in the thymus has not been addressed. T lymphocytes play a central role in controlling the acquired immune response and furthermore serve as crucial effector cells through antigen specific cytotoxic activity and the production of soluble mediators. Central tolerance is established by the repertoire selection of immature T lymphocytes in the thymus, avoiding the generation of autoreactive T cells. Expression of chimeric antigens in the thymus could modify the generation of specific T cell clones in chimeric subjects and these mechanisms could be important in the induction of central tolerance against foreign antigens important in allo-transplantation. In this review, we discuss the genetics of chimerism and tetragametism and its potential role in thymic selection and the relevance in allotransplantation and autoimmune disorders. C1 Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico. Serv Med Yunis Turbay & Cia, Bogota, DC, Colombia. RP Yunis, EJ (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM edmond_yunis@dfci.harvard.edu NR 133 TC 11 Z9 12 U1 0 U2 8 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0257-277X J9 IMMUNOL RES JI Immunol. Res. PY 2007 VL 38 IS 1-3 BP 213 EP 236 DI 10.1007/s12026-007-0013-3 PG 24 WC Immunology SC Immunology GA 223LQ UT WOS:000250372300026 PM 17917028 ER PT J AU Mizoguchi, E Mizoguchi, A AF Mizoguchi, Emiko Mizoguchi, Atsusi TI Is the sugar always sweet in intestinal inflammation? SO IMMUNOLOGIC RESEARCH LA English DT Review DE galectin-4; chitinase 3-like 1; chi-lectin; inflammatory bowel disease; glycans; T cells; lipid rafts; enteric bacteria ID ALPHA MUTANT MICE; HUMAN CARTILAGE GLYCOPROTEIN-39; OVIDUCT-SPECIFIC GLYCOPROTEIN; ACIDIC MAMMALIAN CHITINASE; BINDING PROTEIN CBP21; SMOOTH-MUSCLE-CELLS; BOWEL-DISEASE; GENE-EXPRESSION; T-CELLS; RHEUMATOID-ARTHRITIS AB Immune responses are mediated mainly by protein/protein interactions. In addition, protein/carbohydrate (sugar) interactions through specific protein families termed lectin and chi-lectin are also involved in several immune and biological responses under not only the state of health but also inflammatory conditions. Interestingly, recent studies have identified unexpected roles of animal lectins (galectin-1 and galectin-4) and chi-lectin (chitinase 3-like-1). in intestinal inflammation. Galectin-1 contributes to the suppression of intestinal inflammation by the induction of effector T cell apoptosis. In contrast, galectin-4 is involved in the exacerbation of this inflammation by specifically stimulating intestinal CD4+ T cells to produce IL-6. CH13L1 enhances the host/microbial interaction that leads to the exacerbation of intestinal inflammation. In this review, we discuss a novel aspect of lectin/carbohydrate interactions in intestinal inflammation. C1 Harvard Univ, Expt Pathol Unit, Massachusetts Gen Hosp, Sch Med,Dept Pathol, Boston, MA 02114 USA. Harvard Univ, Ctr Study Inflammatory Bowel Dis, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. Harvard Univ, Gastrointestinal Unit, Massachusetts Gen Hosp, Sch Med,Dept Med, Boston, MA 02114 USA. RP Mizoguchi, A (reprint author), Harvard Univ, Expt Pathol Unit, Massachusetts Gen Hosp, Sch Med,Dept Pathol, Simches 8234,185 Cambridge St, Boston, MA 02114 USA. EM amizoguchi@partners.org FU NIDDK NIH HHS [DK 064351, DK 064289, DK 074454] NR 113 TC 15 Z9 16 U1 4 U2 5 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0257-277X J9 IMMUNOL RES JI Immunol. Res. PY 2007 VL 37 IS 1 BP 47 EP 60 DI 10.1007/BF02686089 PG 14 WC Immunology SC Immunology GA 144OE UT WOS:000244804900004 PM 17496346 ER PT J AU Srikanth, CV Cherayil, BJ AF Srikanth, Chittur V. Cherayil, Bobby J. TI Intestinal innate immunity and the pathogenesis of Salmonella enteritis SO IMMUNOLOGIC RESEARCH LA English DT Review DE Salmonella; enteritis; innate immunity; mucosa ID SEROVAR TYPHIMURIUM COLITIS; STREPTOMYCIN-PRETREATED MICE; NON-TYPHOIDAL SALMONELLOSIS; SECRETED EFFECTOR PROTEINS; TOLL-LIKE RECEPTORS; NF-KAPPA-B; SEROTYPE TYPHIMURIUM; EPITHELIAL-CELLS; HOST-CELL; BACTERIAL INVASION AB Acute gastroenteritis caused by Salmonella typhimurium infection is a clinical problem with significant public health impact. The availability of several experimental models of this condition has allowed detailed investigation of the cellular and molecular interactions involved in its pathogenesis. Such studies have shed light on the roles played by bacterial virulence factors and host innate immune mechanisms in the development of intestinal inflammation. C1 Massachusetts Gen Hosp, Div Pediat Gastroenterol & Nutr, Mucosal Immunol Lab, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Srikanth, CV (reprint author), Massachusetts Gen Hosp East, Div Pediat Gastroenterol & Nutr, Mucosal Immunol Lab, Room 3400,Bldg 114,16th St, Charlestown, MA 02129 USA. EM cherayil@helix.mgh.harvard.edu FU NIAID NIH HHS [R21 AI 965619, R21 AI065619, R01 AI 48815, R01 AI048815]; NIDDK NIH HHS [P30 DK040561, P30 DK040561-11] NR 106 TC 14 Z9 14 U1 0 U2 5 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0257-277X J9 IMMUNOL RES JI Immunol. Res. PY 2007 VL 37 IS 1 BP 61 EP 77 DI 10.1007/BF02686090 PG 17 WC Immunology SC Immunology GA 144OE UT WOS:000244804900005 PM 17496347 ER PT J AU Rashid, RM Lee, JM Fareed, J Young, MRI AF Rashid, M. Rashid Lee, John M. Fareed, Jawed Young, M. Rita I. TI In vitro heparan sulfate modulates the immune responses of normal and tumor-bearing mice SO IMMUNOLOGICAL INVESTIGATIONS LA English DT Article DE heparan sulfate; Lewis lung carcinoma; tumor; T-cells ID SQUAMOUS-CELL CARCINOMA; MURINE DENDRITIC CELLS; T-CELLS; LUNG-CANCER; PROLIFERATION; HEAD; NECK; COSTIMULATION; LYMPHOCYTES; MACROPHAGE AB Tumor-bearing (TB) patients and TB animal models show a wide array of immunologic deficits. Heparan sulfate (HS) has been shown to both improve immune cell proliferative responses and to induce Th1 cytokine responses in normal animals. These HS effects, if harnessed, would be of great benefit to TB patients. The present study focused on replicating previous HS-induced Th1 and proliferative response results as well as extrapolating the beneficial immunomodulatory effects to an experimental model derived from TB animals of Lewis lung cell carcinoma. Lewis Lung Carcinoma (LLC)-TB and control mouse splenocytes were assessed for proliferation and cytokine response to concanavalin A (Con A) with 1 and 3 days' exposure to HS. Our results found HS treatment stimulated splenocyte proliferation to Con A in control mice splenocytes after 1 and 3 days of treatment, although HS proliferative effects were not seen in unfractionated TB cultures. Furthermore, cytokine studies revealed normal splenocytes treated with HS had increased levels of both Th1 and Th2 cytokines. Surprisingly, HS treated TB-splenocytes showed suppressed cytokine levels. Of particular interest was the decreased levels of the Th2 cytokine IL-4 in TB-derived samples. In conclusion, we found that HS did show immune-modulator properties in both normal and TB environments. Our studies reinforced the possibility that HS could one day be used as an immune-modulating therapeutic agent. C1 Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA. Loyola Univ, Med Ctr, Dept Pharmacol, Maywood, IL 60153 USA. Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Rashid, RM (reprint author), Loyola Univ, Med Ctr, Dept Pathol, 2160 S 1st Ave,Bldg 102,Room 2638, Maywood, IL 60153 USA. EM rrashid@lumc.edu FU NCI NIH HHS [CA85266, CA79768, 1F31CA103768-01, CA97813] NR 40 TC 2 Z9 3 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0882-0139 J9 IMMUNOL INVEST JI Immunol. Invest. PY 2007 VL 36 IS 2 BP 183 EP 201 DI 10.1080/08820130600992024 PG 19 WC Immunology SC Immunology GA 150UI UT WOS:000245244700006 PM 17365019 ER PT B AU Korzenik, JR AF Korzenik, J. R. BE Dignass, A Rachmilewitz, D Stange, EF Weinstock, JV TI The evolving understanding and therapy of Crohn's disease: innate immunity and sargramostim (GM-CSF) SO Immunoregulation in Inflammatory Bowel Diseases - Current Understanding and Innovation SE FALK SYMPOSIUM LA English DT Proceedings Paper CT Falk Symposium 153 on Immunoregulation in Inflammatory Bowel Diseases CY MAY 06-07, 2006 CL Berlin, GERMANY SP Falk Fdn ID CHRONIC GRANULOMATOUS-DISEASE; COLONY-STIMULATING FACTOR; INTESTINAL EPITHELIAL-CELLS; INFLAMMATORY-BOWEL-DISEASE; T-HELPER TYPE-1; NEUTROPHIL DYSFUNCTION; NOD2; ASSOCIATION; ILEOCOLITIS; MUTATION C1 Massachusetts Gen Hosp, Gastrointestinal Unit, Crohns & Colitis Ctr, Boston, MA 02114 USA. RP Korzenik, JR (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. NR 33 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 978-1-4020-5888-2 J9 FALK SYMP PY 2007 VL 153 BP 181 EP 189 PG 9 WC Gastroenterology & Hepatology; Immunology SC Gastroenterology & Hepatology; Immunology GA BGD92 UT WOS:000246214800022 ER PT J AU Dobscha, SK Leibowitz, RQ Flores, JA Doak, M Gerrity, MS AF Dobscha, Steven K. Leibowitz, Ruth Q. Flores, Jennifer A. Doak, Melanie Gerrity, Martha S. TI Primary care provider preferences for working with a collaborative support team SO IMPLEMENTATION SCIENCE LA English DT Article AB Background: Clinical interventions based on collaborative models require effective communication between primary care providers (PCPs) and collaborative support teams. Despite growing interest in collaborative care, we have identified no published studies describing how PCPs prefer to communicate and interact with collaborative support teams. This manuscript examines the communication and interaction preferences of PCPs participating in an ongoing randomized clinical trial of a collaborative intervention for chronic pain and depression. Methods: The trial is being conducted in five primary care clinics of a Veterans Affairs Medical Center. Twenty-one PCPs randomized to the study intervention completed a survey regarding preferences for interacting with the collaborative support team. Results: A majority of PCPs identified email (95%) and telephone calls (68%) as preferred modes for communicating with members of the support team. In contrast, only 29% identified in-person communications as preferred. Most PCPs preferred that the care manager and physician pain specialist assess patients (76%) and make initial treatment changes (71%) without first conferring with the PCP. One-half wanted to be designated cosigners of all support team notes in the electronic medical record, one-half wanted to receive brief and focused information rather than in-depth information about their patients, and one-half wanted their practice nurses automatically included in communications. Panel size was strongly associated (p < 0.001) with preference for brief, to-the-point discussions about patients. Conclusion: The substantial variation in PCP communication preferences suggests the need for knowledge of these preferences when designing and implementing collaborative interventions. Additional research is needed to understand relationships between clinician and practice characteristics and interaction preferences. C1 [Dobscha, Steven K.; Leibowitz, Ruth Q.; Flores, Jennifer A.; Gerrity, Martha S.] Portland VA Med Ctr, Columbia Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA. [Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Doak, Melanie] Portland VA Med Ctr, Primary Care Div, Portland, OR USA. [Doak, Melanie; Gerrity, Martha S.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Gerrity, Martha S.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR USA. RP Dobscha, SK (reprint author), Portland VA Med Ctr, Columbia Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA. EM steven.dobscha@va.gov; ruth.leibowitz@med.va.gov; jennifer.flores@va.gov; melanie.doak@va.gov; gerritym@ohsu.edu FU Department of Veterans Affairs, Veterans Health Administration [PMI 03-195, RCD04129] FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Projects PMI 03-195 and RCD04129. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 21 TC 6 Z9 6 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PY 2007 VL 2 AR 16 DI 10.1186/1748-5908-2-16 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V00IX UT WOS:000206783100016 PM 17537251 ER PT J AU Helfrich, CD Li, YF Mohr, DC Meterko, M Sales, AE AF Helfrich, Christian D. Li, Yu-Fang Mohr, David C. Meterko, Mark Sales, Anne E. TI Assessing an organizational culture instrument based on the Competing Values Framework: Exploratory and confirmatory factor analyses SO IMPLEMENTATION SCIENCE LA English DT Article ID TOTAL-QUALITY-MANAGEMENT; FIT INDEXES; HEALTH-CARE; HOSPITALS; CRITERIA; CLIMATE; IMPACT AB Background: The Competing Values Framework (CVF) has been widely used in health services research to assess organizational culture as a predictor of quality improvement implementation, employee and patient satisfaction, and team functioning, among other outcomes. CVF instruments generally are presented as well-validated with reliable aggregated subscales. However, only one study in the health sector has been conducted for the express purpose of validation, and that study population was limited to hospital managers from a single geographic locale. Methods: We used exploratory and confirmatory factor analyses to examine the underlying structure of data from a CVF instrument. We analyzed cross-sectional data from a work environment survey conducted in the Veterans Health Administration (VHA). The study population comprised all staff in non-supervisory positions. The survey included 14 items adapted from a popular CVF instrument, which measures organizational culture according to four subscales: hierarchical, entrepreneurial, team, and rational. Results: Data from 71,776 non-supervisory employees (approximate response rate 51%) from 168 VHA facilities were used in this analysis. Internal consistency of the subscales was moderate to strong (alpha = 0.68 to 0.85). However, the entrepreneurial, team, and rational subscales had higher correlations across subscales than within, indicating poor divergent properties. Exploratory factor analysis revealed two factors, comprising the ten items from the entrepreneurial, team, and rational subscales loading on the first factor, and two items from the hierarchical subscale loading on the second factor, along with one item from the rational subscale that cross-loaded on both factors. Results from confirmatory factor analysis suggested that the two-subscale solution provides a more parsimonious fit to the data as compared to the original four-subscale model. Conclusion: This study suggests that there may be problems applying conventional CVF subscales to non-supervisors, and underscores the importance of assessing psychometric properties of instruments in each new context and population to which they are applied. It also further highlights the challenges management scholars face in assessing organizational culture in a reliable and comparable way. More research is needed to determine if the emergent two-subscale solution is a valid or meaningful alternative and whether these findings generalize beyond VHA. C1 [Helfrich, Christian D.; Li, Yu-Fang; Sales, Anne E.] VA Puget Sound Healthcare Syst, NW HSR&D Ctr Excellence, Washington, DC USA. [Helfrich, Christian D.; Sales, Anne E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Li, Yu-Fang] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Mohr, David C.; Meterko, Mark] Dept Vet Affairs, Ctr Org Leadership & Management Res, Boston, MA USA. [Mohr, David C.; Meterko, Mark] Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Boston, MA USA. RP Helfrich, CD (reprint author), VA Puget Sound Healthcare Syst, NW HSR&D Ctr Excellence, Washington, DC USA. EM christian.helfrich@va.gov; YuFang.Li@va.gov; david.mohr2@va.gov; mark.meterko@va.gov; ann.sales@va.gov RI Sales, Anne/D-9678-2012; Helfrich, Christian/D-2382-2016; OI Helfrich, Christian/0000-0002-9827-4768; Sales, Anne/0000-0001-9360-3334 FU Veterans Health Administration; VA Center for Organizational Leadership and Management Research; VA Northwest HSR&D Center of Excellence FX We wish to thank the US Department of Veterans Affairs, Veterans Health Administration and especially the VHA All Employee Survey Committee for access to its survey data. We also wish to thank Dr. Haili Sun of the Northwest HSR&D Center of Excellence who assisted with initial evaluation of dataset reliability. Dr. Helfrich conducted this research under a postdoctoral fellowship in Health Services Research and Development from the Veterans Health Administration. Drs. Mohr and Meterko were supported by the VA Center for Organizational Leadership and Management Research and Drs. Li and Sales were supported by the VA Northwest HSR&D Center of Excellence. The authors' conclusions are solely their own and do not necessarily represent the views of the VA. NR 43 TC 21 Z9 21 U1 8 U2 33 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PY 2007 VL 2 AR 13 DI 10.1186/1748-5908-2-13 PG 14 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V00IX UT WOS:000206783100013 PM 17459167 ER PT J AU Kilbourne, AM Neumann, MS Pincus, HA Bauer, MS Stall, R AF Kilbourne, Amy M. Neumann, Mary S. Pincus, Harold A. Bauer, Mark S. Stall, Ronald TI Implementing evidence-based interventions in health care: application of the replicating effective programs framework SO IMPLEMENTATION SCIENCE LA English DT Article AB Background: We describe the use of a conceptual framework and implementation protocol to prepare effective health services interventions for implementation in community-based (i.e., non-academic-affiliated) settings. Methods: The framework is based on the experiences of the U. S. Centers for Disease Control and Prevention (CDC) Replicating Effective Programs (REP) project, which has been at the forefront of developing systematic and effective strategies to prepare HIV interventions for dissemination. This article describes the REP framework, and how it can be applied to implement clinical and health services interventions in community-based organizations. Results: REP consists of four phases: pre-conditions (e. g., identifying need, target population, and suitable intervention), pre-implementation (e. g., intervention packaging and community input), implementation (e. g., package dissemination, training, technical assistance, and evaluation), and maintenance and evolution (e. g., preparing the intervention for sustainability). Key components of REP, including intervention packaging, training, technical assistance, and fidelity assessment are crucial to the implementation of effective interventions in health care. Conclusion: REP is a well-suited framework for implementing health care interventions, as it specifies steps needed to maximize fidelity while allowing opportunities for flexibility (i.e., local customizing) to maximize transferability. Strategies that foster the sustainability of REP as a tool to implement effective health care interventions need to be developed and tested. C1 [Kilbourne, Amy M.] VA Ann Arbor Natl Serious Mental Illness Treatmen, Ann Arbor, MI USA. [Kilbourne, Amy M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Neumann, Mary S.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. [Pincus, Harold A.] Columbia Univ, Dept Psychiat, New York, NY USA. [Bauer, Mark S.] VA Boston Healthcare Syst, Boston, MA USA. [Bauer, Mark S.] Harvard Univ, Sch Med, Boston, MA USA. [Stall, Ronald] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. RP Kilbourne, AM (reprint author), VA Ann Arbor Natl Serious Mental Illness Treatmen, Ann Arbor, MI USA. EM Amy.Kilbourne@va.gov; msn1@cdc.gov; pincush@pi.cpmc.columbia.edu; Mark.Bauer@va.gov; RStall@gsphdean.gsph.pitt.edu FU U. S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 02-283-2]; VA Health Services Research and Development Service FX This research was supported by the U. S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (IIR 02-283-2; A. Kilbourne, PI). Dr. Kilbourne is funded by the Career Development Award Merit Review Entry Program from the VA Health Services Research and Development Service. NR 29 TC 97 Z9 99 U1 4 U2 16 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PY 2007 VL 2 AR 42 DI 10.1186/1748-5908-2-42 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V00IX UT WOS:000206783100042 PM 18067681 ER PT J AU Leykum, LK Pugh, J Lawrence, V Parchman, M Noel, PH Cornell, J McDaniel, RR AF Leykum, Luci K. Pugh, Jacqueline Lawrence, Valerie Parchman, Michael Noel, Polly H. Cornell, John McDaniel, Reuben R., Jr. TI Organizational interventions employing principles of complexity science have improved outcomes for patients with Type II diabetes SO IMPLEMENTATION SCIENCE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; CLINICAL DECISION-MAKING; NURSE FOLLOW-UP; PRIMARY-CARE; HEALTH-CARE; DISEASE MANAGEMENT; CHRONIC ILLNESS; GLYCEMIC CONTROL; GENERAL-PRACTICE; AFRICAN-AMERICANS AB Background: Despite the development of several models of care delivery for patients with chronic illness, consistent improvements in outcomes have not been achieved. These inconsistent results may be less related to the content of the models themselves, but to their underlying conceptualization of clinical settings as linear, predictable systems. The science of complex adaptive systems (CAS), suggests that clinical settings are non-linear, and increasingly has been used as a framework for describing and understanding clinical systems. The purpose of this study is to broaden the conceptualization by examining the relationship between interventions that leverage CAS characteristics in intervention design and implementation, and effectiveness of reported outcomes for patients with Type II diabetes. Methods: We conducted a systematic review of the literature on organizational interventions to improve care of Type II diabetes. For each study we recorded measured process and clinical outcomes of diabetic patients. Two independent reviewers gave each study a score that reflected whether organizational interventions reflected one or more characteristics of a complex adaptive system. The effectiveness of the intervention was assessed by standardizing the scoring of the results of each study as 0 (no effect), 0.5 (mixed effect), or 1.0 (effective). Results: Out of 157 potentially eligible studies, 32 met our eligibility criteria. Most studies were felt to utilize at least one CAS characteristic in their intervention designs, and ninety-one percent were scored as either "mixed effect" or "effective." The number of CAS characteristics present in each intervention was associated with effectiveness (p = 0.002). Two individual CAS characteristics were associated with effectiveness: interconnections between participants and co-evolution. Conclusion: The significant association between CAS characteristics and effectiveness of reported outcomes for patients with Type II diabetes suggests that complexity science may provide an effective framework for designing and implementing interventions that lead to improved patient outcomes. C1 [Leykum, Luci K.; Pugh, Jacqueline; Lawrence, Valerie; Noel, Polly H.; Cornell, John] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Parchman, Michael] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [McDaniel, Reuben R., Jr.] Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA. RP Leykum, LK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. EM leykum@uthscsa.edu; pugh@uthscsa.edu; vlawrence@uthscsa.edu; parchman@uthscsa.edu; noel@uthscsa.edu; cornell@uthscsa.edu; reuben.mcdaniel@mccombs.utexas.edu OI Parchman, Michael/0000-0001-7129-2889 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [TRX 01-091, REA 05-129] FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (TRX # 01-091 & REA 05-129). Investigator salary support is provided through this funding, and through the South Texas Veterans Health Care System. NR 58 TC 29 Z9 29 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PY 2007 VL 2 AR 28 DI 10.1186/1748-5908-2-28 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V00IX UT WOS:000206783100028 PM 17725834 ER PT S AU Chen, GTY Kung, JH Rietzel, E AF Chen, George T. Y. Kung, Jong H. Rietzel, Eike BE Meyer, JL Kavanagh, BD Purdy, JA Timmerman, R TI Four-dimensional Imaging and treatment planning of moving targets SO IMRT, IGRT, SBRT: ADVANCES IN THE TREATMENT PLANNING AND DELIVERY OF RADIOTHERAPY SE FRONTIERS OF RADIATION THERAPY AND ONCOLOGY LA English DT Article; Proceedings Paper CT 38th San Francisco Radiation Oncology Conference CY APR 05-17, 2005 CL San Francisco, CA SP Stanford Univ, Dept Radiat Oncol, Univ Calif San Francisco, St Francis Memorial Hosp, Univ Calif Davis ID COMPUTED-TOMOGRAPHY; RESPIRATORY MOTION; ORGAN MOTION; MULTISLICE CT; REAL-TIME; RADIOTHERAPY; TRACKING; IMRT; LUNG; DELIVERY AB Four-dimensional CT acquisition is commercially available, and provides important information on the shape and trajectory of the tumor and normal tissues. The primary advantage of four-dimensional imaging over light breathing helical scans is the reduction of motion artifacts during scanning that can significantly alter tumor appearance. Segmentation, image registration, visualization are new challenges associated with four-dimensional data sets because of the overwhelming increase in the number of images. Four-dimensional dose calculations, while currently laborious, provide insights into dose perturbations due to organ motion. Imaging before treatment (image guidance) improves accuracy of radiation delivery, and recording transmission images can provide a means of verifying gated delivery. Copyright (C) 2007 S. Karger AG, Basel. C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Chen, GTY (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM gchen@partners.org NR 22 TC 15 Z9 16 U1 2 U2 2 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0071-9676 BN 978-3-8055-8199-8 J9 FRONT RADIAT THER ON JI Front.Radiat.Ther.Oncol. PY 2007 VL 40 BP 59 EP 71 DI 10.1159/000106028 PG 13 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BGN39 UT WOS:000248596600004 PM 17641502 ER PT J AU Sands, BE Kozarek, R Spainhour, J Barish, CF Becker, S Goldberg, L Katz, S Goldblum, R Harrigan, R Hilton, D Hanauer, SB AF Sands, Bruce E. Kozarek, Richard Spainhour, Jack Barish, Charles F. Becker, Scott Goldberg, Lawrence Katz, Seymour Goldblum, Ronald Harrigan, Rena Hilton, Deborah Hanauer, Stephen B. TI Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE natalizumab; infliximab; Crohn's disease; combination therapy; randomized controlled trial ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; INFLAMMATORY-BOWEL-DISEASE; SHORT-TERM; ADALIMUMAB; EFFICACY; THERAPY AB Background: Natalizumab, a humanized monoclonal IgG(4) antibody to alpha 4 integrin, was investigated as a treatment of active Crohn's disease (CD). The safety of natalizumab given in combination with infliximab has not previously been studied. Methods: Seventy-nine adult patients with active CD (Crohn's Disease Activity Index [CDAI] score >= 150) despite ongoing infliximab treatment were randomized 2:1 to receive 3 intravenous infusions of natalizumab (300 mg; n = 52) or placebo (n = 27) every 4 weeks. Patients received infliximab (5 mg/kg) every 8 weeks for at least 10 weeks before randomization and throughout the study. The primary objective was to assess the short-term safety and tolerability of natalizumab in patients concurrently receiving infliximab. Secondary and tertiary objectives included measures of efficacy, health-related quality of life (HRQoL), and effects on inflammatory markers. A subset of patients also participated in a pharmacokinetic/pharmacodynamic (PK/PD) analysis of the effects of concurrent treatment. Results: Incidence of adverse events (AEs) was similar in the treatment groups. AEs frequently reported in both groups were headache, CD exacerbation, nausea, and nasopharyngitis. No patient had a hypersensitivity-like reaction to natalizumab, whereas 4 patients (5%) experienced reactions to infliximab. Two patients (4%) developed anti-natalizumab antibodies; 10 patients (14%) developed anti-infliximab antibodies. The mean CDAI score decreased with natalizumab plus infliximab but was unchanged with infliximab alone (-37.7 versus +3.5; P = 0.084). Patients in both groups showed small increases in HRQoL (P = 0.811). No drug-drug interactions were noted. Conclusions: The combination of natalizumab plus infliximab was well tolerated. Several positive trends suggested that treating patients not in remission with infliximab plus natalizumab had greater efficacy than treatment with infliximab alone. C1 Massachusetts Gen Hosp, Crohns & Colitis Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Virginia Mason Med Ctr, Gastroenterol Sect, Seattle, WA 98101 USA. Internal Med Associates, Danville, VA USA. Wake Internal Med Consultants, Wake Res Associates, Raleigh, NC USA. Austin Gastroenterol, Austin, TX USA. Borland Groover Clin, Jacksonville, FL USA. NYU, Sch Med, New York, NY USA. Elan Pharmaceut Inc, San Diego, CA USA. Univ Chicago, Chicago, IL 60637 USA. RP Sands, BE (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM bsands@partners.org OI katz, seymour/0000-0002-3492-9200 NR 18 TC 43 Z9 45 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2007 VL 13 IS 1 BP 2 EP 11 DI 10.1002/ibd.20014 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 125LZ UT WOS:000243444700002 PM 17206633 ER PT B AU Werner, RM Asch, DA AF Werner, Rachel M. Asch, David A. BE Clarke, S Oakley, J TI Examining the link between publicly reporting healthcare quality and quality improvement SO INFORMED CONSENT AND CLINICIAN ACCOUNTABILITY: THE ETHICS OF REPORT CARDS ON SURGEON PERFORMANCE LA English DT Article; Book Chapter ID NEW-YORK-STATE; BYPASS GRAFT-SURGERY; CARDIAC-SURGERY; OF-CARE; MEDICARE BENEFICIARIES; PERFORMANCE REPORTS; CONTRACTING PRACTICES; HOSPITAL PERFORMANCE; MORTALITY HOSPITALS; CONSUMER REPORTS C1 [Werner, Rachel M.; Asch, David A.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 62 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-86507-4 PY 2007 BP 212 EP 225 DI 10.1017/CBO9780511545467.018 D2 10.1017/CBO9780511545467 PG 14 WC Medical Ethics; Medicine, Legal SC Medical Ethics; Legal Medicine GA BXT24 UT WOS:000297011900018 ER PT S AU Xiong, JP Goodman, SL Arnaout, MA AF Xiong, Jian-Ping Goodman, Simon L. Arnaout, M. Amin BE Cheresh, DA TI Purification, analysis, and crystal structure of integrins SO INTEGRINS SE Methods in Enzymology LA English DT Review; Book Chapter ID X-RAY CRYSTALLOGRAPHY; GLYCOPROTEIN-IIB-IIIA; CD11B A-DOMAIN; CELL-SURFACE; LIGAND-BINDING; I-DOMAIN; ALPHA-IIB-BETA-3 INTEGRIN; ISOMORPHOUS REPLACEMENT; EXTRACELLULAR SEGMENT; ANOMALOUS DIFFRACTION AB Integrins are large modular cell-surface receptors that regulate almost every aspect of cellular function through bidirectional signals transmitted across the lipid bilayer. Regulation of integrin activity is accomplished by complex and still incompletely understood biochemical pathways that modify integrin ligand binding, clustering, trafficking, and signaling functions. The dynamic tertiary and quaternary changes required to channel some of these activities have hampered, until recently, the crystal structure determination of these heterodimeric receptors. In this chapter, we review the methods used to purify and characterize these proteins biophysically and functionally, and to derive their three-dimensional structures. C1 Massachusetts Gen Hosp, Div Nephrol, Leukocyte Biol & Inflammat Program, Struct Biol Program, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA USA. E Merck AG, Preclin Oncol Res, D-6100 Darmstadt, Germany. RP Xiong, JP (reprint author), Massachusetts Gen Hosp, Div Nephrol, Leukocyte Biol & Inflammat Program, Struct Biol Program, Charlestown, MA 02129 USA. FU NHLBI NIH HHS [HL-70219]; NIDDK NIH HHS [DK48549] NR 125 TC 7 Z9 8 U1 0 U2 6 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-373924-7 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2007 VL 426 BP 307 EP + DI 10.1016/S0076-6879(07)26014-8 PG 32 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BGP76 UT WOS:000249589000014 PM 17697890 ER PT J AU Penedo, FJ Traeger, L Dahn, J Molton, I Gonzalez, JS Schneiderman, N Antoni, MH AF Penedo, Frank J. Traeger, Lara Dahn, Jason Molton, Ivan Gonzalez, Jeffrey S. Schneiderman, Neil Antoni, Michael H. TI Cognitive behavioral stress management intervention improves quality of life in Spanish monolingual Hispanic men treated for localized prostate cancer: Results of a randomized controlled trial SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE cognitive-behavioral stress management; prostate carcinoma; quality of life; group intervention; Hispanics; Spanish ID RADICAL PROSTATECTOMY; CARCINOMA; OUTCOMES; VALIDATION; LATINAS; MODEL AB Background: The efficacy of a group-based psychosocial intervention with ethnic minority health populations may depend on consideration for cultural factors that can interact with group processes. Purpose: The current study explored the efficacy of a 10-week group-based cognitive-behavioral stress management (CBSM) intervention that was linguistically and culturally adapted for use with Hispanic monolingual men recently treated for localized prostate carcinoma (PC). Methods: 71 Hispanic monolingual Spanish speakers were randomly assigned to a 10-week CBSM intervention or a half-day stress management seminar (control condition). Hierarchical regression was used to predict post-intervention QoL. Results: After controlling for relevant covariates, assignment to the CBSM condition significantly predicted greater physical well-being, emotional well-being, sexual functioning, and total well-being after the 10-week intervention period. Conclusions: Results suggest that participation in a culturally and linguistically adapted CBSM group intervention improved QoL in Hispanic monolingual men treatedfor localized PC. C1 Univ Miami, Dept Psychol, Coral Gables, FL 33134 USA. Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA. Miami VA Med Ctr, Miami, FL USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. RP Penedo, FJ (reprint author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33134 USA. EM fpenedo@miami.edu FU NCI NIH HHS [1P50CA84944] NR 31 TC 31 Z9 32 U1 2 U2 11 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 1070-5503 J9 INT J BEHAV MED JI Int. J. Behav. Med. PY 2007 VL 14 IS 3 BP 164 EP 172 PG 9 WC Psychology, Clinical SC Psychology GA 217PN UT WOS:000249959900007 PM 18062059 ER PT J AU Nieto, M Finn, S Loda, M Hahn, WC AF Nieto, Maria Finn, Stephen Loda, Massimo Hahn, William C. TI Prostate cancer: Re-focusing on androgen receptor signaling SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY LA English DT Article DE prostate cancer; androgen receptor ID TELOMERASE ACTIVITY; SUPPRESSOR GENE; HOMEOBOX GENE; ALLELIC LOSS; IN-VIVO; PROGRESSION; NKX3.1; DELETION; REGION; BCL-2 AB Prostate cancer is the most common, non-dermatologic cancer in men. Since prostate cancer is highly associated with increased age, the incidence of this disease is expected to increase as the population ages. In its initial stages prostate cancer depends upon the actions of androgen, and androgen deprivation therapy induces tumor regression. Currently, androgen deprivation is achieved by either surgical or chemical androgen blockade. Unfortunately, nearly all prostate cancer patients develop tumors that grow despite androgen blockade and ultimately relapse. Many alterations in prostate cancer cells contribute to this state. Although chemotherapy induces short remissions in some patients, there are no curative therapies for metastatic disease. This review summarizes our current understanding in androgen signaling and the mechanisms that allow tumor cells to bypass androgen manipulation therapy. The identification of novel survival pathways and effector molecules that drive androgen independent growth is necessary to develop effective therapies for advanced prostate cancers. (c) 2007 Elsevier Ltd. All rights reserved. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Broad Inst Harvard, Cambridge, MA 02142 USA. MIT, Cambridge, MA 02142 USA. RP Hahn, WC (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM William_Hahn@dfci.harvard.edu OI Finn, Stephen/0000-0002-8628-5814 FU NCI NIH HHS [K01 CA094223, K01 CA094223-05]; NIA NIH HHS [R01 AG023145, R01 AG023145-03] NR 54 TC 28 Z9 29 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1357-2725 J9 INT J BIOCHEM CELL B JI Int. J. Biochem. Cell Biol. PY 2007 VL 39 IS 9 BP 1562 EP 1568 DI 10.1016/j.biocel.2007.01.005 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 204TZ UT WOS:000249068200002 PM 17321194 ER PT J AU Khor, LY Bae, K Hammond, ME Pollack, A Venkatesan, V Rosenthal, S Sandler, H Hanks, GE Shipley, WU Dicker, AP AF Khor, L.-Y Bae, K. Hammond, M. E. Pollack, A. Venkatesan, V. Rosenthal, S. Sandler, H. Hanks, G. E. Shipley, W. U. Dicker, A. P. TI Cox-2 overexpression in pretreatment diagnostic tissue is associated with prostate cancer outcome in RTOG 92-02 SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS LA English DT Meeting Abstract C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Radiat Therapy Oncol Grp, Philadelphia, PA USA. LDS Hosp, Salt Lake City, UT USA. Univ Western Ontario, London, ON, Canada. Radiol Assoc Sacramento Med Grp Inc, Sacramento, CA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Thomas Jefferson Hosp, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0393-6155 J9 INT J BIOL MARKER JI Int. J. Biol. Markers PD JAN-MAR PY 2007 VL 22 IS 1 BP 73 EP 74 PG 2 WC Biotechnology & Applied Microbiology; Oncology SC Biotechnology & Applied Microbiology; Oncology GA 170BW UT WOS:000246637300047 ER PT J AU Ali, SM Brault, D Brown-Shimer, S Carney, W Esteva, FJ Fornier, M Gligorov, J Hamer, P Harris, L Kostler, WJ Leitzel, K Lotz, JP Luftner, D Pichon, MF Thiel, RP Tse, C Wheler, J Lipton, A AF Ali, S. M. Brault, D. Brown-Shimer, S. Carney, W. Esteva, F. J. Fornier, M. Gligorov, J. Hamer, P. Harris, L. Kostler, W. J. Leitzel, K. Lotz, J. P. Luftner, D. Pichon, M. F. Thiel, R. P. Tse, C. Wheler, J. Lipton, A. TI Decline in serum HER-2/neu predicts response to trastuzumab-based therapy SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS LA English DT Meeting Abstract C1 Penn State Hershey Med Ctr, Hershey, PA USA. Lebanon VA Med Ctr, Lebanon, PA USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Tenon Hosp, Paris, France. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Hosp Vienna, A-1090 Vienna, Austria. Humboldt Univ, Berlin, Germany. Rene Huguenin Canc Ctr, Paris, France. RI Fornier, Monica/F-5899-2010 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0393-6155 J9 INT J BIOL MARKER JI Int. J. Biol. Markers PD JAN-MAR PY 2007 VL 22 IS 1 BP 75 EP 76 PG 2 WC Biotechnology & Applied Microbiology; Oncology SC Biotechnology & Applied Microbiology; Oncology GA 170BW UT WOS:000246637300050 ER PT J AU Pollack, A Moughan, J Khor, LY Al-Saleem, T Hammond, ME Venkatesan, V Rosenthal, S Hanks, GE Shipley, W Sandler, H AF Pollack, A. Moughan, J. Khor, L.-Y Al-Saleem, T. Hammond, M. E. Venkatesan, V. Rosenthal, S. Hanks, G. E. Shipley, W. Sandler, H. TI Bcl-2 and Bax are determinants of prostate cancer outcome in men treated with androgen deprivation and radiotherapy on RTOG 92-02 SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS LA English DT Meeting Abstract C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Radiat Therapy Oncol Grp, Philadelphia, PA USA. LDS Hosp, Salt Lake City, UT USA. Univ Western Ontario, London, ON N6A 3K7, Canada. Radiol Associates, Sacramento, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0393-6155 J9 INT J BIOL MARKER JI Int. J. Biol. Markers PD JAN-MAR PY 2007 VL 22 IS 1 BP 79 EP 79 PG 1 WC Biotechnology & Applied Microbiology; Oncology SC Biotechnology & Applied Microbiology; Oncology GA 170BW UT WOS:000246637300056 ER PT J AU Mulligan, G Mitsiades, C Bryant, B Zhan, F Cheng, W Eschrich, S Burrington, B Richardson, P Trepicchio, W Shaughnessy, J Bergsagel, L Damokosh, A Boral, A Esseltine, D Schenkein, D Anderson, K AF Mulligan, G. Mitsiades, C. Bryant, B. Zhan, F. Cheng, W. Eschrich, S. Burrington, B. Richardson, P. Trepicchio, W. Shaughnessy, J. Bergsagel, L. Damokosh, A. Boral, A. Esseltine, D. Schenkein, D. Anderson, K. TI Pharmacogenomics (PGX) research in the apex randomized multicenter international phase 3 trial comparing bortezomib and high-dose dexamethasone (DEX) SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS LA English DT Meeting Abstract C1 Millennium Pharmaceut Inc, Cambridge, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Arkansas Med Sci, Little Rock, AR 72205 USA. Mayo Clin, Rochester, MN USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33620 USA. Mayo Clin, Scottsdale, AZ USA. RI Eschrich, Steven/K-6848-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0393-6155 J9 INT J BIOL MARKER JI Int. J. Biol. Markers PD JAN-MAR PY 2007 VL 22 IS 1 BP 81 EP 82 PG 2 WC Biotechnology & Applied Microbiology; Oncology SC Biotechnology & Applied Microbiology; Oncology GA 170BW UT WOS:000246637300060 ER PT J AU Xiao, GS Jin, YS Lu, QY Zhang, ZF Belldegrun, A Figlin, R Pantuck, A Yen, Y Li, F Rao, JY AF Xiao, Gui-Shan Jin, Yu-Sheng Lu, Qing-Yi Zhang, Zuo-Feng Belldegrun, Arie Figlin, Robert Pantuck, Allan Yen, Yon Li, Frederick Rao, Jian Yu TI Annexin-I as a potential target for green tea extract induced actin remodeling SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE proteomics; green tea extract; annexin-I; actin remodeling; bladder cancer; chemoprevention ID SURROGATE END-POINTS; OXIDATIVE STRESS; CANCER PREVENTION; MASS-SPECTROMETRY; DRUG DEVELOPMENT; PROSTATE-CANCER; BLADDER-CANCER; CELL CARCINOMA; EXPRESSION; PROTEIN AB Using a multistep human urothelial model, we previously showed that green tea extract (GTE) selectively modulates actin remodeling in transformed cells (MC-T11), which resulted in increased cell adhesion and reduced cell motility (Lu et al, Clin Cancer Res 2005;11:1675-83). This study further analyzed which actin binding proteins (ABPs) might be involved in this process. Proteomic profiles of GTE treated and untreated MC-T11 cells using two-dimensional gel electrophoresis coupled with liquid chromatography tandem mass spectrometry (LC/MS/MS) and matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) identified 20 GTE-induced proteins. Among them, 3 were ABPs (tropomodulin, cofilin and annexin-I), and only annexin-I showed a dose- and time-dependent expression. The increased annexin-I correlated with actin remodeling, and was the result of transcription level up-regulation, as determined by RT-PCR, pull-down immunoblot and siRNA analyses. 5-Azacytidine, a DNA methylation inhibitor, exhibited no effect on annexin-I expression when used alone, but had an additive effect for GTE-induced annexin-I expression. Immunohistochemistry of bladder cancer tissue array showed a decrease of annexin-I expression in carcinoma in situ and low grade papillary carcinoma (n = 32, 0% positive) compared to nontumor urothelium (n = 18, 89% positive) (p < 0.001 by Fisher exact test), but increased in some (6 of 15, 40%) high-grade tumors. Together, GTE induced annexin-I expression plays a role in regulating actin remodeling and decreased annexin-I expression is a common event in early stage of bladder cancer development. (c) 2006 Wiley-Liss, Inc. C1 Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geffen Sch Med, Los Angeles, CA 90095 USA. City Hope Natl Med Ctr, Ctr Comprehens Canc, Dept Clin Mol Pharmacol, Los Angeles, CA USA. Univ Calif Los Angeles, Ctr Human Nutr, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Dana Farber Canc Inst, Dept Epidemiol, Boston, MA 02115 USA. RP Rao, JY (reprint author), Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geffen Sch Med, Box 951732, Los Angeles, CA 90095 USA. EM jrao@mednet.ucla.edu FU NCI NIH HHS [U01CA96116] NR 53 TC 13 Z9 13 U1 1 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD JAN 1 PY 2007 VL 120 IS 1 BP 111 EP 120 DI 10.1002/ijc.22164 PG 10 WC Oncology SC Oncology GA 114FY UT WOS:000242653300016 PM 17019707 ER PT J AU Martinez-Moneder, R Edge, ASB AF Martinez-Moneder, Rodrigo Edge, Albert S. B. TI Stem cells for the replacement of inner ear neurons and hair cells SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY LA English DT Article DE cell therapy; hearing; guidance; regeneration ID CENTRAL-NERVOUS-SYSTEM; SPIRAL GANGLION NEURONS; NEURAL PROGENITOR CELLS; SPINAL-CORD-INJURY; IN-VITRO; PRECURSOR CELLS; AUDITORY-NERVE; DEVELOPMENTAL GUIDANCE; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTOR AB Stem cells in the nervous system have some capacity to restore damaged tissue. Proliferation of stem cells endows them with self-renewal ability and accounts for in vitro formation of neurospheres, clonally derived colonies of floating cells. However, damage to the nervous system is not readily repaired, suggesting that the stem cells do not provide an easily recruited source of cells for regeneration. The vestibular and auditory organs, despite their limited ability to replace damaged cells, appear to contain cells with stem cell properties. These inner ear stem cells, identified by neurosphere formation and by their expression of markers of inner ear progenitors,can differentiate to hair cells and neurons. Differentiated cells obtained from inner ear stem cells expressed sensory neuron markers and, after co-culture with the organ of Corti, grew processes that extended to hair cells. The neurons expressed synaptic vesicle markers at points of contact with hair cells. Exogenous stem cells have also been used for hair cell and neuron replacement. Embryonic stem cells are one potential source of both hair cells and sensory neurons. Neural progenitors made from embryonic stem cells, transplanted into the inner ear of gerbils that had been de-afferented by treatment with a toxin, differentiated into cells that expressed neuronal markers and grew processes both peripherally into the organ of Corti and centrally. The regrowth of these neurons suggests that it may be possible to replace auditory neurons that have degenerated with neurons that restore auditory function by regenerating connections to hair cells. C1 Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Tillotson Unit Cell Biol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. Harvard Univ, MIT, Div Hlth Sci & Technol, Program Speech & Hearing Biosci & Technol, Cambridge, MA 02139 USA. RP Edge, ASB (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Tillotson Unit Cell Biol, 243 Charles St, Boston, MA 02114 USA. EM albert_edge@meei.harvard.edu FU NIDCD NIH HHS [P30 DC05209, R01 DC007174] NR 85 TC 23 Z9 26 U1 0 U2 10 PU U B C PRESS PI BILBAO PA UNIV BASQUE COUNTRY, EDITORIAL SERVICES, PO BOX 1397, E-48080 BILBAO, SPAIN SN 0214-6282 J9 INT J DEV BIOL JI Int. J. Dev. Biol. PY 2007 VL 51 IS 6-7 BP 655 EP 661 DI 10.1387/ijdb.072372rm PG 7 WC Developmental Biology SC Developmental Biology GA 239MW UT WOS:000251523400020 PM 17891724 ER PT J AU Becker, AE Fay, K Gilman, SE Striegel-Moore, R AF Becker, Anne E. Fay, Kristen Gilman, Stephen E. Striegel-Moore, Ruth TI Facets of acculturation and their diverse relations to body shape concern in Fiji SO INTERNATIONAL JOURNAL OF EATING DISORDERS LA English DT Article DE acculturation; assimilation; tradition; body shape concern; Fiji ID BINGE-EATING DISORDER; ANOREXIA-NERVOSA; ADOLESCENT GIRLS; WESTERN CULTURE; FEMALE STUDENTS; MENTAL-HEALTH; ATTITUDES; WOMEN; SCALE; SCHOOLGIRLS AB Objective: The present study examines the relation between acculturation and body shape concern in Fiji society undergoing rapid social change. Method: Data were from two cohorts of ethnic Fijian girls and women collected in 1998 (n = 115). A factor analysis was performed to identify dimensions of acculturation. The association of these with body shape concern was examined with linear regression. Results: Three dimensions of acculturation were identified. Multiple linear regression models demonstrated that each of these dimensions of acculturation had a unique relation to body shape concern. The adjusted R-2 for the fully adjusted model relating acculturation to body concern was 0.63, indicating a substantial degree of shared variation between measures of body shape concern and measures of acculturation. Conclusion: Acculturation may have a strong impact on body shape concern in Fiji. However, acculturation is a multidimensional construct and does not likely have a monolithic relation to body shape concern. (c) 2006 by Wiley Periodicals, Inc. C1 Massachusetts Gen Hosp, Eating Disorders Clin & Res Program, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA. Tufts Univ, Eliot Pearson Dept Appl Child Dev, Medford, MA 02155 USA. Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth & Epidemiol, Boston, MA 02115 USA. Wesleyan Univ, Dept Psychol, Middletown, CT USA. RP Becker, AE (reprint author), Massachusetts Gen Hosp, Eating Disorders Clin & Res Program, Dept Psychiat, WAC 816C,15 Parkman St, Boston, MA 02114 USA. EM abecker@partners.org RI Gilman, Stephen/E-7632-2010; OI Gilman, Stephen/0000-0002-8331-6419; weissman, ruth/0000-0001-6121-4641 FU NIMH NIH HHS [K23 MH068575] NR 47 TC 8 Z9 9 U1 1 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0276-3478 J9 INT J EAT DISORDER JI Int. J. Eating Disord. PD JAN PY 2007 VL 40 IS 1 BP 42 EP 50 DI 10.1002/eat.20332 PG 9 WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology SC Psychology; Nutrition & Dietetics; Psychiatry GA 116YJ UT WOS:000242839400007 PM 16958116 ER PT J AU Phillips, V McCluggage, WG Young, RH AF Phillips, Victoria McCluggage, W. Glenn Young, Robert H. TI Oxyphilic adenomatoid tumor of the ovary: A case report with discussion of the differential diagnosis of ovarian tumors with vacuoles and related spaces SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Article DE ovary; adenomatoid tumor; vacuoles; differential diagnosis; immunohistochemistry ID MALE GENITAL TRACTS; CLINICOPATHOLOGICAL ANALYSIS; CELL-CARCINOMA; EMPHASIS; FEMALE AB We describe an unusual example of ovarian adenomatoid tumor that was an incidental finding in the ovary of a 52-year-old woman and was characterized by cells with abundant eosinophilic cytoplasm, an occasional feature of the adenomatoid tumor but one that, in an ovarian example, may cause added diagnostic confusion to that already engendered by the rarity of this neoplasm in the ovary. The typical numerous small vacuoles of the neoplasm sometimes had the appearance of signet ring cells. These 2 features (oxyphil and signet ring cells) caused a broad differential. Tumor cells were positive with broad-spectrum cytokeratins as well as mesothelial markers CK5/6, WT1, and calretinin. In reporting this case, we focus on the differential diagnosis of ovarian neoplasms and tumorlike conditions with vacuoles and related spaces, a topic that embraces many diverse entities. C1 Royal Grp Hosp Trust, Dept Pathol, Belfast BT12 6BL, Antrim, North Ireland. Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA. RP McCluggage, WG (reprint author), Royal Grp Hosp Trust, Dept Pathol, Grosvenor Rd, Belfast BT12 6BL, Antrim, North Ireland. EM glenn.mccluggage@bll.n-i.nhs.uk NR 23 TC 12 Z9 13 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-1691 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD JAN PY 2007 VL 26 IS 1 BP 16 EP 20 DI 10.1097/01.pgp.0000215303.24653.fc PG 5 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA 119UO UT WOS:000243039700003 PM 17197891 ER PT J AU Barbeau, EM Hartman, C Quinn, MM Stoddard, AM Krieger, N AF Barbeau, Elizabeth M. Hartman, Cathy Quinn, Margaret M. Stoddard, Anne M. Krieger, Nancy TI Methods for recruiting white, black, and Hispanic working-class women and men to a study of physical and social hazards at work: The United for Health Study. SO INTERNATIONAL JOURNAL OF HEALTH SERVICES LA English DT Article ID OCCUPATIONAL-HEALTH; PROMOTION RESEARCH; PUBLIC-HEALTH; CLASS MATTERS; DISCRIMINATION; DISPARITIES; GENDER; INCOME; US AB Despite research on work and health having a long-standing concern about unjust exposures and inequitable burdens of disease, there are few studies that document the joint distribution and health effects of physical and psychosocial hazards (e.g., noise, dusts, fumes, and job strain) and social hazards (e.g., racial discrimination and gender harassment) encountered at work. Also, there is a paucity of data on how these exposures, singly and combined, are distributed in relation to sociodemographic characteristics including race/ethnicity, gender, socioeconomic position, and nativity. This article presents a conceptual model for redressing these knowledge gaps and describes recruitment strategies and the characteristics of study participants in the United for Health study. Working with labor unions, the authors recruited 14 (67%) of 21 worksites from manufacturing, meat processing, retail, and transportation, and 1,282 workers (72% response rate), of whom 62 percent were men, 36 percent were women, 39 percent were black, 23 percent were Hispanic, 25 percent were white, 31% earned less than a living wage, 40 percent were below the poverty level, and 23 percent had less than a high school education. C1 Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. RP Barbeau, EM (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 44 Binney St, Boston, MA 02115 USA. EM elizabeth_barbeau@dfci.harvard.edu FU NIOSH CDC HHS [R01 OH07366-01] NR 38 TC 21 Z9 21 U1 1 U2 6 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0020-7314 J9 INT J HEALTH SERV JI Int. J. Health Serv. PY 2007 VL 37 IS 1 BP 127 EP 144 DI 10.2190/B0N2-5850-6467-0230 PG 18 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 157KJ UT WOS:000245718300007 PM 17436989 ER PT J AU Gomery, P Bullock, A McGettigan, J Munarriz, R Natanegara, F Hague, J Kuepfer, C Abuja, S Wong, D AF Gomery, P. Bullock, A. McGettigan, J. Munarriz, R. Natanegara, F. Hague, J. Kuepfer, C. Abuja, S. Wong, D. TI Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS) SO INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH LA English DT Article DE tadalafil; erectile function; ethnicity; noninferiority trial; erectile dysfunction; MOMENTUS ID RISK-FACTORS; MEXICAN-AMERICANS; SAFETY; HYPERTENSION; IMPOTENCE; WHITES; TRIAL AB To show that tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction (ED) and efficacy is noninferior to that in Caucasian men. Multiple observations in men with ED in national tadalafil study in the US, a multicenter, open-label study, assessed the efficacy of tadalafil 20 mg taken as needed (maximum one dose/day before sexual activity) for 12 weeks by patients with ED in various populations. This analysis focuses on three groups: Caucasian (Reference group), Black American, and Hispanic men. Primary measurement of efficacy was change from baseline in erectile function (EF) domain of the International Index of Erectile Function (IIEF) and the primary analysis was whether efficacy in Black American and Hispanic groups was noninferior to efficacy in the Caucasian group. Secondary efficacy measures included sexual encounter profile (SEP), IIEF intercourse satisfaction (IS) and overall satisfaction (OS) domains, Global Assessment Question (GAQ), and Psychological and Interpersonal Relationship Scale (PAIRS). Safety was assessed from adverse events (AEs) reported by all enrolled patients. The increase in IIEF EF domain score (>= 9.5) from baseline for each group was statistically significant (P < 0.001) and clinically relevant. Efficacy of tadalafil in Black American and Hispanic patients was noninferior to the Caucasian group. IS and OS domains of IIEF had a statistically significant increase from baseline (P < 0.001). Change from baseline in positive responses to SEP questions for each group was significant (P < 0.001). At least 77% of intercourse attempts were successful over various time intervals up to 36 h postdose. At least 88% of patients in the various groups had a positive response to GAQ1. Improvement from baseline in Sexual Self-Confidence and Spontaneity domains of PAIRS was statistically significant (P < 0.001). A low number of AEs and a low AE-related discontinuation rate (2.3%) were reported in all groups. Tadalafil 20 mg was as efficacious in Black American and Hispanic men with ED as in Caucasian patients and was well tolerated. C1 Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. RP Gomery, P (reprint author), Massachusetts Gen Hosp, Dept Urol, 55 Fruit St,GRB 1102, Boston, MA 02114 USA. EM pgomery@partners.org OI Munarriz, Ricardo/0000-0002-6498-7209 NR 23 TC 6 Z9 7 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0955-9930 J9 INT J IMPOT RES JI Int. J. Impot. Res. PD JAN-FEB PY 2007 VL 19 IS 1 BP 76 EP 83 DI 10.1038/sj.ijir.3901484 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 128UW UT WOS:000243685500011 PM 16728966 ER PT J AU Kessler, RC Adler, LA Gruber, MJ Sarawate, CA Spencer, T Van Brunt, DL AF Kessler, Ronald C. Adler, Lenard A. Gruber, Michael J. Sarawate, Chaitanya A. Spencer, Thomas Van Brunt, David L. TI Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members SO INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH LA English DT Article DE attention-deficit/hyperactivity disorder (ADHD); adult ADHD; ASRS screener ID ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; DEFICIT-HYPERACTIVITY-DISORDER; PREVALENCE; SYMPTOMS; RATINGS; POPULATION; AGREEMENT; DIAGNOSIS; PLACEBO AB The validity of the six-question World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener was assessed in a sample of subscribers to a large health plan in the US. A convenience subsample of 668 subscribers was administered the ASRS Screener twice to assess test-retest reliability and then a third time in conjunction with a clinical interviewer for DSM-IV adult ADHD. The data were weighted to adjust for discrepancies between the sample and the population on socio-demographics and past medical claims. Internal consistency reliability of the continuous ASRS Screener was in the range 0.63-0.72 and test-retest reliability (Pearson correlations) in the range 0.58-0.77. A four-category version The ASRS Screener had strong concordance with clinician diagnoses, with an area under the receiver operating characteristic curve (AUC) of 0.90. The brevity and ability to discriminate DSM-IV cases from non-cases make the six-question ASRS Screener attractive for use both in community epidemiological surveys and in clinical outreach and case-finding initiatives. Copyright (c) 2007 John Wiley & Sons, Ltd. C1 Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. NYU, Sch Med, Dept Psychiat, New York, NY 10012 USA. NYU, Sch Med, Dept Neurol, New York, NY 10012 USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Kessler, RC (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM kessler@hcp.med.harvard.edu OI Adler, Len/0000-0002-9812-8234 FU FIC NIH HHS [R01 TW 006481, R03 TW006481, R03 TW006481-03]; NIDA NIH HHS [R01 DA 016558, R01 DA016558, R01 DA016558-04]; NIMH NIH HHS [R13 MH066849, R01 MH 069864, R01 MH 070884, R01 MH069864, R01 MH069864-03, R01 MH070884, R01 MH070884-02, R13 MH 066849, R13 MH066849-04, U13 MH066849] NR 38 TC 182 Z9 184 U1 4 U2 19 PU WHURR PUBLISHERS LTD PI LONDON PA 19B COMPTON TERRACE, LONDON N1 2UN, ENGLAND SN 1049-8931 J9 INT J METH PSYCH RES JI Int. J. Methods Psychiatr. Res. PY 2007 VL 16 IS 2 BP 52 EP 65 DI 10.1002/mpr.208 PG 14 WC Psychiatry SC Psychiatry GA 185GP UT WOS:000247699700002 PM 17623385 ER PT J AU Dello Russo, NM Jeffcoat, MK Marx, RE Fugazzotto, P AF Dello Russo, Nicholas M. Jeffcoat, Marjorie K. Marx, Robert E. Fugazzotto, Paul TI Current issues forum - Could you comment on the risks of oral bisphosphonate use toward the development of osteonecrotic lesions of the jaws? In addition, could you postulate on studies that may better define this risk? SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS LA English DT Editorial Material ID POSTMENOPAUSAL WOMEN; ALENDRONATE; EVENTS; TRIAL; BONE C1 Massachusetts Gen Hosp, Dept Oral Surg, Boston, MA 02114 USA. Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA. Univ Miami, Miller Sch Med, Div Oral & Maxillofacial Surg, Coral Gables, FL 33124 USA. RP Dello Russo, NM (reprint author), Massachusetts Gen Hosp, Dept Oral Surg, Boston, MA 02114 USA. NR 13 TC 10 Z9 11 U1 0 U2 0 PU QUINTESSENCE PUBLISHING CO INC PI HANOVER PARK PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA SN 0882-2786 J9 INT J ORAL MAX IMPL JI Int. J. Oral Maxillofac. Implants PD JAN-FEB PY 2007 VL 22 IS 1 BP 146 EP 153 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 139ZR UT WOS:000244472200017 PM 17340909 ER PT J AU Kamil, SH Kojima, K Vacanti, MP Zaporojan, V Vacanti, CA Eavey, RD AF Kamil, S. H. Kojima, K. Vacanti, M. P. Zaporojan, V. Vacanti, C. A. Eavey, R. D. TI Tissue engineered cartilage: Utilization of autologous serum and serum-free media for chondrocyte culture SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY LA English DT Article; Proceedings Paper CT 7th Conference of the Tissue-Engineering-Society-International CY OCT, 2004 CL Lausanne, SWITZERLAND SP Tissue Engn Soc Int DE tissue engineering; autologous serum; serum free media; chondrocytes culture ID FIBROBLAST-GROWTH-FACTOR; ELASTIC CARTILAGE; GRAFTS; CELLS; SHAPE AB Background: Standard culture medium contains bovine serum. If standard culture methodology is used for future human tissue-engineering, unknown risks of infection from bovine disease or immune reaction to foreign proteins theoretically might occur. In this study we wished to evaluate the potential of chondrocyte expansion using autologous and serum free media. Methods: Autologous auricular cartilage was harvested in a swine model. An initial concentration of 100 x 103 cells per group were expanded in three groups. Group A, F-12 with 10% fetal. calf serum; Group B, F-12 supplemented with 10% autologous serum; Group C, F-12 supplemented with growth factors. Cell numbers were counted at days 3, 6, 9 and. 12. Results: The cells in all the three groups exhibited normal chondrocyte morphology. At early time points there was a statistically significant difference in the number of cells between Group A and the two other groups (p < 0.05). By day 12, both Groups A and C demonstrated greater cell number as compared to Group B (p < 0.05). Conclusion: The results suggest that both autologous serum as well as serum free media might be substituted for the expansion of the number of chondrocytes, thus avoiding the potential need for a bovine serum supplement. (C) 2006 Elsevier Ireland Ltd. All rights reserved. C1 Univ Massachusetts, Dept Otolaryngol, Worcester, MA 01655 USA. Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA. Univ Massachusetts, Dept Pathol, Worcester, MA 01655 USA. Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol,Pediat Otolaryngol Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Kamil, SH (reprint author), Univ Massachusetts, Dept Otolaryngol, 55 Lake Ave N, Worcester, MA 01655 USA. EM kamils@ummhc.org NR 20 TC 21 Z9 26 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-5876 J9 INT J PEDIATR OTORHI JI Int. J. Pediatr. Otorhinolaryngol. PD JAN PY 2007 VL 71 IS 1 BP 71 EP 75 DI 10.1016/j.ijporl.2006.09.002 PG 5 WC Otorhinolaryngology; Pediatrics SC Otorhinolaryngology; Pediatrics GA 128NF UT WOS:000243663900012 PM 17049624 ER PT J AU Papakostas, GI AF Papakostas, G. I. TI Are SSRI still "state of the art" or have we reached the "post SSRI era" in the treatment of major depressive disorder? SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE LA English DT Meeting Abstract ID VENLAFAXINE XR; ESCITALOPRAM C1 [Papakostas, G. I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU TAYLOR & FRANCIS AS PI OSLO PA PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY SN 1365-1501 J9 INT J PSYCHIAT CLIN JI Int. J. Psychiat. Clin. PY 2007 VL 11 IS 4 BP 301 EP 301 PG 1 WC Psychiatry SC Psychiatry GA 232NR UT WOS:000251026900021 ER PT J AU Fraguas, R Iosifescu, DV Bankier, B Perlis, R Clementi-Craven, N Alpert, J Fava, M AF Fraguas, Renerio Iosifescu, Dan V. Bankier, Bettina Perlis, Roy Clementi-Craven, Nicoletta Alpert, Jonathan Fava, Maurizio TI Major depressive disorder with anger attacks and cardiovascular risk factors SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE anger; cardiovascular; cholesterol; depression; hostility; irritability; risk factors; smoking ID CORONARY-HEART-DISEASE; UNIPOLAR DEPRESSION; FLUOXETINE TREATMENT; SERUM-CHOLESTEROL; EDUCATION-PROGRAM; CIGARETTE-SMOKING; YOUNG-ADULTS; SYMPTOMS; HOSTILITY; ASSOCIATION AB Objective: Depression and anger have been separately associated with cardiovascular risk factors. We investigated if major depressive disorder (MDD) with concomitant anger attacks was associated with cardiovascular risk factors. Method: We measured total serum cholesterol, glycemia, resting blood pressure, and smoking parameters in 333 (52.9% women) MDD nonpsychotic outpatients, mean age of 39.4 years. MDD was diagnosed with the Structured Clinical Interview (SCID) in accordance with the Diagnostic and Statistic Manual of Mental Disorders, Third Edition, Revised (DSM-III-R). The presence of anger attacks was established with the Massachusetts General Hospital Anger Attacks Questionnaire. Results: In a logistic regression analysis, anger attacks were independently associated with cholesterol levels >= 200mg/dL (odds ratio [OR], 2.16; 95% confidence interval [CI], 1. 18-3.94) and years of smoking >11 (OR, 2.59; 95%CI, 1.32-5.04). Conclusions: MDD with anger attacks was significantly associated with increased cholesterol levels and years of smoking. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Depress Clin & Res Program, Cambridge, MA 02138 USA. RP Fraguas, R (reprint author), Hosp Clin Sao Paulo, Inst Psiquiatria, Fac Med USP, Rua Ovidio Pires Campos S-N, BR-05403010 Sao Paulo, Brazil. EM rfraguas@hcnet.usp.br OI Alpert, Jonathan/0000-0002-4332-908X FU NIMH NIH HHS [R01-MH48483] NR 44 TC 7 Z9 8 U1 1 U2 7 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2007 VL 37 IS 1 BP 99 EP 111 DI 10.2190/Y361-2W83-268H-5W7V PG 13 WC Psychiatry SC Psychiatry GA 185IN UT WOS:000247704700010 PM 17645202 ER PT J AU Katerndahl, DA Obregon, ML AF Katerndahl, David A. Obregon, Maria Luisa TI An exploration of the spiritual and psychosocial variables associated with husband-to-wife abuse and its effect on women in abusive relationships SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE religion; domestic violence; marital incompatibility; coping; quality of life ID DOMESTIC VIOLENCE; RELIGIOUS INVOLVEMENT AB Objectives: The purpose was to: 1) determine which aspects of religious belief incompatibility were associated with husband-to-wife abuse; 2) determine whether religious coping was independently associated with functional status among victims of spousal abuse; and 3) whether degree of abuse correlated with degrees of religious belief incompatibility or functional status among abused wives. Method: Couples Were asked to complete a structured interview concerning marital satisfaction, argument frequency, alcohol use, witnessing violence as a child, spirituality, functional status, and domestic violence. Results: In four areas of spiritual belief (sense of being judged, closeness to God, congregational benefits, forgiveness), religious belief incompatibility significantly predicted abuse. Perceived congregational help and religious coping were associated with improved social support. Finally, abuse severity and duration correlated with functional status but not with degree of religious belief incompatibility. Conclusions: The addition of religious belief incompatibility may account for more variance in husband-to-wife abuse than non-spiritual predictors alone. Although the presence of abuse was associated with poorer functional status in women, religious coping was only linked to improved social support. C1 Univ Texas, Hlth Sci Ctr, Dept Family & Community Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Katerndahl, DA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Family & Community Med, 7703 Floyd Curl Dr,MC 7795, San Antonio, TX 78229 USA. EM katemdahl@uthscsa.edu NR 27 TC 3 Z9 3 U1 2 U2 4 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2007 VL 37 IS 2 BP 113 EP 128 DI 10.2190/G674-15N5-4626-W138 PG 16 WC Psychiatry SC Psychiatry GA 219DY UT WOS:000250066100001 PM 17953230 ER PT J AU Iosifescu, DV AF Iosifescu, Dan V. TI Research methods in psychiatry SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Book Review C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RP Iosifescu, DV (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2007 VL 37 IS 2 BP 242 EP 243 PG 2 WC Psychiatry SC Psychiatry GA 219DY UT WOS:000250066100012 ER PT J AU Schwarte, S Bremer, M Fruehauf, J Sorge, Y Skubich, S Hoffmann, MW AF Schwarte, Sebastian Bremer, Michael Fruehauf, Joerg Sorge, Yanina Skubich, Susanne Hoffmann, Matthias W. TI Radiation protocols determine acute graft-versus-host disease incidence after allogeneic bone marrow transplantation in murine models SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY LA English DT Article; Proceedings Paper CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol DE total body irradiation; dose rate; graft versus host disease; bone marrow transplantation; mouse ID II H-2 DIFFERENCES; TOTAL-BODY IRRADIATION; T-CELL SUBSETS; HUMAN-ENDOTHELIAL CELLS; TUMOR-NECROSIS-FACTOR; L3T4+ CELLS; EXPRESSION; LEUKEMIA; MICE; GVHD AB Purpose: Effects of radiation sources used for total body irradiation (TBI) on Graft-versus-Host Disease (GvHD) induction were examined. Materials and methods: In a T cell receptor (TCR) transgenic mouse model, single fraction TBI was performed with different radiation devices ((60)Cobalt; (137)Cesium; (MV)-M-6 linear accelerator), dose rates (0.85; 1.5; 2.9; 5 Gy/min) and total doses before allogeneic bone marrow transplantation (BMT). Recipients were observed for 120 days. Different tissues were examined histologically. Results: Acute GvHD was induced by a dose rate of 0.85 Gy/min ((60)Cobalt) and a total dose of 9 Gy and injection of 5 x 10(5) lymph node cells plus 5 x 10(6) bone marrow cells. Similar results were obtained using 6 MV linear accelerator- (linac-) photons with a dose rate of 1.5 Gy/min and 0.85 Gy/min, a total dose of 9.5 Gy and injection of same cell numbers. TBI with (137)Cesium (dose rate: 2.5 Gy/min) did not lead reproducibly to lethal acute GvHD. Conclusions: Experimental TBI in murine models may induce different immunological responses, depending on total energy, total single dose and dose rate. GvHD might also be induced by TBI with low dose rates. C1 Hannover Med Sch, Dept Radiat Oncol, D-3000 Hannover, Germany. Hannover Med Sch, Dept Transplantat Surg, D-3000 Hannover, Germany. RP Schwarte, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,MGH E, Transplantat Biol Res Ctr Bone Marrow Transplanta, 149 13th St, Boston, MA 02129 USA. EM sschwart@tbrc.mgh.harvard.edu NR 45 TC 2 Z9 2 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0955-3002 J9 INT J RADIAT BIOL JI Int. J. Radiat. Biol. PY 2007 VL 83 IS 9 BP 625 EP 636 DI 10.1080/09553000701534572 PG 12 WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 194HE UT WOS:000248334500007 PM 17654104 ER PT J AU Abi-Raad, RF MacDonald, SM El-Din, MAA Goldberg, SI Taghian, AG AF Abi-Raad, R. F. MacDonald, S. M. El-Din, M. A. Ahn Goldberg, S. I. Taghian, A. G. TI Chest wall radiation alone for breast cancer patients with 1-3 positive lymph nodes treated by mastectomy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Abi-Raad, R. F.; MacDonald, S. M.; El-Din, M. A. Ahn; Goldberg, S. I.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S76 EP S77 DI 10.1016/j.ijrobp.2007.07.138 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200135 ER PT J AU Alexander, BM Del-Castillo, CF Kachnic, LA Niemierko, A Blaszkowsky, LS Warshaw, AL Willett, CG Ryan, DP Clark, JW Hong, TS AF Alexander, B. M. Del-Castillo, C. Fernandez Kachnic, L. A. Niemierko, A. Blaszkowsky, L. S. Warshaw, A. L. Willett, C. G. Ryan, D. P. Clark, J. W. Hong, T. S. TI Improved outcomes of invasive papillary mucinous tumors of the pancreas, different biology or different stage? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Alexander, B. M.] Harvard Radiat Oncol Program, Boston, MA USA. [Del-Castillo, C. Fernandez; Niemierko, A.; Blaszkowsky, L. S.; Warshaw, A. L.; Ryan, D. P.; Clark, J. W.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kachnic, L. A.] Boston Med Ctr, Boston, MA USA. [Willett, C. G.] Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S273 EP S273 DI 10.1016/j.ijrobp.2007.07.1300 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200490 ER PT J AU Arvold, ND Lessell, S Rizzo, JF Licbsch, NJ Yock, TI Loeffler, JS Shih, HA AF Arvold, N. D. Lessell, S. Rizzo, J. F. Licbsch, N. J. Yock, T. I. Loeffler, J. S. Shih, H. A. TI Visual outcome and tumor control following Conformal radiotherapy for patients with optic nerve sheath meningioma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Arvold, N. D.; Licbsch, N. J.; Yock, T. I.; Loeffler, J. S.; Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lessell, S.; Rizzo, J. F.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S256 EP S257 DI 10.1016/j.ijrobp.2007.07.1264 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200455 ER PT J AU Batchelor, TT Duda, DG di Tomaso, E Kozak, KR Zhang, W Ancukiewicz, M Loeffler, JS Wen, PY Sorensen, GA Jain, RK AF Batchelor, T. T. Duda, D. G. di Tomaso, E. Kozak, K. R. Zhang, W. Ancukiewicz, M. Loeffler, J. S. Wen, P. Y. Sorensen, G. A. Jain, R. K. TI Normalization of tumor vasculature and alleviation of edema by AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor in glioblastoma patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Batchelor, T. T.; Duda, D. G.; di Tomaso, E.; Kozak, K. R.; Zhang, W.; Ancukiewicz, M.; Loeffler, J. S.; Sorensen, G. A.; Jain, R. K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Wen, P. Y.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S50 EP S51 DI 10.1016/j.ijrobp.2007.07.092 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200090 ER PT J AU Caglar, HB Allen, AM Othus, M Li, Y Burke, E Wirth, L Gougen, LA Haddad, RI Posner, MR Tishler, RB AF Caglar, H. B. Allen, A. M. Othus, M. Li, Y. Burke, E. Wirth, L. Gougen, L. A. Haddad, R. I. Posner, M. R. Tishler, R. B. TI Dose to the larynx predicts for swallowing complications following IMRT and chemotherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Caglar, H. B.; Allen, A. M.; Othus, M.; Li, Y.; Burke, E.; Wirth, L.; Gougen, L. A.; Haddad, R. I.; Posner, M. R.; Tishler, R. B.] Brigham & Womens Hosp, Dana Farber Canc Inst, Head & Neck Oncol Program, Boston, MA 02115 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S53 EP S54 DI 10.1016/j.ijrobp.2007.07.098 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200096 ER PT J AU Chan, AW Kamat, UR McIntyre, JF Goldsmith, TA AF Chan, A. W. Kamat, U. R. McIntyre, J. F. Goldsmith, T. A. TI Accelerated fractionation radiotherapy in advanced oropharyngeal carcinoma: Simultaneous integrated IMRT boost versus concomitant boost SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Chan, A. W.; Kamat, U. R.; McIntyre, J. F.; Goldsmith, T. A.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiat Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S198 EP S198 DI 10.1016/j.ijrobp.2007.07.359 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200349 ER PT J AU Chen, AB D'Amico, AV Neville, BA Earle, CC AF Chen, A. B. D'Amico, A. V. Neville, B. A. Earle, C. C. TI Provider volume and outcomes following prostate brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Chen, A. B.] Harvard Univ, Radiat Oncol Program, Boston, MA 02115 USA. [Chen, A. B.; D'Amico, A. V.; Neville, B. A.; Earle, C. C.] Dana Farber Canc Ctr, Boston, MA USA. [D'Amico, A. V.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S89 EP S90 DI 10.1016/j.ijrobp.2007.07.163 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200159 ER PT J AU Chen, RC Mamon, HJ Niemierko, A Crowley, EM Suh, WW Hong, TS AF Chen, R. C. Mamon, H. J. Niemierko, A. Crowley, E. M. Suh, W. W. Hong, T. S. TI Acute quality of life (QOL) effects of chemoradiation therapy (CRT) for locally-advanced rectal cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Chen, R. C.] Harvard Radiat Oncol Program, Boston, MA USA. [Mamon, H. J.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Niemierko, A.; Crowley, E. M.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S284 EP S284 DI 10.1016/j.ijrobp.2007.07.1319 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200509 ER PT J AU Chen, Y Adams, J Yock, T Esty, B Fullerton, B Tarbell, NJ AF Chen, Y. Adams, J. Yock, T. Esty, B. Fullerton, B. Tarbell, N. J. TI Improved hearing outcomes from cochlear dose reduction using proton posterior fossa boost in pediatric medulloblastoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Chen, Y.; Adams, J.; Yock, T.; Esty, B.; Fullerton, B.; Tarbell, N. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S579 EP S579 DI 10.1016/j.ijrobp.2007.07.1861 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201366 ER PT J AU Choi, NC Chun, T Ancukiewicz, M Niemierko, A Fidias, P Fischman, A AF Choi, N. C. Chun, T. Ancukiewicz, M. Niemierko, A. Fidias, P. Fischman, A. TI FDG uptake at sequential intervals after radiotherapy (RT) or RT of chemo-radiotherapy (CT plus RT) and its predictive value for tumor control probability (TCP) of metastatic lung cancer in regional lymph nodes SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Choi, N. C.; Chun, T.; Ancukiewicz, M.; Niemierko, A.; Fidias, P.; Fischman, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S494 EP S494 DI 10.1016/j.ijrobp.2007.07.1705 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201215 ER PT J AU Chute, CS Yock, T Johnson, J Esty, B Tarbell, N AF Chute, C. S. Yock, T. Johnson, J. Esty, B. Tarbell, N. TI Proton radiation therapy and the incidence of secondary malignancies SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Chute, C. S.] Harvard Radiat Oncol Program, Boston, MA USA. [Yock, T.; Johnson, J.; Esty, B.; Tarbell, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S178 EP S179 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200316 ER PT J AU Coen, JJ Efstathiou, IA Skowronski, RY Grocela, JA Hirsch, AE Zietman, AL AF Coen, J. J. Efstathiou, I. A. Skowronski, R. Y. Grocela, J. A. Hirsch, A. E. Zietman, A. L. TI Body mass index and PSA failure following brachytherapy for localized prostate cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Coen, J. J.; Efstathiou, I. A.; Skowronski, R. Y.; Grocela, J. A.; Zietman, A. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hirsch, A. E.] Boston Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S329 EP S330 DI 10.1016/j.ijrobp.2007.07.1401 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200589 ER PT J AU Craft, DL Halabi, T Bortfeld, T AF Craft, D. L. Halabi, T. Bortfeld, T. TI Multi-objective IMRT treatment planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Craft, D. L.; Halabi, T.; Bortfeld, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S658 EP S658 DI 10.1016/j.ijrobp.2007.07.2009 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201508 ER PT J AU D'Amico, AV Halabi, S Vollmer, R Loffredo, M McMahon, E Sanford, B Archer, L Vogelzang, NJ Small, E Kantoff, P AF D'Amico, A. V. Halabi, S. Vollmer, R. Loffredo, M. McMahon, E. Sanford, B. Archer, L. Vogelzang, N. J. Small, E. Kantoff, P. TI p53 protein expression status and recurrence in men treated with radiation therapy and androgen suppression therapy for higher risk prostate cancer: A prospective phase II cancer and leukemia group B study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Halabi, S.; Vollmer, R.; Sanford, B.; Archer, L.] Brigham & Womens Hosp Dana Farber, Boston, MA 02115 USA. [Halabi, S.; Vollmer, R.; Sanford, B.; Archer, L.] Duke Univ, Ctr Med, Durham, NC 27706 USA. [Vogelzang, N. J.] Nevada Prostate Canc Inst, Las Vegas, NV USA. [Small, E.] Univ San Francisco, San Francisco, CA 94117 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S333 EP S333 DI 10.1016/j.ijrobp.2007.07.1406 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200594 ER PT J AU Dosoretz, AM Court, LE Chen, AB Haglund, KE Petitt, JH Rodrigues, NA Blinder, RA Tishler, RB AF Dosoretz, A. M. Court, L. E. Chen, A. B. Haglund, K. E. Petitt, J. H. Rodrigues, N. A. Blinder, R. A. Tishler, R. B. TI Delineation of lymph node volumes in head and neck IMRT treatment planning: Consistency and variability among physicians SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Dosoretz, A. M.; Chen, A. B.; Haglund, K. E.; Petitt, J. H.; Rodrigues, N. A.] Harvard Radiat Oncol Program, Boston, MA USA. [Court, L. E.; Blinder, R. A.; Tishler, R. B.] Brigham & Womens Hosp, Boston, MA USA. [Blinder, R. A.; Tishler, R. B.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S204 EP S204 DI 10.1016/j.ijrobp.2007.07.369 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200359 ER PT J AU Efstathiou, JA Bae, K Shipley, WU Hanks, GE Pilepich, MV Sandler, HM Smith, MR AF Efstathiou, J. A. Bae, K. Shipley, W. U. Hanks, G. E. Pilepich, M. V. Sandler, H. M. Smith, M. R. TI Cardiovascular mortality following androgen deprivation therapy in men with locally advanced prostate cancer: An analysis of RTOG 85-31 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Efstathiou, J. A.] Harvard Radiat Onco Program, Boston, MA USA. [Bae, K.] Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Shipley, W. U.; Smith, M. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hanks, G. E.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Pilepich, M. V.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Sandler, H. M.] Univ Michigan, Sch Med, Ann Arbor, MI USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S170 EP S171 DI 10.1016/j.ijrobp.2007.07.309 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200302 ER PT J AU El-Din, MAA Feng, JK Niemierko, A Taghian, AG AF El-Din, M. A. Alm Feng, J. K. Niemierko, A. Taghian, A. G. TI Does omitting IMC irradiation reduce cardiac exposure for all breast cancer patients treated with Herceptin-Based chemotherapy? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [El-Din, M. A. Alm; Feng, J. K.; Niemierko, A.; Taghian, A. G.] Massachusetts Gen Hosp, HMS, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S138 EP S139 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200249 ER PT J AU Folken, MR Rebellol, GF Hornicek, FJ Pedlow, FX Mauceri, TC Chen, GTY DeLaney, TF AF Folken, M. R. Rebellol, G. F. Hornicek, F. J. Pedlow, F. X. Mauceri, T. C. Chen, G. T. Y. DeLaney, T. F. TI Status of intraoperative dural irradiation using customized (90)Yttrium brachytherapeutic plaques SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Folken, M. R.; Rebellol, G. F.; Hornicek, F. J.; Pedlow, F. X.; Mauceri, T. C.; Chen, G. T. Y.; DeLaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Folken, M. R.; Rebellol, G. F.; Hornicek, F. J.; Pedlow, F. X.; Mauceri, T. C.; Chen, G. T. Y.; DeLaney, T. F.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S MA 2968 BP S745 EP S745 DI 10.1016/j.ijrobp.2007.07.2302 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201651 ER PT J AU Gabeau-Lacet, D Yock, T Adams, J Fullerton, B Tarbell, N AF Gabeau-Lacet, D. Yock, T. Adams, J. Fullerton, B. Tarbell, N. TI Image guidance in whole ventricular irradiation treatment planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Gabeau-Lacet, D.] Harvard Radiat Oncol Program, Boston, MA USA. [Yock, T.; Adams, J.; Fullerton, B.; Tarbell, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S36 EP S37 DI 10.1016/j.ijrobp.2007.07.067 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200065 ER PT J AU Galper, SL Li, S Feng, Y Neuberg, D Silver, B Ng, AK Mauch, PM AF Galper, S. L. Li, S. Feng, Y. Neuberg, D. Silver, B. Ng, A. K. Mauch, P. M. TI Long-term risk of cardiac events requiring interventions in survivors of hodgkin's lymphoma (HL) treated with mediastinal irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Galper, S. L.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA. [Li, S.; Feng, Y.; Neuberg, D.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. [Silver, B.; Ng, A. K.; Mauch, P. M.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S MA 2637 BP S558 EP S558 DI 10.1016/j.ijrobp.2007.07.1817 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201323 ER PT J AU Garden, AS Tishler, RB Araschl, A Brennan, MT Harari, PM Kudrimoti, MR Schultz, CJ Brachman, DG Vera-Llonchv, M Keefe, D AF Garden, A. S. Tishler, R. B. Araschl, A. Brennan, M. T. Harari, P. M. Kudrimoti, M. R. Schultz, C. J. Brachman, D. G. Vera-Llonchv, M. Keefe, D. TI Adverse impact of mucositis on health related quality of life outcomes and resource use in head and neck cancer patients receiving radiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Garden, A. S.] MD Anderson Canc Ctr, Houston, TX USA. [Tishler, R. B.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Araschl, A.] Univ Alabama, Birmingham, AL USA. [Brennan, M. T.] Carolinas Med Ctr, Charlotte, NC 28203 USA. [Harari, P. M.] Univ Wisconsin, Ctr Canc, Madison, WI USA. [Kudrimoti, M. R.] Univ Kentucky, Lexington, KY USA. [Schultz, C. J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Brachman, D. G.] St Josephs Hosp, Phoenix, AZ USA. [Vera-Llonchv, M.] Policy Anal Inc, Brookline, MA USA. [Keefe, D.] Royal Adelaide Hosp, Adelaide, SA, Australia. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S179 EP S180 DI 10.1016/j.ijrobp.2007.07.325 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200317 ER PT J AU Godinez, J Gombos, EC Birdwel, RL AF Godinez, J. Gombos, E. C. Birdwel, R. L. TI Breast magnetic resonance imaging in patients with locally recurrent cancer after breast conservation therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Godinez, J.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Godinez, J.; Gombos, E. C.; Birdwel, R. L.] Dana Farber Canc Inst, Boston, MA USA. [Gombos, E. C.; Birdwel, R. L.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S219 EP S219 DI 10.1016/j.ijrobp.2007.07.1193 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200385 ER PT J AU Haglund, KE Goldberg, S Rosenberg, A Harmon, D Kirsch, D Hornicek, F Springfield, D Raskin, K Choy, E DeLaney, T AF Haglund, K. E. Goldberg, S. Rosenberg, A. Harmon, D. Kirsch, D. Hornicek, F. Springfield, D. Raskin, K. Choy, E. DeLaney, T. TI Percent necrosis in extremity soft tissue sarcoma after preoperative radiation alone versus preoperative radiation and chemotherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Haglund, K. E.; Goldberg, S.; Rosenberg, A.; Harmon, D.; Kirsch, D.; Hornicek, F.; Springfield, D.; Raskin, K.; Choy, E.; DeLaney, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S95 EP S95 DI 10.1016/j.ijrobp.2007.07.174 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200170 ER PT J AU Hijal, T Rajakesari, S Patel, S Muanza, T AF Hijal, T. Rajakesari, S. Patel, S. Muanza, T. TI Estrogen receptor status is a significant predictor of overall and brain metastasis-free survival in patients with breast cancer and brain metastases treated with Trastuzumab SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Hijal, T.; Rajakesari, S.; Muanza, T.] McGill Univ, Ctr Hlth, Montreal, PQ H3A 2T5, Canada. [Patel, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S218 EP S219 DI 10.1016/j.ijrobp.2007.07.1192 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200384 ER PT J AU Hirsch, AE Medich, DC Martel, CB Hirsch, JA AF Hirsch, A. E. Medich, D. C. Martel, C. B. Hirsch, J. A. TI Dosimetric analysis of a novel approach for the treatment of malignant compression fractures using beta emitting isotopes with vertebral augmentation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Hirsch, A. E.; Martel, C. B.] Boston Univ, Med Ctr, Boston, MA 02215 USA. [Hirsch, A. E.; Hirsch, J. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Medich, D. C.] Univ Massachusetts, Lowell, MA USA. RI Medich, David/B-6006-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S569 EP S569 DI 10.1016/j.ijrobp.2007.07.1841 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201346 ER PT J AU Hoffman, KE Abi-Raad, R Ancukiewicz, M Yeh, E Ryan, P Schapira, L Younger, J Smith, BL Kuter, I Taghian, AG AF Hoffman, K. E. Abi-Raad, R. Ancukiewicz, M. Yeh, E. Ryan, P. Schapira, L. Younger, J. Smith, B. L. Kuter, I. Taghian, A. G. TI Impact of interstitial fluid pressure,tumor oxygenation, and chemotherapy drug sequencing on response to neoadjuvant chemotherapy and on long-term local control in women treated for locally advanced breast cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Hoffman, K. E.; Abi-Raad, R.; Ancukiewicz, M.; Yeh, E.; Ryan, P.; Schapira, L.; Younger, J.; Smith, B. L.; Kuter, I.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S61 EP S62 DI 10.1016/j.ijrobp.2007.07.113 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200110 ER PT J AU Hughes, KS El-Din, MAA Betts, K Finkelstein, DM Aisenberg, AC Taghian, AG AF Hughes, K. S. El-Din, M. A. Alm Betts, K. Finkelstein, D. M. Aisenberg, A. C. Taghian, A. G. TI Breast cancer after supradiaphragtnatic irradiation for Hodgkin's disease; Risk analysis and possible surveillance strategies SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Hughes, K. S.; El-Din, M. A. Alm; Betts, K.; Finkelstein, D. M.; Aisenberg, A. C.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S27 EP S27 DI 10.1016/j.ijrobp.2007.07.049 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200048 ER PT J AU Hurwitz, ND Hansen, JL Prokopios-Davos, S Manola, J Hynynen, K Bornstein, BA Topulos, GP Kaplan, ID AF Hurwitz, N. D. Hansen, J. L. Prokopios-Davos, S. Manola, J. Hynynen, K. Bornstein, B. A. Topulos, G. P. Kaplan, I. D. TI Hyperthermia combined with radiation in treatment of locally advanced prostate cancer: Long-term results of DFCI 94-153 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Hurwitz, N. D.; Hansen, J. L.; Prokopios-Davos, S.; Manola, J.; Hynynen, K.; Bornstein, B. A.; Topulos, G. P.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. [Kaplan, I. D.] Beth Israel Deaconess Med Ctr, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S318 EP S318 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200569 ER PT J AU Kamat, UR McIntyre, JF Lin, DT Deschler, DG Chan, AW AF Kamat, U. R. McIntyre, J. F. Lin, D. T. Deschler, D. G. Chan, A. W. TI Neck management for node positive oropharyngeal carcinoma: A comparison of planned versus response-based neck dissection SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Kamat, U. R.; McIntyre, J. F.; Chan, A. W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Lin, D. T.; Deschler, D. G.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S MA 2408 BP S430 EP S430 DI 10.1016/j.ijrobp.2007.07.1584 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201097 ER PT J AU Knight, A Lee, SP Juillard, G Sayre, J Abelson, J McGibbon, B Sadeghi, A AF Knight, A. Lee, S. P. Juillard, G. Sayre, J. Abelson, J. McGibbon, B. Sadeghi, A. TI Predictors of non-compliance with radiotherapy among patients with squamous cell carcinoma of the head and neck treated at a veterans affairs hospital SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Knight, A.; Lee, S. P.; Juillard, G.; Sayre, J.; Abelson, J.; McGibbon, B.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Sadeghi, A.] W Los Angeles Vet Adm Hosp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S MA 2630 BP S554 EP S554 DI 10.1016/j.ijrobp.2007.07.1810 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201316 ER PT J AU Kozono, D Hutchinson, E Schneider, R Sharp, G Niemierko, A Wolfgang, J Doppke, K Choi, NC AF Kozono, D. Hutchinson, E. Schneider, R. Sharp, G. Niemierko, A. Wolfgang, J. Doppke, K. Choi, N. C. TI Impact of 4D CT planning for lung cancer on tumor control probability as a function of the extent of tumor motion with respiration SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Kozono, D.] Harvard Radiat Oncol Program, Boston, MA USA. [Hutchinson, E.; Schneider, R.; Sharp, G.; Niemierko, A.; Wolfgang, J.; Doppke, K.; Choi, N. C.] Harvard Univ, Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S496 EP S496 DI 10.1016/j.ijrobp.2007.07.1709 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201219 ER PT J AU Kuhnert, VM Kachnic, LA Li, L Purschke, M Lee, R Dunst, J Held, KD Willers, H AF Kuhnert, V. M. Kachnic, L. A. Li, L. Purschke, M. Lee, R. Dunst, J. Held, K. D. Willers, H. TI The role of FANCD2 in determining cellular resistance to ionizing radiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Kuhnert, V. M.; Dunst, J.] Univ Lubeck, Lubeck, Germany. [Kachnic, L. A.; Li, L.; Purschke, M.; Lee, R.; Held, K. D.; Willers, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Dunst, Juergen/D-2138-2010 NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S594 EP S595 DI 10.1016/j.ijrobp.2007.07.1894 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201398 ER PT J AU Lawton, CA Michalski, J El-Naqa, I Kuban, D Lee, WR Rosenthal, S Zietman, A Sandler, H Roach, M AF Lawton, C. A. Michalski, J. El-Naqa, I. Kuban, D. Lee, W. R. Rosenthal, S. Zietman, A. Sandler, H. Roach, M. TI Variation in the definition of clinical target volumes for pelvic node conformal radiation therapy of prostate cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Lawton, C. A.] Med Coll Wisconsin, Milwaukee, WI USA. [Michalski, J.] Mallinckrodth Inst Radiol, St Louis, MO USA. [El-Naqa, I.] Washington Univ, St Louis, MO 63130 USA. [Kuban, D.] MD Anderson Canc Ctr, Houston, TX USA. [Lee, W. R.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Rosenthal, S.] Roseville Radiat Oncol Ctr, Roseville, NSW, Australia. [Zietman, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sandler, H.] Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA. [Roach, M.] Univ San Francisco, Ctr Comprehens Canc, San Francisco, CA 94117 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S327 EP S327 DI 10.1016/j.ijrobp.2007.07.1396 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200584 ER PT J AU Li, XA Arthur, DW Buchholz, TA MacDonald, S Marks, LB Pierce, LJ Taghian, AG Vicini, FA Woodward, VA White, JA AF Li, X. A. Arthur, D. W. Buchholz, T. A. MacDonald, S. Marks, L. B. Pierce, L. J. Taghian, A. G. Vicini, F. A. Woodward, V. A. White, J. A. TI Variability of target and normal structure delineation for breast-cancer radiotherapy: A RTOG multi-institutional and multi-observer study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Li, X. A.; White, J. A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Arthur, D. W.] Virginia Commonwealth Univ, Richmond, VA USA. [Buchholz, T. A.; Woodward, V. A.] MD Anderson Canc Ctr, Houston, TX USA. [MacDonald, S.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Marks, L. B.] Duke Univ, Durham, NC USA. [Pierce, L. J.] Univ Michigan, Ann Arbor, MI 48109 USA. [Vicini, F. A.] William Beaumont Hosp, Royal Oak, MI 48072 USA. RI White, Julia/J-6336-2014 NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S72 EP S73 DI 10.1016/j.ijrobp.2007.07.131 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200128 ER PT J AU Lu, H MacDonald, SM Paetzold, P Beatty, J Adams, J Taghian, A AF Lu, H. MacDonald, S. M. Paetzold, P. Beatty, J. Adams, J. Taghian, A. TI The potential for proton beam radiation for post mastectomy radiation in patients with unfavorable cardiac anatomy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Lu, H.; MacDonald, S. M.; Paetzold, P.; Beatty, J.; Adams, J.; Taghian, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S219 EP S220 DI 10.1016/j.ijrobp.2007.07.1194 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200386 ER PT J AU Luthy, SK Ng, AK Freedman, AS Silver, B Mauch, PM AF Luthy, S. K. Ng, A. K. Freedman, A. S. Silver, B. Mauch, P. M. TI Response to low-dose involved-field radiotherapy (LD-IF-RT) in patients with non-Hodgkin's lymphoma (NHL) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Luthy, S. K.; Ng, A. K.; Silver, B.; Mauch, P. M.] Brigham & Womens Hosp, Dana Faber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Freedman, A. S.] Dana Faber Canc Inst, Dept Adult Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S532 EP S532 DI 10.1016/j.ijrobp.2007.07.1770 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201278 ER PT J AU MacDonald, SI El-Din, MAA Smith, BL Gadd, MA Ancukiewicz, M Powell, S Taghian, AG AF MacDonald, S. I. El-Din, M. A. Alm Smith, B. L. Gadd, M. A. Ancukiewicz, M. Powell, S. Taghian, A. G. TI Low-dose-rate interstitial implants for early stage breast cancer: Outcomes and late toxicity of a dose escalation study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [MacDonald, S. I.; El-Din, M. A. Alm; Smith, B. L.; Gadd, M. A.; Ancukiewicz, M.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Powell, S.] Washington Univ, St Louis, MO 63130 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S144 EP S144 DI 10.1016/j.ijrobp.2007.07.264 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200258 ER PT J AU Mamon, HJ Hader, C Kulkez, MH Lie, J Wang, L Roper, K Killion, L Makrigiorgos, GM AF Mamon, H. J. Hader, C. Kulkez, M. H. Lie, J. Wang, L. Roper, K. Killion, L. Makrigiorgos, G. M. TI Whole genome amplification permits the detection of circulating tumor-derived K-ras mutations in the plasma of patients treated with radiation therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Mamon, H. J.; Roper, K.; Killion, L.; Makrigiorgos, G. M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. [Hader, C.; Kulkez, M. H.; Lie, J.; Wang, L.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S65 EP S65 DI 10.1016/j.ijrobp.2007.07.119 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200116 ER PT J AU Manin, NE Chen, M Catalona, WJ Loeb, S Roehl, KA D'Amico, AV AF Manin, N. E. Chen, M. Catalona, W. J. Loeb, S. Roehl, K. A. D'Amico, A. V. TI The influence of serial prostate-specific antigen screening on the pre-diagnostic PSA velocity level at diagnosis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Manin, N. E.] Harvard Univ, Radiat Oncol Program, Boston, MA 02115 USA. [Chen, M.] Univ Connecticut, Storrs, CT USA. [Catalona, W. J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Loeb, S.] Georgetown Univ, Sch Med, Washington, DC USA. [Roehl, K. A.] Washington Univ, Sch Med, St Louis, MO USA. [D'Amico, A. V.] Brigham & Womens Hosp, Boston, MA 02115 USA. [D'Amico, A. V.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S90 EP S90 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200160 ER PT J AU Moody, JS Kozak, KR Vapiwala, N Plastaras, JP AF Moody, J. S. Kozak, K. R. Vapiwala, N. Plastaras, J. P. TI Stage-specific survival benefit of postoperative radiation therapy for cancers of the rectosigmoid junction SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Moody, J. S.] Univ Alabama, Med Ctr, Birmingham, AL 35294 USA. [Kozak, K. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Vapiwala, N.; Plastaras, J. P.] Univ Penn, Philadelphia, PA 19104 USA. RI Vapiwala, Neha/A-5445-2010 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S267 EP S267 DI 10.1016/j.ijrobp.2007.07.1288 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200478 ER PT J AU Mori, S Lu, H Wolfgang, J Choi, NC Chen, GTY AF Mori, S. Lu, H. Wolfgang, J. Choi, N. C. Chen, G. T. Y. TI Effects of interfractional changes on range in heavy charged particle radiotherapy of lung cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Mori, S.; Lu, H.; Wolfgang, J.; Choi, N. C.; Chen, G. T. Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S MA 2843 BP S670 EP S671 DI 10.1016/j.ijrobp.2007.07.2027 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201526 ER PT J AU Mori, S Chen, GTY Endo, M AF Mori, S. Chen, G. T. Y. Endo, M. TI Effects of intrafractional motion on water equivalent path length in respiratory-gated heavy charged particle beam radiotherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Mori, S.; Chen, G. T. Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Endo, M.] Natl Inst Radiol Sci, Chiba, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S651 EP S651 DI 10.1016/j.ijrobp.2007.07.1997 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201496 ER PT J AU Mutyala, S Khan, AJ Stewart, AJ Connack, RA O'Farrell, DA Bueno, R Baldini, EH Sugarbaker, DJ Devlin, PM AF Mutyala, S. Khan, A. J. Stewart, A. J. Connack, R. A. O'Farrell, D. A. Bueno, R. Baldini, E. H. Sugarbaker, D. J. Devlin, P. M. TI Outcomes of I-125 interstitial planar seed brachytherapy for close or positive margins for thoracic malignancies SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Mutyala, S.] Montefiore Med Ctr, Bronx, NY USA. [Khan, A. J.; Connack, R. A.; O'Farrell, D. A.; Bueno, R.; Baldini, E. H.; Sugarbaker, D. J.; Devlin, P. M.] Albert Einstein Coll Med, Bronx, NY USA. [Khan, A. J.; Connack, R. A.; O'Farrell, D. A.; Bueno, R.; Baldini, E. H.; Sugarbaker, D. J.; Devlin, P. M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Khan, A. J.; Connack, R. A.; O'Farrell, D. A.; Bueno, R.; Baldini, E. H.; Sugarbaker, D. J.; Devlin, P. M.] Harvard Med Sch, Boston, MA USA. [Stewart, A. J.] Royal Marsden Hosp, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S162 EP S162 DI 10.1016/j.ijrobp.2007.07.292 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200286 ER PT J AU Ng, AK Li, S Fisher, DC Silver, B Mauch, PM AF Ng, A. K. Li, S. Fisher, D. C. Silver, B. Mauch, P. M. TI A prospective study of pulmonary function in Hodgkin's lymphoma patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Ng, A. K.; Silver, B.; Mauch, P. M.] Brigham & Womens Hosp, Dana Faber Canc Inst, Boston, MA 02115 USA. [Li, S.; Fisher, D. C.] Dana Faber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S531 EP S532 DI 10.1016/j.ijrobp.2007.07.1769 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201277 ER PT J AU Nguyen, PL Taghian, AG Katz, MS Niemierko, A Raad, RFA Boon, WL Bellon, JR Wong, JS Smith, BL Haris, JR AF Nguyen, P. L. Taghian, A. G. Katz, M. S. Niemierko, A. Raad, R. F. Abi Boon, W. L. Bellon, J. R. Wong, J. S. Smith, B. L. Haris, J. R. TI Breast cancer subtype approximated by ER, PR, and Her2 receptors is associated with local-regional and distant failure after breast-conserving therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Nguyen, P. L.] Harvard Radiat Oncol Progam, Boston, MA USA. [Taghian, A. G.; Katz, M. S.; Niemierko, A.; Raad, R. F. Abi; Smith, B. L.] Massachusetts Gen Hosp, Boston, MA USA. [Boon, W. L.; Bellon, J. R.; Wong, J. S.; Haris, J. R.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S26 EP S26 DI 10.1016/j.ijrobp.2007.07.047 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200046 ER PT J AU Parikh, PJ Bae, K Hanks, CE Shipley, WU Pilepichs, MV Sandler, HM AF Parikh, P. J. Bae, K. Hanks, Cr. E. Shipley, W. U. Pilepichs, M. V. Sandler, H. M. TI The influence of age as a predictor of outcome in prostate cancer patients treated on RTOG trials SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Parikh, P. J.] Washington Univ, Sch Med, St Louis, MO USA. [Bae, K.] Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Hanks, Cr. E.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Shipley, W. U.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pilepichs, M. V.] Univ Calif Los Angeles, Los Angeles, CA USA. [Sandler, H. M.] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S175 EP S175 DI 10.1016/j.ijrobp.2007.07.318 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200310 ER PT J AU Patel, AA Chen, M Renshaw, AA D'Amico, AV AF Patel, A. A. Chen, M. Renshaw, A. A. D'Amico, A. V. TI Tertiary Gleason grade 5 on prostate needle biopsy and recurrence following definitive therapy in men with Gleason score 7 prostate cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Patel, A. A.; D'Amico, A. V.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, M.] Univ Connecticut, Storrs, CT USA. [Renshaw, A. A.] Brigham & Womens Hosp, Baptist Hosp Miami, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S91 EP S91 DI 10.1016/j.ijrobp.2007.07.166 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200162 ER PT J AU Patrice, JR Patrice, SJ Hayman, JA Steinberg, JS Taghian, AG AF Patrice, J. R. Patrice, S. J. Hayman, J. A. Steinberg, J. S. Taghian, A. G. TI Cost-effectiveness of routine radiation therapy when added to tamoxifen following conservative surgery in older women with early-stage breast cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Patrice, J. R.] Ctr Oncol Decis Sci & Econ Evaluat, Osprey, FL USA. [Patrice, S. J.] Radiat Therapy Serv, Ft Myers, FL USA. [Hayman, J. A.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Steinberg, J. S.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S91 EP S92 DI 10.1016/j.ijrobp.2007.07.167 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200163 ER PT J AU Randolph, GW Thompson, GB Branovan, DI Tuttle, RM AF Randolph, Gregory W. Thompson, Geoffrey B. Branovan, Daniel Igor Tuttle, R. Michael TI Treatment of thyroid cancer: 2007 - A basic review SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT 1st Multidisciplinary Head and Neck Cancer Symposium CY JAN 18-20, 2007 CL Rancho Mirage, CA SP Amer Soc Therapeut Radiol & Oncol, Amer Soc Clin Oncol, Amer Head & Neck Soc ID MANAGEMENT; CARCINOMA; GUIDELINES; THERAPY; AUTOPSY; TRENDS C1 Massachusetts Gen Hosp, Massachusetts Eye & Ear Infirm, Endocrinol Surg Serv, Thyroid & Parathyroid Surg Div, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Mayo Clin, Coll Med, Rochester, MN USA. New York Eye & Ear Infirm, New York, NY 10003 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RP Randolph, GW (reprint author), Massachusetts Gen Hosp, Massachusetts Eye & Ear Infirm, Endocrinol Surg Serv, Thyroid & Parathyroid Surg Div, 243 Charles St, Boston, MA 02114 USA. EM gregory_randolph@meei.harvard.edu NR 20 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 2 SU S BP S92 EP S97 DI 10.1016/j.ijrobp.2007.06.027 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 218EO UT WOS:000249999000027 PM 17848306 ER PT J AU Ray, ME Bae, K Hussain, MHA Hanks, GE Shipley, WU Sandler, HM AF Ray, M. E. Bae, K. Hussain, M. H. A. Hanks, G. E. Shipley, W. U. Sandler, H. M. TI Surrogate endpoints for prostate cancer survival: A secondary analysis of RTOG 9202 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Ray, M. E.] Radiol Assoc Appleton, Appleton, WI USA. [Bae, K.] Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Hussain, M. H. A.; Sandler, H. M.] Univ Michigan, Ann Arbor, MI 48109 USA. [Hanks, G. E.] Fox Chase Canc Ctr, Philadelphia, PA USA. [Shipley, W. U.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S81 EP S82 DI 10.1016/j.ijrobp.2007.07.147 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200144 ER PT J AU Riboldi, M Book, LN Chen, GTY Taghian, AG Baroni, G Gierga, DP AF Riboldi, M. Book, L. N. Chen, G. T. Y. Taghian, A. G. Baroni, G. Gierga, D. P. TI Statistical studies of interfractional pose variations due to elastic deformations in IMRT treatment of prostate SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut Radiol & Oncol C1 [Riboldi, M.; Book, L. N.] MIT, Cambridge, MA 02139 USA. [Riboldi, M.; Chen, G. T. Y.; Taghian, A. G.; Gierga, D. P.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA. [Baroni, G.] Politecn Milano Univ, Milan, Italy. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S669 EP S670 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201524 ER PT J AU Riboldi, M Book, LN Chen, GTY Taghian, AG Baroni, G Gierga, DP AF Riboldi, M. Book, L. N. Chen, G. T. Y. Taghian, A. G. Baroni, G. Gierga, D. P. TI Quantitative assessment of surface deformation in accelerated partial breast irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut Radiol & Oncol C1 [Riboldi, M.; Book, L. N.] MIT, Cambridge, MA 02139 USA. [Riboldi, M.; Chen, G. T. Y.; Taghian, A. G.; Gierga, D. P.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. [Baroni, G.] Politecn Milano Univ, Milan, Italy. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S669 EP S669 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201523 ER PT J AU Sher, DJ Wittenberg, E Punglia, R AF Sher, D. J. Wittenberg, E. Punglia, R. TI Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: A decision analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Sher, D. J.] Harvard Univ, Radiat Oncol Program, Boston, MA 02115 USA. [Wittenberg, E.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Punglia, R.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S92 EP S92 DI 10.1016/j.ijrobp.2007.07.168 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200164 ER PT J AU Shipley, YU Bae, K Efstathiou, JA Kaufman, DS Hagan, MP Sandler, HM AF Shipley, Yv. U. Bae, K. Efstathiou, J. A. Kaufman, D. S. Hagan, M. P. Sandler, H. M. TI Late pelvic toxicity following bladder-sparing therapy in patients with invasive bladder cancer: Analysis of RTOG 89-03, 95-06, 97-06, 99-06 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Shipley, Yv. U.; Kaufman, D. S.] Massachusetts Gen Hosp, Boston, MA USA. [Bae, K.] Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Efstathiou, J. A.] Harvard Radiat Oncol Program, Boston, MA USA. [Hagan, M. P.] Virginia Commonwealth Univ, Richmond, VA USA. [Sandler, H. M.] Univ Michigan, Sch Med, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S8 EP S8 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200015 ER PT J AU Suh, WW Chen, M Nguyen, PL Tempany, CM Steele, GS Albert, M Cormack, R Carr-Locke, DL Bleday, R D'Amico, AV AF Suh, W. W. Chen, M. Nguyen, P. L. Tempany, C. M. Steele, G. S. Albert, M. Cormack, R. Carr-Locke, D. L. Bleday, R. D'Amico, A. V. TI Magnetic resonance image guided salvage Brachytherapy following radiation in select men who initially presented with favorable-risk prostate cancer: A prospective phase II study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Suh, W. W.; Nguyen, P. L.; Albert, M.; Cormack, R.; D'Amico, A. V.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Chen, M.] Univ Connecticut, Storrs, CT 06269 USA. [Tempany, C. M.; Steele, G. S.; Carr-Locke, D. L.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S323 EP S323 DI 10.1016/j.ijrobp.2007.07.1389 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200577 ER PT J AU Valicenti, RK Bae, K Michalski, J Cox, J Shipley, W Sandler, H AF Valicenti, R. K. Bae, K. Michalski, J. Cox, J. Shipley, W. Sandler, H. TI Does adjuvant hormonal therapy improve freedom from biochemical relapse in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of RTOG 94-06 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Valicenti, R. K.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Bae, K.] Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Michalski, J.] Washington Univ, St Louis, MO USA. [Cox, J.] MD Anderson Canc Ctr, Houston, TX USA. [Shipley, W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sandler, H.] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S171 EP S171 DI 10.1016/j.ijrobp.2007.07.310 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200303 ER PT J AU Wilson, VC Claghorn, K Guo, M Hampshire, M O'Dwyer, P Sun, W Drebin, J Rosato, E Whittington, R Metz, JM AF Wilson, V. C. Claghorn, K. Guo, M. Hampshire, M. O'Dwyer, P. Sun, W. Drebin, J. Rosato, E. Whittington, R. Metz, J. M. TI Aggressive supportive care improves outcomes in the combined modality treatment of pancreatic and duodenal cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Wilson, V. C.; Claghorn, K.; Guo, M.; Hampshire, M.; O'Dwyer, P.; Sun, W.; Drebin, J.; Rosato, E.; Metz, J. M.] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Whittington, R.] Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S278 EP S279 DI 10.1016/j.ijrobp.2007.07.1309 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950200499 ER PT J AU Winkfield, KM Shih, HA Niemierko, A Bussiere, MR Crowley, EM Beaudette, KP Pope, CJ Loeffler, JS AF Winkfield, K. M. Shih, H. A. Niemierko, A. Bussiere, M. R. Crowley, E. M. Beaudette, K. P. Pope, C. J. Loeffler, J. S. TI Second tumor risk with modern radiotherapy for pituitary adenomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Winkfield, K. M.] Harvard Radiat Oncol Program, Boston, MA USA. [Winkfield, K. M.; Shih, H. A.; Niemierko, A.; Bussiere, M. R.; Crowley, E. M.; Beaudette, K. P.; Pope, C. J.; Loeffler, J. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S701 EP S701 DI 10.1016/j.ijrobp.2007.07.2078 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201576 ER PT J AU Yock, TI MacDonald, SM Safai, S Wolfgang, JA Fullerton, B Trofimov, A Bortfeld, TR Tarbell, NJ AF Yock, T. I. MacDonald, S. M. Safai, S. Wolfgang, J. A. Fullerton, B. Trofimov, A. Bortfeld, T. R. Tarbell, N. J. TI Proton radiotherapy for ependymoma: Initial clinical outcomes and dose comparisons for intensity modulated radiation with photons, proton radiation, and intensity modulated proton therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Yock, T. I.; MacDonald, S. M.; Safai, S.; Wolfgang, J. A.; Fullerton, B.; Trofimov, A.; Bortfeld, T. R.; Tarbell, N. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S BP S575 EP S576 DI 10.1016/j.ijrobp.2007.07.1855 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201360 ER PT J AU Yu, DS Zhuang, J Nam, E Willers, H Xia, F AF Yu, D. S. Zhuang, J. Nam, E. Willers, H. Xia, F. TI Exonuclease activity is essential for Mre11 in controlling microhomology mediated end joining of DNA double-strand breaks SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut & Oncol C1 [Yu, D. S.; Zhuang, J.; Nam, E.; Xia, F.] Vanderbilt Univ, Ctr Med, Nashville, TN USA. [Willers, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2007 VL 69 IS 3 SU S MA 2720 BP S598 EP S599 DI 10.1016/j.ijrobp.2007.07.1902 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 217LU UT WOS:000249950201406 ER PT J AU Krzyzanowska, MK Earle, CC Kuntz, KM Weeks, JC AF Krzyzanowska, Monika K. Earle, Craig C. Kuntz, Karen M. Weeks, Jane C. TI Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT 24th Annual Meeting of the Society-for-Medical-Decision-Making CY OCT 19-23, 2002 CL BALTIMORE, MD SP Soc Med Decis Making DE pancreas cancer; radiation; fluorouracil; gemcitabine; cost-effectiveness analysis ID PHASE-I TRIAL; TWICE-WEEKLY GEMCITABINE; COST-EFFECTIVENESS; GASTROINTESTINAL CANCER; CONCURRENT RADIATION; RANDOMIZED-TRIAL; CARCINOMA; CARE; ADENOCARCINOMA; 5-FLUOROURACIL AB Purpose: Development of new and expensive drugs with activity against pancreatic cancer has made economic considerations more relevant to treatment decision-making for advanced disease. Economic modeling can be used to explore the potential of such novel therapies and to inform clinical trial design. Methods and Materials: We developed a Markov model to evaluate the cost-effectiveness of radiation plus fluorouracil (RT-FU) relative to no treatment in elderly patients with locally advanced pancreatic cancer (LAPC) and to determine the economic potential of radiation plus gemcitabine (RT-GEM), a novel regimen for this disease. We used the SEER-Medicare database to estimate effectiveness and costs supplemented by data from the literature where necessary. Results: Relative to no treatment, RT-FU was associated with a cost-effectiveness ratio (ICER) of $68,724/QALY in the base case analysis. Compared with RT-FU, the ICER for RT-GEM was below $100,000/QALY when the risk of dying with the new regimen was < 85% than with the standard regimen. However, > 1,000 subjects would be necessary to demonstrate this level of efficacy in a randomized trial. The ICER of RT-GEM was most sensitive to utility values, and, at lower efficacy levels, to costs of gemcitabine and treatment-related toxicity. Conclusions: In elderly patients with LAPC, RT-FU is a cost-effective alternative to no treatment. The novel regimen of RT-GEM is likely to be cost-effective at any clinically meaningful benefit, but quality-of-life issues, drug acquisition, and toxicity-related costs may be relevant, especially at lower efficacy levels. (c) 2007 Elsevier Inc. C1 Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada. Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. RP Krzyzanowska, MK (reprint author), Princess Margaret Hosp, Dept Med Oncol & Hematol, 610 Univ Ave,Suite 5-227, Toronto, ON M5G 2M9, Canada. EM monika.krzyzanowska@uhn.on.ca NR 30 TC 16 Z9 16 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2007 VL 67 IS 1 BP 211 EP 218 DI 10.1016/j.ijrobp.2006.07.1390 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 123JK UT WOS:000243292000030 PM 17189071 ER PT J AU Holodniy, M Hornberger, J Rapoport, D Robertus, K MaCurdy, TE Lopez, J Volberding, P Deyton, L AF Holodniy, Mark Hornberger, John Rapoport, Dana Robertus, Katherine MaCurdy, Thomas E. Lopez, Jude Volberding, Paul Deyton, Lawrence TI Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004) SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE antiretroviral; epidemiology; guidelines; HIV; patient safety; regional variation; veterans ID HIV-INFECTED PATIENTS; UNITED-STATES; PROTEASE INHIBITORS; TREATMENT DECISIONS; CLINICAL-PRACTICE; THERAPY; RECOMMENDATIONS; ADHERENCE; PANEL; AIDS AB To analyze temporal patterns of antiretroviral (ARV) prescribing practices relative to nationally defined guidelines in treatment-naive patients with HIV-1 infection. Design: Retrospective cohort study. Methods: We evaluated ARV prescribing patterns among ARV treatment-naive veterans who were receiving care within the US Department of Veterans Affairs (VA) from 1992 through 2004 in comparison to evolving adult HIV-1 treatment guidelines. Results: A total of 15,934 patients initiated ARV treatment. Since 1999, > 94% of patients initiated at least a 3-ARV medication combination, although the percentage of patients who initiated a guideline "preferred" or "alternative" regimen never rose to greater than 72% and was significantly associated with being black and with region of care. After 1999, 20% of patients started 4 or more active ARV agents in combination, which was significantly associated with lower baseline CD4 cell count, higher viral load, and receiving care in the western United States. The proportion of patients receiving guideline "not recommended" regimens (virologically undesirable or overlapping toxicities) was < 1% after 1997. VA prescribing trends generally predated guideline recommendations by 6 to 12 months. Conclusions: VA prescribing patterns for ARV initiation adhere to treatment guidelines that maximize safety. Guidelines designed to maximize efficacy were not followed as stringently. Evaluating clinical practice patterns against contemporary treatment guidelines can inform guideline development. C1 Vet Affairs Palo Alto Hlth Care Syst, AIDS Res Ctr, Palo Alto, CA 94304 USA. Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA. Publ Hlth Strateg Hlth Care Grp, Vet Hlth Adm, Washington, DC USA. Acumen LLC, SPHERE Inst, Burlingame, CA USA. Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. RP Holodniy, M (reprint author), Vet Affairs Palo Alto Hlth Care Syst, AIDS Res Ctr, 3801 Miranda Ave 132, Palo Alto, CA 94304 USA. EM mark.holodniy@med.va.gov NR 48 TC 20 Z9 20 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2007 VL 44 IS 1 BP 20 EP 29 DI 10.1097/01.qai.0000248354.63748.54 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 121XD UT WOS:000243189400004 PM 17091020 ER PT J AU Robbins, GK Daniels, B Zheng, H Chueh, H Meigs, JB Freedberg, KA AF Robbins, Gregory K. Daniels, Brock Zheng, Hui Chueh, Henry Meigs, James B. Freedberg, Kenneth A. TI Predictors of antiretroviral treatment failure in an urban HIV clinic SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE adherence; antiretroviral therapy; electronic health record; HIV; treatment failure; virologic failure ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH INFORMATION-TECHNOLOGY; SELF-REPORTED ADHERENCE; VIROLOGICAL FAILURE; HEPATITIS-C; PROTEASE INHIBITORS; INFECTED PATIENTS; IMMUNOLOGICAL RESPONSE; CONTAINING REGIMENS; DRUG-THERAPY AB Background: Predictors of antiretroviral treatment (ART) failure are not well characterized for heterogeneous clinic populations. Methods: A retrospective analysis was conducted of HIV-infected patients followed in an urban HIV clinic with an HIV RNA measurement <= 400 copies/mL on ART between January 1, 2003, and December 31, 2004. The primary endpoint was treatment failure, defined as virologic failure (>= 1 HIV RNA measurement > 400 copies/mL), unsanctioned stopping of ART, or loss to follow-up. Prior ART adherence and other baseline patient characteristics, determined at the time of the first suppressed HIV RNA load on or after January 1, 2003, were extracted from the electronic health record (EHR). Predictors of failure were assessed using proportional hazards modeling. Results: Of 829 patients in the clinic, 614 had at least I HIV RNA measurement :! 400 copies/mL during the study period. Of these, 167 (27.2%) experienced treatment failure. Baseline characteristics associated with treatment failure in the multivariate model were: poor adherence (hazard ratio [HR] = 3.44; 95% confidence interval [Cl]: 2.34 to 5.05), absolute neutrophil count < 1000/mm(3) (HR 2.90, 95% Cl: 1.26 to 6.69), not suppressed on January 1, 2003 (HR 2.69, 95% Cl: 1.78 to 4.07) or < 12 months of suppression (HR 1.64, 95% Cl: 1.10 to 2.45), CD4 count < 200 cells/mm(3) (HR = 1.90, 95% Cl: 1.31 to 2.76), nucleoside-only regimen (HR = 1.75, 95% Cl: 1.08 to 2.82), prior virologic failure (HR = 1.70, 95% Cl: 1.22 to 2.39) and >= 1 missed visit in the prior year (HR = 1.56, 95% CI: 1.13 to 2.16). Conclusions: More than one quarter of patients in a heterogeneous clinic population had treatment failure over a 2-year period. Prior ART adherence and other EHR data readily identify patient characteristics that could trigger specific interventions to improve ART outcomes. C1 Harvard Univ, Ctr AIDS Res, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. Harvard Univ, CFAR, Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, CFAR, Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02115 USA. RP Robbins, GK (reprint author), Harvard Univ, Ctr AIDS Res, Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,Cox 506, Boston, MA 02114 USA. EM grobbins@partners.org RI Robbins, Gregory/F-7988-2011 FU NIAID NIH HHS [K24 AI062476, P30AI60354, K01AI062435, K01 AI062435-03, P30 AI060354-03, K24AI062476, K24 AI062476-01, K01 AI062435, P30 AI060354] NR 50 TC 44 Z9 46 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2007 VL 44 IS 1 BP 30 EP 37 DI 10.1097/01.qai.0000248351.10383.b7 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 121XD UT WOS:000243189400005 PM 17106280 ER PT J AU Tien, PC Schneider, MF Cole, SR Justman, JE French, AL Young, M DeHovitz, J Nathwani, N Brown, TT AF Tien, Phyllis C. Schneider, Michael F. Cole, Stephen R. Justman, Jessica E. French, Audrey L. Young, Mary DeHovitz, Jack Nathwani, Niyati Brown, Todd T. TI Relation of stavudine discontinuation to anthropometric changes among HIV-infected women SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE anthropometry; antiretroviral therapy; HIV; lipoatrophy; stavudine ID ACTIVE ANTIRETROVIRAL THERAPY; INTERAGENCY HIV; LIPOATROPHY; ABACAVIR; SUBSTITUTION; 48-WEEK; FAT AB Objective: To characterize changes associated with stavudine exposure and Design: Seven hundred thirty-four reported using stavudine (574 of whom later discontinued stavudine) and 698 HIV-infected participants HIV Study provided anthropometrics between July 1999 and March 2005. Methods: Changes in weight, waist, midthigh circumferences were evaluated generalized estimating equations. Results: HIV-uninfected women demonstrated decreases in weight and circumferences of the waist, chest, hip, and thigh. A smaller annual decrease in hip circumference was seen after discontinuing stavudine for > 2.25 years compared with the decrease observed while on stavudine (P = 0.01). Discontinuing stavudine for > 2.25 years was associated with smaller (P < 0.05) decreases in hip (-0.06 cm/y) and thigh (-0.005 cm/y) circumference compared with the decreases observed between 1 and 2.25 years (hip: -0.46 cm/y, thigh: -0.24 cm/y) or : l year (hip: -0.64 cm/y, thigh: -0.27 cm/y) after stavudine discontinuation. Conclusions: Regardless of continuing or discontinuing stavudine, HIV-infected women demonstrate decreases in weight and body circumference measurements over time. The lower limb seems to be most affected by stavudine exposure, with stabilization observed more than 2 years after discontinuation. C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Infect Dis Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA. Columbia Univ, Dept Epidemiol, New York, NY 10027 USA. Columbia Univ, Dept Med, New York, NY 10027 USA. Stroger Hosp Cook Cty, CORE Ctr, Chicago, IL USA. Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA. Univ So Calif, Dept Med, Los Angeles, CA 90033 USA. Johns Hopkins Univ, Dept Med, Baltimore, MD 21218 USA. RP Tien, PC (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Infect Dis Sect, 111W 4150 Clement St, San Francisco, CA 94121 USA. EM ptien@ucsf.edu FU NCRR NIH HHS [M01-RR00083, M01-RR00079]; NIAID NIH HHS [U01-AI-42590, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-35004, U01-AI-34993]; NICHD NIH HHS [U01-HD-32632] NR 21 TC 15 Z9 15 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2007 VL 44 IS 1 BP 43 EP 48 DI 10.1097/01.qai.0000248353.56125.43 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 121XD UT WOS:000243189400007 PM 17091021 ER PT J AU Hess, DR AF Hess, Dean R. TI The mask for noninvasive ventilation: Principles of design and effects on aerosol delivery SO JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG LA English DT Article; Proceedings Paper CT Conference on Aerosol Delivery via Facemask and Other Interfaces CY MAR 11, 2006 CL Miami, FL SP Int Soc Aerosols Med DE aerosol therapy; mechanical ventilation; metered dose inhaler; nebulizer; noninvasive ventilation ID POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE PULMONARY-DISEASE; ACUTE RESPIRATORY-FAILURE; MECHANICAL VENTILATION; SUPPORT VENTILATION; FACE MASK; PHYSIOLOGICAL EVALUATION; HEATED HUMIDIFICATION; ACUTE EXACERBATION; CONTROLLED-TRIAL AB There has been much clinical and academic interest in the use of noninvasive positive-pressure ventilation (NPPV) in patients with acute and chronic respiratory failure. The use of NPPV in appropriately selected patients improves survival and decreases the need for endotracheal intubation. The most commonly used interfaces for NPPV are nasal masks or oronasal masks, but nasal pillows, mouthpieces, total face masks, and helmets can also be used. Critical care ventilators, portable volume ventilators, and ventilators designed specifically for NPPV can be used. There are three options for aerosol delivery during NPPV. The patient can be removed from NPPV and the aerosol administered by nebulizer or MDI in the standard manner, the aerosol can be delivered by nebulizer placed in-line between the circuit and the mask, or a spacer chamber can be placed between the circuit and the mask. There is presently no commercially available system designed specifically for aerosol delivery during NPPV with a bilevel (BiPAP) ventilator. However, in vitro and in vivo studies have demonstrated that a significant amount of bronchodilator can be administered by in-line nebulizer or MDI during NPPV. The evidence base for aerosol delivery during NPPV is not nearly as mature as the evidence for aerosol delivery during invasive mechanical ventilation. With NPVV, issues related to the optimal interface, ventilator settings, and aerosol generator (nebulizer versus MDI) are largely unexplored. C1 Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Anesthesia, Cambridge, MA 02138 USA. RP Hess, DR (reprint author), Massachusetts Gen Hosp, Dept Resp Care, Ellison 401, Boston, MA 02114 USA. EM dhess@partners.org NR 41 TC 29 Z9 29 U1 1 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0894-2684 J9 J AEROSOL MED JI J. Aerosol Med.-Depos. Clear. Eff. Lung PY 2007 VL 20 SU 1 BP S85 EP S98 DI 10.1089/jam.2007.0574 PG 14 WC Public, Environmental & Occupational Health; Respiratory System SC Public, Environmental & Occupational Health; Respiratory System GA 156ES UT WOS:000245631500016 PM 17411410 ER PT J AU Claassen, CA Trivedi, MH Rush, AJ Husain, MM Zisook, S Young, E Leuchter, A Wisniewski, SR Balasubramani, GK Alpert, J AF Claassen, Cynthia A. Trivedi, Madhukar H. Rush, A. John Husain, Mustafa M. Zisook, Sidney Young, Elizabeth Leuchter, Andrew Wisniewski, Stephen R. Balasubramani, G. K. Alpert, Jonathan TI Clinical differences among depressed patients with and without a history of suicide attempts: Findings from the STAR*D trial SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE suicide; suicide attempts; depression; clinical features ID DIAGNOSTIC SCREENING QUESTIONNAIRE; SEQUENCED TREATMENT ALTERNATIVES; NATIONAL COMORBIDITY SURVEY; AXIS-I DISORDERS; MAJOR DEPRESSION; RISK-FACTORS; RELIEVE DEPRESSION; MOOD DISORDERS; PANIC DISORDER; RATING SCALE AB Background: This study Sought to determine whether a history of suicide attempts among outpatients diagnosed with nonpsychotic major depressive disorder (MDD) is correlated with any difference in clinical presentation that should influence patient care. Methods: Baseline data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial on outpatients with MDD treated in primary and specialty care settings were used to model significant demographic and clinical correlates of suicide attempter status. Results: Altogether, 16.5% of participants (n=667) reported prior suicide attempts. Controlling for age, gender, and depressive symptom severity, previous attempters had more current general medical conditions (mu=3.2 vs. 2.9, p <.0001), more current alcohol/substance abuse (p <.0001), and more work hours missed in the past week (26.2% vs. 18.2%, p <.0001) than non-attempters. On average, for the previously suicidal, the onset of MDD occurred 8.9 years earlier in life (p <.0001) and had included 1.2 additional depressive episodes (p=0.001) compared to those without prior suicidal behavior. Previous attempters also reported more current suicidal ideation (61.3% of previous attempters, adjusted OR 1.6, vs. 45.5% of nonattempters, p <.0001). Limitations: Presence or absence of a history of suicide attempts was determined only through self report. Conclusions: Those with a history of suicidal behavior suffer a greater burden of depressive illness. Earlier intervention and ongoing, aggressive care, including maintenance-phase pharmacotherapy, may be critical to mitigating the long-term consequences associated with this increased disease burden. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA. Univ Texas, SW Med Ctr, Div Clin Psychol, Dallas, TX 75235 USA. Univ Texas, SW Med Ctr, Lydia Bryant Test Professorship Psychiat Res, Dept Psychiat, Dallas, TX 75235 USA. Univ Texas, SW Med Ctr, Betty Jo Hay Distinguished Chair Mental Hlth, Dept Psychiat, Dallas, TX 75235 USA. Univ Texas, SW Med Ctr, Rosewood Corp Chair Biomed Sci, Dept Psychiat, Dallas, TX 75235 USA. Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92103 USA. Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA USA. Massachusetts Gen Hosp, Depress & Clin Res Program, Boston, MA 02114 USA. RP Claassen, CA (reprint author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75235 USA. EM Cindy.Claassen@UTSouthwestern.edu OI Wisniewski, Stephen/0000-0002-3877-9860; Alpert, Jonathan/0000-0002-4332-908X; Rush, Augustus/0000-0003-2004-2382; Goundappa K, Balasubramani/0000-0001-7221-1825 FU NIMH NIH HHS [5R0-1MH064062-02, N01MH90003] NR 47 TC 45 Z9 48 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN PY 2007 VL 97 IS 1-3 BP 77 EP 84 DI 10.1016/j.jad.2006.05.026 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 129MW UT WOS:000243734600009 PM 16824617 ER PT J AU Simon, NM Pollack, MH Ostacher, MJ Zalta, AK Chow, CW Fischmann, D Demopulos, CM Nierenberg, AA Otto, MW AF Simon, Naomi M. Pollack, Mark H. Ostacher, Michael J. Zalta, Alyson K. Chow, Candice W. Fischmann, Diana Demopulos, Christina M. Nierenberg, Andrew A. Otto, Michael W. TI Understanding the link between anxiety symptoms and suicidal ideation and behaviors in outpatients with bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE bipolar disorder; anxiety; rumination; suicide; suicidal ideation; emotional coping ID PANIC DISORDER; RISK-FACTORS; I DISORDER; DEPRESSION; VALIDATION; QUESTIONNAIRE; REASONS; MODEL; SCALE; TIME AB Background: Prior studies suggest an association between anxiety comorbidity and suicidal ideation and behaviors in bipolar disorder. However, the nature of this association remains unclear. Methods: We examined a range of anxiety symptoms, including panic, phobic avoidance, anxiety sensitivity, worry and fear of negative evaluation, in 98 patients with bipolar disorder. We predicted that each anxiety dimension would be linked to greater suicidal ideation and behavior as measured by Linehan's Suicide Behaviors Questionnaire (SBQ), greater depressive rumination, and poorer emotional processing and expression. Results: Each anxiety dimension except fear of negative evaluation was associated with greater SBQ score, greater rumination, and lower levels of emotional processing in univariate analyses. Depressive rumination was a significant predictor of higher SBQ scores in a stepwise multivariate model controlling for age, gender, bipolar subtype, and bipolar recovery status; the association between the anxiety symptom dimensions and SBQ score was found to be redundant with depressive rumination. Emotional processing emerged as protective against suicidal ideation and behaviors in men only, while emotional expression was a significant predictor of lower SBQ scores for women and for the full sample; however, emotional expression was not significantly correlated with anxiety symptoms. Confirmatory analyses examining only those in recovery or recovered (n=68) indicated that the link between rumination and suicidality was not explained by depression. Limitations: Interpretation is limited by the cross-sectional study design. Conclusions: These findings indicate that increased ruminations may mediate the association between anxiety and suicidal ideation/behavior. In men, lower emotional processing may also play a role in this relationship. (c) 2006 Elsevier B.V. All rights reserved. C1 Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Boston Univ, Dept Psychol, Boston, MA 02215 USA. RP Simon, NM (reprint author), Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, Dept Psychiat, Simches Res Bldg,185 Cambridge St,Suite 2200, Boston, MA 02114 USA. EM NSIMON@Partners.org OI Ostacher, Michael/0000-0003-0353-7535; Zalta, Alyson/0000-0002-5159-8431 FU NIMH NIH HHS [MH01831-01] NR 45 TC 33 Z9 35 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN PY 2007 VL 97 IS 1-3 BP 91 EP 99 DI 10.1016/j.jad.2006.05.027 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 129MW UT WOS:000243734600011 PM 16820212 ER PT J AU Ahn, CJ Baumann, BM Kysia, RF Radeos, MS Stiffler, K Camargo, CA AF Ahn, C. J. Baumann, B. M. Kysia, R. F. Radeos, M. S. Stiffler, K. Camargo, C. A., Jr. TI Stability of IgE levels during acute asthma: Implications for initiation of omalizumab therapy after the emergency department visit SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 23-27, 2007 CL San Diego, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Ahn, C. J.; Camargo, C. A., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Baumann, B. M.] Cooper Univ Hosp, Camden, NJ USA. [Kysia, R. F.] Cook Cty Hosp, Chicago, IL 60612 USA. [Radeos, M. S.] Lincoln Med & Mental Hlth Ctr, Bronx, NY 10451 USA. [Stiffler, K.] Summa Hlth Syst, Akron, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2007 VL 119 IS 1 SU 1 MA 977 BP S250 EP S250 DI 10.1016/j.jaci.2006.12.345 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 238PT UT WOS:000251460401361 ER PT J AU Camargo, CA Pelletier, AJ Hammel, R Vasas, D Lang, DM AF Camargo, C. A., Jr. Pelletier, A. J. Hammel, R. Vasas, D. Lang, D. M. TI Risk factors for fatal asthma in three US States, 2004 SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 23-27, 2007 CL San Diego, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Camargo, C. A., Jr.; Pelletier, A. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hammel, R.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Vasas, D.; Lang, D. M.] Cleveland Clin, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2007 VL 119 IS 1 SU 1 MA 667 BP S170 EP S170 DI 10.1016/j.jaci.2006.12.029 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 238PT UT WOS:000251460401052 ER PT J AU Hamilos, DL AF Hamilos, D. L. TI Nasal epithelial gene expression in response to cigarette smoke extract and toll-like receptor agonists: Relevance to chronic rhinosinusitis (CRS) SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 23-27, 2007 CL San Diego, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Hamilos, D. L.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2007 VL 119 IS 1 SU 1 MA 949 BP S242 EP S242 DI 10.1016/j.jaci.2006.12.317 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 238PT UT WOS:000251460401333 ER PT J AU Hsu, RT Crawford, WW Klaustermeyer, WB Schatz, M AF Hsu, R. T. Crawford, W. W. Klaustermeyer, W. B. Schatz, M. TI Risk factors for asthma-related emergency hospital utilization differ between high and low users of asthma medications SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 23-27, 2007 CL San Diego, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Hsu, R. T.; Klaustermeyer, W. B.] VA Greater Los Angeles Hlthcare Syst, Los Angeles, CA USA. [Crawford, W. W.] Harbor City Med Ctr, Kaiser Permanente, Harbor, CA USA. [Schatz, M.] San Diego Med Ctr, Kaiser Permanente, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2007 VL 119 IS 1 SU 1 MA 38 BP S10 EP S10 DI 10.1016/j.jaci.2006.11.056 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 238PT UT WOS:000251460400039 ER PT J AU McEldowney, SJ Bush, RK AF McEldowney, S. J. Bush, R. K. TI Idiopathic CD4+lymphocytopenia in a patient with progressive multifocal leukoencephalopathy treated with cidofovir SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 23-27, 2007 CL San Diego, CA SP Amer Acad Allergy, Asthma & Immunol C1 [McEldowney, S. J.; Bush, R. K.] Univ Wisconsin Hosp, William S Middleton Mem Vet Adm Hosp, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2007 VL 119 IS 1 SU 1 MA 990 BP S253 EP S253 DI 10.1016/j.jaci.2006.12.359 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 238PT UT WOS:000251460401374 ER PT J AU Mikhak, Z Fukm, M Hesterberg, P Luster, AD AF Mikhak, Z. Fukm, M. Hesterberg, P. Luster, A. D. TI Mast cell mediated LTB4-BLT1 pathway in asthma and teh therapeutic role of Zileuton in regulating early T cell trafficking in airways SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 23-27, 2007 CL San Diego, CA SP Amer Acad Allergy, Asthma & Immunol C1 Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2007 VL 119 IS 1 SU 1 MA 177 BP S46 EP S46 DI 10.1016/j.jaci.2006.11.199 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 238PT UT WOS:000251460400178 ER PT J AU Oren, E Banerji, A Clark, S Camargo, CA AF Oren, E. Banerji, A. Clark, S. Camargo, C. A., Jr. TI Food-induced anaphylaxis and repeat epinephrine treatments SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 23-27, 2007 CL San Diego, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Oren, E.; Banerji, A.; Clark, S.; Camargo, C. A., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2007 VL 119 IS 1 SU 1 MA 449 BP S114 EP S114 DI 10.1016/j.jaci.2006.11.428 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 238PT UT WOS:000251460400449 ER PT J AU Ishizawa, Y AF Ishizawa, Yumiko TI Mechanisms of anesthetic actions and the brain SO JOURNAL OF ANESTHESIA LA English DT Review DE anesthesia; general; anesthetics; volatile; mechanisms of anesthetic action; brain; neurons; functional imaging; electroencephalography ID GATED ION CHANNELS; SOMATOSENSORY EVOKED-POTENTIALS; POSITRON-EMISSION-TOMOGRAPHY; PROTEIN-COUPLED RECEPTORS; STEM RETICULAR-FORMATION; AIRWAY SMOOTH-MUSCLE; CEREBRAL-BLOOD-FLOW; PATIENT STATE INDEX; GENERAL-ANESTHETICS; INHALED ANESTHETICS AB The neural mechanisms behind anesthetic-induced behavioral changes such as loss of consciousness, amnesia, and analgesia, are insufficiently understood, though general anesthesia has been of tremendous importance for the development of medicine. In this review, I summarize what is currently known about general anesthetic actions at different organizational levels and discuss current and future research, using systems neuroscience approaches such as functional neuroimaging and quantitative electrophysiology to understand anesthesia actions at the integrated brain level. C1 Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Ishizawa, Y (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 55 Fruit St,Clin 3, Boston, MA 02114 USA. FU NIGMS NIH HHS [T32GM007592] NR 146 TC 24 Z9 24 U1 1 U2 11 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 0913-8668 J9 J ANESTH JI J. Anesth. PY 2007 VL 21 IS 2 BP 187 EP 199 DI 10.1007/s00540-006-0482-x PG 13 WC Anesthesiology SC Anesthesiology GA 281PB UT WOS:000254509300012 PM 17458649 ER PT J AU Quinn, LS AF Quinn, L. S. TI Interleukin-15: A cytokine which modulates fat : lean body composition SO JOURNAL OF ANIMAL SCIENCE LA English DT Meeting Abstract DE interleukin-15; muscle; adipose tissue C1 [Quinn, L. S.] Univ Washington, Seattle, WA 98195 USA. [Quinn, L. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC ANIMAL SCIENCE PI SAVOY PA 1111 NORTH DUNLAP AVE, SAVOY, IL 61874 USA SN 0021-8812 J9 J ANIM SCI JI J. Anim. Sci. PY 2007 VL 85 SU 1 BP 1 EP 1 PG 1 WC Agriculture, Dairy & Animal Science SC Agriculture GA 213UN UT WOS:000249692700003 ER PT J AU Hinton, DE Chhean, D Fama, JM Pollack, MH McNally, RJ AF Hinton, Devon E. Chhean, Dara Fama, Jeanne M. Pollack, Mark H. McNally, Richard J. TI Gastrointestinal-focused panic attacks among Cambodian refugees: Associated psychopathology, flashbacks, and catastrophic cognitions SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE posttraumatic stress disorder; panic attack; flashbacks; catastrophic cognitions; Cambodian refugees; gastrointestinal panic ID POSTTRAUMATIC-STRESS-DISORDER; IRRITABLE-BOWEL-SYNDROME; SOUTHEAST-ASIAN REFUGEES; ANXIETY SENSITIVITY; HIERARCHICAL STRUCTURE; INTRUSIVE MEMORIES; SUFFOCATION FEAR; CHEST PAIN; SYMPTOMS; PREVALENCE AB Among Cambodian refugees attending a psychiatric clinic, we assessed psychopathology associated with gastrointestinal panic (GIP), and investigated possible causal mechanisms, including "fear of fear" and GIP-associated flashbacks and catastrophic cognitions. GIP (n = 46) patients had greater psychopathology (Clinician-Administered PTSD Scale [CAPS] and Symptom Checklist-90-R [SCL]) and "fear of fear" (Anxiety Sensitivity Index [ASI]) than did non-GIP patients (n = 84). Logistic regression revealed that general psychopathology (SCL; odds ratio= 4.1) and fear of anxiety-related sensations (ASI; odds ratio = 2.4) predicted the presence of GIP. Among GIP patients, a hierarchical regression revealed that GIP-associated trauma recall and catastrophic cognitions explained variance in GIP severity beyond a measure of general psychopathology (SCL). A mediational analysis indicated that SCL's effect on GIP severity was mediated by GIP-associated flashbacks and catastrophic cognitions. (c) 2006 Elsevier Ltd All rights reserved. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. Arbour Counseling, SE Asian Clin, Lowell, MA USA. Harvard Univ, Cambridge, MA 02138 USA. RP Hinton, DE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 15 Parkman St,WACC 812, Boston, MA USA. EM devon_hinton@luns.harvard.edu NR 85 TC 12 Z9 14 U1 4 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2007 VL 21 IS 1 BP 42 EP 58 DI 10.1016/j.janxdis.2006.03.009 PG 17 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 138PF UT WOS:000244374000003 PM 16650726 ER PT J AU Kozak, AT Spates, CR McChargue, DE Bailey, KC Schneider, KL Liepman, MR AF Kozak, Andrea T. Spates, C. Richard McChargue, Dennis E. Bailey, Katherine C. Schneider, Kristin L. Liepman, Michael R. TI Naltrexone renders one-session exposure therapy less effective: A controlled pilot study SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE phobias; naltrexone; endogenous opiates; behavioral assessment ID STRESS-INDUCED ANALGESIA; LEARNED HELPLESSNESS; CLAUSTROPHOBIA; MORPHINE; ANXIETY; SHOCK AB In vivo exposure has become the gold standard treatment for specific phobia. The endogenous opioid system is one mechanism proposed to explain why exposure provides such quick and effective treatment for specific phobia. The effect of naltrexone on fear and avoidance behavior was investigated among 15 specific phobia participants who received exposure treatment. Participants were randomly assigned to receive naltrexone, placebo, or no drug prior to attending one-session exposure treatment. Mixed effects regression results revealed that across time, the naltrexone group tolerated significantly less time in the room with the feared animal (Behavioral Avoidance Index) as compared to the placebo and no drug groups. Phobic individuals assigned to the naltrexone group had significantly higher fear ratings across time in comparison to the placebo group. Results provide support for the endogenous opioid system as a potential underlying biological mechanism associated with behavioral changes during in vivo exposure. (c) 2006 Elsevier Ltd All rights reserved. C1 Western Michigan Univ, Kalamazoo, MI 49008 USA. Univ Illinois, Chicago, IL 60680 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Michigan State Univ, Kalamazoo Ctr Med Studies, Kalamazoo, MI USA. RP Kozak, AT (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA. EM akozak@northwestern.edu NR 26 TC 14 Z9 14 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2007 VL 21 IS 1 BP 142 EP 152 DI 10.1016/j.janxdis.2006.03.011 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 138PF UT WOS:000244374000010 PM 16647240 ER PT J AU Otto, MW Henin, A Hirshfeld-Becker, DR Pollack, MH Biederman, J Rosenbaum, JF AF Otto, Michael W. Henin, Aude Hirshfeld-Becker, Dina R. Pollack, Mark H. Biederman, Joseph Rosenbaum, Jerrold F. TI Posttraumatic stress disorder symptoms following media exposure to tragic events: Impact of 9/11 on children at risk for anxiety disorders SO JOURNAL OF ANXIETY DISORDERS LA English DT Article; Proceedings Paper CT Conference of the Association-for-the-Advancement-of-Behavior-Therapy CY NOV 20-23, 2003 CL Boston, MA SP Assoc Adv Behavior Therapy DE PTSD symptoms; anxiety; child; behavioral inhibition; media exposure ID AUSTRALIAN VIETNAM VETERANS; BEHAVIORAL-INHIBITION; PSYCHIATRIC-DISORDERS; SOCIAL ANXIETY; PSYCHOLOGICAL SEQUELAE; TERRORIST ATTACKS; EXPRESSED EMOTION; PANIC DISORDER; CHILDHOOD; PARENTS AB With the extensive media coverage on September 11, 200 1, adults and children indirectly witnessed the terrorist attacks leading to the deaths of almost 3,000 people. An ongoing longitudinal study provided the opportunity to examine pre-event characteristics and the impact of this media exposure. We assessed symptoms of PTSD in 166 children and 84 mothers who had no direct exposure to the 9/11 attacks. The sample included children who had parents with or without anxiety and mood disorders, and who had been assessed for the presence or absence of temperamental behavioral inhibition (131). We found a 5.4 percent rate of symptomatic PTSD in response to 9/11 in children and 1.2 percent in their mothers. Children's identification with victims of the attack, and for younger children, the amount of television viewing predicted increased risk of PTSD symptoms. Parental depression was associated with higher symptoms, and pre-event levels of family support was associated with a lower risk for PTSD symptoms. BI in children was also linked to lower rates of PTSD symptoms, suggesting that a cautious and fearful approach to novelty may offer protection against exposure to media-based traumatic images. Media viewing of tragic events is sufficient to produce PTSD symptoms in vulnerable populations such as children. Given the links between PTSD symptoms and viewing habits, parental monitoring of media exposure may be important for younger children. (C) 2007 Elsevier Ltd. All rights reserved. C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Otto, MW (reprint author), Boston Univ, Ctr Anxiety & Related Disorders, 648 Beacon St,6th Floor, Boston, MA 02115 USA. EM mwotto@bu.edu FU NIMH NIH HHS [MH-47077] NR 58 TC 51 Z9 53 U1 6 U2 23 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2007 VL 21 IS 7 BP 888 EP 902 DI 10.1016/j.janxdis.2006.10.008 PG 15 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 217GE UT WOS:000249935600002 PM 17276653 ER PT J AU Kendall, PC Puliafico, AC Barmish, AJ Choudhury, MS Henin, A Treadwell, KS AF Kendall, Philip C. Puliafico, Anthony C. Barmish, Andrea J. Choudhury, Muniya S. Henin, Aude Treadwell, Kimberli S. TI Assessing anxiety with the child behavior checklist and the teacher report form SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE child anxiety; anxiety disorders; assessment; parent report; teacher report ID DISORDERS INTERVIEW SCHEDULE; RANDOMIZED CLINICAL-TRIAL; TEST-RETEST RELIABILITY; DSM-IV; ANXIOUS SYMPTOMATOLOGY; STRUCTURED INTERVIEW; MANIFEST ANXIETY; PARENT VERSIONS; ADOLESCENCE; SCALE AB We evaluated the utility of Anxiety scales for the Child Behavior Checklist (CBCL) and the Teacher Report Form (TRF). The scales (CBCL-A; TRF-A) were examined using mothers and teachers of anxiety-disordered (AD; 157 mothers, 70 teachers) and non-anxiety-disordered (NAD; 100 mothers, 17 teachers) children. Separate samples of parents and teachers of AD (mothers = 145, fathers = 120, teachers = 137) and NAD (mothers = 35, fathers = 29, teachers = 27) children cross-validated the original findings. CBCL-A and TRF-A scores significantly discriminated AD children from NAD children and correlated significantly with other measures of child anxiety. The CBCL-A and TRF-A were sensitive to treatment changes. Relative to the CBCL/TRF Anxious/Depressed syndromes and Internalizing dimensions, the CBCL-A and TRF-A improved prediction of anxiety status. Relative to Achenbach, Demenci, and Rescorla's [Achenbach, T. M., Demenci, L., & Rescorla, L. A. (2003). DSM-oriented and empirically based approaches to constructing scales from the same item pools. Journal of Clinical Child and Adolescent Psychology, 32, 328-340] CBCL Anxiety subscale, the CBCL-A predicted comparably. Findings are discussed in terms of the CBCL-A and TRF-A as clinical tools. (C) 2007 Elsevier Ltd. All rights reserved. C1 Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA. Columbia Univ, New York, NY 10027 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Connecticut, Storrs, CT 06269 USA. RP Kendall, PC (reprint author), Temple Univ, Dept Psychol, 1701 N 13th St, Philadelphia, PA 19122 USA. EM pkendall@temple.edu FU NIMH NIH HHS [MH60653] NR 41 TC 39 Z9 39 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2007 VL 21 IS 8 BP 1004 EP 1015 DI 10.1016/j.janxdis.2006.10.012 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 229GH UT WOS:000250790700003 PM 17270388 ER PT J AU MacDonald, SM Ahmad, S Kachris, S Vogds, BJ DeRouen, M Gitttleman, AE DeWyngaert, K Vlachaki, MT AF MacDonald, Shannon M. Ahmad, Salahuddin Kachris, Stefanos Vogds, Betty J. DeRouen, Melissa Gitttleman, Alicia E. DeWyngaert, Keith Vlachaki, Maria T. TI Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article; Proceedings Paper CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol DE high-grade glioma; IMRT; 3D-CRT ID TUMOR-CONTROL PROBABILITY; GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMAS; NORMAL TISSUE; FRACTIONATED-IRRADIATION; INITIAL MANAGEMENT; MR SPECTROSCOPY; PROSTATE-CANCER; BRAIN-TUMORS; IN-VITRO AB The present study compared the dosimetry of intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) techniques in patients treated for high-grade glioma. A total of 20 patients underwent computed tomography treatment planning in conjunction with magnetic resonance imaging fusion. Prescription dose and normal-tissue constraints were identical for the 3D-CRT and IMRT plans. The prescribed dose was 59.4 Gy delivered at 1.8 Gy per fraction using 4-10 MV photons. Normal-tissue dose constraints were 50 54 Gy for the optic chiasm and nerves, and 55-60 Gy for the brainstem. The IMRT plan yielded superior target coverage as compared with the 3D-CRT plan. Specifically, minimum and mean planning target volume cone down doses were 54.52 Gy and 61.74 Gy for IMRT and 50.56 Gy and 60.06 Gy for 3D- CRT (p <= 0.01). The IMRT plan reduced the percent volume of brainstem receiving a dose greater than 45 Gy by 31% (p = 0.004) and the percent volume of brain receiving a dose greater than 18 Gy, 24 Gy, and 45 Gy by 10% (p = 0.059), 14% (p = 0.015), and 40% (p <= 0.0001) respectively. With IMRT, the percent volume of optic chiasm receiving more than 45 Gy was also reduced by 30.40% (p = 0.047). As compared with 3D- CRT, IMRT significantly increased the tumor control probability (p <= 0.005) and lowered the normal-tissue complication probability for brain and brainstem (p < 0.033). Intensity-modulated radiation therapy improved target coverage and reduced radiation dose to the brain, brainstem, and optic chiasm. With the availability of new cancer imaging tools and more effective systemic agents, IMRT may be used to intensify tumor doses while minimizing toxicity, therefore potentially improving outcomes in patients with high-grade glioma. C1 Wayne State Univ, Dept Radiat Oncol, Detroit, MI 48201 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. NYU, Med Ctr, New York, NY 10016 USA. RP Vlachaki, MT (reprint author), Wayne State Univ, Dept Radiat Oncol, 540 E Canfield Scott Hall 1212, Detroit, MI 48201 USA. EM mvlachaki@med.wayne.edu NR 60 TC 32 Z9 34 U1 0 U2 8 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2007 VL 8 IS 2 BP 47 EP 60 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 183DP UT WOS:000247553200007 PM 17592465 ER PT J AU Harris, RS Schuster, DP AF Harris, R. Scott Schuster, Daniel P. TI Visualizing lung function with positron emission tomography SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Review DE ventilation; perfusion; tracer; permeability ID PULMONARY VASCULAR-PERMEABILITY; RESPIRATORY-DISTRESS-SYNDROME; ENHANCED PARAMETER-ESTIMATION; ISCHEMIA-REPERFUSION INJURY; INTACT SMALL ANIMALS; REGIONAL V/Q RATIOS; NOISY PET DATA; BLOOD-FLOW; GENE-EXPRESSION; TRANSGENE EXPRESSION AB Positron emission tomography (PET) provides three-dimensional images of the distributions of radionuclides that have been inhaled or injected into the lungs. By using radionuclides with short half-lives, the radiation exposure of the subject can be kept small. By following the evolution of the distributions of radionuclides in gases or compounds that participate in lung function, information about such diverse lung functions as regional ventilation, perfusion, shunt, gas fraction, capillary permeability, inflammation, and gene expression can be inferred. Thus PET has the potential to provide information about the links between cellular function and whole lung function in vivo. In this paper, recent advancements in PET methodology and techniques and information about lung function that have been obtained with these techniques are reviewed. C1 Massachusetts Gen Hosp, Pulm & Crit Care Unit, Dept Med, Boston, MA 02114 USA. Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA. Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. RP Harris, RS (reprint author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, Dept Med, Bulfinch 148,55 Fruit St, Boston, MA 02114 USA. EM rharris@partners.org NR 95 TC 41 Z9 41 U1 0 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JAN PY 2007 VL 102 IS 1 BP 448 EP 458 DI 10.1152/japplphysiol.00763.2006 PG 11 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 127QB UT WOS:000243600300062 PM 17038490 ER PT J AU Jones, DP Camargo, CA Speizer, FE Barr, RG AF Jones, Deborah P. Camargo, Carlos A., Jr. Speizer, Frank E. Barr, R. Graham TI Prospective study of short stature and newly diagnosed asthma in women SO JOURNAL OF ASTHMA LA English DT Article DE asthma; body mass index; chronic obstructive pulmonary disease; height; stature ID BODY-MASS INDEX; RESPIRATORY HEALTH SURVEY; OBSTRUCTIVE PULMONARY-DISEASE; ADULT-ONSET ASTHMA; LEG LENGTH; GENERAL-POPULATION; RISK; MEN; HEIGHT; RESPONSIVENESS AB The authors tested the hypothesis that short stature predicts adult-onset asthma independent of obesity among women in the Nurses' Health Study. Height, weight, and physician-diagnosed asthma were assessed with validated questionnaire items. Proportional hazard models adjusted separately for weight and body mass index. The rate of newly diagnosed asthma was 1.55 times greater in the shortest versus the tallest quintile after adjustment for weight (95% CI, 1.26-1.91). After adjustment for body mass index, the rate ratio was 1.16 (95% CI, 0.94-1.42). Short stature predicted adult-onset asthma in a large cohort of women, but this association was not independent of obesity. C1 Columbia Univ, Coll Phys & Surg, Dept Med, Div Gen Med,Med Ctr, New York, NY 10032 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. RP Barr, RG (reprint author), Columbia Univ, Coll Phys & Surg, Dept Med, Div Gen Med,Med Ctr, PH 9-E Room 105,622 W 168th St, New York, NY 10032 USA. EM rgb9@columbia.edu FU NCI NIH HHS [CA87969]; NHLBI NIH HHS [HL077612, HL075476]; NIAID NIH HHS [AI-52338]; PHS HHS [D14-HP-00202] NR 34 TC 5 Z9 5 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PY 2007 VL 44 IS 4 BP 291 EP 295 DI 10.1080/02770900701344116 PG 5 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 176IR UT WOS:000247078700010 PM 17530528 ER PT J AU Sullivan, M Finelli, J Marvin, A Garrett-Mayer, E Bauman, M Landa, R AF Sullivan, Michelle Finelli, Julianna Marvin, Alison Garrett-Mayer, Elizabeth Bauman, Margaret Landa, Rebecca TI Response to joint attention in toddlers at risk for autism spectrum disorder: A prospective study SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE autism; joint attention; longitudinal; phenotype; siblings; social communication ID PERVASIVE DEVELOPMENTAL DISORDERS; VISUAL-ATTENTION; HOME VIDEOTAPES; SOCIAL COMMUNICATION; EARLY RECOGNITION; YOUNG-CHILDREN; LANGUAGE; INDIVIDUALS; SIBLINGS; PARENTS AB Response to joint attention (RJA) is impaired in preschoolers with autism spectrum disorder (ASD) and is pivotal to social and communication development. Response to joint attention was examined at 14 and 24 months in 51 children at high risk for autism (siblings of children with autism). Outcome groups at age 3 years included ASD (n = 16), broader autism phenotype (n = 8), and non-broader autism phenotype (n = 27). The ASD group made minimal improvement in RJA between 14 and 24 months, but stability of RJA across tasks increased for all three groups. Significantly, lower RJA was observed for the ASD group at 24 months. Response to joint attention performance at 14 months predicted ASD outcome. Response to joint attention is an important screening and early intervention target. C1 Johns Hopkins Sch Med, Kennedy Krieger Inst, Dept Psychiat, Ctr Autism & Related Disorders, Baltimore, MD 21211 USA. Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ New Hampshire, Inst Disabil, UCED, Durham, NH 03824 USA. RP Landa, R (reprint author), Johns Hopkins Sch Med, Kennedy Krieger Inst, Dept Psychiat, Ctr Autism & Related Disorders, Baltimore, MD 21211 USA. EM landa@kennedykrieger.org FU NIMH NIH HHS [154MH066417, 5T32MH20033, MH59630] NR 56 TC 85 Z9 91 U1 8 U2 34 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD JAN PY 2007 VL 37 IS 1 BP 37 EP 48 DI 10.1007/s10803-006-0335-3 PG 12 WC Psychology, Developmental SC Psychology GA 131XO UT WOS:000243905900004 PM 17216332 ER PT J AU Ioppolo, J Borlin, N Bragdon, C Li, MG Price, R Wood, D Malchau, H Nivbrant, B AF Ioppolo, James Borlin, Niclas Bragdon, Charles Li, Mingguo Price, Roger Wood, David Malchau, Henrik Nivbrant, Bo TI Validation of a low-dose hybrid RSA and fluoroscopy technique: Determination of accuracy, bias and precision SO JOURNAL OF BIOMECHANICS LA English DT Article DE radiostereometric analysis (RSA); fluoroscopy; accuracy; error; pose estimation; image analysis ID RADIO STEREOMETRIC ANALYSIS; SINGLE-PLANE FLUOROSCOPY; KINEMATICS; IMAGES; REGISTRATION; DISTORTION; MODEL AB Analyzing skeletal kinematics with radiostereometric analysis (RSA) following corrective orthopedic surgery allows the quantitative comparison of different implant designs. The purpose of this study was to validate a technique for dynamically estimating the relative position and orientation of skeletal segments using RSA and single plane X-ray fluoroscopy. Two micrometer-based in vitro phantom models of the skeletal segments in the hip and knee joints were used. The spatial positions of tantalum markers that were implanted into each skeletal segment were reconstructed using RSA. The position and orientation of each segment were determined in fluoroscopy images by minimizing the difference between the markers measured and projected in the image plane. Accuracy was determined in terms of bias and precision by analyzing the deviation between the applied displacement protocol and measured pose estimates. Measured translational accuracy was less than 100 mu m parallel to the image plane and less than 700 mu m in the direction orthogonal to the image plane. The measured rotational error was less than 1 degrees. Measured translational and rotational bias was not statistically significant at the 95% level of confidence. The technique allows real-time kinematic skeletal measurements to be performed on human subjects implanted with tantalum markers for quantitatively measuring the motion of normal joints and different implant designs. (c) 2006 Elsevier Ltd. All rights reserved. C1 Univ Western Australia, Dept Surg & Pathol Orthopaed, Perth Orthopaed Inst, Nedlands, WA 6009, Australia. Sir Charles Gairdner Hosp, Med Technol & Phys Dept, Nedlands, WA 6009, Australia. Umea Univ, Dept Comp Sci, SE-90187 Umea, Sweden. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Biomech & Biomat Lab,Dept Orthopaed Sur, Boston, MA 02114 USA. RP Ioppolo, J (reprint author), Univ Western Australia, Dept Surg & Pathol Orthopaed, Perth Orthopaed Inst, Gate 3,Verdun St, Nedlands, WA 6009, Australia. EM ioppolo@cyllene.uwa.edu.au OI Borlin, Niclas/0000-0002-7657-6917 NR 17 TC 11 Z9 11 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 J9 J BIOMECH JI J. Biomech. PY 2007 VL 40 IS 3 BP 686 EP 692 DI 10.1016/j.jbiomech.2006.01.012 PG 7 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 136RG UT WOS:000244241200025 PM 16533512 ER PT J AU DeFrate, LE Nha, KW Papannagari, R Moses, JM Gill, TJ Li, GA AF DeFrate, Louis E. Nha, Kyung Wook Papannagari, Ramprasad Moses, Jeremy M. Gill, Thomas J. Li, Guoan TI The biomechanical function of the patellar tendon during in-vivo weight-bearing flexion SO JOURNAL OF BIOMECHANICS LA English DT Article DE patellar tendon; tendon; ligament; patellar kinematics; patellar tracking; in-vivo kinematics; tendon biomechanics ID ANTERIOR CRUCIATE LIGAMENT; KNEE FLEXION; MECHANICAL-PROPERTIES; MOMENT ARMS; JOINT KINEMATICS; MUSCLE FORCE; EXTENSION; POSTERIOR; ACL; RECONSTRUCTION AB Few studies have investigated the function of the patellar tendon in-vivo. This study quantified the three-dimensional (31)) kinematics of the patellar tendon during weight-bearing flexion. Eleven subjects were imaged using magnetic resonance (MR). Sagittal plane images were outlined to create a 3D model of the patella, tibia, and femur and included the attachment sites of the patellar tendon. Each attachment site was divided into central, medial, and lateral thirds. Next, the subjects were imaged using fluoroscopy from two orthogonal directions while performing a single-leg lunge. The models and fluoroscopic images were used to reproduce the motion of the patella, tibia, and femur. The apparent elongation, sagittal plane angle, and coronal plane angle of each third of the patellar tendon were measured from the relative motion of the attachment sites. All three portions of the patellar tendon deformed similarly with flexion. The length of the patellar tendon significantly from full extension to 30 degrees. From 30 degrees-10 degrees, no significant change in the length of the patellar tendon was observed. The patellar tendon was oriented anteriorly at flexion angles less than 60 degrees and posteriorly thereafter. From full extension to 60 degrees, the medial orientation of the patellar tendon decreased significantly with flexion. These data may have important implications for anterior cruciate ligament reconstruction using patellar tendon autografts and for the design of rehabilitation regimens for patients of patellar tendon repair. (C) 2006 Published by Elsevier Ltd. C1 Massachusetts Gen Hosp, Bioengn Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Li, GA (reprint author), Massachusetts Gen Hosp, Bioengn Lab, 55 Fruit St,1215 GRJ, Boston, MA 02114 USA. EM gli1@partners.org RI CHASSAGNE, Fanette/B-7212-2012 FU NIAMS NIH HHS [R01 AR052408, R01 AR052408-01, R01 AR052408-02, R01 AR052408-03] NR 31 TC 35 Z9 36 U1 0 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 J9 J BIOMECH JI J. Biomech. PY 2007 VL 40 IS 8 BP 1716 EP 1722 DI 10.1016/j.jbiomech.2006.08.009 PG 7 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 177ZR UT WOS:000247191500009 PM 17070815 ER PT J AU Ledoux, WR Blevins, JJ AF Ledoux, William R. Blevins, Joanna J. TI The compressive material properties of the plantar soft tissue SO JOURNAL OF BIOMECHANICS LA English DT Article DE heel pad; soft tissue properties; viscoelasticity; hallux; metatarsal ID HUMAN HEEL PAD; MECHANICAL-PROPERTIES; FAT PAD; PARADOX; ADULTS; TIME AB The plantar soft tissue is the primary means of physical interaction between a person and the ground during locomotion. Dynamic loads greater than body weight are borne across the entire plantar surface during each step. However, most testing of these tissues has concentrated on the structural properties of the heel pad. The purpose of this study was to determine the material properties of the plantar soft tissue from six locations beneath: the great toe (subhallucal), the 1st, 3rd and 5th metatarsal heads (submetatarsal), the lateral midfoot (lateral submidfoot) and the heel (subcalcaneal). We obtained specimens from these locations from I I young, nondiabetic donors; the tissue was cut into 2 cm x 2 cm blocks and the skin was removed. Stress relaxation experiments were conducted and the data were fit using the quasi-linear viscoelastic (QLV) theory. To determine tissue modulus, energy loss and the effect of test frequency, we also conducted displacement controlled triangle waves at five frequencies ranging from 0.005 to 10 Hz. The subcalcaneal tissue was found to have an increased relaxation time compared to the other areas. The subcalcaneal tissue was also found to have an increased modulus and decreased energy loss compared to the other areas. Across all areas, the modulus and energy loss increased for the I and 10 Hz tests compared to the other testing frequencies. This study is the first to generate material properties for all areas of the plantar soft tissue, demonstrating that the subcalcaneal tissue is different than the other plantar soft tissue areas. These data will have implications for foot computational modeling efforts and potentially for orthotic pressure reduction devices. Published by Elsevier Ltd. C1 VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prothet E, Seattle, WA 98108 USA. Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. Univ Washington, Dept Orthoped & Sports Med, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prothet E, Ms 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 NR 19 TC 45 Z9 45 U1 2 U2 14 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 J9 J BIOMECH JI J. Biomech. PY 2007 VL 40 IS 13 BP 2975 EP 2981 DI 10.1016/j.jbiomech.2007.02.009 PG 7 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 222EB UT WOS:000250277800019 PM 17433335 ER PT J AU Plank, GR Estok, DM Muratoglu, OK O'Connor, DO Burroughs, BR Harris, WH AF Plank, Gordon R. Estok, Daniel M., II Muratoglu, Orhun K. O'Connor, Daniel O. Burroughs, Brian R. Harris, William H. TI Contact stress assessment of conventional and highly crosslinked ultra high molecular weight polyethylene acetabular liners with finite element analysis and pressure sensitive film SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS LA English DT Article DE THR; FEA; Fuji film; acetabular; polyethylene; crosslinked ID TOTAL HIP-ARTHROPLASTY; JOINT SIMULATOR; WEAR; REPLACEMENTS; CONFORMITY; THICKNESS; SOCKETS; LINKING; HEADS; CUPS AB Stress magnitude and distribution of both conventional polyethylene versus a crosslinked polyethylene in the liner of a total hip replacement (THR) were examined using finite element analysis and pressure sensitive film. Both types of polyethylene were assessed against head sizes of 22 and 28 mm with 5-mm thick polyethylene liners and head sizes of 28, 38, and 46 mm with 3-mm thick polyethylene liners. Liners with 5-mm conventional polyethylene represented successful combinations with long track records. Our hypothesis was that although the combination of the large head and the lower modulus of the highly crosslinked polyethylene would lead to lower stresses, the stresses would be excessive if the liner was extremely thin at 3 mm. Von Mises stresses at the articulating surface of the highly crosslinked liners were lower, when compared to conventional polyethylene, in every THR size examined. Specifically, however, the 38- and 46-mm inner diameter (ID) highly crosslinked polyethylene even at the extreme of only 3-mm thick had lower stresses than the 22-mm ID conventional liner of 5-mm thickness. These data indicate that the use of a large head against highly crosslinked material even at 3-mm thickness results in lower stresses than in an existing conventional 22-mm head and 5-mm thick combination. Obviously, other considerations will influence the minimum thickness to be recommended. (c) 2006 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 8013: 1-10, 2007 C1 Massachusetts Gen Hosp, Harris Orthopaed Biomech & Biomat Lab, Boston, MA 02114 USA. RP Harris, WH (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Biomech & Biomat Lab, 55 Fruit St,Jackson 1126, Boston, MA 02114 USA. EM wharris.obbl@partners.org NR 26 TC 9 Z9 9 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4973 EI 1552-4981 J9 J BIOMED MATER RES B JI J. Biomed. Mater. Res. Part B PD JAN PY 2007 VL 80B IS 1 BP 1 EP 10 DI 10.1002/jbm.b.30560 PG 10 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 119NE UT WOS:000243018200001 PM 16680685 ER PT J AU Themelis, G D'Arceuil, H Diamond, SG Thaker, S Huppert, TJ Boas, DA Franceschini, MA AF Themelis, George D'Arceuil, Helen Diamond, Solomon G. Thaker, Sonal Huppert, Theodore J. Boas, David A. Franceschini, Maria Angela TI Near-infrared spectroscopy measurement of the pulsatile component of cerebral blood flow and volume from arterial oscillations SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE cerebral blood flow; cerebral blood volume; near-infrared spectroscopy; arterial oscillations ID NEWBORN-INFANTS; PULSE OXIMETRY; WAVE-FORMS; BRAIN; VELOCITY AB We describe a near-infrared spectroscopy (NIRS) method to noninvasively measure relative changes in the pulsate components of cerebral blood flow (pCBF) and volume (pCBV) from the shape of heartbeat oscillations. We present a model that is used and data to show the feasibility of the method. We use a continuous-wave NIRS system to measure the arterial oscillations originating in the brains of piglets. Changes in the animals' CBF are induced by adding CO2 to the breathing gas. To study the influence of scalp on our measurements, comparative, invasive measurements are performed on one side of the head simultaneously with noninvasive measurements on the other side. We also did comparative measurements of CBF using a laser Doppler system to validate the results of our method. The results indicate that for sufficient source-detector separation, the signal contribution of the scalp is minimal and the measurements are representative of the cerebral hemodynamics. Moreover, good correlation between the results of the laser Doppler system and the NIRS system indicate that the presented method is capable of measuring relative changes in CBF. Preliminary results show the potential of this NIRS method to measure pCBF and pCBV relative changes in neonatal pigs. (c) 2007 Society of Photo-Optical Instrumentation Engineers. RP Themelis, G (reprint author), Massachusetts Gen Hosp, NMR Marinos Ctr, Athinoula A Marinos Ctr Biomed Imagins, Dept Radiol, 13th St Bld 149,Bldg 10, Charlestown, MA 02129 USA. EM themelis@nmr.mgh.harvard.edu; mari@nmr.mgh.harvard.edu OI Diamond, Solomon/0000-0002-7589-2942 FU NICHD NIH HHS [R01 HD042908-03, R01 HD042908, R01 HD042908-02, R01-HD42908] NR 20 TC 14 Z9 14 U1 0 U2 1 PU SPIE-INT SOCIETY OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2007 VL 12 IS 1 AR 014033 DI 10.1117/1.2710250 PG 7 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 154KH UT WOS:000245505400034 PM 17343508 ER PT J AU Yaroslavsky, AN Salomatina, EV Neel, V Anderson, R Flotte, T AF Yaroslavsky, Anna N. Salomatina, Elena V. Neel, Victor Anderson, Rox Flotte, Thomas TI Fluorescence polarization of tetracycline derivatives as a technique for mapping nonmelanoma skin cancers SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE cancer; imaging; fluorescence polarization; tetracycline ID BASAL-CELL CARCINOMA; LOCALIZATION; SPECTROSCOPY; DISTORTION; EXCISIONS; MARGINS AB Nonmelanoma skin cancer is the most common form of human cancer, often resulting in high morbidity. Low visual contrast of these tumors makes their delineation a challenging problem. Employing a linearly polarized monochromatic light source and a wide-field CCD camera, we have developed a technique for fluorescence polarization imaging of the nonmelanoma cancers stained using antibiotics from the tetracycline family. To determine the feasibility of the method, fluorescence polarization images of 86 thick, fresh cancer excisions were studied. We found that the level of endogenous fluorescence polarization was much lower than that of exogenous, and that the average values of fluorescence polarization of tetracycline derivatives were significantly higher in cancerous as compared to normal tissue. Out of 86 tumors [54 stained in demeclocycline (DMN) and 32 in tetracycline (TCN)], in 79 cases (51-DMN, 28-TCN) the location, size, and shape of the lesions were identified accurately. The results of this trial indicate that nonmelanoma skin tumors can be distinguished from healthy tissue based on the differences in exogenous fluorescence polarization of TCN and/or DMN. Therefore, the developed technique can provide an important new tool for image-guided cancer surgery. (c) 2007 Society of Photo-Optical Instrumentation Engineers. C1 Harvard Univ, Wellman Ctr Photomed, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Yaroslavsky, AN (reprint author), Harvard Univ, Wellman Ctr Photomed, Massachusetts Gen Hosp, Sch Med, BAR 314B,55 Fruit St, Boston, MA 02114 USA. EM yaroslav@helix.mgh.harvard.edu FU NIBIB NIH HHS [R01 EB002423-01] NR 24 TC 25 Z9 25 U1 1 U2 9 PU SPIE-INT SOCIETY OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2007 VL 12 IS 1 AR 014005 DI 10.1117/1.2435710 PG 9 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 154KH UT WOS:000245505400006 PM 17343480 ER PT J AU Yang, SY Li, YP AF Yang, Shuying Li, Yi-Ping TI RGS12 is essential for RANKL-evoked signaling for terminal differentiation of osteoclasts in vitro SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE regulator of G signaling protein 12; RANKL; calcium oscillations; osteoclast differentiation; calcium channels ID MEDIATED EXTRACELLULAR ACIDIFICATION; CAPACITATIVE CALCIUM-ENTRY; SMOOTH-MUSCLE-CELLS; BONE-RESORPTION; SEVERE OSTEOPETROSIS; TYROSINE-KINASE; CA2+ TRANSIENTS; C-FOS; OSCILLATIONS; PROTEINS AB How RANKL evokes [Ca2+](i) oscillations and leads to osteoclast differentiation is unclear. We identified a new signaling protein, RGS12, and found that RGS12 is essential for [Ca2+](i) oscillations and osteoclast differentiation induced by RANKL. RGS12 may play a critical role in the RANKL-evoked PLCycalcium channels-[Ca2+](i) oscillation-NFAT2 pathway. C1 Forsyth Inst, Dept Cytokine Biol, Boston, MA USA. Harvard Univ, Sch Med, Dept Dev Biol, Boston, MA 02115 USA. RP Li, YP (reprint author), Forsyth Inst, Dept Cytokine Biol, Boston, MA USA. EM ypli@forsyth.org RI Yang, Shuying/G-4599-2011 FU NIA NIH HHS [R01 AG048388]; NIAMS NIH HHS [R01 AR066101, AR-44741, R01 AR044741, R01 AR048133, AR-48133]; NIDCR NIH HHS [R03 DE016857]; PHS HHS [ED016857] NR 46 TC 30 Z9 30 U1 0 U2 4 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD JAN PY 2007 VL 22 IS 1 BP 45 EP 54 DI 10.1359/JBMR.061007 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 120AR UT WOS:000243056300006 PM 17042716 ER PT J AU Shapiro, M Dodd, JD Brady, TJ Abbara, S AF Shapiro, Michael Dodd, Jonathan D. Brady, Thomas J. Abbara, Suhny TI Common pulmonary venous ostium of the right and left inferior pulmonary veins: An unusual pulmonary vein anomaly depicted with 64-slice cardiac computed tomography SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Editorial Material C1 Harvard Univ, Dept Radiol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Shapiro, M (reprint author), Harvard Univ, Dept Radiol, Massachusetts Gen Hosp, Sch Med, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM mdshapiro@partners.org NR 1 TC 6 Z9 6 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD JAN PY 2007 VL 18 IS 1 BP 110 EP 110 DI 10.1111/j.1540-8167.2006.00677.x PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 116VZ UT WOS:000242833000025 PM 17229308 ER PT J AU Neuzil, P Themistoclakis, S Bonso, A Rossillo, A Raviele, A Saliba, W Schweikert, R Ernst, S Kuck, KH Ruskin, JN Natale, A Reddy, VY AF Neuzil, P. Themistoclakis, S. Bonso, A. Rossillo, A. Raviele, A. Saliba, W. Schweikert, R. Ernst, S. Kuck, K-H Ruskin, J. N. Natale, A. Reddy, V. Y. TI Long-term single-procedure results with an endoscopic laser balloon ablation catheter for the treatment of patients with paroxysmal atrial fibrillation SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Meeting Abstract C1 Homolka Hosp, Dept Cardiol, Prague, Czech Republic. Umberto Hosp, Dept Cardiol, Venice, Italy. Cleveland Clin, Dept Cardiol, Cleveland, OH 44106 USA. St Georg Hosp, Dept Cardiol, Hamburg, Germany. Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD JAN PY 2007 VL 18 IS 1 BP 131 EP 131 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 116VZ UT WOS:000242833000040 ER PT J AU Chang, EJ Kim, HJ Ha, J Kim, HJ Ryu, J Park, KH Kim, UH Lee, ZH Kim, HM Fisher, DE Kim, HH AF Chang, Eun-Ju Kim, Hyon Jong Ha, Jeongim Kim, Hyung Joon Ryu, Jiyoon Park, Kwang-Hyun Kim, Uh-Hyun Lee, Zang Hee Kim, Hyun-Man Fisher, David E. Kim, Hong-Hee TI Hyaluronan inhibits osteoclast differentiation via toll-like receptor 4 SO JOURNAL OF CELL SCIENCE LA English DT Article DE hyaluronan; osteoclast; toll-like receptor; receptor activator of nuclear factor kappaB; macrophage colony stimulating factor ID COLONY-STIMULATING FACTOR; FACTOR-KAPPA-B; BONE-RESORPTION; MOLECULAR-WEIGHT; SYNOVIAL-FLUID; IN-VITRO; CD44; CELLS; ACID; EXPRESSION AB The differentiation of osteoclasts, cells specialized for bone resorption, is governed by two key factors, macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor kappa B ligand (RANKL). The extracellular matrix (ECM) is an important factor influencing cell fate. To date, little investigation on the relationship between ECM components and osteoclast differentiation has been documented. In this study, we uncovered a potent anti-osteoclastogenic effect of hyaluronan (HA), an ECM component present in bone marrow and soft connective tissues, in primary mouse and human osteoclast precursor cell cultures. The anti-osteoclastogenic function of HA was dependent on Toll-like receptor 4 (TLR4) but not on CD44. HA inhibited M-CSF-dependent signaling pathways involving Rac, reactive oxygen species and mitogen-activated protein kinases, resulting in suppression of transcription factors AP-1 and MITF that control RANK expression. Furthermore, in an in vivo mouse model of calvarial bone resorption assays HA reduced RANKL-induced bone erosion and osteoclastogenesis. Our results clearly show that HA inhibits osteoclast differentiation through TLR4 by interfering with M-CSF signaling, and point that the interaction between ECM components and innate immune receptors can play an important role in the regulation of bone metabolism. C1 Seoul Natl Univ, Dept Cell & Dev Biol, Seoul 110749, South Korea. Seoul Natl Univ, Brain Korea Program 21, DRI, Seoul 110749, South Korea. Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561782, South Korea. Chonbuk Natl Univ, Sch Med, Cardiovasc Res Inst, Jeonju 561782, South Korea. Dana Farber Canc Inst, Div Pediat Hematol Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Melanoma Program Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA. RP Kim, HH (reprint author), Seoul Natl Univ, Dept Cell & Dev Biol, Seoul 110749, South Korea. EM hhbkim@snu.ac.kr RI Kim, Hyung Joon/D-6123-2012 NR 44 TC 58 Z9 59 U1 0 U2 4 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0021-9533 J9 J CELL SCI JI J. Cell Sci. PD JAN 1 PY 2007 VL 120 IS 1 BP 166 EP 176 DI 10.1242/jcs.03310 PG 11 WC Cell Biology SC Cell Biology GA 129JA UT WOS:000243723800017 PM 17164294 ER PT J AU Kim, YR van Meer, MP Mandeville, JB Tejima, E Dai, G Topalkara, K Qui, J Dijkhuizen, RM Moskowitz, MA Lo, EH Rosen, BR AF Kim, Young R. van Meer, Maurits Pa Mandeville, Joseph B. Tejima, Emiri Dai, George Topalkara, Kamil Qui, Jianhua Dijkhuizen, Rick M. Moskowitz, Michael A. Lo, Eng H. Rosen, Bruce R. TI fMRI of delayed albumin treatment during stroke recovery in rats: implication for fast neuronal habituation in recovering brains SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE albumin; fMRI; forepaw; neuroprotection; rat; stroke ID FOCAL CEREBRAL-ISCHEMIA; MARKED NEUROPROTECTIVE EFFICACY; BLOOD-VOLUME; NEOCORTICAL DAMAGE; FUNCTIONAL MRI; THERAPY; INFARCTION; CONTRAST; GROWTH; REORGANIZATION AB Accumulating experimental and clinical data suggest that albumin may be neuroprotective for stroke. Here, we use functional magnetic resonance imaging (fMRI) to evaluate the therapeutic efficacy of albumin and its effects on the recovery of stimuli-induced cerebral hemodynamics. For this purpose, fMRI activity in the ipsilesional somatosensory (SS) cortex was assessed using a well established rat model of transient 90 min focal ischemia and electrical forelimb stimulation. Rats were treated with either saline or albumin via intracerebroventricular injections at 12 h poststroke onset. Despite this delayed treatment time, when compared to the saline- treated rats (n = 7), there were significant enhancements of the fMRI activation in the albumin-treated rats (n = 6) for both blood oxygenation level dependence ( BOLD) and functional cerebral blood volume (fCBV) responses. Interestingly, the temporal characteristics of the ipsilesional SS BOLD responses in the albumin-treated rats appeared considerably altered compared to those of contralesional responses while such temporal alterations were not pronounced for the fCBV responses. These characteristic fMRI temporal profiles of the albumin-treated brains may be due to altered neuronal responses rather than altered integrity of neurovascular coupling, which implies an unusually fast habituation of neuronal responses in the lesional SS cortex. The correlation between various MRI-derived structural parameters and the fMRI response magnitude was also characteristic for albumin and control groups. Taken together, these data suggest that restoration of fMRI response magnitudes, temporal profiles, and correlations with structure may reveal the extent and specific traits of albumin treatment associated stroke recovery. C1 Massachusetts Gen Hosp, Athinoula Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA 02129 USA. Univ Utrecht, Med Ctr, Image Sci Inst, NL-3508 TC Utrecht, Netherlands. Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab, Charlestown, MA 02129 USA. RP Kim, YR (reprint author), Massachusetts Gen Hosp, Athinoula Martinos Ctr Biomed Imaging, 149 13th St,Rm 2301, Charlestown, MA 02129 USA. EM spmn@nmr.mgh.harvard.edu RI Dijkhuizen, Richard/A-6506-2008; Moskowitz, Michael/D-9916-2011; OI Dijkhuizen, Rick/0000-0002-4623-4078 FU NIBIB NIH HHS [501EB002066] NR 32 TC 10 Z9 10 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD JAN PY 2007 VL 27 IS 1 BP 142 EP 153 DI 10.1038/sj.jcbfm.9600317 PG 12 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 118HX UT WOS:000242934200015 PM 16736052 ER PT J AU Wu, O Sumii, T Asahi, M Sasamata, M Ostergaard, L Rosen, BR Lo, EH Dijkhuizen, RM AF Wu, Ona Sumii, Toshihisa Asahi, Minoru Sasamata, Masao Ostergaard, Leif Rosen, Bruce R. Lo, Eng H. Dijkhuizen, Rick M. TI Infarct prediction and treatment assessment with MRI-based algorithms in experimental stroke models SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE ischemic stroke; magnetic resonance imaging; mathematical analysis; stroke animal models; thrombolysis; treatment strategies for acute ischemic stroke ID TISSUE-PLASMINOGEN ACTIVATOR; EXPERIMENTAL CEREBRAL-ISCHEMIA; EMBOLIC STROKE; RT-PA; TEMPORAL EVOLUTION; HEMORRHAGIC TRANSFORMATION; ISODATA ANALYSIS; SYMPTOM ONSET; BRAIN-INJURY; RAT-BRAIN AB There is increasing interest in using algorithms combining multiple magnetic resonance imaging (MRI) modalities to predict tissue infarction in acute human stroke. We developed and tested a voxel-based generalized linear model (GLM) algorithm to predict tissue infarction in an animal stroke model in order to directly compare predicted outcome with the tissue's histologic outcome, and to evaluate the potential for assessing therapeutic efficacy using these multiparametric algorithms. With acute MRI acquired after unilateral embolic stroke in rats (n = 8), a GLM was developed and used to predict infarction on a voxel-wise basis for saline (n = 6) and recombinant tissue plasminogen activator (rt-PA) treatment (n = 7) arms of a trial of delayed thrombolytic therapy in rats. Pretreatment predicted outcome compared with post-treatment histology was highly accurate in saline-treated rats (0.92 +/- 0.05). Accuracy was significantly reduced (P = 0.04) in rt-PA-treated animals (0.86 +/- 0.08), although no significant difference was detected when comparing histologic lesion volumes. Animals that reperfused had significantly lower (P < 0.01) GLM-predicted infarction risk (0.73 +/- 0.03) than nonreperfused animals (0.81 +/- 0.05), possibly reflecting less severe initial ischemic injury and therefore tissue likely more amenable to therapy. Our results show that acute MRI-based algorithms can predict tissue infarction with high accuracy in animals not receiving thrombolytic therapy. Furthermore, alterations in disease progression due to treatment were more sensitively monitored with our voxel-based analysis techniques than with volumetric approaches. Our study shows that predictive algorithms are promising metrics for diagnosis, prognosis and therapeutic evaluation after acute stroke that can translate readily from preclinical to clinical settings. C1 Univ Utrecht, Med Ctr, Image Sci Inst, NL-3584 CA Utrecht, Netherlands. Aarhus Univ Hosp, Ctr Functionally Integrat Neurosci, Dept Neuroradiol, DK-8000 Aarhus, Denmark. Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA USA. Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Tsukuba, Ibaraki, Japan. Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA. RP Wu, O (reprint author), Univ Utrecht, Med Ctr, Image Sci Inst, Bolognalaan 50, NL-3584 CA Utrecht, Netherlands. EM ona@invivonmr.uu.nl RI Dijkhuizen, Richard/A-6506-2008; Bonefeld, Birgit/B-7936-2010; Ostergaard, Leif/A-9281-2008; OI Ostergaard, Leif/0000-0003-2930-6997; Dijkhuizen, Rick/0000-0002-4623-4078 NR 49 TC 31 Z9 32 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD JAN PY 2007 VL 27 IS 1 BP 196 EP 204 DI 10.1038/sj.jcbfm.9600328 PG 9 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 118HX UT WOS:000242934200020 PM 16685257 ER PT J AU Prokhorov, AV Fouladi, RT de Moor, C Warneke, CL Luca, M Jones, MM Rosenblum, C Emmons, KM Hudmon, KS Yost, TE Gritz, ER AF Prokhorov, Alexander V. Fouladi, Rachel T. de Moor, Carl Warneke, Carla L. Luca, Mario Jones, Mary Mullin Rosenblum, Carol Emmons, Karen M. Hudmon, Karen Suchanek Yost, Tracey E. Gritz, Ellen R. TI Computer-assisted, counselor-delivered smoking cessation counseling for community college students: Intervention approach and sample characteristics SO JOURNAL OF CHILD & ADOLESCENT SUBSTANCE ABUSE LA English DT Article DE smoking cessation; prevention; interviews; behavioral medicine ID DECISIONAL BALANCE; ADOLESCENT SMOKERS; CIGARETTE-SMOKING; UNITED-STATES; YOUNG-ADULTS; TOBACCO USE; BEHAVIORS; PREVENTION; EXPERIENCE; DEPENDENCE AB This report presents the experimental approach and baseline findings from "Look at Your Health," an ongoing study to develop and evaluate a computer-assisted, counselor-delivered smoking cessation program for community college students. It describes the expert system software program used for data collection and for provision of tailored feedback, individualized quitting strategies, and personalized newsletters. The transtheoretical model of change, the health belief model, and motivational interviewing provided the theoretical framework for the experimental cohort. Intervention participants received Individual counseling, completed computerized questionnaires, performed measures of spirometric lung functioning and carbon monoxide levels, and were given a calculated lung age. At baseline, participants exhibited measurable tobacco-related health problems and an optimism bias. Addressing this optimism bias appropriately might lead smokers to progress through the stages of smoking cessation toward complete abstinence. C1 Univ Texas, MD Anderson Canc Ctr, Dept Behav Sci, Unit 1330, Houston, TX 77230 USA. Simon Fraser Univ, Dept Psychol, Burnaby, BC V5A 1S6, Canada. Childrens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. Dana Farber Canc Inst, Boston, MA USA. Yale Univ, New Haven, CT 06520 USA. RP Prokhorov, AV (reprint author), Univ Texas, MD Anderson Canc Ctr, Dept Behav Sci, Unit 1330, POB 301439, Houston, TX 77230 USA. EM aprokhor@mdanderson.org NR 43 TC 5 Z9 5 U1 0 U2 2 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1067-828X J9 J CHILD ADOLES SUBST JI J. Child Adolesc. Subst. Abus. PY 2007 VL 16 IS 3 BP 35 EP 62 DI 10.1300/J029v16n03_03 PG 28 WC Substance Abuse SC Substance Abuse GA 186BU UT WOS:000247754900003 ER PT J AU de Lissovoy, G Matza, LS Green, H Werner, M Edgar, T AF de Lissovoy, Gregory Matza, Louis S. Green, Hannah Werner, Meghan Edgar, Terence TI Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy SO JOURNAL OF CHILD NEUROLOGY LA English DT Article DE spasticity; baclofen; cost-effectiveness ID QUALITY-OF-LIFE; ADMINISTERED BACLOFEN; POSTERIOR RHIZOTOMY; MOTOR FUNCTION; CHILDREN; INFUSION; UTILITY; HEALTH; ORIGIN; SYSTEM AB Spasticity is relatively common among children with cerebral palsy. This condition can be painful, can severely impair a child's ability to perform basic tasks, and can place an enormous emotional and financial burden on the family. Intrathecal baclofen delivered via an implantable pump is an effective treatment option for children unresponsive to oral medication and needing generalized motor control. However, the initial investment for the delivery device and its surgical placement can be a barrier to access. A cost-effectiveness analysis of intrathecal baclofen for adults in the British health care system concluded that intrathecal baclofen offered good value for the money. No similar analysis of intrathecal baclofen has been conducted in the context of the US health care system, and no study has specifically examined cost-effectiveness of intrathecal baclofen in a pediatric population. The aim of this article is to assess the cost-effectiveness of intrathecal baclofen among children with severe spasticity of cerebral origin who have not responded to less invasive treatments such as oral medications relative to alternative medical and surgical therapy. The authors used mathematical modeling and computer simulation to estimate the incremental cost per quality-adjusted life-year for identical cohorts of children treated with intrathecal baclofen or alternative therapy over a 5-year episode of treatment. Data on treatment costs representative of these children were derived frorn a health insurance claims database that included both commercial and Medicaid data. Utility values used to construct quality-adjusted life-years were obtained from a panel of expert clinicians who used the Health Utilities Index-2 to rate health states associated with the course of treatment. On average, intrathecal baclofen therapy increased the 5-year cost of treatment by $49 000 relative to alternative treatment. However, this was accompanied by an average gain of 1.2 quality-adjusted life-years. The net result was an incremental cost-effectiveness ratio of $42 000 per quality-adjusted life-year, a figure well within the $ 50 000 to $ 100 000 range that is widely accepted as offering good value for the money. C1 United BioSource Corp, Bethesda, MD 20814 USA. Dana Farber Canc Inst, Boston, MA USA. Prevea Clin, Green Bay, WI USA. RP de Lissovoy, G (reprint author), United BioSource Corp, 7101 Wisconsin Ave,Suite 600, Bethesda, MD 20814 USA. EM gregory.delissovoy@unitedbiosource.com NR 48 TC 36 Z9 38 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 J9 J CHILD NEUROL JI J. Child Neurol. PD JAN PY 2007 VL 22 IS 1 BP 49 EP 59 DI 10.1177/0883073807299976 PG 11 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 169EF UT WOS:000246574800009 PM 17608306 ER PT J AU Brent, GA AF Brent, Gregory A. TI Diagnosing thyroid dysfunction in pregnant women: Is case finding enough? SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Editorial Material ID SUBCLINICAL HYPOTHYROIDISM; DISEASE; DISORDERS; OUTCOMES; ASSOCIATION; MANAGEMENT; HORMONE C1 Univ Calif Los Angeles, Endocrinol & Diabet Div, VA Greater Los Angeles Healthcare Syst, Dept Med,David Geffen Sch Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Endocrinol & Diabet Div, VA Greater Los Angeles Healthcare Syst, Dept Physiol,David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Brent, GA (reprint author), Univ Calif Los Angeles, Endocrinol & Diabet Div, VA Greater Los Angeles Healthcare Syst, Dept Med,David Geffen Sch Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu NR 23 TC 28 Z9 34 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2007 VL 92 IS 1 BP 39 EP 41 DI 10.1210/jc.2006-2461 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 123TB UT WOS:000243317500006 PM 17209222 ER PT J AU Chou, R Fu, RW Carson, S Saha, S Helfand, M AF Chou, Roger Fu, Rongwei Carson, Susan Saha, Somnath Helfand, Mark TI Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE postoperative complications; endarterectomy; carotid; cerebrovascular accident; meta-analysis; regression analysis; cyclooxygenase-2 inhibitors ID RANDOMIZED CONTROLLED-TRIALS; CAROTID-ENDARTERECTOMY; RHEUMATOID-ARTHRITIS; HEALTH-CARE; QUALITY; ROFECOXIB; RISKS; MODEL; OSTEOARTHRITIS; METAANALYSIS AB Objectives: High quality harms data are necessary to appropriately assess the balance between benefits and harms of interventions. Little is known, however, about whether perceived methodological shortcomings are associated with lower estimates of harms. Study Design and Setting: Studies reporting harms associated with carotid endarterectomy (CEA) and rofecoxib were identified using published systematic reviews. A standardized abstraction form, including eight predefined criteria for assessing the quality of harms reporting, was used to extract data. Univariate and multivariate analyses were performed to empirically evaluate the association between quality criteria and estimates of harms. Results: In I I I studies of CEA, meeting five of the eight-quality criteria was associated with significantly higher adverse event rates. A quality-rating instrument with four criteria predicted adverse events (5.7% in studies rated "adequate," compared to 3.9% in studies rated "inadequate" [P = 0.0003]). In multivariate analyses, the quality-rating assignment remained significant when controlling for other clinical and study-related variables. Different quality criteria, however, predicted estimates of risk for myocardial infarction in 16 trials of rofecoxib. Conclusion: The presence of methodological shortcomings can predict lower estimates of serious harms. Clinicians and researchers should consider methodological shortcomings when evaluating estimates of harms associated with clinical interventions. (c) 2006 Elsevier Inc. All rights reserved. C1 Oregon Evidence Based Practice Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Dept Med Informat & Clin Epidemiol, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Dept Publ Hlth & Prevent Med, Portland, OR USA. Dept Emergency Med, Portland, OR USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Chou, R (reprint author), 3181 W Sam Jackson Pk Rd,Mailcode BICC, Portland, OR 97239 USA. EM chour@ohsu.edu FU PHS HHS [290-97-0018] NR 45 TC 14 Z9 14 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD JAN PY 2007 VL 60 IS 1 BP 18 EP 28 DI 10.1016/j.jclinepi.2006.02.021 PG 11 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 120AN UT WOS:000243055800003 PM 17161750 ER PT J AU Brugge, WR AF Brugge, William R. TI Picture imperfect pancreas? SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Editorial Material ID CLASSIFICATION; EUS; CHOLANGIOPANCREATOGRAPHY C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Brugge, WR (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD JAN PY 2007 VL 41 IS 1 BP 3 EP 4 DI 10.1097/01.mcg.0000225618.17341.4a PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 123AW UT WOS:000243269700002 PM 17198058 ER PT J AU Cummings, DE Overduin, J AF Cummings, David E. Overduin, Joost TI Gastrointestinal regulation of food intake SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Review ID GLUCAGON-LIKE PEPTIDE-1; CENTRAL-NERVOUS-SYSTEM; ENTEROENDOCRINE STC-1 CELLS; PLASMA GHRELIN LEVELS; BODY-WEIGHT; PANCREATIC-POLYPEPTIDE; RHESUS-MONKEYS; CHOLECYSTOKININ SECRETION; ENERGY-EXPENDITURE; REDUCES APPETITE AB Despite substantial fluctuations in daily food intake, animals maintain a remarkably stable body weight, because overall caloric ingestion and expenditure are exquisitely matched over long periods of time, through the process of energy homeostasis. The brain receives hormonal, neural, and metabolic signals pertaining to body-energy status and, in response to these inputs, coordinates adaptive alterations of energy intake and expenditure. To regulate food consumption, the brain must modulate appetite, and the core of appetite regulation lies in the gut-brain axis. This Review summarizes current knowledge regarding the neuroendocrine regulation of food intake by the gastrointestinal system, focusing on gastric distention, intestinal and pancreatic satiation peptides, and the orexigenic gastric hormone ghrelin. We highlight mechanisms governing nutrient sensing and peptide secretion by enteroendocrine cells, including novel taste-like pathways. The increasingly nuanced understanding of the mechanisms mediating gut-peptide regulation and action provides promising targets for new strategies to combat obesity and diabetes. C1 Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. RP Cummings, DE (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way,S-111-Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu RI Marion-Poll, Frederic/D-8882-2011 OI Marion-Poll, Frederic/0000-0001-6824-0180 FU NIDDK NIH HHS [P01 DK68384, R01 DK061516, P01 DK068384, R01 DK61516] NR 125 TC 560 Z9 582 U1 12 U2 133 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2007 VL 117 IS 1 BP 13 EP 23 DI 10.1172/JCI30227 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 126TM UT WOS:000243538400003 PM 17200702 ER PT J AU Tache, Y Bonaz, B AF Tache, Yvette Bonaz, Bruno TI Corticotropin-releasing factor receptors and stress-related alterations of gut motor function SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Review ID IRRITABLE-BOWEL-SYNDROME; CENTRAL-NERVOUS-SYSTEM; FACTOR CRF RECEPTOR; CYCLIC VOMITING SYNDROME; WATER-AVOIDANCE STRESS; ANXIETY-LIKE BEHAVIOR; GASTROINTESTINAL MOTILITY; COMPETITIVE ANTAGONISTS; PARAVENTRICULAR NUCLEUS; COLONIC MOTILITY AB Over the past few decades, corticotropin-releasing factor (CRF) signaling pathways have been shown to be the main coordinators of the endocrine, behavioral, and immune responses to stress. Emerging evidence also links the activation of CRF receptors type 1 and type 2 with stress-related alterations of gut motor function. Here, we review the role of CRF receptors in both the brain and the gut as part of key mechanisms through which various stressors impact propulsive activity of the gastrointestinal system. We also examine how these mechanisms translate into the development of new approaches for irritable bowel syndrome, a multifactorial disorder for which stress has been implicated in the pathophysiology. C1 VA Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Div Digest Dis, Los Angeles, CA USA. Grenoble Fac Med & Hosp, Dept Gastroenterol & Hepatol, Grp Etud Stress & Interact Neurodigest, EA3744, Grenoble, France. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU NIAMS NIH HHS [P50 AR049550]; NIDDK NIH HHS [DK41301, P30 DK041301, R01 DK033061, R01 DK057236, R01 DK33061, R01 DK57236] NR 123 TC 171 Z9 179 U1 1 U2 6 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2007 VL 117 IS 1 BP 33 EP 40 DI 10.1172/JCI30085 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 126TM UT WOS:000243538400005 PM 17200704 ER PT J AU Omary, MB Lugea, A Lowe, AW Pandol, SJ AF Omary, M. Bishr Lugea, Aurelia Lowe, Anson W. Pandol, Stephen J. TI The pancreatic stellate cell: a star on the rise in pancreatic diseases SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Review ID SUPPRESSES CHRONIC-PANCREATITIS; BINDING PROTEIN-1 EXPRESSION; CONVERTING ENZYME-INHIBITOR; ERK-DEPENDENT PATHWAYS; CHRONIC HEPATITIS-C; EXTRACELLULAR-MATRIX; DESMOPLASTIC REACTION; MOUSE MODEL; STIMULATING PROLIFERATION; ALCOHOLIC PANCREATITIS AB Pancreatic stellate cells (PaSCs) are myofibroblast-like cells found in the areas of the pancreas that have exocrine function. PaSCs are regulated by autocrine and paracrine stimuli and share many features with their hepatic counterparts, studies of which have helped further our understanding of PaSC biology. Activation of PaSCs induces them to proliferate, to migrate to sites of tissue damage, to contract and possibly phagocytose, and to synthesize ECM components to promote tissue repair. Sustained activation of PaSCs has an increasingly appreciated role in the fibrosis that is associated with chronic pancreatitis and with pancreatic cancer. Therefore, understanding the biology of PaSCs offers potential therapeutic targets for the treatment and prevention of these diseases. C1 VA Palo Alto Hlth Care Syst, Dept Med, Palo Alto, CA 94304 USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. Univ Calif Los Angeles, Res Ctr Alcohol Liver & Pancreat Dis, USC, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Omary, MB (reprint author), VA Palo Alto Hlth Care Syst, Dept Med, 3801 Miranda Ave,154J, Palo Alto, CA 94304 USA. EM stephen.pandol@med.va.gov FU NIAAA NIH HHS [AA11999, AA15781, P50 AA011999, R21 AA015781]; NIDDK NIH HHS [DK47918, DK52951, DK56339, DK73909, P30 DK056339, R01 DK047918, R01 DK052951, R21 DK073909, R56 DK052951] NR 125 TC 284 Z9 292 U1 2 U2 34 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2007 VL 117 IS 1 BP 50 EP 59 DI 10.1172/JCI30082 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 126TM UT WOS:000243538400007 PM 17200706 ER PT J AU Coffey, RJ Washington, MK Corless, CL Heinrich, MC AF Coffey, Robert J. Washington, Mary Kay Corless, Christopher L. Heinrich, Michael C. TI Menetrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Review ID GROWTH-FACTOR-ALPHA; RECEPTOR TYROSINE KINASE; OF-FUNCTION MUTATIONS; BONE-SARCOMA-GROUP; EORTC-SOFT-TISSUE; TERM-FOLLOW-UP; INTERSTITIAL-CELLS; EPITHELIAL-CELLS; IMATINIB MESYLATE; TRANSGENIC MICE AB Menetrier disease and gastrointestinal stromal tumors (GISTs) are hyperproliferative disorders of the stomach caused by dysregulated receptor tyrosine kinases (RTKs). In Menetrier disease, overexpression of TGF-alpha, a ligand for the RTK EGFR, results in selective expansion of surface mucous cells in the body and fundus of the stomach. In GISTs, somatic mutations of the genes encoding the RTK KIT (or PDGFRA in a minority of cases) result in constitutive kinase activity and neoplastic transformation of gut pacemaker cells (interstitial cells of Cajal). On the basis of the involvement of these RTKs in the pathogenesis of these disorders, Menetrier disease patients have been effectively treated with a blocking monoclonal antibody specific for EGFR and GIST patients with KIT and PDGFRA tyrosine kinase inhibitors. C1 Vanderbilt Univ, Dept Med, Med Ctr, Nashville, TN 37232 USA. Vanderbilt Univ, Dept Cell & Dev Biol, Med Ctr, Nashville, TN USA. Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA. Nashville Vet Affairs Med Ctr, Nashville, TN USA. Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Coffey, RJ (reprint author), Vanderbilt Univ, Dept Med, Med Ctr, Suite 4140 MRB 3,465 21st Ave S, Nashville, TN 37232 USA. EM robert.coffey@vanderbilt.edu FU NCI NIH HHS [P50 CA95103, P50 CA095103, R01 CA046413, CA46413] NR 109 TC 56 Z9 61 U1 0 U2 5 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2007 VL 117 IS 1 BP 70 EP 80 DI 10.1172/JCI30491 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 126TM UT WOS:000243538400009 PM 17200708 ER PT J AU Weir, GC Bonner-Weir, S AF Weir, Gordon C. Bonner-Weir, Susan TI A dominant role for glucose in beta cell compensation of insulin resistance SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Editorial Material ID MICE; GLUCOKINASE; EXPRESSION; IRS-2; MASS; APOPTOSIS; RECEPTOR; HUMANS; ISLETS; GROWTH AB Increased insulin secretion and expansion of pancreatic beta cell mass work together to maintain normal glucose levels when insulin resistance develops. Changes in glucose concentration have long been known to have profound effects upon the rates of insulin secretion and beta cell mass, but various other agents can also cause changes, raising questions about which mechanisms are dominant. Evidence favoring a dominant role for glucose is provided by Terauchi et al. in this issue of the JCI (see the related article beginning on page 246). Mice haploinsufficient for beta cell glucokinase (Gck) were unable to increase their beta cell mass in response to insulin resistance produced by high-fat feeding. Gck is known to be the glucose sensor for glucose metabolism in beta cells. The study also provides strong evidence that insulin receptor substrate 2 (Irs2),which is known to have major effects on beta cell growth and survival, is a key downstream mediator of the effects of glucose found in this study. C1 Harvard Univ, Sect Islet Transplantat & Cell Biol, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. RP Weir, GC (reprint author), Harvard Univ, Sect Islet Transplantat & Cell Biol, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM gordon.weir@joslin.harvard.edu NR 21 TC 44 Z9 46 U1 0 U2 3 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2007 VL 117 IS 1 BP 81 EP 83 DI 10.1172/JCI30862 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 126TM UT WOS:000243538400010 PM 17200709 ER PT J AU Moore, VD Brown, JR Certo, M Love, TM Novina, CD Letai, A AF Moore, Victoria Del Gaizo Brown, Jennifer R. Certo, Michael Love, Tara M. Novina, Carl D. Letai, Anthony TI Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID BH3-ONLY PROTEINS; BH3 DOMAIN; MITOCHONDRIAL APOPTOSIS; ANTIAPOPTOTIC BCL-2; FAMILY PROTEINS; MYELOMA CELLS; CYTOCHROME-C; T-CELLS; DEATH; BAX AB Antiapoptotic B cell leukemia/lymphoma 2 (BCL2) family proteins are expressed in many cancers, but the circumstances under which these proteins are necessary for tumor maintenance are poorly understood. We exploited a novel functional assay that uses BCL2 homology domain 3 (BH3) peptides to predict dependence on antiapoptotic proteins, a strategy we call BH3 profiling. BH3 profiling accurately predicts sensitivity to BCL2 antagonist ABT-737 in primary chronic lymphocytic leukemia (CLL) cells. BH3 profiling also accurately distinguishes myeloid cell leukemia sequence 1 (MCL1) from BCL2 dependence in myeloma cell lines. We show that the special sensitivity of CLL cells to BCL2 antagonism arises from the requirement that BCL2 tonically sequester proapoptotic BIM in CLL. ABT-737 displaced BIM from BCL2's BH3-binding pocket, allowing BIM to activate BAX, induce mitochondrial permeabilization, and rapidly commit the CLL cell to death. Our experiments demonstrate that BCL2 expression alone does not dictate sensitivity to ABT-737. Instead, BCL2 complexed to BIM is the critical target for ABT-737 in CLL. An important implication is that in cancer, BCL2 may not effectively buffer chemotherapy death signals if it is already sequestering proapoptotic BH3-only proteins. Indeed, activator BH3-only occupation of BCL2 may prime cancer cells for death, offering a potential explanation for the marked chemosensitivity of certain cancers that express abundant BCL2, such as CLL and follicular lymphoma. C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RP Letai, A (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Dana 530, Boston, MA 02115 USA. EM Anthony_Letai@dfci.harvard.edu OI Del Gaizo Moore, Victoria/0000-0002-6317-7693 NR 40 TC 222 Z9 226 U1 2 U2 20 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2007 VL 117 IS 1 BP 112 EP 121 DI 10.1172/JCI28281 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 126TM UT WOS:000243538400016 ER PT J AU Kurihara, N Hiruma, Y Zhou, H Subler, MA Dempster, DW Singer, FR Reddy, SV Gruber, HE Windle, JJ Roodman, GD AF Kurihara, Noriyoshi Hiruma, Yuko Zhou, Hua Subler, Mark A. Dempster, David W. Singer, Frederick R. Reddy, Sakamuri V. Gruber, Helen E. Windle, Jolene J. Roodman, G. David TI Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID INTERACTING PROTEIN P62; KAPPA-B ACTIVATION; MARROW CULTURES; 1,25-DIHYDROXYVITAMIN D-3; MONONUCLEAR PRECURSORS; BONE-RESORPTION; CELLS; NOMENCLATURE; PHENOTYPE; LESIONS AB Paget disease is the most exaggerated example of abnormal bone remodeling, with the primary cellular abnormality in the osteoclast. Mutations in the p62 (sequestosome 1) gene occur in one-third of patients with familial Paget disease and in a minority of patients with sporadic Paget disease, with the P392L amino acid substitution being the most commonly observed mutation. However, it is unknown how p62(P392L) mutation contributes to the development of this disease. To determine the effects of p62(P392L) expression on osteoclasts in vitro and in vivo, we introduced either the p62(P392L) or WT p62 gene into normal osteoclast precursors and targeted p62(P392L) expression to the osteoclast lineage in transgenic mice. p62(P392L)-transduced osteoclast precursors were hyper-responsive to receptor activator of NF-kappa B ligand (RANKL) and TNF-alpha. and showed increased NF-kappa B signaling but did not demonstrate increased 1,25-(OH)(2)D-3 responsivity, TAF(II)-17 expression, or nuclear number per osteoclast. Mice expressing p62(P392L) developed increased osteoclast numbers and progressive bone loss, but osteoblast numbers were not coordinately increased, as is seen in Paget disease. These results indicate that p62(P392L) expression on osteoclasts is not sufficient to induce the full pagetic phenotype but suggest that p62 mutations cause a predisposition to the development of Paget disease by increasing the sensitivity of osteoclast precursors to osteoclastogenic cytokines. C1 VA Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15260 USA. Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY USA. Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA 23284 USA. Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10027 USA. John Wayne Canc Inst, Endocrine Bone Dis Program, Santa Monica, CA USA. Med Univ S Carolina, Childrens Res Inst, Dept Pediat, Charleston, SC 29425 USA. Carolinas Med Ctr, Dept Orthopaed Surg, Charlotte, NC 28203 USA. RP Kurihara, N (reprint author), VA Pittsburgh Healthcare Syst, Res & Dev, 151C-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM kuriharan@upmc.edu OI Windle, Jolene/0000-0001-6690-385X FU NCATS NIH HHS [UL1 TR000005]; NCI NIH HHS [P30 CA016059, P30-CA16059]; NIAMS NIH HHS [P01 AR049363, P01-AR049363] NR 25 TC 62 Z9 65 U1 0 U2 2 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2007 VL 117 IS 1 BP 133 EP 142 DI 10.1172/JCI28267 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 126TM UT WOS:000243538400018 PM 17187080 ER PT J AU Swirski, FK Libby, P Aikawa, E Alcaide, P Luscinskas, FW Weissleder, R Pittet, MJ AF Swirski, Filip K. Libby, Peter Aikawa, Elena Alcaide, Pilar Luscinskas, F. William Weissleder, Ralph Pittet, Milkael J. TI Ly-6C(hi) monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID LOW-DENSITY-LIPOPROTEIN; C-REACTIVE PROTEIN; BLOOD-CELL COUNT; ACUTE MYOCARDIAL-INFARCTION; RECEPTOR-DEFICIENT MICE; HUMAN PERIPHERAL-BLOOD; APOLIPOPROTEIN-E; IN-VIVO; CHEMOATTRACTANT PROTEIN-1; ATHEROSCLEROTIC LESIONS AB Macrophage accumulation participates decisively in the development and exacerbation of atherosclerosis. Circulating monocytes, the precursors of macrophages, display heterogeneity in mice and humans, but their relative contribution to atherogenesis remains unknown. We report here that the Ly-6C(hi) monocyte subset increased dramatically in hypercholesterolemic apoE-deficient mice consuming a high-fat diet, with the number of Ly-6C(hi) cells doubling in the blood every month. Ly-6C(hi) monocytes adhered to activated endothelium, infiltrated lesions, and became lesional macrophages. Hypercholesterolemia-associated monocytosis (HAM) developed from increased survival, continued cell proliferation, and impaired Ly-6C(hi) to Ly-6C(lo) conversion and subsided upon statin-induced cholesterol reduction. Conversely, the number of Ly-6C(lo) cells remained unaffected. Thus, we believe that Ly-6C(hi) monocytes represent a newly recognized component of the inflammatory response in experimental atherosclerosis. C1 Harvard Univ, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA. Brigham & Womens Hosp, Ctr Excellence Vasc Biol, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Donald W Reynolds Cardiovasc Clin Res Ctr, Boston, MA 02115 USA. RP Pittet, MJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Mol Imaging Res, 13th St,Bldg 149,Room 5403, Charlestown, MA 02129 USA. EM mpittet@hms.harvard.edu FU NCI NIH HHS [P01 CA069246, R24 CA69246]; NHLBI NIH HHS [HL36028, HL53393, P01 HL036028, R01 HL034636, R01HL034636, U01 HL080731]; PHS HHS [P01-A154904] NR 56 TC 614 Z9 627 U1 3 U2 23 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2007 VL 117 IS 1 BP 195 EP 205 DI 10.1172/JCI29950 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 126TM UT WOS:000243538400024 PM 17200719 ER PT J AU Jones, RN Ferraro, MJ Reller, LB Schreckenberger, PC Swenson, JM Sader, HS AF Jones, Ronald N. Ferraro, Mary Jane Reller, L. Barth Schreckenberger, Paul C. Swenson, Jana M. Sader, Helio S. TI Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ANTIMICROBIAL RESISTANCE; NOSOCOMIAL PNEUMONIA; BACTERIAL PATHOGENS; IN-VITRO; INFECTIONS; BAUMANNII; GAR-936; EPIDEMIOLOGY; COLLECTION; SPP. AB Acinetobacter sp. isolates having multidrug resistance (MDR) patterns have become common in many medical centers worldwide, limiting therapeutic options. A five-center study tested 103 contemporary clinical Acinetobacter spp., including MDR strains, by reference broth microdilution and disk diffusion (15-mu g disk content) methods against tigecycline. Applying U.S. Food and Drug Administration tigecycline breakpoint criteria for Enterobacteriaceae (susceptibility at <= 2 mu g/ml [<= 1 mu g/ml by the European Committee on Antimicrobial Susceptibility Testing]; disk diffusion breakpoints at >= 19 mm and <= 14 mm) to Acinetobacter spp. led to an unacceptable error rate (23.3%). However, an adjustment of tigecycline disk diffusion breakpoints (susceptible/resistant) to >= 16/<= 12 mm reduced intermethod errors to an acceptable level (only 9.7%, all minor). C1 JMI Labs, N Liberty, IA 52317 USA. Tufts Univ, Sch Med, Boston, MA 02111 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Duke Univ, Med Ctr, Durham, NC USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. RP Jones, RN (reprint author), JMI Labs, 345 Beaver Kreek Ctr,Suite A, N Liberty, IA 52317 USA. EM ronald-jones@jmilabs.com NR 28 TC 108 Z9 114 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JAN PY 2007 VL 45 IS 1 BP 227 EP 230 DI 10.1128/JCM.01588-06 PG 4 WC Microbiology SC Microbiology GA 131RJ UT WOS:000243887200033 PM 17093026 ER PT J AU D'Amico, AV AF D'Amico, Anthony V. TI Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; EXTERNAL-BEAM RADIATION; PHASE-III; CARDIOVASCULAR-DISEASE; DEPRIVATION THERAPY; ARTERIAL STIFFNESS; CARCINOMA; MEN C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. RP D'Amico, AV (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 23 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2007 VL 25 IS 1 BP 8 EP 9 DI 10.1200/JCO.2006.08.8260 PG 2 WC Oncology SC Oncology GA 129JR UT WOS:000243725900004 PM 17194901 ER PT J AU Bogren, A Teles, R Torresyap, G Haffajee, AD Socransky, SS Lindhe, J Wennstrom, JL AF Bogren, Anna Teles, Ricardo Torresyap, Gay Haffajee, Anne D. Socransky, Sigmund S. Lindhe, Jan Wennstrom, Jan L. TI A three-year prospective study of adult subjects with gingivitis. I: clinical periodontal parameters SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE clinical trial; gingivitis; periodontology; plaque; primary prevention ID ORAL HYGIENE PROCEDURES; TOOTH MORTALITY; DISEASE; CARIES; HEALTH; DOGS AB Aim: The objective of this study was to monitor prospectively clinical parameters in subjects without signs of destructive periodontal disease who were involved in a primary prevention programme, and to determine the changes that occurred between yearly examinations over a 3-year period. Material and Methods: One hundred and twenty-six subjects aged at least 20 years with a maximum of two tooth sites with probing pocket depth (PPD)> 4 mm and no proximal sites with clinical attachment loss participated in the study. Primary prevention was provided at baseline of the study and then every 6 months. Plaque, bleeding on probing (BoP) and PPD were scored at baseline, 1, 2 and 3 years. Results: There were no significant changes in the plaque score over the 3 years. After year 1, the BoP score was significantly improved with 5.6%, while no further improvement in BoP was found at years 2 and 3. The mean PPD decreased from 2.3 to 2.1 mm over the 3 years (p < 0.05). Conclusion: Although some individuals exhibiting minor signs of periodontal pathology may have benefited from the primary prevention, the overall clinical improvement was limited for such subjects in the present 3-year study. C1 Univ Gothenburg, Sahlgrenska Acad, Dept Periodontol, Inst Odontol, SE-40530 Gothenburg, Sweden. Forsyth Inst, Boston, MA USA. RP Bogren, A (reprint author), Univ Gothenburg, Sahlgrenska Acad, Dept Periodontol, Inst Odontol, Box 450, SE-40530 Gothenburg, Sweden. EM Anna.Bogren@odontologi.gu.se FU NIDCR NIH HHS [DE-12108, DE-10977, DE-12861, DE-13232, DE-14242] NR 25 TC 9 Z9 9 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6979 J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD JAN PY 2007 VL 34 IS 1 BP 1 EP 6 DI 10.1111/j.1600-051X.2006.01000.x PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 116CW UT WOS:000242781100001 PM 17137469 ER PT J AU Teles, RP Bogren, A Patel, M Wennstrom, JL Socransky, SS Haffajee, AD AF Teles, R. P. Bogren, A. Patel, M. Wennstrom, J. L. Socransky, S. S. Haffajee, A. D. TI A three-year prospective study of adult subjects with gingivitis II: microbiological parameters SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE bacteria; biofilm; gingivitis; periodontal health; periodontal; subgingival plaque ID SUPRAGINGIVAL PLAQUE CONTROL; DNA-DNA HYBRIDIZATION; PERIODONTAL-DISEASE; SUBGINGIVAL MICROBIOTA; INITIAL PERIODONTITIS; CLINICAL-COURSE; HEALTHY; TOOTHBRUSHES; PROGRAM; MAINTENANCE AB Aim: To investigate whether the clinical benefits obtained with a periodontal prevention programme in subjects with periodontal health or minimal disease were accompanied by beneficial changes in the subgingival microbiota. Materials and Methods: One hundred and twenty-four subjects completed the study. Subjects were clinically and microbiologically monitored at baseline, 1, 2 and 3 years. Subgingival plaque samples were taken from the mesiobuccal aspect of every tooth and were analysed for the levels of 40 bacterial species using checkerboard DNA-DNA hybridization (total samples=13,477). The mean counts of each of the 40 test species were calculated for each subject at each time point. Significance of differences over time was sought using the Friedman test. p values were adjusted for multiple comparisons. Results: All clinical parameters, at the microbiologically sampled sites, improved over time. The clinical changes were accompanied by statistically significant decreases in the mean counts of 35 of the 40 test species. Major reductions occurred by year 2 for Actinomyces, Capnocytophaga, Campylobacter, Fusobacterium and Prevotella species. At year 3, there was a modest re-growth of the majority of the species. Conclusions: The clinical improvements obtained through preventive measures were accompanied by a shift to a more host-compatible subgingival microbiota. C1 Forsyth Inst, Dept Periodontol, Boston, MA 02115 USA. Univ Gothenburg, Sahlgrenska Acad, Dept Periodontol, Inst Odontol, Gothenburg, Sweden. RP Teles, RP (reprint author), Forsyth Inst, Dept Periodontol, 140 Fenway, Boston, MA 02115 USA. EM rteles@forsyth.org FU NIDCR NIH HHS [DE-12861, DE-10977, DE-12108, DE-13232, DE-14242] NR 37 TC 13 Z9 13 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6979 J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD JAN PY 2007 VL 34 IS 1 BP 7 EP 17 DI 10.1111/j.1600-051X.2006.01015.x PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 116CW UT WOS:000242781100002 PM 17243995 ER PT J AU Cohen, LS AF Cohen, Lee S. TI Treatment of bipolar disorder during pregnancy SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Teleconference on Special Issues Related to the Management of Bipolar Disorder in Women - Tolerability of Treatment CY JAN-FEB -, 2006 CL ELECTR NETWORK ID SEROTONIN-REUPTAKE INHIBITORS; IN-UTERO EXPOSURE; ANTIDEPRESSANT TREATMENT; MAJOR MALFORMATIONS; BIRTH-DEFECTS; SPINA-BIFIDA; MATERNAL USE; DRUG-USE; WOMEN; RISK AB The treatment of bipolar disorder during pregnancy or in those women who wish to conceive poses a unique set of dilemmas with which clinicians should be familiar. Given the teratogenicity of some psychotropic medications used to treat bipolar disorder and incomplete reproductive safety data for agents frequently employed to manage the illness, patients and clinicians should collaborate as they weigh options regarding appropriate pharmacologic therapy during pregnancy. Ultimately, risk-benefit decisions are made that must factor in the risk of relapse of psychiatric illness during pregnancy and its attendant morbidity versus the risk of fetal exposure to these agents. No clinical decision is risk-free, and patients with comparable information about risks and benefits of treatment options may make different decisions. However, awareness of the latest reproductive safety data across the family of compounds used to treat bipolar disorder, including antipsychotics, antidepressants, mood stabilizers, and anticonvulsants, allows for the most informed decisions. This article (1) describes the treatment dilemmas faced by bipolar women who are either pregnant or who wish to conceive, (2) reviews the teratogenic risks associated with commonly used psychotropic medications used to treat the illness, and (3) provides some clinical guidelines for treating this population during pregnancy. C1 Massachusetts Gen Hosp, Perinatal & Reproduct Psychiat Clin Res Program, Boston, MA 02114 USA. RP Cohen, LS (reprint author), Simches Res Bldg,185 Cambridge St,2nd Floor, Boston, MA 02114 USA. NR 55 TC 24 Z9 25 U1 2 U2 9 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 9 BP 4 EP 9 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 210CZ UT WOS:000249435600001 PM 17764378 ER PT J AU Fava, M AF Fava, Maurizio TI Augmenting antidepressants with folate: A clinical perspective SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Roundtable Meeting on the Role of Folate in Depression and Dementia CY JAN 18, 2007 CL Philadelphia, PA ID MAJOR DEPRESSIVE DISORDER; FOLIC-ACID; RESISTANT DEPRESSION; CHRONIC-ALCOHOLICS; DIABETES-MELLITUS; SERUM FOLATE; FLUOXETINE; HOMOCYSTEINE; SYMPTOMS; DISEASE AB The goal of treatment of depression is full remission, but only a minority of patients will achieve full remission with antidepressant monotherapy. Several forms of augmentation have been found to improve the effect of antidepressants, but in some cases, issues of safety and tolerability may be of concern. Folate in particular has been found to further reduce symptoms in patients with depression when used in conjunction with an antidepressant, and because folate is a water-soluble B vitamin, its safety and tolerability are well established. This strategy would typically be used in patients with low plasma or red blood cell folate levels. Folate augmentation may be used (1) to enhance the efficacy of antidepressants in nonresponders, (2) to enable those who partially respond to antidepressant monotherapy to achieve remission, and (3) to alleviate residual symptoms during antidepressant treatment. C1 Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med,Depress Clin & Res Program, Boston, MA 02114 USA. RP Fava, M (reprint author), Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med,Depress Clin & Res Program, 55 Fruit St,Bulfinch 351, Boston, MA 02114 USA. EM mfava@partners.org NR 34 TC 14 Z9 14 U1 1 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 10 BP 4 EP 7 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 222XV UT WOS:000250332700001 PM 17900202 ER PT J AU Wilens, TE AF Wilens, Timothy E. TI The nature of the relationship between attention-deficit/hyperactivity disorder and substance use SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Teleconferenc on Attention-Deficit/Hyperactivity Disorder and Comorbid Substance Use Disorder CY NOV-DEC -, 2006 CL ELECTR NETWORK ID DEFICIT HYPERACTIVITY DISORDER; NATIONAL-COMORBIDITY-SURVEY; PSYCHIATRIC STATUS; YOUNG-ADULTS; FOLLOW-UP; COCAINE ABUSERS; RISK FACTOR; DRUG-USE; CHILDREN; ADHD AB This report examines the developmental relationship between attention-deficit/hyperactivity disorder (ADHD) and substance use disorders (SUD) and associated concurrent disorders relative to adolescents and adults. ADHD is a risk factor for the development of SUD in adulthood, and it is particularly of concern with conduct and bipolar disorder comorbidities. Conversely, approximately one fifth of adults with SUD have ADHD. Individuals with SUD and ADHD have a more severe and complicated course of SUD. Pharmacotherapeutic treatment of ADHD in children reduces the risk for later cigarette smoking and SUD in adulthood. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Psychiat,Pediat Psychopharmacol Clin, Pediat Psychopharmacol Unit, Boston, MA 02114 USA. RP Wilens, TE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Psychiat,Pediat Psychopharmacol Clin, Pediat Psychopharmacol Unit, ACC 725, Boston, MA 02114 USA. EM TWilens@partners.org FU NIDA NIH HHS [5U10DA015831-0, K24 DA016264, R01 DA14419-01 A1] NR 50 TC 49 Z9 49 U1 0 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 11 BP 4 EP 8 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 218DX UT WOS:000249997300001 PM 18307375 ER PT J AU Joffe, H AF Joffe, Hadine TI Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Teleconference on Special Issues Related to the Management of Bipolar Disorder in Women - Tolerability of Treatment CY JAN-FEB -, 2006 CL ELECTR NETWORK ID POLYCYSTIC-OVARIAN-SYNDROME; ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA; HUMAN BREAST-CANCER; ENDOCRINE DISORDERS; VALPROATE; EPILEPSY; LAMOTRIGINE; HYPERANDROGENISM; MEDICATION; PROLACTIN AB Treating women with bipolar disorder during the reproductive years requires special consideration because of the reproductive risks associated with specific psychotropic drugs and drug interactions with hormonal contraceptives. Some psychotropic drugs can disrupt the menstrual cycle, alter pregnancy potential, and increase the risk for chronic conditions associated with hormone changes, such as prolactin elevation and polycystic ovarian syndrome (PCOS). Valproate has been associated with an increased risk of PCOS features. Typical antipsychotics and risperidone can increase prolactin production, which may also disrupt the menstrual cycle. When the menstrual cycle is altered, fertility is reduced, and medical conditions such as osteoporosis and endometrial hyperplasia can result. This article advises establishing the regularity of menstrual cycles and discussing the potential reproductive impact of specific psychotropic medications before initiating treatment in women with bipolar disorder who are of reproductive age. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Perinatal & Reprod Psychiat Clin Res Program,Dept, Boston, MA 02114 USA. RP Joffe, H (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Perinatal & Reprod Psychiat Clin Res Program,Dept, 185 Cambridge St, Boston, MA 02114 USA. EM hjoffe@partners.org NR 39 TC 6 Z9 7 U1 2 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 9 BP 10 EP 15 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 210CZ UT WOS:000249435600002 PM 17764379 ER PT J AU Papakostas, GI AF Papakostas, George I. TI Limitations of contemporary antidepressants: Tolerability SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Roundtable Meeting on the Role of Folate in Depression and Dementia CY JAN 18, 2007 CL Philadelphia, PA ID MAJOR DEPRESSIVE DISORDER; SEROTONIN REUPTAKE INHIBITORS; BUPROPION SUSTAINED-RELEASE; LONG-TERM TREATMENT; VENLAFAXINE EXTENDED-RELEASE; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIALS; TRAZODONE PROLONGED-RELEASE; PAROXETINE-CONTROLLED TRIAL; DOUBLE-BLIND AB Antidepressant side effects are common and persistent. They can contribute to discomfort, distress, disability, morbidity, and mortality and can compromise the efficacy of treatments. Reducing the side effect burden, either by developing treatments that have a lower incidence of side effects or by using treatment strategies that alleviate side effects, would improve the standard of care for mood and anxiety disorders. In this article, the rates of common adverse events among the newer (posttricyclic era) antidepressants are compared with those among the selective serotonin reuptake inhibitors, the most popular, contemporary first-line treatments for depression. C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Papakostas, GI (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 50 Staniford St,4th Floor, Boston, MA 02114 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 NR 127 TC 26 Z9 27 U1 2 U2 10 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 10 BP 11 EP 17 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 222XV UT WOS:000250332700003 PM 17900204 ER PT J AU Thase, ME AF Thase, Michael E. TI Recognition and diagnosis of atypical depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Roundtable Conference on MAOIs Revisited - Their Role in Depressive Disorders CY JAN 29, 2006 CL Miami, FL ID CORTICOTROPIN-RELEASING HORMONE; STAR-ASTERISK-D; AGE-OF-ONSET; MAJOR DEPRESSION; CUSHINGS-SYNDROME; PSYCHIATRIC MANIFESTATIONS; BIPOLAR DEPRESSION; FEATURES; SYMPTOMS; VALIDATION AB The term atypical depression dates to the first wave of reports describing differential response to monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). In contrast to more TCA-responsive depressions, patients with so-called atypical symptoms (e.g., hypersomnia, interpersonal sensitivity, leaden paralysis, increased appetite and/or weight, and phobic anxiety) were observed to be more responsive to MAOIs. After several decades of controversy and debate, the phrase "with atypical features" was added as an episode specifier in the DSM-IV in 1994. The 1-year prevalence of the defined atypical depression subtype is approximately 1% to 4%; around 15% to 29% of patients with major depressive disorder have atypical depression. Hardly "atypical" in contemporary contexts, atypical depression also is common in dysthymic bipolar II disorders and is notable for its early age at onset, more chronic course, and high rates of comorbidity with social phobia and panic disorder with agoraphobia. The requirement of preserved mood reactivity is arguably the most controversial of the DSM-IV criteria for atypical depression. When compared with melancholia, the neurobiological profiles of patients with atypical depression are relatively normal. The utility of the atypical depression subtype for differential therapeutics diminished substantially when the TCAs were supplanted as first-line antidepressants by the selective serotonin reuptake inhibitors. Although introduction of safer MAOIs has fostered renewed interest in atypical depression, the validity and importance of the DSM-IV definition of atypical depression for the nosology of affective illness remains an open question. C1 Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19380 USA. Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. RP Thase, ME (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St,Room 689, Philadelphia, PA 19380 USA. EM thase@mail.med.upenn.edu NR 57 TC 36 Z9 37 U1 2 U2 10 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 8 BP 11 EP 16 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 196MQ UT WOS:000248487100002 PM 17640153 ER PT J AU Faraone, SV Wilens, TE AF Faraone, Stephen V. Wilens, Timothy E. TI Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Teleconferenc on Attention-Deficit/Hyperactivity Disorder and Comorbid Substance Use Disorder CY NOV-DEC -, 2006 CL ELECTR NETWORK ID DEFICIT-HYPERACTIVITY DISORDER; UNDERGRADUATE STUDENT SAMPLE; PRESCRIPTION STIMULANTS; DOUBLE-BLIND; DOPAMINE TRANSPORTER; ORAL METHYLPHENIDATE; HUMAN BRAIN; ILLICIT USE; RELEASE METHYLPHENIDATE; PSYCHIATRIC-DISORDERS AB The objective of this article is to review literature about the effects of stimulant therapy on substance use disorders and the potential for misuse and diversion of stimulants. We reviewed published literature relevant to these objectives, and studies were selected if they were published or accepted for publication in peer-reviewed journals. Prospective longitudinal studies show that attention-deficit/hyperactivity disorder (ADHD) is a risk factor for subsequent substance use disorders. These studies also suggest that ADHD pharmacotherapy in childhood reduces the risk for substance use disorders. Misuse and diversion of prescribed stimulants occur among a minority of ADHD patients, especially those with conduct or substance use disorders. Long-acting stimulants may be less likely to be misused or diverted. C1 SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. SUNY Upstate Med Univ, Dept Behav Neurosci & Physiol, Syracuse, NY 13210 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Pediat Psychopharmacol Unit, Boston, MA 02115 USA. RP Faraone, SV (reprint author), SUNY Upstate Med Univ, Dept Psychiat & Behav Sci, 750 E Adams St, Syracuse, NY 13210 USA. EM faraones@upstate.edu OI Faraone, Stephen/0000-0002-9217-3982 FU NIMH NIH HHS [R01MH57934] NR 93 TC 39 Z9 40 U1 1 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 11 BP 15 EP 22 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 218DX UT WOS:000249997300003 PM 18307377 ER PT J AU Soares, CN Taylor, V AF Soares, Claudio N. Taylor, Valerie TI Effects and management of the menopausal transition in women with depression and bipolar disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Teleconference on Special Issues Related to the Management of Bipolar Disorder in Women - Tolerability of Treatment CY JAN-FEB -, 2006 CL ELECTR NETWORK ID RANDOMIZED CONTROLLED-TRIAL; BONE-MINERAL DENSITY; HEALTH INITIATIVE MEMORY; ESTROGEN PLUS PROGESTIN; QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; PERIMENOPAUSAL WOMEN; ANTIEPILEPTIC DRUGS; COGNITIVE FUNCTION; OLDER WOMEN AB Unipolar and bipolar disorders are major causes of disease burden for women in the United States. For some women, the menopausal transition can represent a time of increased vulnerability to depression, a greater risk of recurrence or instability of bipolar disorder, and an overall poorer quality of life (QOL). The physical and psychological changes of menopause and symptoms of depression may overlap, but QOL is affected doubly for women experiencing menopause-related complaints concomitantly with a unipolar or bipolar disorder. Treatments for the symptoms of menopause and for unipolar or bipolar disorder need to be chosen with careful consideration for the different stages of the menopausal transition, as well as safety, tolerability, and impact on QOL. Menopausal-related symptoms can be treated with hormonal therapies, antidepressants, and herbal supplements, but a critical window of opportunity may exist for these interventions. Bipolar disorder presents differently in women than in men and may require different medication. For instance, in women, lithium may be less effective for patients who have rapid cycling; adjuvant antidepressant medication may be required with valproate or carbamazepine; and lamotrigine may also be effective. Most of the medications that are standard treatment for bipolar disorder affect bone mineral density, and the risk for impaired QOL should be considered when choosing medication for women during this period. Insufficient information is available, however, to assess the best strategy to treat women with bipolar disorder and depression as they age. C1 McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada. St Josephs Hlth Ctr, Womens Hlth Concerns Clin, Hamilton, ON, Canada. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. RP Soares, CN (reprint author), 301 James St S,FB 638, Hamilton, ON L8P 3B6, Canada. EM csoares@mcmaster.ca RI Taylor, Valerie/H-6242-2015 NR 48 TC 9 Z9 9 U1 1 U2 7 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 9 BP 16 EP 21 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 210CZ UT WOS:000249435600003 PM 17764380 ER PT J AU Henderson, DC AF Henderson, David C. TI Weight gain with atypical antipsychotics: Evidence and insights SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; INSULIN-RESISTANCE; ADJUNCTIVE TREATMENT; RISK-FACTOR; SCHIZOPHRENIA; OBESITY; ABNORMALITIES; DYSFUNCTION; CLOZAPINE AB Weight gain associated with antipsychotic medication can be a barrier to the overall improvement of mental health patients due to a discontinuation of treatment. The goal of this article is to establish a better understanding regarding the mechanisms of antipsychotic medications and their associated risk of weight gain, obesity, and subsequent mortality and morbidity. Additionally, the need to closely monitor patients' lifestyles and homeostatic components in order to prevent weight gain or facilitate weight loss is emphasized. C1 Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA. RP Henderson, DC (reprint author), 512 Springs Rd, Bedford, MA 01730 USA. EM dchenderson@partners.org NR 30 TC 48 Z9 48 U1 3 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 12 BP 18 EP 26 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 223SM UT WOS:000250392600004 PM 17956152 ER PT J AU Mischoulon, D Raab, MF AF Mischoulon, David Raab, Michael Franz TI The role of folate in depression and dementia SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Roundtable Meeting on the Role of Folate in Depression and Dementia CY JAN 18, 2007 CL Philadelphia, PA ID METHYLENETETRAHYDROFOLATE REDUCTASE VARIANT; ADENOSYL-L-METHIONINE; FOLIC-ACID; TOTAL HOMOCYSTEINE; SERUM FOLATE; COGNITIVE FUNCTION; ANTIDEPRESSANT ACTION; MONOAMINE METABOLISM; S-ADENOSYLMETHIONINE; PSYCHIATRIC-PATIENTS AB Adequate levels of folate are crucial for proper brain and body functioning. Folate deficiencies may lead to an increased risk of depression and poorer antidepressant treatment outcomes, as well as an increased risk of cognitive impairment and dementia. In 1996, the U.S. Food and Drug Administration mandated fortification of grain products with folic acid, which has brought about vast reductions in folate deficiency. However, folate deficiencies may be caused by improper absorption and utilization, often due to genetic polymorphisms. Individuals, therefore, can have insufficient levels or lack needed forms of folate, despite adequate intake. Supplementation with the active form of folate, me thy I tetrahydrofolate, which is more readily absorbed, may be effective in the prevention and treatment of both depression and dementia. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. Lee Mem Hlth Syst, Older Adult Serv, Ft Myers, FL USA. RP Mischoulon, D (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Suite 401,50 Staniford St, Boston, MA 02114 USA. EM dinischoulon@partners.org NR 79 TC 28 Z9 29 U1 2 U2 8 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 10 BP 28 EP 33 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 222XV UT WOS:000250332700006 PM 17900207 ER PT J AU Viguera, AC Koukopoulos, A Muzina, DJ Baldessarini, RJ AF Viguera, Adele Casals Koukopoulos, Alexia Muzina, David J. Baldessarini, Ross J. TI Teratogenicity and anticonvulsants: Lessons from neurology to psychiatry SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Teleconference on Special Issues Related to the Management of Bipolar Disorder in Women - Tolerability of Treatment CY JAN-FEB -, 2006 CL ELECTR NETWORK ID PREGNANCY REGISTRY; CHILDREN BORN; EPILEPSY; MALFORMATIONS; LAMOTRIGINE; MANAGEMENT; MOTHERS AB Anticonvulsants are considered first-line treatments for epilepsy, and some also exert useful effects as mood stabilizers for the treatment of bipolar (manic-depressive) disorder. Much of the research on anticonvulsant use during pregnancy has been done by neurologists studying women with epilepsy. Anticonvulsant use during pregnancy is associated with increased risk of fetal malformations, but withdrawing medication is highly risky for most women with epilepsy or bipolar disorder. Thus, careful clinical monitoring and coordinated care among patient, partner, obstetrician, and psychiatrist are necessary to limit both teratogenetic and neuropsychiatric risks. Several pregnancy registries have appeared. They include the International Registry of Antiepileptic Drugs and Pregnancy (EURAP), the North American Antiepileptic Pregnancy Registry, the International Lamotrigine Pregnancy Registry, the United Kingdom Epilepsy and Pregnancy Register, and the Australian Pregnancy Registry. Data from these registries are helping medical professionals in assessing risks associated with anticonvulsant use during pregnancy and communicating those risks to patients. C1 Massachusetts Gen Hosp, Perinatal & Reproduct Psychiat Progran, Boston, MA 02114 USA. Cleveland Clin Fdn, Dept Psychiat & Psychol, Cleveland, OH 44195 USA. McLean Hosp, Dept Neuropharmacol, Belmont, MA 02178 USA. RP Viguera, AC (reprint author), Massachusetts Gen Hosp, Perinatal & Reproduct Psychiat Progran, 185 Cambridge St,Suite 2200, Boston, MA 02114 USA. EM aviguera@partners.org RI Kothari, Khyati/B-5008-2014 NR 22 TC 12 Z9 12 U1 0 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 9 BP 29 EP 33 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 210CZ UT WOS:000249435600005 PM 17764382 ER PT J AU Goff, DC AF Goff, Donald C. TI Integrating general health care in private community psychiatry practice SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Meeting on Strategies to Integrate Physical Health Care Into Mental Health CY AUG 28, 2006 CL Philadelphia, PA ID MENTAL-DISORDERS; MEDICAL-CARE; SCHIZOPHRENIA; MORTALITY; PREVALENCE; ILLNESS; TRIAL; RISKS; CATIE AB Persons with serious mental illness represent a special at-risk population, with elevated medical comorbidity and mortality rates, mainly due to cardiovascular disease. For this reason, the treatment plan for patients with mental illness must include the assessment of medical risk factors, beginning at the time of the initial psychiatric evaluation. Follow-up assessments should proceed as recommended by the Expert Consensus Development Panel convened by the American Diabetes Association, the American Psychiatric Association, and other relevant specialty organizations. Because the various second-generation antipsychotics (SGAs) have unique side effect profiles with respect to cardiometabolic risk factors, such as weight gain and dyslipidemia, the selection of an SGA always should weigh efficacy versus potential risks. Prior to initiating antipsychotic therapy, the psychiatrist should not only explain to the patient the risks of the medication and alternative treatments, but also address preventive strategies and the importance of monitoring. To help evaluate the patient's response and manage SGA-related adverse effects, the psychiatrist should spend considerable time in contact with the patient, the patient's family and/or caregivers (as appropriate), and the patient's primary care physician. To enhance overall patient care, the psychiatrist in private practice should implement procedures to ensure adequate patient education and address overall health monitoring. Furthermore, the psychiatrist must serve as a patient advocate, actively working to foster communication with medical colleagues, especially primary care practitioners, and identify resources in the community that facilitate preventive health care. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Schizophrenia Program,Freedom Trail Clin, Boston, MA 02114 USA. RP Goff, DC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Schizophrenia Program,Freedom Trail Clin, 25 Staniford St,2nd Floor, Boston, MA 02114 USA. EM goff@psych.mgh.harvard.edu NR 30 TC 12 Z9 12 U1 4 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2007 VL 68 SU 4 BP 49 EP 54 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 167PD UT WOS:000246462700009 PM 17539701 ER PT J AU Cusin, C Fava, M Amsterdam, JD Quitkin, FM Reimherr, FW Beasley, CM Rosenbaum, JE Perlis, RH AF Cusin, Cristina Fava, Maurizio Amsterdam, Jay D. Quitkin, Frederic M. Reimherr, Frederick W. Beasley, Charles M., Jr. Rosenbaum, Jerrold E. Perlis, Roy H. TI Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: Prevalence and implications SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 45th Annual Meeting of the New-Clinical-Drug-Evaluation-Unit CY JUN 06-09, 2005 CL Boca Raton, FL SP NIMH, New Clin Drug Evaluat Unit ID TRUE DRUG RESPONSE; PATTERN-ANALYSIS; ANTIDEPRESSANT RESPONSE; CLINICAL-SIGNIFICANCE; RELAPSE; METAANALYSIS; ONSET; RISK; RATIONALE; SUICIDE AB Background: A subset of patients experience worsening of depressed mood after beginning antidepressant treatment, which could represent the natural history of the illness or a treatment-related effect. While patterns of response have been examined as possible predictors of outcome, the clinical correlates and implications of early worsening per se have not been investigated. Method: In a post hoc analysis, we studied the clinical correlates of early worsening in a large sample of outpatients (N=694) diagnosed with a DSM-III-R-defined major depressive episode and treated with fluoxetine (20 mg/day) for up to 12 weeks. We defined early worsening as an increase of at least 5 points on a modified 17-item Hamilton Rating Scale for Depression (mHAM-D, including reverse vegetative symptoms) compared to the previous visit, and occurring during the acute phase of treatment. The primary analysis compared remission and response at week 12 between those patients with and without worsening. Results: In our sample, 211 patients (30.4%) experienced early worsening of depression. An increase in mHAM-D score at week 2, 3, 4, or 6 was associated with a significantly lower probability of remission and response at both week 8 and week 12, while no significant difference was observed in study discontinuation. Baseline features, including gender, age, mHAM-D score at entry, number of previous depressive episodes, and duration of illness were not associated with the development of early worsening during fluoxetine treatment. Conclusion: Early clinical worsening is common and associated with a decreased likelihood of achieving remission. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA 02114 USA. Univ Penn, Med Ctr, Univ Sci Ctr, Depress Res Unit, Philadelphia, PA 19104 USA. Columbia Univ, Sch Med, New York State Psychiat Inst, New York, NY USA. Univ Utah, Sch Med, Salt Lake City, UT USA. Lilly Res Labs, Indianapolis, IN USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Cusin, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, 50 Staniford St,4th Floor,Suite 401, Boston, MA 02114 USA. EM ccusin@partners.org OI Beasley, Charles/0000-0001-8743-7691 FU NIMH NIH HHS [K23 MH-067060] NR 30 TC 14 Z9 14 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2007 VL 68 IS 1 BP 52 EP 57 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 131VH UT WOS:000243898400006 PM 17284130 ER PT J AU Keck, PE Sachs, GS Vieta, E AF Keck, Paul E., Jr. Sachs, Gary S. Vieta, Eduard TI The evolving paradigm for bipolar disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID PLACEBO-CONTROLLED TRIAL; RELEASE CARBAMAZEPINE CAPSULES; LITHIUM MAINTENANCE TREATMENT; CONTROLLED 18-MONTH TRIAL; D-2 RECEPTOR OCCUPANCY; DOUBLE-BLIND PET; I-DISORDER; ANTIPSYCHOTIC-DRUGS; ACUTE MANIA; RISPERIDONE MONOTHERAPY C1 Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. Partners Bipolar Treatment Ctr, Boston, MA USA. Univ Barcelona, Hosp Clin IDIBAPS, Bipolar Disorders Program, Barcelona, Spain. RP Keck, PE (reprint author), Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA. RI Vieta, Eduard/I-6330-2013 OI Vieta, Eduard/0000-0002-0548-0053 NR 73 TC 1 Z9 1 U1 3 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2007 VL 68 IS 1 BP 139 EP 150 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 131VH UT WOS:000243898400018 ER PT J AU Krystal, A Fava, M Rubens, R Wessel, T Caron, J Wilson, P Roth, T McCall, WV AF Krystal, Andrew Fava, Maurizio Rubens, Robert Wessel, Thomas Caron, Judy Wilson, Phebe Roth, Thomas McCall, W. Vaughn TI Evaluation of Eszopiclone Discontinuation After Cotherapy With Fluoxetine for Insomnia With Coexisting Depression SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE Insomnia; major depressive disorder; rebound; withdrawal; fluoxetine; eszopiclone AB Background: Insomnia and major depressive disorder (MDD) may coexist. This study evaluated hypnotic discontinuation effects following an 8-week placebo-controlled study of eszopiclone/fluoxetine cotherapy in patients with insomnia and comorbid MDD. Methods: Patients meeting DSM-IV criteria for MDD and insomnia received fluoxetine each morning for 8 weeks and were randomized to concomitant treatment with nightly eszopiclone 3mg (cotherapy) or placebo (monotherapy). Thereafter, patients received 2 weeks of continued fluoxetine plus single-blind placebo. Results: Incidence rates of central nervous system (CNS) and potentially CNS-related adverse events (AEs) during the run-out period were similar between treatment groups (8.8% with monotherapy vs 9.8% with cotherapy), and there was no evidence of benzodiazepine withdrawal AEs. Physician-assessed Clinical Global Impression improvements in depressive symptoms were maintained after eszopiclone discontinuation. Improvements in 17-item Hamilton-Depression Rating Scale (HAM-D-17) scores with cotherapy versus monotherapy seen at Week 8 (p=.0004) were maintained at Week 10 (p<.0001) and significantly higher depression response and remission rates were observed after cotherapy at Week 10 (p<.02). Patients discontinued from eszopiclone maintained improvements in SL (sleep latency), WASO (wake after sleep onset), and TST (total sleep time) during the 2 weeks following discontinuation (p<.05). Conclusions: In this study, eszopiclone discontinuation did not result in significant CNS or benzodiazepine withdrawal AEs, rebound insomnia, or rebound depression; and improvements in sleep and depressive symptoms were maintained. C1 [Krystal, Andrew] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Fava, Maurizio] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rubens, Robert; Wessel, Thomas; Caron, Judy; Wilson, Phebe] Sepracor Inc, Marlborough, MA USA. [Roth, Thomas] Henry Ford Sleep Disorders Ctr, Detroit, MI USA. [McCall, W. Vaughn] Wake Forest Univ Hlth Sci, Winston Salem, NC USA. RP Krystal, A (reprint author), Trent Dr Room 54221, Durham, NC 27710 USA. EM krystal@phy.duke.edu RI Krystal, Andrew/J-7109-2013 OI Krystal, Andrew/0000-0002-6702-781X FU Sepracor Inc., Marlborough, MA FX Support for this study provided by Sepracor Inc., Marlborough, MA. The authors wish to acknowledge Kimberly Pfleeger of Sepracor Inc. for her assistance in the preparation of this manuscript. NR 30 TC 51 Z9 52 U1 1 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2007 VL 3 IS 1 BP 48 EP 55 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA V44VH UT WOS:000209776000009 PM 17557453 ER PT J AU Castriotta, RJ Wilde, MC Lai, JM Atanasov, S Masel, BE Kuna, ST AF Castriotta, Richard J. Wilde, Mark C. Lai, Jenny M. Atanasov, Strahil Masel, Brent E. Kuna, Samuel T. TI Prevalence and Consequences of Sleep Disorders in Traumatic Brain Injury SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE Trauma; brain injury; hypersomnia; sleep apnea; narcolepsy; sleep disorders AB Study Objectives: Determine prevalence and consequences of sleepiness and sleep disorders after traumatic brain injury (TBI). Methods: Prospective evaluation with polysomnography (PSG), multiple sleep latency test (MSLT), Epworth Sleepiness Scale (ESS) and neuropsychological testing including Psychomotor Vigilance Test (PVT), Profile of Mood States (POMS), and Functional Outcome of Sleep Questionnaire (FOSQ). Setting: Three academic medical centers with level I trauma centers, accredited sleep disorders centers, and rehabilitative medicine programs. Participants: Eighty-seven (87) adults at least 3 months post TBI. Measurements And Results: Abnormal sleep studies were found in 40 subjects (46%), including 20 (23%) with obstructive sleep apnea (OSA), 10 (11%) with posttraumatic hypersomnia (PTH), 5 (6%) with narcolepsy, and 6 (7%) with periodic limb movements in sleep (PLMS). Among all subjects, 22 (25%) were found to have objective excessive daytime sleepiness with MSLT score <10 minutes. There was no correlation between ESS score and MSLT (r = 0.10). There were no differences in age, race, sex, or education between the sleepy and non-sleepy subjects. injury between sleepy and non-sleepy subjects. Sleepy subjects had a greater body mass index (BMI) than those who were not sleepy (p = 0.01). OSA was more common in obese subjects (BMI = 30, p <0.001). Sleepy subjects demonstrated poorer PVT scores (p <0.05), better self-reported sleep related quality of life (FOSQ scores [p <0.05]), and no differences in POMS. Conclusions: There is a high prevalence of sleep disorders (46%) and of excessive daytime sleepiness (25%) in subjects with TBI. Sleepy subjects may be more impaired than comparable non-sleepy TBI subjects, yet be unaware of problems. Given the high prevalence of OSA (23%), PTH (11%), and narcolepsy (7%) in this population, there is a clinical indication for NPSG and MSLT. C1 [Castriotta, Richard J.; Wilde, Mark C.; Lai, Jenny M.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Castriotta, Richard J.; Wilde, Mark C.; Lai, Jenny M.] Mem Hermann Hosp Sleep Disorders Ctr, Houston, TX USA. [Atanasov, Strahil] Univ Texas Med Branch, Galveston, TX 77555 USA. [Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA. [Kuna, Samuel T.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Castriotta, RJ (reprint author), Univ Texas Hlth Sci Ctr Houston, Div Pulm Crit Care & Sleep Med, 6431 Fannin St,MSB 1-274, Houston, TX 77030 USA. EM Richard.J.Castriotta@uth.tmc.edu OI Castriotta, Richard/0000-0003-3502-4558 FU Moody Foundation; Cephalon, Inc. FX This research was supported by the Moody Foundation and Cephalon, Inc. We would like to express our appreciation to Amal Abuelheiga, RPSGT for her assistance with this project. NR 41 TC 126 Z9 128 U1 1 U2 6 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2007 VL 3 IS 4 BP 349 EP 356 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA V44VK UT WOS:000209776300003 PM 17694722 ER PT J AU Collop, NA Anderson, WM Boehlecke, B Claman, D Goldberg, R Gottlieb, DJ Hudgel, D Sateia, M Schwab, R AF Collop, Nancy A. Anderson, W. McDowell Boehlecke, Brian Claman, David Goldberg, Rochelle Gottlieb, Daniel J. Hudgel, David Sateia, Michael Schwab, Richard TI Clinical Guidelines for the Use of Unattended Portable Monitors in the Diagnosis of Obstructive Sleep Apnea in Adult Patients SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE Clinical guidelines; portable monitoring; home study; obstructive sleep apnea; comprehensive evaluation AB Based on a review of literature and consensus, the Portable Monitoring Task Force of the American Academy of Sleep Medicine (AASM) makes the following recommendations: unattended portable monitoring (PM) for the diagnosis of obstructive sleep apnea (OSA) should be performed only in conjunction with a comprehensive sleep evaluation. Clinical sleep evaluations using PM must be supervised by a practitioner with board certification in sleep medicine or an individual who fulfills the eligibility criteria for the sleep medicine certification examination. PM may be used as an alternative to polysomnography (PSG) for the diagnosis of OSA in patients with a high pretest probability of moderate to severe OSA. PM is not appropriate for the diagnosis of OSA in patients with significant comorbid medical conditions that may degrade the accuracy of PM. PM is not appropriate for the diagnostic evaluation of patients suspected of having comorbid sleep disorders. PM is not appropriate for general screening of asymptomatic populations. PM may be indicated for the diagnosis of OSA in patients for whom in-laboratory PSG is not possible by virtue of immobility, safety, or critical illness. PM may also be indicated to monitor the response to non-CPAP treatments for sleep apnea. At a minimum, PM must record airflow, respiratory effort, and blood oxygenation. The airflow, effort, and oximetric biosensors conventionally used for in-laboratory PSG should be used in PM. The Task Force recommends that PM testing be performed under the auspices of an AASM-accredited comprehensive sleep medicine program with written policies and procedures. An experienced sleep technologist/technician must apply the sensors or directly educate patients in sensor application. The PM device must allow for display of raw data with the capability of manual scoring or editing of automated scoring by a qualified sleep technician/technologist. A board certified sleep specialist, or an individual who fulfills the eligibility criteria for the sleep medicine certification examination, must review the raw data from PM using scoring criteria consistent with current published AASM standards. Under the conditions specified above, PM may be used for unattended studies in the patient's home. A follow-up visit to review test results should be performed for all patients undergoing PM. Negative or technically inadequate PM tests in patients with a high pretest probability of moderate to severe OSA should prompt in-laboratory polysomnography. C1 [Collop, Nancy A.] Johns Hopkins Univ, Div Pulm & Crit Care Med, 1830 East Monument St,Room 555, Baltimore, MD 21205 USA. [Anderson, W. McDowell] James A Haley VA Hosp, Tampa, FL USA. [Boehlecke, Brian] Univ N Carolina, Chapel Hill, NC USA. [Claman, David] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Goldberg, Rochelle] Lankenau Hosp, Sleep Med, Wynnewood, PA USA. [Gottlieb, Daniel J.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Gottlieb, Daniel J.] VA Boston Healthcare Syst, Boston, MA USA. [Hudgel, David] Henry Ford Sleep Disorders Ctr, Detroit, MI USA. [Sateia, Michael] Dartmouth Hitchcock Med Ctr, Sect Sleep Med, Hanover, NH USA. [Schwab, Richard] Univ Penn, Div Sleep Med, Philadelphia, PA 19104 USA. RP Collop, NA (reprint author), Johns Hopkins Univ, Div Pulm & Crit Care Med, 1830 East Monument St,Room 555, Baltimore, MD 21205 USA. FU American Academy of Sleep Medicine FX The Task Force acknowledges the assistance provided for data extraction by Loretta Colvin, CRNP. This project was funded by the American Academy of Sleep Medicine. NR 61 TC 457 Z9 477 U1 3 U2 11 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2007 VL 3 IS 7 BP 737 EP + PG 16 WC Clinical Neurology SC Neurosciences & Neurology GA V44VN UT WOS:000209776600012 PM 18198809 ER PT J AU Sugiura, M Colby, K Mihm, M Zembowicz, A AF Sugiura, M. Colby, K. Mihm, M. Zembowicz, A. TI Low- and high-risk histological features in conjunctival melanoma in situ (primary acquired melanosis with atypia): Clinicopathological analysis of 29 cases SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA. Harvard Univ, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2007 VL 34 IS 1 BP 80 EP 80 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 122NL UT WOS:000243233600017 ER PT J AU Sepehr, A Avram, M Mihm, M AF Sepehr, A. Avram, M. Mihm, M. TI Case report: Congenital Self-Healing Langerhans Cell Histiocytosis SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2007 VL 34 IS 1 BP 96 EP 96 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 122NL UT WOS:000243233600086 ER PT J AU Sugiura, A Sugiura, M Piris, A Tomita, Y Mihm, M AF Sugiura, A. Sugiura, M. Piris, A. Tomita, Y. Mihm, M. TI Apocrine cystadenoma and apocrine hidrocystoma: Examination of the 23 cases with emphasis on nomenclature according to proliferative features SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2007 VL 34 IS 1 BP 101 EP 101 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 122NL UT WOS:000243233600107 ER PT J AU Sepehr, A Kamangar, F Flotte, T AF Sepehr, A. Kamangar, F. Flotte, T. TI Distinct age-associated morphological variation in pilomatricoma SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Natl Canc Inst, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2007 VL 34 IS 1 BP 122 EP 122 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 122NL UT WOS:000243233600198 ER PT J AU Davis, T Zembowicz, A Bevona, C Moschella, S Staszewski, R AF Davis, T. Zembowicz, A. Bevona, C. Moschella, S. Staszewski, R. TI Cutaneous collagenous vasculopathy: A report of two cases SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Lahey Clin Fdn, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2007 VL 34 IS 1 BP 126 EP 126 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 122NL UT WOS:000243233600214 ER PT J AU Johnson, M Davis, T Zembowicz, A AF Johnson, M. Davis, T. Zembowicz, A. TI Penile Kaposi's Sarcoma in an HIV-negative patient with a history of multiple penile procedures SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2007 VL 34 IS 1 BP 128 EP 128 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 122NL UT WOS:000243233600224 ER PT J AU Nazarian, R Zembowicz, A Duncan, L AF Nazarian, R. Zembowicz, A. Duncan, L. TI Giant cell malignant melanoma mimicking atypical fibroxanthoma SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2007 VL 34 IS 1 BP 132 EP 133 PG 2 WC Dermatology; Pathology SC Dermatology; Pathology GA 122NL UT WOS:000243233600244 ER PT J AU Quinn, LS AF Quinn, L. S. TI Interleukin-15: A cytokine which modulates fat : lean body composition SO JOURNAL OF DAIRY SCIENCE LA English DT Meeting Abstract CT Joint Annual Meeting of the American-Dairy-Science-Association/Poultry-Science-Association-Asociacio n-Mexicana-de-Produccion-Animal/American-Society-of-Animal-Science CY JUL 08, 2007 CL San Antonio, TX SP Amer Diary Sci Assoc, Poultry Sci Assoc, Asociac Mexicana Prod Anim, Amer Soc Anim Sci DE interleukin-15; muscle; adipose tissue C1 [Quinn, L. S.] Univ Washington, Seattle, WA 98195 USA. [Quinn, L. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER DAIRY SCIENCE ASSOC PI SAVOY PA 1111 N DUNLAP AVE, SAVOY, IL 61874 USA SN 0022-0302 J9 J DAIRY SCI JI J. Dairy Sci. PY 2007 VL 90 SU 1 BP 1 EP 1 PG 1 WC Agriculture, Dairy & Animal Science; Food Science & Technology SC Agriculture; Food Science & Technology GA 213UP UT WOS:000249692900003 ER PT J AU Bushberg, JT Kroger, LA Hartman, MB Leidholdt, EM Miller, KL Derlet, R Wraa, C AF Bushberg, Jerrold T. Kroger, Linda A. Hartman, Marcia B. Leidholdt, Edwin M., Jr. Miller, Kenneth L. Derlet, Robert Wraa, Cheryl TI Nuclear/radiological terrorism: Emergency department management of radiation casualties SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE radiological emergency; radiological casualties; terrorism; dirty bombs; emergency planning AB Recent world events have increased concern that hospitals must be prepared for radiological emergencies. Emergency departments (EDs) must be ready to treat patients suffering from injuries in combination with radiation exposure or contamination with radioactive material. Every hospital should have a Radiological Emergency Medical Response Plan, tested through periodic drills, which will allow effective handling of contaminated and injured patients. Treatment of life-threatening or severe traumatic injuries must take priority over radiation-related issues. The risk to ED staff from radioactive contamination is minimal if universal precautions are used. The likelihood of significant radiation exposure to staff under most circumstances is small. Educating medical staff on the magnitude of the radiological hazards allows them to promptly and confidently provide the necessary patient care. Measures must be taken to prevent the "worried well" and uninjured people with radioactive contamination from overwhelming the ED. (c) 2007 Elsevier Inc. C1 Univ Calif Davis, Hlth Syst, Dept Environm Hlth & Safety, Sacramento, CA 95817 USA. Univ Calif Davis, Hlth Syst, Dept Radiol, Sacramento, CA 95817 USA. Univ Calif Davis, Hlth Syst, Dept Emergency Med, Sacramento, CA 95817 USA. US Dept Vet Affairs, Natl Hlth Phys Program, Mare Isl, CA USA. Penn State Univ, Milton S Hershey Med Ctr, Dept Radiol, Hershey, PA 17033 USA. RP Bushberg, JT (reprint author), Univ Calif Davis, Hlth Syst, Dept Environm Hlth & Safety, 2315 Stockton Blvd,FSSB 2500, Sacramento, CA 95817 USA. NR 31 TC 22 Z9 23 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD JAN PY 2007 VL 32 IS 1 BP 71 EP 85 DI 10.1016/j.jemermed.2006.05.034 PG 15 WC Emergency Medicine SC Emergency Medicine GA 130SO UT WOS:000243819500012 PM 17239736 ER PT J AU El-Ghandour, A Selim, A Khachemoune, A AF El-Ghandour, Ahmad Selim, Abdulhafez Khachemoune, Amor TI Bilateral lesions on the legs SO JOURNAL OF FAMILY PRACTICE LA English DT Editorial Material ID ERYTHEMA-AB-IGNE; ABIGNE; CELL C1 NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY 10016 USA. Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. RP Khachemoune, A (reprint author), NYU, Sch Med, Ronald O Perelman Dept Dermatol, 530 1st Ave,Suite 7R, New York, NY 10016 USA. EM amorkh@pol.net NR 13 TC 0 Z9 0 U1 0 U2 0 PU DOWDEN HEALTH MEDIA PI MONTVALE PA 110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA SN 0094-3509 J9 J FAM PRACTICE JI J. Fam. Pract. PD JAN PY 2007 VL 56 IS 1 BP 37 EP 39 PG 3 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 196XS UT WOS:000248517200010 PM 17217896 ER PT J AU Taft, CT Murphy, CM AF Taft, Casey T. Murphy, Christopher M. TI The working alliance in intervention for partner violence perpetrators: Recent research and theory SO JOURNAL OF FAMILY VIOLENCE LA English DT Article DE working alliance; partner violence; confrontation; abuser intervention ID COGNITIVE-BEHAVIORAL THERAPY; HEALTH CONSEQUENCES; BATTERERS TREATMENT; PSYCHOTHERAPY; MEN; WOMEN; PREDICTORS; DEPRESSION; PROGRAMS; SUCCESS AB The working alliance consists of therapist and client agreement on the goals and tasks of therapy, and the therapeutic bond. Measures of the working alliance, assessed during the course of therapy, have consistently predicted positive therapeutic change across various client populations and treatment approaches. This paper reviews recent research highlighting the importance of the working alliance with respect to treatment compliance and outcome in interventions for perpetrators of partner violence. The common promotion and use of confrontational intervention tactics in these interventions and the potentially negative impact of confrontational tactics on the working alliance is also discussed. C1 VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA. Boston Univ, Sch Med, Boston, MA 02130 USA. Univ Maryland Baltimore Cty, Dept Psychol, Baltimore, MD 21228 USA. RP Taft, CT (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave, Boston, MA 02130 USA. EM casey.taft@va.gov NR 61 TC 16 Z9 20 U1 3 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7482 J9 J FAM VIOLENCE JI J. Fam. Violence PD JAN PY 2007 VL 22 IS 1 BP 11 EP 18 DI 10.1007/s10896-006-9053-z PG 8 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA 129ZC UT WOS:000243767600002 ER PT J AU Sands, BE AF Sands, Bruce E. TI Inflammatory bowel disease: past, present, and future SO JOURNAL OF GASTROENTEROLOGY LA English DT Review DE Crohn's disease; ulcerative colitis; inflammatory bowel diseases; medical therapy; pathogenesis ID ACTIVE CROHNS-DISEASE; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; COLONY-STIMULATING FACTOR; SEVERE ULCERATIVE-COLITIS; MONOCLONAL-ANTIBODY CA2; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; MAINTENANCE THERAPY; MICROBIAL ANTIGENS AB Crohn's disease and ulcerative colitis, collectively known as the inflammatory bowel diseases (IBD), are largely diseases of the twentieth century, and are associated with the rise of modern, Westernized industrial society. Although the causes of these diseases remain incompletely understood, the prevailing model is that the intestinal flora drives an unmitigated intestinal immune response and inflammation in the genetically susceptible host. A review of the past and present of these diseases shows that detailed description preceded more fundamental elucidation of the disease processes. Working out the details of disease pathogenesis, in turn, has yielded dividends in more focused and effective therapy for IBD. This article highlights the key descriptions of the past, and the pivotal findings of current studies in disease pathogenesis and its connection to medical therapy. Future directions in the IBD will likely explicate the inhomogeneous causes of these diseases, with implications for individualized therapy. C1 Massachusetts Gen Hosp, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Sands, BE (reprint author), Massachusetts Gen Hosp, MGH Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. NR 103 TC 133 Z9 143 U1 3 U2 14 PU SPRINGER TOKYO PI TOKYO PA 3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN SN 0944-1174 J9 J GASTROENTEROL JI J. Gastroenterol. PD JAN PY 2007 VL 42 IS 1 BP 16 EP 25 DI 10.1007/s00535-006-1995-7 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 140DM UT WOS:000244483900002 PM 17322989 ER PT J AU Opotowsky, AR McWilliams, JM Cannon, CP AF Opotowsky, Alexander R. McWilliams, J. Michael Cannon, Christopher P. TI Gender differences in aspirin use among adults with coronary heart disease in the United States SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE coronary heart disease; myocardial infarction; aspirin; secondary prevention; gender; insurance; health; medical expenditure panel survey ID ACUTE MYOCARDIAL-INFARCTION; EXPENDITURE PANEL SURVEY; ADVERSE DRUG-REACTIONS; LONG-TERM ADHERENCE; RISK-FACTOR SURVEY; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; SECONDARY PREVENTION; AMBULATORY-CARE; ARTERY-DISEASE AB BACKGROUND: Aspirin reduces mortality for men and women with coronary heart disease (CHD). Previous research suggests women with acute coronary syndromes receive less aggressive care, including less frequent early administration of aspirin. The presence of gender differences in aspirin use for secondary prevention is less clear. OBJECTIVE: To determine if a gender difference exists in the use of aspirin for secondary prevention among individuals with CHD. DESIGN: We analyzed data from the nationally representative 2000-2002 Medical Expenditure Panel Surveys to determine the prevalence of regular aspirin use among men and women with CHD. PARTICIPANTS: Participants, 1,869, 40 years and older who reported CHD or prior myocardial infarction. RESULTS: Women were less likely than men to use aspirin regularly (62.4% vs 75.6%, p <. 001) even after adjusting for demographic, socioeconomic and clinical characteristics (adjusted OR= 0.62, 95% CI, 0.48-0.79). This difference narrowed but remained significant when the analysis was limited to those without self-reported contraindications to aspirin (79.8% vs 86.4%, P =.002, adjusted OR= 0.68, 95% CI, 0.48-0.97). Women were more likely than men to report contraindications (20.5% vs 12.5%, P <.001). Differences in aspirin use were greater between women and men with private health insurance (61.8% vs 79.0%, P <.001, adjusted OR = 0.48, 95% CI, 0.35-0.67) than among those with public coverage (62.5% vs 70.7%, P =.04, adjusted OR = 0.74, 95% CI, 0.50-1.11) (P <. 001 for gender-insurance interaction). CONCLUSION: We found a gender difference in aspirin use among patients with CHD not fully explained by differences in patient characteristics or reported contraindications. These findings suggest a need for improved secondary prevention of cardiovascular events for women with CHD. C1 Univ Penn, Med Ctr, Dept Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. TIMI Study Grp, Boston, MA 02115 USA. RP Opotowsky, AR (reprint author), Univ Penn, Med Ctr, Dept Med, Div Cardiovasc Med, 9 Founders Pavil,3400 Spruce St, Philadelphia, PA 19104 USA. EM alexander.opotowsky@uphs.upenn.edu FU AHRQ HHS [T32 HS000020, T32 HS00020-20] NR 55 TC 21 Z9 21 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2007 VL 22 IS 1 BP 55 EP 61 DI 10.1007/s11606-007-0116-5 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 140QW UT WOS:000244521800007 PM 17351840 ER PT J AU Kirchner, JE Zubritsky, C Cody, M Coakley, E Chen, HT Ware, JH Oslin, DW Sanchez, HA Durai, UNB Miles, KM Llorente, MD Costantino, G Levkoff, S AF Kirchner, JoAnn E. Zubritsky, Cynthia Cody, Marisue Coakley, Eugenie Chen, Hongtu Ware, James H. Oslin, David W. Sanchez, Herman A. Durai, U. Nalla B. Miles, Keith M. Llorente, Maria D. Costantino, Giuseppe Levkoff, Sue TI Alcohol consumption among older adults in primary care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE elderly; alcohol; drinking patterns; primary care ID COGNITIVE IMPAIRMENT; PROBLEM DRINKING; DISABILITY; TRENDS; ABUSE; LIFE AB BACKGROUND: Alcohol misuse is a growing public health concern for older adults, particularly among primary care patients. OBJECTIVES: To determine alcohol consumption patterns and the characteristics associated with at-risk drinking in a large sample of elderly primary care patients. DESIGN: Cross-sectional analysis of multisite screening data from 6 VA Medical Centers, 2 hospital-based health care networks, and 3 Community Health Centers. PARTICIPANTS: Patients, 43,606, aged 65 to 103 years, with scheduled primary care appointments were approached for screening; 27,714 (63.6%) consented to be screened. The final sample of persons with completed screens comprised 24,863 patients. MEASUREMENTS: Quantity and frequency of alcohol use, demographics, social support measures, and measures of depression/anxiety. RESULTS: Of the 24,863 older adults screened, 70.0% reported no consumption of alcohol in the past year, 21.5% were moderate drinkers (1-7 drinks/week), 4.1% were at-risk drinkers (8-14 drinks/ week), and 4.5% were heavy (> 14 drinks/ week) or binge drinkers. Heavy drinking showed significant positive association with depressive/anxiety symptoms [Odds ratio (OR) (95% CI): 1.79 (1.30, 2.45)] and less social support [OR ( 95% CI): 2.01 (1.14, 2.56)]. Heavy drinking combined with binging was similarly positively associated with depressive/ anxiety symptoms [OR (95%): 1.70 (1.33, 2.17)] and perceived poor health [OR ( 95% CI): 1.27 (1.03, 1.57)], while at-risk drinking was not associated with any of these variables. CONCLUSIONS: The majority of participants were nondrinkers; among alcohol users, at-risk drinkers did not differ significantly from moderate drinkers in their characteristics or for the 3 health parameters evaluated. In contrast, heavy drinking was associated with depression and anxiety and less social support, and heavy drinking combined with binge drinking was associated with depressive/ anxiety symptoms and perceived poor health. C1 VA S Cent Mental Illness Res Educ & Clin Ctr, Little Rock, AR USA. Univ Arkansas Med Sci, Little Rock, AR 72205 USA. VA HSR&D Ctr Mental Hlth & Outcomes Res, Little Rock, AR 72114 USA. John Snow Inc, Boston, MA USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Chicago VA Hlth Care Syst, Chicago, IL USA. Dartmouth Coll Sch Med, Dept Psychiat, Lebanon, NH USA. Univ Miami, Sch Med, Miami VA Med Ctr, Miami Beach, FL USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Lutheran Med Ctr, Sunset Pk Family Hlth Ctr Network, Brooklyn, NY USA. Trinity Partners Inc, Waltham, MA USA. RP Kirchner, JE (reprint author), VA S Cent Mental Illness Res Educ & Clin Ctr, Little Rock, AR USA. EM kirchnerjoanne@uams.edu NR 28 TC 64 Z9 65 U1 3 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2007 VL 22 IS 1 BP 92 EP 97 DI 10.1007/s11606-006-0017-z PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 140QW UT WOS:000244521800013 PM 17351846 ER PT J AU Nwasuruba, C Khan, M Egede, LE AF Nwasuruba, Chiagozie Khan, Mokbul Egede, Leonard E. TI Racial/ethnic differences in multiple self-care behaviors in adults with diabetes SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE diabetes; racial/ethnic differences; self-care behavior ID RISK-FACTOR SURVEY; BLOOD-GLUCOSE; MANAGED-CARE; PHYSICAL-ACTIVITY; UNITED-STATES; LEISURE-TIME; HEALTH; COMPLICATIONS; ASSOCIATION; RELIABILITY AB OBJECTIVE: To assess racial/ethnic differences in multiple diabetes self-care behaviors. DESIGN: Cross-sectional study. PARTICIPANTS: 21,459 participants with diabetes in the 2003 Behavioral Risk Factor Surveillance survey. MEASUREMENTS: The study assessed self-care behaviors including physical activity, fruits/vegetables consumption, glucose testing, and foot examination, as well as a composite of the 4 self-care behaviors across racial/ethnic groups. Multiple logistic regression was used to assess the independent association between race/ethnicity, the composite variable, and each self-care behavior controlling for covariates. STATA was used for statistical analysis. RESULTS: Overall, 6% engaged in all 4 self-care behaviors, with a range of 5% in non-insulin users to 8% in insulin users. Blacks were less likely to exercise (OR 0.63, 95% CI 0.51, 0.79), while Hispanics and "others" were not significantly different from whites. Hispanics (OR 0.64, 95% CI 0.49, 0.82) and others (OR 0.69, 95% CI 0.49, 0.96) were less likely to do home glucose testing, while blacks were not significantly different from whites. Blacks (OR 1.42, 95% CI 1.12, 1.80) were more likely to do home foot examinations, while Hispanics and others were not significantly different from whites. Blacks (OR 0.56, 95% CI 0.36, 0.87) were less likely to engage in all 4 behaviors, while Hispanics and others were not significantly different from whites. There were no significant racial/ ethnic differences in fruit and vegetable consumption. CONCLUSIONS: Few patients engage in multiple selfcare behaviors at recommended levels, and there are significant racial/ ethnic differences in physical activity, dietary, and foot care behaviors among adults with diabetes. C1 Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Tyler, TX 75710 USA. Ralph H Johnson VA Med Ctr, Charleston VA TREP, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu FU AHRQ HHS [5K08HS11417]; NIMHD NIH HHS [R24 MD000536] NR 27 TC 49 Z9 49 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2007 VL 22 IS 1 BP 115 EP 120 DI 10.1007/s11606-007-0120-9 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 140QW UT WOS:000244521800017 PM 17351850 ER PT J AU Tierney, WM Gerrity, MS AF Tierney, William M. Gerrity, Martha S. TI A new look and continued growth for JGIM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 Indiana Univ, Wishard Mem Hosp, Sch Med, Regenstrief Inst Inc, Indianapolis, IN 46202 USA. Oregon Hlth Sci Univ, Portland VA Med Ctr, Indianapolis, IN 46202 USA. RP Tierney, WM (reprint author), Indiana Univ, Wishard Mem Hosp, Sch Med, Regenstrief Inst Inc, Room M200-OPW,1001 W 10th St, Indianapolis, IN 46202 USA. EM wtierney@iupui.edu NR 5 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2007 VL 22 IS 1 BP 157 EP 159 DI 10.1007/s11606-006-0070-7 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 140QW UT WOS:000244521800027 ER PT J AU Adey, L Souer, JS Lozano-Calderon, S Palmer, W Lee, SG Ring, D AF Adey, Lauren Souer, J. Sebastiaan Lozano-Calderon, Santiago Palmer, William Lee, Sang-Gil Ring, David TI Computed tomography of suspected scaphoid fractures SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE suspected scaphoid fracture; diagnosis; computed tomography ID BONE-SCINTIGRAPHY; RATIONAL APPROACH; EARLY-DIAGNOSIS; RADIOGRAPHS; WRIST; WAIST; MRI AB Purpose: Computed tomography (CT) can be used to triage suspected scaphoid fractures. This study assessed intraobserver and interobserver reliability and positive and negative predictive values of CT for the diagnosis of a nondisplaced scaphoid fracture. Methods: Eight observers evaluated CT scans from 30 patients (13 with nondisplaced scaphoid fracture s, 17 with no scaphoid fractures) for the presence or absence of a fracture. Five observers evaluated the scans a second time. Statistical analyses included intraobserver and interobserver reliability and diagnostic characteristics. Results: Computed tomography had substantial intraobserver and interobserver reliability for the diagnosis of a nondisplaced scaphoid fracture. The average sensitivity, specificity, and accuracy of CT for a nondisplaced scaphoid fracture were 89%, 91%, and 90% for the first round and 97%, 85%, and 88% for the second round of observations, respectively. Based on an estimated prevalence of 5% true fractures among patients with suspected scaphoid fractures, the average positive predictive value for the detection of radiographically occult scaphoid fractures with tomography of the wrist was 0.28. The average negative predictive value was 0.99. Conclusions: Computed tomography should be used with caution for triage of nondisplaced scaphoid fractures because false-positive results occur, perhaps from misinterpretation of vascular foraminae or other normal lines in the scaphoid. Given the relative infrequency of true fractures among patients with suspected scaphoid fractures, CT is better for ruling out a fracture than for ruling one in. C1 Massachusetts Gen Hosp, Yawkey Ctr Outpatient Care, MSK Imaging & Intervent, Hand & Upper Extrem Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey Ctr Outpatient Care, MSK Imaging & Intervent, Hand & Upper Extrem Serv, Boston, MA 02114 USA. EM dring@partners.org NR 38 TC 46 Z9 46 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD JAN PY 2007 VL 32A IS 1 BP 61 EP 66 DI 10.1016/j.jhsa.2006.10.009 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 127WF UT WOS:000243616300008 PM 17218177 ER PT J AU Cao, Q Mak, KM Lieber, CS AF Cao, Qi Mak, Ki M. Lieber, Charles S. TI Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells SO JOURNAL OF HEPATOLOGY LA English DT Article DE LX-2 human hepatic stellate cells; leptin; matrix metalloproteinase-1 gene; janus kinase; signal transducer and activator of transcription; extracellular signal-regulated kinase; p38; H2O2 ID GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; H2O2-DEPENDENT MAPK PATHWAYS; FIBROTIC HUMAN LIVER; BREAST-CANCER CELLS; TISSUE INHIBITOR; SIGNALING PATHWAYS; MESSENGER-RNA; RESPONSIVE ELEMENT; HYDROGEN-PEROXIDE AB Background/Aims: Collagen accumulation in liver fibrosis is due in part to decreased expression of matrix metalloproteinase (MMP)-1 relative to TIMP-1. LX-2 hepatic stellate cells produce increased amounts of collagen and tissue inhibitor of metalloproteinase (TIMP)-1 in response to leptin. The effect of leptin on MMP-1 production has not been reported. Methods: LX-2 cells were treated with leptin with or without inhibitors. We determined: phosphorylation of Janus kinase (JAK) 1 and -2, signal transducer and activator of transcription (STAT)3 and -5, extracellular signal-regulated kinase (ERK)1/2 and p38 by Western blot; H2O2 concentration by a colorimetric method; MMP-1 mRNA levels and stability by Northern blot; MMP-1 promoter activity as well as pro-MMP-1 by ELISA; and active MMP-1 by fluorescence. Results: LX-2 cells constitutively expressed the MMP-1 gene and leptin repressed the basal level of MMP-1 mRNA and its promoter activity. The repression was mediated by JAK/STAT pathway in synergism with JAK-mediated H2O2-dependent ERK1/2 and p38 pathways. ERK1/2 inhibited MMP-1 promoter activity, whereas p38 decreased the message stability, contributing to mRNA down-regulation. Inhibition of MMP-1 gene diminished secreted pro-MMP-1 and active MMP-1. Conclusions: Leptin represses MMP-1 gene expression via the synergistic actions of the JAK/STAT pathway and JAK-mediated H2O2-dependent ERK1/2 and p38 pathways. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 James J Peters VA Med Ctr, Alcohol Res & Treatment Ctr, Bronx, NY USA. Mt Sinai Sch Med, New York, NY 10029 USA. RP Lieber, CS (reprint author), James J Peters VA Med Ctr, Alcohol Res & Treatment Ctr, Bronx, NY USA. EM liebercs@aol.com FU NIAAA NIH HHS [R01 AA011115, AA11115] NR 41 TC 46 Z9 53 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PD JAN PY 2007 VL 46 IS 1 BP 124 EP 133 DI 10.1016/j.jhep.2006.07.027 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 124ES UT WOS:000243350900017 PM 17030072 ER PT J AU Bihl, F Loggi, E Chisholm, JV Fortini, C Margotti, M Faircloth, K Cursaro, C Bernardi, M Andreone, P Blander, C AF Bihl, F. Loggi, E. Chisholm, J. V., III Fortini, C. Margotti, M. Faircloth, K. Cursaro, C. Bernardi, M. Andreone, P. Blander, C. TI Clustering of CD8 T cell responses against the HBV core and surface proteins within different hla alleles: Immunodominance analysis in patients with diverse genetic backgrounds SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 11-15, 2007 CL Barcelona, SPAIN SP European Assoc Study Liver C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr, Boston, MA USA. Univ Studi Bologna, Cardioangiol & Epatol Osped S Orsola Malpighi, Dipartimento Med Interna, Bologna, Italy. EM f.bihl@mac.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2007 VL 46 SU 1 MA 96 BP S43 EP S43 DI 10.1016/S0168-8278(07)61694-8 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 168WQ UT WOS:000246555100097 ER PT J AU Khan, UA McGinnis, K Skanderson, M Butt, AA AF Khan, U. A. McGinnis, K. Skanderson, M. Butt, A. A. TI Comorbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 11-15, 2007 CL Barcelona, SPAIN SP European Assoc Study Liver C1 Albany Med Ctr, Albany, NY USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. EM u_khan@yahoo.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2007 VL 46 SU 1 MA 548 BP S208 EP S208 DI 10.1016/S0168-8278(07)62146-1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 168WQ UT WOS:000246555100547 ER PT J AU Kuntzen, T Timm, J Berical, A Lewis, L Jones, A Wiesch, JSZ Li, B Chung, RT Lauer, GM Walker, BD Allen, TM AF Kuntzen, T. Timm, J. Berical, A. Lewis, L. Jones, A. Wiesch, J. Schulze zur Li, B. Chung, R. T. Lauer, G. M. Walker, B. D. Allen, T. M. TI Viral sequence evolution in acute HCV infection SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 11-15, 2007 CL Barcelona, SPAIN SP European Assoc Study Liver C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr,Infect Dis Div, Boston, MA USA. Univ Hosp Essen, Dept Virol, Essen, Germany. Inst Oswaldo Cruz, Dept Virol, BR-20001 Rio De Janeiro, Brazil. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA USA. EM tkuntzen@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2007 VL 46 SU 1 MA 92 BP S41 EP S42 DI 10.1016/S0168-8278(07)61690-0 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 168WQ UT WOS:000246555100093 ER PT J AU Loggi, E Tan, AT Boni, C Ho, ZZ Fisicaro, P Hua, L Fortini, C Chua, W Chisholm, JV Gehring, AJ Grandini, E Andreone, P Brander, C Lim, SG Ferrari, C Bihl, F Bertoletti, A AF Loggi, E. Tan, A. T. Boni, C. Ho, Z. Z. Fisicaro, P. Hua, L. Fortini, C. Chua, W. Chisholm, J. V., III Gehring, A. J. Grandini, E. Andreone, P. Brander, C. Lim, S. G. Ferrari, C. Bihl, F. Bertoletti, A. TI Comprehensive analysis of hbv genotype-specific T cell response in genetically different populations persistently infected with hbv genotype B or D SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 11-15, 2007 CL Barcelona, SPAIN SP European Assoc Study Liver C1 Univ Bologna, Osped Orsola Malpighi, Dept Internal Med & Hepatol, Bologna, Italy. Agcy Sci Technol & Res, Ctr Mol Med, Singapore, Singapore. Univ Parma, Azienda Osped, Unit Infect Dis & Hepatol, Lab Viral Immunopathol, I-43100 Parma, Italy. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Partner AIDS Res Ctr, Boston, MA 02115 USA. UCL, Royal Free Hosp, Inst Hepatol, London, England. EM antonio@cmm.a-star.edu.sg RI Boni, Carolina/J-5249-2016; Ferrari, Carlo/D-5663-2017 OI Boni, Carolina/0000-0002-7630-5180; Ferrari, Carlo/0000-0002-7843-4963 NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2007 VL 46 SU 1 MA 407 BP S157 EP S157 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 168WQ UT WOS:000246555100406 ER PT J AU Loggi, E Bihl, FK Testa, L Chisholm, JV Grandini, E Bernardi, M Brander, C Andreone, P AF Loggi, E. Bihl, F. K. Testa, L. Chisholm, J. V. Grandini, E. Bernardi, M. Brander, C. Andreone, P. TI Immunodominance analysis of HBV-specific cellular immune response in two HLA identical, vertically infected siblings SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 11-15, 2007 CL Barcelona, SPAIN SP European Assoc Study Liver C1 Univ Degli Stud Bologna, Dipartimento Med Interna Cardioangiol Epatol, Bologna, Italy. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partnes AIDS Res Ctr, Boston, MA USA. EM andreone@med.unibo.it RI Testa, Lilia/G-2451-2016 OI Testa, Lilia/0000-0003-1511-090X NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2007 VL 46 SU 1 BP S157 EP S157 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 168WQ UT WOS:000246555100407 ER PT J AU Mueller, T Shibolet, O Pratt, DS Podolsky, DK AF Mueller, T. Shibolet, O. Pratt, D. S. Podolsky, D. K. TI Pro-inflammatory Th1 cytokines promote TLR and nod protein signaling in primary human extra- and intra-hepatic biliary epithelial cells SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 11-15, 2007 CL Barcelona, SPAIN SP European Assoc Study Liver C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Study Inflammat Bowel Dis,Gastrointestinal Un, Boston, MA USA. EM tobiashp.mueller@charite.de NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2007 VL 46 SU 1 MA 315 BP S124 EP S124 DI 10.1016/S0168-8278(07)61913-8 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 168WQ UT WOS:000246555100315 ER PT J AU Nevzorova, YA Tschaharganeh, DE Sicinski, P Trautwein, C Liedtke, C AF Nevzorova, Y. A. Tschaharganeh, D. E. Sicinski, P. Trautwein, C. Liedtke, C. TI Depletion of cyclin E2 in mice increases cell cycle activity and regeneration efficiency of the liver after partial hepatectomy SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 11-15, 2007 CL Barcelona, SPAIN SP European Assoc Study Liver C1 Univ Aachen, Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Med 3, D-5100 Aachen, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. EM ynevzorova@ukaachen.de NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2007 VL 46 SU 1 MA 42 BP S20 EP S20 DI 10.1016/S0168-8278(07)61640-7 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 168WQ UT WOS:000246555100043 ER PT J AU Wiesch, JSZ Kasprowicz, V Kim, AY Kuntzen, T Longworth, SA Nolan, BE Wurcel, AG McMahon, C Allen, TM McGovern, B Lewis-Ximenes, L Chung, RT Kwok, W Walker, BD Lauer, GM AF Wiesch, J. Schulze zur Kasprowicz, V. Kim, A. Y. Kuntzen, T. Longworth, S. A. Nolan, B. E. Wurcel, A. G. McMahon, C. Allen, T. M. McGovern, B. Lewis-Ximenes, L. Chung, R. T. Kwok, W. Walker, B. D. Lauer, G. M. TI Detection of CD4+ T cell responses in patients with acute hcv infection irrespective of clinical outcome SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 11-15, 2007 CL Barcelona, SPAIN SP European Assoc Study Liver C1 Harvard Univ, Sch Med, Partners AIDS Res ctr, Boston, MA 19104 USA. Howard Hughes Med Inst, Chevy Chase, MD 02111 USA. Univ Penn, Philadelphia, PA 02114 USA. Tufts Univ, Shattuck Hosp, BR-20001 Boston, MA USA. Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA USA. Inst Oswaldo Cruz, Dept Virol, Rio De Janeiro, Brazil. Univ Klin Eppendorf, Med Klin 1, Hamburg, Germany. Benaroya Res Inst Virginia Mason, Seattle, WA USA. EM Julianszw@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2007 VL 46 SU 1 MA 463 BP S176 EP S176 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 168WQ UT WOS:000246555100462 ER PT J AU Shan, LB He, P Sheen, J AF Shan, Libo He, Ping Sheen, Jen TI Endless hide-and-seek: Dynamic co-evolution in plant-bacterium warfare SO JOURNAL OF INTEGRATIVE PLANT BIOLOGY LA English DT Article; Proceedings Paper CT Conference on Frontiers of Plant Molecular Biology CY MAY, 2006 CL Changsha, PEOPLES R CHINA SP Hunan Univ, Hunan Normal Univ, Hunan Agr Univ DE MAMP; type III effector; gene-for-gene resistance ID PROGRAMMED CELL-DEATH; ARABIDOPSIS INNATE IMMUNITY; CAMPESTRIS PV. VESICATORIA; SYSTEM EFFECTOR PROTEINS; PSEUDOMONAS-SYRINGAE; SECRETION SYSTEM; III EFFECTORS; DISEASE-SUSCEPTIBILITY; NICOTIANA-BENTHAMIANA; FLAGELLIN PERCEPTION AB Plants possess innate immune systems to prevent most potential infections. The ancient and conserved innate immune responses are triggered by microbe-associated molecular patterns (MAMPs) and play important roles in broad-spectrum defenses. However, successful bacterial pathogens evolved type III virulence effectors to suppress MAMP-mediated immunity. To survive, plants further developed highly specific resistance (R) genes to trigger gene-for-gene-mediated immunity and turn the virulent pathogens into avirulent ones. We summarize here the very recent advances in this dynamic coevolution of plant-bacterium interaction. C1 Harvard Univ, Sch Med, Dept Mol Biol, Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. RP Shan, LB (reprint author), Harvard Univ, Sch Med, Dept Mol Biol, Massachusetts Gen Hosp, Boston, MA 02114 USA. EM shan@molbio.mgh.harvard.edu NR 50 TC 10 Z9 11 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1672-9072 J9 J INTEGR PLANT BIOL JI J. Integr. Plant Biol. PD JAN PY 2007 VL 49 IS 1 BP 105 EP 111 DI 10.1111/j.1672-9072.2007.00409.x PG 7 WC Biochemistry & Molecular Biology; Plant Sciences SC Biochemistry & Molecular Biology; Plant Sciences GA 123LA UT WOS:000243296200017 ER PT J AU Ahmed, S Veena, MS Tang, CG Wang, MB Srivatsan, ES AF Ahmed, S. Veena, M. S. Tang, C. G. Wang, M. B. Srivatsan, E. S. TI Differential sensitivity of head and neck squamous cell cancer cell lines to cisplatin-mediated cell death. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S155 EP S155 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692400490 ER PT J AU Castiglioni, A Caldwell, J Estrada, C Massie, S AF Castiglioni, A. Caldwell, J. Estrada, C. Massie, S. TI Performance of physical examination skills by second- and fourth-year medical students: Does clinical experience matter? SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S311 EP S312 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692401379 ER PT J AU Daines, SB Rohr, ES Pace, AP Fassbind, MH Sangeorzan, BJ Ledoux, WR AF Daines, S. B. Rohr, E. S. Pace, A. P. Fassbind, M. H. Sangeorzan, B. J. Ledoux, W. R. TI Simulation of a high-arch foot. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 VA Puget Sound, RR&D Ctr Excell Limb Loss Prevent & Prosthet Engn, Seattle, WA USA. Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA USA. RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S153 EP S154 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692400483 ER PT J AU Estrada, CA Shewchuk, RM Staton, LJ Bigby, J Houston, TK Allison, J AF Estrada, C. A. Shewchuk, R. M. Staton, L. J. Bigby, J. Houston, T. K. Allison, J. TI What should we include in a cultural competence curriculum? A formative evaluation? SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Univ Alabama, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Tennessee, Chattanooga, TN USA. Harvard Univ, Sch Med, Boston, MA USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S309 EP S309 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692401363 ER PT J AU Farnad, SA Hakimi, M Huang, W Rudkin, GH Ishida, K Huang, C Yamaguch, DT Miller, TA AF Farnad, S. A. Hakimi, M. Huang, W. Rudkin, G. H. Ishida, K. Huang, C. Yamaguch, D. T. Miller, T. A. TI Differentiation of MC3T3-E1 preosteoblastic cells on two-dimensional poly(lactide-co-glycolide) (PLGA) films and three-dimensional PLGA scaffolds: A real-time reverse transcriptase-polymerase chain reaction study. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. VA Greater LA Healthcare Syst, Plast Surg Res Lab, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Surg, Div Plast Surg, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S104 EP S104 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692400177 ER PT J AU Hedlund, R Leitner, JW Draznin, B AF Hedlund, R. Leitner, J. W. Draznin, B. TI Reduced expression of p85 alpha rescues 3T3-L1 adipocytes from the insulin resistance induced via serine phosphorylation of insulin receptor substrate-1 (IRS-1) SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S124 EP S124 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692400300 ER PT J AU Houston, TK Slovensky, D Moye, K Pryor, E Terndrup, T Weissman, N Kiefe, CI AF Houston, T. K. Slovensky, D. Moye, K. Pryor, E. Terndrup, T. Weissman, N. Kiefe, C. I. TI Impact of a veteran-centric, case-based, internet-delivered intervention on providers' bioterrorism knowledge: A randomized trial at 15 VAMCS. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S309 EP S309 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692401366 ER PT J AU Njoku, CJ Gilkeson, GS Hofbauer, A Ruiz, P Oates, JC AF Njoku, C. J. Gilkeson, G. S. Hofbauer, A. Ruiz, P. Oates, J. C. TI The response of MRL/lpr-inducible nitric oxide synthase knockout mice to inducible nitric oxide synthase inhibitor. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. Univ Miami, Sch Med, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S278 EP S278 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692401191 ER PT J AU Pace, AP Fassbind, MJ Daines, SB Rohr, ES Sangeorzan, BJ Ledoux, WR AF Pace, A. P. Fassbind, M. J. Daines, S. B. Rohr, E. S. Sangeorzan, B. J. Ledoux, W. R. TI Simulation of a dorsal bunion. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 VA Puget Sound, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Seattle, WA USA. Univ Washington, Dept Engn Mech, Seattle, WA 98195 USA. Univ Washington, Dept Orthopaed, Seattle, WA 98195 USA. RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S155 EP S155 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692400493 ER PT J AU Page, ST Amory, JK Anawalt, BD Matsumoto, AM Bremner, WJ AF Page, S. T. Amory, J. K. Anawalt, B. D. Matsumoto, A. M. Bremner, W. J. TI Acceptibility of a combination of testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Univ Washington, Dept Med, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S138 EP S138 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692400390 ER PT J AU Tabibian, JH Pierre, JM Wirshing, WC Wirshing, DA Kisicki, MD Guzik, L Menu, SJ AF Tabibian, J. H. Pierre, J. M. Wirshing, W. C. Wirshing, D. A. Kisicki, M. D. Guzik, L. Menu, S. J. TI Hepatitis B and C among veterans on a psychiatric ward. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S146 EP S146 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692400438 ER PT J AU Tang, CG Ho, B Wang, D Veena, MS Ahmed, S Srivatsan, ES Wang, MB AF Tang, C. G. Ho, B. Wang, D. Veena, M. S. Ahmed, S. Srivatsan, E. S. Wang, M. B. TI Liposomal curcumin reduces growth in head and neck squamous cell carcinoma cell lines. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Univ Calif Los Angeles, Div Head & Neck Surg, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Dept Surg, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S154 EP S154 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692400487 ER PT J AU Tang, CG Hoz, B Wang, D Veena, MS Ahmed, S Srivatsan, ES Wang, MB AF Tang, C. G. Hoz, B. Wang, D. Veena, M. S. Ahmed, S. Srivatsan, E. S. Wang, M. B. TI Liposomal curcumin reduces growth in head and neck squamous cell carcinoma cell lines. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Univ Calif Los Angeles, Div Head & Neck Surg, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Healthcare Ctr, Dept Surg, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S79 EP S79 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692400033 ER PT J AU Wesseling, K Jueppner, H Lavigne, J Zahranik, R Salusky, IB AF Wesseling, K. Jueppner, H. Lavigne, J. Zahranik, R. Salusky, I. B. TI Phosphate wasting and FGF-23 kinetics post-renal transplantation. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Immutopics, San Clemente, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S127 EP S128 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692400325 ER PT J AU Willett, LL Castiglioni, A Heudebert, G Kertesz, S Centor, RM Estrada, CA AF Willett, L. L. Castiglioni, A. Heudebert, G. Kertesz, S. Centor, R. M. Estrada, C. A. TI Measuring the impact of a clinical vignette workshop: Differing perceptions between faculty and trainees. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT 8th Conference of the Western Student Medical Research Forum CY FEB 02, 2007 CL Monterey, CA C1 Univ Alabama, Birmingham, AL USA. Birmingham Vet Aff Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2007 VL 55 IS 1 SU S BP S313 EP S313 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 185DU UT WOS:000247692401385 ER PT J AU Grabher, C Cliffe, A Miura, K Hayflick, J Pepperkok, R Rorth, P Wittbrodt, J AF Grabher, Clemens Cliffe, Adam Miura, Kota Hayflick, Joel Pepperkok, Rainer Rorth, Pernille Wittbrodt, Joachim TI Birth and life of tissue macrophages and their migration in embryogenesis and inflammation in medaka SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article; Proceedings Paper CT EMBO Workshop on Innate Danger Signals and HMGB1 CY FEB 08-11, 2006 CL Milan, ITALY DE macrophage; cell migration; medaka; PI3K; inflammation ID 3-DIMENSIONAL COLLAGEN MATRICES; CELL-MIGRATION; PHOSPHOINOSITIDE 3-KINASE; ZEBRAFISH; CHEMOTAXIS; LEUKOCYTES; MOVEMENT; ONTOGENY; BIOLOGY; PROTEOLYSIS AB Macropbages detecting and migrating toward sites of injury and infection represent one of the first steps in an immune response. Here we directly image macrophage birth and migration in vivo in transgenic medaka fish. Macrophages are born as frequently dividing, immotile cells with spherical morphology that differentiate into flat, highly motile cells. They retain mitotic activity while spreading over the entire body. Cells follow restricted paths not only in directed migration, but also during patrolling. Along those paths the macrophages rapidly patrol the tissue and respond to wounding and bacterial infection from long distances. Upon injury they increase their speed and migratory persistence. Specifically targeting PI3-kinase isoforms efficiently blocks the wounding response and results in a distinct inhibition of cell motility and chemotaxis. Our study provides in situ insights into the properties of immature and migratory macrophages and presents a unique model to further test modulating compounds in vivo. C1 European Mol Biol Lab, Dev Biol Unit, Heidelberg, Germany. European Mol Biol Lab, Cell Biol & Biophys Unit, Heidelberg, Germany. ICOS Corp, Bothell, WA USA. RP Grabher, C (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA. EM clemens_grabher@dfci.harvard.edu; wittbrodt@embl.de RI Rorth, Pernille/H-3020-2011; Grabher, Clemens/H-2064-2013; Wittbrodt, Joachim/D-4735-2014; OI Wittbrodt, Joachim/0000-0001-8550-7377; Pepperkok, Rainer/0000-0002-9762-3583 NR 47 TC 27 Z9 27 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD JAN PY 2007 VL 81 IS 1 BP 263 EP 271 DI 10.1189/jlb.0806526 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 121WN UT WOS:000243187800032 PM 17046968 ER PT J AU Jin, Z Wan, HC Soberman, RJ Weller, PF AF Jin, Zhuang Wan, Hsiao-Ching Soberman, Roy J. Weller, Peter F. TI Cytosolic lipid bodies are sites of 5-lipoxygenase synthesis in rat basophil leukemia cells SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the Society-for-Leukocyte-Biology CY OCT 11-13, 2007 CL Cambridge, MA SP Soc Leukocyte Biol C1 [Jin, Zhuang; Wan, Hsiao-Ching; Weller, Peter F.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Allergy & Inflamat, Cambridge, MA 02138 USA. [Soberman, Roy J.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PY 2007 SU S MA 12 BP 18 EP 18 PG 1 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 217LR UT WOS:000249949900013 ER PT J AU Takahashi, K Stuart, LM Kasper, DL Carroll, MC Chen, J Ezekowitz, AB Guttormsen, HK AF Takahashi, Kazue Stuart, Lynda M. Kasper, Dennis L. Carroll, Mike C. Chen, Jianzhu Ezekowitz, Alan B. Guttormsen, Hilde-Kari TI Mannose-binding lectin modulates antigen-specific IgG response SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the Society-for-Leukocyte-Biology CY OCT 11-13, 2007 CL Cambridge, MA SP Soc Leukocyte Biol C1 [Takahashi, Kazue; Stuart, Lynda M.; Ezekowitz, Alan B.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. [Kasper, Dennis L.; Guttormsen, Hilde-Kari] Brigham & Womens Hosp, Harvard Med Sch, Dept Med, Channing Lab, Boston, MA 02115 USA. [Carroll, Mike C.] Harvard Med Sch, Ctr Blood Res, Boston, MA 02115 USA. [Chen, Jianzhu] MIT, Ctr Canc Res, Cambridge, MA 02139 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PY 2007 SU S MA 60 BP 33 EP 33 PG 1 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 217LR UT WOS:000249949900060 ER PT J AU Epardaud, M Rubinstein, MP Yonekura, AR Bellemare-Pelletier, A Bronson, R Goldrath, A Turley, SJ AF Epardaud, Mathieu Rubinstein, Mark P. Yonekura, Ai-Ris Bellemare-Pelletier, Angelique Bronson, Roderick Goldrath, Ananda Turley, Shannon J. TI IL-15/IL-15Ra complexes circumvent tumor immune escape by activating memory phenotype CD8+T cells within malignant lesions SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the Society-for-Leukocyte-Biology CY OCT 11-13, 2007 CL Cambridge, MA SP Soc Leukocyte Biol C1 [Epardaud, Mathieu; Rubinstein, Mark P.; Bellemare-Pelletier, Angelique; Turley, Shannon J.] Dana Farber Canc Inst, Dept Canc Immunol, AIDS, Boston, MA 02115 USA. [Epardaud, Mathieu] INRA, UR892, F-78352 Jouy En Josas, France. [Rubinstein, Mark P.; Goldrath, Ananda] Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA. [Yonekura, Ai-Ris] Harvard MIT, Div Hlth Sci & Technol, Boston, MA 02115 USA. [Bronson, Roderick] Harvard Med Sch, Boston, MA 02115 USA. [Turley, Shannon J.] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PY 2007 SU S MA 83 BP 40 EP 40 PG 1 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 217LR UT WOS:000249949900083 ER PT J AU Tauzin, L Graf, C Sun, M Rovina, P Bouveyron, N Jaritz, M Winiski, A Hartmann, N Staedtler, F Billich, A Baumruker, T Zhang, M Bornancin, F AF Tauzin, Loic Graf, Christine Sun, Mei Rovina, Philipp Bouveyron, Nicolas Jaritz, Markus Winiski, Anthony Hartmann, Nicole Staedtler, Frank Billich, Andreas Baumruker, Thomas Zhang, Mei Bornancin, Frederic TI Effects of ceramide-1-phosphate on cultured cells: dependence on dodecane in the vehicle SO JOURNAL OF LIPID RESEARCH LA English DT Article DE ceramide kinase; sphingolipid; mitochondria; viability; phosphatidic acid; phospholipase A(2); prostaglandin E-2 ID CERAMIDE KINASE; LIPID KINASE; 1-PHOSPHATE; PATHWAY; ACTIVATION; VESICLES; RELEASE AB Ceramide-1-phosphate (C1P), the product of ceramide kinase, is a sphingophospholipid with recently recognized signaling properties. In particular, it was reported to be mitogenic and capable of direct stimulation of cytosolic phospholipase A(2 alpha). Much of the present knowledge has relied on the use of C1P of various acyl chain lengths, together with diverse protocols to deliver it to cultured cells. A mixture of ethanol (or methanol) with dodecane, as the vehicle, has become popular. However, the contribution of this solvent to the observed effects of C1P has not been documented. Here, we show that addition of C1P in ethanoldodecane to culture medium leads to irreversible cytotoxic effects. These culminate in mitochondrial swelling, vacuole formation, and cell death. Not only the toxicity of C1P, but also its ability to trigger prostaglandin E-2 release, is fully dependent upon addition of a premade C1P-dodecane mixture. Furthermore, we show that these effects are not restricted to C1P. They result from the capacity of dodecane to interact with phospholipids; hence, they go undetected with a vehicle control. This study should raise awareness about the use of dodecane for phospholipid delivery and, in turn, help in unraveling C1P signaling, which is still poorly understood. C1 Novartis Inst Biomed Res, A-1235 Vienna, Austria. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA. Novartis Inst Biomed Res, CH-4057 Basel, Switzerland. Synta Pharmaceut Corp, Lexington, MA USA. RP Bornancin, F (reprint author), Novartis Inst Biomed Res, A-1235 Vienna, Austria. EM frederic.bornancin@novartis.com RI Jaritz, Markus/B-4081-2008 NR 27 TC 18 Z9 18 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD JAN PY 2007 VL 48 IS 1 BP 66 EP 76 DI 10.1194/jlr.M600399-JLR200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 121AW UT WOS:000243130000007 PM 17018884 ER PT J AU Burd, L Roberts, D Olson, M Odendaal, H AF Burd, Larry Roberts, Drucilla Olson, Meredith Odendaal, Hein TI Ethanol and the placenta: A review SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE LA English DT Review DE placenta; prenatal alcohol exposure; fetal alcohol spectrum disorders; fetal mortality; stillbirth; abruption ID FETAL-ALCOHOL-SYNDROME; ACID ETHYL-ESTERS; HUMAN CHORIONIC-GONADOTROPIN; PERFUSED HUMAN-PLACENTA; EPIDERMAL GROWTH-FACTOR; LOW-BIRTH-WEIGHT; PREGNANT-WOMEN; PRENATAL ALCOHOL; AMNIOTIC-FLUID; RISK-FACTORS AB Objective. In this paper we review published studies of alcohol exposure on placentation, placenta growth and function. Methods. We searched PubMed using the MeSH terms: placenta, ethanol, fetal alcohol syndrome and prenatal exposure with delayed effects. We searched the years 1996-2006 and used the references from other articles to expand our search. We limited the search to English only and human only. We excluded studies using choriocarcinoma and animal studies. We grouped the 66 papers into seven topic areas for ease of review. Results. Alcohol exposure is associated with placental dysfunction, decreased placental size, impaired blood flow and nutrient transport, endocrine changes, increased rates of stillbirth and abruption, umbilical cord vasoconstriction, and low birth weight. Conclusions. Prenatal alcohol exposure has a broad range of adverse effects on placental development and function. Additional research on placental development from populations with heavy alcohol exposure should be encouraged. A tissue bank of placentas with detailed assessment of exposure to alcohol, smoking and other relevant data should be considered as a repository to support additional research. C1 Univ N Dakota, Dept Pediat, Sch Med & Hlth Sci, Grand Forks, ND 58201 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA. Univ Stellenbosch, Dept Obstet & Gynecol, Cape Town, South Africa. Tygerberg Acad Hosp, Cape Town, South Africa. RP Burd, L (reprint author), N Dakota Fetal Alcohol Syndrome Ctr, 501 N Columbia Rd, Grand Forks, ND 58203 USA. EM laburd@medicine.nodak.edu FU NICHD NIH HHS [1 U01 HD045935-01] NR 111 TC 57 Z9 58 U1 0 U2 7 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1476-7058 J9 J MATERN-FETAL NEO M JI J. Matern.-Fetal Neonatal Med. PY 2007 VL 20 IS 5 BP 361 EP 375 DI 10.1080/14767050701298365 PG 15 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 183ZH UT WOS:000247610400001 PM 17674239 ER PT J AU Bertram, L Mullin, K Parkinson, M Hsiao, M Moscarillo, TJ Wagner, SL Becker, KD Velicelebi, G Blacker, D Tanzi, RE AF Bertram, Lars Mullin, Kristina Parkinson, Michele Hsiao, Monica Moscarillo, Thomas J. Wagner, Steven L. Becker, K. David Velicelebi, Gonul Blacker, Deborah Tanzi, Rudolph E. TI Is alpha-T catenin (VR22) an Alzheimer's disease risk gene? SO JOURNAL OF MEDICAL GENETICS LA English DT Article ID FAMILY-BASED ASSOCIATION; CHROMOSOME-10; LINKAGE; LOCUS; PEDIGREES; GENOME AB Background: Recently, conflicting reports have been published on the potential role of genetic variants in the alpha-T catenin gene (VR22; CTNNA3) on the risk for Alzheimer's disease. In these papers, evidence for association is mostly observed in multiplex families with Alzheimer's disease, whereas case-control samples of sporadic Alzheimer's disease are predominantly negative. Methods: After sequencing VR22 in multiplex families with Alzheimer's disease linked to chromosome 10q21, we identified a novel non-synonymous (Ser596Asn; rs4548513) single nucleotide polymorphism (SNP). This and four non-coding SNPs were assessed in two independent samples of families with Alzheimer's disease, one with 1439 subjects from 437 multiplex families with Alzheimer's disease and the other with 489 subjects from 217 discordant sibships. Results: A weak association with the Ser596Asn SNP in the multiplex sample, predominantly in families with late-onset Alzheimer's disease (p = 0.02), was observed. However, this association does not seem to contribute substantially to the chromosome 10 Alzheimer's disease linkage signal that we and others have reported previously. No evidence was found of association with any of the four additional SNPs tested in the multiplex families with Alzheimer's disease. Finally, the Ser596Asn change was not associated with the risk for Alzheimer's disease in the independent discordant sibship sample. Conclusions: This is the first study to report evidence of an association between a potentially functional, non-synonymous SNP in VR22 and the risk for Alzheimer's disease. As the underlying effects are probably small, and are only seen in families with multiple affected members, the population-wide significance of this finding remains to be determined. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Neurol, MassGen Inst Neurodegenerat,Genet & Aging Res Uni, Charlestown, MA 02129 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Gerontol Res Unit, Cambridge, MA 02138 USA. TorreyPines Therapeut, La Jolla, CA USA. RP Bertram, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Neurol, MassGen Inst Neurodegenerat,Genet & Aging Res Uni, 113,16th St, Charlestown, MA 02129 USA. EM bertram@helix.mgh.harvard.edu RI Bertram, Lars/K-3889-2015 OI Bertram, Lars/0000-0002-0108-124X FU NIA NIH HHS [1R01 AG023667-01, R01 AG023667] NR 15 TC 16 Z9 16 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-2593 J9 J MED GENET JI J. Med. Genet. PD JAN PY 2007 VL 44 IS 1 AR e63 DI 10.1136/jmg.2005.039263 PG 4 WC Genetics & Heredity SC Genetics & Heredity GA 123OR UT WOS:000243305700017 PM 17209133 ER PT J AU Kontos, EZ Bennett, GG Viswanath, K AF Kontos, Emily Z. Bennett, Gary G. Viswanath, K. TI Barriers and facilitators to home computer and Internet use among urban novice computer users of low socioeconomic position SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE digital divide; health information seeking; health disparities ID HEALTH INFORMATION; CONSUMER HEALTH; ACCESS; COMMUNITY; TECHNOLOGY; LITERACY AB Background: Despite the increasing penetration of the Internet and amount of online health information, there are significant barriers that limit its widespread adoption as a source of health information. One is the "digital divide," with people of higher socioeconomic position (SEP) demonstrating greater access and usage compared to those from lower SEP groups. However, as the access gap narrows over time and more people use the Internet, a shift in research needs to occur to explore how one might improve Internet use as well as website design for a range of audiences. This is particularly important in the case of novice users who may not have the technical skills, experience, or social connections that could help them search for health information using the Internet. The focus of our research is to investigate the challenges in the implementation of a project to improve health information seeking among low SEP groups. The goal of the project is not to promote health information seeking as much as to understand the barriers and facilitators to computer and Internet use, beyond access, among members of lower SEP groups in an urban setting. Objective: The purpose was to qualitatively describe participants' self-identified barriers and facilitators to computer and Internet use during a 1-year pilot study as well as the challenges encountered by the research team in the delivery of the intervention. Methods: Between August and November 2005 12 low-SEP urban individuals with no or limited computer and Internet experience were recruited through a snowball sampling. Each participant received a free computer system, broadband Internet access, monthly computer training courses, and technical support for 1 year as the intervention condition. Upon completion of the study, participants were offered the opportunity to complete an in-depth semistructured interview. Interviews were approximately I hour in length and were conducted by the project director. The interviews were held in the participants' homes and were tape recorded for accuracy. Nine of the 12 study participants completed the semistructured interviews. Members of the research team conducted a qualitative analysis based on the transcripts from the nine interviews using the crystallization/immersion method. Results: Nine of the 12 participants completed the in-depth interview (75% overall response rate), with three men and six women agreeing to be interviewed. Major barriers to Internet use that were mentioned included time constraints and family conflict over computer usage. The monthly training classes and technical assistance components of the intervention surfaced as the most important facilitators to computer and Internet use. The concept of received social support from other study members, such as assistance with computer-related questions, also emerged as an important facilitator to overall computer usage. Conclusions: This pilot study offers important insights into the self-identified barriers and facilitators in computer and Internet use among urban low-SEP novice users as well as the challenges faced by the research team in implementing the intervention. C1 [Kontos, Emily Z.; Bennett, Gary G.; Viswanath, K.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Kontos, Emily Z.; Bennett, Gary G.; Viswanath, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Kontos, EZ (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Soc Human Dev & Hlth, LW 627,44 Binney St, Boston, MA 02115 USA. EM emily_kontos@dfci.harvard.edu NR 37 TC 38 Z9 38 U1 5 U2 14 PU JOURNAL MEDICAL INTERNET RESEARCH PI TORONTO PA TORONTO GENERAL HOSPITAL, R FRASER ELLIOTT BLDG, 4TH FL, R 4S435, 190 ELIZABETH ST, TORONTO, ON M5G 2C4, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PY 2007 VL 9 IS 4 AR e31 DI 10.2196/jmir.9.4.e31 PG 28 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 263JB UT WOS:000253212300004 PM 17951215 ER PT J AU McNeill, LH Puleo, E Bennett, GG Emmons, KM AF McNeill, Lorna H. Puleo, Elaine Bennett, Gary G. Emmons, Karen M. TI Exploring social contextual correlates of computer ownership and frequency of use among urban, low-income, public housing adult residents SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article ID AFRICAN-AMERICAN WOMEN; NATIONAL TRENDS SURVEY; HEALTH INFORMATION; MULTIETHNIC POPULATIONS; CANCER PREVENTION; BREAST-CANCER; WORKING-CLASS; PROMOTION; INTERNET; CARE AB Background: As advances in computer access continue to be made, there is a need to better understand the challenges of increasing access for racial/ethnic minorities, particularly among those with lower incomes. Larger social contextual factors, such as social networks and neighborhood factors, may influence computer ownership and the number of places where individuals have access to computers. Objectives: We examined the associations of sociodemographic and social contextual factors with computer ownership and frequency of use among 1554 adults living in urban public housing. Methods: Bivariate associations between dependent variables (computer ownership and regular computer use) and independent variables were used to build multivariable logistic models adjusted for age and site clusters. Results: Participants (N = total weighted size of 2270) were on average 51.0 (+/- 21.4) years old, primarily African American or Hispanic, and earned less than US $20000 per year. More than half owned a computer, and 42% were regular computer users. Reporting computer ownership was more likely if participants lived above the poverty level (OR = 1.78, 95% CI = 1.39-2.25), completed high school (OR = 2.46, 95% CI = 1.70-3.55), were in financial hardship (OR = 1.38, 95% CI = 1.06-1.81), were employed and supervised others (OR 1.94, 95% CI = 1.08-3.46), and had multiple role responsibilities (OR = 2.18, 95% CI = 1.31-3.61). Regular computer use was more likely if participants were non-Hispanic (OR = 1.94, 95% CI = 1.30-2.91), lived above the poverty level (OR = 2.84, 95% CI = 1.90-4.24), completed high school (OR = 4.43, 95% CI = 3.04-6.46), were employed and supervised others (OR = 2.41, 95% CI = 1.37-4.22), felt safe in their neighborhood (OR = 1.57, 95% CI = 1.08-2.30), and had greater social network ties (OR = 3.09, 95% CI = 1.26-7.59). Conclusions: Disparities in computer ownership and use are narrowing, even among those with very low incomes; however, identifying factors that contribute to disparities in access for these groups will be necessary to ensure the efficacy of future technology-based interventions. A unique finding of our study is that it may be equally as important to consider specific social contextual factors when trying to increase access and use among low-income minorities, such as social network ties, household responsibilities, and neighborhood safety. C1 [McNeill, Lorna H.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Hlth Dispar Res, Houston, TX 77030 USA. [Puleo, Elaine] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Biostat, Amherst, MA USA. [Bennett, Gary G.; Emmons, Karen M.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Bennett, Gary G.; Emmons, Karen M.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. RP McNeill, LH (reprint author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Hlth Dispar Res, 1100 Holcombe Blvd,Unit 125, Houston, TX 77030 USA. EM lmcneill@mdanderson.org FU NCI NIH HHS [R01 CA098864, 3R01CA098864-02S1, 5R01CA098864-02] NR 54 TC 20 Z9 20 U1 2 U2 12 PU JOURNAL MEDICAL INTERNET RESEARCH PI TORONTO PA TORONTO GENERAL HOSPITAL, R FRASER ELLIOTT BLDG, 4TH FL, R 4S435, 190 ELIZABETH ST, TORONTO, ON M5G 2C4, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PY 2007 VL 9 IS 4 AR e35 DI 10.2196/jmir.9.4.e35 PG 27 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 263JB UT WOS:000253212300007 PM 18093903 ER PT J AU Saul, JE Schillo, BA Evered, S Luxenberg, MG Kavanaugh, A Cobb, N An, LC AF Saul, Jessle E. Schillo, Barbara A. Evered, Sharrilyn Luxenberg, Michael G. Kavanaugh, Annette Cobb, Nathan An, Lawrence C. TI Impact of a statewide Internet-based tobacco cessation intervention SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE tobacco use cessation; internet; behavior; evaluation studies ID NICOTINE REPLACEMENT THERAPY; SMOKING-CESSATION; POSTAL QUESTIONNAIRE; RESPIRATORY HEALTH; NONRESPONSE BIAS; REAL-WORLD; PROGRAM; DEPENDENCE; TRIAL; RISK AB Background: An increasing number of people have access to the Internet, and more people are seeking tobacco cessation resources online every year. Despite the proliferation of various online interventions and their evident acceptance and reach, little research has addressed their impact in the real world. Typically, low response rates to Internet-based follow-up surveys generate unrepresentative samples and large confidence intervals when reporting results. Objectives: The aim of this study was to achieve a high response rate on follow-up evaluation in order to better determine the impact of an Internet-based tobacco cessation intervention provided to tobacco users in Minnesota, United States. Methods: Participants included 607 men and women aged 18 and over residing in Minnesota who self-reported current tobacco use when registering for an Internet-based tobacco cessation program between February 2 and April 13, 2004. Participants were given access to an interactive website with features including social support, expert systems, proactive email, chat sessions, and online counselors. Mixed-mode follow-up (online survey with telephone survey for online nonrespondents) occurred 6 months after registration. Results: Of the study participants, 77.6% (471/607) responded to the 6-month follow-up survey (39.4% online and 38.2% by telephone). Among respondents, 17.0% (80/471, 95% CI = 13.6%-20.4%) reported that they had not smoked in the past 7 days (observed rate). Assuming all nonresponaents were still smoking (missing =smoking rate), the quit rate was 13.2% (80/607, 95% CI = 10.5%-15.9%). Conclusions: This mixed-mode follow-up survey of an online smoking cessation program achieved a high response rate and provides a more accurate estimate of long-term cessation rates than has been previously reported. Quit rates for the Internet-based tobacco cessation program were higher than those expected for unassisted quit attempts and are comparable to other evidence-based behavioral interventions. The similarities between quit rates demonstrates that an Internet-based cessation program may have as great an impact as, and can have wider reach than, other cessation programs such as those delivered by telephone. With over 100000 people having visited the website and over 23000 having registered, a 6-month self-reported quit rate of 13.2% suggests that the quitplan.com program helped over 3000 Minnesotans remain tobacco free for at least 6 months. Results of this study suggest that an Internet-based cessation program is a useful tool in states' efforts to provide comprehensive cessation tools for smokers. C1 [Evered, Sharrilyn] Ctr Prevent Blue Cross & Blue Shield Minnesota, St Paul, MN USA. [Saul, Jessle E.; Schillo, Barbara A.] Clearway Minnesota, Minneapolis, MN 55425 USA. [Luxenberg, Michael G.; Kavanaugh, Annette] Profess Data Analysts Inc, Minneapolis, MN USA. [Cobb, Nathan] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. [An, Lawrence C.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. RP Saul, JE (reprint author), Clearway Minnesota, 8011 34th Ave S,Suite 400, Minneapolis, MN 55425 USA. EM jsaul@clearwaymn.org OI Cobb, Nathan/0000-0003-4210-226X NR 55 TC 48 Z9 48 U1 1 U2 6 PU JOURNAL MEDICAL INTERNET RESEARCH PI TORONTO PA TORONTO GENERAL HOSPITAL, R FRASER ELLIOTT BLDG, 4TH FL, R 4S435, 190 ELIZABETH ST, TORONTO, ON M5G 2C4, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PY 2007 VL 9 IS 3 AR e28 DI 10.2196/jmir.9.4.e28 PG 24 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 263IZ UT WOS:000253212100007 PM 17942390 ER PT J AU Hank, SW David, SO Gordon, VO Pisegna, JR AF Hank, S. Wang David, S. Oh Gordon, V. Ohning Pisegna, Joseph R. TI Elevated serum ghrelin exerts an orexigenic effect that may maintain body mass with metastatic neuroendocrine index in patients tumors SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article; Proceedings Paper CT Joint Meeting of the Summer Neuropeptide Conference/European Neuropeptide Club CY JUN 27-JUL 01, 2006 CL Miami Beach, FL DE ghrelin; metastatic neuroendocrine tumors endogenous; orexigenic; cancer eachexia; somatostatin; gastrin ID SOMATOSTATIN ANALOGS; OCTREOTIDE THERAPY; ENDOCRINE TUMORS; EXPRESSION; SECRETION; APPETITE; CACHEXIA; STOMACH; HUMANS; CELLS AB Ghrelin is a potent orexigenic peptide principally produced in the stomach by a distinct population of neuroendocrine cells in the oxyntic mucosa of the fundus. Exogenous ghrelin given as an intravenous infusion has been shown to increase caloric intake in patients with cancer cachexia. In this study, we hypothesized that elevated endogenous ghrelin, produced by increased neuroendocrine cell tumor burden, also exerts an orexigenic effect helping to maintain body mass index. To evaluate the effect of elevated endogenous ghrelin, 35 patients with neuroendocrine tumors were enrolled, assigning them to one of two groups depending on the presence of hepatic metastases. Following an overnight fast, serum was collected and sent for ghrelin measurement by an outside laboratory. The two groups were well matched for all other relevant clinical variables including subtype of tumor, primary location of tumor and tumor treatment history. Nearly all patients with hepatic metastases had elevated levels of ghrelin compared to the standard reference range given for matched controls. The presence of hepatic metastases was associated with significantly elevated ghrelin levels (p<0.05) and a greater mean body mass index. In addition, we report a positive correlation between serum ghrelin and total tumor surface area and between serum ghrelin and body mass index, suggesting that elevated endogenous ghrelin may be sufficient to overcome any partial ghrelin resistance typically seen in cancer cachexia. These results support the possibility that ghrelin is co-released from neuroendocrine tumors and exerts an orexigenic effect in these patients, helping to maintain their body mass index despite widely disseminated disease. C1 VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Pisegna, JR (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Bldg 115,Room 316,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu NR 34 TC 0 Z9 0 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PY 2007 VL 33 IS 3 BP 225 EP 231 PG 7 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 224HA UT WOS:000250436900001 ER PT J AU Lemer, EA Iuga, A Reddy, VB AF Lemer, Ethan A. Iuga, Aurel Reddy, Vemuri B. TI Sand flies, maxadilan, and the PAC1 receptor SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Meeting Abstract CT 8th International Symposium on VIP, PACAP and Related Peptides CY SEP 03-08, 2007 CL Manchester, VT C1 Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp,Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PY 2007 VL 33 IS 3 BP 317 EP 317 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 224HA UT WOS:000250436900031 ER PT J AU Pekary, AE Stevens, SA Sattin, A AF Pekary, Albert Eugene Stevens, Schetema A. Sattin, Albert TI Lipopolysaccharide modulation of thyrotropin-releasing hormone (TRH) and TRH-Like peptide levels in rat brain and endocrine organs SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE thyrotropin-releasing hormone; limbic system; reproductive system; pancreas; HPLC; radioimmunoassay ID NECROSIS-FACTOR-ALPHA; PITUITARY-THYROID AXIS; GLIAL TNF-ALPHA; MICROGLIAL ACTIVATION; DOPAMINERGIC-NEURONS; BACTERIAL LIPOPOLYSACCHARIDE; INTERLEUKIN-6 LEVELS; INDUCED SUPPRESSION; PERIPHERAL-TISSUES; MAJOR DEPRESSION AB Lipopolysaccharide (LPS) is a proinflammatory and depressogenic agent whereas thyrotropin-releasing hormone (TRH; pGlu-His-Pro-NH2) is an endogenous antidepressant and neuroprotective peptide. LPS and TRH also have opposing effects on K+ channel conductivity. We hypothesized that LPS can modulate the expression and release of not only TRH but also TRH-like peptides with the general structure pGlu-X-Pro-NH2, where "X" can be any amino acid residue. The response might be "homeostatic," that is, LPS might increase TRH and TRH-like peptide release, thereby moderating the cell damaging effects of this bacterial cell wall constituent. On the other hand, LPS might impair the synthesis and release of these neuropeptides, thus facilitating the induction of early response genes, cytokines, and other downstream biochemical changes that contribute to the "sickness syndrome." Sprague-Dawley rats (300 g) received a single intraperitoneal injection of 100 mu g/kg LPS. Animals were then decapitated 0, 2, 4, 8, and 24 h later. Serum cytokines and corticosterone peaked 2 h after intraperitoneal LPS along with a transient decrease in serum T3. TRH and TRH-like peptides were measured by a combination of high-performance liquid chromatography and radioimmunoassay. TRH declined in the nucleus accumbens and amygdala in a manner consistent with LPS-accelerated release and degradation. Various TRH-like peptide levels increased at 2 h in the anterior cingulate, hippocampus, striatum, entorhinal cortex, posterior cingulate, and cerebellum, indicating decreased release and clearance of these peptides. These brain regions are part of a neuro-immunomodulatory system that coordinates the behavioral, endocrine, and immune responses to the stresses of sickness, injury, and danger. A sustained rise in TRH levels in pancreatic beta-cells accompanied LPS-impaired insulin secretion. TRH and Leu-TRH in prostate and TRH in epididymis remained elevated 2-24 h after intraperitoneal LPS. We conclude that these endogenous neuroprotective and antidepressant-like peptides both mediate and moderate some of the behavioral and toxic effects of LPS. C1 VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. RP Pekary, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. EM Eugene.Pekary@va.gov NR 67 TC 13 Z9 15 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PY 2007 VL 31 IS 3 BP 245 EP 259 DI 10.1385/JMN/31:03:245 PG 15 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 169JP UT WOS:000246588800005 PM 17726229 ER PT J AU Johnson, JG Zhang, BH Greer, JA Prigerson, HG AF Johnson, Jeffrey G. Zhang, Baohui Greer, Joseph A. Prigerson, Holly G. TI Parental control, partner dependency, and complicated grief among widowed adults in the community SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE bereavement; dependency; parenting; grief ID BEREAVEMENT-RELATED DEPRESSION; TRAUMATIC GRIEF; PRELIMINARY EXPLORATIONS; DYADIC ADJUSTMENT; YOUNG-ADULTS; ATTACHMENT; DISORDERS; QUALITY; RISK; SEPARATION AB Data from the Yale Bereavement Study, a community based longitudinal study, were used to investigate the association of 192 widowed individuals' recollections of parenting affection and control during childhood with dependency on the deceased spouse and the development of severe grief symptoms following bereavement. The hypothesis that dependency on the deceased spouse mediates the association of parental affection and control during childhood with the development of severe grief following bereavement was investigated. Findings indicated that a high level of perceived parental control during childhood was associated with elevated levels of dependency on the deceased spouse and with symptoms of complicated grief. Dependency on the deceased spouse mediated the association of perceived parental control with the development of complicated grief following bereavement. C1 Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, Boston, MA 02115 USA. Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10025 USA. New York State Psychiat Inst & Hosp, New York, NY 10025 USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA 02115 USA. RP Prigerson, HG (reprint author), Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, 44 Binney St SW G440A, Boston, MA 02115 USA. EM holly_prigerson@dfci.harvard.edu FU NCI NIH HHS [CA106370, R01 CA106370]; NIA NIH HHS [P30AG21342]; NIMH NIH HHS [MH56529, MH63892] NR 34 TC 22 Z9 23 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD JAN PY 2007 VL 195 IS 1 BP 26 EP 30 DI 10.1097/01.nmd.0000252009.45915.b2 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 125AN UT WOS:000243414000004 PM 17220736 ER PT J AU Santagata, S Kesari, S Black, PM Chan, JA AF Santagata, Sandro Kesari, Santosh Black, Peter M. Chan, Jennifer A. TI Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE medulloblastoma; acoustic neuroma; cerebellum C1 Brigham & Womens Hosp, Dept Pathol, Div Neuropathol, Boston, MA 02115 USA. Ctr Neurooncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Chan, JA (reprint author), Brigham & Womens Hosp, Dept Pathol, Div Neuropathol, 75 Francis St, Boston, MA 02115 USA. EM jachan@partners.org RI Kesari, Santosh/E-8461-2013 NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2007 VL 81 IS 1 BP 49 EP 51 DI 10.1007/s11060-006-9235-9 PG 3 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 118VC UT WOS:000242970100006 PM 17146596 ER PT J AU Nandigam, RNK Chen, YW Gurol, ME Rosand, J Greenberg, SM Smith, EE AF Nandigam, R. N. Kaveer Chen, Yu-Wei Gurol, Mahmut E. Rosand, Jonathan Greenberg, Steven M. Smith, Eric E. TI Validation of intracranial area as a surrogate measure of intracranial volume when using clinical MRI SO JOURNAL OF NEUROIMAGING LA English DT Article DE magnetic resonance imaging; intracranial area; intracranial volume ID CEREBRAL AMYLOID ANGIOPATHY; WHITE-MATTER LESIONS; HIPPOCAMPAL; SCHIZOPHRENIA; RISK AB Background and Purpose: We sought to determine whether mid-sagittal intracranial area (ICA) is a valid surrogate of intracranial volume (ICV) when using retrospective data with relatively thick (6-7 mm) sagittal slices. Methods: Data were retrospectively analyzed from 47 subjects who had two MRI scans taken at least nine months apart. Twenty-three subjects had manual segmentation of ICV on the T2-weighted sequence for comparison. Results: Intraclass correlation coefficient (ICC) for intraobserver, interobserver, and intraobserver scan-rescan comparisons were 0.96, 0.97 and 0.95. Pearson correlation coefficients between ICV and ICA, averaging the cumulative 1, 2, 3, and 4 most midline slices, were 0.89, 0.94, 0.93, and 0.95. There was a significant marginal increase in explained variance of ICV by measuring two, rather than one, slices (P = 0.001). Conclusions: These data suggest that ICA, even measured without high-resolution imaging, is a reasonable substitute for ICV. C1 Massachusetts Gen Hosp, Dept Neurol, Neurol Clin Trials Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Li Shin Hosp, Dept Neurol, Taipei, Taiwan. Natl Taiwan Univ Hosp, Taipei, Taiwan. Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA. Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Smith, EE (reprint author), Massachusetts Gen Hosp, Dept Neurol, Neurol Clin Trials Unit, CPZ Suite 200,55 Fruit St, Boston, MA 02114 USA. EM eesmith@partners.org RI Smith, Eric/C-5443-2012; Gurol, Edip/J-2279-2014 OI Smith, Eric/0000-0003-3956-1668; Gurol, Edip/0000-0002-2169-4457 FU NINDS NIH HHS [K23 NS046327] NR 10 TC 25 Z9 26 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1051-2284 J9 J NEUROIMAGING JI J. Neuroimaging PD JAN PY 2007 VL 17 IS 1 BP 74 EP 77 DI 10.1111/j.1552-6569.2006.00069.x PG 4 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 123KX UT WOS:000243295900010 PM 17238873 ER PT J AU Bohnen, NI Gedela, S Kuwabara, H Constantine, GM Mathis, CA Studenski, SA Moore, RY AF Bohnen, Nicolaas I. Gedela, Satyanarayana Kuwabara, Hiroto Constantine, Gregory M. Mathis, Chester A. Studenski, Stephanie A. Moore, Robert Y. TI Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease SO JOURNAL OF NEUROLOGY LA English DT Article DE basal ganglia; [C-11]-beta-CFT; dopamine; olfaction; Parkinson's disease; PET ID SMELL IDENTIFICATION TEST; POSITRON-EMISSION-TOMOGRAPHY; DIAGNOSTIC-TEST BATTERY; REFERENCE TISSUE MODEL; ADULT OLFACTORY-BULB; C-11 METHYL TRIFLATE; PET RADIOLIGANDS; HUMAN BRAIN; DYSFUNCTION; DISTURBANCES AB Olfactory dysfunction is a frequent and early feature of Parkinson's disease (PD), often preceding the motor symptoms by several years. Assessment of olfactory deficits may be used in the diagnostic assessment of PD. In this study we investigated the relationship between selective deficits in smell identification and nigrostriatal dopaminergic denervation in patients with PD. Twenty-seven PD patients (Hoehn and Yahr stages I-III) and 27 healthy controls matched for gender and age underwent olfactory testing using the 40-odor University of Pennsylvania Smell Identification Test (UPSIT). PD patients underwent C-11-beta-CFT dopamine transporter (DAT) positron emission tomography (PET) imaging and clinical motor examination. We found that total UPSIT scores were significantly lower in the PD than in the control subjects (z = 4.7, p < 0.0001). Analysis of the individual smell scores identified 3 odors with an accuracy of > 0.75 for the diagnosis of PD. These odors were banana, licorice, and dill pickle. A PD-specific smell identification score (UPSIT-3) was calculated for these 3 odors. Analysis of the patient PET data demonstrated significant correlations between dorsal striatal DAT activity and the UPSIT-3 (R-S = 0.53, p = 0.0027) and total UPSIT (R-S = 0.44, p = 0.023) scores. UPSIT-3 (R-S = 0.43, p = 0.027) but not total UPSIT (R-S = 0.20, ns) correlated with nigral DAT activity. We conclude that patients with PD have selective hyposmia. A simplified UPSIT smell identification test consisting of 3 PD-selective odors had more robust correlation with nigral and dorsal striatial dopaminergic activity compared with the full UPSIT scores in patients with PD. Assessment of selective olfactory deficits may be used as a simplified olfactory screening test in the evaluation of subjects with possible PD. C1 Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Math & Stat, Pittsburgh, PA 15260 USA. Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA. Dept Vet Affairs Med Ctr, Neurol Serv, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Geriatr Res Educ Ctr, Pittsburgh, PA USA. RP Bohnen, NI (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. EM nbohnen@umich.edu RI Mathis, Chester/A-8607-2009 NR 48 TC 53 Z9 57 U1 0 U2 7 PU DR DIETRICH STEINKOPFF VERLAG PI DARMSTADT PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY SN 0340-5354 J9 J NEUROL JI J. Neurol. PD JAN PY 2007 VL 254 IS 1 BP 84 EP 90 DI 10.1007/s00415-006-0284-y PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 137NV UT WOS:000244300200012 PM 17508142 ER PT J AU Alberici, A Armani, M Paterlini, A Benussi, L Nicosia, F Ghidoni, R Signorini, S Cotelli, M Frisoni, GB Geroldi, C Trevisan, CP Growdon, JH Borroni, B Padovani, A Rossini, PM Binetti, G AF Alberici, Antonella Armani, Mario Paterlini, Anna Benussi, Luisa Nicosia, Francesca Ghidoni, Roberta Signorini, Simona Cotelli, Maria Frisoni, Giovanni B. Geroldi, Cristina Trevisan, Carlo P. Growdon, John H. Borroni, Barbara Padovani, Alessandro Rossini, Paolo M. Binetti, Giuliano TI Tau missing from CSF - A case report SO JOURNAL OF NEUROLOGY LA English DT Article ID FRONTOTEMPORAL DEMENTIA; CEREBROSPINAL-FLUID; TAUOPATHIES; BIOMARKERS; MUTATION C1 IRCCS, Ctr S Giovanni di Dio, FBF, NeuroBioGen Lab, I-25123 Brescia, Italy. IRCCS, Ctr S Giovanni di Dio, FBF, Memory Clin, I-25123 Brescia, Italy. Univ Padua, Dept Neurosci, I-35100 Padua, Italy. IRCCS, Ctr S Giovanni di Dio, FBF, Alzheimer Unit, I-25123 Brescia, Italy. IRCCS, Ctr S Giovanni di Dio, FBF, LENITEM, I-25123 Brescia, Italy. Univ Brescia, Dept Neurol, I-25121 Brescia, Italy. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Univ Turin, Ctr Cognit Sci, Dept Psychol, I-10124 Turin, Italy. IRCCS, AFaR Dip Neurosci Osp, FBF, Isola Tiberina,Clin Neurol, I-25123 Brescia, Italy. RP Binetti, G (reprint author), IRCCS, Ctr S Giovanni di Dio, FBF, NeuroBioGen Lab, Via Pilastroni 4, I-25123 Brescia, Italy. EM gbinetti@fatebenefratelli.it RI Rossini, Paolo /D-4994-2013; Cotelli, Maria/K-1355-2016; Geroldi, Cristina/K-1524-2016; Frisoni, Giovanni B/K-1360-2016; BENUSSI, LUISA/K-4409-2016; Ghidoni, Roberta/K-4507-2016; Binetti, Giuliano/K-4519-2016; Paterlini, Anna/D-8955-2017 OI Rossini, Paolo /0000-0003-2665-534X; Cotelli, Maria/0000-0003-3208-3798; Geroldi, Cristina/0000-0001-7861-1678; Frisoni, Giovanni B/0000-0002-6419-1753; BENUSSI, LUISA/0000-0003-2836-8141; Ghidoni, Roberta/0000-0002-7691-1957; Binetti, Giuliano/0000-0003-2759-5844; Paterlini, Anna/0000-0002-2311-8322 NR 13 TC 1 Z9 1 U1 0 U2 0 PU DR DIETRICH STEINKOPFF VERLAG PI DARMSTADT PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY SN 0340-5354 J9 J NEUROL JI J. Neurol. PD JAN PY 2007 VL 254 IS 1 BP 107 EP 109 DI 10.1007/s00415-006-0282-0 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 137NV UT WOS:000244300200015 PM 17277912 ER PT J AU Cosgrove, GR Delashaw, JB Grotenhuis, JA Tew, JM van Loveren, H Spetzler, RF Payner, T Rosseau, G Shaffrey, ME Hopkins, LN Byrne, R Norbash, A AF Cosgrove, G. Rees Delashaw, Johnny B. Grotenhuis, J. Andre Tew, John M. van Loveren, Harry Spetzler, Robert F. Payner, Troy Rosseau, Gail Shaffrey, Mark E. Hopkins, L. Nelson Byrne, Ricrard Norbash, Alex TI Safety and efficacy of a novel polyethylene glycol hydrogel sealant for watertight dural repair SO JOURNAL OF NEUROSURGERY LA English DT Article; Proceedings Paper CT 55th Annual Meeting of the Congress-of-Neurological-Surgeons CY OCT 08-13, 2005 CL Boston, MA SP Congress Neurol Surg DE cerebrospinal fluid leak; craniectomy; craniotomy; dural defect repair; polyethelene glycol hydrogel sealant ID CEREBROSPINAL-FLUID LEAK; ACOUSTIC NEUROMA SURGERY; CEREBELLOPONTINE ANGLE; I MALFORMATION; TUMOR SURGERY; RISK-FACTORS; FIBRIN CLUE; NEUROSURGERY; CLOSURE; CRANIOTOMY AB Object. The authors prospectively evaluated the safety and efficacy of a novel polyethylene glycol (PEG) hydrogel sealant in patients undergoing elective cranial surgery with documented cerebrospinal fluid (CSF) leakage after sutured dural repair. Methods. The PEG hydrogel sealant was used at 11 different study sites in 111 patients with documented intraoperative CSF leakage after neurosurgical dural repair for a variety of conditions. Intraoperative CSF leakage was either spontaneous or induced by a Valsalva maneuver. Patients were monitored for 3 months postoperatively with physical examinations, clinical laboratory analyses, and diagnostic imaging. The PEG hydrogel sealant was 100% effective in stopping CSF leakage in all patients. There were no sealant-related adverse events and all clinical outcomes were consistent with expectations for seriously ill patients undergoing prolonged neurosurgical procedures. Conclusions. The PEG hydrogel sealant provides a safe and effective watertight closure when used as an adjunct to sutured dural repair during cranial surgery. C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands. Univ Cincinnati, Mayfield Clin, Cincinnati, OH USA. Univ S Florida, Tampa Gen Hosp, Tampa, FL USA. Barrow Neurol Inst, Phoenix, AZ 85013 USA. Indianapolis Neurosurg Grp Inc, Indianapolis, IN USA. Chicago Inst Neurosurg & Neurores, Chicago, IL 60614 USA. Univ Virginia, Hlth Syst, Charlottesville, VA USA. Univ Buffalo, Millard Fillmore Hosp, Dept Neurosurg, Buffalo, NY 14222 USA. Rush Univ, Med Ctr, Chicago, IL 60612 USA. Boston Med Ctr, Boston, MA USA. RP Cosgrove, GR (reprint author), Lahey Clin Fdn, Med Ctr, Dept Neurosurg, 41 Mall Rd, Burlington, MA 01805 USA. EM g.rees.cosgrove@lahey.org RI Grotenhuis, J.A./H-8040-2014 NR 41 TC 68 Z9 70 U1 1 U2 10 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 0022-3085 EI 1933-0693 J9 J NEUROSURG JI J. Neurosurg. PD JAN PY 2007 VL 106 IS 1 BP 52 EP 58 DI 10.3171/jns.2007.106.1.52 PG 7 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 125ZZ UT WOS:000243483300010 PM 17236487 ER PT J AU Soulas, C Kim, WK Lentz, M Ratai, EM Annamalai, L Westmoreland, S Gonzalez, RG Williams, KC AF Soulas, Caroline Kim, Woong-Ki Lentz, Margaret Ratai, Eva-Maria Annamalai, Lakshmanan Westmoreland, Susan Gonzalez, R. Gilberto Williams, Kenneth C. TI Clade specific variation in HIV-1 transactivating protein (Tat) induced neurotoxicity in human neurons SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 8th International Symposium on Neurovirology CY OCT 30-NOV 02, 2007 CL San Diego, CA SP NIMH, NINDS, NIDA, Biogen Idec, Dept Microbiol & Immunol, Drexel Univ Coll Med, Inst Mol Med & Infect Dis, Temple Univ Sch Med, Dept Neurosci, Sbarro Inst Canc Res & Mol Med, Journal NeuroVirol C1 [Soulas, Caroline; Kim, Woong-Ki; Williams, Kenneth C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA. [Lentz, Margaret; Ratai, Eva-Maria; Gonzalez, R. Gilberto] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,AA Martinos Ctr Biomed, Charlestown, MA 02129 USA. [Annamalai, Lakshmanan; Westmoreland, Susan] Harvard Univ, Sch Med, Div Comparat Pathol, New England Reg Primate Res Ctr, Southborough, MA 01772 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2007 VL 13 SU 1 BP 29 EP 30 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228SX UT WOS:000250754000051 ER PT J AU Westmoreland, SV Lentz, MR Lee, V Knight, H Halpern, EF Gonzalez, G AF Westmoreland, Susan V. Lentz, Margaret R. Lee, Vallent Knight, Heather Halpern, Elkan F. Gonzalez, Gilberto TI Metabolic markers of neuronal injury correlate with SIVCNS disease severity and inoculum in the macaque model of NeuroAIDS SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 8th International Symposium on Neurovirology CY OCT 30-NOV 02, 2007 CL San Diego, CA SP NIMH, NINDS, NIDA, Biogen Idec, Dept Microbiol & Immunol, Drexel Univ Coll Med, Inst Mol Med & Infect Dis, Temple Univ Sch Med, Dept Neurosci, Sbarro Inst Canc Res & Mol Med, Journal NeuroVirol C1 [Westmoreland, Susan V.; Knight, Heather] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Westmoreland, Susan V.; Knight, Heather] Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA. [Lentz, Margaret R.; Lee, Vallent; Halpern, Elkan F.; Gonzalez, Gilberto] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2007 VL 13 SU 1 BP 46 EP 46 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228SX UT WOS:000250754000081 ER PT J AU Soulas, C Kim, WK Lentz, M Ratai, EM Annamalai, L Westmoreland, S Gonzalez, RG Williams, KC AF Soulas, Caroline Kim, Woong-Ki Lentz, Margaret Ratai, Eva-Maria Annamalai, Lakshmanan Westmoreland, Susan Gonzalez, R. Gilberto Williams, Kenneth C. TI Non SIV-infected MAC387+ macrophages accumulate within encephalitic lesions of SIV-infected rhesus monkeys: MAC387 as a potential marker of disease SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 8th International Symposium on Neurovirology CY OCT 30-NOV 02, 2007 CL San Diego, CA SP NIMH, NINDS, NIDA, Biogen Idec, Dept Microbiol & Immunol, Drexel Univ Coll Med, Inst Mol Med & Infect Dis, Temple Univ Sch Med, Dept Neurosci, Sbarro Inst Canc Res & Mol Med, Journal NeuroVirol C1 [Soulas, Caroline; Kim, Woong-Ki; Williams, Kenneth C.] Beth Israel Deaconess Med Ctr, Harvard Med Sch, Div Viral Pathogenesis, Boston, MA 02215 USA. [Lentz, Margaret; Ratai, Eva-Maria; Gonzalez, R. Gilberto] Massachusetts Gen Hosp, A Martinos Ctr Biomed, Harvard Med Sch, Dept Radiol, Charlestown, MA 02129 USA. [Annamalai, Lakshmanan; Westmoreland, Susan] New England Reg Primate Res Ctr, Harvard Med Sch, Div Comparat Pathol, Southborough, MA 01772 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2007 VL 13 SU 1 BP 54 EP 55 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228SX UT WOS:000250754000095 ER PT J AU Lentz, MR Lee, V Kim, WK Williams, K Gonzalez, RG Rosenberg, E AF Lentz, Margaret R. Lee, Vallent Kim, Woong-Ki Williams, Kenneth Gonzalez, Ramon G. Rosenberg, Eric TI Brain metabolism changes observed in subjects during primary/early HIV infection SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 8th International Symposium on Neurovirology CY OCT 30-NOV 02, 2007 CL San Diego, CA SP NIMH, NINDS, NIDA, Biogen Idec, Dept Microbiol & Immunol, Drexel Univ Coll Med, Inst Mol Med & Infect Dis, Temple Univ Sch Med, Dept Neurosci, Sbarro Inst Canc Res & Mol Med, Journal NeuroVirol C1 [Lentz, Margaret R.; Lee, Vallent; Gonzalez, Ramon G.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Neuroradiol, Cambridge, MA 02138 USA. [Kim, Woong-Ki; Williams, Kenneth] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Cambridge, MA 02138 USA. [Rosenberg, Eric] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Infect Dis Unit,Partners AIDS Res Ctr, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2007 VL 13 SU 1 BP 96 EP 97 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228SX UT WOS:000250754000185 ER PT J AU Marzocchetti, A Lima, M Tompkins, T Kavanagh, DG Ghandi, RT Bhardwaj, N Koralnik, IJ AF Marzocchetti, Angela Lima, Marco Tompkins, Troy Kavanagh, Daniel G. Ghandi, Rajesh T. Bhardwaj, Nina Koralnik, Igor J. TI Dendritic cells as a therapeutic vaccine against Progressive Multifocal Leukoencephalopathy SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 8th International Symposium on Neurovirology CY OCT 30-NOV 02, 2007 CL San Diego, CA SP NIMH, NINDS, NIDA, Biogen Idec, Dept Microbiol & Immunol, Drexel Univ Coll Med, Inst Mol Med & Infect Dis, Temple Univ Sch Med, Dept Neurosci, Sbarro Inst Canc Res & Mol Med, Journal NeuroVirol C1 [Marzocchetti, Angela; Lima, Marco; Tompkins, Troy; Koralnik, Igor J.] Harvard Univ, Sch Med, Div Viral Pathogenesis, BIDMC, Cambridge, MA 02138 USA. [Lima, Marco; Koralnik, Igor J.] Harvard Univ, Sch Med, Dept Neurol, BIDMC, Cambridge, MA 02138 USA. [Kavanagh, Daniel G.; Ghandi, Rajesh T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr, Boston, MA 02114 USA. [Bhardwaj, Nina] NYU, Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2007 VL 13 SU 1 BP 101 EP 102 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228SX UT WOS:000250754000198 ER PT J AU Tyor, WR Sas, AR Bimonte-Nelson, H AF Tyor, William R. Sas, Andrew R. Bimonte-Nelson, Heather TI Neutralizing antibody to interferon-alpha treatment in SCID mice with HIV encephalitis SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 8th International Symposium on Neurovirology CY OCT 30-NOV 02, 2007 CL San Diego, CA SP NIMH, NINDS, NIDA, Biogen Idec, Dept Microbiol & Immunol, Drexel Univ Coll Med, Inst Mol Med & Infect Dis, Temple Univ Sch Med, Dept Neurosci, Sbarro Inst Canc Res & Mol Med, Journal NeuroVirol C1 [Tyor, William R.; Sas, Andrew R.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Tyor, William R.] Ralph H Johnson VAMC, Charleston, SC USA. [Bimonte-Nelson, Heather] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2007 VL 13 SU 1 BP 130 EP 131 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228SX UT WOS:000250754000263 ER PT J AU Westmoreland, SV Annamalai, L Ratai, E Lentz, MR Williams, KC Gonzalez, G AF Westmoreland, Susan V. Annamalai, Lakshmanan Ratai, Eva Lentz, Margaret R. Williams, Kenneth C. Gonzalez, Gilberto TI CART results in decreased brain virus burden and reversal of neuronal injury in treated SIV-infected CD8-depleted rhesus macaques SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 8th International Symposium on Neurovirology CY OCT 30-NOV 02, 2007 CL San Diego, CA SP NIMH, NINDS, NIDA, Biogen Idec, Dept Microbiol & Immunol, Drexel Univ Coll Med, Inst Mol Med & Infect Dis, Temple Univ Sch Med, Dept Neurosci, Sbarro Inst Canc Res & Mol Med, Journal NeuroVirol C1 [Westmoreland, Susan V.; Annamalai, Lakshmanan] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Westmoreland, Susan V.; Annamalai, Lakshmanan] New England Reg Primate Res Ctr, Southborough, MA 01772 USA. [Ratai, Eva; Lentz, Margaret R.; Gonzalez, Gilberto] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Williams, Kenneth C.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2007 VL 13 SU 1 BP 133 EP 133 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228SX UT WOS:000250754000269 ER PT J AU Kramer, M Maguire, P Schmalenberg, CE Andrews, B Burke, R Chmielewski, L Donohue, MAT Ellsworth, M Poduska, D Smith, ME Tachibana, C AF Kramer, Marlene Maguire, Patricia Schmalenberg, Claudia E. Andrews, Betsy Burke, Rebecca Chmielewski, Linda Donohue, Mary Ann T. Ellsworth, Mary Poduska, Donna Smith, Mary Ellin Tachibana, Chaleen TI Excellence through evidence - Structures enabling clinical autonomy SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article ID NURSE-PHYSICIAN RELATIONSHIPS; JOB-SATISFACTION; CRITICAL CARE AB Autonomy is a multidimensional process. Clinical autonomy, the dimension in which patients are the primary beneficiaries, is the focus of this study. Despite high valuation and persistent challenges to nurses to function autonomously, the relationship between autonomous practice and patient outcomes has not been empirically established due, in large measure, to a lack of correspondence between concepts and measurement of autonomy and to a lack of knowledge of enabling structures. The purpose of the research reported here is to identify the structures, practices, elements in the environment, and interventions that nurses, nurse managers and physicians identify as promoting staff nurse clinical autonomy. Implementation of these interventions would then enable clinical decision making at the frontline and would foster studies to determine whether the expected linkage between clinical autonomy and positive patient outcomes prevails. C1 Hlth Sci Res Associates, Nursing, Apache Junction, AZ USA. Hlth Sci Res Associates, Seattle, WA USA. Hlth Sci Res Associates, Tahoe City, CA USA. Winchester Hosp, Dept Nursing, Winchester, MA USA. Miriam Hosp, CNO, Patient Care Serv, Providence, RI 02906 USA. St Cloud Hosp, Hosp Operat CNO, St Cloud, MN USA. Hackensack Univ, Med Ctr, Psychiat Serv & Nursing Res, Hackensack, NJ USA. Rush Univ, Med Ctr, Dept Nursing Syst, Chicago, IL 60612 USA. Poudre Valley Hosp, Resource Serv Dept, Ft Collins, CO USA. Massachusetts Gen Hosp, Knight Nursing Ctr Clin & Profess Dev, Boston, MA 02114 USA. Virginia Mason Med Ctr, Seattle, WA 98101 USA. RP Kramer, M (reprint author), 3285 N Prospector Rd, Apache Junction, AZ 85219 USA. EM mcairzona@juno.com NR 46 TC 22 Z9 22 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD JAN PY 2007 VL 37 IS 1 BP 41 EP 52 DI 10.1097/00005110-200701000-00007 PG 12 WC Nursing SC Nursing GA 123AQ UT WOS:000243269100007 PM 17172971 ER PT J AU Fletcher, CE Baker, SJ Copeland, LA Reeves, PJ Lowery, JC AF Fletcher, Carol E. Baker, S. Jill Copeland, Laurel A. Reeves, Pamela J. Lowery, Julie C. TI Nurse practitioners' and physicians' views of NPs as providers of primary care to veterans SO JOURNAL OF NURSING SCHOLARSHIP LA English DT Article DE nurse practitioner; primary care; collaborative practice; veterans ID QUALITATIVE RESEARCH AB Purpose: To describe NPs' and MDs' perceptions of the role of NPs, the degree of collegiality between professions, and NPs' feeling of acceptance, three relationship components that may affect the acceptance of NPs as providers of primary care. Design and Methods: A descriptive study including both closed- and open-ended questions plus several Likert-type questions conducted June-August 2004. Our sample included all primary care NPs (87) and MDs (162) within a Midwestern Veterans Health Administration (VHA) region. Data were collected from 153 providers. Findings: NPs saw their role as one of autonomous practice with physician back-up as needed, while MD respondents envisioned a role akin to a physician extender. Most of the physician respondents did not think NPs could provide adequate primary care to veterans who tend to have many comorbid conditions. Yet both groups considered their relationships to be collegial and most NPs felt accepted by physicians. MDs particularly valued NPs' teaching and interpersonal skills leading to greater patient satisfaction. Conclusions: To facilitate the teamwork of NPs and MDs while improving utilization of NPs as primary care providers, VHA officials should routinely clarify roles, monitor quality of care of both MDs and NPs, and provide feedback to all concerned. C1 VA Ann Arbor Healthcare Syst, Ctr Practice Management & Outcomes Res, Ann Arbor, MI 48113 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. RP Fletcher, CE (reprint author), VA Ann Arbor Healthcare Syst, Ctr Practice Management & Outcomes Res, 11-H,Box 130170, Ann Arbor, MI 48113 USA. EM cefletch@umich.edu NR 31 TC 12 Z9 12 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1527-6546 J9 J NURS SCHOLARSHIP JI J. Nurs. Scholarsh. PY 2007 VL 39 IS 4 BP 358 EP 362 DI 10.1111/j.1547-5069.2007.00193.x PG 5 WC Nursing SC Nursing GA 231YL UT WOS:000250985000012 PM 18021137 ER PT J AU Gravaghi, C Peppas, M Kang, JX La Perle, KMD Quimby, F Altholtz, L Hudgins, LC Lamprecht, SA AF Gravaghi, Claudia Peppas, Martha Kang, Jing X. La Perle, Krista M. D. Quimby, Fred Altholtz, Lotus Hudgins, Lisa C. Lamprecht, Sergio A. TI Transgenic fat-1 mice convert dietary (n-6) PUFAs to (n-3) PUFAs in colonic cells SO JOURNAL OF NUTRITION LA English DT Meeting Abstract CT International Research Conference on Food, Nutrition, and Cancer CY JUL 13-14, 2006 CL Washington, DC SP Amer Inst Canc Res, World Canc Res Fund Int, Calif Walnut Commiss, Campbell Soup Co, Cranberry Inst, Hormel Inst, IP 6 Int Inc, Kyushu Univ, Japan Grad Sch Agr, Natl Fisheries Inst, United Soybean Board C1 Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA. Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, Anim Resource Ctr, New York, NY 10021 USA. Rockefeller Univ, Lab Anim Res Ctr, New York, NY 10021 USA. Rockefeller Univ, Rogosin Inst, Iris & B Gerard Cantor Clin Res Lab, New York, NY 10021 USA. RI La Perle, Krista/B-3099-2015 NR 1 TC 1 Z9 1 U1 0 U2 0 PU AMER SOCIETY NUTRITIONAL SCIENCE PI BETHESDA PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD JAN PY 2007 VL 137 IS 1 SU S BP 292S EP 292S PG 1 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 123XQ UT WOS:000243330800076 ER PT J AU Garcia, R Hart, JE Davis, ME Reaser, P Natkin, J Laden, F Garshick, E Smith, TJ AF Garcia, Ronald Hart, Jaime E. Davis, Mary E. Reaser, Paul Natkin, Jonathan Laden, Francine Garshick, Eric Smith, Thomas J. TI Effects of wind on background particle concentrations at truck freight terminals SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE air pollution; diesel emissions; occupational exposures; wind; wind roses ID DIESEL EXHAUST EXPOSURE; LUNG-CANCER; AIR-POLLUTION; ULTRAFINE PARTICLES; RAILROAD WORKERS; MAJOR HIGHWAY; EMISSIONS AB Truck freight terminals are predominantly located near highways and industrial facilities. This proximity to pollution sources, coupled with meteorological conditions and wind patterns, may affect occupational exposures to particles at these work locations. To understand this process, data from an environmental sampling study of particles at U. S. trucking terminals, along with weather and geographic maps, were analyzed to determine the extent to which the transportation of particles from local pollutant sources elevated observed occupational exposures at these locations. To help identify potential upwind sources, wind direction weighted averages and speed measurements were used to construct wind roses that were superimposed on overhead photos of the terminal and examined for upwind source activity. Statistical tests were performed on these "source" and "nonsource" directions to determine whether there were significant differences in observed particle levels between the two groups. Our results provide evidence that nearby upwind pollution sources significantly elevated background concentrations at only a few of the locations sampled, whereas the majority provided little to no evidence of a significant upwind source effect. C1 Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA. Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA. Univ Massachusetts, Environm Earth & Ocean Sci Dept, Boston, MA 02125 USA. VA Boston Healthcare Syst, Med Serv, Pulm & Crit Care Med Sect, W Roxbury, MA USA. RP Hart, JE (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA. EM Jaime.hart@channing.harvard.edu FU NCI NIH HHS [R01 CA090792, CA 9072, T32 CA009072] NR 23 TC 4 Z9 4 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD JAN PY 2007 VL 4 IS 1 BP 36 EP 48 DI 10.1080/15459620601070302 PG 13 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 118IE UT WOS:000242934900006 PM 17162479 ER PT J AU Davis, ME Smith, TJ Laden, F Hart, JE Blicharz, AP Reaser, P Garshick, E AF Davis, M. E. Smith, T. J. Laden, F. Hart, J. E. Blicharz, A. P. Reaser, P. Garshick, E. TI Driver exposure to combustion particles in the U.S. trucking industry SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE diesel; occupational health; PM; traffic; trucking industry ID DIESEL EXHAUST; CARBON-MONOXIDE; SUBMICROMETER PARTICLES; ULTRAFINE PARTICLES; SAMPLING ARTIFACTS; PARTICULATE MATTER; ELEMENTAL CARBON; ORGANIC-CARBON; MAJOR HIGHWAY; LUNG-CANCER AB A large study of combustion particle exposures for drivers of diesel-powered trucks was conducted in collaboration with an epidemiologic study of lung cancer outcomes for workers in the trucking industry. Three components of diesel exhaust combustion particles (PM2.5, elemental carbon, and organic carbon) were measured inside the driver cabs of diesel-powered trucks from 36 different trucking terminals across the United States between 2001 and 2005. In-cab particle exposures for drivers assigned to both short and long distance trips were observed, as well as information on the smoking status of the driver, truck characteristics such as age and model, and weather conditions during the sampling session. This article summarizes these findings and describes the relationship between exhaust particles and various determinants of exposure. The results suggest that in-cab particle exposures are positively related to smoking, ambient particle concentrations, truck age, and open windows, with other significant modifying factors such as weather. This study represents the largest and most comprehensive exposure assessment of drivers in the trucking industry, encompassing a 4-year period of observations on diesel and exhaust particle exposures nationwide. The results are relevant not only to the occupational group of truck drivers being examined but also to the general population that live, commute, or work within proximity to diesel-fueled traffic or trucking terminals. C1 Univ Maine, Sch Econ, Orono, ME 04469 USA. Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA. VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA. RP Davis, ME (reprint author), Univ Maine, Sch Econ, 5782 Winslow Hall, Orono, ME 04469 USA. EM mary.davis@umit.maine.edu FU NCI NIH HHS [R01 CA090792, R01 CA090792-05] NR 33 TC 22 Z9 22 U1 2 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PY 2007 VL 4 IS 11 BP 848 EP 854 DI 10.1080/15459620701643347 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 227PN UT WOS:000250670400007 PM 17885912 ER PT J AU Susarla, SM Kaban, LB Donoff, RB Dodson, TB AF Susarla, Srinivas M. Kaban, Leonard B. Donoff, R. Bruce Dodson, Thomas B. TI Functional sensory recovery after trigeminal nerve repair SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID INFERIOR ALVEOLAR NERVE; MOLAR SURGICAL EXTRACTION; LINGUAL NERVE; 3RD MOLARS; MANAGEMENT; REMOVAL; INJURY; CORONECTOMY; EXPERIENCE; SURGERY AB Purpose: The aim of this study was to estimate the proportion of subjects who achieved functional sensory recovery (FSR) 1 year after inferior alveolar or lingual nerve repair and to identify risk factors associated with failure to achieve FSR. Methods: Using a retrospective cohort study design, we developed a sample composed of subjects who underwent lingual or inferior alveolar nerve repair. Eligible subjects had at least 1 postoperative visit. For subjects having bilateral nerve repair, 1 side was selected randomly for analysis. Predictor variables were categorized as demographic, anatomic, and operative. The outcome variable was the time to FSR, measured in days. Kaplan-Meier survival methods were used to estimate the proportion of subjects with FSR at 1 year. Uni- and multivariate Cox proportional hazard models were used to identify risk factors for the failure to reach FSR at 1 year. Results: The study sample was composed of 60 subjects with a mean age of 28.7 +/- 8.3 years; 68.3% were female. The majority (86.7%) of subjects presented with a preoperative chief complaint of altered sensation and had lingual nerve damage (93.3%) that was repaired by direct suturing (75%). The mean interval between injury and repair was 145.9 +/- 200.0 days. At 1 year postoperatively, 75% of the subjects had achieved FSR (95% confidence interval [CI]: 64% to 86%). Conclusions: The majority of subjects undergoing trigeminal (V-3) nerve repair achieved functional sensory recovery within 1 year of surgical repair. Patients with evidence of neuroma formation were less likely to achieve FSR at 1 year in a multivariate model. (c) 2007 American Association of Oral and Maxillofacial Surgeons. C1 Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Ctr Appl Clin Invest, Boston, MA 02114 USA. RP Susarla, SM (reprint author), Harvard Univ, Sch Dent Med, 188 Longwood Ave, Boston, MA 02115 USA. EM srinivas_susarla@student.hms.harvard.edu OI Susarla, Srinivas/0000-0003-0155-8260 NR 21 TC 27 Z9 27 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD JAN PY 2007 VL 65 IS 1 BP 60 EP 65 DI 10.1016/j.joms.2005.11.115 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 123FZ UT WOS:000243283100012 PM 17174765 ER PT J AU Susarla, SM Dodson, TB AF Susarla, Srinivas M. Dodson, Thomas B. TI Preoperative computed tomography imaging in the management of impacted mandibular third molars SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID INFERIOR ALVEOLAR NERVE; DYSESTHESIA; EXTRACTION; 3RD-MOLAR; SURGERY; INJURY; AGE AB Purpose: The purpose of this study was to examine the role of preoperative computed tomography (CT) imaging of the inferior alveolar nerve (IAN) for patients at increased risk for nerve injury during mandibular third molar (M3) extraction. Materials and Methods: To address the research purpose, the investigators enrolled a sample composed of Subjects who presented for mandibular M3 extraction and had panoramic radiographic signs interpreted as being associated with an increased risk for inferior alveolar nerve injury. All subjects had preoperative CT imaging studies done to ascertain the position of the IAN with respect to M3. The predictor variable was the preoperative assessment of risk for IAN injury based on panoramic imaging. The outcome variable was the preoperative assessment of IAN injury risk after reviewing the CT studies. We documented the number of IAN injuries. Descriptive statistics were computed as indicated. Results: The sample consisted of 23 patients who had bilaterally impacted wisdom teeth. The sample's mean age was 26 +/- 6 years (range: 18-48 years); 69.6% of the patients were female. After reviewing the panoramic radiographic, 80.4% of M3s were classified as having an increased risk for IAN injury. Upon examining the CT imaging, 32.6% were classified as high risk for IAN injury. After reviewing all imaging studies, 71.7% of the teeth in the sample were extracted. Intraoperative IAN visualization occurred in 21.2% of the cases. At 1 week postoperative, 3 patients had dysesthesia (9.1%); none had a permanent nerve injury. Conclusion: In this small series of patients, the additional information provided by 3-dimensional imaging changed the majority of patients from increased risk for nerve injury to low risk for nerve injury. (c) 2007 American Association of Oral and Maxillofacial Surgeons. C1 Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Ctr Appl Clin Invest, Boston, MA 02114 USA. Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. RP Susarla, SM (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Ctr Appl Clin Invest, 55 Fruit St,Warren 1201, Boston, MA 02114 USA. EM ssusarla@student.hms.harvard.edu OI Susarla, Srinivas/0000-0003-0155-8260 FU NIDCR NIH HHS [K24 DE000448] NR 10 TC 42 Z9 44 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD JAN PY 2007 VL 65 IS 1 BP 83 EP 88 DI 10.1016/j.joms.2005.10.052 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 123FZ UT WOS:000243283100016 PM 17174769 ER PT J AU Mudgal, CS Ring, D AF Mudgal, Chaitanya S. Ring, David TI Stacked plating for metadiaphyseal fractures of the distal radius: A technique report SO JOURNAL OF ORTHOPAEDIC TRAUMA LA English DT Article DE dual; stacked; plating; metadiaphyseal; fractures; radius ID TIBIAL FRACTURES; FIXATION AB Combined injuries of the distal radius and shaft are rare, are usually caused by high energy, and pose a surgical dilemma. Surgical tactics and implants that are routinely used either for isolated fractures of the distal radius or for fractures of the radial shaft are often not applicable for this combined injury. We describe a technique of dual-stacked plating for these metadiaphyseal fractures and its use in two patients. C1 Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand Serv, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Orthopaed Hand Serv, Boston, MA 02114 USA. RP Mudgal, CS (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand Serv, Suite 2100,Fruit St, Boston, MA 02114 USA. EM cmudgal@partners.org NR 7 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-5339 J9 J ORTHOP TRAUMA JI J. Orthop. Trauma PD JAN PY 2007 VL 21 IS 1 BP 63 EP 66 DI 10.1097/01.bot.0000245682.07078.89 PG 4 WC Orthopedics; Sport Sciences SC Orthopedics; Sport Sciences GA 127SK UT WOS:000243606400012 PM 17211272 ER PT J AU Gomez, FE Lan, JG Kang, WD Ueno, C Kudsk, KA AF Gomez, F. Enrique Lan, Jinggang Kang, Woodae Ueno, Chikara Kudsk, Kenneth A. TI Parenteral nutrition and fasting reduces mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) mRNA in Peyer's patches of mice SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article ID UPPER RESPIRATORY-TRACT; IMMUNOGLOBULIN-A LEVELS; MAJOR ABDOMINAL-TRAUMA; LYMPHOID-TISSUE; ENTERAL NUTRITION; SEPTIC MORBIDITY; GENE-EXPRESSION; L-SELECTIN; IMMUNITY; GLUTAMINE AB Background: Mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) in Peyer's patches (PP) is the gateway molecule for cellular migration into the mucosal immune system. Lack of enteral feeding during parenteral nutrition (PN) rapidly decreases PP MAdCAM-1, leading to drops in mucosal T and B cells and intestinal and respiratory IgA. We determined the molecular events associated with MAdCAM-1 mRNA and protein during PN (short and long term) and fasting (1 and 2 days). Methods: Experiment 1: Cannulated mice received PN for 8 hours (short-term PN, n = 6) or chow + saline (chow, n = 6). Experiment 2: Cannulated mice received PN (long-term PN, n = 4) or chow (n = 3) for 5 days. Experiment 3: Noncannulated chow mice were fasted for 1 and 2 days (n = 2/time). Total cellular RNA from the PP was quantified for MAdCAM-1 mRNA by real-time polymerase chain reaction (PCR). MAdCAM-1 protein was measured by Western blot. Results: PN rapidly down-regulated MAdCAM-1 gene expression. After 8 hours of PN with lack of enteral feeding, MAdCAM-1 mRNA levels dropped 20% (0.8-fold us chow, p >.05); 5 days of PN reduced MAdCAM-1 levels 64% (0.34-fold us chow, p <.05). PN reduced MAdCAM-1 protein levels by 30% (chow: 329 +/- 14 us PN: 230 +/- 35, p <.05) after 5 days. Fasting of uncannulated mice decreased MAdCAM-1 mRNA levels by 16% (0.84-fold, p <.05) at day 1 and 30% 47-fold, p <.05) by day 2 compared with chow. Conclusions: Both PN with lack of enteral feeding and fasting down-regulate MAdCAM-1 mRNA and protein levels in PP. The MAdCAM-1 changes are due to lack of enteral stimulation rather than toxic effects of PN. C1 William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI 53705 USA. Univ Wisconsin, Coll Med & Publ Hlth, Dept Surg, Madison, WI 53706 USA. RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU NIGMS NIH HHS [R01 GM53439] NR 28 TC 8 Z9 10 U1 0 U2 1 PU AMER SOC PARENTERAL & ENTERAL NUTRITION PI SILVER SPRING PA 8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910 USA SN 0148-6071 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD JAN-FEB PY 2007 VL 31 IS 1 BP 47 EP 52 DI 10.1177/014860710703100147 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 195XD UT WOS:000248444800009 PM 17202440 ER PT J AU Lee, Y Miron, A Drapkin, R Nucci, MR Medeiros, F Saleemuddin, A Garder, J Birch, C Mou, H Gordon, RW Cramer, DW McKeon, FD Crum, CP AF Lee, Y. Miron, A. Drapkin, R. Nucci, M. R. Medeiros, F. Saleemuddin, A. Garder, J. Birch, C. Mou, H. Gordon, R. W. Cramer, D. W. McKeon, F. D. Crum, C. P. TI A candidate precursor to serous carcinoma that originates in the distal fallopian tube SO JOURNAL OF PATHOLOGY LA English DT Article ID PROPHYLACTIC OOPHORECTOMY SPECIMENS; DNA-DAMAGE RESPONSE; OVARIAN-CANCER; EPITHELIAL-CELLS; HIGH-FREQUENCY; P53; MUTATION; EXPRESSION; GENE; H2AX AB The tubal fimbria is a common site of origin for early (tubal intraepithelial carcinoma or TIC) serous carcinomas in women with familial BRCA1 or 2 mutations (BRCA+). Somatic p53 tumour suppressor gene mutations in these tumours suggest a pathogenesis involving DNA damage, p53 mutation, and progressive loss of cell cycle control. We recently identified foci of strong p53 immunostaining - termed 'p53 signatures' - in benign tubal mucosa from BRCA+ women. To examine the relationship between p53 signatures and TIC, we compared location (fimbria vs ampulla), cell type (ciliated vs secretory), evidence of DNA damage, and p53 mutation status between the two entities. p53 signatures were equally common in non-neoplastic tubes from BRCA+ women and controls, but more frequently present (53%) and multifocal (67%) in fallopian tubes also containing TIC. Like prior studies of TIC, p53 signatures predominated in the fimbriae (80-100%) and targeted secretory cells (HMFG2+/p73-), with evidence of DNA damage by co-localization of gamma-H2AX. Laser-capture microdissected and polymerase chain reaction-amplified DNA revealed reproducible p53 mutations in eight of 14 fully-analysed p53 signatures and all of the 12 TICs; TICs and their associated ovarian carcinomas shared identical mutations. In one case, a contiguous p53 signature and TIC shared the same mutation. Morphological intermediates between the two, with p53 mutations and moderate proliferative activity, were also seen. This is the first report of an early and distinct alteration in non-neoplastic upper genital tract mucosa that fulfils many requirements for a precursor to pelvic serous cancer. The p53 signature and its malignant counterpart (TIC) underline the significance of the fimbria, both as a candidate site for serous carcinogenesis and as a target for future research on the early detection and prevention of this disease. Copyright (c) 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. C1 Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Canc Biol, Boston, MA USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. Harvard Univ, Sch Med, Dept Cell Biol, Cambridge, MA 02138 USA. Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA. RP Crum, CP (reprint author), Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, 75 Francis St, Boston, MA 02115 USA. EM ccrum@partners.org RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 FU NCI NIH HHS [P50 CA10500, CA83944, K08 CA108748] NR 38 TC 372 Z9 399 U1 2 U2 9 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0022-3417 J9 J PATHOL JI J. Pathol. PD JAN PY 2007 VL 211 IS 1 BP 26 EP 35 DI 10.1002/path.2091 PG 10 WC Oncology; Pathology SC Oncology; Pathology GA 126AV UT WOS:000243485500004 PM 17117391 ER PT J AU Fishman, DS Manfredi, MA LaBelle, JL Levine, JE Shamberger, RC Rufo, PA AF Fishman, Douglas S. Manfredi, Michael A. LaBelle, James L. Levine, Jason E. Shamberger, Robert C. Rufo, Paul A. TI Pancreatitis as the initial manifestation of stage IV neuroblastoma SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION LA English DT Article ID OBSTRUCTIVE-JAUNDICE; RHABDOMYOSARCOMA; LYMPHOMA; CHILD; TUMORS C1 Childrens Hosp, Div Pediat Gastroenterol & Nutr, Boston, MA 02115 USA. Childrens Hosp, Dept Surg, Boston, MA 02115 USA. Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Fishman, DS (reprint author), Childrens Hosp, Div Pediat Gastroenterol & Nutr, Hunnewell Ground Floor,300 Longwood Ave, Boston, MA 02115 USA. EM douglas.fishman@childrens.harvard.edu NR 19 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-2116 J9 J PEDIATR GASTR NUTR JI J. Pediatr. Gastroenterol. Nutr. PD JAN PY 2007 VL 44 IS 1 BP 146 EP 148 DI 10.1097/01.mpg.0000235973.29378.fb PG 3 WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics GA 118ZG UT WOS:000242981400028 PM 17204969 ER PT J AU Wylie, BJ Epps, KC Gaddipati, S Waksmonski, CA AF Wylie, Blair J. Epps, Kelly C. Gaddipati, Sreedhar Waksmonski, Carol A. TI Correlation of transthoracic echocardiography and right heart catheterization in pregnancy SO JOURNAL OF PERINATAL MEDICINE LA English DT Article; Proceedings Paper CT 30th Annual Scientific Meeting of the New-York-Perinatal-Society CY APR 18, 2007 CL New York, NY SP New York Perinatal Soc DE cardiomyopathy; critical care obstetrics; echocardiography; pulmonary hypertension ID PULMONARY-ARTERY PRESSURE; DOPPLER-ECHOCARDIOGRAPHY; TRICUSPID REGURGITATION; NONINVASIVE ESTIMATION; HYPERTENSION; OUTCOMES; DISEASE; WOMEN AB Objectives: To correlate estimated pulmonary artery pressures (PAP) by echocardiography with right heart catheterization (RHC) measurements and to correlate estimated left ventricular ejection fraction (EF) by echocardiography with cardiac output (CO) measurements by RHC. Study design: All women who had echocardiography at a single institution during a 6-year period and underwent RHC during pregnancy were included. Echocardiography estimates of right ventricular systolic pressure (RVSP) and EF were correlated with measured RHC PAP and CO, respectively. Results: Eighteen patients underwent 21 RHCs, 10 antepartum at the catheterization laboratory and the remaining 11 intrapartum, performed with the use of a pulmonary artery catheter placed prior to the onset or induction of labor. Correlation between RVSP and PAP was good (rho=0.79, P<0.0001); nonetheless, in 30% of cases RHC eliminated the concern for pulmonary hypertension (PHTN). There was minimal correlation between EF and CO. Conclusion: Despite good statistical correlation between echocardiography and RHC for determining pulmonary artery pressure, RHC should be considered for major decisions such as pregnancy interruption or preterm delivery given the proportion of cases where concern for PHTN was excluded by RHC. EF provides a poor proxy for CO. C1 [Wylie, Blair J.; Gaddipati, Sreedhar] Columbia Univ, Div Maternal Fetal Med, Dept Obstet & Gynecol, New York, NY USA. [Epps, Kelly C.; Waksmonski, Carol A.] Columbia Univ, Dept Med, Div Cardiol, New York, NY USA. RP Wylie, BJ (reprint author), Massachusetts Gen Hosp, Founders 4,55 Fruit St, Boston, MA 02114 USA. EM bwylie@partners.org NR 15 TC 12 Z9 12 U1 0 U2 2 PU WALTER DE GRUYTER & CO PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 0300-5577 J9 J PERINAT MED JI J. Perinat. Med. PY 2007 VL 35 IS 6 BP 497 EP 502 DI 10.1515/JPM.2007.133 PG 6 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 246XT UT WOS:000252042400008 PM 18052837 ER PT J AU Turner, JH Garnovskaya, MN Coaxum, SD Vlasova, TM Yakutovich, M Lefler, DM Raymond, JR AF Turner, Justin H. Garnovskaya, Maria N. Coaxum, Sonya D. Vlasova, Tamara M. Yakutovich, Margarita Lefler, David M. Raymond, John R. TI Ca2+-calmodulin and Janus kinase 2 are required for activation of sodium-proton exchange by the G(i)-coupled 5-hydroxytryptamine(1a) receptor SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID NA+-H+ EXCHANGER; PROTEIN-KINASE-C; EPIDERMAL-GROWTH-FACTOR; TYROSINE RESIDUES; 5-HT1A RECEPTOR; JANUS KINASE-2; PHOSPHORYLATION; CALMODULIN; NHE1; CELLS AB The type 1 sodium-proton exchanger (NHE-1) is expressed ubiquitously and regulates key cellular functions, including mitogenesis, cell volume, and intracellular pH. Despite its importance, the signaling pathways that regulate NHE- 1 remain incompletely defined. In this work, we present evidence that stimulation of the 5- hydroxytryptamine(1A) ( 5- HT1A) receptor results in the formation of a signaling complex that includes activated Janus kinase 2 ( Jak2), Ca2+/calmodulin ( CaM), and NHE- 1, and which involves tyrosine phosphorylation of CaM. The signaling pathway also involves rapid agonist- induced association of CaM and NHE- 1 as assessed by coimmunoprecipitation studies and by bioluminescence resonance energy transfer studies in living cells. We propose that NHE- 1 is activated through this pathway: 5- HT1A receptor -> G(i2)alpha and/ or G(i3)alpha -> Jak2 activation -> tyrosine phosphorylation of CaM -> increased binding of CaM to NHE -> induction of a conformational change in NHE- 1 that unmasks an obscured protonsensing and/ or proton- transporting region of NHE-1 -> activation of NHE-1. The G(i/o)-coupled 5-HT1A receptor now joins a handful of G(q)-coupled receptors and hypertonic shock as upstream activators of this emerging pathway. In the course of this work, we have presented clear evidence that CaM can be activated through tyrosine phosphorylation in the absence of a significant role for elevated intracellular Ca2+. We have also shown for the first time that the association of CaM with NHE-1 in living cells is a dynamic process. C1 Med Univ S Carolina, Med & Res Serv, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. RP Raymond, JR (reprint author), Off Provost, 179 Ashley Ave, Charleston, SC 29425 USA. EM raymondj@musc.edu FU NIDDK NIH HHS [DK52448]; NIGMS NIH HHS [GM08716, GM63909] NR 40 TC 15 Z9 15 U1 0 U2 0 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD JAN PY 2007 VL 320 IS 1 BP 314 EP 322 DI 10.1124/jpet.106.112581 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 119ER UT WOS:000242995600037 PM 17050776 ER PT J AU Barbeau, EM Delaurier, G Kelder, G McLellan, D Sorensen, G Balbach, ED Levenstein, C AF Barbeau, Elizabeth M. Delaurier, Gregory Kelder, Graham McLellan, Deborah Sorensen, Glorian Balbach, Edith D. Levenstein, Charles TI A decade of work on organized labor and tobacco control: Reflections on research and coalition building in the United States SO JOURNAL OF PUBLIC HEALTH POLICY LA English DT Article DE organized labor; labor unions; tobacco control; labor-tobacco; tobacco control policy; smoking cessation ID SMOKING-CESSATION INTERVENTION; RANDOMIZED CONTROLLED TRIAL; CIGARETTE-SMOKING; OCCUPATION; HEALTH; DISPARITIES; PREVALENCE; EMPLOYMENT; POSITIONS; INDUSTRY AB Labor unions can and should make strong allies in tobacco control efforts. Through much of the 1980s and 1990s, however, the organized labor and tobacco control communities rarely formed coalitions to achieve mutual gains. Recently, labor unions and tobacco control organizations have begun to work together on smoking cessation programs, smoke-free worksite policies, and increased insurance coverage for cessation treatments. This paper explores the historic and present-day intersections among organized labor and tobacco control advocates. We summarize research in this area and report on our recent programmatic efforts to promote collaboration between the labor and tobacco control communities. We discuss lessons learned with the aims of promoting deeper understanding among tobacco control and labor advocates of how each views tobacco control issues, and most importantly, stimulating further collaboration toward mutual gains in protecting workers' health. C1 Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. Univ Massachusetts, Lowell, MA 01854 USA. Tufts Univ, Community Hlth Program, Medford, MA 02155 USA. RP Barbeau, EM (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 44 Binney St, Boston, MA 02115 USA. EM Elizabeth_barbeau@dfci.harvard.edu; gdelaurier@comcast.net; gkelder@comcast.net; deborah_mclellan@dfci.harvard.edu; edith.balbach@tufts.edu; chuck_lev@comcast.net NR 43 TC 6 Z9 6 U1 0 U2 3 PU PALGRAVE MACMILLAN LTD PI BASINGSTOKE PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND SN 0197-5897 J9 J PUBLIC HEALTH POL JI J. Public Health Policy PY 2007 VL 28 IS 1 BP 118 EP 135 DI 10.1057/palgrave.jphp.3200118 PG 18 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 153IN UT WOS:000245425900013 PM 17363942 ER PT J AU Liu, Y Buck, DC Macey, TA Lan, HX Neve, KA AF Liu, Yong Buck, David C. Macey, Tara A. Lan, Hongxiang Neve, Kim A. TI Evidence that calmodulin binding to the dopamine D-2 receptor enhances receptor signaling SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION LA English DT Article DE D2 receptor; calmodulin; protein : protein interaction; receptor signaling; mitogen-activated protein kinase; adenylate cyclase ID ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; D2 RECEPTORS; TRANSACTIVATION; STIMULATION; ERK; PHOSPHORYLATION; RECOGNITION; CALCIUM; NEURONS AB The Ca2+ sensor calmodulin (CaM) regulates numerous proteins involved in G protein-coupled receptor (GPCR) signaling. CaM binds directly to some GPCRs, including the dopamine D-2 receptor. We confirmed that the third intracellular loop of the D-2 receptor is a direct contact point for CaM binding using coimmunoprecipitation and a polyHis pulldown assay, and we determined that the D-2-like receptor agonist 7-OH-DPAT increased the colocalization of the D-2 receptor and endogenous CaM in both 293 cells and in primary neostriatal cultures. The N-terminal three or four residues of D-2-IC3 were required for the binding of CaM; mutation of three of these residues in the full-length receptor (I210C/K211C/I212C) decreased the coprecipitation of the D-2 receptor and CaM and also significantly decreased D-2 receptor signaling, without altering the coupling of the receptor to G proteins. Taken together, these findings suggest that binding of CaM to the dopamine D-2 receptor enhances D-2 receptor signaling. C1 Portland Vet Affairs Med Ctr, R&D 30, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. RP Neve, KA (reprint author), Portland Vet Affairs Med Ctr, R&D 30, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM nevek@ohsu.edu FU NIMH NIH HHS [MH045372] NR 33 TC 17 Z9 18 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1079-9893 J9 J RECEPT SIG TRANSD JI J. Recept. Signal Transduct. PY 2007 VL 27 IS 1 BP 47 EP 65 DI 10.1080/10799890601094152 PG 19 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 131PQ UT WOS:000243882600003 PM 17365509 ER PT J AU Henry, JA Loovis, C Montero, M Kaelin, C Anselmi, KA Coombs, R Hensley, J James, KE AF Henry, James A. Loovis, Carl Montero, Melissa Kaelin, Christine Anselmi, Kathryn-Anne Coombs, Rebecca Hensley, June James, Kenneth E. TI Randomized clinical trial: Group counseling based on tinnitus retraining therapy SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article; Proceedings Paper CT 57th Annual Meeting of the American-Academy-of-Neurology CY APR 09-16, 2005 CL Miami Beach, FL SP Amer Acad Neurol DE auditory; clinical trial; educational counseling; hearing disorders; intervention; outcomes; rehabilitation; tinnitus; tinnitus retraining therapy; Tinnitus Severity Index ID MECHANISMS; MANAGEMENT AB The main component of tinnitus retraining therapy (TRT) is structured counseling. We conducted a randomized clinical trial to test the hypothesis that group educational counseling based on TRT principles would effectively treat veterans who have clinically significant tinnitus. Veterans with clinically significant tinnitus were randomized into one of three groups: educational counseling, traditional support, and no treatment. Subjects in the first two groups attended four 1.5 h group sessions each week. All subjects completed outcome questionnaires at baseline and at 1, 6, and 12 mo. A total of 269 subjects participated: 94 in the educational counseling group, 84 in the traditional support group, and 91 in the no-treatment group. Statistical analyses showed that educational counseling provided significantly more benefit than either traditional support or no treatment, as measured by the Tinnitus Severity Index. Results suggest that group educational counseling can significantly benefit many tinnitus patients and could be integral to a "progressive intervention" approach to tinnitus clinical management. C1 VA Med Ctr, Natl Ctr Rehabil Auditory Res, Dept Vet Affairs, VA Rehabil Res & Dev Serv, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. VA Puget Sound Hlth Care Syst, VA Audiol Clin, Seattle, WA USA. Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. RP Henry, JA (reprint author), VA Med Ctr, Natl Ctr Rehabil Auditory Res, Dept Vet Affairs, VA Rehabil Res & Dev Serv, Portland, OR USA. EM james.henry@med.va.gov NR 31 TC 17 Z9 17 U1 0 U2 12 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 1 BP 21 EP 31 DI 10.1682/JRRD.2006.02.0018 PG 11 WC Rehabilitation SC Rehabilitation GA 178PG UT WOS:000247232000004 PM 17551855 ER PT J AU Scarborough, DM McGibbon, CA Krebs, DE AF Scarborough, Donna Moxey McGibbon, Chris A. Krebs, David E. TI Chair rise strategies in older adults with functional limitations SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article; Proceedings Paper CT 57th Annual Meeting of the American-Academy-of-Neurology CY APR 09-16, 2005 CL Miami Beach, FL SP Amer Acad Neurol DE chair rise; dominant vertical rise; exaggerated trunk flexion; functional limitations; momentum transfer; movement strategy; older adults; peak trunk flexion; rehabilitation; sit-to-stand ID SIT-TO-STAND; ELDERLY PERSONS; DYNAMIC STABILITY; STRENGTH; EXERCISE; MOMENTUM; BALANCE; YOUNG; AGE AB Studies investigating chair rise (CR) strategies in older adults, including the identification of CR strategies in the clinical setting, are limited. We identified biomechanical differences between CR strategies performed by older adults. The "healthy" momentum transfer (MT), the exaggerated trunk flexion (ETF), and the dominant vertical rise (DVR) CR strategies were observed in 29 women and 17 men (64-88 yr) with functional limitations. The DVR strategy required the greatest knee torque (mean = 12.76 moment-% body weight). Maximum knee torque occurred significantly earlier for the ETF strategy (mean = 47% CR time). Lift-off time was earliest for the ETF strategy (mean = 32% CR time). Peak trunk flexion was the primary distinguishing biomechanical measure for classifying CR strategy. This finding may offer clinicians an easy method of identifying CR strategies during evaluation. Because of DVR and ETF movement timing and torque demands, we conclude that MT is the safest and most preferable CR strategy. C1 Massachusetts Gen Hosp, Inst Hlth Profess, Harris Orthoped Biomech & Biomat Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Orthoped, Biomot Lab, Boston, MA 02114 USA. Univ New Brunswick, Inst Biomed Engn, Fredericton, NB E3B 5A3, Canada. RP Scarborough, DM (reprint author), Massachusetts Gen Hosp, Inst Hlth Profess, Harris Orthoped Biomech & Biomat Lab, 55 Fruit St,GRJ 1125, Boston, MA 02114 USA. EM dscarborough@partners.org FU NIA NIH HHS [P50AG11669-03, R01AG12561] NR 22 TC 20 Z9 21 U1 2 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 1 BP 33 EP 41 DI 10.1682/JRRD.2005.08.0134 PG 9 WC Rehabilitation SC Rehabilitation GA 178PG UT WOS:000247232000005 PM 17551856 ER PT J AU Shipherd, JC Keyes, M Jovanovic, T Ready, DJ Baltzell, D Worley, V Gordon-Brown, V Hayslett, C Duncan, E AF Shipherd, Jillian C. Keyes, Megan Jovanovic, Tanja Ready, David J. Baltzell, David Worley, Virginia Gordon-Brown, Vanessa Hayslett, Cantrina Duncan, Erica TI Veterans seeking treatment for posttraumatic stress disorder: What about comorbid chronic pain? SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE chart review; chronic pain; comorbidity; generalizability; pain; posttraumatic stress disorder; PTSD; rehabilitation; treatment; veterans ID MOTOR-VEHICLE ACCIDENT; FIBROMYALGIA SYNDROME; SEXUAL ASSAULT; ANXIETY SENSITIVITY; MUTUAL MAINTENANCE; HEADACHE PATIENTS; SYMPTOMS; PTSD; HEALTH; PREVALENCE AB Our primary aim was to document the rate of comorbidity of physician-diagnosed chronic pain conditions in veterans who were seeking treatment for posttraumatic stress disorder (PTSD). Chronic pain diagnoses (e.g., chronic low-back pain and osteoarthritis) were examined with retrospective chart review. Of the patients with PTSD, 66% had chronic pain diagnoses at pretreatment. These findings are consistent with previous studies that documented the high comorbidity of chronic pain and PTSD using samples of pain patients. Our secondary aim was to examine pain ratings before, during, and after PTSD treatment. Using data that were a part of clinical practice, we found that patients with more pain before treatment reported reductions in pain over the course of PTSD treatment and in the 4 months following treatment. While our results must be interpreted cautiously because of multiple confounding factors and the absence of experimental manipulation, they highlight the importance of PTSD and pain comorbidity. C1 Dept Vet Affairs VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA USA. Boston Univ, Sch Med, Boston, MA 02118 USA. Vet Affairs Med Ctr, New Orleans, LA USA. VAMC, Atlanta, GA USA. Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. RP Shipherd, JC (reprint author), Vet Adm Med Ctr Jamaica Plain, Natl Ctr PTSD, Womens Hlth Sci Div 116B3, 150 S Huntington Ave, Boston, MA 02130 USA. EM jillian.shipherd@va.gov RI Duncan, Erica/B-1671-2016 FU NIMH NIH HHS [1R24MH067314-10A1, F32 MH070129-01A2] NR 79 TC 82 Z9 84 U1 1 U2 35 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 2 BP 153 EP 165 DI 10.1682/JRRD.2006.06.0065 PG 13 WC Rehabilitation SC Rehabilitation GA 176NJ UT WOS:000247091700004 PM 17551870 ER PT J AU Tan, G Craine, MH Bair, MJ Garcia, MK Giordano, J Jensen, MP McDonald, SM Patterson, D Sherman, RA Williams, W Tsao, JCI AF Tan, Gabriel Craine, Michael H. Bair, Matthew J. Garcia, M. Kay Giordano, James Jensen, Mark P. McDonald, Shelley M. Patterson, David Sherman, Richard A. Williams, Wright Tsao, Jennie C. I. TI Efficacy of selected complementary and alternative medicine interventions for chronic pain SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE biologically based medicine; chronic pain; complementary and alternative medicine; efficacy; energy medicine; manipulative and body-based medicine; mind-body medicine; pain management; rehabilitation; whole or professionalized CAM practices ID LOW-BACK-PAIN; PULSED ELECTROMAGNETIC-FIELDS; RANDOMIZED CONTROLLED-TRIAL; CRANIAL ELECTROTHERAPY STIMULATION; COGNITIVE-BEHAVIORAL THERAPY; CHRONIC MUSCULOSKELETAL PAIN; MUSCULAR COACTIVATION DMC; IRRITABLE-BOWEL-SYNDROME; HERB-DRUG INTERACTIONS; SHAM-CONTROLLED TRIAL AB Complementary and alternative medicine (CAM) is a group of diverse medical and healthcare systems, therapies, and products that are not presently considered part of conventional medicine. This article provides an up-to-date review of the efficacy of selected CAM modalities in the management of chronic pain. Findings are presented according to the classification system developed by the National Institutes of Health National Center for Complementary and Alternative Medicine (formerly Office of Alternative Medicine) and are grouped into four domains: biologically based medicine, energy medicine, manipulative and body-based medicine, and mind-body medicine. Homeopathy and acupuncture are discussed separately as "whole or professionalized CAM practices." Based on the guidelines of the Clinical Psychology Division of the American Psychological Association, findings indicate that some CAM modalities have a solid track record of efficacy, whereas others are promising but require additional research. The article concludes with recommendations to pain practitioners. C1 Michael E DeBakey VAMC, Dept Anesthesiol, Houston, TX 77030 USA. Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. Denver VAMC, VA Eastern Colorado Hlth Care Syst, Patient Focused Care Serv, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Dept Phys Med & Rehabil, Denver, CO 80202 USA. Richard L Roudebush VAMC, Hlth Serv Res & Dev Ctr Excellence Implementing, Indianapolis, IN USA. Univ Texas, MD Anderson Canc Ctr, Dept Anesthesiol & Pain Med, Houston, TX 77030 USA. Amer Coll Acupuncture & Oriental Med, Houston, TX USA. Georgetown Univ, Med Ctr, Ctr Clin Bioeth, Washington, DC 20007 USA. Georgetown Univ, Med Ctr, Div Palliat Med, Washington, DC 20007 USA. Samueli Inst, Alexandria, VA USA. Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. Behav Med Res & Training Fdn, Port Angeles, WA USA. Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Univ Calif Los Angeles, Pediat Pain Program, Dept Pediat, David Geffen Sch Med, Los Angeles, CA USA. RP Tan, G (reprint author), Michael E DeBakey VAMC, Dept Anesthesiol, Anesthesiol Care Line 145,2002 Holcombe Blvd, Houston, TX 77030 USA. EM tan.gabriel@med.va.gov FU NICHD NIH HHS [P01 HD33988]; NIDA NIH HHS [5R03 DA17026-2]; NIGMS NIH HHS [R01 GM42725-09A1]; NIMH NIH HHS [5R01 MH063779-03] NR 174 TC 21 Z9 22 U1 8 U2 20 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 2 BP 195 EP 222 DI 10.1682/JRRD.2006.06.0063 PG 28 WC Rehabilitation SC Rehabilitation GA 176NJ UT WOS:000247091700007 PM 17551873 ER PT J AU Silberbogen, AK Janke, EA Hebenstreit, C AF Silberbogen, Amy K. Janke, E. Amy Hebenstreit, Claire TI A closer look at pain and hepatitis C: Preliminary data from a veteran population SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE arthritis; depression; fibromyalgia; hepatitis C; pain; peripheral nervous system diseases; pilot projects; quality of life; rehabilitation; substance abuse ID VIRUS-RELATED ARTHRITIS; QUALITY-OF-LIFE; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; UNITED-STATES; PERIPHERAL NEUROPATHY; RHEUMATOID-ARTHRITIS; EXTRAHEPATIC MANIFESTATIONS; MIXED CRYOGLOBULINEMIA; ALCOHOL-CONSUMPTION; INITIAL TREATMENT AB An association between the hepatitis C virus (HCV) and various pain diagnoses, including arthritis, fibromyalgia, and peripheral neuropathy, has been reported. hi this article, we review the literature on the relationship between HCV and pain, highlighting current knowledge as well as methodological issues that exist in many studies. We also present preliminary findings from a survey conducted at two Department of Veterans Affairs facilities to assess the scope and impact of pain on functioning in veterans with HCV. Our results indicate that pain is very prevalent within this population and that HCV-positive veterans who experience persistent pain have significant depressive symptoms and engage in highrisk behaviors, such as cigarette smoking and alcohol use. Finally, we draw upon our review and preliminary results to propose areas of future rehabilitative research and to address the implications for clinicians working with patients with comorbid HCV and pain. C1 VA Boston Healthcare Syst, Psychol Serv, Dept Vet Affairs, Boston, MA 02130 USA. Boston Univ, Sch Med, Boston, MA 02215 USA. Edward J Hines Jr VA Hosp, Hines, IL USA. RP Silberbogen, AK (reprint author), VA Boston Healthcare Syst, Psychol Serv, Dept Vet Affairs, 116B,150 S Huntington Ave, Boston, MA 02130 USA. EM amy.silberbogen@va.gov NR 91 TC 18 Z9 18 U1 3 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 2 BP 231 EP 244 DI 10.1682/JRRD.2006.05.0053 PG 14 WC Rehabilitation SC Rehabilitation GA 176NJ UT WOS:000247091700009 PM 17551875 ER PT J AU Janke, EA Collins, A Kozak, AT AF Janke, E. Amy Collins, Allison Kozak, Andrea T. TI Overview of the relationship between pain and obesity: What do we know? Where do we go next? SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE back pain; body mass index; body weight; literature review; obesity; osteoarthritis; pain; quality of life; rehabilitation; risk factors; weight loss ID LOW-BACK-PAIN; QUALITY-OF-LIFE; BODY-MASS INDEX; ACTIVITY PROMOTION TRIAL; LOW-ENERGY DIET; KNEE OSTEOARTHRITIS; WEIGHT-LOSS; GENERAL-POPULATION; FAT DISTRIBUTION; MORBIDLY OBESE AB Overweight/obesity and pain are significant problems of increasing prevalence; understanding the relationship between the two is the focus of a growing body of research. Findings from this review support a likely relationship between increasing weight and pain conditions such as osteoarthritis and low back pain. Longitudinal studies suggest overweight/obesity early in life is a risk factor for pain, and the co-occurrence of pain and overweight/obesity negatively affects quality of life. The mechanism of relationship is unknown but is hypothesized to include mechanical and metabolic abnormalities, possibly secondary to lifestyle choices. Observations from a few studies demonstrate that treatments for obesity reduce pain secondary to weight loss. Few studies examine both pain and weight as primary outcomes, and variability in measurement makes comparisons and conclusions difficult. Research should focus on expanding knowledge about mechanisms of the relationship between pain and obesity, testing explanatory models addressing their co-occurrence, and developing treatments that most effectively target this comorbidity. C1 Edward Hines Jr Dept VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. VA Boston Healthcare Syst, Psychol Serv, Boston, MA USA. Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA. Edward Hines Jr VA Hosp, Res Serv, Hines, IL 60141 USA. RP Janke, EA (reprint author), Edward Hines Jr Dept VA Hosp, Ctr Management Complex Chron Care, 151H,POB 5000, Hines, IL 60141 USA. EM elizabeth.janke@va.gov NR 103 TC 86 Z9 87 U1 1 U2 12 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 2 BP 245 EP 261 DI 10.1682/JRRD.2006.06.0060 PG 17 WC Rehabilitation SC Rehabilitation GA 176NJ UT WOS:000247091700010 PM 17551876 ER PT J AU Chang, VT Sorger, B Rosenfeld, KE Lorenz, KA Bailey, AF Bui, T Weinberger, L Montagnini, M AF Chang, Victor T. Sorger, Brooke Rosenfeld, Kenneth E. Lorenz, Karl A. Bailey, Amos F. Bui, Trinh Weinberger, Lawrence Montagnini, Marcos TI Pain and palliative medicine SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE cancer; health services; heart failure; HIV; information technology; pain; palliative; PTSD; quality of care; rehabilitation; veterans ID QUALITY-OF-LIFE; OBSTRUCTIVE PULMONARY-DISEASE; TRANSMUCOSAL FENTANYL CITRATE; CONGESTIVE-HEART-FAILURE; ADVANCED CANCER-PATIENTS; LAST 6 MONTHS; SYMPTOM-ASSESSMENT; HOSPITALIZED-PATIENTS; CHRONIC ILLNESS; METASTATIC CANCER AB Severe pain is highly prevalent, with rates of 40% to 70% in patients with advanced cancer, liver disease, heart failure, human immunodeficiency virus, and renal failure. Wide variations in pain assessment and reporting methods and the measurement of multiple symptoms should be addressed in future studies. Regarding psychological approaches, determining whether hypnotherapy or other individual psychotherapeutic interventions reduce pain and/or psychological distress in a palliative care population is difficult. Interest is increasing in the concept of demoralization syndromes and the role of posttraumatic stress disorder in modulating responses to pain at the end of life. We review evidence from multiple studies that the use of rehabilitative therapy improves functional status and pain control among patients with advanced cancer, and we raise the possibility that rehabilitation therapy will be helpful in patients with other advanced diseases. We summarize ongoing clinical trials of electronic order sets, clinical care pathways, and care management pathways to improve pain management in palliative care. Wagner's Chronic Illness Model provides a way of analyzing how healthcare systems can be changed to provide adequate and continuing pain management in palliative care. Much work remains to ensure that pain is recognized, treated, and monitored effectively. C1 Dept VA New Jersey Hlth Care Syst, Sect Hematol Oncol 111, E Orange, NJ 07018 USA. Univ Med & Dent New Jersey, Newark, NJ 07103 USA. James J Peters VA Med Ctr, Bronx, NY USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Birmingham VAMC, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. RP Chang, VT (reprint author), Dept VA New Jersey Hlth Care Syst, Sect Hematol Oncol 111, 385 Tremont Ave, E Orange, NJ 07018 USA. EM Victor.chang@med.va.gov RI Montagnini, Marcos /B-6873-2014 NR 123 TC 7 Z9 7 U1 2 U2 7 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 2 BP 279 EP 294 DI 10.1682/JRRD.2006.06.0067 PG 16 WC Rehabilitation SC Rehabilitation GA 176NJ UT WOS:000247091700013 PM 17551879 ER PT J AU Jones, KR Vojir, CP Hutt, E Fink, R AF Jones, Katherine R. Vojir, Carol P. Hutt, Evelyn Fink, Regina TI Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE dementia; elderly; Faces Pain Scale; Numeric Rating Scale; nursing homes; pain assessment; pain intensity; pain-intensity tools; pain-level equivalency; rehabilitation ID IMPAIRED OLDER-ADULTS; CANCER PAIN; CUTPOINTS; DEMENTIA; SCALE AB Older adults in nursing homes experience pain that is often underassessed and undertreated. Visual analog pain-intensity scales, recommended for widespread use in adults, do not work well in the older adult population. A variety of other tools are in use, including the Verbal Descriptor Scale, the Faces Pain Scale (FPS), and the Numeric Rating Scale. These tools are more acceptable to older adults, but no agreement exists about how to compare the resulting pain-intensity scores across residents. This study examined the equivalency of pain-intensity scores for 135 nursing home residents who reported their pain on the three different instruments. The results were validated with a second sample of 135 nursing home residents. The pain levels across the three tools were highly correlated, but residents were found to underrate higher pain intensity on the FPS. A modification of scoring for the FPS led to greater agreement across the three tools. The findings have implications for use of these tools for quality improvement and public reporting of pain. C1 Univ Colorado, Sch Nursing, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Denver Dept Vet Affairs Med Ctr, Res Enhancement Award Program, Denver, CO USA. Univ Colorado, Sch Med, Denver, CO 80202 USA. Univ Colorado Hosp, Denver, CO USA. RP Hutt, E (reprint author), Denver VAMC, 151,1055 Clermont St, Denver, CO 80220 USA. EM evelyn.hutt@uchsc.edu FU AHRQ HHS [U18-HS11093] NR 34 TC 60 Z9 64 U1 0 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 2 BP 305 EP 314 DI 10.1682/JRRD.2006.05.0051 PG 10 WC Rehabilitation SC Rehabilitation GA 176NJ UT WOS:000247091700015 PM 17551881 ER PT J AU Buffum, MD Hutt, E Chang, VT Craine, MH Snow, AL AF Buffum, Martha D. Hutt, Evelyn Chang, Victor T. Craine, Michael H. Snow, A. Lynn TI Cognitive impairment and pain management: Review of issues and challenges SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE amnestic; analgesia; cognitive disorders; delirium; dementia; intensive care; nursing homes; pain; pain measurement; palliative care ID NURSING-HOME RESIDENTS; ALZHEIMERS-DISEASE; OLDER PERSONS; DEMENTIA; SCALES; INSTRUMENTS; VETERANS; SYSTEM; ADULTS AB The assessment and treatment of pain in persons with cognitive impairments pose unique challenges. Disorders affecting cognition include neurodegenerative, vascular, toxic, anoxic, and infectious processes. Persons with memory, language, and speech deficits and consciousness alterations are often unable to communicate clearly about their pain and discomfort. Past research has documented that persons with cognitive impairments, particularly dementia, are less likely to ask for and receive analgesics. This article provides an overview of the assessment, treatment, and management of pain in adults with cognitive impairments. We review types of cognitive impairment; recent work specific to best practices for pain management in patients with dementia, including assessment-tool development and pharmacological treatment; challenges in patients with delirium and in medical intensive care and palliative care settings; and directions for future research. C1 Dept VA Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. Denver VAMC, VA Eastern Colorado Hlth Care Syst, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. VA New Jersey Hlth Care Syst E Orange, E Orange, NJ USA. Univ Med & Dent New Jersey, Newark, NJ 07103 USA. Univ Alabama, Tuscaloosa, AL USA. RP Buffum, MD (reprint author), Dept VA Med Ctr, 4150 Clement St 118, San Francisco, CA 94121 USA. EM Martha.Buffum@va.gov NR 32 TC 40 Z9 41 U1 1 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 2 BP 315 EP 326 DI 10.1682/JRRD.2006.06.0064 PG 12 WC Rehabilitation SC Rehabilitation GA 176NJ UT WOS:000247091700016 PM 17551882 ER PT J AU Stevens, AB Strasser, DC Uomoto, J Bowen, SE Falconer, JA AF Stevens, Alan B. Strasser, Dale C. Uomoto, Jay Bowen, Susan E. Falconer, Judith A. TI Utility of treatment implementation methods in clinical trial with rehabilitation teams SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article; Proceedings Paper CT 82nd Annual Meeting of the American-Congress-of-Rehabilitation-Medicine CY SEP 28-OCT 02, 2005 CL Chicago, IL SP Amer Congress Rehabil Med DE behavioral science; clinical trials; effectiveness; interdisciplinary teams; patient care team; rehabilitation outcomes; research methods; stroke rehabilitation; team training; treatment implementation ID DEMENTIA CAREGIVERS; HOSPITALS; OUTCOMES AB Clinical trials of rehabilitation interventions pose unique challenges to researchers. Treatments can be technically complex, often requiring a multidisciplinary team of professions. This article demonstrates the application of Treatment Implementation (TI) methods in a rehabilitation team-training intervention conducted with 29 team leaders (12 medical doctors, 4 physical therapists, 3 speech-language pathologists, 2 occupational therapists, 3 kinesiotherapists, 2 registered nurses, I social worker, I program coordinator, and I administrator) from 15 Department of Veterans Affairs hospitals. We describe the intervention along with the influence of three TI categories (delivery, receipt, and enactment) on the design and implementation of the team-training intervention. Positive findings from the use of TI methods include (1) consistent and accurate presentation of intervention components and (2) evidence of study participants' receipt and enactment of intervention strategies. C1 Atlanta VA Med Ctr, Decatur, GA 30033 USA. Scott & White Mem Hosp & Clin, Temple, TX 76508 USA. Texas A&M Univ, Hlth Sci Ctr, College Stn, TX USA. Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. Emory Univ, Atlanta, GA 30322 USA. VA Puget Sound Hlth Care Syst, Seattle Div, Ctr Polytrauma Care Neuropsychol & Rehabil Psycho, Seattle, WA USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. Atlanta Dept Vet Affairs VA Med Ctr, Decatur, GA USA. RP Strasser, DC (reprint author), Atlanta VA Med Ctr, 1670 Clairmont Rd 11B, Decatur, GA 30033 USA. EM Dale.Strasser@va.gov NR 12 TC 12 Z9 12 U1 1 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 4 BP 537 EP 546 DI 10.1682/JRRD.2006.09.0120 PG 10 WC Rehabilitation SC Rehabilitation GA 223DV UT WOS:000250350700007 PM 18247250 ER PT J AU Tolerico, ML Ding, D Cooper, RA Spaeth, DM Fitzgerald, SG Cooper, R Kelleher, A Boninger, ML AF Tolerico, Michelle L. Ding, Dan Cooper, Rory A. Spaeth, Donald M. Fitzgerald, Shirley G. Cooper, Rosemarie Kelleher, Annmarie Boninger, Michael L. TI Assessing mobility characteristics and activity levels of manual wheelchair users SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE activity levels; activity monitor; data logger; manual wheelchair; mobility; mobility characteristics; national veterans wheelchair games; physical activity; rehabilitation; wheelchair users ID SPINAL-CORD-INJURY; PHYSICAL-ACTIVITY; HEALTH; PROPULSION; EMPLOYMENT; CAPACITY; VALIDITY; STRAIN; LIFE AB Although engaging in an active lifestyle is beneficial for maintaining quality of life, a majority of wheelchair users are inactive. This study investigated the mobility characteristics and activity levels of manual wheelchair users in the residential setting and at the National Veterans Wheelchair Games (NVWG). Demographic factors that may have influenced activity in the home environment were also identified. Fifty-two manual wheelchair users completed a brief survey, and their activity was monitored with a custom data logger over a period of 13 or 20 days. We found that they traveled a mean +/- standard deviation of 2,457.0 +/- 1,195.7 m/d at a speed of 0.79 +/- 0.19 m/s for 8.3 +/- 3.3 h/d while using their primary wheelchair in the home environment. No significant differences in mobility characteristics or activity levels were found for level of spinal cord injury or disability. We also found that subjects traveled significantly farther and faster and were active for more hours during an average day at the NVWG than in the home environment (p < 0.001). We found that manual wheelchair users who were employed covered more distance, accumulated more minutes, and traveled a greater average maximum distance between consecutive stops than those who were unemployed. Results from this study provide a better understanding of the activity levels achieved by manual wheelchair users and insight into factors that may influence this activity. C1 Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Dept Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Univ Pittsburgh, Sch Engn, Dept Bioengn, Pittsburgh, PA 15261 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,151R-1H, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Boninger, Michael/0000-0001-6966-919X NR 29 TC 72 Z9 72 U1 1 U2 9 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 4 BP 561 EP 571 DI 10.1682/JRRD.2006.02.0017 PG 11 WC Rehabilitation SC Rehabilitation GA 223DV UT WOS:000250350700010 PM 18247253 ER PT J AU Wolf, E Cooper, RA Pearlman, J Fitzgerald, SG Kelleher, A AF Wolf, Erik Cooper, Rory A. Pearlman, Jonathan Fitzgerald, Shirley G. Kelleher, Annmarie TI Longitudinal assessment of vibrations during manual and power wheelchair driving over select sidewalk surfaces SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE accessible surface; concrete; injury; manual wheelchair; power wheelchair; rehabilitation; sidewalks; vibration; wheelchairs; whole-body vibrations ID WHOLE-BODY VIBRATION; LOW-BACK-PAIN; SEAT SUSPENSION DESIGN; EXPOSURE; POSTURE AB Wheelchair users rely on their wheelchairs for mobility for extended periods of time every day. According to the International Standards Organization 2631-1 standard on human vibration, individuals in a seated position when exposed to whole-body vibrations (WBV) are at risk of injury. This study evaluated vibration exposure during manual and power wheelchair driving over nine sidewalk surfaces and differences in vibration exposure over 3 years. Ten nondisabled subjects were asked to drive a manual wheelchair at 1 m/s and a power wheelchair at I m/s and 2 m/s over nine sidewalk surfaces while WBV were measured at the seat and footrest of the wheelchair. At I rn/s, significant differences existed between surfaces and years at both the seat and the footrest for the manual and power wheelchair users. At 2 m/s, significant differences existed between surfaces and years at the seat and the footrest for power wheelchair users. Our results show that both manual and power wheelchair users may. be at risk for secondary injuries from WBV when traveling over certain surfaces. C1 Univ Pittsburgh, Sch Engn, Dept Bioengn, Pittsburgh, PA 15261 USA. Dept Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,151R-1H, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Wolf, Erik/0000-0002-6353-7978; Pearlman, Jon/0000-0003-0830-9136 NR 20 TC 8 Z9 8 U1 0 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 4 BP 573 EP 580 DI 10.1682/JRRD.2006.05.0049 PG 8 WC Rehabilitation SC Rehabilitation GA 223DV UT WOS:000250350700011 PM 18247254 ER PT J AU Collins, MP Souza, PE O'Neill, S Yueh, B AF Collins, Margaret P. Souza, Pamela E. O'Neill, Sami Yueh, Bevan TI Effectiveness of group versus individual hearing aid visits SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE education; group visits (non-Medical Subject Heading); health resources; health services research; hearing aids; hearing impaired; hearing loss; outcome assessment; patient satisfaction; rehabilitation of hearing impaired; veterans ID HEALTH MAINTENANCE ORGANIZATION; BEHAVIORAL TREATMENT APPROACH; CHRONIC CARE CLINICS; 2-YEAR FOLLOW-UP; RANDOMIZED-TRIAL; AUDIOLOGICAL REHABILITATION; COMMUNICATION COURSE; HANDICAP INVENTORY; DIABETES EDUCATION; OLDER-ADULTS AB Demand for hearing aid services in the Veterans Health Administration increased over 300% from 1996 to 2005, challenging the delivery of timely, high-quality care. Using group visits may help meet these needs, but whether this approach would still provide high-quality rehabilitation is unclear. This study determined whether group visits worsen hearing aid outcomes. It included a retrospective observational cohort in veterans seeking hearing aids at the Department of Veterans Affairs Puget Sound Health Care System from September 2004 to March 2005, when the clinic was using both individual and group visits. Medical records were reviewed for all new hearing aid patients seen during this period. Hearing-related outcome questionnaires were compared between patients seen for individual versus group fitting and/or follow-up visits. Results revealed that hearing thresholds were similar between patients seen individually and in groups. Of 74 patients who returned self-administered questionnaires after the follow-up, those who received both fitting and follow-up in a group format reported similar hearing handicap and better hearing-related function, satisfaction, and adherence than patients who received individual visits. Group visits did not appear to yield worse outcomes in this nonrandomized retrospective chart review. Definitive statements must await randomized comparisons. C1 [Collins, Margaret P.; Yueh, Bevan] Dept Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA 98108 USA. [Collins, Margaret P.; Souza, Pamela E.; O'Neill, Sami] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA. [Yueh, Bevan] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Yueh, Bevan] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [O'Neill, Sami] Dept Vet Affairs Puget Sound Hlth Care Syst, Rehabil Care Serv, Audiol Clin, Seattle, WA 98108 USA. RP Collins, MP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Audiol Clin, 1600 S Columbian Way, Seattle, WA 98108 USA. EM margaret.collins@va.gov OI Yueh, Bevan/0000-0003-1380-1053 NR 53 TC 7 Z9 8 U1 2 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2007 VL 44 IS 5 BP 739 EP 749 DI 10.1682/JRRD.2007.02.009 PG 11 WC Rehabilitation SC Rehabilitation GA 242SA UT WOS:000251744800013 PM 17943685 ER PT J AU Silverman, SL Shen, W Minshall, ME Xie, S Moses, KH AF Silverman, Stuart L. Shen, Wei Minshall, Michael E. Xie, Sunny Moses, Kathryn H. TI Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: Results from the Multiple Outcomes of Raloxifene Evaluation (MORE) Study SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE vertebral fracture; osteoporosis; depression; geriatric depression scale; health-related quality of life ID QUALITY-OF-LIFE; OSTEOPOROSIS; ASSOCIATION; QUESTIONNAIRE; RISK AB Objective. To examine the prevalence of depressive symptoms in a cross-sectional study of postmenopausal women with osteoporosis with and without prevalent vertebral fracture. Methods. Participants were a subset of English-speaking women (n = 3798, mean age 66.7 yrs) from the Multiple Outcomes of Raloxifene Evaluation trial, who had low bone mineral density (BMD) and/or prevalent vertebral fractures. Vertebral fractures were measured at baseline by radiography using a semiquantitative technique. Depressive symptoms were assessed at baseline using the Geriatric Depression Scale (GDS), a valid and reliable scale for depression screening in elderly patients. Women were considered as probably depressed if >= 6 symptoms of depression were reported. Results. Postmenopausal women with prevalent vertebral fracture reported more depressive symptoms as assessed by the GDS than women without prevalent vertebral fracture (1.54 vs 1.26; p = 0.001). There was an absolute increase of 2.5% (p = 0.008) in the prevalence of probable depression (GDS score >= 6) in women with prevalent fracture compared to those without prevalent fracture. The prevalence of probable depression was 4.1 % among women without prevalent vertebral fracture and 6.6% in women with a prevalent vertebral fracture. The prevalence of probable depression was 3-fold higher in women with at least 3 prevalent vertebral fractures compared to women without prevalent fracture (12.8% vs 4.1%; p < 0.001). Conclusion. Postmenopausal women with prevalent vertebral fractures had greater prevalence of depressive symptoms and probable depression as assessed by the GDS than women without vertebral fracture with low BMD. The dual diagnosis of depression and osteoporosis may mean worse health outcomes. Patients with prevalent vertebral fractures may be considered not only for interventions that address fracture risk reduction, but also for psychosocial interventions that address depressive symptoms. C1 Univ Calif Los Angeles, Cedars Sinai Med Ctr, Greater Los Angeles Vet Adm Hlth Syst, Los Angeles, CA 90048 USA. Eli Lilly & Co, Indianapolis, IN 46285 USA. Indiana Univ, Sch Med, Ctr Outcomes Res, Dept Publ Hlth, Indianapolis, IN 46204 USA. Forest Labs Inc, New York, NY USA. RP Silverman, SL (reprint author), OMC Clin Res Ctr, 8641 Wilshire Blvd,Suite 310, Beverly Hills, CA 90211 USA. EM stuarts@OMCresearch.org NR 26 TC 27 Z9 28 U1 1 U2 1 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD JAN PY 2007 VL 34 IS 1 BP 140 EP 144 PG 5 WC Rheumatology SC Rheumatology GA 125UC UT WOS:000243467300024 PM 17216681 ER PT J AU Wecht, JM Weir, JP Krothe, AH Spungen, AM Bauman, WA AF Wecht, Jill M. Weir, Joseph P. Krothe, AnnMarie H. Spungen, Ann M. Bauman, William A. TI Normalization of supine blood pressure after nitric oxide synthase inhibition in persons with tetraplegia SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE spinal cord injuries; arterial pressure; orthostatic hypotension; nitro-L-arginine methyl ester; nitric oxide inhibitor; tetraplegia ID SPINAL-CORD-INJURY; ORTHOSTATIC HYPOTENSION; SIMULATED MICROGRAVITY; VASCULAR ADAPTATION; L-NAME; COUNTERMEASURE; SPACEFLIGHT; INTOLERANCE; MECHANISMS; EXPRESSION AB Background/Objective: Orthostatic hypotension is a well-defined clinical consequence of spinal cord injury (SCI), particularly in those with tetraplegia. The etiology of orthostatic hypotension is thought to be loss of sympathetic vasomotor control, although other factors may play a role. There is evidence of up-regulation of nitric oxide synthase (NOS) activity after hind-limb suspension in rats, a condition of antigravity that may have similar vascular effects as shown in persons with tetraplegia caused by paralysis. The study objective was to determine the effect of a NOS inhibitor (nitro-L-arginine methyl ester [L-NAME]) on supine mean arterial pressure in persons with chronic tetraplegia compared with non-SCI controls. Methods: Fourteen individuals participated (7 with tetraplegia and 7 controls). Subjects visited the laboratory twice for placebo on day 1 and L-NAME (1 mg/kg) on day 2; both were infused intravenously over 60 minutes. Blood pressure was monitored for 3 hours after infusion at the brachial artery using a standard manual cuff. Results: Mean arterial pressure (MAP) was lower at baseline (P < 0.05) and after placebo administration (P < 0.0001) in the tetraplegia group compared with the control group. L-NAME increased MAP in both groups; however, the relative increase was greater in the tetraplegia group compared with the control group, Such that group differences for MAP were eliminated. Supine MAP was normalized with L-NAME, and there was an increased sensitivity to NOS inhibition in the group with tetraplegia. Conclusions: These findings indicate that blood pressure dysregulation in persons with tetraplegia may reflect increased vascular NO and suggest a novel treatment of hypotension using NOS inhibition in this population. C1 James J Peters VA Med Ctr, VA Ctr Excellence, Bronx, NY 10468 USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, VA Ctr Excellence, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM jwecht@hotmail.com NR 28 TC 13 Z9 14 U1 0 U2 1 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2007 VL 30 IS 1 BP 5 EP 9 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 145ZL UT WOS:000244904200003 PM 17385265 ER PT J AU Weaver, FM Smith, B LaVela, S Wallace, C Evans, CT Hammond, M Goldstein, B AF Weaver, Frances M. Smith, Bridget LaVela, Sherri Wallace, Carolyn Evans, Charlesnika T. Hammond, Margaret Goldstein, Barry TI Interventions to increase influenza vaccination rates in veterans with spinal cord injuries and disorders SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE vaccination; spinal cord injuries; influenza; prevention; veterans; respiratory infections ID CONTROLLED-TRIAL; IMMUNIZATION; REMINDERS; BEHAVIOR; OLDER; IMPLEMENTATION; METAANALYSIS; STRATEGIES; ATTITUDES; DELIVERY AB Objective: To increase the percentage of veterans with spinal cord injuries and disorders (SCI&D) who receive annual influenza vaccinations. Design: A repeated measures quality improvement project using several integrated evidence-based interventions. Setting: 23 Veterans Affairs (VA) SCI Centers. Patients: Veterans with SCI&D average age = 57.3 years (range 21-102 y). Interventions: Patient reminder letters and education; provider reminders and posters; computerized clinical reminders for vaccination targeted to SCI & D; standing orders. Main outcome measures: Patient self-reported vaccination status. Results: Baseline vaccination rate was 33% in fiscal year (FY) 2001. The percentage of veterans with SCI&D who reported receiving vaccinations increased from 62.5% in year 1 (FY2002) to 67.4% in FY2003 (P = 0.004); for individuals younger than 50 years of age, rates increased from 50% to 54%. Predictors of vaccination were age 65 years of age or older, VA health care visit in past year, nonsmoker, believing vaccination is important, having a health condition that may contribute to respiratory complications, and self-reported influenza in prior year. Conclusions: Vaccination rates were higher than baseline and higher than reported for other high-risk groups. Interventions that incorporate system-wide approaches plus patient and provider education and reminders were moderately effective in increasing vaccination rates. Targeting younger persons, smokers, and those who do not use VA care may further improve rates. C1 Northwestern Univ, Midwest Ctr Hlth Serv & Policy Res, Chicago, IL 60611 USA. Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. Northwestern Univ, Inst Hlth Serv & Policy Res, Chicago, IL 60611 USA. Edward Hines Vet Adm Med Ctr, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. VA Puget Sound Hlth Care Syst, SCI QUERI Dept Vet Affairs, Seattle, WA USA. Seattle Spinal Cord Injury & Disorders Strateg He, Seattle, WA USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Weaver, FM (reprint author), Hines VA Hosp, Midwest Ctr Hlth Serv & Policy Res 151H, Hines, IL 60141 USA. EM frances.weaver@va.gov NR 42 TC 18 Z9 18 U1 0 U2 1 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2007 VL 30 IS 1 BP 10 EP 19 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 145ZL UT WOS:000244904200004 PM 17387805 ER PT J AU Evans, CT LaVela, SL Smith, B Wallace, C Goldstein, B Weaver, FM AF Evans, Charlesnika T. LaVela, Sherri L. Smith, Bridget Wallace, Carolyn Goldstein, Barry Weaver, Frances M. TI Response to the 2004-2005 influenza vaccine shortage in veterans with spinal cord injuries and disorders and their providers SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE influenza; vaccination; health care workers; spinal cord injuries; prevention ID ATTITUDES AB Background/Objectives: To assess patient and provider behaviors regarding influenza vaccination, diagnosis, and testing strategies and the availability of influenza vaccine during the 2004-2005 nationwide influenza vaccine shortage. Design/Methods: Multisite, anonymous, cross-sectional surveys of patients and providers and qualitative interviews after the 2004-2005 influenza season. Setting: Department of Veterans Affairs (VA) health care facilities with spinal cord injury centers or clinics. Participants: Stratified random sample of 3,958 veterans with spinal cord injuries and disorders (SCI & D; 31% response rate), 177 providers who treat persons with SCI&D, and 17 key informants. Results: Most patient respondents (96.1%) reported awareness of a vaccine shortage (n = 938). When asked whether the shortage affected their ability to get the vaccine, 64.8% said they had no problem, whereas 12.1% reported an inability to get the vaccine. The vaccination rate was 71.8%; most veterans received the vaccine early (October-November) at the VA, and vaccination rates increased with age (P < 0.0001). Although vaccine shortages were reported by 47.5% of provider survey respondents (n = 177), most reported that the vaccine shortage did not affect availability of vaccine for patients with SCI&D. Few clinicians conducted diagnostic tests for influenza more often than in past years (4.9%). Although providers reported shortages at 12 centers (n = 23), patients with SCI&D had priority at 11 of 12 centers. Conclusions: Most patients were aware of the vaccine shortage, and the vaccination rate remained high and comparable with previous years. VA providers and facilities targeted SCI&D as a high-risk group and prioritized use of the limited vaccine supply for them. C1 Vet Affairs Edward Hines Jr Hosp, Dept Vet Affairs, Spinal Cord Injury Qual Enhancement Res Initiat, Midwest Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. Vet Affairs Puget Sound Healthcare Syst, Spinal Cord Injury Qual Enhancement Res Initiat, Dept Vet Affairs, Spinal Cord Injury & Disorders Strateg Healthcare, Seattle, WA USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. Northwestern Univ, Inst Hlth Serv & Policy Res, Chicago, IL 60611 USA. RP Evans, CT (reprint author), Edward J Hines Jr VA Hosp 151H, 5th Ave & Roosevelt Rd,POB 5000,Room D302, Hines, IL 60141 USA. EM charlesnika.evansc@va.gov NR 19 TC 2 Z9 2 U1 0 U2 1 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2007 VL 30 IS 1 BP 20 EP 26 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 145ZL UT WOS:000244904200005 PM 17387806 ER PT J AU Korsten, MA Singal, AK Monga, A Chaparala, G Khan, AM Palmon, R Mendoza, JRD Lirio, JP Rosman, AS Spungen, A Bauman, WA AF Korsten, Mark A. Singal, Ashwani K. Monga, Amit Chaparala, Geeta Khan, Amir M. Palmon, Ron Mendoza, John Reagan D. Lirio, Juan P. Rosman, Alan S. Spungen, Ann Bauman, William A. TI Anorectal stimulation causes increased colonic motor activity in subjects with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE digital rectal stimulation; spinal cord injury; neurogenic bowel; colonic motility; anorectal colonic reflex; paraplegia; tetraplegia ID NEUROGENIC BOWEL; DYSFUNCTION; MANAGEMENT; MOTILITY; CARE AB Background: Difficulty with evacuation (DWE) is a major problem after spinal cord injury (SCI). Stimulation of the anal canal and lower rectum, accomplished using a gloved finger (so-called digital rectal stimulation or DRS) is often used as an adjunct to laxatives and enemas to facilitate bowel evacuation. However, the basis for the efficacy of DRS is not known. This study assessed the effect of DRS on colonic motility. Methods: Six subjects with SCI were studied several hours after a bowel care session. Colonic motility was assessed using a manometric catheter (affixed endoscopically to the splenic flexure) at baseline, during DRS, and after DRS. In addition, evacuation of barium oatmeal paste (with the consistency of stool and introduced into the rectum and descending colon) was assessed simultaneously using fluoroscopic techniques. Results: The mean number (+/- SEM) of peristaltic waves per minute increased from 0 at baseline to 1.9 (+/-0.5/min) during DRS and 1.5 (+/-0.3/min) during the period immediately after cessation of DRS (P < 0.05). The mean amplitude (+/-SEM) of the peristaltic contractions was 43.4 (+/-2.2) mmHg. The frequency of contractions, as well as amplitude of contractions, during or immediately after DRS was not significantly different. These manometric changes in response to DRS were accompanied by expulsion of barium oatmeal paste in every subject by the fifth DRS. Conclusions: DRS causes left-sided colonic activity in subjects with SCI. At least in part, an anorectal colonic reflex that results in enhanced contractions of the descending colon and rectum may contribute to bowel evacuation in individuals with SCI. C1 James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rehabil Res & Dev Serv, Dept Vet Affairs, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. RP Korsten, MA (reprint author), VAMC, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM mark.korsten@med.va.gov NR 17 TC 9 Z9 13 U1 0 U2 0 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2007 VL 30 IS 1 BP 31 EP 35 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 145ZL UT WOS:000244904200007 PM 17385267 ER PT J AU Cardozo, CP AF Cardozo, Christopher P. TI Respiratory complications of spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Editorial Material C1 James J Peters VA Med Ctr, Spinal Cord Damage Res Ctr, Bronx, NY 10468 USA. RP Cardozo, CP (reprint author), James J Peters VA Med Ctr, Spinal Cord Damage Res Ctr, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM chris.cardozo@mssm.edu NR 5 TC 8 Z9 10 U1 0 U2 0 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2007 VL 30 IS 4 BP 307 EP 308 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 201SQ UT WOS:000248853300002 PM 17853651 ER PT J AU Smith, BM Evans, CT Kurichi, JE Weaver, FM Patel, N Burns, SP AF Smith, Bridget M. Evans, Charlesnika T. Kurichi, Jibby E. Weaver, Frances M. Patel, Nayna Burns, Stephen P. TI Acute respiratory tract infection visits of veterans with spinal cord injuries and disorders: Rates, trends, and risk factors SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE spinal cord injuries; veterans; acute respiratory tract infection; pneumonia; influenza; bronchitis; paraplegia; tetraplegia ID UNITED-STATES; HOSPITALIZATIONS; COMPLICATIONS; DEATH AB Background/Objectives: Respiratory complications are a major cause of illness and death in persons with spinal cord injuries and dysfunction (SCI&Ds). The objectives of this study were to examine rates of outpatient visits over 5 years for acute respiratory tract infections (ARIs), including pneumonia and influenza (P&I), lower respiratory tract infections (LRIs), and upper respiratory tract infections (URIs), in veterans with SCI&Ds and to determine whether individual characteristics were associated with the number of annual visits for each type of ARI. Methods: This was a longitudinal (fiscal years 1998-2002) study of ARI visits at the Veterans Health Administration (VA) in 18,693 veterans with SCI&Ds. To examine the associations between time, patient characteristics, and annual number of ARI visits, we used random effect negative binomial models. Results: Veterans with SCI&Ds had a total of 11,113 ARI visits over the 5-year period. There was a slightly decreasing trend for LRI visits over time (P < 0.01) but no significant change for other ARIs over time. There were 30 to 35 pneumonia visits and 21 to 30 acute bronchitis visits per 1,000 SCI&D veterans per year. Older veterans were more likely than younger to have P&I visits and less likely to have URI visits (P < 0.01). Veterans with paraplegia had fewer P&I visits than subjects with tetraplegia (IRR = 0.58; CI = 0.51-0.67). Conclusions: Visit rates for ARIs are stable for veterans with SCI&Ds. Identifying risk factors associated with ARI visits is an important first step to improve prevention and treatment of ARIs and to improve the health of veterans with SCI&Ds. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, SCI QUERI, Hines, IL 60141 USA. Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA. Univ Penn, Philadelphia, PA 19104 USA. Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Smith, BM (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, SCI QUERI, 151-H,POB 5000, Hines, IL 60141 USA. EM Bridget.Smith@va.gov NR 18 TC 15 Z9 15 U1 0 U2 1 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2007 VL 30 IS 4 BP 355 EP 361 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 201SQ UT WOS:000248853300008 PM 17853657 ER PT J AU Bryce, TN Norrbrink, C Cardenas, DD Dijkers, M Felix, ER Finnerup, NB Kennedy, P Lundeberg, T Richards, JS Rintala, DH Siddall, P Widerstrom-Noga, E AF Bryce, Thomas N. Norrbrink, Cecilia Cardenas, Diana D. Dijkers, Marcel Felix, Elizabeth R. Finnerup, Nanna B. Kennedy, Paul Lundeberg, Thomas Richards, J. Scott Rintala, Diana H. Siddall, Philip Widerstrom-Noga, Eva TI From the 2006 NIDRR SCI measures meeting - Pain after spinal cord injury: An evidence-based review for clinical practice and research SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Review DE pain; chronic; classification; neuropathic; non-neuropathic; treatment outcome; spinal cord injuries; pain scales; reproducibility of results ID QUALITY-OF-LIFE; LOW-BACK-PAIN; RANDOMIZED CONTROLLED-TRIAL; VISUAL ANALOG SCALE; NEUROPATHIC PAIN; SHORT-FORM; DOUBLE-BLIND; COPING STRATEGIES; OUTCOME MEASURES; LEEDS ASSESSMENT AB Background/Objectives: To examine the reliability, validity, sensitivity, and practicality of various outcome measures for pain after spinal cord injury (SCI), and to provide recommendations for specific measures for use in clinical trials. Data Sources: Relevant articles were obtained through a search of MEDLINE, EMBASE, CINAHL, and PubMed databases from inception through 2006. Study Selection: The authors performed literature searches to find articles containing data relevant to the reliability and validity of each pain outcome measure in SCI and selected non-SCI populations. Data Extraction: After reviewing the articles, an investigator extracted information utilizing a standard template. A second investigator reviewed the chosen articles and the extracted pertinent information to confirm the findings of the first investigator. Data Synthesis: Taking into consideration both the quantity and quality of the studies analyzed, judgments on reliability and validity of the measures were made by the two investigators. Based upon these judgments, recommendations were formulated for use of specific measures in future clinical trials. In addition, for a subset of measures a voting process by a larger group of SCI experts allowed formulation of recommendations including determining which measures should be incorporated into a minimal dataset of measures for clinical trials and which ones need revision and further validity and reliability testing before use. Conclusions: A 0-10 Point Numerical Rating Scale (NRS) is recommended as the outcome measure for pain intensity after SCI, while the 7-Point Guy/Farrar Patient Global Impression of Change (PGIC) scale is recommended as the outcome measure for global improvement in pain. The SF-36 single pain interference question and the Multidimensional Pain Inventory (MPI) or Brief Pain Inventory (BPI) pain interference items are recommended as the outcome measures for pain interference after SCI. Brush or cotton wool and at least one high-threshold von Frey filament are recommended to test mechanical allodynia/hyperalgesia while a Peltier-type thermotester is recommended to test thermal allodynia/hyperalgesia. The International Association for the Study of Pain (IASP) or Bryce-Ragnarsson pain taxonomies are recommended for classification of pain after SCI, while the Neuropathic Pain Scale (NPS) is recommended for measuring change in neuropathic pain and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) for quantitating neuropathic and nociceptive pain discrimination. C1 Mt Sinai Med Ctr, New York, NY 10021 USA. Dandyryds Hosp Karolinska Inst, Stockholm, Sweden. Miami Univ, Dept Rehabil Med, Miami, FL USA. Univ Miami, Miami VA Med Ctr, Miami Project Cure Paralysis, Miami, FL 33124 USA. Univ Aarhus, Danish Res Pain Ctr, DK-8000 Aarhus, Denmark. Univ Oxford, Oxford OX1 2JD, England. Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA. VA Med Ctr, Houston, TX USA. Univ Sydney, Royal N Shore Hosp, Pain Management Res Inst, Sydney, NSW 2006, Australia. RP Bryce, TN (reprint author), Mt Sinai Med Ctr, Dept Rehabil Med, 5 E 98th St,6th Flr,Box 1240B, New York, NY 10021 USA. EM Thomas.bryce@mssm.edu RI Heinemann, Allen /K-6283-2012; OI Heinemann, Allen /0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596 NR 124 TC 61 Z9 64 U1 2 U2 6 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2007 VL 30 IS 5 BP 421 EP 440 PG 20 WC Clinical Neurology SC Neurosciences & Neurology GA 236PE UT WOS:000251314400002 PM 18092558 ER PT J AU Bauman, WA Zhang, RL Spungen, AM AF Bauman, William A. Zhang, Run Lin Spungen, Ann M. TI Original contribution - Provocative stimulation of growth hormone: A monozygotic twin study discordant for spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE spinal cord injuries; growth hormone; insulin-like growth factor-1; paraplegia; arginine stimulation test; monozygotic twins ID GH-DEFICIENT ADULTS; BODY-COMPOSITION; FACTOR-I; INTRAVENOUS ARGININE; MEN; THERAPY; FAT AB Background/Objective: A blunted growth hormone (GH) response to provocative testing and/or low levels of plasma insulin-like growth factor-I (IGF-I) have been reported in persons with spinal cord injury (SCI). A reduction in activity of the GH-IGF-I axis may have deleterious effects on body composition and function. Provocative testing for GH stimulation was performed to determine the response in monozygotic twins that were discordant for SCI. Methods: GH stimulation testing was performed by the administration of intravenous arginine. Results: Nine SCI twins with paraplegia, a mean age of 39 +/- 9 years, and duration of injury of 14 +/- 9 years were studied. The twins with SCI had a significantly lower body mass index than non-SCI twins (22.5 +/- 4.0 vs 25.1 +/- 4.2 kg /m(2); P < 0.05); percent fat mass was greater in the twins with SCI (30 +/- 11 % vs 22 +/- 10%; P < 0.05). Baseline serum GH was correlated with percent fat only in the SCI twins. The response to GH provocative stimulation was less in the twins with SCI: peak GH response was 5.8 6.6 vs 13.0 7.3 ng/mL (P < 0.05), and sum GH response was 15.7 +/- 15.6 vs 30.2 +/- 17.3 ng/mL (P 0.06). Although baseline serum GH was correlated with stimulated response in the SCI twins, this relationship was not found in the non-SCI twins. Adiposity was positively related to the provocative serum GH response in twins with SCI rather than negatively related, as noted in the non-SCI twins. Conclusions: This study confirms and extends prior work that reported a reduction in stimulated GH release in persons with SCI, which was related to baseline values. C1 James J Peters Vet Affairs Med Ctr, Res Serv, Bronx, NY USA. Mt Sinai Sch Med, Spinal Cord Damage Res Ctr, New York, NY USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Bauman, WA (reprint author), Vet Affairs Med Ctr, Ctr Med Consequence Spinal Cord Injury, SCI Serv, Rm 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM william.bauman@med.va.gov NR 23 TC 7 Z9 7 U1 0 U2 0 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2007 VL 30 IS 5 BP 467 EP 472 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 236PE UT WOS:000251314400007 PM 18092562 ER PT J AU Zhou, XH Qin, GS AF Zhou, Xiao-Hua Qin, Gengsheng TI A supplement to: "A new confidence interval for the difference between two binomial proportions of paired data" SO JOURNAL OF STATISTICAL PLANNING AND INFERENCE LA English DT Editorial Material C1 Univ Washington, Dept Biostat, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Biostat Unit, HSR&D Ctr Excellence, Seattle, WA 98108 USA. Georgia State Univ, Dept Math & Stat, Atlanta, GA 30303 USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, F600 Hlth Sci Box 357232, Seattle, WA 98195 USA. EM azhou@u.washington.edu NR 5 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-3758 J9 J STAT PLAN INFER JI J. Stat. Plan. Infer. PD JAN 1 PY 2007 VL 137 IS 1 BP 357 EP 358 DI 10.1016/j.jspi.2006.01.001 PG 2 WC Statistics & Probability SC Mathematics GA 092LT UT WOS:000241099000031 ER PT J AU Shinoda, M Tilles, AW Kobayashi, N Wakabayashi, G Takayanagi, A Totsugawa, T Harada, H Obara, H Suganuma, K Berthiaume, F Shimazu, M Shimizu, N Tanaka, N Kitajima, M Tompkins, RG Toner, M Yarmush, ML AF Shinoda, Masahiro Tilles, Arno W. Kobayashi, Naoya Wakabayashi, Go Takayanagi, Atsushi Totsugawa, Toshinori Harada, Hirohisa Obara, Hideaki Suganuma, Kazuhiro Berthiaume, Francois Shimazu, Motohide Shimizu, Nobuyoshi Tanaka, Noriaki Kitajima, Masaki Tompkins, Ronald G. Toner, Mehmet Yarmush, Martin L. TI A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE fulminant hepatic failure; primary rat hepatocytes; immortalized human hepatocytes; interleukin-1 receptor antagonist; bio-artificial liver device ID TUMOR-NECROSIS-FACTOR; FLAT-PLATE BIOREACTOR; IN-VITRO; ISCHEMIA/REPERFUSION INJURY; SANDWICH CONFIGURATION; ISCHEMIA-REPERFUSION; PORCINE HEPATOCYTES; CONTROLLED-TRIAL; SUPPORT SYSTEM; IL-6 AB Background. Liver transplantation is the treatment of choice for many patients with fulminant hepatic failure (FHF). A major limitation of this treatment is the lack of available donors. An optimally functioning bio-artificial liver (BAL) device has the potential to provide critical hepatic support to patients with FHF. In this study, we examined the efficacy of combining interleukin-1 (IL-1) receptor blockade with the synthetic function of hepatocytes in a BAL device for the treatment of FHF. Materials and methods. We injected an adenoviral vector encoding human IL-1 receptor antagonist (AdIL-1Ra) into the liver of D-galactosamine (GalN) intoxicated rats via the portal vein. We also transfected primary rat hepatocytes and reversibly immortalized human hepatocytes (TTNT cells) with AdIL-1Ra, and incorporated these transfected hepatocytes into our flat-plate BAL device and evaluated their efficacy in our GalN-induced FHF rat model after 10 h of extracorporeal perfusion. Results. Rats injected with AdIL-1Ra showed significant reductions in the plasma levels of hepatic enzymes. Primary rat hepatocytes transfected with AdIL-1Ra secreted IL-1Ra without losing their original synthetic function. Incorporating these cells into the BAL device and testing in a GaIN-induced FHF rat model resulted in significant reductions in plasma IL-6 levels and significantly improved animal survival. Incorporating the AdIL-1Ra transfected TTNT cells in the BAL device and testing in the GaIN-induced FHF rat model resulted in significantly reduced plasma IL-6 levels, and a trend toward improved survival was seen. Conclusion. Hepatocytes producing IL-1Ra are a promising cell source for BAL devices in the treatment of GalN-induced FHF. (c) 2007 Elsevier Inc. All rights reserved. C1 Shriners Hosp Children, Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA. Shriners Hosp Children, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Okayama Univ, Grad Sch Med & Dent, Dept Surg, Okayama, Japan. Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan. Keio Univ, Sch Med, Dept Mol Biol, Tokyo 160, Japan. RP Yarmush, ML (reprint author), Shriners Hosp Children, Massachusetts Gen Hosp, Ctr Engn Med, 51 Blossom St, Boston, MA 02114 USA. EM ireis@sbi.org FU NIDDK NIH HHS [K08 DK66040, K08 DK066040, P30 DK040561, P30 DK040561-11, R01 DK043371, R01 DK43371] NR 41 TC 17 Z9 18 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD JAN PY 2007 VL 137 IS 1 BP 130 EP 140 DI 10.1016/j.jss.2006.08.009 PG 11 WC Surgery SC Surgery GA 125NS UT WOS:000243449400019 PM 17081566 ER PT J AU de Boer, E Nuttall, AL Shera, CA AF de Boer, Egbert Nuttall, Alfred L. Shera, Christopher A. TI Wave propagation patterns in a "classical" three-dimensional model of the cochlea SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID PRODUCT OTOACOUSTIC EMISSIONS; BASILAR-MEMBRANE OSCILLATION; COHERENT REFLECTION; GUINEA-PIG; GROUP DELAYS; FORM; ORIGIN; TONE AB The generation mechanisms of cochlear waves, in particular those that give rise to otoacoustic emissions (OAEs), are often complex. This makes it difficult to analyze wave propagation. In this paper two unusual excitation methods are applied to a three-dimensional stylized classical nonlinear model of the cochlea. The model used is constructed on the basis of data from an experimental animal selected to yield a smooth basilar-membrane impedance function. Waves going in two directions can be elicited by exciting the model locally instead of via the stapes. Production of DPOAEs was simulated by presenting the model with two relatively strong primary tones, with frequencies f(1) and f(2), estimating the driving pressure for the distortion product (DP) with frequency 2f(1)-f(2), and computing the resulting DP response pattern - as a function of distance along the basilar membrane. For wide as well as narrow frequency separations the resulting DP wave pattern in the model invariably showed that a reverse wave is dominant in nearly the entire region from the peak of the f(2)-tone to the stapes. The computed DP wave pattern was further analyzed as to its constituent components with the aim to isolate their properties. (c) 2007 Acoustical Society of America. C1 Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Portland, OR 97239 USA. Univ Michigan, Kresge Hearing Res Inst, Ann Arbor, MI 48109 USA. Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. RP de Boer, E (reprint author), Univ Amsterdam, Acad Med Ctr, Room D2-226,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. FU NIDCD NIH HHS [R01 DC00141, R01 DC003687] NR 32 TC 11 Z9 11 U1 0 U2 2 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD JAN PY 2007 VL 121 IS 1 BP 352 EP 362 DI 10.1121/1.2385068 PG 11 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 129WX UT WOS:000243761900033 PM 17297790 ER PT J AU Saunders, G Forsline, A Jacobs, P AF Saunders, Gabrielle Forsline, Anna Jacobs, Peter TI The attitudes towards loss of hearing questionnaire (ALHQ): A comparison of paper and electronic formats SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE counseling; hearing aids; hearing aid outcome; questionnaires ID OF-LIFE DATA; QUALITY; SATISFACTION; COLLECTION; STANDARD AB The purpose of the study was to determine whether scores obtained on the ALHQ when completed in electronic format are the same as when completed in paper format. Four groups of 25 individuals participated. Each completed the ALHQ on two occasions in either its paper version, its electronic version, or both. The variance in ALHQ scores from the first to second administrations was compared across test groups. Data showed that the two forms of the questionnaire yielded equivalent scores but that completion in different modes on both occasions resulted in more variability in scores than completion in the same mode on both occasions. It is concluded that when comparing questionnaire data across administrations, the same response format should be used. Electronic completion took longer than paper completion, but it is concluded that the numerous advantages of electronic administration outweigh the disadvantages of additional completion time. C1 Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97213 USA. RP Saunders, G (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97213 USA. EM Gabrielle.saunders@med.va.gov NR 16 TC 2 Z9 3 U1 0 U2 2 PU AMER ACADEMY OF AUDIOLOGY PI RESTON PA 11730 PLAZA DRIVE, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD JAN PY 2007 VL 18 IS 1 BP 66 EP 77 DI 10.3766/jaaa.18.1.6 PG 12 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 123WF UT WOS:000243326200006 PM 17252959 ER PT J AU Badgwell, C Rosen, T AF Badgwell, Christy Rosen, Ted TI Cutaneous sarcoidosis therapy updated SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Review ID TUMOR-NECROSIS-FACTOR; ACTIVE PULMONARY SARCOIDOSIS; HUMAN ALVEOLAR MACROPHAGES; BLOOD MONONUCLEAR-CELLS; FACTOR-ALPHA PRODUCTION; LOW-DOSE METHOTREXATE; PULSED DYE-LASER; LUPUS-PERNIO; REFRACTORY SARCOIDOSIS; TNF-ALPHA AB The widely accepted standard therapy for cutaneous sarcoidosis includes corticosteroids, antimalarials, and methotrexate. However, a better understanding of the basic immunopathogenic properties of sarcoidosis has elucidated number of steps critical to the persistence mid progression of disease that may be vulnerable to treatment by targeted therapy. This article reviews both standard and newer therapeutic options for cutaneous sarcoidosis. C1 Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Houston, TX USA. RP Rosen, T (reprint author), 2815 Plumb, Houston, TX 77005 USA. EM vampireted@aol.com NR 142 TC 47 Z9 52 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD JAN PY 2007 VL 56 IS 1 BP 69 EP 83 DI 10.1016/j.jaad.2006.06.019 PG 15 WC Dermatology SC Dermatology GA 124AL UT WOS:000243339100008 PM 17190623 ER PT J AU Enwonwu, CO Ritchie, CS AF Enwonwu, Cyril O. Ritchie, Christine S. TI Nutrition and inflammatory markers SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE nutrition; inflammation; periodontal disease ID ACUTE-PHASE RESPONSE; PERIODONTAL-DISEASE; PATHOGENESIS; NUTRIENTS; CYTOKINES; CHILDREN AB Background: Inflammation underlies many chronic diseases. The goal of nutritional support in such diseases is to provide adequate energy and nutrients to. meet the increased requirements for synthesis of acute phase proteins, inflammatory mediators, antioxidant defenses and the promotion of tissue repair and restoration of cellular function. Conclusions. Systemic inflammation alters utilization of various nutrients (fats, carbohydrates and protein) and promotes increased cellular consumption of key I antioxidant vitamins and minerals. Some nutrients play a direct role in the resolution of inflammation. These relationships necessitate consideration of the adjunctive role of diet in the natural history of periodontitis. Clinical Implications: Little. is known about the role of nutrition in periodontitis. With rapid advances in molecular biology and nutritional genomics in particular, oral health scientists can address this important area of study. C1 Univ Maryland, Sch Med, Baltimore, MD 21201 USA. Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama, Dept Med, Div Gerontol Geriatr & Pallat Care, Birmingham, AL 35294 USA. RP Ritchie, CS (reprint author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA. EM critchie@uab.edu NR 33 TC 9 Z9 12 U1 0 U2 4 PU AMER DENTAL ASSN PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD JAN PY 2007 VL 138 IS 1 BP 70 EP 73 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 127PI UT WOS:000243598400019 PM 17197404 ER PT J AU Jervis, LL Shore, J Hutt, E Manson, SM AF Jervis, Lori L. Shore, Jay Hutt, Evelyn Manson, Spero M. TI Suboptimal pharmacotherapy in a tribal nursing home SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE nursing homes; medications; psychiatric disorders; rural; American Indians ID INAPPROPRIATE MEDICATION USE; EXPLICIT CRITERIA; DRUG-USE; DEMENTIA; RESIDENTS; INTERVENTIONS; EPIDEMIOLOGY; POPULATION; DEPRESSION; FACILITIES AB Objective: Suboptimal medication use among nursing home (NH) residents is common. NH residentstend to be older, suffer from multiple conditions, and take numerous medications, increasing their risk of serious complications. This article examines pharmacotherapy in a rural, tribally owned NH. Design: Medical records were reviewed and case studies were conducted by a team composed of a medical anthropologist, psychiatrist, and geriatrician. Setting: A rural, American Indian-owned NH in the US northern plains. Participants: 40 American Indian and 5 EuroAmerican NH residents. Measurements: Minimum Data Set assessments, admission records, care plans, social histories, prescription lists, and behavioral consultation reports. Results: Potential underuse affected almost 75% of residents; undertreatment of depressive and psychotic/agitated symptoms was especially common. Potential inappropriate use, especially of analgesics, psychotropics, and antihistamines, affected 30% of residents. A smaller, but still substantial, number of residents (21%) experienced potential overuse, much of which involved anticonvulsants, antibiotics, cardiovascular, and psychotropic agents. The prescription of 10 or more medications was significantly associated with potential drug interactions, as well as underuse, inappropriate medication use, and overuse. Conclusions: Psychotropic medications were the most potentially problematic medication category, and were strongly implicated in potential underuse, inappropriate use, and overuse. Fewer medications; the discontinuation of drugs known to be potentially problematic for NH residents; modification of psychotropic medication regimens; use of cognitive-enhancing medications where appropriate; implementation of an electronic medical record system; and greater use of nonpharmacological behavioral interventions may have substantially improved residents' treatment regimens. C1 Univ Colorado Denver, Dept Psychiat, Amer Indian & Alaska Nat Programs, Aurora, CO 80045 USA. Hlth Sci Ctr UCDHSC, Aurora, CO USA. Denver VA Med Ctr, Denver, CO USA. UCDHSC, Dept Med, Denver, CO USA. RP Jervis, LL (reprint author), Univ Colorado Denver, Dept Psychiat, Amer Indian & Alaska Nat Programs, POB 6508,MS F800, Aurora, CO 80045 USA. EM lori.jervis@uchsc.edu FU NIA NIH HHS [K01 AG 20232] NR 53 TC 6 Z9 6 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD JAN PY 2007 VL 8 IS 1 BP 1 EP 7 DI 10.1016/j.jamda.2006.03.010 PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 128HY UT WOS:000243650000001 PM 17210496 ER PT J AU Ko, Y Ararca, J Malone, DC Dare, DC Geraets, D Houranieh, A Jones, WN Nichol, WP Schepers, GP Wilhardt, M AF Ko, Yu Ararca, Jagob Malone, Daniel C. Dare, Donna C. Geraets, Doug Houranieh, Antoun Jones, William N. Nichol, W. Paul Schepers, Gregory P. Wilhardt, Michelle TI Practitioners' views on computerized drug-drug interaction alerts in the VA system SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article; Proceedings Paper CT 42nd Annual Meeting of the Drug-Information-Association CY JUN 19, 2006 CL Philadelphia, PA SP Drug Informat Assoc ID PHYSICIAN ORDER ENTRY; HOSPITALIZED-PATIENTS; HEALTH-CARE; CROSS-SITE; SATISFACTION; EVENTS; ERRORS; IMPLEMENTATION; EMERGENCY; BENEFITS AB Objectives: To assess Veterans Affairs (VA) prescribers' and pharmacists' opinions about computer-generated drug-drug interaction (DDI) alerts and obtain suggestions for improving DDI alerts. Design: A mail survey of 725 prescribers and 142 pharmacists from seven VA medical centers across the United States. Measurements: A questionnaire asked respondents about their sources of drug and DDI information, satisfaction with the combined inpatient and outpatient computerized prescriber order entry (CPOE) system, attitude toward DDI alerts, and suggestions for improving DDI alerts. Results: The overall response rate was 40% (prescribers: 36%; pharmacists: 59%). Both prescribers and pharmacists indicated that the CPOE system had a neutral to positive impact on their jobs. DDI alerts were not viewed as a waste of time and the majority (61%) of prescribers felt that DDI alerts had increased their potential to prescribe safely. However, only 30% of prescribers felt DDI alerts provided them with what they needed most of the time. Both prescribers and pharmacists agreed that DDI alerts should be accompanied by management alternatives (73% and 82%, respectively) and more detailed information (65% and 89%, respectively). When asked about suggestions for improving DDI alerts, prescribers most preferred including management options whereas pharmacists most preferred making it more difficult to override lethal interactions. Prescribers and pharmacists reported primarily relying on electronic references for general drug information (62% and 55%, respectively) and DDI information (51% and 79%, respectively). Conclusion: Respondents reported neutral to positive views regarding the effect of CPOE on their jobs. Their opinions suggest DDI alerts are useful but still require additional work to increase their clinical utility. C1 Univ Arizona, Coll Pharm, Dept Pharmaceut Sci, Tucson, AZ 85721 USA. Univ Arizona, Coll Pharm, Ctr Hlth Outcomes & Pharmoecon Res, Tucson, AZ 85721 USA. San Francisco VA Med Ctr, San Francisco, CA USA. VA Iowa City Hlth Care Syst, Iowa City, IA USA. VA Boston Hlth Care Syst, Boston, MA USA. VA PBM CMOP, Tucson, AZ USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. Cart T Hayden VA Med Ctr, Phoenix, AZ USA. RP Malone, DC (reprint author), Univ Arizona, Coll Pharm, Dept Pharmaceut Sci, Drachman B307F,1295 N Martin, Tucson, AZ 85721 USA. EM malone@pharmacy.arizona.edu FU AHRQ HHS [U18 HS10385-05, U18 HS010385] NR 42 TC 54 Z9 55 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD JAN-FEB PY 2007 VL 14 IS 1 BP 56 EP 64 DI 10.1197/jamia.M2224 PG 9 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 127FT UT WOS:000243571400009 PM 17068346 ER PT J AU Moeller, CC Wei, C Altintas, MM Li, J Greka, A Ohse, T Pippin, JW Rastaldi, MP Wawersik, S Schiavi, S Henger, A Kretzler, M Shankland, SJ Reiser, J AF Moeller, Clemens C. Wei, Changli Altintas, Mehmet M. Li, Jing Greka, Anna Ohse, Takamoto Pippin, Jeffrey W. Rastaldi, Maria P. Wawersik, Stefan Schiavi, Susan Henger, Anna Kretzler, Matthias Shankland, Stuart J. Reiser, Jochen TI Induction of TRPC6 channel in acquired forms of proteinuric kidney disease SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article; Proceedings Paper CT 39th Annual Meeting of the American-Society-of-Nephrology CY NOV 17, 2006 CL San Diego, CA SP Amer Soc Nephrol ID PODOCYTE; EXPRESSION; ACTIN; GLOMERULOSCLEROSIS; MEMBRANE; COMPLEX; INJURY; CA2+ AB Injury to podocytes and their slit diaphragms typically leads to marked proteinuria. Mutations in the TRPC6 gene that codes for a slit diaphragm-associated, cation-permeable ion channel have been shown recently to co-segregate with hereditary forms of progressive kidney failure. Herein is shown that induced expression of wild-type TRPC6 is a common feature of human proteinuric kidney diseases, with highest induction observed in membranous nephropathy. Cultured podocytes that are exposed to complement upregulate TRPC6 protein. Stimulation of receptor-operated channels in puromycin aminonucleoside-treated podocytes leads to increased calcium influx in a time- and dosage-dependent manner. Mechanistically, it is shown that TRPC6 is functionally connected to the podocyte actin cytoskeleton, which is rearranged upon overexpression of TRPC6. Transient in vivo gene delivery of TRPC6 into mice leads to expression of TRPC6 protein at the slit diaphragm and causes proteinuria. These studies suggest the involvement of TRPC6 in the pathology of nongenetic forms of proteinuric disease. C1 Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02129 USA. Harvard Univ, Sch Med, Boston, MA 02129 USA. Univ Washington, Div Nephrol, Seattle, WA 98195 USA. San Carlo Borromeo Hosp, Assoc Nuova Nefrol, Renal Immunopathol Lab, Milan, Italy. San Carlo Borromeo Hosp, Fdn Amico Ricerca Malattie Renali, Milan, Italy. Genzyme Corp, Endocrine & Renal Sci, Framingham, MA 01701 USA. Univ Munich, Med Poliklin, Nephrol Zentrum, D-8000 Munich, Germany. RP Reiser, J (reprint author), Massachusetts Gen Hosp, Dept Med, Div Nephrol, NGH-E,149 13th St, Boston, MA 02129 USA. EM jreiser@partners.org OI Altintas, Mehmet/0000-0002-1871-6985 NR 21 TC 31 Z9 33 U1 0 U2 4 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2007 VL 18 IS 1 BP 29 EP 36 DI 10.1681/ASN.2006091010 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 126TG UT WOS:000243537800006 PM 17167110 ER PT J AU He, JCJ Lu, TC Fleet, M Sunamoto, M Husain, M Fang, W Neves, S Chen, Y Shankland, S Iyengar, R Klotman, PE AF He, John Cijiang Lu, Ting-Chi Fleet, Margaret Sunamoto, Masaaki Husain, Mohammad Fang, Wei Neves, Susana Chen, Yibang Shankland, Stuart Iyengar, Ravi Klotman, Paul E. TI Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE PROMYELOCYTIC LEUKEMIA; HIV-ASSOCIATED NEPHROPATHY; SIGNALING PATHWAYS; CROSS-TALK; IN-VIVO; EXPRESSION; RECEPTORS; NEF; ACTIVATION; PROTEIN AB HIV-associated nephropathy is characterized by renal podocyte proliferation and dedifferentiation. This study found that all-trans retinoic acid (atRA) reverses the effects of HIV-1 infection in podocytes. Treatment with atRA reduced cell proliferation rate by causing G1 arrest and restored the expression of the differentiation markers (synaptopodin, nephrin, podocin, and WT-1) in HIV-1-infected podocytes. It is interesting that both atRA and 9-cis RA increased intracellular cAMP levels in podocytes. Podocytes expressed most isoforms of retinoic acid receptors (RAR) and retinoid X receptors (RXR) with the exception of RXR gamma. RAR alpha antagonists blocked atRA-induced cAMP production and its antiproliferative and prodifferentiation effects on podocytes, suggesting that RARa is required. For determination of the effect of increased intracellular cAMP on HIV-infected podocytes, cells were stimulated with either forskolin or 8-bromo-cAMP. Both compounds inhibited cell proliferation significantly and restored synaptopodin expression in HIV-infected podocytes. The effects of atRA were abolished by Rp-cAMP, an inhibitor of the cAMP/protein kinase A pathway and were enhanced by rolipram, an inhibitor of phosphodiesterase 4, suggesting that the antiproliferative and prodifferentiation effects of atRA on HIV-infected podocytes are cAMP dependent. Furthermore, both atRA and forskolin suppressed HIV-induced mitogen-activated protein kinase I and 2 and Stat3 phosphorylation. In vivo, atRA reduced proteinuria, cell proliferation, and glomerulosclerosis in HIV-1-transgenic mice. These findings suggest that atRA reverses the abnormal phenotype in HIV-1-infected podocytes by stimulating RAR alpha-mediated intracellular cAMP production. These results demonstrate the mechanism by which atRA reverses the proliferation of podocytes that is induced by HIV-1. C1 CUNY Mt Sinai Sch Med, Div Nephrol, Dept Med, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Div Nephrol, Dept Pharmacol & Biochem, New York, NY 10029 USA. James J Peters VA Med Ctr, Bronx, NY USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP He, JCJ (reprint author), CUNY Mt Sinai Sch Med, Div Nephrol, Dept Med, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA. EM cijiang.he@mssm.edu FU NIDDK NIH HHS [K08 DK065495, DK-65495, P01 DK056492, P01DK056492, R01 DK078897]; NIGMS NIH HHS [F31 GM065065, GM-54508, GM-65065, R01 GM054508] NR 43 TC 55 Z9 58 U1 0 U2 3 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2007 VL 18 IS 1 BP 93 EP 102 DI 10.1681/ASN.2006070727 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 126TG UT WOS:000243537800013 PM 17182884 ER PT J AU de Boer, IH Sibley, SD Kestenbaum, B Sampson, JN Young, B Cleary, PA Steffes, MW Weiss, NS Brunzell, JD AF de Boer, Ian H. Sibley, Shalamar D. Kestenbaum, Bryan Sampson, Joshua N. Young, Bessie Cleary, Patricia A. Steffes, Michael W. Weiss, Noel S. Brunzell, John D. CA Diabet Control & Complicat Trial TI Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; RISK-FACTORS; INTENSIVE TREATMENT; ALBUMIN EXCRETION; RENAL-FUNCTION; WEIGHT-GAIN; NEPHROPATHY; MELLITUS AB Weight gain and central obesity are associated with insulin resistance, hypertension, and dyslipidemia in type 1 diabetes. These metabolic abnormalities are risk factors for kidney disease in the general population, but data addressing the relationship of central obesity with kidney disease in type I diabetes are limited. Whether waist circumference is associated with incident microalbuminuria and change in creatinine clearance was examined among 1279 participants who had type 1 diabetes and were enrolled in the Epidemiology of Diabetes Interventions and Complications Study, the observational extension of the Diabetes Control and Complications Trial (DCCT). Ninety-three of 1105 participants with normal albumin excretion rate (AER) at DCCT closeout developed incident microalbuminuria over 5.8 yr of follow-up. The hazard ratio for incident microalbuminuria that was associated with each 10-cm greater waist circumference at DCCT closeout was 1.34 (95% confidence interval 1.07 to 1.68), after adjustment for DCCT closeout age, gender, duration of diabetes, treatment group, smoking status, glycosylated hemoglobin, and AER. This increased risk was modestly attenuated when additional adjustment was made for levels of BP and serum lipids. Creatinine clearance declined by an average of 0.34 ml/min per 1.73 m(2) each yr over 8 yr of follow-up. Greater rate of decline in creatinine clearance was associated with greater age, conventional insulin therapy during the DCCT, smoking, and greater glycosylated hemoglobin and AER at DCCT closeout but not with waist circumference. In conclusion, waist circumference predicts the subsequent development of microalbuminuria in type 1 diabetes. In contrast, no association of waist circumference with decline in creatinine clearance was observed. C1 Univ Washington, Div Nephrol, Seattle, WA 98195 USA. Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Div Gen Internal Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. Univ Minnesota, Div Diabet Endocrinol, Minneapolis, MN USA. George Washington Univ, Ctr Biostat, Rockville, MD USA. RP de Boer, IH (reprint author), Univ Washington, Div Nephrol, Box 356521,BB-1265 Hlth Sci Bldg,1959 NE Pacific, Seattle, WA 98195 USA. EM deboer@u.washington.edu FU NCRR NIH HHS [M01-RR01066, 5 K12 RR023265-03, K12 RR023265, M01 RR001066]; NHLBI NIH HHS [HL004136, K30 HL004136]; NIDDK NIH HHS [DK007247, DK02456, DK599445, N01 DK062204, N01 DK062204-007, P01 DK002456, T32 DK007247] NR 36 TC 70 Z9 73 U1 0 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2007 VL 18 IS 1 BP 235 EP 243 DI 10.1681/ASN.2006040394 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 126TG UT WOS:000243537800026 PM 17151331 ER PT J AU Fried, LF Biggs, ML Shlipak, MG Seliger, S Kestenbaum, B Stehman-Breen, C Sarnak, M Siscovick, D Harris, T Cauley, J Newman, AB Robbins, J AF Fried, Linda F. Biggs, Mary Louise Shlipak, Michael G. Seliger, Stephen Kestenbaum, Bryan Stehman-Breen, Catherine Sarnak, Mark Siscovick, David Harris, Tamara Cauley, Jane Newman, Anne B. Robbins, John TI Association of kidney function with incident hip fracture in older adults SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; CYSTATIN-C; CARDIOVASCULAR HEALTH; SERUM CREATININE; ELDERLY PERSONS; RENAL-DISEASE; RISK; HOMOCYSTEINE; OSTEOPOROSIS; FAILURE AB Kidney dysfunction is associated with bone loss, and patients with ESRD have an increased risk for hip fracture. However, the association of mild to moderate kidney disease with hip fracture has not been studied previously. The association of kidney function with incident hip fracture was examined among participants in the Cardiovascular Health Study, a community-based cohort of older individuals. The primary measure of kidney function was serum cystatin C, a measure that does not depend on lean mass. Hip fractures were identified using International Classification of Diseases, Ninth Revision codes for hospitalizations. A total of 4699 individuals had cystatin C measured in 1992 to 1993 and did not have a hip fracture before cystatin C measurement. The association of kidney function with hip fracture was analyzed with Cox proportional hazards models. Analyses were conducted separately for men and women. After a mean follow-up of 7.1 yr, 195 incident hip fractures occurred in women and 79 occurred in men. Higher cystatin C levels were associated with a higher risk for fracture in women (hazard ratio [HR] 1.26; 95% confidence interval [CI] 1.14 to 1.38 per SD) and in men (HR 1.27; 95% CI 1.11 to 1.46). After multivariable adjustment, higher cystatin C levels were significantly associated with hip fracture in women (HR 1.16; 95% Cl 1.01, 1.33) but not in men (HR 1.14; 95% CI 0.86 to 1.52), although the magnitude of the association was similar. Kidney dysfunction, as assessed by cystatin C, is associated with an increased risk for hip fracture. Further studies are needed to evaluate potential mediators of this relationship and to assess whether interventions can decrease this risk. C1 Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Div Geriatr, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, VA Med Ctr, San Francisco, CA 94143 USA. Univ Maryland, Sch Med, Div Nephrol, Baltimore, MD 21201 USA. Univ Washington, Sch Med, Div Nephrol, Seattle, WA USA. Amgen Inc, Thousand Oaks, CA USA. Tufts Univ, New England Med Ctr, Dept Med, Boston, MA 02111 USA. NIA, NIH, Bethesda, MD 20892 USA. Univ Calif Davis, Dept Med, Davis, CA 95616 USA. RP Fried, LF (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Univ Dr C,Mailstop 111F-U, Pittsburgh, PA 15240 USA. EM linda.fried@med.va.gov RI Newman, Anne/C-6408-2013; Cauley, Jane/N-4836-2015 OI Newman, Anne/0000-0002-0106-1150; Cauley, Jane/0000-0003-0752-4408 FU NHLBI NIH HHS [N01-HC-15103, N01-HC-35129, N01-HC-85079, N01-HC-85086] NR 25 TC 90 Z9 90 U1 1 U2 7 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2007 VL 18 IS 1 BP 282 EP 286 DI 10.1681/ASN.2006050546 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 126TG UT WOS:000243537800031 PM 17167115 ER PT J AU Sachse, MM Guldbakke, KK Khachemoune, A AF Sachse, M. M. Guldbakke, K. K. Khachemoune, A. TI Tunga penetrans: a stowaway from around the world SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY LA English DT Review DE chigoe; ectoparasite; prophylaxis; therapy; Tunga penetrans; tungiasis ID CONTROLLED-TRIAL; IMPORTED TUNGIASIS; LAGOS-STATE; CASE SERIES; BRAZIL; EPIDEMIOLOGY; PATHOLOGY; BIOLOGY; INFESTATION; COMMUNITIES AB Tungiasis is a cutaneous ectoparasitic infestation by the female sand flea Tunga penetrans. It is predominantly a health problem in sub-Saharan Africa, the Caribbean, Latin America and South America. However, increasing numbers of returning travellers, immigrants, and adopted children are also affected in non-tropical countries. It is a cause of substantial morbidity, with prevalence rates as high as 76% in certain endemic areas. To date, the early extraction of the flea is still the first line therapy. C1 NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY 10016 USA. Santa Casa Misericordia, Inst Dermatol Prof RD Azulay, BR-22020020 Rio De Janeiro, Brazil. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA. Hosp Bremen Mitte, Dept Dermatol, D-28205 Bremen, Germany. RP Khachemoune, A (reprint author), NYU, Sch Med, Ronald O Perelman Dept Dermatol, 530 1st Ave,Suite 7R, New York, NY 10016 USA. EM amorkh@pol.net NR 52 TC 16 Z9 16 U1 1 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0926-9959 J9 J EUR ACAD DERMATOL JI J. Eur. Acad. Dermatol. Venereol. PD JAN PY 2007 VL 21 IS 1 BP 11 EP 16 DI 10.1111/j.1468-3083.2006.01888.x PG 6 WC Dermatology SC Dermatology GA 123LP UT WOS:000243297700002 PM 17207161 ER PT J AU Schmahmann, JD Pandya, DN AF Schmahmann, Jeremy D. Pandya, Deepak N. TI The complex history of the fronto-occipital fasciculus SO JOURNAL OF THE HISTORY OF THE NEUROSCIENCES LA English DT Article DE fronto-occipital fasciculus; occipitofrontal fasciculus; Muratoff subcallosal fascicle; corpus callosum; tapetum; callosal agenesis ID CORPUS-CALLOSUM; RHESUS-MONKEY; COMMISSURES; PATHWAYS; TOPOGRAPHY; MOVEMENTS; AGENESIS; FIBERS; LOBE AB We investigated the history of the fronto-occipital fasciculus (FOF) and related tracts in the cerebral white matter because of their contemporary relevance for connectional neuroanatomy, magnetic resonance tractography, and clinical neurology. The term "FOF" originated with Forel and Onufrowicz who misidentified aberrant longitudinally oriented callosal fibers in patients with callosal agenesis. This error was soon recognized, and Dejerine described an actual FOF linking frontal and occipital lobes, but gross dissection and lesion-degeneration methods could not distinguish the FOF from the subcallosal fasciculus of Muratoff and neighboring white matter bundles. Subsequent descriptions of a probably nonexistent "inferior FOF" have led to the FOF being misnamed post-hoc "superior FOF," and other imprecise anatomical concepts and terminologies from the early literature are still perpetuated. Our analysis of brain fiber pathways using isotope anterograde tract tracers (Schmahmann & Pandya, 2006) resolves the earlier uncertainties and provides hypotheses regarding functions of these fiber pathways. C1 Massachusetts Gen Hosp, Dept Neurol, Cognit Behav Neurol Unit, Ataxia Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA. RP Schmahmann, JD (reprint author), Massachusetts Gen Hosp, Dept Neurol, Cognit Behav Neurol Unit, Ataxia Unit, CPZS-340,55 Fruit St, Boston, MA 02114 USA. EM jschmahmann@partners.org NR 57 TC 60 Z9 60 U1 1 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0964-704X J9 J HIST NEUROSCI JI J. Hist. Neurosci. PY 2007 VL 16 IS 4 BP 362 EP 377 DI 10.1080/09647040600620468 PG 16 WC History & Philosophy Of Science; Neurosciences SC History & Philosophy of Science; Neurosciences & Neurology GA 229MV UT WOS:000250809000002 PM 17966054 ER PT J AU Li, Y Tiwari, RC Guha, S AF Li, Yi Tiwari, Ram C. Guha, Subharup TI Mixture cure survival models with dependent censoring SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY LA English DT Article DE Archimedean copula model; asymptotic normality; consistency; cure model; dependent censoring; latency distribution; martingale processes; testing cure fraction ID COPULA AB The paper is motivated by cure detection among the prostate cancer patients in the National Institutes of Health surveillance epidemiology and end results programme, wherein the main end point (e.g. deaths from prostate cancer) and the censoring causes (e.g. deaths from heart diseases) may be dependent. Although many researchers have studied the mixture survival model to analyse survival data with non-negligible cure fractions, none has studied the mixture cure model in the presence of dependent censoring. To account for such dependence, we propose a more general cure model that allows for dependent censoring. We derive the cure models from the perspective of competing risks and model the dependence between the censoring time and the survival time by using a class of Archimedean copula models. Within this framework, we consider the parameter estimation, the cure detection and the two-sample comparison of latency distributions in the presence of dependent censoring when a proportion of patients is deemed cured. Large sample results by using martingale theory are obtained. We examine the finite sample performance of the proposed methods via simulation and apply them to analyse the surveillance epidemiology and end results prostate cancer data. C1 Harvard Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NCI, Bethesda, MD 20892 USA. RP Li, Y (reprint author), Harvard Sch Publ Hlth, Dept Biostat, LW211,44 Binney St, Boston, MA 02115 USA. EM yili@jimmy.harvard.edu NR 25 TC 11 Z9 12 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1369-7412 J9 J ROY STAT SOC B JI J. R. Stat. Soc. Ser. B-Stat. Methodol. PY 2007 VL 69 BP 285 EP 306 DI 10.1111/j.1467-9868.2007.00589.x PN 3 PG 22 WC Statistics & Probability SC Mathematics GA 171CW UT WOS:000246713500001 ER PT J AU Wang, ML Hanfelt, JJ AF Wang, Molin Hanfelt, John J. TI Orthogonal locally ancillary estimating functions for matched pair studies and errors in covariates SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY LA English DT Article DE ancillarity; estimating function; matched pair study; measurement error; nuisance parameter; orthogonality ID NUISANCE PARAMETERS; SIMULATION-EXTRAPOLATION; CONDITIONAL SCORES; MODELS; SENSITIVITY; POPULATION; LIKELIHOOD; REGRESSION AB We propose an estimating function method for two related applications, matched pair studies and studies with errors in covariates under a functional model, where a mismeasured unknown scalar covariate is treated as a fixed nuisance parameter. Our method addresses the severe inferential problem that is posed by an abundance of nuisance parameters in these two applications. We propose orthogonal locally ancillary estimating functions for these two applications that depend on merely the mean model and partial modelling of the variances of the observations (and observed mismeasured covariate, if applicable), and we achieve first-order bias correction of inferences under a 'small dispersion and large sample size' asymptotic. Simulation results confirm that the estimator proposed is largely improved over that using a regular profile estimating function. We apply the approach proposed to a length of hospital stay study with a mismeasured covariate. C1 Harvard Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Emory Univ, Atlanta, GA 30322 USA. RP Wang, ML (reprint author), Harvard Sch Publ Hlth, Dept Biostat, 44 Binney St, Boston, MA 02115 USA. EM mwang@jimmy.harvard.edu NR 24 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1369-7412 J9 J ROY STAT SOC B JI J. R. Stat. Soc. Ser. B-Stat. Methodol. PY 2007 VL 69 BP 411 EP 428 DI 10.1111/j.1467-9868.2007.00595.x PN 3 PG 18 WC Statistics & Probability SC Mathematics GA 171CW UT WOS:000246713500007 ER PT J AU Henderson, R AF Henderson, Robin TI Maximum likelihood estimation in semiparametric regression models with censored data - Discussion on the paper by Zeng and Lin SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY LA English DT Editorial Material ID PROPORTIONAL-HAZARDS MODEL; RECURRENT EVENT DATA; GAMMA-FRAILTY MODEL; SURVIVAL-DATA; TRANSFORMATION MODELS; UNOBSERVED HETEROGENEITY; HIERARCHICAL LIKELIHOOD; QUANTILE REGRESSION; DYNAMIC-ANALYSIS; CASE-COHORT C1 Univ Newcastle, Newcastle, NSW 2308, Australia. Univ Oslo, N-0316 Oslo, Norway. Univ Bordeaux 2, F-33076 Bordeaux, France. Univ Copenhagen, DK-1168 Copenhagen, Denmark. Hong Kong Univ Sci & Technol, Hong Kong, Hong Kong, Peoples R China. Columbia Univ, New York, NY 10027 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Oxford Nuffield Coll, Oxford OX1 1NF, England. Univ London Imperial Coll Sci Technol & Med, London, England. Univ Warwick, Coventry CV4 7AL, W Midlands, England. Univ Calif Berkeley, Berkeley, CA 94720 USA. Univ Washington, Seattle, WA 98195 USA. Open Univ, Milton Keynes MK7 6AA, Bucks, England. Inst Natl Sante & Rech Med, Paris, France. Univ Wisconsin, Madison, WI USA. NW Univ, Evanston, IL USA. Natl Univ Singapore, Singapore 117548, Singapore. Univ N Carolina, Chapel Hill, NC USA. Seoul Natl Univ, Seoul, South Korea. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Pompeu Fabra, Barcelona, Spain. Umea Univ, S-90187 Umea, Sweden. Uppsala Univ, Uppsala, Sweden. Inst Labour Market Policy Evaluat, Uppsala, Sweden. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Univ Greenwich, London SE18 6PF, England. Ecole Polytech Fed Lausanne, Lausanne, Switzerland. Queen Mary Univ London, London E1 4NS, England. Brunel Univ, Uxbridge UB8 3PH, Middx, England. Guangxi Normal Univ, Guilin, Peoples R China. Conservatoire Natl Arts & Metiers, Paris, France. RP Henderson, R (reprint author), Univ Newcastle, Newcastle, NSW 2308, Australia. NR 106 TC 3 Z9 3 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1369-7412 J9 J R STAT SOC B JI J. R. Stat. Soc. Ser. B-Stat. Methodol. PY 2007 VL 69 BP 536 EP 564 PN 4 PG 29 WC Statistics & Probability SC Mathematics GA 207KM UT WOS:000249250000002 ER PT J AU Betancourt, JR AF Betancourt, Joseph R. TI Commentary on "Current approaches to integrating elements of cultural competence in nursing education" SO JOURNAL OF TRANSCULTURAL NURSING LA English DT Editorial Material C1 Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. Massachusetts Gen Hosp, Multicultural Educ Multicultural Affairs Off, Boston, MA 02114 USA. Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Ctr Multicultural & Minor Hlth, Ithaca, NY 14853 USA. NR 0 TC 4 Z9 4 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1043-6596 J9 J TRANSCULT NURS JI J. Transcult. Nurs. PD JAN PY 2007 VL 18 IS 1 SU S BP 25S EP 27S DI 10.1177/1043659606296120 PG 3 WC Nursing SC Nursing GA 122AT UT WOS:000243198800006 ER PT J AU Karmy-Jones, R Jurkovich, GJ Velmahos, GC Burdick, T Spaniolas, K Todd, SR McNally, M Jacoby, RC Link, D Janczyk, RJ Ivascu, FA McCann, M Obeid, F Hoff, WS McQuay, N Tieu, BH Schreiber, MA Nirula, R Brasel, K Dunn, JA Gambrell, D Huckfeldt, R Harper, J Schaffer, KB Tominaga, GT Vinces, FY Sperling, D Hoyt, D Coimbra, R Rosengart, MR Forsythe, R Cothren, C Moore, EE Haut, ER Hayanga, AJ Hird, L White, C Grossman, J Nagy, K Livaudais, W Wood, R Zengerink, I Kortbeek, JB AF Karmy-Jones, Riyad Jurkovich, Gregory J. Velmahos, George C. Burdick, Thomas Spaniolas, Konstantinos Todd, Samuel R. McNally, Michael Jacoby, Robert C. Link, Daniel Janczyk, Randy J. Ivascu, Felicia A. McCann, Michael Obeid, Farouck Hoff, William S. McQuay, Nathaniel, Jr. Tieu, Brandon H. Schreiber, Martin A. Nirula, Ram Brasel, Karen Dunn, Julie A. Gambrell, Debbie Huckfeldt, Roger Harper, Jayna Schaffer, Kathryn B. Tominaga, Gail T. Vinces, Fausto Y. Sperling, David Hoyt, David Coimbra, Raul Rosengart, Mathew R. Forsythe, Raquel Cothren, Clay Moore, Ernest E. Haut, Elliott R. Hayanga, Awori J. Hird, Linda White, Christopher Grossman, Jodi Nagy, Kimberly Livaudais, West Wood, Rhonda Zengerink, Imme Kortbeek, John B. TI Practice patterns and outcomes of retrievable vena cava filters in trauma patients: An AAST multicenter study SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma CY SEP 28-30, 2006 CL New Orleans, LA SP Amer Assoc Surg Trauma ID DEEP-VEIN THROMBOSIS; PRACTICE MANAGEMENT GUIDELINES; SURGICAL INFERIOR PATIENTS; TERM-FOLLOW-UP; PULMONARY-EMBOLISM; HIGH-RISK; VENOUS THROMBOEMBOLISM; ACUTE COMPLICATIONS; TEMPORARY; PROPHYLAXIS AB Background: The purpose of this study is to describe practice patterns and outcomes of posttraumatic retrievable inferior vena caval filters (R-IVCF). Methods: A retrospective review of R-IVCFs placed during 2004 at 21 participating centers with follow up to July 1, 2005 was performed. Primary outcomes included major complications (migration, pulmonary embolism [PE], and symptomatic caval occlusion) and reasons for failure to retrieve. Results: Of 446 patients (69% male, 92% blunt trauma) receiving R-IVCFs, 76% for prophylactic indications and 79% were placed by interventional radiology. Excluding 33 deaths, 152 were Gunter-Tulip (G-T), 224 Recovery (R), and 37 Optease (Opt). Placement occurred 6 8 days after admission and retrieval at 50 61 days. Follow up after discharge (5.7 +/- 4.3 months) was reported in 51%. Only 22% of R-IVCFs were retrieved. Of 115 patients in whom retrieval was attempted, retrieval failed as a result of technical issues in 15 patients (10% of G-T, 14% of R, 27% of Opt) and because of significant residual thrombus within the filter in 10 patients (6% of G-T, 4% of R, 46% Opt). The primary reason R-IVCFs were not removed was because of loss to follow up (31%), which was sixfold higher (6% to 44%, p = 0.001) when the service placing the R-IVCF was not directly responsible for follow up. Complications did not correlate with mechanism, injury severity, service placing the R-IVCF, trauma volume, use of anticoagulation, age, or sex. Three cases of migration were recorded (all among R, 1.3%), two breakthrough PE (G-T 0.6% and R 0.4%) and six symptomatic caval occlusions (G-T 0, R 1%, Opt 11%) (p < 0.05 Opt versus both G-T and R). Conclusion: Most R-IVCFs are not retrieved. The service placing the R-IVCF should be responsible for follow up. The Optease was associated with the greatest incidence of residual thrombus and symptomatic caval occlusion. The practice patterns of R-IVCF placement and retrieval should be re-examined. C1 Harborview Med Ctr, Seattle, WA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Texas, Houston, TX USA. Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. William Beaumont Hosp, Royal Oak, MI 48072 USA. Hurley Med Ctr, Flint, MI USA. St Lukes Hosp, Bethlehem, PA USA. Oregon Hlth & Sci Univ, Portland, OR USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. James H Quillen Coll Med, Johnson City, TN USA. St Johns Reg Hlth Ctr, Springfield, MO USA. Scripps Mem Hosp, La Jolla, CA USA. St Barnabas Hosp, Bronx, NY USA. Univ Calif San Diego, San Diego, CA 92103 USA. Univ Pittsburgh, Pittsburgh, PA USA. Denver Hlth Med Ctr, Denver, CO USA. Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA. Rush Univ, Chicago, IL 60612 USA. Stroger Hosp Cook Cty, Chicago, IL USA. Salem Hosp, Salem, OR USA. Univ Calgary, Calgary, AB, Canada. RP Karmy-Jones, R (reprint author), SW Washington Med Ctr, Phys Pavil,Suite 300,200 Mother Joseph Pl, Vancouver, WA 98866 USA. EM rkarmyjo@swmedicalcenter.com OI Haut, Elliott/0000-0001-7075-771X NR 43 TC 150 Z9 156 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD JAN PY 2007 VL 62 IS 1 BP 17 EP 24 DI 10.1097/TA.0b013e31802dd72a PG 8 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 126CP UT WOS:000243490100002 PM 17215729 ER PT J AU Kane, CJ Presti, JC Amling, CL Aronson, WJ Terris, MK Freedland, SJ AF Kane, Christopher J. Presti, Joseph C. Amling, Christopher L. Aronson, William J. Terris, Martha K. Freedland, Stephen J. CA SEARCH Database Study Grp TI Changing nature of high risk patients undergoing radical prostatectomy SO JOURNAL OF UROLOGY LA English DT Article DE prostate; adenocarcinoma; prostate-specific antigen; prostatectomy; outcome assessment (health care) ID EXTERNAL-BEAM RADIATION; CANCER; MANAGEMENT; OUTCOMES; THERAPY; RADIOTHERAPY; RECURRENCE; CAPSURE; TRENDS AB Purpose: We examined the outcomes of radical prostatectomy alone in high risk patients with prostate cancer and evaluated changes in high risk prostate cancer outcomes with time. Materials and Methods: From 1988 to 2003, 251 men with high risk prostate cancer (prostate specific antigen more than 20 ng/ml and/or biopsy Gleason greater than 7) were identified in a cohort of 1,796 (14%) enrolled in the Shared Equal Access Regional Cancer Hospital Database. Temporal changes in clinicopathological characteristics and prostate specific antigen recurrence rates were examined stratified by 4, 4-year periods. Results: With time significantly more men were considered at high risk due to a high biopsy Gleason score relative to prior years; when the most common reason for being considered at high risk was increased PSA (p < 0.001). Only 3% of high risk men from 2000 to 2003 had increased prostate specific antigen and high biopsy Gleason score compared to 23% from 1988 to 1991. With time there were no differences in biochemical recurrence rates (p = 0.147). Men with a high biopsy Gleason score and increased prostate specific antigen had worse outcomes than men with only a high Gleason score or men with only high prostate specific antigen (p = 0.046 and 0.081, respectively). On multivariate analysis that only included preoperative clinical characteristics only prostate specific antigen was an independent predictor of prostate specific antigen failure following radical prostatectomy (p = 0.014). There was a trend, which did not attain statistical significance, for higher biopsy Gleason scores and higher clinical stage to be associated with higher failure rates (p = 0.060 and 0.081, respectively). Conclusions: Patients are designated as high risk by Gleason grade more commonly now than early in the prostate specific antigen era. Outcomes in high risk patients undergoing radical prostatectomy alone have not significantly improved with time. New treatment strategies, such as multimodality therapy, are needed to improve outcomes in high risk patients with prostate cancer. C1 Univ Calif San Francisco, Dept Urol, Sch Med, San Francisco, CA 94143 USA. Vet Adm Med Ctr, Dept Surg, Urol Sect, San Francisco, CA 94121 USA. Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA. Vet Adm Med Ctr, Dept Surg, Urol Sect, Palo Alto, CA 94304 USA. USN Hosp, Dept Urol, San Diego, CA 92134 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. Vet Adm Med Ctr, Dept Surg, Augusta, GA 30904 USA. Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. Vet Adm Med Ctr, Dept Surg, Durham, NC 27705 USA. Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Durham, NC USA. Duke Univ, Sch Med, Dept Pathol, Durham, NC USA. Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC USA. RP Kane, CJ (reprint author), Univ Calif San Francisco, Dept Urol, Sch Med, 1600 Divisadero St,Room A607, San Francisco, CA 94143 USA. OI Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [R01CA100938, P50 CA92131-01A1] NR 20 TC 47 Z9 49 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2007 VL 177 IS 1 BP 113 EP 117 DI 10.1016/j.juro.2006.08.057 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 116ZV UT WOS:000242843200029 PM 17162017 ER PT J AU Lee, SWH Cheah, PY Liong, ML Yuen, KH Schaeffer, AJ Propert, K Krieger, JN AF Lee, Shaun Wen Huey Cheah, Phaik Yeong Liong, Men Long Yuen, Kah Hay Schaeffer, Anthony J. Propert, Kathleen Krieger, John N. CA M Study Grp CPCRN Grp TI Demographic and clinical characteristics of chronic prostatitis: Prospective comparison of the University of Sciences Malaysia Cohort with the United States National Institutes of Health Cohort SO JOURNAL OF UROLOGY LA English DT Article; Proceedings Paper CT 101st Annual Meeting of the American-Urological-Association CY MAY 20-25, 2006 CL Atlanta, GA SP Amer Urolog Assoc DE pelvic pain; prostate; cohort studies; academic medical centers; National Institutes of Health (US) ID PELVIC PAIN SYNDROME; SYMPTOM INDEX; DOUBLE-BLIND; MEN; TRIAL; CIPROFLOXACIN; THERAPY AB Purpose: We compared demographic and clinical characteristics of the University of Sciences Malaysia Chronic Prostatitis Cohort to the United States National Institutes of Health Chronic Prostatitis Cohort. Materials and Methods: Participants met the same definition of chronic prostatitis/chronic pelvic pain syndrome. Each participant had extensive demographic, medical history, previous treatment, clinical and laboratory evaluations. Results: The University of Sciences Malaysia and National Institutes of Health cohorts proved similar in most respects. National Institutes of Health-Chronic Prostatitis Symptom Index total scores, pain and urinary subscores were similar for the 332 University of Sciences Malaysia Chronic Prostatitis Cohort and 488 National Institutes of Health Chronic Prostatitis Cohort. participants. Differences included worse quality of life subscore for the University of Sciences Malaysia Chronic Prostatitis Cohort., differences in the location, number of sites, and types of pain/discomfort between the 2 populations, and that the University of Sciences Malaysia participants had received less previous treatment. Conclusions: The demographic characteristics and clinical presentation of chronic prostatitis/chronic pelvic pain syndrome proved remarkably similar in these diverse populations. Both cohorts experienced major reduction in their quality of life from chronic pelvic pain and urinary symptoms. Comparison of diverse populations using standard clinical, laboratory and assessment. instruments is feasible, and may provide important insights into chronic prostatitis/chronic pelvic pain syndrome and the factors that determine clinical outcome. C1 Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Dept Urol Surg, Seattle, WA 98108 USA. Lam Wah Ee Hosp, Dept Urol, George Town, Malaysia. Northwestern Univ, Dept Urol, Chicago, IL 60611 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Krieger, JN (reprint author), Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Dept Urol Surg, 1660 S Columbian Way, Seattle, WA 98108 USA. EM jkrieger@u.washington.edu RI Yuen, Kah Hay /F-9059-2010; OI Lee, Shaun/0000-0001-7361-6576 FU NIDDK NIH HHS [R01 DK53732, R01 DK53730, R01 DK53734, R01 DK53736, R01 DK53746, R01 DK53752, U01 DK065266-02] NR 13 TC 14 Z9 16 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2007 VL 177 IS 1 BP 153 EP 157 DI 10.1016/j.juro.2006.08.098 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 116ZV UT WOS:000242843200039 PM 17162027 ER PT J AU Carnevale, E Fogel, E Aplin, AC Gelati, M Howson, KM Zhu, WH Nicosia, RF AF Carnevale, Edvige Fogel, Eric Aplin, Alfred C. Gelati, Maurizio Howson, Karen M. Zhu, Wen-Hui Nicosia, Roberto F. TI Regulation of postangiogenic neovessel survival by beta(1) and beta(3) integrins in collagen and fibrin matrices SO JOURNAL OF VASCULAR RESEARCH LA English DT Article DE aorta; vascular regression; angiogenesis; collagen; fibrin; GM6001; endothelium ID ENDOTHELIAL GROWTH-FACTOR; RAT AORTA MODEL; ALPHA(2)BETA(1) INTEGRINS; 3-DIMENSIONAL COLLAGEN; CELL MORPHOGENESIS; LUMEN FORMATION; ANGIOGENESIS; REGRESSION; EXPRESSION; METALLOPROTEINASE AB We used the aortic ring model of angiogenesis to investigate the role of beta(1) and beta(3) integrins in postangiogenic vascular survival in collagen and fibrin matrices. Confocal microscopy studies showed that both beta(1) and beta(3) integrins were expressed in endothelial cells and pericytes of sprouting neovessels. Antibody blocking experiments demonstrated that beta(1) integrins but not beta(3) integrins were required for angiogenic sprouting in collagen. Conversely, in fibrin, blockade of both integrins was needed to inhibit angiogenesis whereas treatment with either antibody alone was ineffective. Antibody-mediated blockade of beta(1) but not beta(3) integrins accelerated vascular regression in collagen. In contrast, both anti-beta(1) and -beta(3) integrin antibodies were required to promote neovessel breakdown in fibrin. These results demonstrate that angiogenic sprouting and postangiogenic neovessel survival in collagen are critically dependent on beta(1) integrins. They also indicate that these processes involve a redundant repertoire of beta(1) and beta(3) integrins when angiogenesis occurs in fibrin. Thus, pharmacologic targeting of integrin receptors aimed at blocking neovessel formation and survival must be tailored to the specific extracellular matrix environment in which angiogenesis takes place. Copyright (c) 2007 S. Karger AG, Basel. C1 VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med S 113 Lab, Seattle, WA 98108 USA. Univ Washington, Dept Pathol, Seattle, WA 98108 USA. Carlo Besta Inst, Lab Neurobiol & Neuroregenerat Med, Milan, Italy. RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med S 113 Lab, 1660 S Columbian Way, Seattle, WA 98108 USA. EM roberto.nicosia@va.gov RI Gelati, Maurizio/H-2110-2016 OI Gelati, Maurizio/0000-0002-4828-9849 FU NHLBI NIH HHS [HL 52585] NR 31 TC 17 Z9 19 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2007 VL 44 IS 1 BP 40 EP 50 DI 10.1159/000097976 PG 11 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 127DA UT WOS:000243564300005 PM 17167269 ER PT J AU Goldstein, RE Atwater, DZ Cazolli, DM Goldstein, O Wade, CM Lindblad-Toh, K AF Goldstein, Richard E. Atwater, Daniel Z. Cazolli, Dava M. Goldstein, Orly Wade, Claire M. Lindblad-Toh, Kerstin TI Inheritance, mode of inheritance, and candidate genes for primary hyperparathyroidism in Keeshonden SO JOURNAL OF VETERINARY INTERNAL MEDICINE LA English DT Article DE canine genetics; hypercalcemia; parathyroid disease ID FAMILIAL ISOLATED HYPERPARATHYROIDISM; PARATHYROID TUMORS; DOGS; GERMLINE; HRPT2 AB Background: Primary hyperparathyroidism (PHPT) is caused by inappropriate secretion of parathyroid hormone (PTH) by autonomously functioning neoplastic or hyperplastic parathyroid "chief" cells. Keeshonden are thought to be over-represented in studies on canine PHPT, but no proof of heritability or mode of inheritance has been published. The canine disease clinically resembles human familial isolated hyperparathyroidism (FIHP). Hypothesis: Primary hyperparathyroid ism in Keeshonden is genetically transmitted and is caused by a mutation in I of 4 genes implicated in human FIHP: MEN1, CASR, HRPT2, or RET. Animals: Pedigrees consisting of 1647 Keeshonden were created including 219 Keeshonden with known PHPT phenotypes (69 positive). DNA samples were obtained from 176 of the 219 Keeshonden (34 positive). Methods: Heritability and mode of inheritance were determined by segregation analysis. Canine homologs to the human genes were identified. Exons and Surrounding intron regions were sequenced and scanned for sense-altering polymorphisms or polymorphisms that segregated with the disease. Messenger RNA from a parathyroid tumor of an affected Keeshond was analyzed for polymorphisms and splice alterations. Results: PHPT follows an autosomal dominant mode of inheritance in Keeshonden with possible age-dependent penetrance. No polymorphisms identified in the genes analyzed were associated with a change in predicted protein or in hypothesized splice sites. Conclusions and Clinical Importance: PHPT is an autosomal dominant, genetically transmitted disease in Keeshonden. Once the mutation locus is identified, genetic testing should quickly decrease the incidence of PHPT in this breed. It is unlikely that mutations in MEN1, CASR, HRPT2, or RET cause PHPT in Keeshonden. C1 Cornell Univ, Dept Clin Sci, Coll Vet Med, Ithaca, NY 14853 USA. Cornell Univ, James A Baker Inst, Ithaca, NY USA. Harvard Univ, Broad Inst, Boston, MA 02115 USA. MIT, Boston, MA USA. Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Goldstein, RE (reprint author), Cornell Univ, Dept Clin Sci, Coll Vet Med, Ithaca, NY 14853 USA. EM rg225@cornell.edu OI Wade, Claire/0000-0003-3413-4771 NR 15 TC 10 Z9 11 U1 1 U2 13 PU AMER COLL VETERINARY INTERNAL MEDICINE PI LAKEWOOD PA 1997 WADSWORTH BOULEVARD, STE A, LAKEWOOD, CO 80214-5293 USA SN 0891-6640 J9 J VET INTERN MED JI J. Vet. Intern. Med. PD JAN-FEB PY 2007 VL 21 IS 1 BP 199 EP 203 DI 10.1892/0891-6640(2007)21[199:IMOIAC]2.0.CO;2 PG 5 WC Veterinary Sciences SC Veterinary Sciences GA 135OH UT WOS:000244162400029 PM 17338170 ER PT J AU Bourne, EJ Dienstag, JL Lopez, VA Sander, TJ Longlet, JM Hall, JG Kwiatkowski, RW Wright, T Lai, CL Condreay, LD AF Bourne, E. J. Dienstag, J. L. Lopez, V. A. Sander, T. J. Longlet, J. M. Hall, J. G. Kwiatkowski, R. W. Wright, T. Lai, C. L. Condreay, L. D. TI Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE hepatitis B virus (HBV); cccDNA; lamivudine ID HEPATITIS-B-VIRUS; CLOSED CIRCULAR DNA; E-ANTIGEN SEROCONVERSION; OLIGONUCLEOTIDE PROBES; LAMIVUDINE TREATMENT; HEPATOCYTE CULTURES; TRANSGENIC MICE; UNITED-STATES; REPLICATION; AMPLIFICATION AB Attempts to investigate changes in various forms of intrahepatic hepatitis B virus (HBV) DNA during antiviral therapy have been hampered by limitations in technologies and scarcity of adequate tissue for analysis. We used a sensitive, specific assay to detect and quantitate covalently closed circular DNA (cccDNA) from total intrahepatic HBV DNA in clinical liver specimens. Total HBV DNA and cccDNA from 21 needle-biopsy specimens were quantified, with levels ranging from 0.1 to 9.8 copies/cell and 0.3 to 491.0 copies/cell, respectively. Then, we performed the same determinations on baseline and week-52 liver needle-biopsy specimens from eight patients enrolled in a clinical trial and evaluated the association between intrahepatic HBV DNA levels and serological and virological endpoints. In most patients, levels of intrahepatic HBV DNA, including cccDNA, decreased over the 52-week study, regardless of therapy or serological outcome. Higher ratios of cccDNA to total HBV DNA were detected at week 52 than at baseline indicating a shift in predominance of nonreplicating virus in posttreatment specimens. In patients who achieved treatment-related or spontaneous hepatitis B e antigen (HBeAg) responses, including those harbouring tyrosine-methionine-aspartate-aspartate-mutant HBV, levels of intrahepatic and serum HBV DNA suppression were greater than those in patients without HBeAg responses. In conclusion, this pilot study of intrahepatic HBV replicative forms in patients with chronic hepatitis B indicated that total intrahepatic and, specifically, cccDNA levels are not static but change as a reflection of serological and virological events. C1 GlaxoSmithKline Res & Dev Ltd, Discovery Virol Dept, Res Triangle Pk, NC 27709 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA USA. Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA 02114 USA. Third Wave Technol Inc, Madison, WI USA. Vet Affairs Med Ctr, Dept Med, Gastroenterol Unit, San Francisco, CA 94121 USA. Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China. RP Condreay, LD (reprint author), GlaxoSmithKline Res & Dev Ltd, Discovery Virol Dept, 5 Moore Dr, Res Triangle Pk, NC 27709 USA. EM Lynn.D.condreay@gsk.com RI Lai, Ching Lung/C-4298-2009 FU NCRR NIH HHS [M01RR-01066] NR 34 TC 30 Z9 38 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD JAN PY 2007 VL 14 IS 1 BP 55 EP 63 DI 10.1111/j.1365-2893.2006.00775.x PG 9 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 119JH UT WOS:000243008100008 PM 17212645 ER PT J AU Shun, MC Daigle, JE Vandegraaff, N Engelman, A AF Shun, Ming-Chieh Daigle, Janet E. Vandegraaff, Nick Engelman, Alan TI Wild-type levels of human immunodeficiency virus type 1 infectivity in the absence of cellular emerin protein SO JOURNAL OF VIROLOGY LA English DT Article ID TO-AUTOINTEGRATION FACTOR; PREINTEGRATION COMPLEX; NUCLEAR-LOCALIZATION; GENETIC ANALYSES; DNA; INTEGRATION; CELLS; HIV; REPLICATION; RETROVIRUS AB Preintegration complexes (PICs) mediate retroviral integration, and recent results indicate an important role for the inner nuclear membrane protein emerin in orienting human immunodeficiency virus type 1 (HfV-1) PICs to chromatin for integration. Two other host cell proteins, the barrier-to-autointegration factor (BAF) and lamina-associated polypeptide 2 alpha (LAP2 alpha), seemed to play a similar preintegrative role for Moloney murine leukemia virus (MMLV) in addition to HIV-1. In contrast, we determined efficient HfV-1 and MMLV infection of HeLa-P4 cells following potent down-regulation of emerin, BAF, or LAP2 alpha protein by using short interfering RNA. Mouse embryo fibroblasts ablated for emerin protein through gene knockout support the same level of HIV-1 infection as cells derived from wild-type littermate control animals. As the expression of human emerin in mouse knockout cells fails to affect the level of infectivity achieved in its absence, we conclude that HIV-1 efficiently infects cells in the absence of emerin protein and, by extension, that emerin is not a universally important regulator of HIV-1 infectivity. C1 Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Sch Med, Div Aids, Boston, MA 02115 USA. RP Engelman, A (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM alan_engelman@dfci.harvard.edu FU NIAID NIH HHS [AI52014, R01 AI052014] NR 43 TC 49 Z9 54 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2007 VL 81 IS 1 BP 166 EP 172 DI 10.1128/JVI.01953-06 PG 7 WC Virology SC Virology GA 118RE UT WOS:000242958600015 PM 17035312 ER PT J AU Li, B Gladden, AD Altfeld, M Kaldor, JM Cooper, DA Kelleher, AD Allen, TM AF Li, Bin Gladden, Adrianne D. Altfeld, Marcus Kaldor, John M. Cooper, David A. Kelleher, Anthony D. Allen, Todd M. TI Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution SO JOURNAL OF VIROLOGY LA English DT Article ID T-CELL RESPONSES; ACUTE HIV-1 INFECTION; CTL ESCAPE; LYMPHOCYTE ESCAPE; VIRAL ESCAPE; HIV-1-SPECIFIC CD4(+); IMMUNE-RESPONSES; SUBTYPE-C; DISEASE PROGRESSION; FITNESS COST AB The error-prone replication of human immunodeficiency virus type 1 (HIV-1) enables it to continuously evade host CD8(+) T-cell responses. The observed transmission, and potential accumulation, of CD8(+) T-cell escape mutations in the population may suggest a gradual adaptation of HIV-1 to immune pressures. Recent reports, however, have highlighted the propensity of some escape mutations to revert upon transmission to a new host in order to restore efficient replication capacity. To more specifically address the role of reversions in early HIV-1 evolution, we examined sequence polymorphisms arising across the HIV-1 genome in seven subjects followed longitudinally 1 year from primary infection. As expected, numerous nonsynonymous mutations were associated with described CD8(+) T-cell epitopes, supporting a prominent role for cellular immune responses in driving early HIV-1 evolution. Strikingly, however, a substantial proportion of substitutions (42%) reverted toward the clade B consensus sequence, with nearly one-quarter of them located within defined CD8 epitopes not restricted by the contemporary host's HLA. More importantly, these reversions arose significantly faster than forward mutations, with the most rapidly reverting mutations preferentially arising within structurally conserved residues. These data suggest that many transmitted mutations likely incur a fitness cost that is recovered through retrieval of an optimal, or ancestral, form of the virus. The propensity of mutations to revert may limit the accumulation of immune pressure-driven mutations in the population, thus preserving critical CD8(+) T-cell epitopes as vaccine targets, and argue against an unremitting adaptation of HfV-1 to host immune pressures. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA. Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia. RP Allen, TM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Partners AIDS Res Ctr, CNY 6616,149 13th St,MGH E, Charlestown, MA 02129 USA. EM tallen2@partners.org RI Kaldor, John /D-4545-2011; Allen, Todd/F-5473-2011 FU NIAID NIH HHS [R01 AI054178, R01-AI054178, R21 AI067078, R21-AI067078] NR 69 TC 88 Z9 89 U1 2 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2007 VL 81 IS 1 BP 193 EP 201 DI 10.1128/JVI.01231-06 PG 9 WC Virology SC Virology GA 118RE UT WOS:000242958600018 PM 17065207 ER PT J AU Day, CL Kiepiela, P Leslie, AJ van der Stok, M Nair, K Ismail, N Honeyborne, I Crawford, H Coovadia, HM Goulder, PJR Walker, BD Klenerman, P AF Day, Cheryl L. Kiepiela, Photini Leslie, Alasdair J. van der Stok, Mary Nair, Kriebashne Ismail, Nasreen Honeyborne, Isobella Crawford, Hayley Coovadia, Hoosen M. Goulder, Philip J. R. Walker, Bruce D. Klenerman, Paul TI Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection SO JOURNAL OF VIROLOGY LA English DT Article ID HIV; VIREMIA; LYMPHOCYTES; EXPRESSION; HLA AB The relationship between the function of human immunodeficiency virus (HIV)-specific CD8 T-cell responses and viral load has not been defined. In this study, we used a panel of major histocompatibility complex class I tetramers to examine responses to frequently targeted CD8 T-cell epitopes in a large cohort of antiretroviral-therapy-naive HIV type 1 clade C virus-infected persons in KwaZuJu Natal, South Africa. In terms of effector functions of proliferation, cytokine production, and degranulation, only proliferation showed a significant correlation with viral load. This robust inverse relationship provides an important functional correlate of viral control relevant to both vaccine design and evaluation. C1 Nuffield Dept Med, Oxford OX1 3SY, England. Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, ZA-4013 Durban, South Africa. Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Med, Div AIDS, Boston, MA 02115 USA. Howard Hughes Med Inst, Chevy Chase, MD 20185 USA. RP Klenerman, P (reprint author), Nuffield Dept Med, Peter Medawar Bldg Pathogen Res,S Parks Rd, Oxford OX1 3SY, England. EM paul.klenerman@medawar.ox.ac.uk RI Day, Cheryl/J-9844-2012 FU Wellcome Trust NR 17 TC 59 Z9 60 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2007 VL 81 IS 1 BP 434 EP 438 DI 10.1128/JVI.01754-06 PG 5 WC Virology SC Virology GA 118RE UT WOS:000242958600043 PM 17050606 ER PT J AU Madani, N Hubicki, AM Perdigoto, AL Springer, M Sodroski, J AF Madani, Navid Hubicki, Amy M. Perdigoto, Ana Luisa Springer, Martin Sodroski, Joseph TI Inhibition of human immunodeficiency virus envelope glycoprotein-mediated single cell lysis by low-molecular-weight antagonists of viral entry SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN LYMPHOID-TISSUE; CD4(+) T-CELLS; HTLV-III/LAV ENVELOPE; HIV-1 NEF PROTEIN; MEMBRANE-FUSION; CHEMOKINE RECEPTORS; CONFORMATIONAL-CHANGES; APOPTOTIC CYTOLYSIS; SYNCYTIUM FORMATION; PEPTIDE INHIBITOR AB The coexpression of human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins and receptors leads to the lysis of single cells by a process that is dependent upon membrane fusion. This cell lysis was inhibited by low-molecular-weight compounds that interfere with receptor binding or with receptor-induced conformational transitions in the envelope glycoproteins. A peptide, T20, potently inhibited cell-cell fusion but had no effect on single cell lysis mediated by the HIV-1 envelope glycoproteins. Thus, critical events in the lysis of single cells by the HIV-1 envelope glycoproteins occur in intracellular compartments accessible only to small inhibitory compounds. C1 Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pathol, Div Aids, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. Merck & Co Inc, Dept Biochem Immunol, Rahway, NJ 07065 USA. RP Sodroski, J (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. EM joseph_sodroski@dfci.harvard.edu FU NIAID NIH HHS [AI41851, AI24755, R37 AI024755, R01 AI041851]; NIGMS NIH HHS [GM56550, P01 GM056550]; NINDS NIH HHS [F32 NS043260, F32 NS43260] NR 69 TC 18 Z9 18 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2007 VL 81 IS 2 BP 532 EP 538 DI 10.1128/JVI.01079-06 PG 7 WC Virology SC Virology GA 124EK UT WOS:000243350100011 PM 16943294 ER PT J AU Dailey, SH Spanou, K Zeitels, SM AF Dailey, Seth H. Spanou, Konstantina Zeitels, Steven M. TI The evaluation of benign glottic lesions: Rigid telescopic stroboscopy versus suspension microlaryngoscopy SO JOURNAL OF VOICE LA English DT Article; Proceedings Paper CT 33rd Annual Symposium of the Voice-Foundation CY JUN 02-06, 2004 CL Philadelphia, PA SP Voice Fdn DE phonosurgery; phonomicrosurgery; glottis; microlaryngoscopy; laryngoscopy; stroboscopy; vocal fold; vocal cord; dysphonia; hoarseness; voice ID VOCAL FOLD LESIONS; DIAGNOSIS; MANAGEMENT; CANCER; CYSTS; LASER AB Rigid telescopic strobo-video-laryngoscopy (RTS) is a primary clinical assessment methodology in the office evaluation of benign glottic lesions. However, diagnostic observations can be made only at the time of suspension microlaryngoscopy (SML). The records of 100 consecutive patients undergoing microlaryngoscopy for benign glottic lesions were retrospectively reviewed. Nine of 100 patients were found to have additional glottic lesions during SML. Sixteen additional lesions were noted in these nine patients. Fifteen of 16 lesions were sulci and/or mucosal bridges. Forty-five percent (4/9) of the patients with additional lesions underwent a management change intraoperatively. Three patients underwent additional surgical dissection, and one underwent less dissection than was planned. The discrepancy in diagnosis between rigid telescopic strobo-video-laryngoscopy and suspension microlaryngoscopy highlights certain key points: (1) During office endoscopy, tangential views of the medial surface of the glottis limit the diagnostic sensitivity. (2) Sulci and mucosal bridges are most subject to this limitation. (3) Informed consent should address the potential need for a change in intraoperative management. It is advisable to discuss the possibility for dissection in both vocal folds, even if a unilateral lesion is observed in the office. (4) Microlaryngoscopy is the final diagnostic step in the evaluation of glottic pathology. Meticulous inspection and palpation of the glottis are recommended during C1 Univ Wisconsin Hosp & Clin, Sch Med, Div Otolaryngol Head & Neck Surg, Dept Surg, Madison, WI 53792 USA. Harvard Univ, Sch Med, Dept Surg,Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02115 USA. RP Dailey, SH (reprint author), Univ Wisconsin Hosp & Clin, Sch Med, Div Otolaryngol Head & Neck Surg, Dept Surg, K4-720,600 Highland Ave, Madison, WI 53792 USA. EM dailey@surgery.wisc.edu NR 31 TC 10 Z9 15 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0892-1997 J9 J VOICE JI J. Voice PD JAN PY 2007 VL 21 IS 1 BP 112 EP 118 DI 10.1016/j.jvoice.2005.09.006 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA 126YA UT WOS:000243550300013 PM 16442777 ER PT J AU Ayala, C Selig, M Faquin, W Franco, RA AF Ayala, Carlos Selig, Martin Faquin, William Franco, Ramon A., Jr. TI Ultrastructural evaluation of 585-nm pulsed-dye laser-treated glottal dysplasia SO JOURNAL OF VOICE LA English DT Article DE laryngeal dysplasia; pulsed-dye laser; electron microscopy; basement membrane; cleavage plane ID BASEMENT-MEMBRANE ZONE; PAPILLOMATOSIS AB Objective/Hypothesis: To describe the ultrastructural changes occurring within pulsed-dye laser (PDL)-treated glottal tissues. Study Design: Prospective. Methods: Nine patients presenting with glottal dysplasia requiring biopsy to rule out microinvasive carcinoma were enrolled in this prospective study. At least two samples were obtained in each case: one from a PDL-treated area and another from a non-PDL-treated area (obtained from a nonphonatory region as an internal control). In some cases, a third sample was obtained from the junction between PDL- and non-PDL-treated areas. All samples were examined with light microscopy (H&E stain) and transmission electron microscopy. Observations were made of morphological changes within the epithelium, epithelial/ superficial lamina propria (SLP) junction, and the lamina propria of tissues treated with the PDL. Eight of nine patients were followed for a period of 9-25 months (mean, 18 months) with two recurrences that were retreated with awake-PDL and followed for an additional 8.3 and 9.5 months without recurrence. Vocal fold appearance returned to normal within 3-4 weeks post-treatment. Results: Intraepithelial desmosome junctions were preferentially destroyed, and regional blood vessels were coagulated. The PDL consistently caused a separation of epithelial cells away from the basement membrane. Conclusions: The PDL allowed for both a surgical and a nonsurgical multimodality method for treatment of precancerous lesions with minimal effects on the SLP. C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol,Div Laryngol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Dept Electron Microscopy, Boston, MA 02114 USA. RP Franco, RA (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol,Div Laryngol, 243 Charles St, Boston, MA 02114 USA. EM ramon_franco@meei.harvard.edu NR 12 TC 10 Z9 10 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0892-1997 J9 J VOICE JI J. Voice PD JAN PY 2007 VL 21 IS 1 BP 119 EP 126 DI 10.1016/j.voice.2005.08.015 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA 126YA UT WOS:000243550300014 PM 16457987 ER PT J AU Martin, JL Marler, MR Harker, JO Josephson, KR Alessi, CA AF Martin, Jennifer L. Marler, Matthew R. Harker, Judith O. Josephson, Karen R. Alessi, Cathy A. TI A multicomponent nonpharmacological intervention improves activity rhythms among nursing home residents with disrupted sleep/wake patterns SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID PHASE RESPONSE CURVE; BRIGHT LIGHT THERAPY; ALZHEIMERS-DISEASE; CIRCADIAN-RHYTHMS; INCONTINENCE CARE; PHYSICAL-ACTIVITY; ELDERLY SUBJECTS; OLDER-ADULTS; DISTURBANCES; DEMENTIA AB Background. Sleep and circadian rhythms are disrupted among many nursing home (NH) residents. We examined the impact of a multicomponent nonpharmacological intervention on 24-hour rest/activity rhythms among long-stay NH residents. Methods. The study was a randomized controlled trial in which, following a 3-day baseline, participants received 5 days of either usual care (control condition) or the active intervention. The intervention combined increased exposure to outdoor bright light, efforts to keep residents out of bed during the day, structured physical activity, institution of a bedtime routine, and efforts to reduce nighttime noise and light in residents' rooms. For 100 residents with baseline and follow-up wrist actigraphy data (mean age = 87 years; 76% women), rest/activity rhythms were modeled to determine the rhythm acrophase (peak time), nadir (trough time), midline estimating statistic of rhythm (MESOR) (midpoint), amplitude (height of peak), slope, and the rest period/active period ratio (a). Results. The intervention led to an increase in the duration of the "active" portion of the rhythm, which was primarily accounted for by a shift in the rest/activity rhythm rise to an earlier time. Findings persisted when analyses were adjusted for age, cognitive functioning, medical comorbidities, and behavioral disturbances. Conclusions. These findings suggest that the intervention may effectively improve the robustness of rest/activity rhythms in NH residents. Further research is needed to examine the impact of similar interventions on other measures of circadian rhythms (e.g., body temperature, melatonin) among NH residents. C1 Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA. Geriatr Res Educ & Clin Ctr, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Martin, JL (reprint author), GRECC, VA Sepulveda, 11E,16111 Plummer St, North Hills, CA 91343 USA. EM jennifer.martin@va.gov FU NIA NIH HHS [AG-10415, R29 AG13885] NR 46 TC 47 Z9 48 U1 3 U2 8 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2007 VL 62 IS 1 BP 67 EP 72 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 178KS UT WOS:000247220200010 PM 17301040 ER PT J AU Marson, DC Moye, J AF Marson, Daniel C. Moye, Jennifer TI Empirical studies of capacity in older adults: Finding clarity amidst complexity - Reply SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Editorial Material C1 [Marson, Daniel C.] Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. [Marson, Daniel C.] Univ Alabama, Alzheimers Dis Res Ctr, Birmingham, AL 35294 USA. [Moye, Jennifer] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA. [Moye, Jennifer] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Marson, DC (reprint author), Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. RI Moye, Jennifer/F-2240-2017 OI Moye, Jennifer/0000-0002-3434-347X FU NIMH NIH HHS [R29 MH057104] NR 0 TC 0 Z9 0 U1 0 U2 1 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5014 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD JAN PY 2007 VL 62 IS 1 BP P18 EP P19 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA 272CF UT WOS:000253835600015 PM 17284552 ER PT J AU Moye, J Marson, DC AF Moye, Jennifer Marson, Daniel C. TI Assessment of decision-making capacity in older adults: An emerging area of practice and research SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article ID MACARTHUR TREATMENT COMPETENCE; PHYSICIANS LEGAL STANDARD; MILD ALZHEIMERS-DISEASE; TO-MODERATE DEMENTIA; LONG-TERM-CARE; INFORMED CONSENT; PROTOTYPE-INSTRUMENT; ADVANCE DIRECTIVES; PERSONAL JUDGMENTS; MEDICAL-TREATMENT AB The convergence of the aging of our society, the increase in blended families, and an enormous intergenerational transfer of wealth has greatly expanded the incidence and importance of capacity assessment of older adults. In this article we discuss the emergence of capacity assessment as a distinct field of study. We review research efforts in two domains: medical decision-making capacity and financial capacity. Existing research in these two areas provides a first pass at many key questions related to capacity assessment, but additional studies that replicate, extend, and improve on this research are urgently needed. An agenda for future is detailed that recommends studies of a wide range of capacity constructs, focusing on clinical markers of diminished capacity, methods to improve clinical assessment, and the many intersections of law and clinical practice. C1 [Moye, Jennifer] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Brockton, MA 02301 USA. [Moye, Jennifer] Harvard Univ, Sch Med, Dept Psychiat, Brockton, MA 02301 USA. [Marson, Daniel C.] Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. [Marson, Daniel C.] Univ Alabama, Alzheimers Dis Res Ctr, Birmingham, AL 35294 USA. RP Moye, J (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, Brockton Campus,940 Belmont ST, Brockton, MA 02301 USA. EM jennifer.moye@va.gov RI Moye, Jennifer/F-2240-2017 OI Moye, Jennifer/0000-0002-3434-347X FU NIMH NIH HHS [R29 MH057104] NR 89 TC 55 Z9 58 U1 3 U2 15 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5014 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD JAN PY 2007 VL 62 IS 1 BP P3 EP P11 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA 272CF UT WOS:000253835600011 PM 17284555 ER PT J AU Gutierrez, OM Lin, HY AF Gutierrez, O. M. Lin, H. Y. TI Refractory hyponatremia SO KIDNEY INTERNATIONAL LA English DT Article ID SALT-WASTING SYNDROME; ANEURYSMAL SUBARACHNOID HEMORRHAGE; BRAIN NATRIURETIC PEPTIDE; NEUROSURGICAL PATIENTS; PLASMA-CONCENTRATIONS; ANTIDIURETIC-HORMONE; SECRETION; SODIUM AB A 51-year-old woman with a history of an olfactory neuroblastoma treated with radiation, chemotherapy, and surgical resection 13 years ago was admitted for evaluation and treatment of persistent nausea, vomiting, fatigue, and dehydration. The patient suffered from significant cosmetic defects since resection of the neuroblastoma, and had undergone a left eyebrow lift 1 year before presentation for chronic left facial droop. The surgery was complicated by recurrent left scalp wound infections requiring long antibiotic courses. Owing to the persistence of infection despite appropriate antibiotic therapy, she underwent partial resection of a mesh in the wound 3 weeks before presentation. She was doing well after this procedure until 2 days before admission, when she developed persistent nausea, vomiting, and diarrhea. She was subsequently admitted for further evaluation and treatment. Other than the neuroblastoma, her past medical history was remarkable only for depression. Her outpatient medications at the time of admission included intravenous vancomycin and piperacillin/tazobactam, rifampin, amitriptyline at a stable dose for the past 6 months, and vitamin 136 supplements. She was unemployed, did not use tobacco or alcohol, and lived with her husband. She had one child, a daughter, who is a registered nurse. Her vital signs on admission were notable for a temperature of 98 degrees F, pulse of 75/min, and blood pressure of 84/50 mm Hg. Her blood pressure before surgery averaged around 105/70 mmHg. Orthostatic vital signs were not able to be obtained owing to extreme dizziness when she attempted to stand or sit up. Her physical exam was notable for dry mucous membranes, flat neck veins, clear lungs, benign abdominal examination, no lower extremity edema, and markedly decreased skin turgor. Initial laboratory results included were Na 120 mmol/l (her most recent serum Na 4 weeks ago was 140 mmol/l), K 3.0 mmol/l, Cl 87 mmol/l, HCO3 22.0 mmol/l, blood urea nitrogen 5 mg/dl, Cr 0.6 mg/dl, and serum osmolality 242 mosm/kg (Table 1). Urine electrolytes obtained on the same afternoon of admission were notable for Na 110 mmol/l and osmolality 351 mosm/kg (Table 2). Her white blood cell count was 41 001,mu l, hemoglobin 10.6 g/dl, hematocrit 28.1%, and platelets 251 0001,mu l. Her serum glutamic pyruvic transaminase (SGPT) was 66 U/l, serum glutamic oxaloacetic transaminase (SGOT) 50 U/l, and albumin was 3.2 g/dl. Her uric acid level was 2.2 mg/dl. Her urinalysis had an specific gravity (SPGR) of 1.019, pH of 6.5, and was negative for leukocytes, heme, and glucose. A chest radiograph was unremarkable. She was initially treated with intravenous normal saline with 5% dextrose for a total of 2.41 and anti-emetics through the first 2 days of admission. With this regimen her serum sodium increased from 120 to 123 mmol/l (Table 1 and Figure 1), although she remained hypotensive and orthostatic. Repeat urine electrolytes were notable for Na 222 mmol/l, K 36.8 mmol/l, and osmollality 550 mosm/kg (Table 2). Owing to the increase in urine osmolality, she was placed on a 11 daily fluid restriction to treat presumed syndrome of inappropriate antidiuretic hormone (SIADH). After 2 days of fluid restriction, she remained hypotensive and her serum sodium decreased to 118 mmol/l. A renal consult was then obtained on the fourth hospital day for 'refractory SIADH. Her vital signs at the time of renal consultation included a blood pressure of 80/61 mmHg, a heart rate of 66/min, and a temperature of 98.8 degrees F. Her physical examination was again notable for dry mucous membranes, marked skin tenting, and inability to obtain orthostatic vital signs owing to dizziness with sitting or standing. Her thyroid and adrenal function were tested and were found to be normal. Owing to prominent signs of extracellular fluid (ECF) contraction, her fluid restriction was discontinued, and she was started on a normal saline infusion at 100 ml/h (hospital day 4). Within the first 24 h of normal saline infusion, her serum sodium increased from 118 to 132 mmol/l (Table 1 and Figure 1), and her urine output was noted to increase from an average of 600 ml/day in the preceding 2 days to 3.61 over the course of the next day. Her urine electrolytes, however, continued to demonstrate inappropriate natriuresis in the face of persistent hyponatremia and signs and symptoms of ECF contraction, and her serum sodium again fell after hospital day 5 when continuous IV saline infusions were stopped and sporadic IV saline boluses were administered instead (Table 1 and Figure 1). An magnetic resonance imaging of the brain obtained 2 days later revealed two basal frontal lobe lesions demonstrating relatively thin peripheral enhancement, most compatible with abscesses or residual/recurrent tumor (Figure 2). On hospital day 10, her sodium balance was estimated to be negative by 406 mEq with a urine output of 5.81 the preceding 24h despite remaining hypotensive and orthostatic. C1 Harvard Univ, Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Gutierrez, OM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Nephrol, 55 Fruit St,GRB 1003, Boston, MA 02114 USA. EM ogutierrez@partners.org NR 19 TC 9 Z9 9 U1 1 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2007 VL 71 IS 1 BP 79 EP 82 DI 10.1038/sj.ki.5001845 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 121YV UT WOS:000243193800016 PM 16985516 ER PT J AU King, KR Wang, SH Irimia, D Jayaraman, A Toner, M Yarmush, ML AF King, Kevin R. Wang, Sihong Irimia, Daniel Jayaraman, Arul Toner, Mehmet Yarmush, Martin L. TI A high-throughput microfluidic real-time gene expression living cell array SO LAB ON A CHIP LA English DT Article ID IN-VITRO MODEL; INDUCED APOPTOSIS; DYNAMICS; NETWORK; RAT; INFLAMMATION; HEPATOCYTES; FIBROBLASTS; ACTIVATORS; PROGRAM AB The dynamics of gene expression are fundamental to the coordination of cellular responses. Measurement of temporal gene expression patterns is currently limited to destructive low-throughput techniques such as northern blotting, reverse transcription polymerase chain reaction (RT-PCR), and DNA microarrays. We report a scalable experimental platform that combines microfluidic addressability with quantitative live cell imaging of fluorescent protein transcriptional reporters to achieve real-time characterization of gene expression programs in living cells. Integrated microvalve arrays control row-seeding and column-stimulation of 256 nanoliter-scale bioreactors to create a high density matrix of stimulus-response experiments. We demonstrate the approach in the context of hepatic inflammation by acquiring similar to 5000 single-time-point measurements in each automated and unattended experiment. Experiments can be assembled in hours and perform the equivalent of months of conventional experiments. By enabling efficient investigation of dynamic gene expression programs, this technology has the potential to make significant impacts in basic science, drug development, and clinical medicine. C1 Massachusetts Gen Hosp, Ctr Engn & Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. MIT, Div Hlth Sci & Technol, Boston, MA 02114 USA. Texas A&M Univ, Dept Chem Engn, Boston, MA 02114 USA. Shriners Hosp Children, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Yarmush, ML (reprint author), Massachusetts Gen Hosp, Ctr Engn & Med, 51 Blosson St,Rm 406, Boston, MA 02114 USA. EM ireis@sbi.org OI Irimia, Daniel/0000-0001-7347-2082 FU NIAID NIH HHS [AI063795, R01 AI063795]; NIBIB NIH HHS [P41 EB-002503, P41 EB002503]; NIDDK NIH HHS [P30 DK040561, P30 DK040561-11]; NIGMS NIH HHS [GM065474, R01 GM065474] NR 28 TC 158 Z9 163 U1 3 U2 42 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2007 VL 7 IS 1 BP 77 EP 85 DI 10.1039/b612516f PG 9 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 141YW UT WOS:000244616200012 PM 17180208 ER PT J AU Cheng, XH Irimia, D Dixon, M Sekine, K Demirci, U Zamir, L Tompkins, RG Rodriguez, W Toner, M AF Cheng, Xuanhong Irimia, Daniel Dixon, Meredith Sekine, Kazuhiko Demirci, Utkan Zamir, Lee Tompkins, Ronald G. Rodriguez, William Toner, Mehmet TI A microfluidic device for practical label-free CD4+T cell counting of HIV-infected subjects SO LAB ON A CHIP LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; ATOMIC-FORCE MICROSCOPY; LYMPHOCYTE COUNTS; WHOLE-BLOOD; SHEAR-FLOW; SURFACE; INDIVIDUALS; QUANTIFICATION; PROGRESSION; LEUKOCYTES AB Practical HIV diagnostics are urgently needed in resource-limited settings. While HIV infection can be diagnosed using simple, rapid, lateral flow immunoassays, HIV disease staging and treatment monitoring require accurate counting of a particular white blood cell subset, the CD4+ T lymphocyte. To address the limitations of current expensive, technically demanding and/or time-consuming approaches, we have developed a simple CD4 counting microfluidic device. This device uses cell affinity chromatography operated under differential shear flow to specifically isolate CD4+ T lymphocytes with high efficiency directly from 10 microlitres of unprocessed, unlabeled whole blood. CD4 counts are obtained under an optical microscope in a rapid, simple and label-free fashion. CD4 counts determined in our device matched measurements by conventional flow cytometry among HIV-positive subjects over a wide range of absolute CD4 counts (R-2 = 0.93). This CD4 counting microdevice can be used for simple, rapid and affordable CD4 counting in point-of-care and resource-limited settings. C1 Massachusetts Gen Hosp, Parnters AIDS Res Ctr, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Surg Serv, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA. Shriners Hosp Children, Boston, MA 02114 USA. Harvard Univ, Sch Med, Div AIDS, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02114 USA. RP Rodriguez, W (reprint author), Massachusetts Gen Hosp, Parnters AIDS Res Ctr, Boston, MA 02114 USA. EM wrodriguez@partners.org; mtoner@sbi.org RI Sekine, Kazuhiko/I-5835-2012; OI Irimia, Daniel/0000-0001-7347-2082 FU NIBIB NIH HHS [EB002503, P41 EB002503] NR 42 TC 189 Z9 196 U1 3 U2 64 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2007 VL 7 IS 2 BP 170 EP 178 DI 10.1039/b612966h PG 9 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 141YX UT WOS:000244616300003 PM 17268618 ER PT J AU Lee, H Liu, Y Ham, D Westervelt, RM AF Lee, Hakho Liu, Yong Ham, Donhee Westervelt, Robert M. TI Integrated cell manipulation system - CMOS/microfluidic hybrid SO LAB ON A CHIP LA English DT Article ID MAGNETIC NANOPARTICLES; BIOLOGICAL CELLS; DNA; MICROFLUIDICS; ARRAY; MICROELECTROMAGNETS; MATRIX; CHIP AB Manipulation of biological cells using a CMOS/microfluidic hybrid system is demonstrated. The hybrid system starts with a custom-designed CMOS ( complementary metal-oxide semiconductor) chip fabricated in a semiconductor foundry. A microfluidic channel is post-fabricated on top of the CMOS chip to provide biocompatible environments. The motion of individual biological cells that are tagged with magnetic beads is directly controlled by the CMOS chip that generates microscopic magnetic field patterns using an on-chip array of micro-electromagnets. Furthermore, the CMOS chip allows high-speed and programmable reconfiguration of the magnetic fields, substantially increasing the manipulation capability of the hybrid system. Extending from previous work that verified the concept of the hybrid system, this paper reports a set of manipulation experiments with biological cells, which further confirms the advantage of the hybrid approach. To enhance the biocompatibility of the system, the microfluidic channel is redesigned and the temperature of the device is monitored by on-chip sensors. Combining microelectronics and microfluidics, the CMOS/microfluidic hybrid system presents a new model for a cell manipulation platform in biological and biomedical applications. C1 Harvard Univ, Dept Phys, Cambridge, MA 02138 USA. Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. RP Westervelt, RM (reprint author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA. EM westervelt@deas.harvard.edu NR 30 TC 89 Z9 89 U1 0 U2 24 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2007 VL 7 IS 3 BP 331 EP 337 DI 10.1039/b700373k PG 7 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 141ZD UT WOS:000244616900006 PM 17330164 ER PT J AU Park, J Cho, CH Parashurama, N Li, YW Berthiaume, F Toner, M Tilles, AW Yarmush, ML AF Park, Jaesung Cho, Cheul H. Parashurama, Natesh Li, Yawen Berthiaume, Francois Toner, Mehmet Tilles, Arno W. Yarmush, Martin L. TI Microfabrication-based modulation of embryonic stem cell differentiation SO LAB ON A CHIP LA English DT Article ID IN-VITRO DIFFERENTIATION; COLONY-FORMING CELLS; HEMATOPOIETIC DEVELOPMENT; DEFINITIVE ENDODERM; DIVERGING POINT; E-CADHERIN; CULTURE; HEPATOCYTES; EXPRESSION; GENERATION AB Embryonic stem (ES) cells form spontaneous aggregates during differentiation, and cell-cell communication in the aggregates plays an important role in differentiation. The development of a controlled differentiation scheme for ES cells has been hindered by the lack of a reliable method to produce uniform aggregate sizes. Conventional techniques, such as hanging drop and suspension cultures, do not allow precise control over size of ES cell aggregates. To surmount this problem, we microfabricated adhesive stencils to make mouse ES (mES) cell aggregates of specific sizes ranging from 100 mu m to 500 mu m in diameter. With this technique, we studied the effect of the initial aggregate size on ES cell differentiation. After 20 days of induction of differentiation, we analyzed the stem cell populations using gene and protein expression assays as well as biochemical functions. Notably, we found that germ layer differentiation depends on the initial size of the ES cell aggregate. Among the ES cell aggregate sizes tested, the aggregates with 300 mu m diameter showed similar differentiation profiles of three germ layers as embryoid bodies made using the "hanging drop'' technique. The smaller (100 mu m) aggregates showed the increased expression of ectodermal markers compared to the larger (500 mu m) aggregates, while the 500 mu m aggregates showed the increased expression of mesodermal and endodermal markers compared to the 100 mu m aggregates. These results indicate that the initial size of the aggregate is an important factor for ES cell differentiation, and can affect germ layer selection as well as the extent of differentiation. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Shriners Hosp Children, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA. Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08845 USA. RP Yarmush, ML (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Shriners Hosp Children, GRB 1401,55 Fruit St, Boston, MA 02114 USA. EM ireis@sbi.org FU NIBIB NIH HHS [P41 EB002503, P41 EB02503]; NIDDK NIH HHS [K08 DK66040, R01 DK43371] NR 50 TC 91 Z9 94 U1 0 U2 13 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2007 VL 7 IS 8 BP 1018 EP 1028 DI 10.1039/b704739h PG 11 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 193NU UT WOS:000248281600018 PM 17653344 ER PT J AU Irimia, D Charras, G Agrawal, N Mitchison, T Toner, M AF Irimia, Daniel Charras, Guillaume Agrawal, Nitin Mitchison, Timothy Toner, Mehmet TI Polar stimulation and constrained cell migration in microfluidic channels SO LAB ON A CHIP LA English DT Article ID CHEMOTAXIS; NEUTROPHILS; LOCOMOTION; RECEPTOR AB Asymmetrical delivery of stimuli to moving cells for perturbing spatially-heterogeneous intracellular signaling is an experimental challenge not adequately met by existing technologies. Here, we report a robust microfluidic platform allowing localized treatment of the front and/or back of moving cells which crawl through narrow channels that they completely occlude. The enabling technical element for this study is a novel design for precise, passive balancing of flow inside the microfluidic device by contacting two fluid streams before splitting them again. The microchannels constrain cell morphology and induce qualitative and quantitative changes in neutrophil chemotaxis that mimic cells crawling through tissues. C1 Shriners Hosp Children, Massachusetts Gen Hosp, Ctr Engn Med, BioMEMS Res Ctr, Boston, MA 02114 USA. Shriners Hosp Children, Massachusetts Gen Hosp, Boston, MA USA. Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. RP Irimia, D (reprint author), Shriners Hosp Children, Massachusetts Gen Hosp, Ctr Engn Med, BioMEMS Res Ctr, Boston, MA 02114 USA. EM dirimia@hms.harvard.edu; g.charras@ucl.ac.uk RI Charras, Guillaume/F-8571-2014; OI Charras, Guillaume/0000-0002-7902-0279; Irimia, Daniel/0000-0001-7347-2082 FU NIBIB NIH HHS [P41 EB002503, P41 EB002503-01]; NIGMS NIH HHS [R01 GM048027, GM48027, R01 GM048027-10] NR 22 TC 73 Z9 73 U1 2 U2 19 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2007 VL 7 IS 12 BP 1783 EP 1790 DI 10.1039/b710524j PG 8 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 233WM UT WOS:000251121000030 PM 18030401 ER PT J AU D'Amico, AV Roehrborn, CG AF D'Amico, Anthony V. Roehrborn, Claus G. TI Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial SO LANCET ONCOLOGY LA English DT Article ID CANCER PREVENTION; HYPERPLASIA; PSA AB Background Use of 5 mg/day finasteride (Proscar) for benign prostatic hyperplasia is known to affect serum concentrations of prostate-specific antigen (PSA). When men taking this treatment undergo screening for prostate cancer, a compensatory adjustment of the PSA concentration (to multiply the value by two) is recommended. Whether this recommendation should apply to men taking 1 mg/day finasteride (Propecia) for the treatment of androgenic alopecia is unknown. We aimed to assess the effect of 1 mg/day finasteride on serum PSA in men aged 40-60 years with male-pattern hair loss. Methods Between March 13, 1998, and Jan 12, 2000, 355 men aged 40-60 years with male-pattern hair loss were stratified by age decade (40-49 years and 50-60 years), and randomised in a ratio of four to one to 1 mg/day finasteride or placebo. The primary endpoint was the effect of this treatment for 48 weeks on serum PSA concentration compared with placebo. This trial is in the process of being registered on the US National Institutes of Health website http://www.clinicaltrials.gov/ct/show/NCT00396175. Analyses were according to protocol. Findings Within 48 weeks of randomisation, men aged 40-49 years and 50-60 years who were assigned 1 mg/day finasteride had a median decrease in serum PSA concentration of 40% (95% CI 34-46) and 50% (44-57), respectively. In men assigned placebo, the median changes were 0% [-14 to 14] and a median increase of 13% [2 to 24], respectively. Interpretation In men aged 40-60 years, 1 mg/day finasteride for 48 weeks lowers serum PSA concentration. Therefore, the existing recommendation for the adjustment of serum PSA concentration in prostate-cancer screening in men taking 5 mg/day finasteride should also apply to men taking the 1 mg/day preparation for male-pattern hair loss. Research is needed to assess the effect of 1 mg/day finasteride preparation beyond 48 weeks of treatment. C1 Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX USA. RP D'Amico, AV (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02215 USA. EM adamico@lroc.harvard.edu NR 15 TC 44 Z9 44 U1 0 U2 3 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD JAN PY 2007 VL 8 IS 1 BP 21 EP 25 DI 10.1016/S1470-2045(06)70981-0 PG 5 WC Oncology SC Oncology GA 123CU UT WOS:000243274700019 PM 17196507 ER PT J AU Ditman, T Holcomb, PJ Kuperberg, GR AF Ditman, Tali Holcomb, Phillip J. Kuperberg, Gina R. TI The contributions of lexico-semantic and discourse information to the resolution of ambiguous categorical anaphors SO LANGUAGE AND COGNITIVE PROCESSES LA English DT Article ID EVENT-RELATED POTENTIALS; LANGUAGE COMPREHENSION; BRAIN POTENTIALS; ELECTROPHYSIOLOGICAL EVIDENCE; SEMANTIC MEMORY; SENTENCE; WORD; ACTIVATION; CONTEXT; INTEGRATION AB The present studies employed event-related potentials (ERPs) to examine the time course for the integration of lexico-semantic and discourse information during the resolution of categorical anaphors. Scenarios were constructed to include three potential antecedents. Anaphors were semantically ambiguous in that two of the potential antecedents were exemplars of the anaphor. Final sentences resolved the anaphor with the correct ( associatively related/contextually appropriate), incorrect ( associatively related/contextually inappropriate), or control antecedent ( associatively unrelated/contextually inappropriate). We examined the amplitude of the N400 component, which is thought to reflect the ease of semantic integration, at several points following the anaphor. The smallest N400 was evoked when the text referred back to a correct antecedent following an anaphor; an intermediate N400 was evoked by incorrect antecedents and the largest N400 was evoked by reinstating the control antecedent following an anaphor. Results demonstrated that, following an ambiguous anaphor, readers are able to use both lexico-semantic and discourse-level information to semantically integrate an antecedent into its larger discourse context. C1 Tufts Univ, Medford, MA 02155 USA. Massachusetts Gen Hosp, Charlestown, MA USA. RP Ditman, T (reprint author), Tufts Univ, 490 Boston Ave, Medford, MA 02155 USA. EM Tali.Ditman@tufts.edu NR 50 TC 16 Z9 16 U1 2 U2 4 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0169-0965 J9 LANG COGNITIVE PROC JI Lang. Cogn. Process. PY 2007 VL 22 IS 6 BP 793 EP 827 DI 10.1080/01690960601057126 PG 35 WC Linguistics; Psychology, Experimental SC Linguistics; Psychology GA 214TE UT WOS:000249760200001 ER PT J AU Anderson, RR AF Anderson, R. Rox TI What is safe? An introduction SO LASERS IN SURGERY AND MEDICINE LA English DT Editorial Material C1 Harvard Univ, Massachusetts Gen Hosp, WEllman Ctr Photomed, Boston, MA 02114 USA. RP Anderson, RR (reprint author), Harvard Univ, Massachusetts Gen Hosp, WEllman Ctr Photomed, BHX-630 55 Fruit St, Boston, MA 02114 USA. EM rranderson@partners.org NR 0 TC 2 Z9 3 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD JAN PY 2007 VL 39 IS 1 BP 7 EP 7 DI 10.1002/lsm.20462 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 133OI UT WOS:000244021800002 PM 17252572 ER PT J AU Laubach, H Chan, HH Rius, F Anderson, RR Manstein, D AF Laubach, Hans Chan, Henry H. Rius, Francisca Anderson, R. Rox Manstein, Dieter TI Effects of skin temperature on lesion size in fractional photothermolysis SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE temperature; lesion size; MTZ; fractional photothermolysis; fractional ID LASER TREATMENT; FACIAL RHYTIDES; DIODE-LASER; COMBINATION AB Background and Objectives: Fractional photothermolysis is a new concept in cutaneous re-modeling whereby laser-induced microscopic zones of thermal injury (MTZ-Microscopic Treatment Zones) are surrounded by normal, viable tissue. This unique thermal damage pattern allows re-epithelialization in less than 24 hours. To increase patient comfort level during the procedure of fractional photothermolysis, simultaneous skin cooling has been proposed and is now extensively used. The purpose of this in vitro study was to examine the influence of skin temperature on the diameter of the epidermal microthermal zone and the extent of thermal injury per unit area. The determination of the changes in these parameters that are due to skin temperature will allow the better control and understanding of fractional photothermolysis at different skin temperatures. Materials and Methods: Fractional photothermolysis was performed with a 1,550 nm fiber laser (Fraxel SR(R) Laser) with 10 mJ per pulse on full-thickness cadaver skin. The skin samples were brought prior to exposure to temperatures that ranged from 0 to 45 degrees C. The epidermis of the skin samples was separated by dispase treatment, stained for thermal damage by NBTC stain, and lesion diameter was assessed by a blinded investigator. Results : The average MTZ diameter exhibits a positive, linear relationship with skin temperature (R-2 = 0.904, P < 0.0001). As the skin temperature increases from 0 to 45 degrees C. The MTZ diameter increases from 93 to 147 mu m (58%), and the MTZ area from 6,870 to 17,050 mu m(2) (148%). Conclusion : The skin temperature affects the size of epidermal MTZs during fractional photothermolysis and is an important variable factor. The use of simultaneous skin cooling increases patient comfort; however, as it also decreases MTZ size, it may interfere with treatment efficacy. The control of skin temperature is necessary to provide a consistent outcome and to be able to compare treatments. C1 Massachusetts Gen Hosp, Wellman Labs Photomed, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. Univ Malaga, E-29071 Malaga, Spain. RP Manstein, D (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Wellman Labs Photomed, Boston, MA 02115 USA. EM Dmanstein@partners.org RI Chan, Henry Hin Lee/L-2267-2013 NR 18 TC 29 Z9 29 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD JAN PY 2007 VL 39 IS 1 BP 14 EP 18 DI 10.1002/lsm.20453 PG 5 WC Dermatology; Surgery SC Dermatology; Surgery GA 133OI UT WOS:000244021800004 PM 17252573 ER PT J AU Garcez, AS Ribeiro, MS Tegos, GP Nunez, SC Jorge, AOC Hamblin, MR AF Garcez, Aguinaldo S. Ribeiro, Martha S. Tegos, George P. Nunez, Silvia C. Jorge, Antonio O. C. Hamblin, Michael R. TI Antimicrobial photodynamic therapy combined with conventional endodontic treatment to eliminate root canal biofilm infection SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE endodontic therapy; root canal infection; photodynamic therapy; polyethyleneimine chlorin(e6) conjugate; bioluminescence imaging; biofilm ID IN-VIVO; REAL-TIME; LETHAL PHOTOSENSITIZATION; BIOLUMINESCENT BACTERIA; WOUND INFECTIONS; ORAL INFECTIONS; FILLED TEETH; VITRO; DISINFECTION; MICROFLORA AB Background and Objective: To compare the effectiveness of antimicrobial photodynamic therapy (PDT), standard endodontic treatment and the combined treatment to eliminate bacterial biofilms present in infected root canals. Study Design/Materials and Methods: Ten single-rooted freshly extracted human teeth were inoculated with stable bioluminescent Gram-negative bacteria, Proteus mirabilis and Pseudomonas aeruginosa to form 3-day biofilms in prepared root canals. Biolumineseence imaging was used to serially quantify bacterial burdens. PDT employed a conjugate between polyethylenimine and chlorin(e6) as the photosensitizer (PS) and 660-nm diode laser light delivered into the root canal via a 200-mu fiber, and this was compared and combined with standard endodontie treatment using mechanical debridement and antiseptic irrigation. Results: Endodontic therapy alone reduced bacterial bioluminescence by 90% while PDT alone reduced bioluminescence by 95%. The combination reduced bioluminescence by >98%, and importantly the bacterial regrowth observed 24 hours after treatment was much less for the combination (P < 0.0005) than for either single treatment. Conclusions: Bioluminescence imaging is an efficient way to monitor endodontic therapy. Antimicrobial PDT may have a role to play in optimized endodontic therapy. C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. IPEN CNEN SP, Ctr Laser & Applicat, Sao Paulo, SP, Brazil. Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA. Univ Taubate, Sch Dent, Sao Paulo, Brazil. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR414,40 Blossom St, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu RI Tegos, George/C-8830-2011; Garcez, Aguinaldo/B-3556-2013; Ribeiro, Martha/G-3517-2012; Nunez, Silvia/C-7241-2017; OI Garcez, Aguinaldo/0000-0003-2037-7211; Ribeiro, Martha/0000-0002-4203-1134; Nunez, Silvia/0000-0003-2101-8333; Hamblin, Michael/0000-0001-6431-4605 FU NIAID NIH HHS [R01 AI050875, R01 AI050875-05A1] NR 57 TC 94 Z9 104 U1 5 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD JAN PY 2007 VL 39 IS 1 BP 59 EP 66 DI 10.1002/lsm.20415 PG 8 WC Dermatology; Surgery SC Dermatology; Surgery GA 133OI UT WOS:000244021800010 PM 17066481 ER PT J AU Watanabe, K Wanner, M Laubach, H Farinelli, B Anderson, RR Manstein, D AF Watanabe, Kanna Wanner, Molly Laubach, Hans Farinelli, Bill Anderson, R. Rox Manstein, Dieter TI Selective photothermolysis of lipid rich tissue SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 11-15, 2007 CL Grapevine, TX SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2007 SU 19 MA 11 BP 4 EP 4 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 154XF UT WOS:000245540600012 ER PT J AU Mukherjee, S Yaroslavsky, A Tannous, Z AF Mukherjee, Sonali Yaroslavsky, Anna Tannous, Zeina TI Imaging melanoma using a reflectance and fluorescence polarization imaging technique SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 11-15, 2007 CL Grapevine, TX SP Amer Soc Laser Med & Surg C1 Harvard Med Sch, Boston, MA USA. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2007 SU 19 MA 35 BP 12 EP 12 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 154XF UT WOS:000245540600036 ER PT J AU Salomatina, E Al-Arashi, M Anderson, RR Yaroslavsky, AN AF Salomatina, E. Al-Arashi, M. Anderson, R. R. Yaroslavsky, A. N. TI Spectrally-resolved reflectance versus fluorescence polarization for the detection of nonmelanoma skin cancers SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 11-15, 2007 CL Grapevine, TX SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Harvard Med Sch, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2007 SU 19 MA 34 BP 12 EP 12 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 154XF UT WOS:000245540600035 ER PT J AU Laubach, H Chan, H Manstein, D Anderson, RR AF Laubach, Hans Chan, Henry Manstein, Dieter Anderson, R. Rox TI Effects of skin temperature on lesion size in fractional resurfacing SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 11-15, 2007 CL Grapevine, TX SP Amer Soc Laser Med & Surg C1 Harvard Univ, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2007 SU 19 MA 47 BP 15 EP 15 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 154XF UT WOS:000245540600046 ER PT J AU Manstein, D Watanabe, K Chan, HH Anderson, RR AF Manstein, D. Watanabe, K. Chan, H. H. Anderson, R. R. TI Threshold, extent and anisotropy of thermally induced skin shrinkage SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 11-15, 2007 CL Grapevine, TX SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. Univ Hong Kong, Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2007 SU 19 MA 59 BP 19 EP 19 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 154XF UT WOS:000245540600058 ER PT J AU Park, JM Tsao, S AF Park, Jong Min Tsao, Sandy TI Combined use of intense pulsed light and Q-SWITCHED ruby laser for complex dyspigmentation among Asian patients SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 11-15, 2007 CL Grapevine, TX SP Amer Soc Laser Med & Surg C1 Harvard Univ, Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2007 SU 19 MA 72 BP 24 EP 24 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 154XF UT WOS:000245540600071 ER PT J AU Sakamoto, FH Doukas, A Farinelli, W Tannous, Z Anderson, RR AF Sakamoto, Fernanda H. Doukas, Apostolos Farinelli, William Tannous, Zeina Anderson, R. Rox TI Intradermal aminolevulinic acid photodynamic therapy (ALA-PDT) SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 11-15, 2007 CL Grapevine, TX SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2007 SU 19 MA 85 BP 35 EP 35 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 154XF UT WOS:000245540600106 ER PT J AU Sakamoto, FH Doukas, A Farinelli, W Tannous, Z Anderson, RR AF Sakamoto, Fernanda H. Doukas, Apostolos Farinelli, William Tannous, Zeina Anderson, R. Rox TI Skin temperature can control ALA-photodynamic therapy SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 11-15, 2007 CL Grapevine, TX SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2007 SU 19 MA 251 BP 77 EP 77 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 154XF UT WOS:000245540600231 ER PT J AU Tannous, Z Mukherjee, S Konnikov, N AF Tannous, Zeina Mukherjee, Sonali Konnikov, Nellie TI Effect of pulsed dye laser on basal cell carcinoma SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 11-15, 2007 CL Grapevine, TX SP Amer Soc Laser Med & Surg C1 Harvard Med Sch, VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2007 SU 19 MA 258 BP 79 EP 79 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 154XF UT WOS:000245540600237 ER PT J AU Jagannath, S Richardson, PG Sonneveld, P Schuster, MW Irwin, D Stadtmauer, EA Facon, T Harousseau, JL Cowan, JM Anderson, KC AF Jagannath, S. Richardson, P. G. Sonneveld, P. Schuster, M. W. Irwin, D. Stadtmauer, E. A. Facon, T. Harousseau, J-L Cowan, J. M. Anderson, K. C. TI Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials SO LEUKEMIA LA English DT Article DE bortezomib; chromosome 13; FISH; metaphase cytogenetics; multiple myeloma; survival ID IN-SITU HYBRIDIZATION; HIGH-DOSE THERAPY; RELAPSED MULTIPLE-MYELOMA; CELL TRANSPLANTATION; REFRACTORY MYELOMA; STAGING SYSTEM; FISH ANALYSIS; ABNORMALITIES; CYTOGENETICS; DEXAMETHASONE AB In multiple myeloma, deletion of chromosome 13 ( del( 13)) is associated with poor prognosis regardless of treatment. This study analyzed the impact of del( 13) status on response and survival following treatment with either bortezomib or high-dose dexamethasone in patients in the SUMMIT and APEX trials. Additionally, matched-pairs subset analyses were conducted of patients with and without del( 13), balanced for age and International Staging System parameters. In both SUMMIT and APEX, prognosis appeared to be poorer in bortezomib-treated patients with del( 13) compared with patients with no del( 13) by metaphase cytogenetics. In the SUMMIT and APEX matched-pairs analysis, response and survival appeared comparable in bortezomib-treated patients with or without del( 13) by metaphase cytogenetics. However, patients with del( 13) receiving dexamethasone in APEX appeared to have markedly decreased survival compared with those without del( 13) by metaphase cytogenetics. These matched-pairs analyses suggest that bortezomib may overcome some of the poor impact of del( 13) as an independent prognostic factor. However, sample sizes were very small; these findings require confirmation from further studies. C1 St Vincents Comprehens Canc Ctr, Dept Med Oncol, New York, NY 10011 USA. Dana Farber Canc Inst, Dept Med Oncol Hematol Malignancies, Boston, MA 02115 USA. Erasmus MC, Dept Hematol, Rotterdam, Netherlands. Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Ctr Lymphoma & Myeloma, New York, NY 10021 USA. Alta Bates Canc Ctr, Bone & Marrow Transplantat Program, Berkeley, CA USA. Univ Penn, Abramson Canc Ctr, Bone Marrow & Stem Cell Transplant Program, Philadelphia, PA 19104 USA. Hosp Claude Huriez, Serv Malad Sang, Lille, France. Hop Hotel Dieu, Dept Hematol, Nantes, France. Tufts New England Med Ctr, Dept Pathol, Boston, MA USA. RP Jagannath, S (reprint author), St Vincents Comprehens Canc Ctr, Dept Med Oncol, 325 W 15th St, New York, NY 10011 USA. EM sjagannath@aptiumoncology.com RI FACON, THIERRY/M-9736-2014 OI FACON, THIERRY/0000-0001-7705-8460 NR 30 TC 176 Z9 191 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD JAN PY 2007 VL 21 IS 1 BP 151 EP 157 DI 10.1038/sj.leu.2404442 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 118IA UT WOS:000242934500022 PM 17096017 ER PT J AU Czuczman, MS Porcu, P Johnson, J Niedzwiecki, D Kelly, M Hsi, ED Cook, JR Canellos, G Cheson, BD AF Czuczman, Myron S. Porcu, Pierluigi Johnson, Jeffrey Niedzwiecki, Donna Kelly, Michael Hsi, Eric D. Cook, James R. Canellos, George Cheson, Bruce D. CA Canc Leukemia Grp B TI Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901 SO LEUKEMIA & LYMPHOMA LA English DT Article DE nelarabine; 506U78; CTCL; PTCL; T-cell lymphoma ID REFRACTORY HEMATOLOGIC MALIGNANCIES; CLASSIFICATION; TOXICITY; CHILDREN; ADULTS AB Nelarabine (compound 506U78), a novel purine nucleoside, is a soluble pro-drug of 9-beta-D-arabinofuranosylguanine (ara-G). Nelarabine is rapidly demethoxylated in blood by adenosine deaminase to ara-G. Pre-clinical and clinical studies have demonstrated the selective cytotoxicity of ara-G to T-lineage derived cells. CALGB Protocol 59901 was a Phase II study of nelarabine in patients with systemically untreated cutaneous T-cell lymphoma (CTCL) or refractory/relapsed systemic T-cell lymphoma (STCL). The objectives were to determine response rate, remission duration and safety profile associated with nelarabine given at 1.5 g m(-2) per day on days 1, 3 and 5 as an intravenous infusion every 21 days for a minimum of two cycles and to continue up to two cycles beyond CR up to a maximum of eight cycles. Nineteen patients were enrolled in the study: 11 CTCL and eight STCL patients. Grade 3 or 4 adverse events were documented in 50% and 28%, respectively. In particular, 33% of patients experienced Grade 3 or 4 neurologic toxicities. There were two partial remissions lasting 3 months and 5.5 months, respectively. Median event-free survival was 1.2 months and median overall survival was 3 months. Due to lack of efficacy and excessive toxicity, nelarabine is not recommended as monotherapy in adult patients with CTCL and STCL at this dose schedule. C1 Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. CALGB Stat Ctr, Durham, NC USA. Cleveland Clin, Cleveland, OH 44106 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Georgetown Univ Hosp, Washington, DC 20007 USA. RP Czuczman, MS (reprint author), Roswell Pk Canc Inst, Elm & Carlton St, Buffalo, NY 14263 USA. EM myron.czuczman@roswellpark.org FU NCI NIH HHS [CA77406, CA02599, CA04326, CA11789, CA31946, CA33601, CA35113, CA41287, CA47577, CA77440, CA77658] NR 10 TC 25 Z9 25 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD JAN PY 2007 VL 48 IS 1 BP 97 EP 103 DI 10.1080/10428190600961058 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 136UP UT WOS:000244249900015 PM 17325852 ER PT J AU Peterson, BA Johnson, J Shipp, MA Barcos, M Gockerman, JP Canellos, GP AF Peterson, Bruce A. Johnson, Jeffrey Shipp, Margaret A. Barcos, Maurice Gockerman, Jon P. Canellos, George P. CA Canc Leukemia Grp B TI High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and leukemia group B 9351 SO LEUKEMIA & LYMPHOMA LA English DT Article DE diffuse aggressive lymphoma; therapy ID B-CELL LYMPHOMA; BONE-MARROW-TRANSPLANTATION; PROSPECTIVE RANDOMIZED-TRIAL; CHEMOTHERAPY PLUS RITUXIMAB; COLONY-STIMULATING FACTOR; STANDARD REGIMEN CHOP; DETUDE-DES-LYMPHOMES; ELDERLY-PATIENTS; INTERMEDIATE-GRADE; CONVENTIONAL CHEMOTHERAPY AB Cyclophosphamide and doxorubicin, two important drugs in the treatment of lymphoma, exhibit a relationship between dose and fractional cell kill, and because of their toxicity profiles, they are candidates for significant dose escalation. We performed a phase II trial to determine the response rate, toxicity, and feasibility of escalated doses of both drugs as part of high dose CHOP in diffuse aggressive lymphoma. Patients who had advanced, previously untreated diffuse aggressive lymphomas ( IWF E-H) and an International Prognostic Index of intermediate to high risk were eligible. Treatment was cyclophosphamide 2 gm/m(2)/day intravenously on Days 1 and 2 ( total cycle dose 4 gm/m(2)), doxorubicin 35 mg/m(2)/day as a continuous infusion on Days 1 and 2 ( total 70 mg/m(2)), vincristine 1.4 mg/m(2) ( maximum 2 mg) on Day 1 and prednisone 100 mg/day orally on Days 1-5 repeated every 3 weeks for a total of four cycles. G-CSF, prophylactic antibiotics, and mesna were provided. A total of 99 patients were enrolled; 98 received therapy. Major toxicities were Grade 4 neutropenia and thrombocytopenia occurring in 97% and 92%, respectively. Serious infections occurred in 53%. Treatment-related mortality was 2%. The overall response rate is 85%, and two-year failure free and overall survival are 39% and 64%, respectively. Persistent or relapsed lymphoma was the overwhelming cause of death. Six patients have developed AML or MDS. In view of the substantial toxicity accompanying high dose CHOP, the observed outcome suggests that its efficacy is not sufficient to make further study feasible. C1 Univ Minnesota, Div Hematol Oncol, Minneapolis, MN 55455 USA. CALGB, Ctr Stat, Durham, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. New York State Dept Hlth, Roswell Pk Canc Inst, Buffalo, NY USA. Duke Univ, Med Ctr, Durham, NC USA. RP Peterson, BA (reprint author), Univ Minnesota, Div Hematol Oncol, MMC 286, Minneapolis, MN 55455 USA. EM peter001@umn.edu FU NCI NIH HHS [CA47642, CA60138, CA04457, CA26806, CA31946, CA12499, CA04326, CA47575, CA41287, CA32291, CA08025, CA16450, CA77440, CA02599, CA35279, CA33601, CA03927, CA31983, CA47577, CA47555, CA21060, CA47559] NR 43 TC 2 Z9 2 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2007 VL 48 IS 5 BP 870 EP 880 DI 10.1080/10428190701259758 PG 11 WC Oncology; Hematology SC Oncology; Hematology GA 171FH UT WOS:000246719800008 PM 17487729 ER PT J AU Lafuente, EM Iwamoto, Y Carman, CV Van Puijenbroek, AAFL Constantine, E Li, LQ Boussiotis, VA AF Lafuente, Esther M. Iwamoto, Yoshiko Carman, Christopher V. Van Puijenbroek, Andre A. F. L. Constantine, Erica Li, Lequn Boussiotis, Vassiliki A. TI Active Rap1, a small GTPase that induces malignant transformation of hematopoietic progenitors, localizes in the nucleus and regulates protein expression SO LEUKEMIA & LYMPHOMA LA English DT Article DE morphology neoplasia; cell lines and animal models; signal transduction ID CELL-ADHESION; T-CELL; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; INTEGRIN ACTIVATION; SUPPRESSOR ACTIVITY; BINDING PROTEINS; GOLGI-COMPLEX; RAS; GENE AB Rap1, a member of the Ras superfamily, regulates cytoskeletal changes in lower eukaryots and integrin-mediated adhesion in hematopoietic cells. Sustained activation of Rap1 in mouse hematopoietic stem cells causes expansion of hematopoietic progenitors, followed by a myeloproliferative disorder mimicking chronic myeloid leukemia. Moreover, these mice develop a B-cell lymphoproliferative disorder resembling chronic lymphocytic leukemia. Here, we used HEK 293 cells as a tool to examine the molecular effects of Rap1. We observed that a constitutively active Rap1 mutant localized predominantly in the nucleus. Nuclear localization of endogenous Rap1-GTP was also detected upon physiologic activation. A potential consequence of nuclear localization of Rap1-GTP is the regulation of gene expression. We used a high throughput proteomic approach to identify gene products potentially modulated by Rap1-GTP. Out of 1000 proteins examined, 64 proteins were upregulated and 66 proteins were downregulated. The differentially expressed gene products belong to cytoskeletal regulator proteins, signaling molecules, transcription factors, viability regulators, and protein transporters. This analysis provides the first fingerprint of gene product expression regulated by Rap1 and may contribute to our understanding of malignant transformation mechanisms regulated by this small GTPase. C1 CUNY, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02129 USA. Harvard Univ, Sch Med, Ctr Blood Res, Dept Pathol, Boston, MA USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA USA. RP Boussiotis, VA (reprint author), CUNY, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, 149-5106,13th St, Boston, MA 02129 USA. EM vboussiotis@partners.org RI Lafuente, Esther M/K-5684-2014; Carman, Christopher/L-8108-2016 OI Lafuente, Esther M/0000-0001-8466-1022; Carman, Christopher/0000-0001-7358-2548 FU NIAID NIH HHS [AI 43552] NR 73 TC 5 Z9 5 U1 0 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2007 VL 48 IS 5 BP 987 EP 1002 DI 10.1080/10428190701242341 PG 16 WC Oncology; Hematology SC Oncology; Hematology GA 171FH UT WOS:000246719800022 PM 17487743 ER PT J AU Blum, KA Johnson, JL Niedzwiecki, D Canellos, GP Cheson, BD Bartlett, NL AF Blum, Kristie A. Johnson, Jeffrey L. Niedzwiecki, Donna Canellos, George P. Cheson, Bruce D. Bartlett, Nancy L. TI Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206 SO LEUKEMIA & LYMPHOMA LA English DT Article DE bortezomib; relapsed; refractory; Hodgkin lymphoma ID NF-KAPPA-B; PROTEASOME INHIBITOR BORTEZOMIB; REED-STERNBERG CELLS; PHASE-II; RECEPTOR ACTIVATOR; DISEASE; EXPRESSION; MUTATIONS; APOPTOSIS; GENE AB Constitutive activation of nuclear factor-kappa B (NF-kappa B) has been described in patient-derived Reed - Sternberg cells and Hodgkin lymphoma ( HL) cell lines and contributes to the proliferation and survival of HL. Therapeutic inhibition of the proteasome with bortezomib may inhibit over-expression of nuclear NF-kappa B by preventing degradation of I kappa B, which sequesters NF-kappa B in the cytoplasm. To evaluate this hypothesis, the Cancer and Leukemia Group B (CALGB) conducted a multi-institutional phase II trial of single agent bortezomib in patients with relapsed or refractory classical HL. Thirty patients received bortezomib 1.3 mg/m(2) on days 1, 4, 8, 11 and every 21 days for a median of 2 cycles ( range, 1 - 8). Patients were heavily pre-treated with a median of four prior therapies, and 83% were previously transplanted. No responses were observed, 9 patients had stable disease, and 21 progressed. The median progression-free and overall survivals were 1.4 months [95% CI, ( 1.28, 1.91)] and 14.8 months [95% CI ( 11.2, 22.3)], respectively. Grade 3 - 4 adverse events, primarily thrombocytopenia, occurred in 15 patients. Therefore, although well tolerated, 1.3 mg/m(2) bortezomib administered biweekly has no single agent activity in relapsed/ refractory classical HL. C1 Ohio State Univ, Dept Internal Med, Div Haematol Oncol, Columbus, OH 43210 USA. Duke Univ, GALGB Stat Ctr, Durham, NC USA. Dana Farber Canc Inst, Dept Internal Med, Div Hematol Oncol, Boston, MA 02115 USA. Georgetown Univ Hosp, Dept Internal Med, Div Hematol Oncol, Washington, DC 20007 USA. Washington Univ, Dept Internal Med, Div Hematol Oncol, St Louis, MO USA. RP Blum, KA (reprint author), Ohio State Univ, Div Hematol Oncol, Starling Loving Hall,Rm B315, Columbus, OH 43210 USA. EM kristie.blum@osumc.edu RI Blum, Kristie/E-2768-2011 FU NCI NIH HHS [CA33601, CA77597, CA77658, K23 CA109004-01A1] NR 35 TC 45 Z9 47 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2007 VL 48 IS 7 BP 1313 EP 1319 DI 10.1080/10428190701411458 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 186LD UT WOS:000247779300011 PM 17613759 ER PT J AU Mckibbin, T Burzynski, J Greene, R Ochoa-Bayona, J Tsai, TW Callander, N Freytes, C AF Mckibbin, Trevor Burzynski, Julianna Greene, Rebecca Ochoa-Bayona, Jose Tsai, T. W. Callander, Natalie Freytes, Cesar TI Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen SO LEUKEMIA & LYMPHOMA LA English DT Article DE stem cell mobilization; marrow and stem cell transplantation; paclitaxel; leukapheresis; hematopoietic stem cell ID BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; NON-HODGKINS-LYMPHOMA; HIGH-DOSE CYCLOPHOSPHAMIDE; BLOOD STEM-CELLS; PLUS G-CSF; MULTIPLE-MYELOMA; RANDOMIZED-TRIAL; STEADY-STATE; CHEMOTHERAPY AB Paclitaxel and G-CSF have been evaluated for HPC mobilization in breast cancer and found to have tolerable toxicity with a predictable time to initiate leukapheresis. However, this approach has not been reported in patients with hematologic malignancies failing prior mobilization. We report a case-series of 26 adults given paclitaxel and G-CSF for HPC mobilization after failure of an initial mobilization. Patients received paclitaxel 250 mg/m(2) followed by G-CSF 10-16 mcg/kg/day. Compared to the initial regimen, paclitaxel mobilization produced greater CD34+ cell yields ( median 1.53 x 10(6) CD34+ cells/kg vs. 0.79 x 10(6) CD34+ cells/kg, p = 0.004). Seventy-six percent of patients initiated leukapheresis on day 8, the remainder on day 9 or 10. Three patients developed febrile neutropenia resulting in one death prior to leukapheresis. Overall, 73% of patients proceeded with autologous HPC transplant. This case-series suggests paclitaxel may be an option for HPC mobilization in patients failing prior regimens. C1 [Mckibbin, Trevor; Burzynski, Julianna; Greene, Rebecca] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacotherapy, San Antonio, TX 78229 USA. [Mckibbin, Trevor; Burzynski, Julianna; Greene, Rebecca] Univ Texas, Coll Pharm, Austin, TX USA. [Mckibbin, Trevor; Burzynski, Julianna; Greene, Rebecca; Ochoa-Bayona, Jose; Freytes, Cesar] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ochoa-Bayona, Jose; Tsai, T. W.; Callander, Natalie; Freytes, Cesar] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. RP Mckibbin, T (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacotherapy, 7703 Floyd Curl Dr, MSC 6220, San Antonio, TX 78229 USA. EM trevor.mckibbin@gmail.com NR 29 TC 3 Z9 3 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2007 VL 48 IS 12 BP 2360 EP 2366 DI 10.1080/10428190701665970 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 239KI UT WOS:000251516800028 PM 18067011 ER PT J AU Kuzel, TM Li, S Eklund, J Foss, F Gascoyne, R Abramson, N Schwerkoske, JF Weller, E Horning, SJ AF Kuzel, Timothy M. Li, Shuli Eklund, John Foss, Francine Gascoyne, Randy Abramson, Neil Schwerkoske, John F. Weller, Edie Horning, Sandra J. TI Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497 SO LEUKEMIA & LYMPHOMA LA English DT Article DE non-Hodgkins lymphoma; targeted therapy; interleukin-2 receptor; denileukin diftitox ID TUMOR LYSIS SYNDROME; INTERLEUKIN-2 FUSION PROTEIN; CHRONIC LYMPHOCYTIC-LEUKEMIA; RECEPTOR; DAB(389)IL-2; EXPRESSION; TRIAL; CELLS AB Denileukin diftitox (DD) is approved for treatment of CD-25 expressing cutaneous T-cell lymphomas (CTCL). Initial studies of DD demonstrated responses in patients with B-cell non-Hodgkin lymphoma (NHL). This phase II trial evaluated response rate (RR) and tolerability of DD in this population. Patients were stratified into two arms: those with NHL expressing >= 20% IL-2R (IL-2R+) or < 20% IL-2R (IL-2R-). DD was dosed at 18 mu g/kg/day for 5 days every 21 days. Corticosteroid pre-medication was not allowed. Thirty-five patients of a planned 77 accrued due to closure for slow accrual. This report is on 29 patients (18 males) with indolent B-cell NHL (11 IL-2R+ and 18 IL-2R-). Histologic subtypes included small lymphocytic (SLL) (8 patients) and follicular grade I/II lymphoma (21 patients). Patients received a median of three prior regimens, including rituximab in 76%. Three partial responses were observed (RR 10%). The RR for the IL-2R- and IL-2R+ patients was 11% and 9%, respectively. Of 8 patients with SLL, 2 responded. Toxicities were generally grade I-II and transient but 1 patient experienced a fatal thrombo-embolism. Therapy with DD is tolerable and modest efficacy was observed in SLL subtype. Measured IL-2R status did not correlate with efficacy. C1 [Kuzel, Timothy M.; Eklund, John] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Foss, Francine] Tufts Univ New England Med Ctr, Boston, MA 02111 USA. [Gascoyne, Randy] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. [Abramson, Neil] Baptist Reg Canc Inst, Jacksonville, FL USA. [Schwerkoske, John F.] United Hosp, St Paul, MN USA. [Horning, Sandra J.] Stanford Univ, Stanford, CA 94305 USA. [Li, Shuli; Weller, Edie] Dana Farber Canc Inst, Biostat Sci & Computat Biol, Boston, MA 02115 USA. RP Kuzel, TM (reprint author), Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, 676 N St Clair,Suite 850, Chicago, IL 60611 USA. EM t-kuzel@northwestern.edu NR 17 TC 17 Z9 18 U1 0 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2007 VL 48 IS 12 BP 2397 EP 2402 DI 10.1080/10428190701694186 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 239KI UT WOS:000251516800033 PM 17943599 ER PT S AU Milad, MR Rauch, SL AF Milad, Mohammed R. Rauch, Scott L. BE Schoenbaum, G Gottfried, JA Murray, EA Ramus, SJ TI The role of the orbitofrontal cortex in anxiety disorders SO LINKING AFFECT TO ACTION: CRITICAL CONTRIBUTIONS OF THE ORBITOFRONTAL CORTEX SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Linking Affect to Action - Critical Contributions of the Orbitofrontal Cortex CY MAR 11-14, 2007 CL New York, NY SP New York Acad Sci DE amygdala; fear extinction; conditioning; ventromedial; prefrontal cortex; neuroimaging ID OBSESSIVE-COMPULSIVE DISORDER; MEDIAL PREFRONTAL CORTEX; POSTTRAUMATIC-STRESS-DISORDER; CEREBRAL-BLOOD-FLOW; COGNITIVE-BEHAVIORAL THERAPY; POSITRON-EMISSION-TOMOGRAPHY; CHILDHOOD SEXUAL-ABUSE; ORBITAL FRONTAL-CORTEX; SCRIPT-DRIVEN IMAGERY; FEAR EXTINCTION AB Advances in neuroimaging techniques over the past two decades have allowed scientists to investigate the neurocircuitry of anxiety disorders. Such research has implicated the orbitofrontal cortex (OFC). Characterizing the role of OFC in anxiety disorders, however, is principally complicated by two factors-differences in underlying pathophysiology across the anxiety disorders and heterogeneity in function across different OFC sub-territories. Contemporary neurocircuitry models of anxiety disorders have primarily focused on amygdalocortical interactions. The amygdala is implicated in generating fear responses, whereas cortical regions, specifically the medial OFC (mOFC) and the ventromedial prefrontal cortex (vmPFC), are implicated in fear extinction. In contrast to mOFC, anterolateral OFC (lOFC) has been associated with negative affects and obsessions and thus dysfunctional lOFC may underlie different aspects of certain anxiety disorders. Herein, we aim to review the above-mentioned theories and provide a heuristic model for conceptualizing the respective roles of mOFC and lOFC in the pathophysiology and treatment of anxiety disorders. We will also review the role of the OFC in fear extinction and the implications of this role to the pathophysiology of anxiety disorders. C1 [Milad, Mohammed R.; Rauch, Scott L.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. [Milad, Mohammed R.; Rauch, Scott L.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Rauch, Scott L.] McLean Hosp, Belmont, MA 02478 USA. RP Milad, MR (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Bldg 149,13th St,2nd Floor, Charlestown, MA 02129 USA. EM milad@nmr.mgh.harvard.edu FU NIMH NIH HHS [R21MH072156, R01MH60219] NR 120 TC 129 Z9 131 U1 6 U2 22 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-683-5 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2007 VL 1121 BP 546 EP 561 DI 10.1196/annals.1401.006 PG 16 WC Behavioral Sciences; Multidisciplinary Sciences; Neurosciences; Psychiatry SC Behavioral Sciences; Science & Technology - Other Topics; Neurosciences & Neurology; Psychiatry GA BHD18 UT WOS:000252265300032 PM 17698998 ER PT S AU Spassieva, S Bielawski, A Anelli, V Obeid, LM AF Spassieva, Stefka Bielawski, Acek Anelli, Viviana Obeid, Lina M. BE Brown, HA TI Combination of C(17) sphingoid base homologues and mass spectrometry analysis as a new approach to study sphingolipid metabolism SO LIPIDOMICS AND BIOACTIVE LIPIDS: LIPIDS AND CELL SIGNALING SE Methods in Enzymology LA English DT Review; Book Chapter ID LONGEVITY ASSURANCE GENES; LONG-CHAIN BASES; FUNCTIONAL-CHARACTERIZATION; CERAMIDE SYNTHESIS; MOLECULAR-CLONING; KINASE-ACTIVITY; FAMILY-MEMBERS; PHOSPHORYLATION; LAG1; BIOSYNTHESIS AB In recent years, sphingolipid metabolites ceramide, sphingosine, and sphingosine-1-phosphate have emerged as important second messengers in addition to their role as precursors of biomembrane components. The investigation of these sphingolipid metabolites requires the development of new, more sensitive methods for assaying the enzymes involved in their production. This chapter describes the utilization of mass spectrometry technology in combination with nonnaturally occurring C(17) sphingoid bases in the in vitro assays of two of the enzymes of the sphingolipid pathway, ceramide synthase and sphingosine kinase. These new in vitro methods provide high sensitivity and extreme accuracy even when crude extracts are used as enzyme sources. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Spassieva, S (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01 CA097132]; NIA NIH HHS [R01 AG016583]; NIGMS NIH HHS [R01 GM062887] NR 31 TC 21 Z9 21 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-373965-0 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2007 VL 434 BP 233 EP 241 DI 10.1016/S0076-6879(07)34012-3 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BGX42 UT WOS:000251128300012 PM 17954250 ER PT J AU Hardy, S Kleinman, RE AF Hardy, Stephen Kleinman, Ronald E. BE Suchy, FJ Sokol, RJ Balistreri, WF TI CIRRHOSIS AND CHRONIC LIVER FAILURE SO LIVER DISEASE IN CHILDREN, 3RD EDITION LA English DT Article; Book Chapter ID SPONTANEOUS BACTERIAL PERITONITIS; FULMINANT HEPATIC-FAILURE; PORTAL-SYSTEMIC ENCEPHALOPATHY; EPIDERMAL-GROWTH-FACTOR; GAMMA-AMINOBUTYRIC-ACID; CHAIN AMINO-ACIDS; RANDOMIZED CONTROLLED TRIAL; FUNCTIONAL RENAL-FAILURE; BLOOD CULTURE BOTTLES; CONTINUOUS ARTERIOVENOUS HEMOFILTRATION C1 [Hardy, Stephen; Kleinman, Ronald E.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Hardy, Stephen] Massachusetts Gen Hosp, Dept Pediat Gastroenterol, Boston, MA 02114 USA. [Kleinman, Ronald E.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. RP Hardy, S (reprint author), Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. NR 428 TC 5 Z9 5 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-85657-7 PY 2007 BP 97 EP 137 DI 10.1017/CBO9780511547409.008 PG 41 WC Gastroenterology & Hepatology; Pediatrics SC Gastroenterology & Hepatology; Pediatrics GA BYD08 UT WOS:000298055500008 ER PT J AU Novak, DA Lauwers, GY Kradin, RL AF Novak, Donald A. Lauwers, Gregory Y. Kradin, Richard L. BE Suchy, FJ Sokol, RJ Balistreri, WF TI BACTERIAL, PARASITIC, AND FUNGAL INFECTIONS OF THE LIVER SO LIVER DISEASE IN CHILDREN, 3RD EDITION LA English DT Article; Book Chapter ID CAT-SCRATCH DISEASE; MYCOBACTERIUM-AVIUM COMPLEX; PYOGENIC HEPATIC-ABSCESS; Q-FEVER HEPATITIS; CHRONIC DISSEMINATED CANDIDIASIS; SUCCESSFUL SURGICAL REPAIR; SEVERE FALCIPARUM-MALARIA; VISCERAL LARVA MIGRANS; TOXIC-SHOCK-SYNDROME; RIGHT UPPER QUADRANT C1 [Novak, Donald A.] Univ Florida, Coll Med, Dept Pediat, Shands AGH Childrens Hosp, Gainesville, FL 32611 USA. [Lauwers, Gregory Y.; Kradin, Richard L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Lauwers, Gregory Y.; Kradin, Richard L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kradin, Richard L.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Novak, DA (reprint author), Univ Florida, Coll Med, Dept Pediat, Shands AGH Childrens Hosp, Gainesville, FL 32611 USA. NR 307 TC 1 Z9 1 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-85657-7 PY 2007 BP 871 EP 896 DI 10.1017/CBO9780511547409.039 PG 26 WC Gastroenterology & Hepatology; Pediatrics SC Gastroenterology & Hepatology; Pediatrics GA BYD08 UT WOS:000298055500039 ER PT J AU James, JA Kim-Howard, XR Bruner, BF Jonsson, MK McClain, MT Arbuckle, MT Walker, C Dennis, GJ Merrill, JT Harley, JB AF James, J. A. Kim-Howard, X. R. Bruner, B. F. Jonsson, M. K. McClain, M. T. Arbuckle, M. T. Walker, C. Dennis, G. J. Merrill, J. T. Harley, J. B. TI Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus SO LUPUS LA English DT Article DE hydroxychloroquine; SLE; systemic lupus erythematosus; therapy ID CONNECTIVE-TISSUE DISEASE; REVISED CRITERIA; LONG-TERM; FOLLOW-UP; ANTIBODIES; COHORT; AUTOANTIBODIES; CLASSIFICATION; EXACERBATIONS; ANTIMALARIALS AB Systemic lupus erythematosus (SLE) is a clinically diverse, complex autoimmune disease which may present with coincident onset of many criteria or slow, gradual symptom accrual. Early intervention has been postulated to delay or prevent the development of more serious sequelae. One option for treatment in this setting is hydroxychloroquine. Using 130 US military personnel who later met ACR SLE criteria, a retrospective study of onset, development and progression of SLE with and without pre-classification hydroxychloroquine (n = 26) use was performed. Patients treated with hydroxychloroquine prior to diagnosis had a longer (Wilcoxon signed rank test, P = 0.018) time between the onset of the first clinical symptom and SLE classification (median: 1.08 versus 0.29 years). Patients treated with prednisone before diagnosis also more slowly satisfied the classification criteria (Wilcoxon signed rank test, P = 0.011). The difference in median times between patients who received NSAIDs before diagnosis, as opposed to those who did not, was not different (P = 0.19). Patients treated with hydroxychloroquine also had a lower rate of autoantibody accumulation and a decreased number of autoantibody specificities at and after diagnosis. These findings are consistent with early hydroxychloroquine use being associated with delayed SLE onset. A prospective, blinded trial testing the capacity of hydroxychloroquine to delay or prevent SLE in high risk populations is warranted. C1 Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. Univ Oklahoma Hlth Sci, Dept Med, Oklahoma City, OK 73104 USA. Univ Oklahoma Hlth Sci, Dept Pathol, Oklahoma City, OK 73104 USA. Oklahoma Med Res Fdn, Genet Epidemiol Unit, Oklahoma City, OK 73104 USA. Univ Bergen, Broegelmann Res Lab, N-5020 Bergen, Norway. Walter Reed Army Med Ctr, Dept Rheumatol, Washington, DC 20307 USA. NIAMSD, Bethesda, MD 20892 USA. Oklahoma Med Res Fdn, Clin Pharmacol Program, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Oklahoma City, OK 73104 USA. RP James, JA (reprint author), Oklahoma Med Res Fdn, Arthritis & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM jamesj@omrf.ouhsc.edu FU NCRR NIH HHS [RR15577, RR20143]; NIAID NIH HHS [AI31584, AI50350, AI62629]; NIAMS NIH HHS [AR45084, AR45451, AR48045, AR48980, AR49084, P30 AR053483]; PHS HHS [ARC24717, ARC49084] NR 21 TC 59 Z9 62 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PY 2007 VL 16 IS 6 BP 401 EP 409 DI 10.1177/0961203307078579 PG 9 WC Rheumatology SC Rheumatology GA 196GZ UT WOS:000248471000003 PM 17664230 ER PT J AU Richter, SS Ferraro, MJ AF Richter, Sandra S. Ferraro, Mary Jane BE Baron, EJ Jorgensen, JH Landry, ML Pfaller, MA TI Susceptibility Testing Instrumentation and Computerized Expert Systems for Data Analysis and Interpretation SO MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED LA English DT Article; Book Chapter ID COAGULASE-NEGATIVE STAPHYLOCOCCI; SPECTRUM BETA-LACTAMASES; LEVEL AMINOGLYCOSIDE RESISTANCE; LATEX AGGLUTINATION-TEST; VIDEO READER SYSTEM; AUTOMATED MICROBIOLOGY SYSTEM; DETECT VANCOMYCIN RESISTANCE; VITEK 2 SYSTEM; ANTIMICROBIAL SUSCEPTIBILITY; PSEUDOMONAS-AERUGINOSA C1 [Richter, Sandra S.] Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, Iowa City, IA 52242 USA. [Ferraro, Mary Jane] Massachusetts Gen Hosp, Clin Microbiol Lab, Boston, MA 02114 USA. [Ferraro, Mary Jane] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Richter, SS (reprint author), Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, C606 GH,200 Hawkins Dr, Iowa City, IA 52242 USA. NR 99 TC 8 Z9 8 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-371-0 PY 2007 BP 245 EP 256 PG 12 WC Microbiology SC Microbiology GA BOY07 UT WOS:000278004500018 ER PT J AU Turnidge, JD Ferraro, MJ Jorgensen, JH AF Turnidge, John D. Ferraro, Mary Jane Jorgensen, James H. BE Baron, EJ Jorgensen, JH Landry, ML Pfaller, MA TI Susceptibility Test Methods: General Considerations SO MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED LA English DT Article; Book Chapter ID STREPTOCOCCUS-PNEUMONIAE; CLINICAL IMPACT; VITEK 2; BACTERIAL IDENTIFICATION; ANTIMICROBIAL RESISTANCE; VANCOMYCIN RESISTANCE; STAPHYLOCOCCUS-AUREUS; RAPID IDENTIFICATION; AUTOMICROBIC SYSTEM; ANAEROBIC-BACTERIA C1 [Turnidge, John D.] Womens & Childrens Hosp, Adelaide, SA 5006, Australia. [Ferraro, Mary Jane] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Ferraro, Mary Jane] Massachusetts Gen Hosp, Clin Microbiol Lab, Boston, MA 02114 USA. [Jorgensen, James H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Turnidge, JD (reprint author), Womens & Childrens Hosp, 72 King William Rd, Adelaide, SA 5006, Australia. NR 44 TC 4 Z9 4 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-371-0 PY 2007 BP 1146 EP 1151 PG 6 WC Microbiology SC Microbiology GA BOY07 UT WOS:000278004500073 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Fundamentals SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 1 EP 18 D2 10.1017/CBO9780511547249 PG 18 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200001 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Diagnostic Ultrasound SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 21 EP 22 D2 10.1017/CBO9780511547249 PG 2 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200002 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Focused Assessment with Sonography in Trauma (FAST) SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID BLUNT ABDOMINAL-TRAUMA; NONOPERATIVE MANAGEMENT; ULTRASOUND EXAMINATION; CHEST RADIOGRAPHY; SPLENIC TRAUMA; EMERGENCY; HEMOPERITONEUM; PNEUMOTHORAX; ULTRASONOGRAPHY; MULTICENTER C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 33 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 23 EP 51 DI 10.1017/CBO9780511547249.003 D2 10.1017/CBO9780511547249 PG 29 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200003 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Echocardiography SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID VENTRICULAR EJECTION FRACTION; SUSPECTED PULMONARY-EMBOLISM; CENTRAL VENOUS-PRESSURE; EMERGENCY-DEPARTMENT; ULTRASOUND; FEASIBILITY C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 39 TC 1 Z9 1 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 53 EP 83 DI 10.1017/CBO9780511547249.004 D2 10.1017/CBO9780511547249 PG 31 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200004 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI First Trimester Ultrasound SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID ECTOPIC PREGNANCY; INTRAUTERINE PREGNANCY; EMERGENCY-DEPARTMENT; ULTRASONOGRAPHY; TIME C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 21 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 85 EP 103 DI 10.1017/CBO9780511547249.005 D2 10.1017/CBO9780511547249 PG 19 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200005 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Abdominal Aortic Aneurysm SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID RUPTURE; ULTRASOUND C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 105 EP 118 DI 10.1017/CBO9780511547249.006 D2 10.1017/CBO9780511547249 PG 14 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200006 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Renal and Bladder SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID UNENHANCED HELICAL CT; ACUTE FLANK PAIN; PORTABLE ULTRASOUND; EMERGENCY; ASPIRATION; VOLUME; US C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 119 EP 133 DI 10.1017/CBO9780511547249.007 D2 10.1017/CBO9780511547249 PG 15 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200007 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Gallbladder SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID ULTRASOUND EVALUATION; EMERGENCY PHYSICIANS; CHOLECYSTITIS; GALLSTONES; DISEASE; WALL C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 135 EP 151 DI 10.1017/CBO9780511547249.008 D2 10.1017/CBO9780511547249 PG 17 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200008 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Deep Vein Thrombosis SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID VENOUS THROMBOSIS; COMPRESSION ULTRASONOGRAPHY; PULMONARY-EMBOLISM; OUTPATIENTS; ULTRASOUND; DIAGNOSIS; DOPPLER C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 153 EP 167 DI 10.1017/CBO9780511547249.009 D2 10.1017/CBO9780511547249 PG 15 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200009 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Chest Ultrasound SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID LUNG ULTRASOUND C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 169 EP 173 DI 10.1017/CBO9780511547249.010 D2 10.1017/CBO9780511547249 PG 5 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200010 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Ocular Ultrasound SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID OPTIC-NERVE SHEATH; CEREBROSPINAL-FLUID PRESSURE; INTRACRANIAL-PRESSURE; ULTRASONOGRAPHY; EMERGENCY C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 10 TC 2 Z9 2 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 175 EP 181 DI 10.1017/CBO9780511547249.011 D2 10.1017/CBO9780511547249 PG 7 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200011 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Fractures SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID ULTRASOUND; SONOGRAPHY; DIAGNOSIS; BONE C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 183 EP 189 DI 10.1017/CBO9780511547249.012 D2 10.1017/CBO9780511547249 PG 7 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200012 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Vascular Access SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID CENTRAL VENOUS CANNULATION; CATHETERIZATION; METAANALYSIS C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 195 EP 208 DI 10.1017/CBO9780511547249.014 D2 10.1017/CBO9780511547249 PG 14 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200013 ER PT J AU Noble, VE Nelson, B Sutingco, AN AF Noble, Vicki E. Nelson, Bret Sutingco, A. Nicholas BA Noble, VE Nelson, B Sutingco, AN BF Noble, VE Nelson, B Sutingco, AN TI Ultrasound for Procedure Guidance SO MANUAL OF EMERGENCY AND CRITICAL CARE ULTRASOUND LA English DT Article; Book Chapter ID PUNCTURE C1 [Noble, Vicki E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Bret] Mt Sinai Sch Med, New York, NY USA. RP Noble, VE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-68869-7 PY 2007 BP 209 EP 237 DI 10.1017/CBO9780511547249.015 D2 10.1017/CBO9780511547249 PG 29 WC Emergency Medicine SC Emergency Medicine GA BXW53 UT WOS:000297328200014 ER PT J AU Baggish, AL Januzzi, JL AF Baggish, Aaron L. Januzzi, James L. BE Adams, JE Apple, F Jaffe, AS TI Outpatient evaluation for cardiovascular diseases using natriuretic peptide testing SO MARKERS IN CARDIOLOGY: A CASE-ORIENTED APPROACH LA English DT Article; Book Chapter ID VENTRICULAR SYSTOLIC DYSFUNCTION; CONGESTIVE-HEART-FAILURE; CORONARY-ARTERY-DISEASE; EMERGENCY-DEPARTMENT PRIDE; PRIMARY PULMONARY-HYPERTENSION; CHRONIC AORTIC REGURGITATION; POPULATION-BASED SAMPLE; N-TERMINAL PROBNP; ATRIAL-FIBRILLATION; MITRAL REGURGITATION C1 [Baggish, Aaron L.; Januzzi, James L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02163 USA. RP Baggish, AL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02163 USA. NR 113 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-69198-4 PY 2007 BP 146 EP 169 DI 10.1002/9780470691984.ch14 D2 10.1002/9780470691984 PG 24 WC Cardiac & Cardiovascular Systems; Medical Laboratory Technology SC Cardiovascular System & Cardiology; Medical Laboratory Technology GA BDM40 UT WOS:000313831800015 ER PT J AU Aguilar, MI Hart, RG Kase, CS Freeman, WD Hoeben, MBJ Garcia, RC Ansell, JE Mayer, SA Norrving, B Rosand, J Steiner, T Wijdicks, EFM Yamaguchi, T Yasaka, M AF Aguilar, Maria I. Hart, Robert G. Kase, Carlos S. Freeman, William D. Hoeben, Maj Barbara J. Garcia, Rosa C. Ansell, Jack E. Mayer, Stephan A. Norrving, Bo Rosand, Jonathan Steiner, Thorsten Wijdicks, Eelco F. M. Yamaguchi, Takenori Yasaka, Masahiro TI Treatment of warfarin-associated intracerebral hemorrhage: Literature review and expert opinion SO MAYO CLINIC PROCEEDINGS LA English DT Review ID PROTHROMBIN COMPLEX CONCENTRATE; PROSTHETIC HEART-VALVES; RECOMBINANT FACTOR VIIA; ORAL ANTICOAGULANT REVERSAL; ACTIVATED FACTOR-VII; FRESH-FROZEN PLASMA; INTRACRANIAL HEMORRHAGE; ATRIAL-FIBRILLATION; CEREBRAL MICROBLEEDS; ISCHEMIC-STROKE AB Wider use of oral anticoagulants has led to an increasing frequency of warfarin-related intracerebral hemorrhage (ICH). The high early mortality of approximately 50% has remained stable in recent decades. In contrast to spontaneous ICH, the duration of bleeding is, 12 to 24 hours in many patients, offering a longer opportunity for Intervention. Treatment varies widely, and optimal therapy has yet to be defined. An OVID search was conducted from January 1996 to January 2006, combining the terms warfarin or anticoagulation with intracranial hemorrhage or intracerebral hemorrhage. Seven experts on clinical stroke, neurologic intensive care, and hematology were provided with the available information and were asked to independently address 3 clinical scenarios about acute reversal and resumption of anticoagulation in the setting of warfarin-associated ICH. No randomized trials assessing clinical outcomes were found on management of warfarin-associated ICH. All experts agreed that anticoagulation should be urgently reversed, but how to achieve it varied from use of prothrombin complex concentrates only (3 experts) to recombinant factor Vila only (2 experts) to recombinant factor Vila along with fresh frozen plasma (1 expert) and prothrombin complex concentrates or fresh frozen plasma (1 expert). All experts favored resumption of warfarin therapy within 3 to 10 days of ICH in stable patients in whom subsequent anticoagulation is mandatory. No general agreement occurred regarding subsequent anticoagulation of patients with atrial fibrillation who survived warfarin-associated ICH. For warfarin-associated ICH, discontinuing warfarin therapy with administration of vitamin K does not reverse the hemostatic defect for many hours and is inadequate. Reasonable management based on expert opinion includes a wide range of additional measures to reverse anticoagulation in the absence of solid evidence. C1 Mayo Clin, Coll Med, Dept Neurol, Scottsdale, AZ 85259 USA. Univ Texas, Hlth Sci Ctr, Dept Med Neurol, San Antonio, TX 78285 USA. Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA. Boston Univ, Sch Med, Dept Hematol, Boston, MA 02215 USA. Mayo Clin, Coll Med, Dept Neurol, Jacksonville, FL 32224 USA. Wilford Hall USAF Med Ctr, Clin Pharm, Lackland AFB, TX USA. Univ Texas, Hlth Syst, Serv Pharm, San Antonio, TX 78285 USA. Columbia Univ, Med Ctr, Inst Neurol, New York, NY 10027 USA. Univ Lund Hosp, Dept Neurol, S-22185 Lund, Sweden. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. Univ Heidelberg, D-6900 Heidelberg, Germany. Mayo Clin, Coll Med, Dept Neurol, Rochester, MN USA. Natl Cardiovasc Ctr, Osaka, Japan. Kyushu Med Ctr, Fukuoka, Japan. RP Aguilar, MI (reprint author), Mayo Clin, Coll Med, Dept Neurol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA. EM aguilar.maria@mayo.edu RI Steiner, Thorsten/A-7391-2014; OI Norrving, Bo/0000-0002-8024-5096 NR 86 TC 163 Z9 171 U1 1 U2 12 PU MAYO CLINIC PROCEEDINGS PI ROCHESTER PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD JAN PY 2007 VL 82 IS 1 BP 82 EP 92 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 122MF UT WOS:000243230400013 PM 17285789 ER PT S AU Hamblin, MR Demidova-Rice, TN AF Hamblin, Michael R. Demidova-Rice, Tatiana N. BE Hamblin, MR Waynant, RW Anders, J TI Cellular chromophores and signaling in low level light therapy. - art. no. 642802 SO Mechanisms for Low-Light Therapy II SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Mechanisms for Low-High Therapy II CY JAN 21, 2007 CL San Jose, CA DE biostimulation; low level laser therapy; mitochondria; cytochrome c oxidase; nitric oxide ID CYTOCHROME-C-OXIDASE; HELIUM-NEON LASER; NF-KAPPA-B; MONOCHROMATIC VISIBLE-LIGHT; ENDOTHELIAL GROWTH-FACTOR; RAT-LIVER MITOCHONDRIA; PROTEIN-KINASE-A; NITRIC-OXIDE; INDEPENDENT PATHWAYS; GENE-EXPRESSION AB The use of low levels of visible or near infrared light (LLLT) for reducing pain, inflammation and edema, promoting healing of wounds, deeper tissues and nerves, and preventing tissue damage by reducing cellular apoptosis has been known for almost forty years since the invention of lasers. Originally thought to be a peculiar property of laser light (soft or cold lasers), the subject has now broadened to include photobiomodulation and photobiostimulation using non-coherent light. Despite many reports of positive findings from experiments conducted in vitro, in animal models and in randomized controlled clinical trials, LLLT remains controversial. This likely is due to two main reasons; firstly the biochemical mechanisms underlying the positive effects are incompletely understood, and secondly the complexity of rationally choosing amongst a large number of illumination parameters such as wavelength, fluence, power density, pulse structure and treatment timing has led to the publication of a number of negative studies as well as many positive ones. In recent years major advances have been made in understanding the mechanisms that operate at the cellular and tissue levels during LLLT. Mitochondria are thought to be the main site for the initial effects of light and specifically cytochrome c oxidase that has absorption peaks in the red and near infrared regions of the electromagnetic spectrum matches the action spectra of LLLT effects. The discovery that cells employ nitric oxide (NO) synthesized in the mitochondria by neuronal nitric oxide synthase, to regulate respiration by competitive binding to the oxygen binding of cytochrome c oxidase, now suggests how LLLT can affect cell metabolism. If LLLT photodissociates inhibitory NO from cytochrome c oxidase, this would explain increased ATP production, modulation of reactive oxygen species, reduction and prevention of apoptosis, stimulation of angiogenesis, increase of blood flow and induction of transcription factors. In particular, signaling cascades are initiated via cyclic adenosine monophosphate (cAMP) and nuclear factor kappa B (NF-kappa B). These signal transduction pathways in turn lead to increased cell proliferation and migration (particularly by fibroblasts), modulation in levels of cytokines, growth factors and inflammatory mediators, and increases in anti-apoptotic proteins. The results of these biochemical and cellular changes in animals and patients include such benefits as increased healing in chronic wounds, improvements in sports injuries and carpal tunnel syndrome, pain reduction in arthritis and neuropathies, and amelioration of damage after heart attacks, stroke, nerve injury and retinal toxicity. C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. OI Hamblin, Michael/0000-0001-6431-4605 NR 76 TC 2 Z9 2 U1 1 U2 6 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-6541-2 J9 P SOC PHOTO-OPT INS PY 2007 VL 6428 BP 42802 EP 42802 AR 642802 DI 10.1117/12.712885 PG 14 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BGF72 UT WOS:000246491900001 ER PT S AU Castano, AP Dai, T Demidova-Rice, TN Salomatina, EV Yaroslavsky, AN Yaroslavsky, I Cohen, R Apruzzese, WA Smotrich, MH Hamblin, MR AF Castano, Ana P. Dai, Tianhong Demidova-Rice, Tatiana N. Salomatina, Elena V. Yaroslavsky, Anna N. Yaroslavsky, Ilya Cohen, Richard Apruzzese, William A. Smotrich, Michael H. Hamblin, Michael R. BE Hamblin, MR Waynant, RW Anders, J TI Low-level light therapy for zymosan induced arthritis in rats. - art. no. 64280F SO Mechanisms for Low-Light Therapy II SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Mechanisms for Low-High Therapy II CY JAN 21, 2007 CL San Jose, CA DE biostimulation; low-level light therapy; zymosan-induced arthritis; wound healing; bioniodulation; cold laser ID CYTOCHROME-C-OXIDASE; LASER THERAPY; INFLAMMATION; PHOTOBIOMODULATION; CYCLOOXYGENASE-2; IRRADIATION; MICE AB It has been known for many years that low level laser (or light) therapy (LLLT) can ameliorate the pain, swelling and inflammation associated with various forms of arthritis. Light is absorbed by mitochondrial chromophores leading to an increase in ATP, reactive oxygen species and/or cyclic AMP production and consequent gene transcription via activation of transcription factors. However, despite many reports about the positive effects of LLLT in medicine, its use remains controversial. Our laboratory has developed animal models designed to objectively quantify response to LLLT and compare different light delivery regimens. In the arthritis model we inject zymosan into rat knee joints to induce inflammatory arthritis. We have compared illumination regimens consisting of a high and low fluence (3 J/cm(2) and 30 J/cm(2)), delivered at a high and low irradiance (5 mW/cm(2) and 50 mW/cm(2)) using 810-nm laser light daily for 5 days, with the effect of conventional corticosteroid (dexamethasone) therapy. Results indicated that illumination with 810-nm laser is highly effective (almost as good as dexamethasone) at reducing swelling and that longer illumination time was more important in determining effectiveness than either total fluence delivered or irradiance. Experiments carried out using 810-nm LLLT on excisional wound healing in mice also confirmed the importance of longer illumination times. These data will be of value in designing clinical trials of LLLT. C1 Massachusetts Gen Hosp, Wellman Ctr Photon, Boston, MA 02114 USA. RP Castano, AP (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photon, Boston, MA 02114 USA. OI Hamblin, Michael/0000-0001-6431-4605 NR 24 TC 0 Z9 0 U1 0 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-6541-2 J9 P SOC PHOTO-OPT INS PY 2007 VL 6428 BP F4280 EP F4280 AR 64280F DI 10.1117/12.698193 PG 10 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BGF72 UT WOS:000246491900011 ER PT S AU Gupta, S Alt, F Cooper, M Melchers, F Rajewsky, K AF Gupta, Sudhir Alt, Frederick Cooper, Max Melchers, Fritz Rajewsky, Klaus BE Gupta, S Alt, F Cooper, M Melchers, F Rajewsky, K TI Mechanisms of Lymphocyte Activation and Immune Regulation XI B Cell Biology Preface SO MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION XI: B CELL BIOLOGY SE Advances in Experimental Medicine and Biology LA English DT Editorial Material; Book Chapter C1 [Gupta, Sudhir] Univ Calif Irvine, Coll Hlth Sci, Sch Med, Irvine, CA 92697 USA. [Alt, Frederick] Childrens Hosp Boston, Dept Genet, Boston, MA 02115 USA. [Cooper, Max] Univ Alabama, Inst Med, Tumor Res Labs, Birmingham, AL 35294 USA. [Melchers, Fritz] Max Planck Inst Infect Biol, BiozentrumAbt Zellbiol, D-4056 Berlin, Germany. [Rajewsky, Klaus] Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA. RP Gupta, S (reprint author), Univ Calif Irvine, Coll Hlth Sci, Sch Med, Irvine, CA 92697 USA. EM sgupta@uci.edu; alt@enders.tch.harvard.edu; max.cooper@ccc.uab.edu; fritz.melchers@unibas.ch; rajewsky@cbr.med.harvard.edu; sgupta@uci.edu; alt@enders.tch.harvard.edu; max.cooper@ccc.uab.edu; fritz.melchers@unibas.ch; rajewsky@cbr.med.harvard.edu NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 0065-2598 BN 978-0-387-46530-2 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2007 VL 596 BP VII EP VIII D2 10.1007/0-387-46530-8 PG 2 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA BLQ19 UT WOS:000270764700001 ER PT S AU Basu, U Chaudhuri, J Phan, RT Datta, A Alt, FW AF Basu, Uttiya Chaudhuri, Jayanta Phan, Ryan T. Datta, Abhishek Alt, Frederick W. BE Gupta, S Alt, F Cooper, M Melchers, F Rajewsky, K TI Regulation of Activation Induced Deaminase via Phosphorylation SO MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION XI: B CELL BIOLOGY SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter ID CLASS-SWITCH RECOMBINATION; INDUCED CYTIDINE DEAMINASE; SINGLE-STRANDED-DNA; ANTIBODY DIVERSIFICATION ENZYME; REPLICATION PROTEIN-A; SOMATIC HYPERMUTATION; B-CELLS; R-LOOPS; AID; TRANSCRIPTION AB Immunoglobulin gene diversification by somatic hypermutation (SHM), class switch recombination (CSR), and gene conversion is dependent upon activation-induced cytidine deaminase (AID). AID is a single-stranded DNA specific cytidine deaminase that is expressed primarily in activated mature B lymphocytes. AID appears to catalyze DNA cytidine deamination of immunoglobulin heavy (IgH) and light chain (IgL) variable region (V) exons and IgH switch (S) region sequences to initiate, respectively, IgH and IgL somatic hypermutation (SHM) and IgH class switch recombination (CSR). Here, we will discuss the implications of recent studies that demonstrate the role of AID phosphorylation in augmenting AID activity with respect to these two processes. C1 [Basu, Uttiya] Childrens Hosp, Howard Hughes Med Inst, CBR Inst Biomed Res, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. RP Basu, U (reprint author), Childrens Hosp, Howard Hughes Med Inst, CBR Inst Biomed Res, Boston, MA 02115 USA. FU NIAID NIH HHS [AI31541] NR 38 TC 14 Z9 15 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 0065-2598 BN 978-0-387-46530-2 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2007 VL 596 BP 129 EP 137 D2 10.1007/0-387-46530-8 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA BLQ19 UT WOS:000270764700012 PM 17338181 ER PT S AU Sasaki, Y Schmidt-Supprian, M Derudder, E Rajewsky, K AF Sasaki, Yoshiteru Schmidt-Supprian, Marc Derudder, Emmanuel Rajewsky, Klaus BE Gupta, S Alt, F Cooper, M Melchers, F Rajewsky, K TI Role of NF kappa B Signaling in Normal and Malignant B Cell Development SO MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION XI: B CELL BIOLOGY SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter ID BAFF; ACTIVATION; SURVIVAL; KINASE; MICE C1 [Sasaki, Yoshiteru; Schmidt-Supprian, Marc; Derudder, Emmanuel; Rajewsky, Klaus] Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. RP Sasaki, Y (reprint author), Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. RI Schmidt-Supprian, Marc/F-5893-2011 OI Schmidt-Supprian, Marc/0000-0002-8543-6166 NR 12 TC 17 Z9 17 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 0065-2598 BN 978-0-387-46530-2 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2007 VL 596 BP 149 EP 154 D2 10.1007/0-387-46530-8 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA BLQ19 UT WOS:000270764700014 PM 17338183 ER PT S AU Matthews, BD Thodeti, CK Ingber, DE AF Matthews, Benjamin D. Thodeti, Charles K. Ingber, Donald E. BE Hamill, OP TI Activation of mechanosensitive ion channels by forces transmitted through integrins and the cytoskeleton SO MECHANOSENSITIVE ION CHANNELS, PART A SE Current Topics in Membranes LA English DT Review; Book Chapter ID ENDOTHELIAL-CELLS; LIVING CELLS; HAIR-CELLS; MECHANICAL-PROPERTIES; ESCHERICHIA-COLI; FOCAL ADHESIONS; SHEAR-STRESS; CELLULAR MECHANOTRANSDUCTION; FUNCTIONAL RECONSTITUTION; CONFORMATIONAL REGULATION C1 Childrens Hosp, Vasc Biol Program, Dept Pathol, Boston, MA 02115 USA. Childrens Hosp, Vasc Biol Program, Dept Surg, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02114 USA. RP Matthews, BD (reprint author), Childrens Hosp, Vasc Biol Program, Dept Pathol, Boston, MA 02115 USA. NR 131 TC 5 Z9 6 U1 1 U2 11 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 1063-5823 BN 978-0-12-153358-8 J9 CURR TOP MEMBR JI Curr. Top. Membr. PY 2007 VL 58 BP 59 EP 85 DI 10.1016/S1063-5823(06)58003-2 PG 27 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA BGB61 UT WOS:000245920100003 ER PT S AU Erem, B Sharp, GC Wu, Z Kaeli, D AF Erem, Burak Sharp, Gregory C. Wu, Ziji Kaeli, David BE Zhang, D TI Interactive deformable registration visualization and analysis of 4D computed tomography SO MEDICAL BIOMETRICS, PROCEEDINGS SE Lecture Notes in Computer Science LA English DT Proceedings Paper CT 1st International Conference on Medical Biometrics CY JAN 04-05, 2008 CL Hong Kong, PEOPLES R CHINA SP Int Assoc Pattern Recognit, IEEE Computat Intelligence Soc, Natl Nat Sci Fdn China, Springer ID DEFORMATIONS; IMAGES AB This paper presents a new interactive method for analyzing 4D Computed Tomography (4DCT) datasets for patient care and research. Deformable registration algorithms are commonly used to observe the trajectories of individual voxels from one respiratory phase to another. Our system provides users with the capability to visualize these trajectories while simultaneously rendering anatomical volumes, which can greatly improve the accuracy of deformable registration. C1 [Erem, Burak; Kaeli, David] Northeastern Univ, Dept Elect & Comp Engn, Boston, MA 02115 USA. [Sharp, Gregory C.; Wu, Ziji] Massachusetts Gen Hosp, Radiat Dept, Boston, MA 02114 USA. RP Erem, B (reprint author), Northeastern Univ, Dept Elect & Comp Engn, Boston, MA 02115 USA. FU Gordon-CenSSIS; Gordon Center for Subsurface Sensing and Imaging Systems, under the Engineering Research Centers Program of the National Science Foundation [EEC-9986821]; NIH/NCRR Center for Integrative Biomedical Computing [P41-RR12553-07] FX This work was supported in part by Gordon-CenSSIS, the Bernard M. Gordon Center for Subsurface Sensing and Imaging Systems, under the Engineering Research Centers Program of the National Science Foundation (Award Number EEC-9986821). This work was made possible in part by software from the NIH/NCRR Center for Integrative Biomedical Computing, P41-RR12553-07. NR 5 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 978-3-540-77410-5 J9 LECT NOTES COMPUT SC PY 2007 VL 4901 BP 232 EP + PG 2 WC Computer Science, Theory & Methods; Mathematical & Computational Biology SC Computer Science; Mathematical & Computational Biology GA BHE35 UT WOS:000252428200030 ER PT J AU Ganz, DA Wenger, NS Roth, CP Kamberg, CJ Chang, JT MacLean, CH Young, RT Solomon, DH Higashi, T Min, LL Reuben, DB Shekelle, PG AF Ganz, David A. Wenger, Neil S. Roth, Carol P. Kamberg, Caren J. Chang, John T. MacLean, Catherine H. Young, Roy T. Solomon, David H. Higashi, Takahiro Min, Lillian Reuben, David B. Shekelle, Paul G. TI The effect of a quality improvement initiative on the quality of other aspects of health care - The law of unintended consequences? SO MEDICAL CARE LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc DE quality improvement; quality of care; geriatrics; health services research ID VULNERABLE ELDERS; OLDER PATIENTS; MEDICAL-CARE; INDICATORS; COMMUNITY; INFORMATION; DEMENTIA; INCONTINENCE; INTERVENTION; MANAGEMENT AB Problem: Policymakers and clinicians are concerned that initiatives to improve the quality of care for some conditions may have unintended negative consequences for quality in other conditions. Objective: We sought to determine whether a practice redesign intervention that improved care for falls, incontinence, and cognitive impairment by an absolute 15% change also affected quality of care for masked conditions (conditions not targeted by the intervention). Design, Setting, and Participants: Controlled trial in 2 community medical groups, with 357 intervention and 287 control patients age 75 years or older who had difficulty with falls, incontinence, or cognitive impairment. Intervention: Both intervention and control practices implemented case-finding for target conditions, but only intervention practices received a multicomponent practice-change intervention. Quality of care in the intervention practices improved for 2 of the target conditions (falls and incontinence). Main Outcome Measures: Percent of quality indicators satisfied for a set of 9 masked conditions measured by abstraction of medical records. Results: Before the intervention, the overall percent of masked indicators satisfied was 69% in the intervention group and 67% in the control group. During the intervention period, these percentages did not change, and there was no difference between intervention and control groups for the change in quality between the 2 periods (P = 0.86). The intervention minus control difference-in-change for the percent of masked indicators satisfied was 0.2% (bootstrapped 95% confidence interval, -2.7% to 2.9%). Subgroup analyses by clinical condition and by type of care process performed by the clinician did not show consistent results favoring either the intervention or the control group. Conclusion: A practice-based intervention that improved quality of care for targeted conditions by an absolute 15% change did not affect measurable aspects of care on a broad set of masked quality measures encompassing 9 other conditions. C1 Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. UCLA STAR Program, Los Angeles, CA USA. RAND Hlth, Santa Monica, CA USA. Kyoto Univ, Dept Epidemiol & Hlth Care Res, Kyoto, Japan. RP Ganz, DA (reprint author), Robert Wood Johnson VA Clin Scholars Program, 911 Broxton Plaza,3rd Floor, Los Angeles, CA 90024 USA. EM dganz@mednet.ucla.edu NR 22 TC 34 Z9 34 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2007 VL 45 IS 1 BP 8 EP 18 DI 10.1097/01.mlr.0000241115.31531.15 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 123RO UT WOS:000243313400004 PM 17279017 ER PT J AU Kahn, KL MacLean, CH Liu, HH Rubenstein, LZ Wong, AL Harker, JO Chen, WP Fitzpatrick, DM Bulpitt, KJ Traina, SB Mittman, BS Hahn, BH Paulus, HE AF Kahn, Katherine L. MacLean, Catherine H. Liu, Honghu Rubenstein, Laurence Z. Wong, Andrew L. Harker, Judith O. Chen, Wen-Pin Fitzpatrick, Diane M. Bulpitt, Ken J. Traina, Shana B. Mittman, Brian S. Hahn, Bevra H. Paulus, Harold E. TI The complexity of care for patients with rheumatoid arthritis - Metrics for better understanding chronic disease care SO MEDICAL CARE LA English DT Article DE chronic disease; rheumatoid arthritis; quality ID IMPROVING PRIMARY-CARE; CHRONIC ILLNESS; PUBLIC-HEALTH; QUESTIONNAIRE; MANAGEMENT; MEDICINE; CRITERIA; OUTCOMES; SCALES; SF36 AB Background: Patients with rheumatoid arthritis (RA) provide an important opportunity for understanding care of patients with a serious chronic condition. Objectives: We sought to characterize the complexity of care for patients with RA, including metrics describing the patient, the disease, and use of the health care system across time and place. Methods: We undertook a prospective cohort study of 568 community-dwelling patients with RA by using observational data from clinically detailed telephone interviews at baseline and 2 years later in addition to medical record abstraction. Health status, comorbidity, use of disease-modifying antirheumatic drugs, visits, providers, provider types, encounter settings, and the discontinuity between patients and providers were studied. Results: Within a 12-month window, 568 patients had 8686 outpatient encounters with the health care system with a mean of 3.41 unique providers per patient associated with a mean of 5 primary care and 6 rheumatologist visits. Half did not see a primary care physician, and 20% did not see a rheurnatologist during 6-month periods despite their use of potentially toxic drugs, a mean of 4 comorbidities and progressive RA. Over the course of 24 months, 29% of patients changed their primary care provider, and 15% changed their rheumatologist. Patients were moderately impaired with mean SF-12 physical component score 37 (SD, 9). Conclusion: Patients with RA have frequent encounters with multiple providers and also frequent discontinuity of care. Recognizing the complexity of the care of patients with a chronic disease across multiple dimensions provides an opportunity to better understand challenges and opportunities in delivering high quality care. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. RAND Corp, Santa Monica, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA USA. Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. RP Kahn, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Ave,Box 951736, Los Angeles, CA 90095 USA. EM kkahn@mednet.ucla.edu FU NIAMS NIH HHS [5 P60 AR36834] NR 34 TC 19 Z9 20 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2007 VL 45 IS 1 BP 55 EP 65 DI 10.1097/01.mlr.0000237425.58554.66 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 123RO UT WOS:000243313400008 PM 17279021 ER PT J AU Steinman, MA Rosenthal, GE Landefeld, CS Bertenthal, D Sen, S Kaboli, PJ AF Steinman, Michael A. Rosenthal, Gary E. Landefeld, C. Seth Bertenthal, Daniel Sen, Saunak Kaboli, Peter J. TI Conflicts and concordance between measures of medication prescribing quality SO MEDICAL CARE LA English DT Article; Proceedings Paper CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc Gen Internal Med DE drug therapy; aged; health care evaluation mechanisms; reproducibility of results; quality of health care ID APPROPRIATENESS INDEX; ELDERLY PATIENTS; BEERS CRITERIA; OLDER PATIENTS; POLYPHARMACY; CARE; RELIABILITY; OUTPATIENTS; GUIDELINES; INPATIENTS AB Background: Several instruments commonly are used to assess the quality of medication prescribing. However, little is known about the relationship between these instruments or the concordance of their quality assessments when applied to the same group of patients. Methods: We assessed 3 indicators of prescribing quality in a cohort of 196 veterans age 65 and older who were taking 5 or more medications. These 3 indicators assessed whether each patient was (1) taking any medication from the drugs-to-avoid criteria of Beers et al, (2) taking any medication with a score of 3 or more on the Medication Appropriateness Index (MAI), and/or (3) taking 9 or more medications (polypharmacy). Kappa statistics were used to assess agreement between measures. Results: Mean age was 74.6 years, and patients used a mean of 8.1 medications. Six percent of drugs were rated inappropriate by the Beers drugs-to-avoid criteria, whereas 23% of drugs received an MAI score of 3 or more. Overall agreement between these metrics was 78%, little more than expected by chance (kappa statistic 0.14, P < 0.01). At the level of the patient, the proportion of subjects taking one or more inappropriate drugs was 37% by drugs-to-avoid criteria and 82% by MAI, whereas 37% had polypharmacy of 9 drugs. Prescribing was classified as inappropriate by all 3 metrics in 18% of patients and as appropriate by all 3 metrics in 13%. Together, this level of agreement was slightly better than chance (3-way kappa statistic 0.08, P = 0.03). Agreement remained low in sensitivity analyses using different cutoffs for the Beers criteria, a range of thresholds for MAI scores, and different definitions of polypharmacy, with kappa statistics : 0.30 for all comparisons. Conclusions: Commonly used measures of drug prescribing quality yield widely discordant results. Because the overall quality of prescribing may not be readily inferred from a single measure, multidimensional approaches will likely be necessary for robust assessment of prescribing quality. C1 San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. Iowa City VA Hlth Care Syst, CRIISP, Iowa City, IA USA. Univ Iowa, Dept Internal Med, Div Gen Internal Med, Roy A & Lucille J Carver Coll Med, Iowa City, IA 52242 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clemet St,Box 181-G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU NIA NIH HHS [AG 00912, AG 10418] NR 26 TC 29 Z9 34 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2007 VL 45 IS 1 BP 95 EP 99 DI 10.1097/01.mlr.0000241111.11991.62 PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 123RO UT WOS:000243313400013 PM 17279026 ER PT J AU Bolcic-Jankovic, D Clarridge, BR Fowler, FJ Weissman, JS AF Bolcic-Jankovic, Dragana Clarridge, Brian R. Fowler, Floyd J., Jr. Weissman, Joel S. TI Do characteristics of HIPAA consent forms affect the response rate? SO MEDICAL CARE LA English DT Article DE consent forms; HIPAA; health-protected information; response rate ID HEALTH-SERVICES RESEARCH; INFORMED-CONSENT; QUALITY; IMPROVE; PRIVACY AB Objective: Under the The Health Insurance Portability and Accountability Act Privacy Rule, researchers are required to obtain written authorization from patients to gain access to protected health information. The purpose of this research was to examine how the characteristics of authorization forms used by hospitals affect the likelihood of consent. Method: This work reports on a recent telephone survey (administered January to August 2004) of previously hospitalized patients from 16 Massachusetts hospitals. Respondents were asked to provide authorization for review of their medical records. Those respondents who agreed over the phone to be mailed authorization forms were sent a copy of their hospital's form and were asked to sign and return it. Measured characteristics of the forms included number of pages, number of fields, distinctness of institution's name, whether a witness was required, and requirement of Social Security Number (SSN). Results: We received 1021 signed forms (50.3% of all sent forms). The likelihood of return was affected by the requirement of the SSN, the clarity of the hospital name, and providing an extra copy for respondents' records. In logistic regression analysis, besides age and gender, only the SSN and clarity of the hospital name identification were significant. Conclusion: Forms should be clear about the institution from which they come, easy to understand, and should not ask for SSN or other highly sensitive information unrelated to health care. C1 Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA. Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. RP Bolcic-Jankovic, D (reprint author), Univ Massachusetts, Survey Res Ctr, 100 Morrissey Blvd, Boston, MA 02125 USA. EM dragana.bjankovic@umb.edu NR 10 TC 8 Z9 8 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2007 VL 45 IS 1 BP 100 EP 103 DI 10.1097/01.mlr.0000241062.79855.35 PG 4 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 123RO UT WOS:000243313400014 PM 17279027 ER PT J AU Horowitz, SH AF Horowitz, Steven H. TI The diagnostic workup of patients with neuropathic pain SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article ID ENZYME REPLACEMENT THERAPY; NERVE-FIBER DENSITY; SENSORY NEUROPATHY; PERIPHERAL NEUROPATHY; FABRY-DISEASE; SKIN BIOPSY; IMPAIRMENT; MECHANISMS; SUDOMOTOR; REFLEX AB Current concepts of acute and chronic pain disorders distinguish "nociceptive," "inflammatory," "functional," and "neuropathic" pains [1]. Nociceptive pain is the common pain experienced from trauma, cancer, and so forth in which pain receptors (nociceptors) are activated. Transduction, conduction, and transmission of nociceptor activity to a conscious level involves peripheral and central nervous system pain pathways, which, when intact, function in a protective and adaptive manner [1]. However, damage to, or dysfunction of, these pain pathways, peripherally or centrally, can result in a different, much less frequent, but nevertheless important pain picture-that of neuropathic pain. Neuropathic pain is not a disease in and of itself, but rather a manifestation of multiple and varied disorders affecting the nervous system, particularly its somatosensory components. They include polyneuropathies such as those secondary to diabetes mellitus, alcoholism, and amyloidosis; idiopathic small-fiber neuropathy; hereditary neuropathies; mononeuropathies such as trigeminal, glossopharyngeal, and post-herpetic neuralgias; entrapment neuropathies; and traumatic nerve injuries producing complex regional pain syndrome (CRPS) type II. CRPS type I is also considered a neuropathic pain disorder, although evidence for nerve damage as the underlying mechanism is more controversial. Neuropathic pain can occur in central nervous system disorders, especially spinal cord injury, multiple sclerosis, and cerebrovascular lesions of the brainstem and thalamus. Neuropathic pain in these conditions confers no functional benefit and may be considered a "maladaptive" response of the nervous system to the primary pathology [1]. Unfortunately, the diagnosis of neuropathic pain is often problematic. Clinically, a distinction between nociceptive and neuropathic types of pain is not precise and conditions such as diabetes mellitus, cancer, and neurologic diseases with dystonia or spasticity can produce mixed pain pictures [2]. As with other pains, the perception of neuropathic pain is purely subjective, not easily described, nor directly measured. Also, pain pathway responses to damage are not static, but dynamic; signs and symptoms change with pathway activation and responsiveness, and with chronicity. Further, the multiplicity of disorders that have neuropathic pain as a component of their clinical presentations makes a single underlying pathophysiologic mechanism unlikely; more than one type of pain, and therefore probably more than one pain mechanism, can occur in a single patient, and some symptoms can be attributed to multiple mechanisms [2,3]. For these and other reasons the current management of neuropathic pain should be mechanistic in approach rather than disease-based [1]. Existing disease-based symptom palliation strategies should be supplemented with "targeted" mechanism-specific pharmacologic management [4]. C1 Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Univ Vermont, Coll Med, Burlington, VT 05405 USA. RP Horowitz, SH (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. EM shhorowitz@partners.org NR 28 TC 24 Z9 28 U1 0 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD JAN PY 2007 VL 91 IS 1 BP 21 EP + DI 10.1016/j.mcna.2006.10.002 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 121DI UT WOS:000243137900004 PM 17164102 ER PT J AU Deisboeck, TS Wang, ZH AF Deisboeck, Thomas S. Wang, Zhihui TI Cancer dissemination: A consequence of limited carrying capacity? SO MEDICAL HYPOTHESES LA English DT Article ID TUMOR-GROWTH; SOIL HYPOTHESIS; ANGIOGENESIS; METASTASIS; MECHANISMS; MODEL; AGE; PROGRESSION; PHENOTYPE; EVOLUTION AB Assuming that there is feedback between an expanding cancer system and its organ-typical microenvironment, we argue here that such local tumor growth is initially guided by co-existence rather than competition with the surrounding tissue. We then present a novel concept that understands cancer dissemination as a biological mechanism to evade the specific carrying capacity limit of its host organ. This conceptual framework allows us to relate the tumor system's volumetric growth rate to the host organ's functionatity-conveying composite infrastructure, and, intriguingly, already provides useful insights into several clinical findings. (C) 2006 Elsevier Ltd. All rights reserved. C1 Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Complex Biosyst Modeling Lab, Charlestown, MA 02129 USA. RP Deisboeck, TS (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Complex Biosyst Modeling Lab, 2301 Bldg 149,13th St, Charlestown, MA 02129 USA. EM deisboec@helix.mgh.harvard.edu FU NCI NIH HHS [CA 113004, U56 CA113004, U56 CA113004-03, U56 CA113004-02, U56 CA113004-01, CA 085139, R01 CA085139] NR 31 TC 4 Z9 4 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2007 VL 69 IS 1 BP 173 EP 177 DI 10.1016/j.mehy.2006.11.007 PG 5 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 178PP UT WOS:000247232900034 PM 17196762 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Why is academic medicine run by former C-students? SO MEDICAL HYPOTHESES LA English DT Article AB The present paper hypothesizes that the top positions in academic medicine are generally occupied by less talented and skilled physicians who find more time to spare for administrative activities as compared to physicians who are successful in their research projects or enjoy their skills as practicing clinicians. A physician's utility in advancing a medical career can be modeled as the product of two preferences, administration and biomedical work, weighted by time and talent, respectively. It corresponds with a characteristic Cobb-Douglass utility function of economics, which physicians will try to maximize in pursuing their preferences. The utility function becomes maximized if the split between administration and research mirrors the split between free time and talent, respectively. Physicians with few talents and tots of time to spare will accumulate in administration and politics, whereas those with talents and little time will remain committed to biomedical research or clinical practice. (C) 2007 Elsevier Ltd. All rights reserved. C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, P3-G1,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 7 TC 3 Z9 3 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2007 VL 69 IS 1 BP 218 EP 220 DI 10.1016/j.mehy.2007.01.045 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 178PP UT WOS:000247232900044 PM 17363180 ER PT S AU Cai, WL Yoshida, H Zalis, M Nappi, J AF Cai, Wenli Yoshida, Hiroyuki Zalis, Michael Nappi, Janne BE Giger, ML Karssemeijer, N TI Delineation of tagged region by use of local iso-surface roughness in electronic cleansing for CT colonography - art. no. 651409 SO Medical Imaging 2007: Computer-Aided Diagnosis, Pts 1 and 2 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2007 Conference CY FEB 18-20, 2007 CL San Diego, CA SP SPIE, Amer Assoc Physicists, Amer Physiol Soc, Comp Assisted Radiol & Surg, Soc Imaging Sci & Technol, Med Image Percept Soc, Radiol Soc N Amer, Soc Imaging Informat Med, Soc Mole Imaging, DICOM Standards Comm DE computer-aided diagnosis; X-ray and CT; abdominal ID COLORECTAL-CANCER; COLONOSCOPY; PREFERENCES AB Electronic cleansing (EC) is an emerging method for segmentation of fecal materials, which are tagged by an X-rayopaque oral contrast agent in CT colonography (CTC) images, effectively removing them for digital cleansing of the colon. Due to the partial volume effect, voxels at the boundary between the lumen and tagged materials, called the L-T boundary, not only have CT values that are close to those of soft-tissue structures, but also have gradient values that are similar to a thin soft-tissue structure that is sandwiched between the tagged region and the lumen, which we call a tagging-tissue-air layer. Degradation of thin colonic wall and folds, as well as creation of pseudo soft-tissue structures at the periphery of tagged regions, are main artifacts in existing EC approaches, which tend to use a gradient-based method to delineate tagged regions. In this study, we developed a novel delineation method of tagged regions by applying local iso-surface roughness. The local iso-surface roughness is defined by the sum of differences between the local curvedness at adjacent scales over all scales. In our approach, the roughness values around the periphery of the tagged regions are integrated into the speed function of a level-set segmentation method for delineation of the tagged regions. As a result, L-T boundaries are subtracted along with tagged regions, whereas the thin soft-tissue structures within the taggingtissue-air layers are preserved. Application of our computer-aided detection (CAD) scheme showed that the use of the new EC method substantially reduced the number of false-positive detections compared with that of our previous gradient-based method. C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. RP Cai, WL (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 17 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-6632-7 J9 P SOC PHOTO-OPT INS PY 2007 VL 6514 BP 51409 EP 51409 AR 651409 DI 10.1117/12.710088 PN 1-2 PG 9 WC Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BGI25 UT WOS:000247298700008 ER PT S AU Nappi, J Yoshida, H Zalis, M Cai, WL Lefere, P AF Nappi, Janne Yoshida, Hiroyuki Zalis, Michael Cai, Wenli Lefere, Philippe BE Giger, ML Karssemeijer, N TI Pseudo-enhancement correction for computer-aided detection in fecal-tagging CT colonography - art. no. 65140A SO Medical Imaging 2007: Computer-Aided Diagnosis, Pts 1 and 2 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2007 Conference CY FEB 18-20, 2007 CL San Diego, CA SP SPIE, Amer Assoc Physicists, Amer Physiol Soc, Comp Assisted Radiol & Surg, Soc Imaging Sci & Technol, Med Image Percept Soc, Radiol Soc N Amer, Soc Imaging Informat Med, Soc Mole Imaging, DICOM Standards Comm DE pre-processing; x-ray CT; detection ID CATHARTIC PREPARATION; COLONOSCOPY; BARIUM AB Fecal-tagging CT colonography (CTC) presents an opportunity to minimize colon cleansing while maintaining high diagnostic accuracy for the detection of colorectal lesions. However, the pseudo-enhancement introduced by tagging agents presents several problems for the application of computer-aided detection (CAD). We developed a correction method that minimizes pseudo-enhancement in CTC data by modeling of the pseudo-enhancement as a cumulative Gaussian energy distribution. The method was optimized by use of an anthropomorphic colon phantom, and its effect on our fully automated CAD scheme was tested by use of leave-one-patient-out evaluation on 23 clinical CTC cases with reduced colon cleansing based upon dietary fecal tagging. There were 28 colonoscopy-confirmed polyps >= 6 mm. Visual evaluation indicated that the method reduced CT attenuation of pseudo-enhanced polyps to standard soft-tissue Hounsfield unit (HU) range without affecting, untagged regions. At a 90% detection sensitivity for polyps >= 6 mm, CAD yielded 8.5 false-positive (FP) detections and 3.9 FP detections per volumetric scan without and with the application of the pseudo-enhancement correction method. These results indicate that the pseudo-enhancement correction method is a potentially useful pre-processing step for automated detection of polyps in fecal-tagging CTC, and that CAD can yield a high detection sensitivity with a relatively low FP rate in CTC with patient-friendly reduced colon preparation. C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. RP Nappi, J (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 11 TC 1 Z9 1 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-6632-7 J9 P SOC PHOTO-OPT INS PY 2007 VL 6514 BP A5140 EP A5140 AR 65140A DI 10.1117/12.710186 PN 1-2 PG 8 WC Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BGI25 UT WOS:000247298700009 ER PT S AU Cai, WL Yoshida, H Harris, GJ AF Cai, Wenli Yoshida, Hiroyuki Harris, Gordon J. BE Giger, ML Karssemeijer, N TI Dynamic-thres holding level set: a novel computer-aided volumetry method for liver tumors in hepatic CT images - art. no. 65142W SO Medical Imaging 2007: Computer-Aided Diagnosis, Pts 1 and 2 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2007 Conference CY FEB 18-20, 2007 CL San Diego, CA SP SPIE, Amer Assoc Physicists, Amer Physiol Soc, Comp Assisted Radiol & Surg, Soc Imaging Sci & Technol, Med Image Percept Soc, Radiol Soc N Amer, Soc Imaging Informat Med, Soc Mole Imaging, DICOM Standards Comm DE computer-aided volumetry; X-ray and CT; abdominal ID LESIONS; TOMOGRAPHY; SIZE AB Measurement of the volume of focal liver tumors, called liver tumor volumetry, is indispensable for assessing the growth of tumors and for monitoring the response of tumors to oncology treatments. Traditional edge models, such as the maximum gradient and zero-crossing methods, often fail to detect the accurate boundary of a fuzzy object such as a liver tumor. As a result, the computerized volumetry based on these edge models tends to differ from manual segmentation results performed by physicians. In this study, we developed a novel computerized volumetry method for fuzzy objects, called dynamic-thresholding level set (DT level set). An optimal threshold value computed from a histogram tends to shift, relative to the theoretical threshold value obtained from a normal distribution model, toward a smaller region in the histogram. We thus designed a mobile shell structure, called a propagating shell, which is a thick region encompassing the level set front. The optimal threshold calculated from the histogram of the shell drives the level set front toward the boundary of a liver tumor. When the volume ratio between the object and the background in the shell approaches one, the optimal threshold value best fits the theoretical threshold value and the shell stops propagating. Application of the DT level set to 26 hepatic CT cases with 63 biopsy-confirmed hepatocellular carcinomas (HCCs) and metastases showed that the computer measured volumes were highly correlated with those of tumors measured manually by physicians. Our preliminary results showed that DT level set was effective and accurate in estimating the volumes of liver tumors detected in hepatic CT images. C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. RP Cai, WL (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 16 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-6632-7 J9 P SOC PHOTO-OPT INS PY 2007 VL 6514 BP W5142 EP W5142 AR 65142W DI 10.1117/12.710117 PN 1-2 PG 8 WC Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BGI25 UT WOS:000247298700102 ER PT J AU Westbrook, SD Kirkpatrick, WR Freytes, CO Toro, JJ Bernardo, S Patterson, TF Redding, SW Lee, SA AF Westbrook, Steven D. Kirkpatrick, William R. Freytes, Cesar O. Toro, Juan J. Bernardo, Stella Patterson, Thomas F. Redding, Spencer W. Lee, Samuel A. TI Candida krusei sepsis secondary to oral colonization in a hemopoietic stem cell transplant recipient SO MEDICAL MYCOLOGY LA English DT Article DE Candida krusei; oral colonization; hemopoietic stem cell transplantation; Candida sepsis ID FLUCONAZOLE AB Yeasts other than Candida albicans have emerged as important causes of fungal infection in hemopoietic stem cell transplant (HSCT) patients, particularly those receiving fluconazole prophylaxis. We report on an autologous hemopoietic stem cell transplant recipient who developed Candida krusei sepsis from pre-existing oral colonization. C1 Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Westbrook, SD (reprint author), Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, 7703 Floyd Curl Dr,MSC 7919, San Antonio, TX 78229 USA. EM westbrooks@uthscsa.edu FU NIDCR NIH HHS [DE-18096] NR 8 TC 12 Z9 12 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PY 2007 VL 45 IS 2 BP 187 EP 190 DI 10.1080/1369378060116430 PG 4 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 167VC UT WOS:000246479600010 PM 17365656 ER PT J AU Glick, SJ Thacker, S Gong, X Liu, B AF Glick, Stephen J. Thacker, Samta Gong, Xing Liu, Bob TI Evaluating the impact of x-ray spectral shape on image quality in flat-panel CT breast imaging SO MEDICAL PHYSICS LA English DT Article ID SCREEN-FILM MAMMOGRAPHY; CONE-BEAM CT; DIGITAL RADIOGRAPHY; COMPUTED MAMMOTOMOGRAPHY; AVALANCHE GAIN; NOISE; DETECTOR; SYSTEM; ANODE; OPTIMIZATION AB In recent years, there has been an increasing interest in exploring the feasibility of dedicated computed tomography (CT) breast imaging using a flat-panel digital detector in a truncated cone-beam imaging, geometry. Preliminary results are promising and it appears as if three-dimensional tomographic imaging of the breast has great potential for reducing the masking effect of superimposed parenchymal structure typically observed with conventional mammography. In this study, a mathematical framework used for determining optimal design and acquisition parameters for such a CT breast imaging system is described. The ideal observer signal-to-noise ratio (SNR) is used as a figure of merit, under the assumptions that the imaging system is linear and shift invariant. Computation of the ideal observer SNR used a parallel-cascade model to predict signal and noise propagation through the detector, as well as a realistic model of the lesion detection task in breast imaging. For all evaluations, the total mean glandular dose for a CT breast imaging study was constrained to be approximately equivalent to that of a two-view conventional mammography study. The framework presented was used to explore the effect of x-ray spectral shape across an extensive ran-e of kVp settings, filter material types, and filter thicknesses. The results give an indication of how spectral shape can affect image quality in flat-panel CT breast imaging. (c) 2007 American Association of Physicists in Medicine. C1 Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01655 USA. Radiat Monitoring Devices Inc, Watertown, MA 02172 USA. Rush Univ, Med Ctr, Dept Med Phys & Radiat Oncol, Chicago, IL 60612 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Glick, SJ (reprint author), Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01655 USA. EM stephen.glick@umassmed.edu FU NCRR NIH HHS [RR016689]; NIBIB NIH HHS [EB02133] NR 53 TC 41 Z9 42 U1 0 U2 6 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JAN PY 2007 VL 34 IS 1 BP 5 EP 24 DI 10.1118/1.2388574 PG 20 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 127GW UT WOS:000243574500002 PM 17278485 ER EF